0000741815-13-000046.txt : 20131118 0000741815-13-000046.hdr.sgml : 20131118 20131115193748 ACCESSION NUMBER: 0000741815-13-000046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131118 DATE AS OF CHANGE: 20131115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOOPER HOLMES INC CENTRAL INDEX KEY: 0000741815 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 221659359 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09972 FILM NUMBER: 131225133 BUSINESS ADDRESS: STREET 1: 170 MT AIRY ROAD CITY: BASKING RIDGE STATE: NJ ZIP: 07920 BUSINESS PHONE: 9087665000 MAIL ADDRESS: STREET 1: 170 MT AIRY ROAD CITY: BASKING RIDGE STATE: NJ ZIP: 07920 10-Q 1 hh09301310q.htm 10-Q Q3 2013 HH.093013.10Q


 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
x        Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
For the quarterly period ended September 30, 2013
 
or
 
o        Transition Report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
For the transition period from         to         
__________________
 
Commission File Number: 001-09972
 
HOOPER HOLMES, INC.
(Exact name of registrant as specified in its charter)

 
New York
 
22-1659359
 
 
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
 
 
 
 
170 Mt. Airy Road, Basking Ridge, NJ
 
07920
 
 
(Address of principal executive offices)
 
(Zip code)
 
 
Registrant's telephone number, including area code:   (908) 766-5000
 
Former name, former address and former fiscal year, if changed since last report
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes x
 
No o
 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
Yes x
 
No o
 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer o
 
Accelerated Filer o 
 
Non-accelerated Filer o
 
Smaller Reporting Company x

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes o
 
No x
 

The number of shares outstanding of the Registrant's common stock as of October 31, 2013 was:
Common Stock, $.04 par value - 70,082,737 shares




HOOPER HOLMES, INC. AND SUBSIDIARIES
INDEX


 
 
 
Page No.
PART I –
Financial Information
 
 
 
 
 
 
ITEM 1 –
Financial Statements (unaudited)
 
 
 
 
 
 
 
Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012
 
 
 
 
 
 
Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2013 and 2012
 
 
 
 
 
 
Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012
 
 
 
 
 
 
Notes to Unaudited Consolidated Financial Statements
 
 
 
 
 
ITEM 2 –
Management's Discussion and Analysis of Financial Condition and Results of Operations
 
 
 
 
 
ITEM 3 –
Quantitative and Qualitative Disclosures About Market Risk
 
 
 
 
 
ITEM 4 –
Controls and Procedures
 
 
 
 
PART II –
Other Information
 
 
 
 
 
ITEM 1 –
Legal Proceedings
 
 
 
 
 
ITEM 1A –
Risk Factors
 
 
 
 
 
ITEM 2 –
Unregistered Sales of Equity Securities and Use of Proceeds
 
 
 
 
 
ITEM 3 –
Defaults Upon Senior Securities
 
 
 
 
 
ITEM 4 –
Mine Safety Disclosures
 
 
 
 
 
ITEM 5 –
Other Information
 
 
 
 
 
ITEM 6 –
Exhibits
 
 
 
 
 
 
Signatures





PART I - Financial Information

Item 1. Financial Statements (unaudited)

Hooper Holmes, Inc. and Subsidiaries
Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share data)
 
September 30, 2013
December 31, 2012
ASSETS
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash and cash equivalents
 
$
6,655

 
 
$
8,319

 
 Accounts receivable, net of allowance for doubtful accounts of $622 and $662 at September 30, 2013 and December 31, 2012, respectively
 
 
 
 
 
 
 
 
 
 
 
 
 
15,983

 
 
17,018

 
Inventories
 
1,773

 
 
1,290

 
Other current assets
 
1,607

 
 
374

 
Assets held for sale
 
—

 
 
3,646

 
Total current assets 
 
26,018

 
 
30,647

 
 
 
 
 
 
 
 
Property, plant and equipment at cost
 
21,092

 
 
20,829

 
Less: Accumulated depreciation and amortization
 
16,474

 
 
15,195

 
Property, plant and equipment, net
 
4,618

 
 
5,634

 
 
 
 
 
 
 
 
Other assets
 
2,094

 
 
137

 
Total assets  
 
$
32,730

 
 
$
36,418

 
 
 
 
 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
Short-term borrowings
 
$
2,608

 
 
$
—

 
Accounts payable
 
8,127

 
 
6,783

 
Accrued expenses
 
5,895

 
 
4,439

 
Liabilities held for sale
 
—

 
 
220

 
Total current liabilities 
 
16,630

 
 
11,442

 
Other long-term liabilities
 
920

 
 
1,115

 
Commitments and contingencies (Note 10)
 

 
 

 
 
 
 
 
 
 
 
Stockholders' Equity:
 
 
 
 
 
 
Common stock, par value $.04 per share; Authorized: 240,000,000 shares; Issued: 70,140,864 shares and 69,844,782 shares at September 30, 2013 and December 31, 2012, respectively; Outstanding: 70,131,469 shares and 69,835,387 shares at September 30, 2013 and December 31, 2012, respectively.
 
2,806

 
 
2,794

 
Additional paid-in capital
 
150,125

 
 
149,542

 
Accumulated deficit 
 
(137,680
)
 
 
(128,404
)
 
 
 
15,251

 
 
23,932

 
Less: Treasury stock, at cost; 9,395 shares at September 30, 2013 and December 31, 2012
 
(71
)
 
 
(71
)
 
Total stockholders' equity
 
15,180

 
 
23,861

 
Total liabilities and stockholders' equity
 
$
32,730

 
 
$
36,418

 
 
 
 
 
 
 
 
See accompanying notes to consolidated financial statements.
 
 
 
 
 
 

1


Hooper Holmes, Inc. and Subsidiaries
Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)

 
 
Three Months Ended
 
Nine Months Ended
 
 
September 30
 
September 30
 
 
2013
 
2012
 
2013
 
2012
Revenues
 
$
10,993

 
$
12,299

 
$
34,193

 
$
35,786

Cost of operations
 
8,730

 
8,762

 
25,663

 
25,529

 Gross profit
 
2,263

 
3,537

 
8,530

 
10,257

Selling, general and administrative expenses
 
5,002

 
4,655

 
15,372

 
15,054

Impairment of long-lived assets
 
—

 
—

 
212

 
—

Restructuring charges 
 
362

 
—

 
671

 
445

 Operating loss from continuing operations
 
(3,101
)
 
(1,118
)
 
(7,725
)
 
(5,242
)
Other expense:
 
 
 
 
 
 
 
 
Interest expense
 
(54
)
 
(2
)
 
(80
)
 
(8
)
Interest income
 
—

 
6

 
4

 
22

Other expense, net
 
(131
)
 
(71
)
 
(343
)
 
(217
)
 
 
(185
)
 
(67
)
 
(419
)
 
(203
)
Loss from continuing operations before income taxes
 
(3,286
)
 
(1,185
)
 
(8,144
)
 
(5,445
)
 
 
 
 
 
 
 
 
 
Income tax expense
 
5

 
4

 
14

 
11

 
 
 
 
 
 
 
 
 
Loss from continuing operations
 
(3,291
)
 
(1,189
)
 
(8,158
)
 
(5,456
)
 
 
 
 
 
 
 
 
 
Discontinued operations:
 
 
 
 
 
 
 
 
Gain on sale of Portamedic and subsidiary
 
3,543

 
—

 
3,618

 
65

     Loss from discontinued operations, including income taxes
 
(1,966
)
 
(1,004
)
 
(4,736
)
 
(5,470
)
    Income (loss) from Discontinued Operations
 
1,577

 
(1,004
)
 
(1,118
)
 
(5,405
)
Net loss
 
$
(1,714
)
 
$
(2,193
)
 
$
(9,276
)
 
$
(10,861
)
Basic and diluted earnings (loss) per share:
 
 
 
 
 
 
 
 
Continuing operations
 
 
 
 
 
 
 
 
Basic
 
$
(0.05
)
 
$
(0.02
)
 
$
(0.12
)
 
$
(0.08
)
Diluted
 
$
(0.05
)
 
$
(0.02
)
 
$
(0.12
)
 
$
(0.08
)
Discontinued operations
 
 
 
 
 
 
 
 
Basic
 
$
0.02

 
$
(0.01
)
 
$
(0.02
)
 
$
(0.08
)
Diluted
 
$
0.02

 
$
(0.01
)
 
$
(0.02
)
 
$
(0.08
)
Net loss
 
 
 
 
 
 
 
 
Basic
 
$
(0.02
)
 
$
(0.03
)
 
$
(0.13
)
 
$
(0.16
)
Diluted
 
$
(0.02
)
 
$
(0.03
)
 
$
(0.13
)
 
$
(0.16
)
 
 
 
 
 
 
 
 
 
Weighted average number of shares - Basic
 
69,952,153

 
69,789,628

 
69,877,878

 
69,713,178

Weighted average number of shares - Diluted
 
69,952,153

 
69,789,628

 
69,877,878

 
69,713,178

 
 
 
 
 
 
 
 
 
See accompanying notes to consolidated financial statements.
 
 
 
 



2


Hooper Holmes, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(unaudited, in thousands)
 
Nine Months Ended September 30,
 
2013
 
2012
Cash flows from operating activities:
 
 
 
Net loss
$
(9,276
)
 
(10,861
)
 
 
 
 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
 Gain on sale of Portamedic and subsidiary
(3,618
)
 
—

Depreciation
1,828

 
2,970

Amortization
—

 
159

Amortization of debt financing fees
213

 
102

Provision for bad debt expense
80

 
55

Share-based compensation expense
581

 
539

Impairment and loss on disposal of fixed assets
486

 
208

Change in assets and liabilities:
 
 
 
Accounts receivable
955

 
(171
)
Inventories
(598
)
 
(512
)
Other assets
(155
)
 
1,053

Accounts payable, accrued expenses and other long-term liabilities
1,718

 
1,311

Net cash used in operating activities
(7,786
)
 
(5,147
)
Cash flows from investing activities:
 
 
 
Capital expenditures
(1,062
)
 
(3,346
)
Costs paid to sell Portamedic
(411
)
 
—

Proceeds from the sale of Portamedic
6,053

 
—

Proceeds from sale of equipment
—

 
51

Net cash provided by (used in) investing activities
4,580

 
(3,295
)
Cash flows from financing activities:
 
 
 
Cumulative borrowings under credit facility
49,023

 
—

Cumulative payments under credit facility
(46,415
)
 
—

Reduction in capital lease obligations
(113
)
 
(214
)
Proceeds related to the exercise of stock options
14

 
—

Debt financing fees
(967
)
 
(100
)
Net cash provided by (used in) financing activities
1,542

 
(314
)
 
 
 
 
Net decrease in cash and cash equivalents
(1,664
)
 
(8,756
)
Cash and cash equivalents at beginning of period
8,319

 
16,917

Cash and cash equivalents at end of period
$
6,655

 
$
8,161

 
 
 
 
Supplemental disclosure of non-cash investing activities:
 
 
 
Fixed assets vouchered but not paid
$
556

 
$
570

     Fixed assets acquired by capital lease
$
74

 
$
—

    Costs to sell Portamedic but not paid
$
534

 
—

Supplemental disclosure of cash paid during period for:
 
 
 
Income taxes
$
52

 
$
40

 
 
 
 
See accompanying notes to consolidated financial statements.
 
 
 

3


Hooper Holmes, Inc. and Subsidiaries

Notes to Unaudited Consolidated Financial Statements
September 30, 2013
(unaudited)

Note 1: Basis of Presentation

Hooper Holmes, Inc. (“Hooper Holmes” or the "Company”) mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. The Company also conducts laboratory testing, assembles collection kits, conducts telephone interviews of life insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.

As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles.

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2012 Annual Report on Form 10-K, filed with the SEC on April 1, 2013.

Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented.

The results of operations for the three and nine month periods ended September 30, 2013 and 2012 are not necessarily indicative of the results to be expected for any other interim period or the full year. See “Management's Discussion and Analysis of Financial Condition and Results of Operations” for additional information.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the assets and liabilities of Portamedic that were sold have been reclassified and are reported as assets and liabilities held for sale on the December 31, 2012 consolidated balance sheet. The operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Certain costs presented within continuing operations in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among service lines and the continuing operations have been and are being restructured. There is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated in future periods. For further discussion on Discontinued Operations, please see Note 6.

Note 2: Liquidity

For the nine month periods ended September 30, 2013 and 2012, the Company incurred losses from continuing operations of $8.2 million and $5.5 million, respectively. Restructuring charges are included in results for each of the three and nine month periods ended September 30, 2013 and 2012.  The Company has managed its liquidity through a series of cost reduction and accounts receivable collection initiatives, by obtaining a new credit facility in February 2013 and the sale of Portamedic on September 30, 2013.
        
At September 30, 2013, the Company had $6.7 million in cash and cash equivalents and working capital of $9.4 million.  The Company's net cash used in operating activities for the nine month periods ended September 30, 2013 and 2012 was $7.8 million and $5.1 million, respectively, and includes the cash flow impact of accounts receivable, accounts payable, and accrued expenses related to the Portamedic service line that were retained after the sale of Portamedic. For the nine month periods ended September 30, 2013 and 2012, the Company's capital expenditures totaled $1.1 million and $3.3 million, respectively.



4



On September 30, 2013, the Company completed the sale of its Portamedic service line to American Para Professional Systems, Inc. ("APPS", "Piston Acquisition Inc.", and/or "Piston"). The adjusted purchase price (the “Purchase Price”) was approximately $8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital, of which $2.0 million (the “Holdback Amount”) was held back by Piston as security for the Company’s obligations and agreements between the Company and Piston (see note 6).

The first $1.0 million tranche of the Holdback Amount is expected to be received in early 2014, with the second approximately one year later. There cannot be any assurance that the Holdback Amount will be collected by the Company in full, however management currently expects to realize the amounts in full and has recorded receivables in other current assets and other assets totaling $2.0 million.

In the first quarter of 2013, the Company entered into a three year Loan and Security Agreement, amended as of March 28, 2013 by the First Amendment (collectively, the “2013 Loan and Security Agreement”), with Keltic Financial Partners II, LP (“Keltic Financial”), the proceeds of which are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any one time outstanding which does not exceed 85% of Eligible Receivables less any reserves established by Keltic Financial, at its sole discretion, provided that in no event can the aggregate amount of the revolving credit loans outstanding at any time exceed $10 million. Eligible Receivables do not include Heritage Labs receivables certain Hooper Holmes Services receivables, unbilled Portamedic and Health & Wellness receivables and other receivables deemed ineligible by Keltic Financial.

As of September 30, 2013 there were $2.6 million in borrowings outstanding under our 2013 Loan and Security Agreement and the Company's available borrowing capacity was $0.04 million based on September 30, 2013 Eligible Receivables and a $0.8 million reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation method and timeline, available borrowing capacity increased to approximately $6.0 million by October 4, 2013 and the reserve established by Keltic Financial was increased back to $1.5 million from a temporary reduction to increase available borrowing at the end of September 2013.
    
The sale of the Portamedic service line, which accounted for approximately 60-75% of Eligible Receivables prior to September 30, 2013, will result in a future decrease in borrowing capacity, although Portamedic receivables were not sold in the transaction and will continue to be included as Eligible Receivables until collected, in accordance with the 2013 Loan and Security Agreement. The Company estimates Portamedic related receivables to be approximately $9 million as of September 30, 2013. We may request that other receivables qualify but we are not able to reliably estimate the future borrowing capacity.

The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The minimum EBIDTA required for the twelve months ending June 30, 2014 is negative $3.2 million. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013.

Certain costs presented in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among all service lines. For the nine months ended September 30, 2013, $7.4 million of such selling, general and administrative costs were allocated to discontinued operations. While the Company is attempting to reduce these costs for its continuing operations, there is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated or reduced in future periods.

Since the Company historically has not tracked accounts receivable, accounts payable and other accounts by service line, its service lines had customers and suppliers in common, and its continuing and discontinued operations shared certain selling, general and administrative services, the Company does not have reliable information for the historical impact of Portamedic on the Company’s cash flows. However, the Company feels that without the Portamedic service line and with selling, general and administrative cost reductions, cash flow from operations will improve.

In the fourth quarter of 2013, the Company began relocating its headquarters to Kansas and put its Basking Ridge real estate up for sale. Establishing a new team and transitioning functions to Kansas will take months and transition costs may be higher than expected. In addition, the sale of the Basking Ridge real estate may not occur when expected or for the amount expected. Any sale of the real estate is subject to consent by Keltic Financial.


5


The Company's Heritage Labs service line shared some customers with the Portamedic service line. While not all Heritage Labs life insurance samples originated from Portamedic exams, the sale of the Portamedic service line may have an impact on life insurance related lab volumes.

The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.

Through the increased focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue. 

If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, reduce its selling, general and administrative costs as it seeks to streamline operations and improve efficiency, grow the Health and Wellness service line and maintain Heritage Labs revenues as expected, and timely realize sufficient proceeds from the Holdback Amount and the sale of the Basking Ridge real estate, it may violate covenants or otherwise not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect the Company's liquidity and its ability to generate cash flow in the future.

Based on the Company's anticipated level of future revenues, sale of the Basking Ridge real estate, collection of the Holdback amount and restructuring initiatives, and the Company's existing cash, cash equivalents, working capital and credit facility, the Company believes it has sufficient funds to meet its cash needs through at least September 30, 2014.

Note 3:
(Loss) Earnings Per Share

Outstanding stock options to purchase approximately 6,280,000 and 6,180,000 shares of the Company's common stock were excluded from the calculation of diluted loss per share for the three and nine month periods ended September 30, 2013, respectively, and approximately 5,565,000 and 5,543,000 shares for the three and nine month periods ended September 30, 2012, respectively, because their exercise prices exceeded the average market price of the Company's common stock for such periods and, therefore, were antidilutive.

Note 4: Impairment of Long-lived Assets

During the nine month period ended September 30, 2013, the Company recorded an impairment charge in continuing operations of $0.2 million, which is included in impairment of long-lived assets in the accompanying consolidated statement of operations for the nine month period ended September 30, 2013. The charge of $0.2 million for the nine month period ended September 30, 2013 relates to the write-off of certain financial system software which will not be utilized in the future.

During the nine month periods ended September 30, 2013 and 2012, the Company recorded impairment of long-lived assets of Portamedic of $0.1 million and $0.2 million, respectively, which is included in the loss from discontinued operations, including income taxes.

Note 5: Share-Based Compensation

Employee Share-Based Compensation Plans - On May 29, 2008, the Company's shareholders approved the 2008 Omnibus Employee Incentive Plan (the “2008 Plan”) providing for the grant of stock options, stock appreciation rights, non-vested stock and performance shares. The 2008 Plan provides for the issuance of an aggregate of 5,000,000 shares. For the three and nine months ended September 30, 2013, the Company granted 325,000 options to purchase shares under the 2008 Plan. For the nine months ended September 30, 2012, 900,000 options for the purchase of shares were granted under the 2008 Plan as well as 205,332 shares of restricted stock granted to the Company's Chief Executive Officer as settlement for a discretionary bonus of $0.1 million. As of September 30, 2013, approximately 1,479,900 shares remain available for grant under the 2008 Plan.

    

6


On May 24, 2011, the Company's shareholders approved the 2011 Omnibus Employee Incentive Plan (the "2011 Plan") providing for the grant of stock options and non-vested stock awards. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the 2011 Plan which increased the number of shares of the Company's common stock available for issuance from 1,500,000 shares to 3,500,000 shares (subject to adjustment as provided in the Amended and Restated Omnibus Plan). The 2011 Plan is to remain in effect until the earlier of (i) the 10th anniversary of the plan's original effective date (May 24, 2011), or (ii) the date all shares of stock available for issuance have been issued. During the three and nine months ended September 30, 2013, an aggregate of 2,000,000 options for the purchase of shares were granted under the 2011 Plan. During the three and nine months ended September 30, 2012, an aggregate of 1,225,000 options for the purchase of shares were granted under the 2011 Plan. As of September 30, 2013, approximately 1,092,500 shares remain available for grant under the 2011 Plan as amended.

Options awarded under the 2008 and 2011 Plans (as amended) are granted at fair value on the date of grant, are exercisable in accordance with a vesting schedule specified in the grant agreement, and have contractual lives of 10 years from the date of grant. Options to purchase an aggregate of 500,000 shares of the Company's stock granted to certain executives of the Company in December 2010 vested 50% on each of the first and second anniversaries of the grant. Options to purchase an aggregate of 325,000, 1,277,500 and 337,600 shares of the Company's stock granted to certain executives of the Company in September 2013, July 2012 and July 2011, respectively, vest one-third on each of the first, second and third anniversaries of the grant. Options to purchase 2,000,000 shares of the Company's stock granted to the Chief Executive Officer of the Company in September 2013, vest 25% upon receipt of the grant and 25% on the first, second and third anniversary of the grant. All other options granted by the Company vest 25% on each of the second through fifth anniversaries of the grant.

The fair value of the stock options granted during the three and nine month periods ended September 30, 2013 and 2012 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Expected life (years)
5.4
 
5.5
 
5.4
 
5.5
Expected volatility
89.6%
 
92.4%
 
89.6
%
 
 
92.4%
Expected dividend yield
—%
 
—%
 
—%
 
—%
Risk-free interest rate
1.5%
 
0.7%
 
1.5%
 
0.7%
Weighted average fair value of options granted during the period
$0.34
 
$0.47
 
$0.34
 
$0.47

The following table summarizes stock option activity for the nine month period ended September 30, 2013:
 
 
Number of Shares
 
Weighted Average Exercise Price Per Share
 
Weighted Average remaining Contractual Life (years)
 
Aggregate Intrinsic Value (in thousands)
Outstanding balance at December 31, 2012
 
6,429,250

 
$
1.28

 
 
 
 
Granted
 
2,325,000

 
0.47

 
 
 
 
Exercised
 
(60,550
)
 
0.24

 
 
 
 
Expired
 
(1,016,950
)
 
2.67

 
 
 
 
Forfeited
 
(1,371,650
)
 
0.63

 
 
 
 
Outstanding balance at September 30, 2013
 
6,305,100

 
0.91

 
7.7
 
$4
Options exercisable at September 30, 2013
 
3,526,850

 
$
1.20

 
6.3
 
$4

The aggregate intrinsic value disclosed in the table above represents the difference between the Company's closing stock price on the last trading day of the quarter ended September 30, 2013 and the exercise price, multiplied by the number of in-the-money stock options.

7


Under the 2008 Plan, during the three and nine months ended September 30, 2013, an aggregate of 60,550 stock options valued at $0.24 were exercised. No stock options were exercised during the nine months ended September 30, 2012. Options for the purchase of an aggregate of 1,498,850 shares of common stock vested during the nine month period ended September 30, 2013, and the aggregate fair value at grant date of these options was $0.7 million. As of September 30, 2013, there was approximately $0.9 million of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighted average period of 2.5 years.
In July 2009, an aggregate of 500,000 shares of non-vested stock were granted under the 2008 Plan. The shares vest as follows: 25% after two years and 25% on each of the next three anniversary dates thereafter. As of September 30, 2013, an aggregate of 337,500 shares of such non-vested stock were forfeited and 150,000 were vested. In July 2011, an aggregate of 305,000 shares of non-vested stock were granted under the 2008 Plan. As of September 30, 2013, an aggregate of 112,500 shares of such non-vested stock were forfeited and 155,100 were vested. The shares vest as follows: 33% on each of the first and second anniversary dates and 34% on the third anniversary. As of September 30, 2013, there was approximately $0.03 million of total unrecognized compensation cost related to non-vested stock awards. The cost is expected to be recognized over a weighted average period of 0.8 years.
Employee Stock Purchase Plan - In February 2012, under the Stock Purchase Plan (2004) of Hooper Holmes, Inc. (the "2004 Plan"), purchase rights for approximately 273,000 shares of the Company's stock were granted to eligible participating employees with an aggregate grant date fair value of $0.05 million, based on the Black-Scholes pricing model. This offering period concluded in March 2013 and, in accordance with the 2004 Plan's automatic termination provision, no shares were issued. In February 2013, under the 2004 Plan, purchase rights for approximately 233,000 shares were granted with an aggregate fair value of $0.03 million, based on the Black-Scholes option pricing model. The February 2013 offering period will conclude in March 2014. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the Employee Stock Purchase Plan (2004), to be effective January 1, 2014 (as amended and restated, the "2014 Plan"). The aggregate number of shares of the Company's common stock available for purchase under the 2014 Plan is 2,000,000. Unless terminated earlier by the Board of Directors, the 2014 Plan will terminate December 31, 2024.
Other Stock Awards - On May 30, 2007, the Company's shareholders approved the Hooper Holmes, Inc. 2007 Non-Employee Director Restricted Stock Plan (the “2007 Plan”), which provides for the automatic grant, on an annual basis for 10 years, of shares of the Company's stock to the Company's non-employee directors. The total number of shares that may be awarded under the 2007 Plan is 600,000. As of September 30, 2013, there remain available for grant approximately 360,000 shares under the 2007 Plan. Effective June 1, 2007, each non-employee member of the Board of Directors other than the non-executive chair receives 5,000 shares annually and the non-executive chair receives 10,000 shares annually of the Company's stock, with such shares vesting immediately upon issuance. The Company believes that the shares awarded under the 2007 Plan are “restricted securities”, as defined in SEC Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"). The Company filed a Registration Statement on Form S-8 with respect to the 2007 Plan on April 16, 2008. The directors who receive shares under the 2007 Plan are "affiliates" as defined in Rule 144 under the Securities Act and thus remain subject to the applicable provisions of Rule 144. In addition, the terms of the awards (whether or not restricted) specify that the shares may not be sold or transferred by the recipient until the director ceases to serve on the Board or, if at that time the director has not served on the Board for at least four years, on the fourth anniversary of the date the director first became a Board member. During the nine months ended September 30, 2013 and 2012, shares awarded under the 2007 Plan totaled 30,000 and 30,000, respectively.

The Company recorded $0.4 million and $0.8 million of share-based compensation expense in selling, general and administrative expenses for the three and nine month periods ended September 30, 2013, respectively, and $0.2 million and $0.5 million for the three and nine month periods ended September 30, 2012, respectively, related to stock options, non-vested stock, restricted stock awards and the 2004 Plan. In connection with resignations of former members of management, the Company reversed previously recorded share-based compensation expense totaling $0.1 million and $0.2 million during the three and nine month periods ended September 30, 2013 and $0.0 million for the three and nine month periods ended September 30, 2012. The reversal was recorded in restructuring charges on the Company's consolidated statement of operations (See note 8).

Note 6: Discontinued Operations

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with its Portamedic service line, including, among other things, fixed assets and intellectual property, to Piston, and Piston assumed certain specified liabilities (the “Portamedic Disposition”). The adjusted purchase price (the "Purchase Price") was approximately $8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital, of which $2.0 million (the “Holdback Amount”) was held back by Piston as security for the Company’s obligations and agreements.


8


The Holdback Amount will be released as follows: within three business days after the date on which final closing adjustments for inventory and other current assets are determined and (the “Closeout Date”) (and after giving effect to any deductions from the Holdback Amount prior to such date), Piston will pay to the Company all amounts, if any, in excess of $1.0 million and the remaining $1.0 million of the Holdback Amount, less any deductions with respect to indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid to the Company on the first anniversary of the Closeout Date. There cannot be any assurance that the Holdback Amount will be collected by the Company in full however, management currently expects to realize the amount in full and has recorded receivables in other current assets and other assets totaling $2.0 million.

The Company decided to sell its underperforming Portamedic service line and shift its focus towards the growth of its remaining health care service lines. In connection with the sale of Portamedic, the Company received $6.1 million of cash proceeds and incurred $0.9 million of financial advisory, legal and accounting fees, as of September 30, 2013. The Portamedic sale provides the Company with capital to invest in its Health and Wellness and Heritage Lab service lines. In addition, the Company retains the Portamedic accounts receivable and accounts payable, giving the Company over $9.4 million of working capital at September 30, 2013 to utilize in supporting wellness programs, clinical research and government studies.
    
The following summarizes the operating results of Portamedic and the gain on sale of Portamedic which are reported in discontinued operations in the accompanying consolidated statements of operations:

 
Three Months Ended
Nine Months Ended
 
September 30
September 30
(in thousands)
2013
2012
2013
2012
Revenues
$
19,173

$
21,371

$
62,437

$
72,077

Loss from operations before income taxes
$
(1,958
)
$
(997
)
$
(4,709
)
$
(5,446
)
Gain on sale of Portamedic and subsidiary
$
3,543

$
—

$
3,618

65

Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than $0.1 million for each period
presented and there were no income taxes on the gain of the sale due to the availability of net operating loss carry forwards with a
full valuation allowance.

The assets and liabilities of Portamedic are presented separately under the captions “Assets held for sale” and “Liabilities held for sale,” respectively, in the accompanying consolidated balance sheet as of December 31, 2012 and consist of the following:

(in thousands)
December 31, 2012

Assets held for sale:
 
Inventories
941

Other current assets
400

Property, plant and equipment, net
2,080

Other assets
225

Total assets
$
3,646

 
 
Liabilities held for sale:
 
Deferred rent
104

Capital leases
116

Total liabilities
$
220


In June 2008, the Company sold substantially all of the assets and liabilities of its Claims Evaluation Division ("CED") operating segment. In connection with the sale of the CED, the Company released as the primary obligor for certain lease obligations acquired but remain secondarily liable in the event the buyer defaults. In September 2013, the Company reduced the reserve for this liability by $0.1 million and reported the corresponding gain in discontinued operations. At September 30, 2013, the Company maintained a liability of $0.1 million for this lease obligation. The guarantee is provided for the term of the lease, which expires in July 2015. As of September 30, 2013, the maximum potential amount of future payments under the guarantee is $0.1 million.

Note 7: Inventories

Included in inventories at September 30, 2013 and December 31, 2012 are $0.7 million and $0.4 million, respectively, of finished goods and $1.1 million and $0.9 million, respectively, of components.

9



Note 8: Restructuring Charges

During the three and nine month periods ended September 30, 2013, the Company recorded restructuring charges in continuing operations totaling $0.4 million and $0.7 million, respectively. The restructuring charges for the three month period ended September 30, 2013 consisted of severance related to the resignation of the former CFO and other employee severance. The restructuring charges for the nine month period ended September 30, 2013 consisted of severance related to the resignation of the former CEO and CFO and other employee severance.

During the three and nine month periods ended September 30, 2012, the Company recorded restructuring charges totaling $0.0 million and $0.4 million, respectively. The restructuring charges consisted of employee severance.

At September 30, 2013, $1.7 million related to restructuring charges are recorded in accrued expenses and $0.1 million are recorded as other long-term liabilities in the accompanying consolidated balance sheet. These amounts include $1.2 million related to Portamedic that have been retained by the Company after the sale of Portamedic. These accruals include severance and branch closure expenses.

Note 9: Loan and Security Agreement
    
2013 Loan and Security Agreement
  
As of February 28, 2013, in conjunction with the Company entering into the 2013 Loan and Security Agreement, the Company terminated the 2009 Loan and Security Agreement with TD Bank, N.A. During the three and nine months ended September 30, 2013, in connection with the 2013 Loan and Security Agreement, the Company incurred unused line fees of $0.04 million and $0.08 million respectively. During the three and nine months ended September 30, 2012 in connection with the 2009 Loan and Security Agreement, the Company incurred unused line fees of $0.00 million and $0.02 million, respectively.

Proceeds from the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any time outstanding which does not exceed 85% of “Eligible Receivables” (as defined in the 2013 Loan and Security Agreement) less any reserves established by Keltic Financial, provided that in no event can the aggregate amount of the revolving credit loans at any time exceed $10 million. Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, unbilled Portamedic and Health & Wellness receivables, and other receivables deemed ineligible by Keltic Financial.

As of September 30, 2013 there were $2.6 million in borrowings outstanding under our 2013 Loan and Security Agreement, and the Company's available borrowing capacity was $0.04 million based on September 30, 2013 Eligible Receivables and a $0.8 million reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation method and timeline, available borrowing capacity increased to approximately $6.0 million by October 4, 2013 and the reserve established by Keltic Financial was increased back to $1.5 million from a temporary reduction to increase available borrowing at the end of September 2013.
    
As of March 28, 2013, the Company entered into the First Amendment to the 2013 Loan and Security Agreement. Under the First Amendment, the annual facility fee increased to 1.5% from 1.0% of the revolving credit limit of $10 million; the monthly collateral management fee increased to $2,500 per month from $1,500 per month; and the monthly collateral management fee increased to $5,000 per month from $3,000 per month if there is an occurrence or event of default. In addition, the early termination fee changed a) if prior to the first anniversary of the effective date, from 3% to 5% of the revolving credit limit; b) if after the first anniversary but before the second anniversary of the effective date, from 2% to 3% of the revolving credit; and c) if after the second anniversary but prior to the third anniversary of the effective date, from 1% to 2% of the revolving credit limit. In regard to the financial covenants, the first EBITDA measurement date changed from the six months ended June 30, 2013 to the twelve months ending June 30, 2014. The Company paid an amendment fee of $0.2 million.
    
    

10


Interest on revolving credit loans is calculated based on the greatest of (i) the annualized prime rate plus 2.75%, (ii) the 90 day LIBOR rate plus 5.25%, and (iii) 6% per annum. In connection with the 2013 Loan and Security Agreement, the Company incurred a commitment fee of $0.1 million and other issue costs totaling $0.7 million. During the three and nine months ended September 30, 2013, in connection with the 2013 Loan and Security Agreement the Company incurred $0.04 million and $0.1 million in facility fees, respectively.

The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans, however the Company would be required to pay an early termination fee as noted above.

As security for the Company's payment and other obligations under the 2013 Loan and Security Agreement, the Company granted Keltic Financial a security interest in all existing and after-acquired property of the Company and its subsidiary guarantors, including its receivables (which are subject to a lockbox account arrangement), inventory, equipment and corporate headquarters.  The aforementioned security interest is collectively referred to herein as the “collateral”. In addition, in connection with entering into the First Amendment to the 2013 Loan and Security Agreement as March 28, 2013, the Company granted to the lender a mortgage of the Company's headquarters building as additional security.

Pursuant to the terms of the 2013 Loan and Security Agreement, Keltic Financial may establish one or more reserves at its reasonable discretion and, at its sole discretion, may establish reserves with respect to (a) any event which in Keltic Financial's reasonable determination, diminishes the value of any collateral or (b) any contingent liability of the Company. A reserve may reduce the aggregate amount of indebtedness that may be incurred under the 2013 Loan and Security Agreement.
        
The 2013 Loan and Security Agreement contains covenants that, among other things, restrict the Company's ability, and that of its subsidiaries, to:

•
pay any dividends or distributions on, or redeem or retire any shares of any class of its capital stock or other equity interests;

•
incur additional indebtedness or otherwise become liable for the indebtedness, except for transactions in the ordinary course of business;

•
permit a change of control of the board of directors and certain senior management positions of the Company without prior consent of Keltic Financial;

•
sell or otherwise dispose of any of the Company's assets, other than in the ordinary course of business;

•
create liens or encumbrances on the Company's assets; and

•
enter into transactions with any of its affiliates on other than an arm's-length or no less favorable basis.

Keltic Financial consented to the change in CEO and CFO that occurred during 2013 as well as the sale of Portamedic. There were no waiver or amendment fees paid or associated with these consents.

The 2013 Loan and Security Agreement also contains financial covenants, which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) with the twelve months ending June 30, 2014, as amended, as the first measurement date. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013.
    
The failure of the Company or any subsidiary guarantor to comply with any of the covenants or the breach of any of its or their representations and warranties, contained in the 2013 Loan and Security Agreement, constitutes an event of default under the agreement. In addition, the 2013 Loan and Security Agreement provides that "Events of Default" include the occurrence or failure of any event or condition that, in Keltic Financial's sole judgment, could have a material adverse effect (i) on the business, operations, assets, management, liabilities or condition of the Company, (ii) in the value, collectability or salability of the collateral, or (iii) on the ability of the Company and its subsidiary guarantors to perform under the 2013 Loan and Security Agreement.
    


11


Note 10: Commitments and Contingencies

The Company has employment retention or change in control agreements with certain executive officers that provide, in defined circumstances, for the payment of severance payments of 12 months base compensation, among other things.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. The Asset Purchase Agreement also provides, among other things, that (1) if Piston incurs any losses relating to any governmental inquiry received by Piston or the Company within 18 months of the closing date, the Company will pay up to $100,000 for one half of such losses, (2) if Piston elects to pursue, prosecute, defend, settle, compromise, appeal or take other actions with respect to certain matters relating to matters disclosed by the Company to Piston pre-closing (“Pre-Closing Matters”), the Company will cooperate with Piston (including joining in any legal proceeding related to such matters) and pay up to $100,000 for one half of all losses in connection with such matters, and (3) Piston or its designees will make required payments for rents, charges, maintenance fees and all utility services to the Company associated with Piston’s or such designee’s occupancy of each premises that is the subject of a Company lease to be assumed by Piston or its designees, but the assignment of which was not completed by closing, until such time as the lease is duly assigned (or otherwise superseded by an agreement between Piston and the applicable landlord). The Company has agreed to bear all liability relating to the occupancy arrangements until they are transferred to Piston. With respect to Pre-Closing Matters, the Company also agreed that in the event Piston elects to pursue a claim relating to a Pre-Closing Matter and desires to add the Company as a plaintiff, Piston and the Company will cooperate to select counsel and to jointly prosecute such claim, but Piston will control such claim.

On July 11, 2003, the Company received a determination from the Internal Revenue Service that one individual the Company contracted with as an independent contractor should have been classified as an employee in 2002. This ruling also applied to any other individuals engaged by the Company under similar circumstances. The ruling stated that the Company may not be subject to adverse consequences as the Company may be entitled to relief under applicable tax laws (Section 530 of the Revenue Act of 1978). Management believes that the Company qualifies for relief under Section 530. To date, the Company has not received any further communication from the Internal Revenue Service.

In the past, some state agencies have claimed that the Company improperly classified its health professionals as independent contractors for purposes of state unemployment and/or worker's compensation tax laws and that the Company was therefore liable for taxes in arrears, or for penalties for failure to comply with their interpretation of the laws.  There are no assurances that the Company will not be subject to similar claims in other states in the future.
    
Note 11: Litigation

With respect to the complaint filed against the Company in U.S. District Court for the District of New Jersey on May 24, 2012 alleging that the Company failed to pay overtime compensation to a purported class of certain independent contractor examiners, preliminary motion practice and discovery is continuing. The Company has denied all of the allegations in the case and believes them to be without merit.

The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company’s liquidity, its consolidated results of operations or its consolidated financial position.

Note 12: Income Taxes

The Company recorded tax expense of less than $0.01 million and $0.01 million in continuing operations for the three and nine month periods ended September 30, 2013, respectively, reflecting a state tax liability to one state. For the three and nine month periods ended September 30, 2012, the Company recorded tax expense of less than $0.01 million and $0.01 million, respectively, reflecting a state tax liability to one state. No amounts were recorded for unrecognized tax benefits or for the payment of interest and penalties during the three and nine month periods ended September 30, 2013 and 2012. No federal or state tax benefits were recorded relating to the current year loss, as the Company continues to believe that a full valuation allowance is required on its net deferred tax assets.
In July 2008, the Company received notification from the Internal Revenue Service that it had completed its audits of the Company's tax returns for the years 2001 through 2006 with no adjustments. An examination of the Company's 2011 federal income tax return is currently underway. State income tax returns for the year 2008 and forward are subject to examination.


12


As of September 30, 2013, the Company has U.S. federal and state net operating loss carryforwards in excess of $100 million each. The net operating loss carryforwards, if unutilized, will expire in the years 2013 through 2033.

ITEM 2
Management's Discussion and Analysis of Financial Condition and Results of Operations

In this Report, the terms “Hooper Holmes,” “Company,” “we,” “us” and “our” refer to Hooper Holmes, Inc. and its subsidiaries.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including, but not limited to, statements about our plans, strategies and prospects. When used in this Report, the words “expects,” “anticipates,” “believes,” “estimates,” “plans,” “intends,” “could,” “will,” “may” and similar expressions are intended to identify forward-looking statements.  These are statements that relate to future periods and include statements as to our operating results, revenues, sources of revenues, cost of revenues, gross margins, operating and net profits/losses, changes in certain service line offerings and strategic focus.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expected. These risks and uncertainties include, but are not limited to, risks related to customer concerns about our financial health, our liquidity and ability to comply with financial covenants in our Loan and Security Agreement, declines in our business, our competition, and our ability to successfully implement cost reduction and strategic initiatives. The section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, entitled “Risk Factors” and similar discussions in our other filings with the Securities and Exchange Commission (“SEC”) discuss these and other important risks that may affect our business, results of operations, cash flows and financial condition. Investors should consider these factors before deciding to make or maintain an investment in our securities. The forward-looking statements included in this Report are based on information available to us as of the date of this Report. We expressly disclaim any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

Overview

Our Company was founded in 1899. We are a publicly-traded New York corporation whose shares of common stock (HH) are listed on the NYSE MKT Stock Exchange.  Our corporate headquarters are located in Basking Ridge, New Jersey. Over the last 40 years, our business focus has been on providing health risk assessment services.

Hooper Holmes is currently engaged in the following service lines:  

•
Health & Wellness – mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions;

•
Heritage Labs – performs tests of blood, urine and oral fluid specimens, primarily in connection with life insurance exams and wellness screenings performed by our Health & Wellness service line, and assembles and sells specimen collection kits; and

•
Hooper Holmes Services – provides telephone interviews of insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.

As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles.

    
    

13


On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the assets and liabilities of Portamedic that were sold have been reclassified and are reported as assets and liabilities held for sale on the December 31, 2012 consolidated balance sheet. The operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Certain costs presented within continuing operations in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among service lines and the continuing operations have been and are being restructured. There is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated in future periods. For the three and nine month periods ended September 30, 2013 and 2012 Portamedic services accounted for 66% and 67%, 68% and 70%, respectively of the Company's total revenue.

As a result of the sale of the Portamedic service line we will re-evaluate segment reporting in the fourth quarter of 2013 based on any changes in the discrete financial information that the Chief Operating Decision Maker, as required by ASC 280, receives in that period, We will determine whether the Company continues to have one reportable segment or more than one reportable segment in accordance with ASC 280.

In the fourth quarter of 2013, the Company began relocating our headquarters to Kansas. At this time we cannot determine with reasonable certainty whether the relocation or potential restructuring initiatives associated with the relocation may have a material positive, negative or any impact in the aggregate on our future performance.

Sale of Portamedic

On August 15, 2013, the Company entered into a definitive agreement (“Asset Purchase Agreement”) to sell its Portamedic brand and other assets comprising the Company's Portamedic service line to American Para Professional Systems, Inc. (“APPS”, “Piston Acquisition, Inc.”, and/or “Piston”) for $8.4 million in cash, subject to adjustments.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with its Portamedic service line, including, among other things, fixed assets and intellectual property, to Piston, and Piston assumed certain specified liabilities (the “Portamedic Disposition”). The adjusted purchase price (the "Purchase Price") was approximately$8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital, of which $2.0 million (the “Holdback Amount”) was held back by Piston as security for the Company’s obligations and agreements under the Asset Purchase Agreement and certain other agreements between the Company and Piston.

The Holdback Amount will be released as follows: within three business days after the date on which final closing adjustments for inventory and other current assets are determined (the “Closeout Date”) (and after giving effect to any deductions from the Holdback Amount prior to such date), Piston will pay to the Company all amounts, if any, in excess of $1.0 million and the remaining $1.0 million of the Holdback Amount, less any deductions with respect to indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid to the Company on the first anniversary of the Closeout Date. There cannot be any assurance that the Holdback Amount will be collected by the Company in full, however management currently expects to realize the amount in full and has recorded receivables in other current assets and other assets totaling $2.0 million.

Strategic Rationale

By selling its underperforming Portamedic business, the Company is creating a streamlined health care company positioned to capitalize on growing healthcare trends. The Company’s focus has shifted from turning around Portamedic to growth in our health care related service lines. Our continuing operations include the Company's Health and Wellness service line, which provides biometric screenings for national wellness and disease management companies, employers and government customers, and Heritage Labs International, Inc., the Company's clinical reference laboratory located in Olathe, KS. Heritage Labs will continue to support the life insurance market through its lab business with carriers. The Company also retains its outsourced underwriting and other non-paramedical exam insurance services operations in Lenexa, KS and Omaha, NE.

The Portamedic sale provides the Company with capital to invest in our Health and Wellness and Heritage Lab service lines. In addition, the Company retains the Portamedic accounts receivable and accounts payable, giving the Company over $9.4 million of working capital at September 30, 2013 to utilize in supporting wellness programs, clinical research and government studies.


14


The overall market for our wellness services is growing and is expected to continue to grow with the increased focus nationally on healthcare initiatives. According to the 2013 Towers Watson - National Business Group on Health Employer Survey, more employers are considering offering financial rewards to encourage participation by employees and spouses in health management programs.

Further, under the wellness rules for the Affordable Care Act that will take effect in January 2014, companies are permitted to offer a reward of up to 30 percent of health costs for employees who complete a participatory program like a risk assessment, or biometric tests like waist measurement. According to the 2013 RAND Workplace Wellness Program Study, about half of all employers with 50 or more employees already offer wellness programs, and almost half of employers with a wellness program conduct biometric screenings such as those provided by the Company.
 
Highlights for the Three and Nine Month Periods Ended September 30, 2013

Continuing Operations Financial Results for the Three Month Period Ended September 30, 2013

For the three month period ended September 30, 2013, consolidated revenues from continuing operations totaled $11.0 million, a 10.6% decline from the corresponding prior year period. Our gross profit from continuing operations totaled $2.3 million for the three month period ended September 30, 2013 versus $3.5 million in the comparable period of the prior year. Our gross profit percentage from continuing operations was 20.6% for the three month period ended September 30, 2013, representing a decline from the gross profit percentage of 28.8% for the three month period ended September 30, 2012, primarily attributable to a decrease in revenue from one of our Health and Wellness customers, increases in event management labor and travel costs for field specialists and examiners and a decrease in revenue from the Company's life insurance lab testing services.

SG&A expenses from continuing operations were $5.0 million in the three month period ended September 30, 2013, an increase of $0.3 million, or 7.5%, in comparison to the three month period ended September 30, 2012 due in large part to increases in professional and consulting expenses. During the three month periods ended September 30, 2013 and 2012, restructuring charges totaled $0.4 million and $0.0 million, respectively, primarily consisting of employee severance costs.

Our operating loss from continuing operations for the three month period ended September 30, 2013 was $3.1 million compared to a $1.1 million loss for the comparable prior year period.

For the three month period ended September 30, 2013, we incurred a loss from continuing operations of $3.3 million, or $0.05 per share on both a basic and diluted basis, compared to loss from continuing operations of $1.2 million, or $0.03 per share on both a basic and diluted basis, for the comparable prior year period.

Discontinued Operations Financial Results for the Three Month Period Ended September 30, 2013

For the three month period ended September 30, 2013, we recognized income from discontinued operations of $1.6 million or $0.02 per share on both a basic and diluted basis, compared to loss from discontinued operations of $1.0 million or $0.01 per share on both a basic and diluted basis, for the comparable prior year period. Included in the operations from discontinued operations is a gain on sale of $3.5 million.
    
Continuing Operations Financial Results for the Nine Month Period Ended September 30, 2013

For the nine month period ended September 30, 2013, consolidated revenues from continuing operations totaled $34.2 million, a 4.5% decline from the corresponding prior year period. Our gross profit from continuing operations totaled $8.5 million for the nine month period ended September 30, 2013 versus $10.3 million in the comparable period of the prior year. Our gross profit percentage from continuing operations was 24.9% for the nine month period ended September 30, 2013, representing a decline from the gross profit percentage of 28.7% for the nine month period ended September 30, 2012, primarily attributable to a decrease in revenue from one of our Health and Wellness customers and a decrease in revenue from the Company's life insurance lab testing services.

SG&A expenses from continuing operations were $15.4 million in the nine month period ended September 30, 2013, an increase of $0.3 million, or 2.1%, in comparison to the nine month period ended September 30, 2012 due in large part to increases in professional and consulting expenses. During the nine month periods ended September 30, 2013 and 2012, restructuring charges totaled $0.7 million and $0.4 million, respectively, primarily consisting of employee severance costs.


15


Our operating loss from continuing operations for the nine month period ended September 30, 2013 was $7.7 million compared to a $5.2 million loss for the comparable prior year period.

For the nine month period ended September 30, 2013, we incurred a loss from continuing operations of $8.2 million, or $0.12 per share on both a basic and diluted basis, compared to a loss of $5.5 million, or $0.08 per share on both a basic and diluted basis, for the comparable prior year period.

Discontinued Operations Financial Results for the Nine Month Period Ended September 30, 2013

For the nine month period ended September 30, 2013, we incurred a loss from discontinued operations of $1.1 million or $0.02 per share on both a basic and diluted basis, compared to loss from discontinued operations of $5.4 million, or $0.08 per share on both a basic and diluted basis, for the comparable prior year period. Included in the loss from discontinued operations is a gain on sale of $3.6 million.

Health & Wellness

Health & Wellness revenues in the third quarter of 2013 were $5.0 million, a decrease of $0.3 million, or 5.5%, from the prior year period, reflecting lower volumes from one customer, as it made changes in its business which reduced demand. For the first nine months of 2013, Health & Wellness revenues were $14.2 million, representing a 7.6% increase from the prior year period. In the third quarter of 2013, Health & Wellness performed approximately 89,000 health screenings, compared to 102,000 health screenings in the prior year period. This 13% unit decline was partially offset by an increase in average unit price. We have conducted screening events in every state in the U.S. as well as the District of Columbia and Puerto Rico. To date, we have certified approximately 3,300 of the examiners in our network to be “wellness certified” examiners.

Health & Wellness services include event scheduling, provision and fulfillment of all supplies (such as sample collection kits, blood pressure cuffs, stadiometers, scales, centrifuges and lab coats) at screening events, professional event management, biometric screenings (height, weight, body mass index, hip, waist and neck measurements, pulse, blood pressure), blood draws via venipuncture or finger stick, lab testing, participant and aggregate data reporting, data processing and data transmission. Heritage Labs does all of the testing on the venipuncture samples we collect at health and wellness screenings.

We believe the market for health and wellness is likely to grow over the next three to five years, and that we are well positioned to increase revenues from our biometric screening and other related services. Several recent milestones include:

•
Reorganized operations in client focused teams to both schedule and manage events, providing a single point of contact for event quality;

•
Appointed 60 field Examiner Specialists to mentor local health professionals;

•
Dedicated an in-house recruiting team to add new health professionals to our nationwide network;

•
Created new, hands-on training facility in Olathe, KS; and

•
Developed new training programs to certify new health professionals more efficiently and effectively.

We believe that we are well-positioned to capture a significant share of the health and care management market given our Company’s unique set of assets, including Heritage Labs, our proprietary Health & Wellness IT system, and our network of certified health professionals.   However, the success of Health & Wellness will also depend in part upon the success of our sponsors and the results their health and care management programs demonstrate to their employer clients.

Heritage Labs

Heritage Labs services consist principally of performing tests of blood, urine and oral fluid specimens and the assembly and sale of kits used in the collection and transportation of such specimens. Heritage Labs revenues in the third quarter of 2013 were $2.6 million, a decrease of 15.8% as compared to the prior year period due to decreased revenue from both lab testing and kit assembly. In the third quarter of 2013, approximately 61% of Heritage Labs revenue came from lab testing and 39% came from the sale of specimen kits.


16


Hooper Holmes Services

Hooper Holmes Services revenues for the third quarter 2013 were $3.4 million, a decrease of 13.4% in comparison to the prior year period. The three main sources of Hooper Holmes Services revenue are Health Information Services, including the collection of attending physicians’ statements (APS), disease state profiles provided by the Company’s Physicians Information Line or PIL service, Consumer Services such as tele-interviewing or tele-underwriting, and Health Risk Analytics, which includes outsourced underwriting services.

Health Information Services revenues totaled $0.6 million in the third quarter of 2013, a decrease of 24.2% in comparison with the prior year period. This decrease in revenue is primarily due to a decline in the number of APS/PIL units performed compared to the prior year period, along with 3.2% decrease in the average price per APS/PIL unit over the same comparable periods. Revenues from Consumer Services totaled $1.4 million in the third quarter of 2013, a decline of 5.5% as compared to the prior year period. Third quarter 2013 revenue from Health Risk Analytics totaled $1.0 million an increase of 11.7% compared to the prior year period.

Key Financial and Other Metrics Monitored by Management

In our periodic reports filed with the SEC we provide certain financial information and measurements of our service lines used by management in evaluating our performance and financial condition. Our objective in providing this information is to help our shareholders understand our overall performance and assess the profitability of our service lines and prospects for future net cash flows.

In the third quarter of 2013, we tracked:

•
the number of health screenings completed by Health & Wellness;

•
the number of tele-interviewing/underwriting reports we generate;

•
the number of specimens tested by Heritage Labs;

•
the average revenue per specimen tested;

•
budget to actual performance at the service line level as well as in the aggregate; and

•
customer and product line margins.

Certain of the above-cited metrics are discussed in the comparative discussion and analysis of our results of operations that follows.


Results of Continuing Operations    
    
Comparative Discussion and Analysis of Results of Continuing Operations for the three and nine month periods ended September 30, 2013 and 2012


17


Revenues from Continuing Operations

The table below sets forth our revenue by service line for the periods indicated. For the three and nine month periods ended September 30, 2012 revenues previously reported as part of Portamedic totaling $0.9 million and $2.2 million, respectively, have been reclassified to Hooper Holmes Services to conform with current period presentation. This results from a change in data reporting methodology for revenue and costs associated with certain services performed by Hooper Holmes Services.
        
 
 
 (in thousands)
 
For the Three Months Ended September 30,
 
For the Nine Months Ended September 30,
 
 
2013
 
2012
 
% Change
 
2013
 
2012
 
% Change
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health & Wellness
 
4,989

 
5,280

 
(5.5
)%
 
14,196

 
13,191

 
7.6
 %
 
Hooper Holmes Services
 
3,427

 
3,957

 
(13.4
)%
 
11,374

 
12,543

 
(9.3
)%
 
Heritage Labs
 
2,577

 
3,062

 
(15.8
)%
 
8,623

 
10,052

 
(14.2
)%
 
   Total
 
$
10,993

 
$
12,299

 
(10.6
)%
 
$
34,193

 
$
35,786

 
(4.5
)%

Heritage Labs sales amounts include sales to Portamedic

Consolidated revenues from continuing operations for the three month period ended September 30, 2013 were $11.0 million, a decline of $1.3 million, or 10.6%, from the prior year period. For the nine month period ended September 30, 2013, our consolidated revenues from continuing operations were $34.2 million compared to $35.8 million in the corresponding period of the prior year, a decline of $1.6 million, or 4.5%.

Health & Wellness

Health & Wellness revenues in the third quarter of 2013 were $5.0 million, a decrease of $0.3 million, or 5.5%, compared to $5.3 million in the prior year period. This performance reflects lower volumes from one customer, as it made changes in its business which reduced demand. For the nine month period ended September 30, 2013, revenue increased to $14.2 million or 7.6% compared to $13.2 million for the same period in the prior year.

Our revenue decrease in the three month period ended September 30, 2013, as compared to the prior year period, is primarily due to a decreased number of screenings partially offset by a higher average price per unit. Our revenue increase in the nine month period ended September 30, 2013, as compared to the prior period, is primarily due to an increased number of screenings at a higher average unit price. Health & Wellness performed 12.7% fewer health screenings in the third quarter of 2013 compared to the third quarter of 2012 (89,000 in third quarter of 2013 vs. 102,000 in third quarter of 2012), and 4.5% more health screenings during the nine month period ended September 30, 2013 compared to the same period in 2012 (258,000 in the nine months ended September 30, 2013 vs. 247,000 in the nine months ended September 30, 2012).  

Hooper Holmes Services

Hooper Holmes Services revenues for the third quarter of 2013 were $3.4 million, a decrease of 13.4% from the prior year period. For the nine month periods ended September 30, 2013 and 2012, revenues totaled $11.4 million and $12.5 million, respectively.

Health Information Services revenue declined 25.5% in the third quarter of 2013 compared to the prior year period, and decreased 14.8% for the nine months ended September 30, 2013 as compared to the prior year period. Revenue from our APS retrieval and PIL decreased 31.4% in the third quarter of 2013 compared to the prior year period primarily due to a decrease in the number of APS/PIL units performed during the third quarter combined with a lower average price as compared to the prior year period. For the nine month period ended September 30, 2013, revenue from our APS retrieval and PIL declined 17.8% in comparison to the prior year period primarily due to a decrease in the number of APS/PIL units performed during the third quarter combined with a lower average price as compared to the prior year period. Inspection and Motor Vehicle Report ("MVR") reporting revenue decreased 4.1% in the third quarter of 2013 compared to the prior year period. For the nine month period ended September 30, 2013, Inspection and MVR reporting revenue declined 3.4% as compared to the prior year period.


18


Consumer Services includes our tele-underwriting/interviewing services. Revenues from Consumer Services for the third quarter of 2013 decreased 8.3% as compared to the prior year period. The decrease in revenue is primarily due to a decline in the number of tele-underwriting/interviewing units completed of 6.6% combined with a 1.9% decline in the average price per unit in the third quarter 2013 as compared to the prior year period. For the nine month period ended September 30, 2013 revenues decreased 8.5% as compared to the prior year period. The decrease in revenue is primarily due to a decline in the number of tele-underwriting/interviewing units completed offset, to some extent, by an increase in the average price per unit in the nine month period ended September 30, 2013 as compared to the prior year period.

Health Risk Analytics includes our risk management and underwriting services. Revenues increased 11.7% in the third quarter of 2013 compared to the prior year period. For the nine month period ended September 30, 2013 revenues increased 5.7% compared to the prior year period.

Heritage Labs

Heritage Labs revenues in the third quarter of 2013 were $2.6 million, a decrease of $0.5 million, or 15.8%, compared to the prior year period. For the nine month period ended September 30, 2013, revenue decreased to $8.6 million compared to $10.1 million for the same period of the prior year, or 14.2%.

During the third quarter of 2013, revenue from lab testing (approximately 61% of total Heritage Labs revenue in the third quarter of 2013) decreased 14.4% in comparison to the prior year period. For the nine month period ended September 30, 2013, revenue from lab testing decreased 12.9% in comparison to the prior year period. Heritage Labs tested 14.0% fewer specimens in the third quarter of 2013 compared to the prior year period (92,000 in the third quarter of 2013 vs. 107,000 in the third quarter of 2012), and 12.5% fewer specimens in the first nine months of 2013 compared to the same period in 2012 (309,000 in the nine months ended September 30, 2013 vs. 353,000 in the nine months ended September 30, 2012). These declines are due in large part to a decrease in demand for the Company's life insurance lab testing services and the loss of some life insurance customers. Heritage Labs average revenue per specimen tested decreased in the third quarter of 2013 compared to the prior year period ($17.02 in the third quarter of 2013 vs. $17.26 in the third quarter of 2012). Average revenue per specimen decreased in the first nine months of 2013 compared to the same period in 2012 ($16.73 in the nine month period ended September 30, 2013 vs. $16.92 in the nine month period ended September 30, 2012) primarily due to a decrease in average service price, partially offset by an increase in shipping costs passed on to our customers.

During the third quarter of 2013, revenue from lab kit assembly (approximately 39% of Heritage Labs revenue in the third quarter of 2013) decreased 18.1% as compared to the prior year period. For the nine month period ended September 30, 2013, revenue from lab kit assembly decreased to $3.4 million, or 16.2%, as compared to the prior year period.

Cost of Operations

For the three and nine month periods ended September 30, 2012 costs previously reported as part of Portamedic totaling $0.8 million and $2.2 million, respectively, have been reclassified to Hooper Holmes Services to conform with current period presentation. This results from a change in data reporting methodology for revenue and costs associated with certain services performed by Hooper Holmes Services.

Consolidated cost of continuing operations was $8.7 million for the third quarter of 2013, compared to $8.8 million for the prior year period. For the nine months ended September 30, 2013, cost of continuing operations was $25.7 million compared to $25.5 million for the nine months ended September 30, 2012. The following table shows cost of operations as a percentage of revenues broken down by service line.

(in thousands)
 
For the Three Months Ended September 30,
 
For the Nine Months Ended September 30,
 
 
2013
 
As a % of
Revenues
 
2012
 
As a % of
Revenues
 
2013
 
As a % of
Revenues
 
2012
 
As a % of
Revenues
Health & Wellness
 
$
4,208

 
84.3
%
 
$
3,600

 
68.2
%
 
$
10,679

 
75.2
%
 
$
8,936

 
67.7
%
Hooper Holmes Services
 
3,001

 
87.6
%
 
3,402

 
86.0
%
 
9,820

 
86.3
%
 
10,873

 
86.7
%
Heritage Labs
 
1,521

 
59.0
%
 
1,760

 
57.5
%
 
5,164

 
59.9
%
 
5,720

 
56.9
%
     Total
 
$
8,730

 
79.4
%
 
$
8,762

 
71.2
%
 
$
25,663

 
75.1
%
 
$
25,529

 
71.3
%

Heritage Labs costs include costs related to sales to Portamedic

19



Cost of continuing operations, as a percentage of revenue, increased to 79.4% and 75.1% for the three and nine month periods ended September 30, 2013, respectively, compared to the comparable prior year period.

Health & Wellness cost of operations increased as a percentage of revenues to 84.3% and 75.2% for the three and nine months ended September 30, 2013, respectively, as compared to the prior year periods. The increases are primarily due to increases in the cost of materials, event and field management labor and travel costs for field specialists and examiners.

Hooper Holmes Services cost of operations increased and decreased, respectively, as a percentage of revenues to 87.6% and 86.3% for the three and nine month periods ended September 30, 2013, compared to the prior year period. The increase in the third quarter of 2013 is primarily attributable to increased labor requirements of certain services.
    
Heritage Labs cost of operations increased as a percentage of revenues to 59.0% and 59.9% for the three and nine months ended September 30, 2013, respectively, as compared to the prior year period. The increase is primarily attributable to the effect of reduced revenues against the fixed costs needed to provide these services.

Selling, General and Administrative Expenses from Continuing Operations

(in thousands)
 
For the Three Months Ended September 30,
 
Increase
 
For the Nine Months Ended September 30,
 
Increase
 
 
2013
 
2012
 
2013 vs. 2012
 
2013
 
2012
 
2013 vs. 2012
Selling, general and administrative expenses
 
$
5,002

 
$
4,655

 
$
347

 
$
15,372

 
$
15,054

 
$
318


    
In the fourth quarter of 2013, the Company began relocating our headquarters to Kansas. As the Company continues to explore cost-reduction and strategic options in the future, the expenses shown here may not be indicative of costs going forward. Historically, certain functions have been shared among all of our service lines, including Portamedic and our continuing operations. There is no guarantee that costs allocated to Portamedic and included in discontinued operations for the three and nine month periods ended September 30, 2013 and 2012 will be eliminated in future periods.

Consolidated SG&A expenses from continuing operations for the three month period ended September 30, 2013 increased $0.3 million compared to the prior year period. The increase is primarily attributable to increases of:

•
Outside legal fees and Board of Director fees totaling $0.2 million;
•
Executive consulting services and expenses totaling $0.3 million, and
•
Stock compensation and bonuses totaling $0.3 million.
    
These increases in SG&A were partially offset by decreases of:

•
Reduced health insurance costs totaling $0.1 million;
•
Executive salaries and expenses totaling $0.1 million;
•
Business license fees and use taxes totaling $0.1 million;
•
Paid time off (PTO) expense totaling $0.1 million, and
•
Heritage Labs management fees totaling $0.1 million.

Consolidated SG&A expenses from continuing operations for the nine month period ended September 30, 2013 increased $0.3 million compared to the prior year period. The increase is primarily attributable to increases of:

•
Executive consulting services and expenses totaling $1.0 million;
•
Outside legal fees and Board of Director fees totaling $0.4 million;
•
Workers Compensation insurance totaling $0.2 million, and
•
Stock compensation and bonuses totaling $0.1 million.

These increases in SG&A were partially offset by decreases of:

•
Reduced health insurance costs totaling $0.5 million;
•
Heritage Labs management fees totaling $0.3 million

20


•
Executive salaries and expenses totaling $0.2 million;
•
Paid time off (PTO) expense totaling $0.2 million;
•
Business license fees and use taxes totaling $0.1 million, and
•
Reduced payroll taxes totaling $0.1 million
  
Restructuring

During the three and nine month periods ended September 30, 2013, the Company recorded restructuring charges totaling $0.4 million and $0.7 million, respectively. The restructuring charges for the three month period ended September 30, 2013 consisted of employee severance related to the resignation of the former CFO and other employee severance. For the nine month period ended September 30, 2013 restructuring charges consisted of severance related to the resignation of the former CEO and CFO and other employee severance.

During the three and nine month periods ended September 30, 2012, the Company recorded restructuring charges totaling $0.0 million and $0.4 million, respectively. The restructuring charges consisted of employee severance.

At September 30, 2013, $1.7 million related to restructuring charges are recorded in accrued expenses and $0.1 million are recorded as other long-term liabilities in the accompanying consolidated balance sheet. These amounts include $1.2 million related to Portamedic that have been retained by the Company after the sale of Portamedic. These accruals include severance and branch closure expenses.

Operating Loss

Our consolidated operating loss for the three month period ended September 30, 2013 was $3.1 million, compared to a consolidated operating loss for the three month period ended September 30, 2012 of $1.1 million. For the nine month period ended September 30, 2013, our consolidated operating loss from continuing operations was $7.7 million, compared to a consolidated operating loss from continuing operations for the nine month period ended September 30, 2012 of $5.2 million.

Other Expense
        
Other expense, net for the three and nine month periods ended September 30, 2013 was $0.1 million and $0.3 million, respectively. Other expense, net for the three and nine month periods ended September 30, 2012 was $0.1 million and $0.2 million, respectively. These 2013 and 2012 charges consisted primarily of bank credit facility fees and amortization of deferred financing costs.

Income Taxes

We recorded a net tax expense of less than $0.01 million and $0.01 million for the three and nine month periods ended September 30, 2013, respectively. For the three and nine month periods ended September 30, 2012, we recorded a net tax expense of less than $0.01 million and $0.01 million, respectively. These 2012 and 2013 charges reflect certain state tax liabilities. No federal or state tax benefits were recorded relating to the current or prior year loss, as we continue to believe that a full valuation allowance is required on our net deferred tax assets.
    
Loss from Continuing Operations

Loss from continuing operations for the three month period ended September 30, 2013 was $3.3 million, or $0.05 per share on both a basic and diluted basis, compared to a net loss of $1.2 million, or $0.02 per share on both a basic and diluted basis, in the same period of the prior year. Loss from continuing operations for the nine month period ended September 30, 2013 was $8.2 million, or $0.12 per share on both a basic and diluted basis, compared to a net loss of $5.5 million, or $0.08 per share on both a basic and diluted basis, in the same period of the prior year.

Discontinued Operations
    
In connection with the sale of Portamedic, the Company received $6.1 million of cash proceeds and incurred $0.9 million of financial advisory, legal and accounting fees, as of September 30, 2013. The Portamedic sale provides the Company with capital to invest in our Health and Wellness and Heritage Lab service lines. In addition, the Company retains the Portamedic accounts receivable and accounts payable, giving the Company over $9.4 million of working capital at September 30, 2013 to utilize in supporting wellness programs, clinical research and government studies.
   

21


Loss from discontinued operations, including income taxes was $2.0 million and $1.0 million for the three months ended September 30, 2013 and 2012, respectively. The loss represents the results of operations for the Company's Portamedic service line that was sold to Piston on September 30, 2013. The Company recognized a gain on sale of $3.5 million

Loss from discontinued operations, including income taxes was $4.7 million and $5.5 million for the nine months ended September 30, 2013 and 2012, respectively. The loss represents the results of operations for the Company's Portamedic service line that was sold to Piston on September 30, 2013.
 
In June 2008, we sold substantially all of the assets and liabilities of our Claims Evaluation Division ("CED") operating segment. In connection with the sale of the CED, we were released as the primary obligor for certain lease obligations acquired but remain secondarily liable in the event the buyer defaults. In June 2013, we reduced the reserve for this liability by $0.08 million and reported the corresponding gain in discontinued operations. At September 30, 2013, we maintained a liability of $0.1 million for this lease obligation. The guarantee is provided for the term of the lease, which expires in July 2015. As of September 30, 2013, the maximum potential amount of future payments under the guarantee is $0.1 million.

Liquidity and Capital Resources

Our primary sources of liquidity are our cash and cash equivalents and our 2013 Loan and Security Agreement. At September 30, 2013, our working capital was $9.4 million before adjustment for assets and liabilities held for sale. Our current ratio as of September 30, 2013 was 1.6 to 1.
    
We present and discuss our cash flows inclusive of the Portamedic service line, which is the way our cash flows have been presented historically. Given the nature of our business, we have not historically separated much of our working capital by service line and thus we are not able to reliably distinguish between continuing and discontinued operations in our consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012. As such, changes in accounts payable, accounts receivable, inventory and other financial line items associated with the Portamedic service line may impact future cash flow statement presentation. We provide information about the impact of Portamedic on our cash flows below in the discussion of our cash flows from operating, investing and financing activities. Significant uses affecting our cash flows for the nine month period ended September 30, 2013 include:

•
a net loss of $9.3 million, net of non-cash adjustments related to gain on sale of Portamedic and subsidiary of $3.6 million, $1.8 million in depreciation expense, $0.6 million in share-based compensation expense, and impairment and loss on disposal of fixed assets of $0.5 million;

•
the payment of debt issue and amendment fees of $1.0 million

•
a decrease in inventory of $0.6 million;
 
•
a decrease in other assets of $0.2 million;

•
a combined net decrease in accounts payable, accrued expense and other long term liabilities of $1.7 million, and

•
capital expenditures of $1.1 million.

These uses of cash were partially offset by:

•
proceeds from the sale of Portamedic of $6.1 million;

•
a decrease in accounts receivable of $1.0 million; and

•
net borrowings under our credit facility of $2.6 million
    

22


Sale of Portamedic
        
On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with its Portamedic service line, including, among other things, fixed assets and intellectual property, to Piston, and Piston assumed certain specified liabilities (the “Portamedic Disposition”). The adjusted purchase price (the "Purchase Price") was approximately $8.1 million in cash, subject to adjustment, of which $2.0 million (the “Holdback Amount”) was held back by Piston as security for the Company’s obligations and agreements under the Asset Purchase Agreement and certain other agreements between the Company and Piston. The Holdback Amount will be released as follows: within three business days after the date on which final closing adjustments for inventory and other current assets are determined and paid to Piston (the “Closeout Date”) (and after giving effect to any deductions from the Holdback Amount prior to such date), Piston will pay to the Company all amounts, if any, in excess of $1.0 million and the remaining $1.0 million of the Holdback Amount, less any deductions with respect to indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid to the Company on the first anniversary of the Closeout Date.

In connection with the sale of Portamedic, the Company received $6.1 million of cash proceeds and incurred $0.9 million of financial advisory, legal and accounting fees, as of September 30, 2013. We expect to receive additional cash proceeds of $1 million subject to adjustment, in each of 2014 and 2015.
    
The Purchase Agreement also provides, among other things, that (1) if Piston incurs any losses relating to any governmental inquiry received by Piston or the Company within 18 months of the closing date, the Company will pay for one-half of such losses, up to $100,000, (2) if Piston elects to pursue, prosecute, defend, settle, compromise, appeal or take other actions with respect to certain matters relating to matters disclosed by the Company to Piston pre-closing (“Pre-Closing Matters”), the Company will cooperate with Piston (including joining in any legal proceeding related to such matters) and pay for one-half of all losses in connection with such matters, up to $100,000 and (3) Piston or its designees will make required payments for rents, charges, maintenance fees and all utility services to the Company associated with Piston’s or such designee’s occupancy of each premises that is the subject of a Company lease to be assumed by Piston or its designees, but the assignment of which was not completed by closing, until such time as the lease is duly assigned (or otherwise superseded by an agreement between Piston and the applicable landlord). The Company has agreed to bear all liability relating to the occupancy arrangement referenced in clause (3) of the immediately preceding sentence, other than with respect to the payment obligations described in such clause (3). With respect to Pre-Closing Matters, the Company also agreed that in the event Piston elects to pursue a claim relating to a Pre-Closing Matter and desires to add the Company as a plaintiff, Piston and the Company will cooperate to select counsel and to jointly prosecute such claim, but Piston will control such claim.

There are no relationships between the Company, any of its affiliates, any director or officer of the Company, or any associate of any such director or officer, and Piston, or any of its affiliates.
    
Loan and Security Agreements

    As of February 28, 2013, in conjunction with the Company entering into the 2013 Loan and Security Agreement, the Company terminated the 2009 Loan and Security Agreement with TD Bank, N.A. During the three and nine months ended September 30, 2013, in connection with the 2013 Loan and Security Agreement, the Company incurred unused line fees of $0.04 million and $0.08 million respectively. During the three and nine months ended September 30, 2012 in connection with the 2009 Loan and Security Agreement, the Company incurred unused line fees of $0.00 million and $0.02 million, respectively.     

Proceeds from the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any time outstanding which does not exceed 85% of “Eligible Receivables” (as defined in the 2013 Loan and Security Agreement) less any reserves established by Keltic Financial, provided that in no event can the aggregate amount of the revolving credit loans at any time exceed $10 million. Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, unbilled Portamedic and Health & Wellness receivables, and other receivables deemed ineligible by Keltic Financial. In June 2013, Keltic Financial established a $1.5 million reserve which limits the maximum amount that may be outstanding under the credit facility to the lesser of $10 million and 85% of Eligible Receivables less $1.5 million


23


As of September 30, 2013 there were $2.6 million in borrowings outstanding under our 2013 Loan and Security Agreement. As of September 30, 2013, the Company's available borrowing capacity was $0.04 million based on September 30, 2013 Eligible Receivables and a $0.8 million reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation timeline, availability borrowing capacity increased to approximately $6.0 million by October 4, 2013 and the reserve established by Keltic Financial was increased back to $1.5 million from a temporary reduction to increase available borrowing at the end of September 2013.

The sale of the Portamedic service line, which accounted for approximately 60-75% of Eligible Receivables prior to September 30, 2013, will result in a future decrease in borrowing capacity, although Portamedic receivables were not sold in the transaction and will continue to be included as Eligible Receivables until collected, in accordance with the 2013 Loan and Security Agreement. The Company estimates Portamedic related receivables to be approximately $9 million as of September 30, 2013. We may request that other receivables qualify but we are not able to reliably estimate the future borrowing capacity.

As of March 28, 2013, we entered into the First Amendment to the 2013 Loan and Security Agreement. Under the First Amendment, the annual facility fee increased to 1.5% from 1.0% of the revolving credit limit of $10 million; the monthly collateral management fee increased to $2,500 per month from $1,500 per month; and the monthly collateral management fee increased to $5,000 per month from $3,000 per month if there is an occurrence or event of default. In addition, the early termination fee changed a) if prior to the first anniversary of the effective date, from 3% to 5% of the revolving credit limit; b) if after the first anniversary but before the second anniversary of the effective date, from 2% to 3% of the revolving credit; and c) if after the second anniversary but prior to the third anniversary of the effective date, from 1% to 2% of the revolving credit limit. Also, we granted the lender a mortgage of our headquarters building as additional security. In regard to the financial covenants, the first EBITDA measurement date changed from the six months ended June 30, 2013 to the twelve months ending June 30, 2014. We paid an amendment fee of $0.2 million.

Interest on revolving credit loans will be calculated based on the greatest of (i) the annualized prime rate plus 2.75%, (ii) the 90 day LIBOR rate plus 5.25%, and (iii) 6% per annum. In connection with the 2013 Loan and Security Agreement, we incurred a commitment fee of $0.1 million and other issue costs totaling $0.7 million. During the nine months ended September 30, 2013, in connection with the 2013 Loan and Security Agreement we incurred $0.10 million in facility fees.

The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans, however we would be required to pay an early termination fee as noted above.

As security for our payment and other obligations under the 2013 Loan and Security Agreement, we granted Keltic Financial a security interest in all of our, and our subsidiary guarantors, existing and after-acquired property, including our receivables (which are subject to a lockbox account arrangement), inventory, equipment and corporate headquarters.  The aforementioned security interest is collectively referred to herein as the “collateral”. 

Pursuant to the terms of the 2013 Loan and Security Agreement, Keltic Financial may establish one or more reserves at its reasonable discretion and, at its sole discretion, may establish reserves with respect to (a) any event which in Keltic Financial's reasonable determination, diminishes the value of any collateral or (b) any of our contingent liabilities. A reserve may reduce the aggregate amount of indebtedness that may be incurred under the 2013 Loan and Security Agreement.    

The 2013 Loan and Security Agreement contains covenants that, among other things, restrict our ability, and that of our subsidiaries, to:

•
pay any dividends or distributions on, or redeem or retire any shares of any class of our capital stock or other equity interests;

•
incur additional indebtedness or otherwise become liable for the indebtedness, except for transactions in the ordinary course of business;

•
permit a change of control of the board of directors and certain senior management positions of the Company without prior consent of Keltic Financial;

•
sell or otherwise dispose of any of our assets, other than in the ordinary course of business;

•
create liens or encumbrances on our assets; and

24



•
enter into transactions with any of our affiliates on other than an arm's-length or no less favorable basis.

Keltic Financial consented to the change in CEO and CFO that occurred during 2013 as well as the sale of Portamedic. There were no waiver or amendment fees paid or associated with these consents.    

    
The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The minimum EBIDTA required for the twelve months ending June 30, 2014 is negative $3.2 million. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013.

The failure of the Company or any subsidiary guarantor to comply with any of the covenants or the breach of any of its or their representations and warranties, contained in the 2013 Loan and Security Agreement, constitutes an event of default under the agreement. In addition, the 2013 Loan and Security Agreement provides that "Events of Default" include the occurrence or failure of any event or condition that, in Keltic Financial's sole judgment, could have a material adverse effect (i) on the business, operations, assets, management, liabilities or condition of the Company, (ii) in the value, collectability or salability of the collateral, or (iii) on the ability of the Company and its subsidiary guarantors to perform under the 2013 Loan and Security Agreement.

In the fourth quarter of 2013, the Company began relocating its headquarters to Kansas and put its Basking Ridge real estate up for sale. Establishing a new team and transitioning functions to Kansas will take months and transition costs may be higher than expected. In addition, the sale of the Basking Ridge real estate may not occur when expected or for the amount expected. Any sale of the real estate is subject to consent by Keltic Financial.
        
The Company's Heritage Labs service line shared some customers with the Portamedic service line. While not all Heritage Labs life insurance samples originated from Portamedic exams, the sale of the Portamedic service line may have an impact on life insurance related lab volumes.

The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.

Through the increased focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue. 

If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, reduce its selling, general and administrative costs as it seeks to streamline operations and improve efficiency, grow the Health and Wellness service line and maintain Heritage Labs revenues as expected, and timely realize sufficient proceeds from the Holdback Amount and the sale of the Basking Ridge real estate, it may violate covenants or otherwise not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect the Company's liquidity and its ability to generate cash flow in the future.

Based on the Company's anticipated level of future revenues, sale of the Basking Ridge real estate, collection of the Holdback amount and restructuring initiatives, and the Company's existing cash, cash equivalents, working capital and credit facility, the Company believes it has sufficient funds to meet its cash needs through at least September 30, 2014.
    

25


Cash Flows from Operating, Investing and Financing Activities

We discuss below the cash flows from operating, investing and financing activities for the nine months ended September 30, 2013, inclusive of discontinued operations relating to the sale of Portamedic. As a result of our relocation to Kansas and related restructuring activities, future cash flows from operating, investing and financing activities may be materially different from the cash flows from operating, investing and financing activities for the nine months ended September 30, 2013 and prior periods. At this time we cannot assess with reasonable certainty the impact the sale of Portamedic will have on our future cash flows. Since the Company historically has not tracked accounts receivable, accounts payable and other accounts by service line, its service lines had customers and suppliers in common, and its continuing and discontinued operations shared certain selling, general and administrative services, the Company does not have reliable information for the historical impact of Portamedic on the Company’s cash flows. However, the Company feels that without the Portamedic service line and with selling, general and administrative cost reductions, cash flow from operations will improve. As disclosed above we believe based on our anticipated level of future revenues, our anticipated cost reductions, the sale of our Basking Ridge facility, the collection of the first of two $1 million holdbacks, and existing cash and cash equivalents and borrowing capacity, we will have sufficient funds to meet our cash needs through at least September 30, 2014.
    
Cash Flows from Operating Activities

For the nine month period ended September 30, 2013, net cash used in operating activities was $7.8 million, compared to $5.1 million in the prior year period.
    
We present and discuss our cash flows inclusive of the Portamedic service line, which is the way our cash flows have been presented historically. Given the nature of our business, we have not historically separated items and thus there is no distinction between continuing and discontinued operations in our consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012. As such, changes in accounts payable, accounts receivable, inventory and other financial line items associated with the Portamedic business may impact future cash flow statement presentation. The loss from discontinued operations attributable to Portamedic, including income taxes, was $2.0 million and $4.7 million, respectively, for the three and nine month periods ended September 30, 2013.
 
The net cash used in operating activities for the nine month period ended September 30, 2013 of $7.8 million reflects a net loss of $9.3 million, a non-cash gain of $3.6 million from the sale of Portamedic and a subsidiary and non-cash charges of $1.8 million of depreciation, $0.6 million of share-based compensation expense, and impairment and loss on disposal of fixed assets of $0.5 million. Changes in working capital included:

•
a decrease in accounts receivable of $1.0 million. Our consolidated days sales outstanding (“DSO”), measured on a rolling 90-day basis, was 53.7 days at September 30, 2013, compared to 39.9 days at December 31, 2012 and 49.5 days at September 30, 2012. Historically, our accounts receivable balances and our DSO are near their highest point in September and their lowest point in December as many of our customers utilize the remainder of their operating budgets before their year-end budget close-out. Our consolidated allowance for doubtful accounts, which includes a reserve for revenue reductions, declined approximately $0.04 million since December 31, 2012, resulting from net write-offs of $0.13 million and an additional expense provision of $0.08 million;

•
a combined decrease in accounts payable, accrued expenses and other long-term liabilities of $1.7 million;

•
an increase in inventories of $0.6 million; and

•
an increase in other assets of $0.2 million.
 
The net cash used in operating activities for the nine month period ended September 30, 2012 of $5.1 million reflects a net loss of $10.9 million and non-cash charges of $3.1 million of depreciation and amortization, $0.5 million of share-based compensation expense, and a loss on disposal and impairment of fixed assets of $0.2 million. Changes in working capital included:

•
a decrease in accounts receivable of $0.2 million;

•
a combined net increase in accounts payable, accrued expenses and other long-term liabilities of $1.3 million;

•
an increase in inventories of $0.5 million; and

•
a decrease in other assets of $1.1 million.

26



Cash Flows provided by (used in) Investing Activities

For the nine month period ended September 30, 2013, we collected $6.1 million of proceeds from the sale of Portamedic and we used $1.1 million for capital expenditures primarily related to Partnerlink enhancements (the workflow system of our discontinued Portamedic operations), and other hardware and software and $0.4 million in costs to sell Portamedic. For the nine month period ended September 30, 2012, we used $3.3 million for capital expenditures related to the development of Partnerlink, our new inventory management system and new Heritage Lab specimen analyzing equipment. Capital expenditures related to our continuing operations during the nine months ended September 30, 2013 and 2012 were approximately $0.4 million and $1.6 million, respectively.

Cash Flows provided by (used in) Financing Activities

The net cash provided by financing activities for the nine month period ended September 30, 2013 of $1.5 million represents $2.6 million of net borrowings under our credit facility, partially offset by $1.0 million of costs associated with our 2013 Loan and Security Agreement and a reduction in capital lease obligations, which were primarily related to our discontinued Portamedic operation. Cash used in financing activities for the nine month period ended September 30, 2012 represents costs associated with our 2009 Loan and Security Agreement and a reduction in capital lease obligations.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Share Repurchases

We did not purchase any shares of our common stock during the nine month periods ended September 30, 2013 and 2012.

Dividends

No dividends were paid during the nine month periods ended September 30, 2013 and 2012. We are restricted from declaring or making any dividend payments or other distributions of assets with respect to any class of our equity securities under the terms of our 2013 Loan and Security Agreement with Keltic Financial.

Contractual Obligations

The following table sets forth our schedule of contractual obligation at September 30, 2013, including future minimum lease payments under non-cancelable operating and capital leases, and employment contract payments.

(In thousands)
Total
Less than
1 year
1-3 years
3-5 years
More than
5 years
Operating Lease Obligations
$
8,034

$
2,139

$
3,062

$
2,606

$
227

Capital Lease Obligations
15

5

9

1

—

Employment Contracts
490

490

—

—

—

Total
$
8,539

$
2,634

$
3,071

$
2,607

$
227


Inflation

Inflation has not had, nor is it expected to have, a material impact on our consolidated financial results.

Critical Accounting Policies

There were no changes to our critical accounting policies during the nine month period ended September 30, 2013. Such policies are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.


27


ITEM 3
Quantitative and Qualitative Disclosures About Market Risk

We are exposed to interest rate risk primarily through our borrowing activities, which are described in Note 9 to the unaudited interim consolidated financial statements and Item 2 of Part I included in this Report. Our credit facility is based on variable rates and is therefore subject to interest rate fluctuations. Accordingly, our interest expense will vary as a result of interest rate changes and the level of any outstanding borrowings. As of September 30, 2013, there were $2.6 million in borrowings outstanding under our 2013 Loan and Security Agreement.

As of September 30, 2013, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.


ITEM 4
Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

The Company's Chief Executive Officer and Chief Financial Officer, with the assistance of our disclosure committee, have conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2013. The Company's disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports the Company files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, to allow for timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2013, the Company's disclosure controls and procedures were not effective because of a material weakness in our internal control over financial reporting as described below. Notwithstanding the material weakness described below, management has concluded that our consolidated financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with generally accepted accounting principles in the United States for each of the periods presented and that they may still be relied upon.

(b) Changes in Internal Control over Financial Reporting

During the quarter ended During the quarter ended September 30, 2013, there have not been any changes in our internal controls over financial reporting, other than the following: During the quarter ended September 30, 2013, we appointed a new Senior Vice President and Chief Financial Officer and our General Counsel and other personnel responsible for financial reporting left the Company. Our new Senior Vice President and Chief Financial Officer assumed the duties of such position from our prior Chief Financial Officer. We engaged an outside financial consulting firm to fulfill the duties of our former personnel responsible for financial reporting and we engaged a law firm to fulfill the duties of our former General Counsel, until such time as we transition to permanent hires for those positions.

On September 30, 2013, we completed the sale of our Portamedic line of business and the Company was not able to complete the accounting for such sale and the reclassification of the Portamedic business line as discontinued operations within the prescribed time for filing this Report. In connection with this, we have identified certain deficiencies in our internal control over financial reporting that we deemed to be a material weakness. A material weakness is a control deficiency, or a combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. We determined that the turnover of personnel (as described above), and the associated loss of institutional knowledge, adversely affected management’s review of the accounting for non-routine, complex technical accounting matters to ensure proper application of generally accepted accounting principles in a timely manner, as well as its timely identification of certain transactions subject to reporting. In light of this, we will take steps to remediate these weaknesses in internal control.


28


PART II - Other Information

ITEM 1
Legal Proceedings

With respect to the complaint filed against the Company in U.S. District Court for the District of New Jersey on May 24, 2012 alleging that the Company failed to pay overtime compensation to a purported class of certain independent contractor examiners, preliminary motion practice and discovery is continuing. The Company has denied the substantive allegations in the case and believes them to be without merit.

The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company’s liquidity, its consolidated results of operations or its consolidated financial position.

ITEM 1A
Risk Factors

Readers should carefully consider, in connection with the other information in this Report, the risk factors disclosed in Item 1A. “Risk Factors” in our 2012 Annual Report on Form 10-K. There are no material changes to such risk factors, other than the addition of the following risk factor:

As part of the assessment of internal control over financial reporting, a material weakness was identified and our management has concluded that, as of September 30, 2013, our internal control over financial reporting and our disclosure controls and procedures were not effective.  Any failure to maintain effective internal control over financial reporting or effective disclosure controls and procedures could adversely affect our ability to record, process, summarize and report financial information timely and accurately.

Our management is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)).  As disclosed in Item 4. Controls and Procedures of this Quarterly Report on Form 10-Q, a material weakness in our internal control over financial reporting was identified.  A material weakness is a control deficiency, or a combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.  In light of this material weakness, our Chief Executive Officer and Chief Financial Officer also concluded that, as of September 30, 2013, our disclosure controls and procedures were ineffective.  In light of this material weakness, we will take steps to remediate these weaknesses.  Our remediation efforts could be insufficient to address the material weakness and additional material weaknesses in our internal control over financial reporting could be identified in the future.  Any failure to maintain effective internal control over financial reporting or effective disclosure controls and procedures could adversely affect our ability to record, process, summarize and report financial information timely and accurately and could therefore cause the market price of our common stock to decline.

ITEM 2
Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales or repurchases of equity securities during the fiscal quarter ended September 30, 2013.

ITEM 3
Defaults Upon Senior Securities

There were no defaults upon senior securities during the fiscal quarter ended September 30, 2013.

ITEM 4
Mine Safety Disclosure

Not applicable.
ITEM 5
Other Information

None


29


ITEM 6
Exhibits

Exhibit No.
 
Description of Exhibit
 
 
 
10.1
 
Asset Purchase Agreement dated August 15, 2013, by and between Piston Acquisition, Inc. and Hooper Holmes, Inc.
 
 
 
10.2
 
Limited Guaranty dated August 15, 2013 by Gary Gelman, in favor of Hooper Holmes, Inc.
 
 
 
10.3
 
First Amendment to Asset Purchase Agreement and Agreement dated September 30, 2013 by and between Hooper Holmes, Inc. and Piston Acquisition, Inc.
 
 
 
10.4
 
Agreement, dated as of August 15, 2013, by and between Hooper Holmes, Inc. and Piston Acquisition, Inc.
 
 
 
10.5
 
Employment Agreement dated September 30, 2013, by and between Hooper Holmes, Inc. and Henry Dubois.
 
 
 
10.6
 
Employment Agreement dated September 25, 2013, by and between Hooper Holmes, Inc. and Tom Collins.
 
 
 
31.1
 
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
 
 
 
31.2
 
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
 
 
 
32.1
 
Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
 
 
 
32.2
 
Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
 
 
 
101.INS
 
XBRL Instance Document*
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema Document*
 
 
 
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document*
 
 
 
101.DEF
 
XBRL Taxonomy Extension Label Linkbase Document*
 
 
 
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document*
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document*

* Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are not to be deemed "filed" or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, and are not to be deemed "filed" for purposes of Section 18 of the Exchange Act, and otherwise are not subject to liability under those sections, except as shall be expressly set forth by specific reference in such filing.

30


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Hooper Holmes, Inc.

Dated: November 15, 2013

 
 
By: /s/ Henry E. Dubois
 
 
 
Henry E. Dubois
 
 
 
Chief Executive Officer and President
(Principal Executive Officer)
 
 
 
 
 
 
 
By: /s/ Tom Collins
 
 
 
Tom Collins
 
 
 
Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
 


31
 EX-10.1 2 exhibit101q32013.htm EXHIBIT 10.1 ASSET PURCHASE AGREEMENT exhibit101q32013















ASSET PURCHASE AGREEMENT

BY AND BETWEEN

PISTON ACQUISITION, INC.

AND

HOOPER HOLMES, INC.

















Table of Contents
Page
 
DEFINITIONS
1

1.
1.1    Certain Definitions

1

 
1.2    Certain Additional Definitions
6

2.
SALE AND PURCHASE OF TRANSFERRED ASSETS
8

 
2.1    Agreement to Sell and Purchase
8

 
2.2    Excluded Assets
9

 
2.3    [Intentionally Omitted]
10

 
2.4    Purchase Price; Purchase Price Adjustment
10

 
2.5    Allocation of Purchase Price
11

 
2.6    Assumption of Assumed Liabilities; Retained Liabilities
11

 
2.7    Savings Clause
13

3.
REPRESENTATIONS AND WARRANTIES OF SELLER
13

 
3.1    Organization, Standing and Authority
13

 
3.2    Authorization and Binding Obligation
13

 
3.3    Absence of Conflicting Terms; Consents
14

 
3.4    Seller Reports; Financial Statements
14

 
3.5    Undisclosed Liabilities
15

 
3.6    Title to Assets; Etc
15

 
3.7    Leased Real Property
16

 
3.8    [Intentionally Omitted]
17

 
3.9    Inventory
17

 
3.10    Business Contracts; Shared Contracts
17

 
3.11    Intellectual Property
18

 
3.12    Tax Matters
19

 
3.13    Absence of Changes or Events
19

 
3.14    Insurance
19

 
3.15    Employee Plans
20

 
3.16    Employee and Independent Contractor Matters
20

 
3.17    Licenses; Compliance with Laws; Proceedings
21

 
3.18    Environmental Matters
21

 
3.19    Privacy Practices; Security
22

 
3.20    Transactions with Affiliates
22

 
3.21    Bonds; Letters of Credit
22

 
3.22    Customers
22

 
3.23    Solvency
22

 
3.24    Takeover Statutes; Absence of Rights Plan
23

 
3.25    Disclosure
23

 
3.26    Seller’s Disclosure Schedules
23

 
3.27    Brokers of Seller
23

4.
REPRESENTATIONS AND WARRANTIES OF BUYER
23

 
4.1    Organization, Standing and Authority
23

 
4.2    Authorization and Binding Obligation
23

 
4.3    Absence of Conflicting Terms; Consents
24




Table of Contents
(continued)
Page
 
4.4    Guaranty
24

 
4.5    Special Purpose Entity
24

 
4.6    Brokers of Buyer
24

5.
CERTAIN COVENANTS OF THE PARTIES
24

 
5.1    Conduct of the Business Prior to the Closing
24

 
5.2    [Intentionally Omitted]
25

 
5.3    Alternative Transactions
25

 
5.4    Governmental Authority Review
29

 
5.5    Cooperation
30

 
5.6    Certain Agreements; Post-Signing Deliveries
30

 
5.7    Transition Services
32

 
5.8    Insurance
32

 
5.9    Tax Matters
33

 
5.10    Covenants Regarding Portamedic Staff
33

 
5.11    Notification of Certain Matters
34

 
5.12    Access to Properties, Books and Records; Reports
34

 
5.13    Confidentiality
35

 
5.14    Public Announcements
35

 
5.15    Post Closing Access; Transfers
36

 
5.16    Non-Competition
36

 
5.17    Corporate Names
36

 
5.18    Remittance of Payments Received
37

6.
CONDITIONS PRECEDENT TO OBLIGATIONS OF BUYER AND SELLER TO CLOSE
37

 
6.1    Conditions Precedent to Obligations of Buyer to Close
37

 
6.2    Conditions Precedent to Obligations of Seller to Close    
37

7.
CLOSING AND CLOSING DELIVERIES
38

 
7.1    Closing
38

 
7.2    Deliveries by Seller
38

 
7.3    Deliveries by Buyer
39

8.
TERMINATION
39

 
8.1    Method of Termination
39

 
8.2    Effect of Termination
40

 
8.3    Termination Fee; Expenses
40

9.
INDEMNIFICATION
41

 
9.1    Survival
41

 
9.2    Indemnification by Seller
41

 
9.3    Indemnification by Buyer
41

 
9.4    Procedure for Indemnification
41

 
9.5    Limitation on Indemnification
43



Table of Contents
(continued)
Page
10.
MISCELLANEOUS
44

 
10.1    Notices
44

 
10.2    No Assignment; Benefit and Binding Effect
45

 
10.3    Governing Law; Venue
45

 
10.4    Waiver of Jury Trial
45

 
10.5    Heading; Interpretation
46

 
10.6    Entire Agreement
46

 
10.7    Further Assurances
46

 
10.8    Waiver of Compliance
46

 
10.9    Severability
46

 
10.10    Enforcement of Agreement
47

 
10.11    Counterparts
47

 
10.12    No Third Party Beneficiaries
47

 
10.13    Construction
47

 
10.14    Expenses
47

 
 
 










ASSET PURCHASE AGREEMENT

This ASSET PURCHASE AGREEMENT is dated as of August 15, 2013 (this “Agreement”), by and between Piston Acquisition, Inc., a New York corporation (including its successors and permitted assigns, the “Buyer”), and Hooper Holmes, Inc., a New York corporation (“Seller”). Buyer and Seller are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties”.
R E C I T A L S:
A.    Seller is engaged in (i) the business of performing paramedical and medical examinations of individuals throughout the United States, including primarily on behalf of insurance companies in connection with evaluating, offering or rating of insurance coverage (the “Portamedic Business”) and (ii) other businesses involving health risk assessment services as described in Exhibit A (the “Other Businesses”). For clarity, as used herein, Seller’s Portamedic Business shall include the so-called “Portamedic Direct” business, but specifically shall not include the Other Businesses.
B.    Buyer desires to purchase certain assets included within the Portamedic Business from Seller, and Seller desires to sell such assets to Buyer, in each case, on the terms and conditions set forth in this Agreement.
C.    In furtherance of the foregoing and in accordance with the New York Business Corporation Law § 701, the respective boards of directors of each of the Parties have unanimously approved, adopted and declared advisable and in the best interests of the respective equityholders of the Parties, this Agreement, the sale, transfer, assignment and delivery of the Transferred Assets to Buyer and the other transactions contemplated herein, upon the terms and conditions set forth in this Agreement (with respect to the Seller Board, such approval, adoption and declaration being the “Seller Board Recommendation”).
D.    The board of directors of Seller (the “Seller Board”) has determined that the Transferred Assets conveyed by Seller to Buyer hereunder do not constitute all or substantially all of the Seller’s assets.
A G R E E M E N T S:
In consideration of the premises and mutual covenants herein, and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Parties, intending to be legally bound, hereby agree as follows:
1.
DEFINITIONS.

1.1    Certain Definitions. For purposes of this Agreement, the following terms have the respective meanings set forth below:

“Affiliate” means with respect to a Person, any Person directly or indirectly controlling, controlled by or under common control with such first-specified Person. For purposes of this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities or interests, by contract or otherwise.
“Ancillary Agreements” means all exhibits, certificates, instruments and other agreements required to be executed and delivered by any Person pursuant to this Agreement.
“Assumed Leased Real Property” means the real property underlying the Assumed Leases.
“Assumed Leases” means (i) the Leases identified on Schedule 1.1(a) and (ii) any other Leases designated by Buyer as “Assumed Leases” pursuant to Section 5.6.4.

1


“Basking Ridge Facility” means the real property owned by Seller having the address of 170 Mt. Airy Road, Basking Ridge, New Jersey.
“Business Contract” means any Contract used or held for use, in whole or in part, in the Portamedic Business to which Seller or any of its Affiliates is a party. For clarity, Shared Contracts shall not constitute “Business Contracts” hereunder.
“Business Day” means any day other than a Saturday or a Sunday or a day on which banks located in New York, New York generally are authorized or obligated by Law to be closed.
“Business Employee” means any employee of Seller or its Affiliates engaged, full or part time, in the Portamedic Business.
“Business Independent Contractor” means any independent contractor of Seller or its Affiliates engaged in the Portamedic Business.
“Business Intellectual Property” means all Intellectual Property that is used or held for use in connection with Seller’s Portamedic Business, expressly including, without limitation, all right, title and interest in and to the “Portamedic” name, PartnerLink, ePortamedic.com, and iParamed e-Exam.
“Code” means the Internal Revenue Code of 1986, as amended, or any subsequent legislative enactment thereof, each as in effect from time to time.
“Consent” means any consent, permit, registration, authorization or approval of any Person or any Governmental Authority that Seller is, under the terms of any Contract, Law or License, required to obtain (or any notice, report or other filing under the terms of any Contract, Law or License required to be made) in order for Seller to duly sell, assign and transfer to Buyer the Transferred Assets (or any of them) in accordance with this Agreement and otherwise perform its obligations hereunder or to comply with applicable Laws.
“Contract” means any contract, agreement, understanding, instrument, note, mortgage, guaranty, indemnity, deed, assignment, power of attorney, purchase order, work order, binding commitment, lease, license or other arrangement, whether written or oral.
“Employee Plan” means any employee benefit plan, within the meaning of Section 3(3) of ERISA, employee pension plan within the meaning of Section 3(2) of ERISA, employee welfare plan within the meaning of Section 3(1) of ERISA, any other employee benefit plan, program or arrangement of any kind, and each stock option, stock appreciation right, restricted stock, stock purchase, stock unit, incentive, profit-sharing, savings, deferred compensation, health, medical, dental, life insurance, disability, accident, supplemental unemployment or retirement, severance, vacation, overtime, paid leave, benefits continuation, fringe benefits, indemnification rights, reimbursement of expenses, advances, and any and all other plans, programs, agreements, arrangements, policies, and practices that provides benefits to Business Employees, as well as any and all bonus plans, programs and arrangements and other plans, programs and arrangements to pay commissions or similar contingent compensation.
“Encumbrance” means any security interest, pledge, mortgage, lien, charge, right of first or last offer (or any similar rights), right of first or last negotiation (or any similar rights), or other encumbrance.
“Environmental Law” means any Law pertaining to land use, air, soil, surface water, groundwater, or wetlands, including the protection, cleanup, removal, remediation or damage thereof, public or employee health or safety or any other similar matter.
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations thereunder, as in effect from time to time.
“Excluded Leased Real Property” means all Leased Real Property other than the Assumed Leased Real Property.

2


“Excluded Leases” means all Leases other than the Assumed Leases.
“Fundamental Representations” means (i) with respect to Seller, the representations and warranties contained in Sections 3.1 (Organization, Standing and Authority), 3.2 (Authorization and Binding Obligation), 3.6 (Title to Assets; Etc.), 3.12 (Taxes), 3.20 (Transactions with Affiliates), 3.23 (Solvency), 3.26 (Brokers of Seller); and (ii) with respect to Buyer, the representations and warranties contained in Sections 4.1 (Organization, Standing and Authority), 4.2 (Authorization and Binding Obligation), and 4.5 (Brokers of Buyer).
“GAAP” means United States generally accepted accounting principles and practices as in effect from time to time consistently applied.
“Governmental Authority” means any government, any governmental entity, department, commission, regulatory authority, board, agency or instrumentality, and any court, tribunal, arbitral or judicial body, in each case whether federal, state, county, local or foreign.
“Hazardous Substance” means any radioactive, toxic, hazardous, or dangerous material or substance the Release of which is prohibited or regulated by any Environmental Law or any material or substance that has been designated by any Governmental Authority to be radioactive, toxic, hazardous or otherwise a danger to health, reproduction or the environment, including, but not limited to, asbestos, petroleum, radon gas, radioactive matter, PCBs, oils, hydrocarbons, photographic chemicals and products and other pollutants and contaminants.
“Intellectual Property” means all of the following and all common law and statutory rights in, arising out of, or associated therewith, in any jurisdiction throughout the world: (a) inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations, divisions, continuations-in-part, revisions, extensions, and re-examinations thereof, (b) trade secrets, and confidential, technical, and business information and data (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, designs, drawings, specifications, proprietary information, subscriber, customer, advertiser, and supplier lists, databases, pricing and cost information, and business and marketing plans and proposals); (c) copyrights, mask works, copyrightable works, and applications, registrations, and renewals in connection therewith throughout the world; (d) all of the computer systems and related software, information technology systems, including, without limitation, all outsourced information technology services, computer programs, software and software programs, systems, and applications, source code, executable code, and related documentation and passwords (collectively, “Software”); (e) Internet web, digital and mobile sites, related content and links, and all versions, updates, corrections, enhancements, and modifications thereof; (f) domain names, uniform resource locators (URLs) and other names and locators associated with the Internet or mobile publications (collectively, “Domain Names”); (g) trademarks, service marks, logos, slogans, trade names, and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations and renewals in connection therewith, and trade dress (including banners, flags, nameplates, and mastheads); (h) databases and data collections and all rights therein; (i) all other intellectual property and all other proprietary rights, in each case including copies and tangible embodiments thereof (in whatever form or medium); and (j) going concern value, goodwill, telephone, telecopy and e-mail addresses and listings. “Intellectual Property” expressly includes any and all rights to sue for prior claims.
“Knowledge” (a) an individual will be deemed to have “Knowledge” of a particular fact or other matter if such individual has actual knowledge of such fact or other matter, after a careful review of this Agreement and reasonable inquiry; and (b) “Knowledge of Seller,” “Seller’s Knowledge” and other correlative terms mean, with respect to Seller, the Knowledge of the individuals set forth on Schedule 1.1(b).
“Later Delivered Contract” means any and all of the Restrictive Covenant Contracts and the Termination Contracts.
“Laws” means any law, common law, statute, ordinance, code or other law, rule, regulation or order enacted, adopted, promulgated or applied by any Governmental Authority.

3


“Leased Real Property” means any leasehold interest in real estate held by Seller or any of its Affiliates that is used or held for use in connection with the Portamedic Business.
“Leases” means any lease, sublease, license, right to occupy and similar Contract, including all agreements, amendments, supplements, exhibits and schedules thereto.
“Liability” means any debt, obligation or liability of any kind or nature, whether accrued or fixed, absolute or contingent, determined or determinable, liquidated or unliquidated, matured or unmatured, and whether due or to become due, asserted or unasserted, or known or unknown.
“License” means any license, authorization, franchise or permit granted or issued to Seller or any of its Affiliates by any Governmental Authority, including all amendments thereto and renewals or modifications thereof.
“Losses” mean any and all costs, expenses, damages, deficiencies, liabilities, obligations, losses, Taxes, claims, penalties, fines, sanctions, interest, judgments or settlements, including, without limitation, reasonable attorney and professional fees and out of pocket costs of investigation and defense, notification costs, and diminution in value, imposed on or otherwise suffered by any Person, whether or not involving a third party.
“Material Adverse Effect” means a material adverse effect on (a) the assets, condition (financial or otherwise), operating results, or operations of the Portamedic Business or any of the Transferred Assets or (b) the ability of Seller to perform its obligations and consummate the Transactions in accordance with this Agreement, in each case, other than any effect caused by or arising out of (i) any event, change, or development in general economic or political conditions or financial or capital markets; (ii) any change to GAAP (or interpretation thereof) or applicable Laws; (iii) any event, change, or development resulting from natural disasters, hostilities, acts of war, sabotage or terrorism; (iv) the announcement of this Agreement or the pendency of the consummation of the Transactions, in each case, without limitation of Seller’s obligations set forth in this Agreement, including, without limitation, under Section 5.1), so long as, in the case of each of clauses (i), (ii) and (iii) such matters do not adversely affect Seller’s Portamedic Business or the Transferred Assets in a materially disproportionate manner relative to other companies operating in the Portamedic Business.
“Material Business Contract” means each and every Contract meeting any of the following criteria:
(a)    Business Contracts involving annual payments in 2012 or pursuant to which Seller reasonably expects payments in 2013 (in each case, whether to or from Seller) of more than One Hundred Thousand Dollars ($100,000);
(b)    Business Contracts with any Major Customer;
(c)    Contracts which cannot be terminated by Buyer after the Closing without penalty, payment or breach on sixty (60) days’ or less notice (the “Termination Contracts”);
(d)    Business Contracts containing prepayments, advances, recoupable payments or similar provisions (other than Excluded Leases);
(e)    Assumed Leases;
(f)    any Contract concerning a partnership or joint venture;
(g)    any Contract under which Seller has created, incurred, assumed, or guaranteed any indebtedness for borrowed money or pursuant to which Seller has advanced or loaned money;
(h)    any Contract pursuant to which any Encumbrance has been granted by Seller or its Subsidiaries or imposed on any Transferred Assets;

4


(i)    any Contract containing (A) covenants not to compete or exclusivity (in any class of customer or geography, any duration of time, or otherwise); or (B) “key man,” “most favored nations” or similar clauses (but not including non-solicitation and no-hire clauses customarily found in Business Contracts) (all such Contracts described in clauses (A) and (B) being referred to as the “Restrictive Covenant Contracts”);
(j)    any IP Acquisition Contract;
(k)    Contracts evidencing indebtedness (including, without limitation, for capitalized lease and similar obligations); and
(l)    any other Business Contract which is material to the Portamedic Business (other than the Excluded Leases) or to Buyer’s ability to use, exploit, benefit from and enjoy the Transferred Assets at and after the Closing.
“Multiemployer Plan” means a plan, as defined in ERISA Section 3(37) or 4001(a)(3), to which Seller or any trade or business which would be considered a single employer with Seller under Section 4001(b)(1) of ERISA or part of the same “controlled group” as Seller under Section 302(d)(8)(C) of ERISA, contributed, contributes or is required to contribute.
“Order” means any decree, order, injunction, ruling, judgment or charge of any Governmental Authority, whether a temporary restraining order, preliminary or permanent injunction or otherwise.
“Permitted Encumbrance” means (i) liens arising solely by action of the Buyer and (ii) liens under that certain Loan and Security Agreement dated February 28, 2013 between Keltic Financial Partners II, and Seller (the “Keltic Facility”), all of which such liens shall be removed by Seller prior to the Closing.
“Person” means any individual, corporation, limited liability company, partnership, company, sole proprietorship, joint venture, trust, estate, association, organization or other entity.
“Personal Information” means any and all data of information that concerns an identified and/or identifiable Person and includes, but shall not be limited to, an individual’s name, address, date of birth, financial account information, credit card information, email address, medical insurance number, Social Security number and health information, including, without limitation, protected health information as that term is defined under applicable Law (including, without limitation, the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, including, the Standards for Electronic Transactions, Privacy and Security promulgated by the U.S. Department of Health and Human Services under 45 CFR parts 160, 162 and 164, the Health Information Technology for Economic and Clinical Health Act and the Final Omnibus Rule and each of their implementing regulations).
“Proceeding” means any suit, litigation, action, claim, hearing, investigation, complaint, demand, audit, arbitration or other proceeding.
“Registered Business Intellectual Property” means all Business Intellectual Property that is the subject of an application, certificate, filing, registration or other document issued, filed with, or recorded by any Governmental Authority.
“Related Person” means any director, officer, employee, agent or family member of Seller or any Subsidiary.
“Seller’s Disclosure Schedules” means the disclosure schedules delivered to Buyer by Seller on the date of this Agreement in connection with this Agreement.
“Shared Contract” means any Contract which is used in or benefits the Portamedic Business as conducted by Seller, and also is used in or benefits one or more other businesses or operations of Seller or any of its Affiliates (other than Seller’s Portamedic Business being acquired by Buyer under this Agreement).

5


“Subsidiary” means any of the following Persons: (i) any Person the equity interests of which Seller owns, directly or indirectly, 25% or more and (ii) any Person directly or indirectly controlled by or under common control with Seller.
“Taxes” means any federal, state, local or foreign income, sales, bulk sales, use, ad valorem, value added, net or gross proceeds, gains, profits, capital, withholding, payroll, employment, unemployment, social security, excise, license, transfer, environmental (including taxes under Section 59A of the Code), severance, stamp, transfer, premium, occupation, windfall profits, customs duties, franchise, alternative, estimated, real or personal property taxes, or other tax of any kind whatsoever, whether computed on a separate or consolidated, unitary or combined basis or in any other manner, together with any interest thereon and any penalties, additions to tax or additional amounts applicable thereto, whether disputed or not and including any obligation to indemnify or otherwise assume or succeed to the tax liability of any other person or entity.
“Transactions” means all of the transactions contemplated by this Agreement and the Ancillary Agreements.
1.2    Certain Additional Definitions. For all purposes of and under this Agreement, the following terms shall have the respective meanings ascribed thereto in the respective sections of this Agreement set forth opposite each such term below:

Term
Section
Acquisition Proposal
5/3/2006
Agreed Amount
9/4/2004
Agreement
Preamble
Alternative Reimbursement
9/5/2005
Assumed Liabilities
2/6/2001
Business Insurance Policies
3.14
Buyer
Preamble
Buyer Allocable Share Liabilities
5/6/2005
Buyer Allocable Share Rights
5/6/2005
Buyer Expenses
8.3.1(iv)
Claim Notice
9/4/2004
Claimant
9/4/2001
Claimed Amount
9/4/2004
Closeout Date
2/4/2005
Closing
7/1/2001
Closing Date
7/1/2001
Closing Inventory Adjustment
2/4/2003
Closing Inventory Amount
2/4/2003
Closing Inventory Statement
2/4/2003
Closing OCA Adjustment
2/4/2003
Closing OCA Amount
2/4/2003
Closing OCA Statement
2/4/2003
Confidentiality Agreement
5.12
Deductible
9/5/2001
Designated Later Delivered Contract
5/6/2002
Election Notice
5/4/2001
End Date
8.1.2(i)
Exchange Act
5/3/2005
Excluded Assets
2.2

6


Excluded Contracts
2/2/2005
Financial Statements
3.4
Holdback
2/4/2002
Holdback Amount
2/4/2002
Indemnifying Party
9/4/2001
IP Acquisition Contracts
2/1/2003
Inquiry
5/4/2001
Inventories
2/1/2005
Inventory Schedule
3.9
Keltic Facility
Defn of Permitted Encumbrance
Leases
3/7/2001
Major Customers
3.22
Most Recent Balance Sheet
3/4/2002
Most Recent Balance Sheet Date
3/4/2002
Other Businesses
Recitals
Portamedic Business
Recitals
Purchase Price
2.4
Restrictive Covenant Contract
Defn Material Business Contract
Retained Liabilities
2/6/2003
Returns
5/9/2001
Reviewed Inventory and OCA Amount
2/4/2005
Sarbanes-Oxley Act
3/4/2001
SEC
3/4/2001
Seller
Preamble
Seller Adverse Recommendation Change
5/3/2004
Seller Board
Recitals
Seller Board Recommendation
Recitals
Seller Reports
3/4/2001
Seller Representatives
5/3/2001
Seller’s Decision Period
5/4/2001
Software
Defn of Intellectual Property
Takeover Statute
3.24
Tangible Personal Property
2/1/2006
Termination Contract
Defn Material Business Contract
Third Party Claim
9/4/2002
Termination Fee
8.3.1(i)
Transferred Assets
2.1
Transition Services
5/7/2001
Transition Term
5/7/2001
WARN Obligations
5.10



7


2.
SALE AND PURCHASE OF TRANSFERRED ASSETS

2.1    Agreement to Sell and Purchase. Subject to the terms and conditions set forth in this Agreement, Seller hereby agrees to irrevocably convey, assign, sell, transfer and deliver (or to cause to be conveyed, assigned, sold, transferred and delivered) to Buyer at the Closing, and Buyer hereby agrees to purchase and receive from Seller at the Closing, all right, title and interest in and to all real, personal and mixed assets, both tangible and intangible, that are owned, leased, used or held for use by Seller or its Subsidiaries in connection with the Portamedic Business, including, without limitation, the following assets, in each case, free and clear of all Encumbrances, but not including the Excluded Assets or any Retained Liabilities (such acquired assets, collectively, the “Transferred Assets”):
 
2.1.1    all of the Business Contracts, including, without limitation, all of the Assumed Leases and equipment leases;


2.1.2    all of the Business Intellectual Property, including, without limitation the Business Intellectual Property listed on Schedule 3.11.1;

2.1.3    all right, title and interest in and to all Contracts (whether or not such Contracts relate solely to the Portamedic Business) (i) pursuant to which any Business Intellectual Property was developed or pursuant to which Seller or its Affiliates otherwise acquired rights in any Business Intellectual Property (collectively, “IP Acquisition Contracts”); and (ii) to the extent any Contracts contain confidentiality provisions, non-solicitation, non-competition or other restrictive covenants in favor or for the benefit of the Portamedic Business;

2.1.4    all books, data and records related to the operations of the Portamedic Business, including, without limitation, invoices, client and customer lists, addresses and other records, telephone, telex and telecopier numbers, supplier and customer circulation lists, referral sources, research and development reports and records, production reports and records, service and warranty records, equipment logs, operating guides and manuals, financial and accounting records, creative materials, advertising materials, promotional materials and literature, studies, reports, correspondence and other documents, data, plans, files and records and, subject to applicable Laws, copies of all personnel records, examiner and other personnel and contractor reference and background checks, and other records, but excluding those to the extent relating solely to the Excluded Assets (which exclusion applies solely to that portion of any books and records that relate to the Excluded Assets even if included within or comprising a more general book, data or record); provided that Seller shall be entitled to retain, subject to compliance with the terms and conditions of Seller’s confidentiality obligations set forth in Section 5.13, one archival copy of any such records to the extent necessary to comply with its obligations under applicable Law;
 
2.1.5    all inventories wherever located, including, without limitation, all goods and supplies, all inventories of lab kits (including, without limitation, blood kits, urine kits, and oral fluid kits), all finished goods, and all other materials and supplies to be used or consumed in the production thereof (collectively, the “Inventories”);

2.1.6    all machinery, equipment, tools, furniture, furnishings, office equipment, computer hardware, computers, tablets, notebooks, servers, workstations, routers, hubs, supplies, materials, vehicles, leasehold improvements, parts and all other tangible personal property (other than Inventories), whether owned or leased, used or held for use in connection with the ownership or operation of the Portamedic Business (wherever located and whether or not carried on Seller’s books), together with any express or implied warranty by the manufacturers or sellers or lessors of any item or component part thereof and all maintenance records and other documents relating thereto (collectively, the “Tangible Personal Property”);

2.1.7    all guaranties, warranties, indemnities and similar rights with respect to any Transferred Asset (regardless of when such guaranties, warranties, indemnities and similar rights arose or were granted) and, to the extent indemnifiable by Seller hereunder, all insurance benefits, including rights and proceeds, arising from or relating to the Transferred Assets or the Assumed Liabilities prior to the Closing;


8


2.1.8    all rights to causes of action, lawsuits, judgments, claims and demands of any nature in favor of Seller, whether mature, contingent or otherwise, against third parties relating to the Portamedic Business and the Transferred Assets, including those arising during or attributable to any period prior to the Closing, and expressly including any and all rights and benefits under Contracts with Portamedic Staff restricting such Persons from competing against or disparaging the Portamedic Business or from divulging confidential or proprietary information relating to the Portamedic Business and similar provisions;

2.1.9    all claims, rights, audit recoveries, interests and choses of action against third parties relating to the Portamedic Business or the Transferred Assets and all rights of Seller against third parties relating to the Transferred Assets, whether choate or inchoate, known or unknown, contingent or non-contingent;

2.1.10    all prepayments, prepaid expenses, advances, refunds, rebates, abatement, credits from suppliers, landlords, carriers, customers and others (whether or not the foregoing items were made by Seller prior to the Closing) relating to the Portamedic Business, including, without limitation, rights to security deposits under each Assumed Lease, a schedule of all such security deposits is set forth on Schedule 2.1.10;

2.1.11    all goodwill relating to the Portamedic Business;
 
2.1.12    all other assets other than Excluded Assets, whether owned, leased or licensed, real, personal or mixed, or tangible or intangible, which are used or held for use in connection with the ownership and operation of Seller’s Portamedic Business;

2.1.13    all Buyer Allocable Share Rights; and

2.1.14    all rights of Buyer under this Agreement.
 
Notwithstanding the foregoing, the transfer of the Transferred Assets pursuant to this Agreement shall not include the assumption of any Liability related to the Transferred Assets unless Buyer expressly assumes that Liability pursuant to Section 2.6.1.
2.2    Excluded Assets. Notwithstanding anything set forth in this Agreement to the contrary, the Transferred Assets shall not include the following assets (collectively, the “Excluded Assets”), which shall be retained by Seller or its Subsidiaries:

2.2.1    any equity interests in Seller or its Subsidiaries;

2.2.2    any cash or cash equivalents and marketable securities held by Seller (except to the extent set forth in Section 2.1.10);

2.2.3    all minute books, stock records and corporate seals of Seller or its Subsidiaries;

2.2.4    Excluded Leases;

2.2.5    Contracts set forth on Schedule 2.2.5 (the “Excluded Contracts”);

2.2.6    all personnel records pertaining to Business Employees;

2.2.7    the “Hooper Holmes” trademark and tradename;

2.2.8    all desks, chairs and other immaterial office furniture located as of the date of this Agreement at any of the Excluded Leased Real Property;
 
2.2.9    accounts receivable (except to the extent set forth in Section 2.1.10);

9



2.2.10    the real property interest in the Basking Ridge Facility (subject to Seller’s obligations to provide any Transition Services from such facility); and

2.2.11    all rights of Seller under this Agreement.

2.3    [Intentionally Omitted]
 
2.4    Purchase Price; Purchase Price Adjustment.

2.4.1    Subject to adjustment pursuant to Sections 2.4.3 and 2.4.5, the purchase price for the Transferred Assets shall be (i) Eight Million Three Hundred Sixty Two Thousand Forty Four Dollars ($8,362,044) (the “Purchase Price”) and (ii) the assumption of the Assumed Liabilities.
 
2.4.2    Buyer shall retain (the “Holdback”) from the Purchase Price an amount equal to Two Million Dollars ($2,000,000) (the “Holdback Amount”). The Holdback shall be held by Buyer as security for Seller’s obligations and agreements in this Agreement and the Ancillary Agreements. Within three (3) Business Days after the Closeout Date (and after giving effect to any deductions from the Holdback prior to the Closeout Date), Buyer shall release from the Holdback all amounts, if any, in excess of One Million Dollars ($1,000,000) so that the “Holdback Amount” shall be reduced to an amount equal to One Million Dollars ($1,000,000).
 
2.4.3    At least two (2) Business Days prior to the Closing Date, Seller shall deliver to Buyer a statement (the “Closing Inventory Statement”) in the form of the Inventory Schedule, setting forth Seller’s good faith estimate of the Inventory as of the Closing Date (the “Closing Inventory Amount”) and all components thereof. The Closing Inventory Statement shall be accompanied by a certificate executed by an executive financial officer of Seller stating that the Closing Inventory Statement has been prepared in accordance with this Agreement. The “Closing Inventory Adjustment” shall mean an amount equal to (i) $1,041,321 minus (ii) the value of the Inventory set forth on the Closing Inventory Statement. The value of Inventory on the Closing Inventory Statement shall be determined in the same manner as the Inventory set forth on the June 30, 2013 and March 31, 2013 balance sheets of Seller’s Portamedic Business included within the Financial Statements. In no event shall the Closing Inventory Adjustment be a number less than $0. At least two (2) Business Days prior to the Closing Date, Seller shall deliver to Buyer a statement (the “Closing OCA Statement”) setting forth Seller’s good faith estimate of the “Other current assets” as of the Closing Date (the “Closing OCA Amount”) and all components thereof determined in the same manner as “Other current assets” have been calculated on the June 30, 2013 and March 31, 2013 balance sheets of Seller’s Portamedic Business included within the Financial Statements. The Closing OCA Statement shall be accompanied by a certificate executed by an executive financial officer of Seller stating that the Closing OCA Statement has been prepared in accordance with this Agreement. The “Closing OCA Adjustment” shall mean an amount equal to (i) $564,184 minus (ii) the “Other current assets” set forth on the Closing OCA Statement. In no event shall the Closing OCA Adjustment be a number less than $0.

2.4.4    At the Closing, Buyer shall deliver to Seller, via wire transfer of immediately available funds in accordance with Seller’s written instructions (to be provided at least two (2) Business Days prior to the Closing Date), the Purchase Price, less an amount equal to the Holdback less the Closing Inventory Adjustment less the Closing OCA Adjustment (the amount of the Purchase Price, as so reduced, the “Closing Payment”).


10


2.4.5    Within ninety (90) days after the Closing Date, Buyer shall deliver to Seller a statement (the “Reviewed Inventory and OCA Statement”) setting forth Buyer’s good faith calculation of the Closing Inventory Amount and the Closing OCA Amount. Seller shall have thirty (30) days following the receipt of the Reviewed Inventory and OCA Statement to deliver to Buyer a notice indicating that Seller disagrees with the Reviewed Inventory and OCA Statement detailing the nature of such disagreement (a “Dispute Notice”). Seller’s failure to deliver a Dispute Notice within such thirty (30) day period shall be deemed to constitute Seller’s acceptance of the Reviewed Inventory and OCA Statement, which shall be deemed final. The Parties shall attempt in good faith to resolve any dispute within thirty (30) days after Buyer receives a Dispute Notice. If the Parties fail to resolve any dispute within such period of time, then either Buyer or Seller may elect, by written notice delivered to the other, to submit the dispute for final and binding resolution to a nationally recognized independent public accounting firm (which shall be KPMG so long as KPMG is then independent of Buyer, Seller and their respective Affiliates or such other mutually determined independent firm (such firm, the “Selected Accountant”)). The Selected Accountant shall be instructed to resolve all disputes as promptly as practicable, but in any event within thirty (30) days. The Parties shall cooperate with the Selected Accountant and provide to the Selected Accountant such information as the Selected Accountant may reasonably request, in each case in connection with the resolution by the Selected Accountant of the specific items subject to such dispute (and no other items). The determination of the Selected Accountant regarding any such dispute shall (A) be set forth in writing, (B) be within the range of dispute between Buyer and Seller with respect to the Closing Inventory Amount and within the range of dispute between Buyer and Seller with respect to the Closing OCA Amount, (C) constitute an arbitral award, and (D) be final and binding upon the Parties. The fees of the Selected Accountant shall be paid by Seller. In the event that the final Closing Inventory Amount determined in accordance with this Section 2.4.5 is less than the aggregate Inventory amount set forth in the Closing Inventory Statement, then Seller shall promptly (but no later than two (2) Business Days) pay by wire transfer of immediately available funds the amount of such difference (or Buyer may at its election deduct such amount from the Holdback). In the event that the final Closing OCA Amount determined in accordance with this Section 2.4.5 is less than the amount of “Other current assets” set forth in the Closing OCA Statement, then Seller shall promptly (but no later than two (2) Business Days) pay by wire transfer of immediately available funds the amount of such difference (or Buyer may at its election deduct such amount from the Holdback). The later of (i) the date on which the final Closing Inventory Amount is determined and paid in accordance with this Section 2.4.5 and (ii) the date on which the final Closing OCA Amount is determined and paid in accordance with this Section 2.4.5 shall be referred to herein as the “Closeout Date.”

2.5    Allocation of Purchase Price. Seller and Buyer agree to use their respective good faith efforts to agree on an allocation of the Purchase Price (plus Assumed Liabilities, if applicable) among the Transferred Assets in a manner consistent with Section 1060 of the Code within thirty (30) days after the Closing Date. If the Seller and Buyer fail to reach such agreement within such period of time, either Party shall have the right to engage the Selected Accountant to resolve the dispute. The Selected Accountant shall be directed to resolve such dispute within thirty (30) days, and the determination of the Selected Accountant regarding any such dispute shall be final and binding. Seller and Buyer agree to file all income Tax forms and Returns (including IRS Form 8594 or any successor form) in accordance with any allocation mutually agreed by the Parties or determined by the Selected Accountant, as applicable, and agree not to take any position before any taxing authority that is inconsistent with such allocation, except as otherwise required pursuant to a “determination” within the meaning of Section 1313(a) of the Code (or any analogous provision of state, local or foreign laws). In the event any tax authority disputes the allocation, Seller or Buyer, as the case may be, shall promptly notify the other Party of the nature of such dispute.

2.6    Assumption of Assumed Liabilities; Retained Liabilities.
 
2.6.1    At the Closing, Buyer shall assume only the following specific Liabilities (collectively, the “Assumed Liabilities”):
  
(i)all Liabilities under the Business Contracts solely to the extent accruing after the Closing for services performed or rendered after the Closing; and

(ii)all Buyer Allocable Share Liabilities under the Designated Shared Contracts solely to the extent accruing after the Closing for services performed or rendered by Buyer after the Closing.

11


2.6.2    Buyer shall not assume or have any responsibility for any Liabilities or Losses other than the Assumed Liabilities.
  
2.6.3    For clarity, Seller hereby agrees to retain, discharge, perform when due any and all Liabilities or Losses (other than the Assumed Liabilities after the Closing) (collectively, all such retained Liabilities are referred to herein as the “Retained Liabilities.” The Retained Liabilities include, without limitation, the following:
  
(i)    any and all indebtedness (whether or not relating to the Portamedic Business), including without limitation Liabilities arising out of or relating to Seller’s credit facilities or any security interest related thereto;

(ii)    any and all trade account payable pertaining to periods on or prior to the Closing Date;

(iii)any and all Liabilities under the Business Contracts, other than the Liabilities specified in Section 2.6.1(i);

(iv)any and all Liabilities relating to any action, omission or breach of Seller or its Affiliates or Related Persons prior to Closing;

(v)all Liabilities arising out of or relating to the ownership, operation or conduct of the Portamedic Business or the Transferred Assets prior to the Closing, including, without limitation, any and all Proceedings set forth on the Seller Disclosures Schedules;

(vi)any and all Liabilities relating to any of the Excluded Assets;

(vii)any and all Liabilities consisting of, arising out of or relating to (x) Taxes of Seller or its Subsidiaries; or (y) Taxes relating to the conduct or operation of the Portamedic Business by Seller or its Subsidiaries or otherwise arising in connection with the consummation of the Transactions;

(viii)any and all Liabilities relating to any Seller’s or its Affiliates employees (including Business Employees) and Business Independent Contractors, including, without limitation, Liabilities relating to Taxes, Employee Plans (in each case, whether arising under Law, Contract or otherwise), Proceedings (whether grievances, administrative charges, harassment, discrimination, retaliation (including for failure by Buyer to hire or engage such Persons) or otherwise), Business Contracts, or WARN Obligations;
 
(ix)any and all Liabilities consisting of, arising out of or relating to Environmental Laws (other than Liabilities resulting from the actions of Buyer on the Assumed Leased Real Property after the Closing Date);

(x)any and all Liabilities relating to any of Seller’s shareholders or Related Persons of Seller or any creditors of Seller, including, without limitation, Liabilities relating to dissenters’ rights, appraisal rights and any other Liabilities relating to or arising out of Seller’s entry into this Agreement and performance of its obligations hereunder or otherwise relating to the use of Purchase Price proceeds received by Seller pursuant to this Agreement;

(xi)any and all Liabilities arising out of any Proceeding pending as of the Closing, including without limitation those set forth on Schedule 3.17.3, or otherwise relating to the Portamedic Business or the Transferred Assets (or the actions or omissions of Sellers or its Affiliates) prior to the Closing;

(xii)any and all Liabilities arising out of any Proceeding commenced after the Closing and arising out of or relating to any occurrence or event happening prior to the Closing;
 
(xiii)any and all Liabilities arising out of or resulting from Seller’s compliance or noncompliance with any Law or Order;

12


(xiv)any and all Liabilities of Seller under this Agreement or any Ancillary Agreement;

(xv)any use, ownership or operation of Transferred Assets prior to the Closing;

(xvi)any and all Liabilities of Seller based upon Seller’s or its Affiliates’ acts or omissions occurring after the Closing; and
 
(xvii)all Liabilities under the Shared Contracts other than the Buyer Allocable Share Liabilities.

2.7    Savings Clause. Notwithstanding anything to the contrary in this Agreement, but without limitation of the Seller’s obligations under Article 5 of this Agreement shall not constitute an agreement to assign or transfer any Contract if an assignment or transfer or an attempt to make such an assignment or transfer of such Contract without the Consent of a third party would constitute a breach or violation thereof or affect adversely the rights of the Buyer thereunder. In the event any required Consent is not obtained on or prior to the Closing Date, without limitation of Buyer’s rights or remedies, Seller shall continue to use all reasonable best efforts (or best efforts, as applicable) consistent with its obligations under Article 5 to obtain such Consent after the Closing Date until such time as such Consent has been obtained. Until such time as such Consent has been obtained, the Parties shall enter into commercially reasonable cooperative arrangements to deliver to Buyer the full benefits under such Contract (and the assumption of any Assumed Liabilities relating thereto, if any). Nothing in this Section 2.7 shall be deemed a waiver by Buyer of its rights to receive an effective assignment of all of the Transferred Assets.
3.
REPRESENTATIONS AND WARRANTIES OF SELLER
Seller hereby represents and warrants to Buyer as follows:
3.1    Organization, Standing and Authority. Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of New York. Seller is duly authorized, qualified or licensed to do business as a foreign corporation and is in good standing in each jurisdiction in which the nature of its activities makes such qualifications or licensing necessary under the applicable Laws, except for any such failures to be so qualified that would not reasonably be expected to result in a Material Adverse Effect. Seller has all requisite power and authority to own, operate and lease its assets and carry out its business as presently conducted.
 
3.2    Authorization and Binding Obligation. Seller has all corporate power and authority to (i) execute and deliver this Agreement and the Ancillary Agreements, (ii) to consummate the Transactions and (iii) to carry out and perform all of its obligations under this Agreement and the Ancillary Agreements. The execution and delivery of, and performance of the obligations contained in, this Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action. No other proceedings on the part of Seller or its shareholders are necessary to approve this Agreement or the Ancillary Agreements or to consummate the Transactions. No vote of any holder of any class or series of the Seller’s capital stock is necessary for the Seller to duly adopt this Agreement and consummate the Transactions. This Agreement has been duly executed and delivered by Seller, and this Agreement and the Ancillary Agreements each constitute the valid and legally binding obligation of Seller, enforceable against Seller in accordance with their terms, except as enforceability may be limited by bankruptcy, insolvency or similar Laws affecting the enforcement of creditors’ rights generally. The Seller Board has (i) determined that the Transactions, this Agreement and the Ancillary Agreements are fair to and in the best interests of the Seller and its shareholders, (ii) adopted and declared advisable this Agreement, the Ancillary Agreements, and the Transactions, (iii) determined, upon the advice of counsel, that the sale of the Transferred Assets set forth herein does not constitute all or substantially all of Seller’s assets under applicable Law and this Agreement is not required under applicable Law or Seller’s certificate of incorporation or bylaws to be submitted to the holders of capital stock of the Seller for approval at a shareholders’ meeting called and held for such purpose, (iv) taken all actions to comply with § 912 of the New York Business Corporation Law; (v) irrevocably resolved to elect, to the extent permitted by Law, for the Seller not to be subject to any Takeover Statute; and (vi) received a written opinion of its financial advisor to the effect that, as of the date of such opinion, the consideration to be received by the Seller in the Transactions is fair from a financial point of view to the Seller.

13


3.3    Absence of Conflicting Terms; Consents. Neither the execution, delivery or performance by Seller of this Agreement and the Ancillary Agreements, nor the consummation of the Transactions (or the assignment, sale and transfer of the Transferred Assets from Seller to Buyer contemplated herein) will (whether with or without the giving of notice, the lapse of time, or both): (a) require any Consent from any Governmental Authority (other than filings/notices under Form 8-K under the Exchange Act and under the rules of NYSE); (b) conflict with any provision of the certificate of incorporation or bylaws of Seller or any of its Subsidiaries; (c) except as set forth on Schedule 3.3(c), which shall be delivered by Seller pursuant to Section 5.6.9, require the Consent of any Person, or conflict with, result in a breach of, or constitute a default under (or permit termination or modification of or accelerate any rights or obligations under) any Business Contract; (d) except as set forth on Schedule 3.3(d), which shall be delivered by Seller pursuant to Section 5.6.9, require the Consent of any Person, or conflict with, result in a breach of, or constitute a default under (or permit termination or modification of or accelerate any rights or obligations under) under any other material Contract of Seller or its Subsidiaries, (e) violate any Law applicable to the Portamedic Business, the Transferred Assets, or Seller in connection therewith; or (f) result in the creation of any Encumbrance upon any Transferred Assets or otherwise require Buyer to pay any Tax.

3.4    Seller Reports; Financial Statements.
 
3.4.1    Seller has filed with or furnished to (as applicable) the Securities and Exchange Commission (“SEC”) on a timely basis all forms, statements, certifications, reports and documents required to be filed with or furnished to the SEC by the Seller under the Exchange Act or the Securities Act of 1933, as amended since January 1, 2009 (collectively, such forms, statements, certifications, reports and documents, including all exhibits, appendices and attached included or incorporated therein, filed or furnished since such date, being referred to herein as the “Seller Reports”). Each of the Seller Reports, at the time of its filing or being furnished (or, if amended prior to the date of this Agreement, as of the date of such amendment), complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), and any rules and regulations promulgated thereunder applicable to the Seller Reports. As of their respective dates (or, if amended, as of the date of such amendment), the Seller Reports did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances in which they were made, not misleading. The Seller is in compliance in all material respects with the applicable listing and corporate governance rules and regulations of NYSE. Each of the consolidated balance sheets included in or incorporated by reference into the Seller Reports (including the related notes and schedules) fairly presents in all material respects the consolidated financial position of the Seller and its consolidated subsidiaries as of its date and each of the consolidated statements of operations, shareholders’ equity and cash flows included in or incorporated by reference into the Seller Reports (including any related notes and schedules) fairly presents in all material respects the consolidated results of operations, retained earnings and changes in financial position, as the case may be, of the Seller and its consolidated subsidiaries for the periods set forth therein (subject, in the case of unaudited statements, to notes and year-end adjustments), and in each case have been prepared in accordance with GAAP, except as may be noted otherwise therein. The following are all of the Seller’s Subsidiaries: Heritage Labs International, LLC, Hooper Distribution Services, LLC; Hooper Information Services, Inc., Mid-America Agency Services, Incorporated, TEG Enterprises, Inc. All of these Subsidiaries are consolidated for accounting purposes, and none of these subsidiaries engage in or in the past five years have ever engaged in (or otherwise hold any Transferred Assets or in the past five years have held any assets or properties used in the Portamedic Business). Neither Seller nor any such Subsidiary has any equity interest (or right convertible or exchangeable into any equity interest) in any other Person.


14


3.4.2    Attached as Schedule 3.4.2 hereto are complete and correct copies of the following (collectively, the “Financial Statements”): the unaudited balance sheet (the “Most Recent Balance Sheet”) for the Portamedic Business as of June 30, 2013 (the “Most Recent Balance Sheet Date”) and March 31, 2013 and unaudited statements of the operating income for the Portamedic Business for each of the six-month period ended June 30, 2013 and the three-month period ended March 31, 2013 and for the years ended 2012 and 2013. The Financial Statements are true and correct in all material respects. The Financial Statements were derived from the books and records of Seller (which are true, complete and accurate), and fairly present the financial position and results of operations of the Portamedic Business as of the dates thereof and for the periods indicated therein. No business or operations are reflected in the Financial Statements other than the Seller’s Portamedic Business.

3.4.3    Seller has implemented and maintained, since December 31, 2010, a system of internal accounting controls and financial reporting (as required by Rule 13a-15(a) under the Exchange Act) that is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Seller maintains disclosure controls and procedures required by Rule 13a-15 or 15d-15 under the Exchange Act. Such disclosure controls and procedures (i) are designed to ensure that information required to be disclosed by the Seller is recorded and reported on a timely basis to the individuals responsible for the preparation of the Seller’s filings with the SEC and other public disclosure documents, and (ii) have been evaluated for effectiveness in accordance with the Sarbanes-Oxley Act and the results of such evaluations have been disclosed in the Seller Reports to the extent required by the Sarbanes-Oxley Act. There are no significant deficiencies or material weaknesses in the design or operation of Seller’s internal controls over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that would reasonably be likely to adversely affect the Seller’s ability to record, process, summarize and report financial information. Seller has changed its internal controls to correct such deficiencies and material weaknesses, and other than such corrections, since the date of such evaluation, there have been no significant changes in internal controls or in other factors that could significantly affect Seller’s internal controls. Seller has no Knowledge of any fraud, whether or not material, that involves management or other employees who have a significant role in Seller’s internal controls over financial reporting.
   
3.5    Undisclosed Liabilities. Neither Seller nor its Affiliates has any material Liability in respect of the Portamedic Business or the Transferred Assets, except for Liabilities which are reflected or reserved for on the face of the Most Recent Balance Sheet and any other Liabilities incurred in the ordinary course since the Most Recent Balance Sheet Date, which such Liabilities, for purposes of clarity, are “Retained Liabilities” for all purposes of this Agreement.

3.6    Title to Assets; Etc.

3.6.1    Seller has good, valid and marketable title to the Transferred Assets, in each case free and clear of all Encumbrances (other than Permitted Encumbrances), and, at the Closing, Buyer shall own, free and clear of any and all Encumbrances (other than liens arising solely by action of the Buyer), all right, title and interest in and to the Transferred Assets. Upon consummation of the Transactions, Buyer shall own good, valid and marketable title to the Transferred Assets.
 

15


3.6.2    Schedule 3.6.2 sets forth each item of Tangible Personal Property as of the date hereof. The Updated Schedule of Tangible Personal Property, which Seller is required to deliver pursuant to Section 5.6.3, sets forth, as of each of the dates delivered, (i) the location of each such item of Tangible Personal Property whose book value is $10 or more (provided, that the aggregate book value of all such items that each have a book value of less than $10 shall not exceed $5,000 in respect of the business/operations at any one of the Assumed Leased Real Properties); and, (ii) with respect to each “netbook” or similar device, the name and territory of the member of the Portamedic Staff in possession thereof. Each item of Tangible Personal Property is, in all material respects, in good repair and good operating condition, ordinary wear and tear excepted, is suitable for immediate use in the ordinary course of business, is free from latent and patent defects and its use complies in all material respects with all applicable Laws. No item of Tangible Personal Property is in need of repair or replacement other than as part of routine maintenance in the ordinary course of business. All Tangible Personal Property used in the Portamedic Business is in the possession of Seller (and as of the Closing will be in the possession and control of Buyer) and located at (a) the Assumed Leased Real Property (other than the “netbooks” assigned to Portamedic Staff, as set forth on the Updated Schedule of Tangible Personal Property) or (b) Basking Ridge Facility as of the date hereof and at the Assumed Leased Real Properties as of the Closing.
 
3.6.3    The Transferred Assets (i) constitute all of the assets, tangible and intangible, of any nature whatsoever, reasonably necessary to operate the Portamedic Business in the manner operated by Seller as of the date of this Agreement and (ii) include all of the assets and properties of Seller and its Affiliates used, held for use or otherwise relating to the Portamedic Business (other than the Excluded Assets). None of Seller’s Subsidiaries is engaged in or owns or controls (or has at any time owned or controlled) any assets or properties, whether tangible or intangible, used or held for use in the Portamedic Business. No representation is made by Seller as to the adequacy of Buyer’s working capital necessary for the operation of the Portamedic Business or Transferred Assets by Buyer after the Closing Date. No Person holds any power of attorney over any of the Transferred Assets, and no Person has provided any guarantee with respect to any of the Transferred Assets.
3.7    Leased Real Property.
3.7.1    Schedule 3.7.1(a) lists all Assumed Leased Real Property and the Leases by which Seller occupies such Assumed Leased Real Property. Schedule 3.7.1(b) delivered pursuant to Section 5.6.4, lists all Leased Real Property (other than the Assumed Leased Real Property) and the Leases by which Seller occupies such Leased Real Property. Schedule 3.7.1(c) sets forth, with respect to each Assumed Leased Real Property, the lease term, rent payment and other lease terms as set forth on such Schedule (the “Lease Chart”). The Assumed Leased Real Property includes each Leased Real Property where two or more full time Business Employees conduct the Seller’s Portamedic Business. Other than Seller’s Basking Ridge, New Jersey property, Seller’s Portamedic Business is conducted from no facilities or premises other than the Leased Real Properties.
 
3.7.2    Seller has a valid leasehold estate in each Assumed Leased Real Property, free and clear of all Encumbrances. Seller is not in breach of any Assumed Lease and there is no event, that, with or without the giving of notice, the lapse of time, or both, will result in Seller (or Buyer at or after the Closing) being in breach thereof. To Seller’s Knowledge, no other Person party to any Assumed Lease is in breach or violation thereof or, with or without the giving of notice, the lapse of time, or both, will be in breach thereunder. Seller has not received written notice of any default by Seller (or any condition or event which, after notice or lapse of time or both, would constitute a default) under any Assumed Lease. Each Assumed Lease is a legal, valid and binding agreement and obligation, enforceable in accordance with its terms, of Seller and, to Seller’s Knowledge, of each other Person party thereto. The Persons party to each Assumed Lease are the Seller and the landlord thereto, and there is no guarantor of Seller’s obligations under any of the Assumed Leases. Seller has paid all rent and other sums and charges due and payable by Seller under each of the Assumed Leases. Seller enjoys (and as of the Closing, Buyer will enjoy) peaceful and undisturbed possession of the Assumed Leased Real Property. No Person other than Seller has (and, as of the Closing, no Person other than Buyer shall have) any right to occupy or use any Assumed Leased Real Property. Seller does not owe (and Buyer as of the Closing will not owe) any brokerage commissions with respect to any Assumed Leased Real Property. Seller has delivered to Buyer true, correct and complete copies of the Assumed Leases in accordance with Section 5.6.10, including all material contracts to which Seller is a party with respect to construction on or improvement of any Assumed Leased Real Property and all plans and specifications relating to such construction or improvement. The Lease Chart sets forth an accurate, complete and correct description of the material terms in the Assumed Leases.

16


3.7.3    There does not exist any actual or, to Seller’s Knowledge, threatened condemnation or eminent domain proceedings, planned public improvements, annexation, special assessments, zoning or subdivision changes, or other adverse claims affecting any Assumed Leased Real Property or any part thereof, nor has Seller received any notice of the same. All Consents and Licenses that are required for the occupancy and use of the Assumed Leased Real Property by Seller (and by Buyer as of the Closing) have been obtained and are in full force and effect, and Seller is not in any default or violation thereunder. All buildings, structures, facilities, fixtures and other improvements located on the Assumed Leased Real Property are in compliance with all applicable laws (including those pertaining to zoning, building and the disabled) and are in good repair and good condition, ordinary wear and tear excepted, and are free from latent and patent defects.
3.8    [Intentionally Omitted]
3.9    Inventory. Schedule 3.9(a) attached hereto lists each item of inventory, its value (consistent with the fourth sentence below) and location as of June 30, 2013 (the “Inventory Schedule”). All items included in the Inventories consist of a quality and quantity usable in the ordinary course of business. Seller is not in possession of any inventory not owned by Seller, including goods already sold. All of the Inventories have been valued at the lower of cost or net realizable value on a first in, first out basis. Inventories on hand that were purchased after the Most Recent Balance Sheet Date were purchased in the ordinary course of business in quantities consistent with past practice and at a cost not exceeding market prices prevailing at the time of purchase. The quantities of each item of Inventories are not excessive but are reasonable in the circumstances of Seller. Work-in-process Inventories are valued according to GAAP. Except as set forth on Schedule 3.9(b), all Inventories are in the possession of Seller (and as of the Closing will be in the possession of Buyer) and, in each case, located at the Assumed Leased Real Properties.

3.10    Business Contracts; Shared Contracts.
  
3.10.1    Schedule 3.10.1(a) includes a list of all the Material Business Contracts (other than the Later Delivered Contracts) organized in a manner corresponding to the sub-clauses in the definition of “Material Business Contracts”; provided, that such Contracts that fall into the categories of “Material Business Contracts” identified in clauses (a), (b) or (j) of the definition of “Material Business Contract” shall be delivered by Seller in accordance with Section 5.6.2. Schedule 3.10.1(b), which Seller shall deliver in accordance with Section 5.6.2, includes a list of all the Later Delivered Contracts organized in a manner corresponding to the sub-clauses in the definition of “Material Business Contracts.” Seller has delivered to Buyer true, complete and correct copies of all the Material Business Contracts. Schedule 3.10.1 expressly identifies each Material Business Contract, the transfer, conveyance, delivery and assignment of which to Buyer pursuant to this Agreement requires the Consent of any Person or Governmental Authority.
 
3.10.2    Each Business Contract included within the Transferred Assets (except Contracts that naturally expire by their own respective terms) is in full force and effect and constitutes a valid, binding and enforceable obligation of Seller in accordance with the respective terms thereof, and represents a valid, binding and enforceable obligation of each of the other Persons parties thereto (except as enforceability may be limited by bankruptcy, insolvency or similar Laws affecting the enforcement of creditors’ rights generally and by equitable principles, including those limiting the availability of specific performance, injunctive relief, and other equitable remedies and those providing equitable defenses). No Business Contract included within the Transferred Assets is a Shared Contract. There exists no material breach or material default (or event that with or without notice or the lapse of time, or both, would constitute a material breach or material default) on the part of Seller or, to Seller’s Knowledge, on the part of any other Person party thereto, under any Business Contract included within the Transferred Assets, and as of the Closing Buyer will not be in material breach or material default under any such Business Contract. No event has occurred that with or without notice or lapse of time would permit termination, modification, or acceleration, under any Business Contract included within the Transferred Assets, and neither Seller nor, to Seller’s Knowledge, any other Person party thereto has repudiated any material provision of such Business Contract.

3.10.3    No Contracts under which Seller has received advances from or is indebted for money borrowed from vendors, suppliers, customers or other Persons permit such Persons to reduce or offset amounts due to Seller (or as of the Closing due to Buyer) against such amounts
.

17


3.10.4    Schedule 3.10.4, delivered pursuant to Section 5.6.5, lists each Shared Contract and identifies the categories of services provided under such Contract. Each Shared Contract is in full force and effect and constitutes a valid, binding and enforceable obligation of Seller in accordance with the respective terms thereof, and (i) represents a valid, binding and enforceable obligation (except with respect to due authorization of the signatory thereto) of each of the other Persons parties thereto and (ii) to Seller’s Knowledge, with respect to due authorization of the signatory thereto, represents a valid, binding and enforceable obligation, except in each case as enforceability may be limited by bankruptcy, insolvency or similar Laws affecting the enforcement of creditors’ rights generally and by equitable principles, including those limiting the availability of specific performance, injunctive relief, and other equitable remedies and those providing equitable defenses. There exists no material breach or material default (or event that with or without notice or the lapse of time, or both, would constitute a material breach or material default) on the part of Seller or, to Seller’s Knowledge, on the part of any other Person party thereto, under any Shared Contract. No event has occurred that with or without notice or lapse of time would permit termination, modification, or acceleration, under any Shared Contract, and neither Seller nor, to Seller’s Knowledge, any other Person party thereto has repudiated any material provision of Shared Contract

3.10.5    Each Business Contract described on Schedule 3.10.5 is terminable by Seller (and, as of the Closing, by Buyer) upon not more than 30 days’ written notice without penalty, payment or breach.

3.11    Intellectual Property.
 
3.11.1    Set forth on Schedule 3.11.1 is a list of (i) all Registered Business Intellectual Property and material unregistered Business Intellectual Property; (ii) all Domain Names that constitute Business Intellectual Property; and (iii) all databases included in the Transferred Assets.

3.11.2    The Business Intellectual Property contains no material viruses and other malware. None of the Business Intellectual Property is subject to any “open source,” “copyleft” or similar obligations that require the disclosure or licensing of any source code underlying any Business Intellectual Property. The Business Intellectual Property conforms in all material respects to the most recently-published specifications and documentation relating thereto. No governmental or university funding has been used to develop any Business Intellectual Property. None of the Business Intellectual Property is subject to any software escrow agreement. The Seller has exercised all reasonable efforts consistent with industry standards to preserve all trade secrets it may have covering the Business Intellectual Property. All Software comprising any Business Intellectual Property has been developed by individuals who were, at the time of development, either (i) employees of Seller or (ii) party to “work-for-hire” arrangements with Seller and who have executed instruments of assignment in favor of Seller as assignee of all Intellectual Property rights underlying such Software.

3.11.3    (a) Seller owns (and as of the Closing the Buyer will own) all right, title and interest in and to each item of Business Intellectual Property, free and clear of any Encumbrance, license or other restriction, (b) no item of Business Intellectual Property is subject to any outstanding Order restricting the transfer or assignment thereof, or the use thereof in connection with the operation of the Portamedic Business, or which may affect, in any material respect, the legality, validity, enforceability, access, use or ownership thereof, (c) no Proceeding is pending or, to Seller’s Knowledge, threatened that challenges the legality, validity, enforceability, access, use, or ownership of any such item, (d) no loss or expiration of such item is threatened, pending, or reasonably foreseeable; (e) the use of the Business Intellectual Property by Seller (and by Buyer after the Closing) does not and will not violate, conflict with or infringe upon, in any material respect, the rights of any Person; and (f) Seller has taken all reasonably necessary actions to maintain, preserve and protect the Business Intellectual Property. The operation of the Portamedic Business and the use of the Transferred Assets does not and do not infringe upon, violate, dilute, or misappropriate the rights of any Person and, to Seller’s Knowledge, there is no basis for or facts indicating any of the foregoing. Seller has not received any written notices alleging any such infringement, violation, dilution, or misappropriation. To Seller’s Knowledge, no Person has infringed upon, violated, diluted, or misappropriated any Business Intellectual Property rights of Seller.


18


3.11.4    None of the Business Intellectual Property includes any material licenses granted by any Person to Seller. Except as set forth on Schedule 3.11.4, none of the Business Intellectual Property has been licensed by Seller to any Person.
 
3.12    Tax Matters. Seller has timely filed or caused to be filed all Returns it was required to file. All such Returns are true, correct and complete in all material respects and are prepared in material compliance with all applicable Laws. All Taxes owed by Seller (whether or not shown or required to be shown on any Return) have been paid. There are no Encumbrances for Taxes on any of the Transferred Assets. Seller has withheld and paid all Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee or other payee of the Portamedic Business, and all Returns required with respect thereto have been properly completed and timely filed. Except as set forth on Schedule 3.12, to Seller’s Knowledge, no Returns of Seller currently are the subject of an active audit. No representative of any taxing authority is asserting in writing any Tax deficiency against Seller. Seller has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency. There is no tax sharing agreement, tax allocation agreement, tax indemnity obligation or similar written or unwritten agreement, arrangement, understanding or practice with respect to Taxes that will require any payment by Seller as a result of the transaction contemplated by this Agreement.
 
3.13    Absence of Changes or Events. Since the Most Recent Balance Sheet Date, (i) Seller has not taken any action of a type identified in Section 5.1.2; (ii) Seller has conducted and operated the Portamedic Business in the ordinary course of business, (iii) there has not been a material change in any method of accounting or accounting practice for the Portamedic Business; (iv) there has not been any material damage to or destruction or loss of any Transferred Asset (or other assets or properties owned or previously owned by Seller or its Affiliates relating to the Portamedic Business), whether or not such damage, destruction or loss is covered by insurance; (v) there has not been any sale, lease or other disposition (other than uses of Inventories in the ordinary course of business) of any Transferred Asset (or other assets or properties owned or previously owned by Seller or its Affiliates relating to the Portamedic Business); (vi) there has not been any creation of any Encumbrance, other than a Permitted Encumbrance, on any Transferred Asset; (vii) Seller has not received notice in writing (and to Seller’s Knowledge there has been no other indication) by any landlord, carrier, insurer, vendor, customer, supplier or other Person having business dealings with the Portamedic Business of any intention to discontinue, diminish or change the terms or conditions of its relationship with Seller (or with Buyer following the Closing); (viii) there has not been any cancellation or waiver of any claims or rights by Seller or any other Person relating to the Portamedic Business in any material respect; (ix) no Contract involving payments during calendar year 2012 or 2013 of more than $100,000 (in either or a combination of both such years) relating to the Portamedic Business has been terminated ; (x) there has been no acceleration, termination, material modification to, cancellation or, waiver under any material Contract relating to (and there has been no material change in the properties, assets, rights, conduct or operations of) Seller’s Portamedic Business; (xi) there has not been any Contract to take any action identified in any of the clauses of this Section 3.13; and (xii) there has not been any event, change, or development that has had or could reasonably be expected to have a Material Adverse Effect.
  
3.14    Insurance. Seller maintains insurance in respect of the Transferred Assets and the Portamedic Business covering such risks, in such amounts, with such terms and with such insurers as are consistent with industry practice (such insurance, the “Business Insurance Policies”). All of the Business Insurance Policies are in full force and effect. Seller is not in default of any such Business Insurance Policy. None of Seller or its Affiliates has received any notice of cancellation or non-renewal of any such Business Insurance Policy. Schedule 3.14(a) sets forth a true and complete list of (i) the Business Insurance Policies and (ii) with respect to the Business and the Transferred Assets, a list of all pending claims and the claims history for Seller since January 1, 2010. True, correct and complete copies of all Business Insurance Policies shall have been delivered to Buyer in accordance with Section 5.6.8. Except as set forth on Schedule 3.14(b), delivered pursuant to Section 5.6.11, there are no claims relating to the Portamedic Business or the Transferred Assets pending under such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights.
 

19


3.15    Employee Plans.

3.15.1    Set forth on Schedule 3.15.1 is a complete and correct list and summary of each Employee Plan. Copies of all written Employee Plans (and summaries of the material terms of all non-written Employee Plans) have been furnished to Buyer. Except as set forth on Schedule 3.15.1, each Employee Plan has been administered, funded and maintained in compliance in all material respects with its own terms and all Laws. All contributions to an Employee Plan for any period on or before the Closing Date which are not yet due have been paid or properly accrued in the Financial Statements in accordance with applicable Laws and GAAP and, to the extent not paid as of the Closing Date, will be paid when due. All premiums or other payments for all periods ending on or before the Closing Date have been (or will be) timely paid with respect to each Employee Plan. No Proceeding with respect to any Employee Plan is pending or, to the Knowledge of Seller, threatened. None of Seller or its Affiliates contributes to, or is required to contribute to, and none of them has contributed to or been required to contribute to, any Multiemployer Plan. The consummation of the transactions contemplated by this Agreement will not accelerate the time of payment or vesting of, or increase the amount of, or result in the forfeiture of compensation or benefits to any Business Employee under, any Employee Plan (or to any Business Independent Contractor under any Contract). Buyer shall not incur, and could not reasonably be expected to incur, by operation of Laws or otherwise, any liability under any Employee Plan or employment or labor Laws as a result of the Transactions.
 
3.16    Employee and Independent Contractor Matters.

3.16.1    Schedule 3.16.1(a), delivered pursuant to Section 5.6.7, lists by name all Business Employees, whether part-time or full-time, such individual’s job title, location, annual rate of salary or hourly wage rate, eligibility for commission, and first date of employment with Seller. Schedule 3.16.1(b), delivered pursuant to Section 5.6.7 lists by name all Business Independent Contractors who received compensation from Seller during 2013 (including the amounts as of June 30, 2013) and the date on which such Person became engaged by the Seller, their compensation, whether or not they are exclusive and the other material terms of their relationship with Seller.

3.16.2    No Business Employee is or has ever been subject to any collective bargaining agreement, and to Seller’s Knowledge, no union or collective bargaining representative has been certified as representing any Business Employee. To Seller’s Knowledge, there is no union campaign threatened or being conducted to attempt to gain recognition or certification of any union or collective bargaining representative with respect to any Business Employee. Seller has complied in all material respects with all labor and employment Laws and Contracts, and Seller has not received any notice from any Person or Governmental Authority of any actual or alleged violation of any such Law or Contract. There is not pending or, to Seller’s Knowledge, threatened against the Portamedic Business or Transferred Assets any Proceeding or Order relating to the employment of the Business Employees or the engagement of any Independent Contractor. There is no unsatisfied or unremedied grievance, arbitration award, judgment, or administrative fine against Seller or any agent, representative or employee of Seller, in each case related to the Portamedic Business or the Transferred Assets. To Seller’s Knowledge, Seller’s relations with its Business Employees and Business Independent Contractors is good.
 
3.16.3    Buyer is not, and after the Closing will not be, liable for severance pay or any other payment of monies, vacation pay and EBP, to any Business Employees as a result of the execution of this Agreement or for any other reason in any way arising by reason of the consummation of the Transactions contemplated hereby, including any change of ownership of the Transferred Assets.

3.16.4    Section 3.16.4 of the Seller’s Disclosure Schedule, which Seller shall deliver pursuant to Section 5.6.6, sets forth the Seller’s reduction in force plan, including the number of all anticipated terminations planned within the ninety (90) day period after the date hereof (identifying the planned dates of termination and the locations of employment). As of the date hereof and at all times between the date hereof and the earlier of (i) 30 days after the date hereof, (ii) the Closing Date and (iii) the termination of this Agreement in accordance with its terms, Seller has not incurred and will not incur any WARN Obligations.
  

20


3.17    Licenses; Compliance with Laws; Proceedings.
  
3.17.1    Schedule 3.17.1 lists all Licenses that are held by Seller or its Subsidiaries in connection with the Portamedic Business. Each of the Licenses is in full force and effect in accordance with its terms in all material respects. No legal action or other formal proceeding is pending or, to Seller’s Knowledge, threatened, to revoke, terminate, suspend, or cancel any of the Licenses or to impose any material forfeiture or penalty with respect to any of the Licenses. Seller has all material Licenses necessary to operate the Seller’s Portamedic Business.

3.17.2    The Portamedic Business is in compliance in all material respects, and the Transferred Assets are being operated in compliance in all material respects, with all applicable Laws.

3.17.3    The Portamedic Business (i) has not been operating under any Order, (ii) is not subject to any Order, and (iii) is not in default with respect to any Order. Neither Seller nor any of its Subsidiaries or legal advisors has received any inquiry, written or oral, from any such Governmental Authority concerning any alleged violation of Laws in connection with the operations or conduct of the Portamedic Business or the Transferred Assets during the five (5) year period prior to the date of this Agreement. Seller is not charged (or, to the Knowledge of Seller, threatened or under investigation with respect to) any alleged material violation of any Law relating to the Transferred Assets or the Portamedic Business. Except as identified on Schedule 3.17.3, there is no Proceeding pending by or against (or to the Knowledge of Seller, threatened against) Seller or Seller’s Affiliates related to, or affecting in any material respect, any of the Transferred Assets or the Portamedic Business or that could delay or prevent the consummation of the Transactions.

3.18    Environmental Matters.
 
3.18.1    Seller and, to Seller’s Knowledge, all Assumed Leased Real Property is in compliance in all material respects with all applicable Environmental Laws. Seller has never received any written notice of any violation of any Environmental Laws with respect to the Portamedic Business or any Assumed Leased Real Property. Nor has Seller received any written notice of any pending or threatened action by any Governmental Authority alleging Seller is not in compliance under any Environmental Law with respect to the Portamedic Business or the Assumed Leased Real Property.

3.18.2    Seller has not (i) transported or arranged for the treatment, storage or disposal of any Hazardous Substances or treated, stored, or disposed of any Hazardous Substances, in connection with the Portamedic Business that has resulted or is reasonably likely to result in any Liability or any investigative, corrective or remedial obligations under any Environmental Law or (ii) either expressly, by operation of Laws, pursuant to any Contract or otherwise, assumed, undertaken or indemnified any Person for any Liability, including any obligation for corrective or remedial action, of any other Person (other than the landlords under the terms of the applicable Leases) under any Environmental Laws with respect to the Portamedic Business or properties included in the Transferred Assets.

3.18.3    To Seller’s Knowledge, there are no environmental audits, government inspection or enforcement documents, Phase 1 or Phase 2 environmental site assessment reports, site investigation or remediation reports, or other evaluations of the presence of Hazardous Substances on or at the Assumed Leased Real Property that are in the possession of Seller.


21


3.19    Privacy Practices; Security. Seller’s and its Subsidiaries’ practices are and have at all times been in compliance in all material respects with their then-current privacy policies. Since January 1, 2010, Seller has implemented administrative, physical and technical safeguards that reasonably and appropriately protect the confidentiality, integrity and availability of Personal Information. Since January 1, 2010, neither Seller nor any of its Subsidiaries has experienced any material incident in which Personal Information or other sensitive data was or may have been stolen or improperly accessed, used, released or disclosed. There have been no breaches of security relating to Seller’s Portamedic Business which has not been promptly cured or redressed in accordance with applicable Laws. Without limiting the foregoing or any other provision of this Agreement, Seller has taken all necessary and appropriate steps to comply with the regulations set forth in 45 C.F.R. Parts 160, 162 and 164 as promulgated by the U.S. Department of Health and Human Services, and has obtained all written authorizations or assurances required under such regulations. Since January 1, 2010, neither Seller nor its Subsidiaries has received any notices or complaints from any Person or Governmental Authority regarding Personal Information or other data or otherwise relating to its or their privacy and security practices or procedures. Seller encrypts personal information and other sensitive or confidential data when at rest and in transit. Seller’s and its Subsidiaries’ respective collection, access, use, maintenance, storage, transfer and disclosure of any employee, client and/or consumer Personal Information in connection with the Portamedic Business, and access and disclosure to and/or use of such data by any Person conforms, and at all times has conformed, in all material respects to all Laws and Contracts. Seller has and at all times has had in place appropriate “business associate agreements” and confidentiality agreements under applicable Laws in effect with each client and each business associate, vendor, subcontractor and other Person to which it provides access to or discloses Personal Information.

3.20    Transactions with Affiliates. Seller is not a party to any business arrangement or relationship with any of its Affiliates or Related Persons with respect to the Transferred Assets or operation of the Portamedic Business, and none of its Affiliates or Related Persons owns any material property or material right, tangible or intangible, that is used in Seller’s operation of the Portamedic Business. No Business Employee or other employee, officer or director of Seller or its Subsidiaries (or any other Person beneficially owning more than 5% of the outstanding capital stock in Seller) or any other Portamedic Staff is party to any Business Contract, owns, controls or has any rights to any of the Transferred Assets or otherwise provides services or supplies to the Portamedic Business (other than in his or her capacity as a Business Employee or Business Independent Contractor).

3.21    Bonds; Letters of Credit. There are no construction, fidelity, performance, or other bonds, guaranties in lieu of bonds or letters of credit posted by Seller or its Affiliates in connection with Seller’s operation or ownership of the Portamedic Business.

3.22    Customers. Schedule 3.22, sets forth a true, correct and complete list of the fifty (50) largest customers (the “Major Customers”) of the Portamedic Division based on revenue for the six month period ended June 30, 2013. Since January 1, 2012, there has not been, nor to the Seller’s Knowledge is it anticipated that there will be, any material change in business relations with any of the Major Customers.
 
3.23    Solvency. Seller is not now insolvent and will not be rendered insolvent by any of the Transactions. Immediately after giving effect to the consummation of the Transactions: (i) Seller will be able to pay its Liabilities as they become due in the usual course of its business; (ii) Seller will not have unreasonably small capital with which to conduct its present or proposed business; (iii) Seller will have assets (calculated at fair market value) that exceed its Liabilities; and (iv) taking into account all pending and threatened litigation, final judgments against Seller in actions for money damages are not reasonably anticipated to be rendered at a time when, or in amounts such that, Seller will be unable to satisfy any such judgments promptly in accordance with their terms (taking into account the maximum probable amount of such judgments in any such actions and the earliest reasonable time at which such judgments might be rendered) as well as all other obligations of Seller. The cash available to Seller, after taking into account all other anticipated uses of the cash, will be sufficient to pay all such debts and judgments promptly in accordance with their terms.
  

22


3.24    Takeover Statutes; Absence of Rights Plan. No “fair price,” “moratorium,” “control share acquisition” or other similar anti-takeover Law (each, a “Takeover Statute”) or any anti-takeover provision in the Seller’s certificate of incorporation or bylaws is applicable to the Transactions. The adoption of this Agreement and the Transactions by the Seller’s board of directors represents all the actions necessary to render inapplicable to this Agreement and the Transactions, any restrictions on “business combinations” or similar restrictions to the extent, if any, such restrictions would otherwise be applicable to this Agreement or the Transactions. Neither the Seller nor any of its subsidiaries is party to any rights agreement, stockholder rights plan (or similar plan commonly referred to as a “poison pill”) or Contract (except for Employee Plans existing on the date hereof) under which the Seller or any of its subsidiaries is or may become obligated to sell or otherwise issue, register, redeem, repurchase, vote, transfer or dispose of any shares of its capital stock or any other securities.

3.25    Disclosure. No representation or warranty or other statement made by Seller in or pursuant to this Agreement, or otherwise in connection with the Transactions contains any untrue statement or omits to state a material fact necessary to make any of them, in light of the circumstances in which it was made, not misleading. Seller does not have Knowledge of any fact that has specific application to Seller (other than general economic or industry conditions) and that may materially adversely affect the assets, business, prospects, financial condition or results of operations of Seller that has not been set forth in this Agreement or Seller’s Disclosure Schedules.
  
3.26    Seller’s Disclosure Schedules. Seller’s Disclosure Schedules shall be organized based on the sub-sections contained in this Agreement. Seller shall be entitled to make disclosure on any Schedule by way of cross-reference to information disclosed on any other Schedule if the applicability of such other information is readily apparent on the face of such disclosure. No disclosure on a Schedule relating to a possible breach or violation of any Contract, Law or Order shall be construed as an admission or indication to any third party that a breach or violation exists or has actually occurred.

3.27    Brokers of Seller. Except for Cantor Fitzgerald, whose fees will be timely paid by Seller, no investment banker, broker or finder is entitled to any brokerage, finder’s or other fee or commission or reimbursement of expenses in connection with the Transactions.

4.
REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer hereby represents and warrants to Seller as follows:
4.1    Organization, Standing and Authority. Buyer is a corporation, duly organized, validly incorporated and in good standing under the laws of the State of New York. Buyer has all requisite corporate power and authority to own, operate and lease its assets and carry out its business as presently conducted.
  
4.2    Authorization and Binding Obligation. Buyer has the corporate power and authority to execute and deliver this Agreement and the Ancillary Agreements, to carry out and perform all of its other obligations under the terms of this Agreement and the Ancillary Agreements to which it is a party, and to consummate the Transactions. The execution and delivery of, and performance of the obligations contained in, this Agreement and the Ancillary Agreements and the Transactions have been duly authorized by all necessary corporate action on the part of Buyer. This Agreement and all Ancillary Agreements have been duly executed and delivered by Buyer, and this Agreement constitutes the valid and legally binding obligation of Buyer, enforceable against each of them in accordance with their terms, except as enforceability may be limited by bankruptcy, insolvency or similar Laws affecting the enforcement of creditors’ rights generally.


23


4.3    Absence of Conflicting Terms; Consents. Other than the Consents under Section 3.3, neither the execution, delivery or performance by Buyer of this Agreement and the Ancillary Agreements, nor the consummation of the Transactions (or the assumption of the Assumed Liabilities contemplated herein) will (whether with or without the giving of notice, the lapse of time, or both): (a) require the Consent of, notice to, or filing with, any Person or Governmental Authority relating solely to Buyer other than such Consents that Buyer has or at the Closing will obtain and such Consents that will not delay or prevent Buyer from consummating the Transactions; or (b) conflict with any provision of the certificate of incorporation or bylaws of Buyer.

4.4    Guaranty. Concurrently herewith, Buyer has delivered to Seller a guaranty guarantying Buyer’s obligation to pay the Closing Payment in accordance with the terms and conditions of this Agreement. Such guaranty is in full force and effect and is a valid and binding obligation of the guarantor thereunder and has not been amended or modified.

4.5    Special Purpose Entity. Buyer was formed for the purpose of acquiring the Transferred Assets and has no business operations.
 
4.6    Brokers of Buyer. No investment banker, broker or finder is entitled to any brokerage, finder’s or other fee or commission or reimbursement of expenses in connection with the Transactions based upon arrangements made by on behalf of Buyer.

5.
CERTAIN COVENANTS OF THE PARTIES

5.1    Conduct of the Business Prior to the Closing.
  
5.1.1    After the date of this Agreement until the Closing, Seller covenants and agrees on behalf of itself and its Subsidiaries, as follows (i) Seller shall conduct and operate the Portamedic Business in the ordinary course of business and in a manner consistent with past practice, (ii) Seller shall use its best efforts to preserve and maintain the goodwill of the Portamedic Business and Seller’s relationships with carriers, suppliers, regulators, Governmental Authorities, customers, vendors, physicians, examiners, landlords, employees, independent contractors and others with business dealings with the Portamedic Business, and (iii) Seller shall comply, consistent with the terms of this Agreement, with all applicable Laws and contractual requirements applicable to the ownership, conduct and operation, as applicable, of the Transferred Assets and the Portamedic Business.
  
5.1.2    Notwithstanding anything to the contrary in Section 5.1.1, except as required by applicable Law and except as set forth on Schedule 5.1.2, Seller shall not (and shall not permit its Subsidiaries to):

(i)acquire any assets to be used or held for use in the Portamedic Business, other than assets acquired in the ordinary course of business pursuant to existing Business Contracts and assets required to provide services pursuant to customer Contracts; it being agreed that Seller shall continue to purchase (at its sole expense) all Inventories in amounts and quality in the ordinary course consistent with past practice;

(ii)sell, transfer, license, lease, assign, or otherwise dispose of any Transferred Assets (other than uses of Inventory in the ordinary course in amounts and at prices materially consistent with past practice);
 
(iii)(A) sell, transfer, license, lease, assign or otherwise dispose of any material assets of Seller or its Subsidiaries other than in the ordinary course or at an arms’ length basis at fair value or intercompany transfers by or among the Seller and its Subsidiaries consistent with past practice and, in each case, in a manner that, after taking into account such transaction will not render Seller or its Subsidiaries insolvent or otherwise unable to pay their debts as they become due or (B) otherwise take any action that is reasonably likely to render Seller or its Subsidiaries insolvent;
 

24


(iv)adopt or propose any change to its certificate of incorporation (including by way of certificates of designation) or bylaws or any other applicable governing instrument or Contract that is reasonably likely to have the effect of delaying, preventing or rendering more difficult, unlikely or costly the consummation of the Transactions;

(v)adopt a plan of complete or partial liquidation, dissolution, merger, consolidation or recapitalization (other than the liquidation or dissolution of any Subsidiary that has no material assets or business operations as of the date of this Agreement), initiate or become subject to any bankruptcy proceeding or seeks any relief under any insolvency or bankruptcy Law, makes any assignment for the benefit of creditors or ceases material operations;

(vi)amend, modify or terminate (or waive any rights under) any Assumed Lease, Material Business Contract or Shared Contract, or enter into any Contract that would constitute a Material Business Contract or Shared Contract (or otherwise modify any Business Contract in a manner that would increase any of the Assumed Liabilities);

(vii)create, assume or permit to exist any Encumbrance upon any of the Transferred Assets (other than Permitted Encumbrances);

(viii)collect, or accelerate the collection of, any accounts receivable or pay, or delay the payment of, any accounts payable in a manner that is inconsistent with the operation of the Portamedic Business and past practice;
 
(ix)waive or compromise any material right relating to the Portamedic Business or the Transferred Assets;
 
(x)amend any existing Employee Plan or adopt any new Employee Plan, in each case, other than as required by applicable Law;

(xi)amend in any material respect the terms of any Contract with any Business Independent Contractor; or

(xii)agree or commit to take any of the foregoing actions.

5.2    [Intentionally Omitted]

5.3    Alternative Transactions.

5.3.1    Seller shall (and shall cause its officers, directors, employees, agents, advisors, Affiliates and other representatives (collectively, the “Seller Representatives”) to) immediately cease and cause to be terminated any discussions, negotiations or encouragements with any Person conducted heretofore with respect to an Acquisition Proposal and shall immediately request to be returned or immediately destroyed all information provided heretofore by or on behalf of Seller to such Person. Seller shall not, and shall cause the Seller Representatives not to, directly or indirectly (A) initiate, facilitate, solicit, encourage (including, without limitation, by way of furnishing non-public information) or accept any inquiries regarding, or the making of any proposal or offer that constitutes, or could reasonably be expected to result in, an Acquisition Proposal or (B) engage in, continue or otherwise participate in any discussions, communications or negotiations regarding an Acquisition Proposal. Neither Seller nor any of its Subsidiaries shall grant any waiver, amendment or release under any standstill agreement or confidentiality agreement.
 

25


5.3.2    Seller shall promptly (and in any event within twenty-four (24) hours after receipt by or notification from any Seller Representative) notify Buyer of the receipt (or notification) of any Acquisition Proposal or any inquiries relating to an Acquisition Proposal or any request for information from, or any negotiations sought to be initiated or continued with, either Seller or the Seller Representatives concerning an Acquisition Proposal. Seller’s notice shall include (i) a copy of any written Acquisition Proposal and any other documents provided to Seller with respect to such Acquisition Proposal or (ii) in respect of any Acquisition Proposal, any inquiry relating to an Acquisition Proposal or any request for information relating to an Acquisition Proposal not made in writing, a written summary of the material terms of such Acquisition Proposal, inquiry or request, including the identity of the Person or group of Persons making the Acquisition Proposal, inquiry or request. Seller shall keep Buyer informed on a current basis of the status, discussions, negotiations, or developments regarding any Acquisition Proposal, inquiry or request. In addition, Seller shall notify Buyer within one (1) Business Day of receipt of any of the following: (i) any written indication by any Person that could reasonably be expected to result in an Acquisition Proposal, (ii) any request for non-public information relating to Seller, and (iii) any inquiry or request for discussions or negotiations regarding an Acquisition Proposal. Seller shall not, after the date of this Agreement, enter into any agreement that would prohibit them from providing such information to Buyer.

5.3.3    Notwithstanding anything to the contrary in Section 5.3.1, if Seller or any of its Subsidiaries or any Seller Representatives receives an Acquisition Proposal from any Person whom the Seller Board believes in good faith to be bona fide and Seller has not breached any of its obligations under this Section 5.3, (i) Seller may contact and engage in discussions with such Person solely for the purpose of clarifying such Acquisition Proposal and any material terms and conditions thereof so as to determine whether such Acquisition Proposal is, or could reasonably be expected to result in, a Superior Proposal so long as Seller has informed such Person of the provisions of this Agreement; (ii) Seller or its Seller Representatives may, if the Seller Board determines in good faith (after consultation with its independent financial advisor and outside legal counsel) that failure to take such action would be inconsistent with the directors’ fiduciary duties under applicable Law and that such Acquisition Proposal constitutes, or is reasonably expected to result in, a Superior Proposal, then Seller and its Seller Representatives may (A) furnish, pursuant to a confidentiality agreement similar to that entered into with Buyer (with respect to the confidentiality provisions contained therein), information with respect to Seller and the Portamedic Business to the Person making such Acquisition Proposal; provided that Seller shall promptly (but no later than 24 hours) provide to Buyer any information concerning Seller or the Portamedic Business that is provided to any Person given such access which was not previously provided to Buyer or its representatives, and (B) participate in discussions or negotiations regarding such Acquisition Proposal.


26


5.3.4    Neither the Seller Board nor any committee thereof shall (a) approve or recommend, or publicly propose to approve or recommend, to shareholders of Seller any Acquisition Proposal, (b) approve, authorize or permit or allow Seller to enter into any letter of intent, asset purchase agreement, merger or acquisition agreement, share purchase agreement, share exchange agreement, option agreement or any other agreement, arrangement or understanding with respect to any Acquisition Proposal (other than an acceptable confidentiality agreement permitted under Section 5.3.3), (c) enter into any agreement, arrangement or understanding in principle requiring the Seller to abandon, terminate, or fail to consummate the Transactions or breach any of its obligations under this Agreement or (d) resolve, propose (whether or not to a third party) or agree to take any of the foregoing actions set forth in clauses (a), (b) or (c) (each of the items described in clauses (a) through (d) inclusive being referred to herein as a “Seller Adverse Recommendation Change”); provided, however, if the Seller Board determines in good faith, after consultation with outside legal counsel and its independent financial advisor, that a written Acquisition Proposal received by Seller in compliance with Section 5.3.3 (which has not been withdrawn) constitutes a Superior Proposal, the Seller Board may, only after termination of this Agreement in accordance with Section 8.1.4(ii) and payment of all amounts due pursuant to Section 8.3.1(ii), approve and enter into an agreement relating to a Superior Proposal, subject to the satisfaction of the following further conditions precedent: (w) Seller shall have provided prior written notice to Buyer, at least five (5) Business Days in advance of the Seller Board’s final determination whether to take such actions, which notice shall specify the reasons therefor and the material terms of the Acquisition Proposal received by Seller that constitutes a Superior Proposal, including a copy of the relevant proposed transaction agreements and other material documents with, and the identity of, the Person(s) making the Acquisition Proposal; (x) after providing such notice and prior to taking such actions, Seller shall, and shall cause its Seller Representatives to, negotiate with Buyer in good faith (unless Buyer states in writing that it does not desire to negotiate) during such five (5) Business Day period to make such adjustments in the terms and conditions of this Agreement that Buyer may desire to make, if any, so that such Acquisition Proposal would cease to constitute a Superior Proposal; (y) Buyer and its financial and legal advisors shall be permitted to make a presentation to the Seller Board regarding this Agreement and any adjustments thereto (to the extent Buyer desires to make such a presentation); and (z) the Seller Board shall have considered in good faith any changes to this Agreement that may be offered in writing by Buyer by 11:59 PM Eastern Time on the fifth Business Day of such five (5) Business Day period in a manner that could form a binding contract (including the complete form of definitive acquisition agreement executed by Buyer) and shall have determined in good faith after consultation with outside legal counsel and independent financial advisors that the Acquisition Proposal received by Seller has not been withdrawn and continues to constitute a Superior Proposal if such changes offered in writing by Buyer were given effect. In the event of any material revisions to the Superior Proposal (it being agreed that material revisions shall include any change in the purchase price, form of consideration, transaction timing, transaction financing or transaction structure for such Superior Proposal), Seller shall be required to deliver a new written notice to Buyer pursuant to the foregoing clause (w) and to comply again with the requirements of this Section 5.2.4 with respect to such new written notice.

5.3.5    Nothing contained in this Agreement shall prohibit the Seller Board from (i) taking and disclosing to the Seller’s shareholders a position with respect to a tender or exchange offer by a Third Party pursuant to Rules 14d-9 and 14e-2(a) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or (ii) disclosing the fact that the Seller Board has received an Acquisition Proposal if the Seller Board determines after consultation with its outside legal counsel that failure to take such actions would be inconsistent with its fiduciary duties under applicable Law (provided, however, that any such disclosures set forth in clauses (i) and (ii) of this Section 5.3.5 (other than a factually accurate “stop, look and listen” communication contemplated by Rule 14d-9(f) under the Exchange Act) shall be deemed to constitute a “Seller Adverse Recommendation Change” for purposes of this Agreement (including for purposes of Section 8.1.3(ii)) unless the Seller Board expressly publicly reaffirms its Seller Board Recommendation within three (3) Business Days after a written request by Buyer to do so (provided, that if such written notice is delivered to the Seller less than three (3) Business Days prior to the Seller Shareholders Meeting, the Seller Board shall so re-affirm its Seller Board Recommendation at least one Business Day prior to the Seller Shareholders Meeting. In no event shall the Seller Board recommend that Seller’s shareholders tender their shares in connection with any tender or exchange offer (or otherwise approve or recommend any Acquisition Proposal), which, for purposes of clarity, shall be deemed to be a Seller Adverse Recommendation Change for all purposes under this Agreement.

27


5.3.6    As used in this Agreement, “Acquisition Proposal” shall mean any proposal or offer from any Person or group (as defined under Section 13(d) of the Exchange Act) (other than Buyer) relating to, in a single transaction or series of related transactions, and whether or not pursuant to a bankruptcy or similar proceeding, any (i) acquisition of any assets or properties used or held for use in the Portamedic Business (including, without limitation, the Transferred Assets), (ii) acquisition of all or substantially all of the assets of Seller; (iii) acquisition of twenty-five percent (25%) or more of any class of capital stock or other equity securities of Seller, (iv) tender offer or exchange offer that, if consummated, would result in any Person or group beneficially owning twenty-five percent (25%) or more of any class of capital stock or other equity securities of Seller or (v) merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving Seller or any of its Subsidiaries.

5.3.7    As used in this Agreement, a “Superior Proposal” means any bona fide written Acquisition Proposal that (x) is on terms that the Seller Board determines in good faith (after consultation with outside legal counsel and independent financial advisors) are more beneficial and favorable to Seller’s shareholders from the financial point of view, taking into account all of the legal, financial (including the financing terms of such proposal), regulatory and other aspects of such Acquisition Proposal (including the likelihood and timing of consummation thereof) and this Agreement (including any changes in the terms of this Agreement committed to by Buyer to Seller in writing in response to such Acquisition Proposal or otherwise), and (y) the Seller Board has determined in its good faith judgment (after consultation with outside legal counsel and independent financial advisor and after taking into account all legal, financial (including the financing terms of such proposal), regulatory and other aspects of the proposal) is reasonably likely to be consummated (if accepted by Seller), except that (i) the references to “twenty-five percent (25%)” in the definition of “Acquisition Proposal” shall be deemed to be references to “fifty percent (50%)” and (ii) a “Superior Proposal” shall not include any acquisition consisting (whether in one step or a series of related steps) primarily of the assets or properties used or held for use in the Portamedic Business; it being the Parties’ intent that a Superior Proposal shall be limited to an Acquisition Proposal the ultimate purpose and intent of which is to purchase and sell all or substantially all of the assets of Seller (whether through the acquisition of equity, assets or otherwise).
 
5.3.8    If any Takeover Statute is or may become applicable to the Transactions, the Seller and the Seller Board shall grant such approvals and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on such transactions.


28


5.4    Governmental Authority Review.
 
5.4.1    In the event that any Governmental Authority indicates orally or in writing to Buyer or Seller that it has initiated, is considering to initiate, or plans to initiate (or has resumed, recommenced, or reopened or is considering or planning to resume, recommence or reopen) (or, in each case, words of similar import) any Proceeding, whether preliminary, initial phase or otherwise (an “Inquiry”), the Party receiving the Inquiry shall immediately (but no later than within one Business Day) notify in writing (and concurrent with such written notification deliver a copy of such Inquiry to) the other Party; provided, however, that in the event of oral Inquiries, such oral Inquiry shall be confirmed in writing by either Party promptly, but in no event less than three Business Days after receipt of such oral Inquiry (or notification from the other Party) to the applicable inquiring Governmental Authority, with a copy of such confirmation to be provided concurrently to the other Party. In the event any Party receives an Inquiry, Buyer shall have the right to terminate this Agreement pursuant to Section 8.1.3(iii); provided, that Buyer may not exercise this termination right until 11:59 pm Eastern Time on the eighth (8th) Business Day after the date on which both Buyer and Seller have received a copy of the Inquiry (such period of time being the “Seller’s Decision Period”); provided, further, that Buyer may not exercise such right if, prior to the last day of Seller’s Decision Period, the Governmental Authority indicates orally or in writing that it has withdrawn or terminated, or will not pursue (or words of similar import) such Inquiry; provided, further, that in the event of oral indications, such oral indication shall be confirmed in writing by the Party(ies) receiving such oral indication within two Business Days after receipt thereof to the applicable inquiring Governmental Authority, with a copy of such confirmation to be provided concurrently to the other Party. Seller may at any time during the Seller’s Decision Period send to Buyer a written notice (an “Election Notice”) agreeing to assume all Liabilities and Losses relating to the defense and resolution of the Inquiry by each of the Parties (subject to Section 5.4.3). If Seller fails to deliver to Buyer such an Election Notice within the Seller’s Decision Period, Seller shall be deemed to have waived its rights hereunder, and Buyer may at any time thereafter terminate this Agreement pursuant to Section 8.1.3(iii), provided, that Buyer may not exercise such right if, prior thereto, the Governmental Authority indicates orally or in writing that it has withdrawn or terminated or will not pursue (or words of similar import) such Inquiry; provided, further, that in the event of oral indications, such oral indication shall be confirmed in writing by the Party(ies) receiving such oral indication within two Business Days after receipt thereof to the applicable inquiring Governmental Authority, with a copy of such confirmation to be provided concurrently to the other Party.

5.4.2    During the Seller’s Decision Period, the Buyer and Seller shall cooperate with the applicable Governmental Authority with respect to the Inquiry
.
5.4.3    If Seller delivers to Buyer an Election Notice, Seller shall take all actions necessary or reasonable and in a timely manner, to permit and cause the Closing to occur prior to the End Date, including, without limitation, instigating or defending any Proceeding, and promptly removing or causing to be removed any Order, direction, determination, requirement, condition or limitation that prevents or is reasonably likely to prevent, or that makes illegal, the timely consummation of the Transactions before the End Date; provided, however, that Seller shall not be obligated to agree (and Seller shall not agree) to comply with any request, direction, determination, requirement or condition that would involve any undertaking or agreement to divest or hold separate (or impose any other limitation or requirement with respect to) any of the Transferred Assets, Seller’s Portamedic Business, or any of the assets or properties of Buyer or its Affiliates (or any other actions that could otherwise result in Losses or Liabilities to Buyer), in each case, unless Buyer and Seller mutually agree in writing.


29


5.4.4    All filings, applications, notices, analyses, appearances, presentations, memoranda, submissions, briefs, arguments, opinions and proposals made or submitted by or on behalf of any Party before any Governmental Authority in connection with the Transactions shall require the joint approval and be under the joint control of Buyer and Seller, acting with the advice of their respective counsel, it being the intent that the Parties will consult and cooperate with one another, and consider in good faith the views of one another, in connection with any such filing, application, notice, analysis, appearance, presentation, memorandum, submission, brief, argument, opinion and proposal. Notwithstanding the foregoing, nothing herein shall prevent a Party from responding to or complying with a subpoena or other legal process required by applicable Law or submitting factual information in response to a request therefore, copies or, as applicable, a summary of which shall be provided to the other Party except to the extent prohibited by applicable Law. In addition, except as prohibited by applicable Law, each Party shall (i) promptly notify the other Party of any written communication to that Party from any Governmental Authority relating to the Transactions; and (ii) not participate in any meetings or substantive discussions with any Governmental Authority with respect thereto without consulting with or offering the other Party a meaningful opportunity to participate in such meetings or discussions.
  
5.5    Cooperation. Subject to Section 5.4, the Seller and Buyer shall cooperate with each other and use their respective reasonable best efforts (provided, that, with respect to the Consents listed on Schedule 7.2.4, Seller shall use its best efforts) to take or cause to be taken all actions, and do or cause to be done all things reasonably necessary, proper or advisable on its part under this Agreement and applicable Laws to consummate the Transactions as soon as practicable, including preparing and filing as promptly as practicable all documentation to effect all necessary notices, reports, and other filings and to obtain as promptly as practicable all other Consents necessary or advisable to be obtained from any Person or Governmental Authority in order to consummate the Transactions and transfer to Buyer the Transferred Assets;.. Each Party shall keep the other reasonably apprised of the content and status of any material communications with, and material communications from any Person or Governmental Authority with respect to the Transactions. Nothing in this Agreement shall require either Seller or Buyer to make any expenditure or payment of funds (other than in respect of administrative, processing, legal and other normal fees imposed by any Person in connection with separating the Shared Contracts and/or obtaining Consents under the Business Contracts, all of which Seller shall be responsible for and pay). Without limitation of Seller’s obligations anywhere else in this Agreement, Buyer shall cooperate to provide non-confidential, pre-existing information reasonably requested by counterparties to Business Contracts and reasonably agree to any reasonable terms or reasonable conditions required by the counterparties to Business Contracts as a requirement of the consent to the transfer thereof to Buyer; provided, however, that nothing herein shall require Buyer to (i) make any expenditure or payment of funds or (ii) agree to any terms or conditions to which Buyer and its Affiliates do not normally, in the ordinary course of their business, agree. The Parties shall coordinate efforts and reasonably cooperate with one another to communicate with Persons from whom Consents may be sought in connection with the Transactions and with Portamedic Staff. Seller shall reasonably confer in good faith on a regular basis with Buyer regarding the Portamedic Business and Transferred Assets and the general status of ongoing operations and will notify Buyer of any event or occurrence that could reasonably be expected to materially delay, impair or prevent the consummation of the Transactions (provided that such notification shall not affect the covenants or agreements, rights or remedies of Buyer); provided, further, however, that prior to the Closing, Seller shall continue to exercise, in a manner consistent with the terms of this Agreement, control and supervision over its business.

5.6    Certain Agreements; Post-Signing Deliveries.

5.6.1     promptly as practicable after the date of this Agreement, Seller shall use its best reasonable efforts to assist and cooperate with Buyer in seeking amendments to (i) the Contracts listed on Schedule 5.6 and (ii) any Designated Later Delivered Contract In the event such amendments are not obtained to Buyer’s sole satisfaction prior to the Closing, such Contracts shall be designated as “Excluded Contracts” hereunder.
  

30


5.6.2    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer Schedule 3.10.1(b) identifying each Later Delivered Contract and specifying the nature of such Later Delivered Contract). Buyer shall then have the right, but not the obligation, to designate any such as a “Designated Later Delivered Contract.” Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer an updated Schedule 3.10.1(a) identifying each Material Business Contract that falls into any of the categories of “Material Business Contracts” identified in clauses (a), (b) or (j) of the definition of “Material Business Contract.”

5.6.3    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer the Updated Schedule of Tangible Personal Property contemplated in Section 3.6.2. Seller shall update the Schedule of Tangible Personal Property (including the Updated Schedule of Tangible Personal Property) described in Section 3.6.2 as of the date immediately prior to the Closing Date and deliver the same to Buyer at least one day before the Closing Date.
  
5.6.4    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer Schedule 3.7.1(b), including true, correct and complete copies of all Leases identified thereon. Buyer shall then have the right, but not the obligation, to designate any Lease (other than the leases with respect to the facilities at (i) Olathe, Kansas; (ii) Lenexa, Kansas; and (iii) the headquarters of Hooper Holmes Services located in Omaha, Nebraska) included on such Schedule 3.7.1(b) as an “Assumed Lease” for all purposes of this Agreement.

5.6.5    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer Schedule 3.10.4 and a true, correct and complete copy of each Shared Contract. Buyer shall then have the option to identify which, if any, of such Shared Contracts Buyer seeks to have separated (the “Designated Shared Contracts”). All Shared Contracts other than the Designated Shared Contracts shall be deemed “Excluded Assets” for all purposes hereunder. Seller shall use all reasonable best efforts to separate and cause to be separated the Designated Shared Contracts and, if necessary, obtain any applicable third party Consent required thereunder (or, if any such Shared Contract relates to a Consent listed on Schedule 7.2.4, Seller shall use its best efforts to separate and cause to be separated such Shared Contract and, if necessary, obtain any applicable third party Consent required thereunder). If, despite such efforts, the Designated Shared Contracts are not separated by the Closing Date, the rights and obligations under the Designated Shared Contracts shall be equitably allocated among (i) the Portamedic Business, on the one hand, and (ii) the Other Businesses and any other businesses in which Seller and/or its Affiliates engage after the Closing (subject to Section 5.16), on the other hand, in accordance with the following principles: (a) any allocation set forth on the face of a Designated Shared Contract shall control; (b) if there is no allocation set forth on the face of the Designated Shared Contract, then the Parties shall mutually determine the applicable allocation in good faith taking into consideration any quantifiable proportionate benefits to be received by Buyer and Seller thereunder; and (c) any volume discounts, rebates and other aggregated or bundled benefits shall be allocated proportionately based on revenue. Buyer’s share of such equitable allocations shall be referred to as “Buyer Allocable Share Liabilities” and “Buyer Allocable Share Rights,” as applicable. For clarity, to the extent Seller is required to provide any service or benefit to Buyer pursuant to the Transition Services and such service or benefit is subject to any Designated Shared Contract, Buyer shall not be charged for any amounts under such Shared Contract.

5.6.6    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer a true, correct and complete copy of the schedule required under Section 3.16.4.

5.6.7     7 Business Days after the date of this Agreement, Seller shall deliver to Buyer Schedule 3.16.1(a) and Schedule 3.16.1(b).
 
5.6.8    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer the Business Insurance Policies required under Section 3.14.

5.6.9    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer Schedule 3.3(c) and Schedule 3.3(d) required under Section 3.3.


31


5.6.10     7 Business Days after the date of this Agreement, Seller shall deliver to Buyer the Assumed Leases as required under Section 3.7.2.

5.6.11    Within 7 Business Days after the date of this Agreement, Seller shall deliver to Buyer Schedule 3.14(b) required under Section 3.14.

5.6.12    Within 7 Business Days after the date of this Agreement, Seller shall propose to Buyer additional items to add to Schedule 3.11.1, which Buyer may accept or reject in its discretion
.
5.7    Transition Services.
  
5.7.1    In order to facilitate the orderly transition of the Portamedic Business to Buyer after the Closing, for a period of three (3) months following the Closing Date (the “Transition Term”), Seller shall provide, or cause to be provided, to Buyer, the services described on Schedule 5.7.1 (“Transition Services”) in accordance with the material terms set forth on such Schedule 5.7.1. If Buyer wishes to extend the term of any such Transition Services beyond such three (3) month period, Seller and Buyer shall negotiate the terms such extension in good faith. Buyer agrees to reimburse Seller for Seller’s actual, direct, out-of-pocket cost, without markup, to provide the applicable Transition Services to Buyer; provided, however, that all out-of-pocket costs shall be pre-approved by Buyer. Upon Buyer’s request, Seller shall provide Buyer with access to such books, records and other information as may be reasonably necessary for Buyer to verify such cost.
 
5.7.2     limitation of Section 5.7.1, from and after the date hereof, the Seller and Buyer shall use their reasonable efforts and shall cooperate with one another to provide for the orderly separation and transition to Buyer in accordance with all applicable Laws of the information technology systems and databases of the Portamedic Business (including support and maintenance) and other Business Intellectual Property so that the Portamedic Business is independent of Seller’s systems as soon as practicable after the Closing Date (and in any event by the end of the term of Transition Term), and, in this regard, Seller shall provide such accounting, human resources and other information, including historic and archival backups of email communication, to Buyer in a format readable or convertible by the information technology systems of Buyer. To the extent necessary to achieve the transition services described in Section 5.7, Seller hereby grants to Buyer a limited, royalty free right and license to use any of Seller’s or its Subsidiaries’ intellectual property, but solely in connection with such transition services. Seller represents and warrants that it has all right and authority to grant the foregoing license. Seller shall reasonably cooperate with Buyer to provide and maintain, for a period of at least 12 months following the Closing, hyperlinks from Seller’s websites (on the homepages) to Buyer’s websites in a manner that is reasonably apparent and intended to permit customers, examiners and other Persons to patronize Buyer’s and its Affiliates’ businesses and utilize Buyer’s and its Affiliates’ services.

5.7.3    Buyer shall provide such licenses and assistance to Seller as is set forth on Schedule 5.7.3.

5.8    Insurance. Seller shall keep, or cause to be kept, all Business Insurance Policies in full force and effect from the date of this Agreement through the third anniversary of the Closing Date. Seller shall add Buyer as a named insured under such policies effective as of the Closing. Seller shall be responsible for handling the processing of, and obtaining payments for, any pending or future insurance claims arising from events related to the Transferred Assets, the Portamedic Business occurring prior to the Closing or otherwise relating to any Retained Liabilities; and the Parties agree that Seller shall be entitled to any amounts payable under any such insurance claims (subject to Seller’s indemnity obligations under Article 9). For clarity, Seller shall not terminate or permit its Subsidiaries to terminate any coverage under any Business Insurance Policies (i) consisting of occurrence-based policies so as to prevent Buyer from recovering under such policies for Losses from events occurring prior to the Closing or (ii) consisting of claims made policies so as to prevent Buyer from recovering under such policies for Losses prior to the Closing.


32


5.9    Tax Matters.
 
5.9.1    Seller and Buyer shall provide each other with such cooperation and information as each of them may reasonably request in preparing and filing any Tax return, report or form (“Returns”), amended Return or claim for refund, determining or contesting a liability for Taxes or a right to a refund of Taxes, participating in or conducting any audit or other proceeding in respect of Taxes. Such cooperation and information shall include providing copies of relevant Returns or portions thereof, together with accompanying schedules, related work papers and documents relating to rulings or other determinations by Tax authorities. Seller, and Buyer shall make their respective officers, employees, agents and representatives available on a basis mutually convenient to Buyer or Seller, as the case may be, to provide explanations of any documents or information provided hereunder. Seller and Buyer shall each retain all Returns, schedules and work papers, records and other documents in its possession relating to Tax matters of the Transferred Assets for each taxable period first ending after the Closing Date and for all prior taxable periods until the later of (a) the expiration of the statute of limitations of the taxable periods to which such Returns and other documents relate, without regard to extensions except to the extent notified by the other Party in writing of such extensions for the respective Tax periods, or (b) six (6) years following the due date (without extension) for filing such Returns.

5.9.2    Without limitation of Seller’s obligations under Section 2.6.3, Seller shall be responsible for all transfer, sales and other similar Taxes and fees, filing fees, recordation fees and application fees, if any, arising out of the transfer of the Transferred Assets pursuant to this Agreement.
 
5.10    Covenants Regarding Portamedic Staff.
 
5.10.1    Nothing herein shall oblige Seller following the Closing to retain or terminate any specific Business Employee or Business Independent Contractor (collectively, the “Portamedic Staff”), and Seller may in its sole discretion retain or terminate any Portamedic Staff; provided, that nothing herein is intended to modify or limit Seller’s obligations under Section 5.1. Buyer is not obligated to hire or engage any Portamedic Staff in connection with the Transactions. Buyer may elect, however, in its sole discretion, to interview, and to potentially enter into agreements (which may, at Buyer’s discretion, be independent contractor agreements) with, any or all Portamedic Staff. As promptly as practicable after the execution of this Agreement, Seller shall deliver to Buyer a complete schedule of all Portamedic Staff as of the date set forth on such schedule, which such schedule shall be updated every month and further updated one Business Day prior to the Closing Date. Subject to applicable Laws, Buyer shall have reasonable access to the human resources and personnel records of Seller (including, without limitation, salary and wage information, performance appraisals, disciplinary actions, and grievances) for the purposes of preparing for or conducting interviews with any Business Employee, as well as reasonable access to the files and records pertaining to the Business Independent Contractors for the purposes of preparing for or conducting interviews with any Business Independent Contractor. Seller shall provide Buyer with such access upon reasonable prior notice and during normal business hours.
  

33


5.10.2    Seller shall be responsible for the payment of all salaries, wages and other remuneration and all other Liabilities under any and all Employee Plans, including, without limitation, bonus payments and all vacation pay, whether earned prior to or after the Closing, termination and severance payments, and any and all payments required under the Worker Adjustment Restraining Notification Act or under any similar provision of any applicable Laws (collectively, “WARN Obligations”). Without limitation of the foregoing, Seller shall be responsible for the provision of health plan continuation coverage for the Portamedic Staff in accordance with the requirements under the Consolidated Omnibus Budget Reconciliation Act of 1985 or under any similar provision of any applicable Laws. Seller shall be responsible for, and shall cause to be discharged and satisfied in full, all amounts owed to Business Employees under any and all Employee Plans. Seller shall be liable for any claims made or incurred by any Business Employees, regardless of whether such claims are made or incurred before or after the Closing, under any Employee Welfare Benefit Plan or Employee Plan or otherwise arising in connection with any Business Employee’s employment by Seller or its Affiliates. Seller shall be responsible for any and all Liabilities under the Employee Welfare Benefit Plans and the Employee Plans. Seller shall be responsible for (a) complying with any WARN Obligations and (b) any and all Liabilities and Losses that may be assessed or are otherwise due to any Person pursuant to any WARN Obligations. Similarly, Seller shall be solely responsible for and shall discharge and timely pay all Liabilities under all Contracts relating to the Business Independent Contractors. Seller shall comply with any other applicable Laws and otherwise take all other actions necessary to fulfill Seller’s obligations set forth in this Section 5.10. Section 5.10 shall operate exclusively for the benefit of the parties to this Agreement and not for the benefit of any other Person, including, without limitation, any current, former or retired Portamedic Staff or the spouse or dependents of such Persons.

5.11    Notification of Certain Matters. Between the date of this Agreement and the Closing Date, each Party hereto shall promptly notify the other Party in writing of any fact, change, condition, circumstance or occurrence or nonoccurrence of any event of which it is aware that is reasonably likely to result in any of the conditions set forth in Article 6 becoming incapable of being satisfied. Delivery of such notice shall not relieve a Party of any obligations it may have under this Agreement or otherwise be deemed to cure any breach or violation of this Agreement.
 
5.12    Access to Properties, Books and Records; Reports. To the extent permitted by Law, Seller agrees that on and after the date hereof and until the Closing, during normal business hours, it shall permit Buyer and its Representatives reasonable access, upon reasonable notice, to the Transferred Assets and Seller’s books, records, Contracts, work papers, and documents to the extent related to the Portamedic Business and/or the Transferred Assets, as well as to the Portamedic Staff and, to the extent related to the Portamedic Business or the Transferred Assets, to any other Seller Representatives; provided, that the foregoing shall not require the Seller to disclose any information of the Seller or its subsidiaries that is subject to attorney-client privilege; provided, further that no investigation by Buyer shall be deemed to modify any representation or warranty made by Seller in this Agreement or the Ancillary Agreements. Any examination or request for information shall be conducted in such a manner so as not to interfere unreasonably with the business or operations of Seller or its Subsidiaries. Until the Closing, all such information shall be governed by the terms of that certain Non-Disclosure Agreement, dated as of March 27, 2013, by and between Buyer and Seller (the “Confidentiality Agreement”).


34


5.13    Confidentiality. The Confidentiality Agreement shall continue in full force and effect until the Closing, at which time the Confidentiality Agreement shall automatically terminate and, effective as of the Closing, Seller, on behalf of itself and its Subsidiaries, hereby waives, relinquishes and terminates any and all rights it may have under the Confidentiality Agreement. Seller shall, and shall cause its Affiliates and the Seller Representatives to, keep confidential (and not disclose to any Person or use for any purpose) all information relating to (i) the Transferred Assets, (ii) the Assumed Liabilities, (iii) the Retained Liabilities, (iv) the Portamedic Business and (v) Buyer and its businesses (including, without limitation, any archival copy which Seller retains pursuant to Section 2.1.4), except, in each case, to the extent such confidential information (a) becomes publicly available through no breach of this Agreement or (b) is required by Law, applicable regulatory agency or securities exchange to be disclosed. If Seller is ever required by Law to disclose the information subject to this Section 5.13, Seller shall notify Buyer promptly of the requirement so that Buyer may seek an appropriate protective order or waive compliance with this Section 5.13. If, in the absence of a protective order or the receipt of a waiver hereunder, Seller, on the written advice of counsel, is required to disclose the information subject to this Section 5.13, then Seller may disclose the information (and only such portion of the information as is required to be disclosed); provided, however, that Seller shall use its commercially reasonable efforts to obtain, at the request and expense of Buyer, an order or other assurance (as Buyer may designate) that confidential treatment will be accorded to such portion of information required to be disclosed. At the Closing, Seller shall deliver to Buyer assignments of all confidentiality agreements, non-solicitation and other similar Contracts entered into by Seller (or its Affiliates) with another Person in connection with a sales process or other possible transaction solely to the extent involving the Seller’s Portamedic Business or the Transferred Assets, and, promptly following the Closing, Seller shall require that each Person party to such Contracts return to Buyer or destroy (with a certification of such destruction) any and all confidential information (including analyses reflecting confidential information) relating to the Portamedic Business or Transferred Assets, in accordance with the terms of such Contracts. For clarity, Seller shall not waive or modify the terms or conditions of such Contracts.

5.14    Public Announcements. The initial press release with respect to the execution of this Agreement shall be a joint press release to be reasonably agreed upon by Buyer and Seller. Thereafter, neither Buyer nor Seller shall issue any press release or other public statement with respect to the Transactions or this Agreement without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by applicable Law or stock exchange rules as determined in the good faith judgment and upon the advice of outside counsel of the Party proposing to make such release, in which case the parties shall, to the extent lawful and practicable, consult with one another and cooperate as to the timing and contents (including whether to seek confidential treatment or other protective order) of any such press release or public announcement
  

35


5.15     Closing Access; Transfers. After the Closing, upon reasonable notice, Seller agrees to provide or cause to be provided reasonable access during customary business hours to the Seller’s and its subsidiary’s employees and to any books, records, documents, files and correspondence that Buyer may request (i) to comply with reporting, disclosure, filing, and other requirements of any Governmental Authority; or (ii) for use in any other judicial, regulatory, administrative or other proceeding or in order to satisfy Tax, audit, accounting, claims, regulatory, litigation or other similar maters. Seller agrees to (and to cause its Affiliates to) retain the books, records, documents, instruments, accounts, correspondence, writings, evidences of title and other papers relating to the business or operations of the Portamedic Business or the Transferred Assets for a period of at least six years from the Closing Date. After the Closing, Seller shall and shall cause its Subsidiaries to keep Buyer reasonably informed of material developments pertaining to any Retained Liabilities relating to any of Buyer’s of Buyer’s Affiliates employees, independent contractors, customers, carriers, landlords and others have business dealings with Buyer or Buyer’s Affiliates following the Closing, and Seller shall use its commercially reasonable efforts to settle, resolve and/or discharge such Retained Liabilities in manner reasonably designed to minimize any significant adverse impact on Buyer or its relations with such Persons. For clarity, Seller shall timely pay all Retained Liabilities consisting of (a) trade account payables relating to the Portamedic Business or (b) amounts owed under Employee Benefit Plans or Contracts, as applicable, relating to Portamedic Staff. The Parties intend that any and all properties, assets and rights of Seller and its Affiliates related to, used, held for use or contemplated to be used in connection with the Portamedic Business be duly assigned and transferred to Buyer under this Agreement (other than the Excluded Assets and the Retained Liabilities). Without limiting any of Seller’s representations and warranties herein or Buyer’s rights or remedies hereunder, if and to the extent that following the Closing is determined that Seller or any of its Subsidiaries owns, controls or otherwise holds any such properties, assets or rights, Seller shall promptly notify Buyer thereof in writing. Upon Buyer’s request, Seller shall provide Buyer with all information, original files, books and records pertaining thereto and take and cause its Subsidiaries to take any and all actions, and execute, acknowledge and deliver to Buyer all instruments of conveyance and transfer reasonably requested by Buyer to transfer to Buyer all right, title and interest therein, free and clear of all Encumbrances. Further, in such instruments of conveyance and transfer, Seller shall be deemed to make, mutatis mutandis, as of the date of transfer, all representations and warranties set forth in Article 3 applicable to such property, asset or right. Subject to Seller’s obligations in Section 5.13, after the Closing, Buyer agrees to reasonably cooperate with Seller to provide Seller with such reasonable access to such Transferred Assets and Buyer’s employees as may be reasonably necessary in connection with defending and settling proceedings and similar matters (other than (x) proceedings and similar matters with respect to which Seller may be required to provide indemnification under this Agreement or otherwise to Buyer and (y) any information that may be covered by attorney client privilege).

5.16    Non-Competition. As an inducement for Buyer to enter into this Agreement, Seller agrees that, until the fifth anniversary of the Closing Date, neither it nor any of its Subsidiaries shall, directly or indirectly, (i) acquire, own, have an equity interest in, manage, control or participate in the ownership, management or control of, or consult with, advise or provide any other services to, any Person engaged, directly or indirectly, anywhere in the world in any aspect of the Portamedic Business or in any activities which are otherwise competitive with the Portamedic Business (or prepare to do any of the foregoing); (ii) solicit, induce or encourage any employee, independent contractor or consultant of Buyer or Buyer’s Affiliates (other than examiners) to perform any services for or on behalf of Seller or its Subsidiaries or to otherwise terminate or decrease the services such Person is providing to Buyer or Buyer’s Affiliates; or (iii) solicit, induce or encourage any employee, independent contractor or consultant of Buyer or Buyer’s Affiliates (including examiners) to perform any Portamedic services for or on behalf of Seller or its Subsidiaries or to otherwise terminate or decrease the services such Person is providing to Buyer or Buyer’s Affiliates. For the avoidance of doubt, Buyer acknowledges and agrees that the ownership, management, control and operation of the Other Businesses as owned, managed, controlled and operated by Seller as of the date of this Agreement shall not be deemed to violate this covenant
.
5.17    Corporate Names. Without limitation of Seller’s obligations in Section 5.7 (relating to hyperlinks), as soon as practicable after the Closing Date, but in any event no later than 30 days thereafter, Seller shall and shall cause its Affiliates to remove from all websites, materials, corporate names and elsewhere the “Portamedic” and other trademarks and names included within the Transferred Assets and to terminate, cease and desist all use of such trademarks and names, whether under a “d/b/a”, in metadata, in invoices or otherwise.

36


5.18    Remittance of Payments Received. If Seller or any of its Subsidiaries receives any payment or proceeds belonging to Buyer pursuant to the provisions of this Agreement, Seller shall promptly notify and remit (and cause to be remitted) such payment and proceeds to Buyer. If Buyer or any of its Affiliates receives any payment or proceeds belonging to Seller pursuant to the provisions of this Agreement, Buyer shall promptly notify and remit (and cause to be remitted) such payment and proceeds to Seller.
 
6.
CONDITIONS PRECEDENT TO OBLIGATIONS OF BUYER AND SELLER TO CLOSE

6.1    Conditions Precedent to Obligations of Buyer to Close. The obligations of Buyer to consummate the Transactions to occur at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each of the following conditions, all or any of which may be waived in writing, in whole or in part, by Buyer to the extent permitted by applicable Law:

6.1.1    Representations and Warranties of Seller. The representations and warranties of Seller set forth in Article 3 shall be true and correct in all material respects as of the Closing Date (without giving effect to any materiality or Material Adverse Effect qualifiers), as though made on the Closing Date (except for representations or warranties that expressly speak as of a specific date, in which case such representations and warranties shall be true and correct as of such other specific date), with the same force and effect as though such representations and warranties had been made on and as of the Closing Date.

6.1.2    Seller’s Covenants and Conditions. Seller shall have performed and complied in all material respects with all of the covenants, obligations and agreements required by this Agreement to be performed or complied with by it prior to or on the Closing Date.

6.1.3    No Material Adverse Effect. There shall not have occurred or be occurring any Material Adverse Effect.

6.1.4    No Injunction. There shall be no Order issued by any Governmental Authority directing that the Closing not be consummated.

6.1.5    Inquiries. If any Inquiry shall have arisen prior to the Closing Date, such Inquiry shall have been resolved to the mutual satisfaction of Buyer and Seller.

6.1.6    Deliveries. Seller shall have made all the deliveries to Buyer set forth in Section 7.2.

6.2    Conditions Precedent to Obligations of Seller to Close. The obligations of Seller to consummate the Transactions to occur at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each of the following conditions, all or any of which may be waived in writing, in whole or in part, by Seller to the extent permitted by applicable Law:
 
6.2.1    Representations and Warranties of Buyer. The representations and warranties of Buyer set forth in Article 4 shall be true and correct in all material respects as of the Closing Date, as though made on the Closing Date (except for representations or warranties which expressly relate to an earlier date, in which case such representations and warranties shall be true and correct at and as of such earlier date), except where the failure of such representations and warranties to be true and correct has not had and would not reasonably be expected to have a material adverse effect on Buyer’s ability to consummate the Transactions.

6.2.2    Buyer’s Covenants and Conditions. Buyer shall have performed and complied in all material respects with all of the covenants, obligations and agreements required by this Agreement to be performed or complied with by it prior to or on the Closing Date
.
6.2.3    No Injunction. There shall be no Order issued by any Governmental Authority directing that the Closing not be consummated.

37


6.2.4    Inquiries. If any Inquiry shall have arisen prior to the Closing Date, such Inquiry shall have been resolved to the mutual satisfaction of Buyer and Seller.

6.2.5    Deliveries. Buyer shall have made all the deliveries set forth in Section 7.3.

7.
CLOSING AND CLOSING DELIVERIES

7.1    Closing.
 
7.1.1    Closing Date. The consummation of the transactions contemplated by this Agreement (the “Closing”) will take place on the later of (i) September 30, 2013 (which may be extended by Buyer, upon written notice to Seller, to October 15, 2013) and (ii) the first Business Day (such date, the “Closing Date”) that is two (2) Business Days after the satisfaction or waiver of all conditions to Closing identified in Article 6 (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the fulfillment or waiver of those conditions), or such other Business Day as the Parties shall mutually agree in writing. The Closing shall be held at the offices of Munger, Tolles & Olson LLP, commencing at 10:00 a.m., Los Angeles time, on the Closing Date, or at such other time and location as Seller and Buyer mutually agree in writing.
 
7.2    Deliveries by Seller. Prior to or at the Closing, Seller shall deliver to Buyer the following, in form and substance consistent with the terms of this Agreement and reasonably satisfactory to Buyer:
  
7.2.1    General Assignment and Bill of Sale. A duly executed general assignment and bill of sale in the form set forth on Exhibit B attached hereto.

7.2.2    Assignment of Business Intellectual Property. A duly executed trademark assignment in the form set forth on Exhibit C attached hereo, and other duly executed assignments of rights in and to Business Intellectual Property (including, without limitation, Domain Names), in form and substance reasonably satisfactory to Buyer and Seller.

7.2.3    Transferred Assets. Possession of, and physical control over, all Transferred Assets, including, without limitation, originals of all Business Contracts included within the Transferred Assets.

7.2.4    Consents. The originals or copies of each consent to assignment or consent to transfer of business, as applicable, listed on Schedule 7.2.4 in a form reasonably satisfactory to Buyer.

7.25    Secretary’s Certificate. A certificate, dated as of the Closing Date, executed by the secretary of Seller certifying that the resolutions, as attached to such certificate, were duly adopted by the Seller Board, authorizing and approving the execution, delivery and performance of this Agreement and the Ancillary Agreements and the consummation of the Transactions and that such resolutions were duly adopted and remain in full force and effect without amendment.

7.2.6    Officer’s Certificate. A certificate, dated as of the Closing Date, executed by a duly authorized officer of Seller certifying that the conditions set forth in Sections 6.1.1 and 6.1.2 have been satisfied.

7.2.7    Lien Releases. Evidence reasonably satisfactory to Buyer that all Encumbrances encumbering the Transferred Assets have been terminated, released or waived, as appropriate, or original instruments in form reasonably satisfactory to Buyer effecting such terminations, releases or waivers and all amounts owed under the Keltic Facility have been or simultaneous with the Closing will be repaid.
 
7.2.8    Payment of Certain Parties. Evidence reasonably satisfactory to Buyer that all examiners engaged in the Portamedic Business have been paid all amounts due to them within 7 days prior to the Closing consistent with Seller’s prior payment practices as of the Closing Date.

38


7.2.9    Other Instruments. Such other certificates, instruments or other documents reasonably requested by Buyer and necessary to effectuate the Transactions.

7.3    Deliveries by Buyer. Prior to or at the Closing, Buyer shall deliver to Seller the following, in form and substance consistent with the terms of this Agreement and reasonably satisfactory to Seller:

7.3.1    Closing Payment. The Closing Payment.

7.3.2    Secretary’s Certificates. A certificate, dated as of the Closing Date, executed by the secretary of Buyer certifying that the resolutions, as attached to such certificate, were duly adopted by the board of directors of Buyer authorizing and approving the execution, delivery and performance of this Agreement and the Ancillary Agreements and the consummation of the Transactions and that such resolutions were duly adopted and remain in full force and effect without amendment.

7.3.3    Officer’s Certificates. A certificate, dated as of the Closing Date, executed by a duly authorized officer of each of Buyer certifying that the conditions set forth in Sections 6.2.1 and 6.2.2 have been satisfied.
 
8.
TERMINATION

8.1    Method of Termination. This Agreement may be terminated and the Transactions may be abandoned at any time prior to the Closing:
  
8.1.1    by the mutual written consent of Buyer and Seller;

8.1.2     either Buyer or Seller:

(i)if the Transactions shall not have been consummated by December 31, 2013 (the “End Date”), provided, however, that such termination right shall not be available to any Party whose breach of any provision of this Agreement results in the failure of the Transactions to be consummated by the End Date; or

(ii)if there shall be any Order that restrains, enjoins or otherwise prohibits or makes consummation of the Transactions illegal; provided, however, that such termination right shall not be available to any Party whose breach of any provision of this Agreement results in the application or imposition of such Order.
 
8.1.3    by Buyer:

(i)    if a breach of any representation, warranty, covenant, obligation or agreement on the part of Seller set forth in this Agreement has occurred which breach, either individually or in the aggregate with all other breaches by Seller, would reasonably be expected to cause any of the conditions set forth in Section 6.1 not to be satisfied by the End Date and such breach is not cured prior to the earlier of (A) the Business Day immediately preceding the End Date or (B) within thirty (30) days after written notice of such breach has been given to Seller; provided, however, that Buyer is not then in material breach of this Agreement; provided, further, however, that Buyer’s right to terminate this Agreement in connection with breaches of Section 5.3 shall be controlled by Section 8.1.3(ii);
 
(ii)    if (A) there shall have occurred any Seller Adverse Recommendation Change, (B) a tender offer or exchange offer for shares of capital stock of Seller that constitutes an Acquisition Proposal is commenced prior to the Closing and the Seller Board fails to recommend against acceptance of such tender offer or exchange offer by the Seller’s shareholders (including, for these purposes, by taking no position with respect to the acceptance of such tender offer or exchange offer by its shareholders, which shall constitute a failure to recommend against acceptance of such tender offer or exchange offer) within three (3) Business Days after commencement, (C) Seller breaches its obligations in Section 5.3, or (D) Seller publicly announces its intention to do any of the foregoing; or

(iii)pursuant to Section 5.4.1 effective upon written notice delivered to Seller.

39


8.1.4    by Seller
 
(i)    if a breach of any representation, warranty, covenant, obligation or agreement on the part of Buyer set forth in this Agreement has occurred which breach, either individually or in the aggregate with all other breaches by Buyer, would reasonably be expected to cause any of the conditions set forth in Section 6.2 not to be satisfied by the End Date and such breach is not cured prior to the earlier of (A) the Business Day immediately preceding the End Date or (B) within thirty (30) days after written notice of such breach has been given to Buyer; provided, however, that Seller is not then in material breach of this Agreement; or

(ii)    subject to complying with the terms of Section 5.3, the Seller Board authorizes Seller to enter into a binding definitive agreement in respect of a Superior Proposal prior to five (5) Business Days before any scheduled Closing Date; provided that Seller shall have paid all amounts due pursuant to Section 8.3.1(ii) in accordance with the terms, and at the times specified therein; and provided further that in the event of such termination, Seller substantially concurrently enters into a such definitive agreement in respect of such Superior Proposal
.
8.2    Effect of Termination. In the event of the termination of this Agreement pursuant to Section 8.1, this Agreement shall forthwith become null and void and there shall be no Liability on the part of any Party hereto; provided, however, that (a) this Section 8 and Section 10 shall survive any such termination and (b) nothing herein shall relieve any Party from liability for any willful or intentional breach of this Agreement prior to such termination.

8.3    Termination Fee; Expenses.
  
8.3.1    Notwithstanding any other provisions of this Agreement,
 
(i)    if this Agreement is terminated by Buyer pursuant to Section 8.1.3(ii), Seller shall immediately pay Buyer (A) a fee of $450,000 (the “Termination Fee”) and (B) an amount equal to the Buyer Expenses, in each case, by wire transfer of immediately available funds to an account designated in writing by Buyer;

(ii)    if this Agreement is terminated by Seller pursuant to Section 8.1.4(ii), Seller shall, concurrently with such termination, pay Buyer (A) the Termination Fee and (B) an amount equal to the Buyer Expenses, in each case, by wire transfer of immediately available funds to an account designated in writing by Buyer;

(iii)    if (A) this Agreement is terminated pursuant to any provision of this Agreement (other than Section 8.1.3(ii), Section 8.1.4(i) or Section 8.1.4(ii)) and (B) within 12 months after the date of such termination the Seller enters into or consummates a definitive agreement with respect to any Acquisition Proposal, then within one Business Day after entering into such definitive agreement, the Seller shall pay to Buyer the Termination Fee and an amount equal to the Buyer Expenses, in each case, by wire transfer of immediately available funds to an account designated in writing by Buyer; and

(iv)if this Agreement is terminated (A) by either Party pursuant to Section 8.1.2(i) and there has occurred any Inquiry that has not been fully and finally resolved by the End Date, or (B) by Buyer pursuant to Sections 8.1.2(i), 8.1.2(ii), 8.1.3(i), or 8.1.3(iii) then, in each case, Seller shall immediately pay Buyer an amount equal to the Buyer Expenses. “Buyer Expenses” shall mean all out-of-pocket costs and expenses incurred by or on behalf of Buyer in connection with entering into and performing under this Agreement and the Transactions (including, without limitation, all fees and expenses of counsel, accountants, experts and consultants) and expressly including the costs and expenses of enforcing Buyer’s rights hereunder.


40


9.
INDEMNIFICATION

9.1    Survival. The representations and warranties of Seller and Buyer set forth in Articles 3 and 4, respectively, other than the Fundamental Representations, shall survive the Closing until the date that is twenty four (24) months after the Closing Date. The Fundamental Representations shall survive the Closing indefinitely. The covenants and agreements of the Parties contained in this Agreement shall remain operative and in full force and shall survive until the full performance by the applicable Party of such covenant and agreement. Notwithstanding the foregoing, if a claim shall have been made in accordance with this Agreement prior to the expiration of the applicable survival period, then, in each such case, such survival period shall be extended as it relates to such claim until such claim is finally resolved or disposed of in accordance with the terms hereof.

9.2    Indemnification by Seller. After the Closing, Seller shall indemnify and hold Buyer and its Affiliates and their respective directors, officers, managers, employees, agents and representatives harmless against and with respect to, and shall reimburse such Persons for any and all Losses arising from or relating to:
  
9.2.1    any untruth, inaccuracy or breach by Seller of any representation or warranty set forth in Article 3;

9.2.2    any breach by Seller of any covenants, obligations or agreements of Seller contained in this Agreement or any Ancillary Agreement;
 
9.2.3    any of the Retained Liabilities; and

9.2.4    Seller’s failure to comply with any bulk sales laws in respect of the Transactions or any action brought thereunder.

9.3    Indemnification by Buyer. After the Closing, Buyer shall indemnify and hold Seller and its Affiliates and their respective directors, officers, managers, employees, agents and representatives harmless against and with respect to, and shall reimburse such Persons for any and all Losses arising from or relating to:
  
9.3.1    any untruth, inaccuracy or breach by Buyer of any representation or warranty set forth in Article 4;

9.3.2    any breach by Buyer of any covenants, obligations or agreements of Buyer contained in this Agreement or any Ancillary Agreement; and

9.3.3    any of the Assumed Liabilities.
 
9.4    Procedure for Indemnification. The procedure for indemnification shall be as follows:
  
9.4.1    Any Person claiming indemnification (the “Claimant”) shall give notice to the Party from whom indemnification is claimed (the “Indemnifying Party”) of any claim to which the Claimant is entitled indemnification under this Agreement promptly upon learning of such claim; provided, however, that the failure of the Claimant to give timely notice hereunder shall not relieve the Indemnifying Party of its obligations under this Article 9 unless, and only to the extent that, the Indemnifying Party has been actually and materially prejudiced thereby.


41


9.4.2    With respect to any claim by a third party as to which the Claimant is entitled to indemnification under this Agreement (a “Third Party Claim”), the Indemnifying Party shall have the right, at its own expense, to assume control of the defense of such claim with one or more counsel reasonably acceptable to the Claimant, and the Claimant shall cooperate with the Indemnifying Party (at the Indemnifying Party’s sole expense) so long as the Indemnifying Party elects in writing to assume such control and fully indemnifying Claimant hereunder with respect to such Third Party Claim within 20 days after receiving notice of such Third Party Claim. If the Indemnifying Party elects to assume control of the defense of any Third Party Claim, the Claimant shall have the right, but not the obligation, to participate in the defense of such claim at its own expense. If (i) the Indemnifying Party does not elect to assume control of the defense of such Third Party Claim within such 20 day period, or fails to timely and diligently prosecute such defense, or (ii) Claimant, based upon the advice of counsel, concludes that defense of such claim by the Indemnifying Party shall give rise to a conflict of interest (or the Claimant and Indemnifying Party have one or more materially different defenses available to them), then the Claimant may defend through counsel of its own choosing (at the Indemnifying Party expense), subject to the right of the Indemnifying Party to reasonably participate in the defense thereof (at its own expense), provided, that in no event shall the Indemnifying Party be responsible for the fees and expenses of more than one counsel for all Claimants in connection with any one matter. No Party shall compromise or settle any Third Party Claim without the prior written consent of the other Party (not to be unreasonably withheld, delayed or conditioned); provided, however, that if such compromise or settlement consists solely of monetary damages and provides for the full and unconditional general release of the Claimant from all Liability in connection with such claim, then the Indemnifying Party may settle such claim without the Claimant’s consent as long as the Indemnifying Party pays the entire recoverable amount of such claim and the settlement of such claim does not contain an admission of wrongdoing on the part of the Claimant.

9.4.3    As security for Seller's obligations and other agreements contained in this Agreement and the Ancillary Agreements, including but not limited to Seller’s indemnification obligations under the provisions of Article 9 hereof, and to make certain payments to Buyer under the provisions of Section 2.4.5 hereof, but without limitation of Seller's liability under this Agreement (or Buyer's other rights and remedies), Buyer is retaining the Holdback. From time to time, on not less than ten (10) days notice to Seller, Buyer may apply all or any part of the Holdback to pay or to provide for the payment of any Liability of any Seller under this Agreement or the Ancillary Agreements. On the first anniversary of the Closeout Date, Buyer shall pay to Seller, in cash without interest, the Holdback, less the amount of (i) any deductions therefrom under this Section 9.4.3 and (ii) any amounts then under dispute, which such disputed amounts shall be released upon final settlement of all disputed claims. Nothing in this Section 9.4.3 shall be construed as limiting the liability of Seller under this Agreement or the Ancillary Agreements (or otherwise limiting the rights or remedies of Buyer) to the amount of the Holdback.


42


9.4.4    A Claimant wishing to assert a claim for indemnification under this Article 9 which is not subject to Section 9.4.2 shall deliver to the Indemnifying Party a written notice (a “Claim Notice”) which contains (i) a description and, if then known or estimated, the amount (the “Claimed Amount”) of any Losses incurred by the Claimant or, if then known, the method of computation of the amount of such claim of any Losses, (ii) a statement that the Claimant is entitled to indemnification under this Article IX and an explanation of the then-known basis therefor, and (iii) a demand for payment in the amount of such Losses (including wire instructions if payment is requested to be made by wire transfer) or, with respect to the Buyer, if applicable, a statement that it intends in lieu thereof, to apply all or any part of the Holdback pursuant to Section 9.4.3 (which such statement shall be deemed to satisfy the 10 day notice required under Section 9.4.3). Within fifteen (15) days after delivery of a Claim Notice, the Indemnifying Party shall deliver to the Claimant a written response in which the Indemnifying Party shall: (A) agree that the Claimant is entitled to receive all of the Claimed Amount (in which case such response shall be accompanied by a payment by the Indemnifying Party to the Claimant of the Claimed Amount, by wire transfer or, with respect to Buyer, if applicable, an acknowledgment that Buyer will apply all or part of the Holdback Amount in accordance with Section 9.4.3); (B) agree that the Claimant is entitled to receive part, but not all, of the Claimed Amount (the “Agreed Amount”) (in which case such response shall be accompanied by a payment by the Indemnifying Party to the Claimant of the Agreed Amount, by wire transfer or with respect to the Buyer, if applicable, an acknowledgment that Buyer will apply all or part of the Holdback Amount in accordance with Section 9.4.3); or (C) contest that the Claimant is entitled to receive any of the Claimed Amount (or any part of the Claimed Amount other than the Agreed Amount) including the reasonably detailed reasons therefor. If the Indemnifying Party in such response contests the payment of all or part of the Claimed Amount, the Indemnifying Party and the Claimant shall use good faith efforts to resolve such dispute. If such dispute is not resolved within thirty (30) days following the delivery by the Indemnifying Party of such response, the Indemnifying Party and the Claimant shall each have the right to submit such dispute to a court of competent jurisdiction in accordance with the provisions of Section 10.3.
 
9.5    Limitation on Indemnification.
 
9.5.1    No Indemnifying Party shall have an obligation to indemnify the Claimant under Section 9.2.1 or Section 9.3.1, and no Claimant shall make any claim under Section 9.2.1 or Section 9.3.1, unless and until the aggregate amount of such Claimant’s Losses exceeds an amount equal to $100,000 (the “Deductible”), and then the Indemnifying Party shall only be liable for Losses exceeding the Deductible. Notwithstanding anything to the contrary in the foregoing, this Section 9.5.1 shall not apply in respect of (i) an inaccuracy in, or breach of, any Fundamental Representation, (ii) any claim for fraud, intentional misrepresentation or willful misconduct, or (iii) any claim under Sections 9.2.2, 9.2.3, 9.2.4, 9.3.2, or 9.3.3, all of which such claims set forth in the foregoing clauses (i), (ii), and (iii) shall be indemnifiable from “dollar one” without regard to any Deductible.

9.5.2    Notwithstanding anything to the contrary contained in this Agreement, (a) the aggregate maximum liability of any Party to another Party under Section 9.2.1 or Section 9.3.1 (in each case, other than in respect of an inaccuracy in, or breach of, a Fundamental Representation or a claim for fraud, intentional misrepresentation or willful misconduct) shall be limited to an aggregate amount equal to 50% of the Purchase Price, as adjusted, and (b) the aggregate maximum liability of any Party to another Party under Section 9.2.1 or Section 9.3.1 in respect of an inaccuracy in, or breach of, a Fundamental Representation (other than in respect of a claim for fraud, intentional misrepresentation or willful misconduct), shall be limited to an aggregate amount equal to the Purchase Price. For clarity, claims for fraud, intentional misrepresentation and willful misconduct shall not be limited in any way.
 
9.5.3    For the avoidance of doubt, any liability of Seller to Buyer pursuant to Sections 9.2.2, 9.2.3, 9.2.4, and any liability of Buyer to Seller under Sections 9.3.2, or 9.3.3 shall not be subject to any limitations, nor shall such liabilities be included in the calculation of the aggregate liabilities subject to the limitations forth in clause (a) and clause (b) of Section 9.5.2.

9.5.4    Solely for the purpose of calculating the amount of any Losses arising out of or resulting from any breach of any representation or warranty contained in this Agreement (and not for determining the existence of any breach of any representation or warranty contained in this Agreement), any reference to a “Material Adverse Effect” or “materiality” or other correlative terms in such representation or warranty shall be disregarded.

43


9.5.5    The amount of any Losses attributable to any claim by a third party as to which any Claimant is entitled to indemnification under this Article 9 shall be reduced by the amount, if any, actually received by the Claimant claiming indemnification in respect of such third-party claim from any Person (including any third-party insurance provider) less any out-of-pocket cost associated with receiving such amount (such amount being referred to herein as an “Alternative Reimbursement”), with respect to the Losses suffered thereby. If, after receipt by such Claimant of any indemnification payment hereunder in respect of such third-party claim, such Claimant receives an Alternative Reimbursement in respect of the same Losses for which indemnification was made and such Alternative Reimbursement was not taken into account in assessing the amount of indemnifiable Losses, then such Claimant shall accept such Alternative Reimbursement for the account of the Indemnifying Party and shall turn over all of such Alternative Reimbursement to the Indemnifying Party up to the amount of the indemnification paid by the Indemnifying Party pursuant to this Agreement in respect of the applicable claim for indemnification. The parties shall reasonably cooperate with each other to maximize the availability of any Alternative Reimbursements for indemnifiable claims hereunder arising from third-party claims, and, if any insurance provider for a Party agrees to defend any such third-party claim, such Person may tender the defense to such third-party insurance provider.

9.5.6    After the Closing, the sole and exclusive remedy of any Party for any claim (whether such claim is framed in tort, contract or otherwise) arising out of a breach of any representation, warranty, covenant or agreement of Seller or Buyer set forth in or made pursuant to this Agreement shall be a claim for indemnification under and pursuant to this Article 9, except for the remedies of specific performance, injunctive or other equitable relief; provided, however, that nothing in this Article 9 shall be deemed to limit a Party’s remedies for claims for fraud, intentional misrepresentation or willful misconduct.

9.5.7    Seller’s Representations Not Modified by Knowledge. Buyer’s rights to indemnification, payment of damages and other remedies based on Seller’s representations, warranties, covenants and agreements will not be affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) by Buyer at any time, whether before or after the Closing, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or agreement. The waiver by Buyer of any condition based on the accuracy of any representation or warranty, or on the performance of or compliance with any covenant or agreement (or the consummation of the transaction contemplated by this Agreement), will not waive, foreclose or otherwise affect Buyer’s right to indemnification, payment of damages or other remedy based on such representations, warranties, covenants and obligations.

10.
MISCELLANEOUS

10.1    Notices. All notices, demands and requests which may be or are required or permitted to be given, served, sent or delivered under the provisions of this Agreement shall be (a) in writing, (b) delivered by personal delivery, facsimile transmission (to be followed promptly by written confirmation mailed by certified mail as provided below) or sent by overnight courier service, (c) deemed to have been given on the earliest of: the date of personal delivery, the date of transmission and receipt of facsimile transmissions, or the next Business Day if delivered by overnight courier and (d) addressed as follows:

If to Seller:    Hooper Holmes, Inc.
170 Mt. Airy Road
Basking Ridge, New Jersey 07920
Attention: Henry E. Dubois, President
Facsimile: (908) 953-6304

with copies to (which shall not constitute notice):

Sills Cummis & Gross P.C.
30 Rockefeller Plaza
New York, New York 10112
Attention: David E. Weiss

44


Tel: (212) 500-1579
Facsimile: (212) 643-6500

If to Buyer:    Piston Acquisition, Inc.
One Jericho Plaza
Jericho, New York 11753
Attention: Gary Gelman
Tel: (516) 822 6230
Facsimile:

with copies to (which shall not constitute notice):

Munger, Tolles & Olson LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
Attention: Maria Seferian
Tel: (213) 683-9198
Facsimile: (213) 683-4098

or to any such other persons or addresses as the parties may from time to time designate in a writing delivered in accordance with this Section 10.1. Rejection or other refusal to accept or inability to deliver because of a change of address of which no notice was given shall be deemed to be receipt of the notice.
10.2    No Assignment; Benefit and Binding Effect. Seller may not assign this Agreement (or its rights or obligations hereunder) without the prior written consent of Buyer. Buyer may assign this Agreement (or its rights or obligations hereunder) in whole or in part to any Affiliate. This Agreement and the Ancillary Agreements shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.

10.3    Governing Law; Venue. This Agreement shall be governed, construed and enforced in accordance with the internal laws of the State of New York, without regard to the choice of law provisions or conflicts of law principles of such state. Each of the Parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of any court of the State of New York or any federal court sitting in the City of New York, New York County for purposes of any suit, action or other proceeding arising out of this Agreement (and agrees not to commence any action, suit or proceeding relating hereto except in such courts). Each of the Parties agrees that service of any process, summons, notice of document by U.S. registered mail at its address set forth herein shall be effective service of process of any action, suit or proceeding brought against it in any such court. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement, which is brought by or against it, in the courts of the State of New York or any federal court sitting in the City of New York, New York County and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

10.4    Waiver of Jury Trial. The Parties hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of or relating to this Agreement or the Ancillary Agreements or the actions of any Party in the negotiation, performance or enforcement hereof or thereof.


45


10.5    Heading; Interpretation. The descriptive headings of the several Articles and Sections of this Agreement are inserted for convenience only and do not constitute a part of this Agreement. References to Sections or Articles (whether or not capitalized), unless otherwise indicated, are references to Sections and Articles of this Agreement. References to Schedules and Exhibits (whether or not capitalized), unless otherwise indicated, are references to the disclosure schedules and exhibits to this Agreement. The words “include” and “including” and variations thereof shall not be deemed terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” The terms “hereof”, “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (including all of the schedules and exhibits hereto) and not to any particular provision of this Agreement. Each of the representations, warranties, covenants and conditions herein is separate and not limited or satisfied by the existence, wording or satisfaction of any other representation, warranty, covenant or condition contained herein. All references to “$” or “Dollars” shall mean United States Dollars. Words used herein, regardless of the gender and number specifically used, shall be deemed and construed to include any other gender, masculine, feminine or neuter, and any other number, singular or plural, as the context requires.

10.6    Entire Agreement. This Agreement and the Ancillary Agreements represent the entire understanding and agreement between Buyer and Seller with respect to the subject matter hereof and supersede all prior agreements and negotiations between Buyer and Seller with respect to the transactions contemplated hereby, and all letters of intent (including, without limitation, that certain letter agreement from American Para Professional Systems, Inc. to Hooper Holmes, Inc., dated July 31, 2013) and other writings relating to such negotiations, and cannot be amended, supplemented or modified except by an agreement in writing which makes specific reference to this Agreement or an agreement delivered pursuant hereto, as the case may be, and which is executed by the Party against which enforcement of any such amendment, supplement or modification is sought. All schedules and exhibits attached to this Agreement shall be deemed part of this Agreement and incorporated herein, as if fully set forth herein.

10.7    Further Assurances. From time to time at and after the Closing Date, Buyer and Seller shall and shall cause their respective Affiliates to execute and deliver or cause to be executed and delivered such further instruments of conveyance, assignment, and transfer, as may reasonably be requested by the other Party in order to effect or facilitate the Transactions. The Parties acknowledge and agree that it is their mutual intent that any and all right, title and interest in and to the Transferred Assets are fully and duly transferred to Buyer. If and to the extent that following the Closing it is determined that Seller or any of its Subsidiaries owns, controls or otherwise holds any Transferred Assets, Seller shall hold the same in trust and promptly notify Buyer thereof in writing, including providing Buyer with all information, files, and books and records (other than Excluded Assets, if any) pertaining to such Transferred Asset, and, at Buyer’s request, shall promptly take (or cause to be taken) any and all actions, and execute, acknowledge and deliver (or cause to be executed, acknowledged and delivered) to Buyer all instruments of conveyance and transfer as Buyer reasonably deems necessary or desirable to evidence and/or effectuate the transfer to Buyer all of the right, title and interest of Seller or such Subsidiaries in and to such Transferred Asset, free and clear of any Encumbrance. After the Closing, to the extent that Buyer or any of its Affiliates discovers or receives possession of any of the Excluded Assets, Buyer shall hold such Excluded Assets in trust and promptly assign and transfer such Excluded Assets to Seller at Seller’s sole cost and expense.

10.8    Waiver of Compliance. Any failure of any of the Parties to comply with any obligation, representation, warranty, covenant, agreement or condition herein may be waived by the Party entitled to the benefits thereof, but such waiver or failure to insist upon strict compliance with such obligation, representation, warranty, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure not so specifically waived.

10.9    Severability. Any provision of this Agreement that is held to be invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, shall be ineffective only to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions hereof; provided, however, that the Parties will attempt in good faith to reform this Agreement in a manner consistent with the intent of any such ineffective provision for the purpose of carrying out such intent.
  

46


10.10    Enforcement of Agreement. The Parties acknowledge and agree that money damages would not be a sufficient remedy for any breach of this Agreement by a Party, that the Parties would suffer irreparable harm as a result of any such breach, and that, in addition to all other remedies available under this Agreement or at law or in equity, the Parties shall be entitled to specific performance and injunctive or other equitable relief as a remedy for any such breach or threatened breach.

10.11    Counterparts. This Agreement may be signed in any number of counterparts with the same effect as if the signature on each such counterpart were upon the same instrument, and a facsimile or portable document format (pdf) transmission shall be deemed to be an original signature for all purposes under this Agreement.

10.12    No Third Party Beneficiaries. This Agreement constitutes an agreement solely among the Parties, and, except as otherwise provided herein, is not intended to and shall not confer any rights, remedies, obligations or liabilities, legal or equitable on any Person other than the Parties and their respective successors or permitted assigns, or otherwise constitute any Person a third party beneficiary under or by reason of this Agreement (except under Article 9).

10.13    Construction. This Agreement has been negotiated by Buyer and Seller and their respective legal counsel, and legal or equitable principles that might require the construction of this Agreement or any provision of this Agreement against the Party drafting this Agreement shall not apply in any construction or interpretation of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.

10.14    Expenses. Except as expressly set forth elsewhere in this Agreement, including without limitation, in Article 10 and Section 5.4, the Parties shall bear their own costs and expenses incurred in connection with the negotiation, preparation or execution of this Agreement (including fees and expenses of attorneys, accountants, consultants, finders and investment bankers), whether or not the Closing occurs.
 



[Signatures on the following page]



 
    

47


IN WITNESS WHEREOF, this Agreement has been duly executed by Buyer and Seller as of the date first above written.

SELLER:
HOOPER HOLMES, INC.


By:     /s/ Henry E. Dubois    
Name:     Henry E. Dubois
Title:     President and CEO

    

48


IN WITNESS WHEREOF, this Agreement has been duly executed by Buyer and Seller as of the date first above written.

BUYER:
PISTON ACQUISITION, INC.


By:     /s/ Gary Gelman    
Name:     Gary Gelman
Title:     Executive Chairman and Secretary


49


Exhibit A
Other Services
1.Heritage Labs

The performance of (1) laboratory testing of blood, urine and oral fluid specimens and (2) the assembly and sale of kits used in the collection and transportation of such specimens to its lab facility (including sales to other companies). Such testing services include, without limitation, specimen profiles designed to provide its customers with specific information of relevance to the assessment of a person's health profile, including, without limitation:
•
the presence of antibodies to the human immunodeficiency virus (HIV);
•
cholesterol and related lipids;
•
liver or kidney disorders;
•
the presence of antibodies to hepatitis;
•
prostate specific antigens;
•
immune disorders;
•
tobacco/nicotine use; and
•
the use of certain medications, cocaine and other drugs.

2.Health & Wellness

The performance of risk assessment and risk management services via biometric screenings, health risk assessments and onsite wellness coaching for health and care management companies, including wellness companies, disease management organizations, clinical research organizations and health plans (but expressly not including exam services). The information collected from such services is used by such customers, among other things, to measure the populations they manage, to identify risks in those populations, to target interventional programs, to promote positive lifestyle behaviors and to measure the results of their health and care management programs, but not in connection with underwriting insurance.
Such health & wellness services include:
•
scheduling of individual and group screenings;
•
provision and fulfillment of needed supplies (e.g., assessment kits, blood pressure cuffs, stadiometers, scales, centrifuges, etc.) at screening events;
•
end-to-end biometric screening management;
•
non-insurance biometric screenings (e.g., height, weight, body mass index, the taking of a person’s hip, waist and neck measurements, as well as his or her pulse and blood pressure) and blood draws via venipuncture or fingerstick, all performed by our wellness certified health professionals, but not in connection with underwriting insurance;
•
lab testing of blood specimens utilizing our Heritage Labs laboratory;
•
data processing and transmission; and
•
analytics to identify critical values of lab tests and notification services to individuals and customers to better manage risk.

Health & Wellness also provides Hooper Holmes OnSitesm, a face-to-face, on-premises health coaching service for work locations. The service is delivered by specially trained "Health Champions", many of whom are physical therapists, personal trainers and nutritionists.

50



3.Hooper Holmes Services

The Hooper Holmes Services line provides four categories of service: Health Information Services, Health Risk Analytics, Consumer Services and Business Entity Services.
a)Health Information Services - collects and provides applicant health documentary information (other than information customarily obtained in the paramedical exam industry) to insurance company underwriters and expressly excluding work previously performed as part of the Portamedic business.

•
Medical Record Retrieval: obtain documentary medical records of an applicant for life insurance.
•
Inspection Report: conduct personal health interviews over the telephone during which we gather verbally-delivered, historical and other factual information about an insurance applicant's health, as well as financial and employment history.
•
Health Risk Assessment / Physicians Information Line (“PIL”): request detailed information from an insured’s physician about a single disease state or multiple impairments.
•
Record and Database Check and Employment Verification: collect a variety of information from public records and private database sources, such as motor vehicle reports, real estate owned and criminal history.

b)Health Risk Analytics - provides risk management consultative support and underwriting services to insurance carriers and reinsurance companies active in the life, annuity and health insurance markets.

•
Full Underwriting: assess health and lifestyle data associated with a prospective insured and then make an evaluation about insurability and appropriate rate class to be used by the insurance carrier consistent with its product pricing, risk tolerances and reinsurance agreements.
•
Simplified Underwriting: review information about a proposed insured’s general health to evaluate insurability for products having predetermined benefit limits. This service provides for limited medical and non-medical data collection when compared to fully underwritten applications.
•
Medical Record Summarization: review medical records of an insurance applicant. Our underwriters provide an analysis of the records and provide an indication of general insurability and indicative rate class.
•
Impaired Risk Underwriting Services: gather non-exam information, review medical records and review lab test results on proposed insureds attempting to purchase life insurance or long-term care insurance who have known health or lifestyle conditions that may affect insurability; assess the degree of impairment, project life expectancy and make recommendations about insurability and the appropriate rate class.


51


c)Consumer Services - gather information via telephonic interviews with insurance applicants to complete all or a portion of an insurance application, verifies information provided by the applicant (other than through services customarily performed by the paramedical industry), gathers information regarding an applicant's general cognitive state and assists the insurance carrier to facilitate the insurance purchase process.

d)Business Entity Services - helps an insurance company assess the quality of decisions made by the carrier's underwriting group, determine adherence to the carrier's underwriting policies, evaluates benefit claims, both pre and post-payment, and ensures that underwriting files are complete and accurate.





52
 EX-10.2 3 exhibit102q32013.htm EXHIBIT 10.2 LIMITED GUARANTY exhibit102q32013






LIMITED GUARANTY

This Limited Guaranty, dated as of August 15, 2013 (this “Limited Guaranty”), is entered into by and among Gary Gelman, a natural person (“Limited Guarantor”), in favor of Hooper Holmes, Inc., a New York corporation (“HH”). Reference is hereby made to that certain Asset Purchase Agreement, dated as of the date hereof (the “APA”), by and among HH and Piston Acquisition, Inc., a New York corporation (“PAI”). Capitalized terms used but not defined herein have the meanings ascribed to them in the APA.
RECITALS:
WHEREAS, HH and PAI are entering into the APA, providing for, among other things, the purchase and sale of the Transferred Assets upon the terms and subject to the conditions set forth therein; and
WHEREAS, as a material inducement to HH agreeing to enter into the APA, Limited Guarantor has agreed to enter into this Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Limited Guarantor and HH hereby agree as follows:
1. Limited Guaranty. Limited Guarantor hereby absolutely guarantees to HH, on the terms and conditions set forth herein, the due and punctual payment of the Closing Payment and the Holdback Amount, in each case, if and when due in accordance with the terms of the APA (the “Guaranteed Obligation”). All payments hereunder shall be made in lawful money of the United States, in immediately available funds. HH and PAI agree that in no event shall the Limited Guarantor have any obligation or liability to any Person relating to, arising out of or in connection with the APA or the transactions contemplated thereby other than as expressly set forth in this Section 1.

2. Nature of Guaranty. This Limited Guaranty is a guarantee of payment and not of collection, and a separate action or actions may be brought and prosecuted against Limited Guarantor to enforce this Limited Guaranty, regardless of whether an action is brought against PAI. In the event that any payment to HH in respect of the Guaranteed Obligation is rescinded or must otherwise be returned as a result of any final, non-appealable Order of a Governmental Authority, Limited Guarantor shall no longer remain liable hereunder with respect to the Guaranteed Obligation.

    




3. Certain Waivers. To the fullest extent permitted by applicable Laws, Limited Guarantor hereby expressly waives any and all rights or defenses arising by reason of any Laws that would otherwise require any election of remedies by HH. Without limiting the foregoing, Limited Guarantor waives promptness, diligence, notice of the acceptance of this Limited Guaranty and of the Guaranteed Obligation, presentment, demand for payment, notice of nonperformance, default, dishonor and protest, and all other notices of any kind (other than notices required to be provided to PAI pursuant to the APA), any right to require HH to proceed against PAI, and all guarantor or suretyship defenses generally (other than (i) as a result of payment of the Guaranteed Obligation, (ii) fraud, willful misconduct or bad faith by HH or any of its Affiliates, (iii) breach by HH of this Limited Guaranty, or (iv) defenses to the payment of the Guaranteed Obligation that are available to PAI under the APA; the foregoing (i) through (iv), the “Retained Defenses”). Limited Guarantor hereby further agrees that it shall not, directly or indirectly, institute any proceeding or make any claim asserting that, or assert as a defense that, this Limited Guaranty is illegal, invalid or unenforceable in accordance with its terms.

4. No Waiver; Cumulative Rights. No failure on the part of HH to exercise, and no
delay in exercising, any right, remedy or power under this Limited Guaranty shall operate as a waiver thereof, nor shall any single or partial exercise by HH of any right, remedy or power under this Limited Guaranty preclude any other or future exercise of any right, remedy or power under this Limited Guaranty. Each and every right, remedy and power hereby granted to HH or allowed it by applicable Laws, except as specifically provided otherwise in this Limited Guaranty, shall be cumulative and not exclusive of any other, and may be exercised by HH at any time or from time to time.
    
5. Representations and Warranties. Limited Guarantor hereby represents and warrants that this Limited Guaranty constitutes a legal, valid and binding obligation of Limited Guarantor, enforceable against Limited Guarantor in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium, and other similar laws of general applicability relating to or affecting creditors’ rights or general equity principles (regardless of whether considered at law or in equity).

6. Continuing Guaranty; Termination.
(a) Except to the extent that the obligations and liabilities of Limited Guarantor are terminated pursuant to this Section 6, this Limited Guaranty may not be revoked or terminated and shall remain in full force and effect in accordance with its terms and be binding on Limited Guarantor until the payment and satisfaction in full of the Guaranteed Obligation, and shall inure to the benefit of, and be enforceable by, HH and its successors and permitted assigns.
(b) This Limited Guaranty shall terminate and Limited Guarantor shall have no further obligations under this Limited Guaranty as of the earliest to occur of: (i) the valid termination of the APA in accordance with the provisions thereof, (ii) the time at which Limited Guarantor has paid in full the Guaranteed Obligation and (iii) any of the events described in the second sentence of Section 2 hereof.
(c) Upon the request of Limited Guarantor after any termination of this Limited Guaranty pursuant to the provisions of this Section 6, HH shall provide the Limited Guarantor with written confirmation of such termination. Notwithstanding anything set forth in this Section 6 hereof, Section 7 hereof shall survive indefinitely (subject to applicable statute of limitations) following the termination of this Limited Guaranty.




7. Sole Remedy; No Contest; No Recourse. In the event that HH or any of its Affiliates or their respective successors and assigns asserts in any litigation or other proceeding relating to this Limited Guaranty, the APA or the transactions contemplated thereby that any provisions of this Limited Guaranty or the APA are illegal, invalid or unenforceable, in whole or in part, or asserts any theory of liability in such litigation or proceeding that the Limited Guarantor is liable in excess of or to a greater extent than the Guaranteed Obligation, then (a) the obligations and liabilities of Limited Guarantor under this Limited Guaranty shall automatically, and without further action, terminate ab initio and shall thereupon be null and void, (b) if Limited Guarantor has previously made any payments under this Limited Guaranty, HH shall promptly repay all such payments, and (c) none of Limited Guarantor or PAI or any of PAI’s directors, officers, employees, agents or representatives shall have any liability to HH or any of its Affiliates under this Limited Guaranty.
8. Entire Agreement. This Limited Guaranty constitutes the entire agreement with respect to the subject matter hereof and supersedes any and all prior discussions, negotiations, proposals, undertakings, understandings and agreements, whether written or oral, between Limited Guarantor or any of its Affiliates, on the one hand, and HH on the other hand with respect to the subject matter hereof.
9. Amendments and Waivers. No amendment or waiver of any provision of this Limited Guaranty shall be valid and binding unless it is in writing and signed, in the case of an amendment, by all of the parties hereto, or in the case of waiver, by the party against whom the waiver is sought to be enforced. No waiver by a party of any breach or violation of, or default under, this Limited Guaranty shall be deemed to extend to any prior or subsequent breach, violation or default hereunder or to affect in any way any rights arising by virtue of any such prior or subsequent occurrence. No delay or omission by any party in exercising any right, power or remedy under this Limited Guaranty shall operate as a waiver thereof.
10. Counterparts. This Limited Guaranty may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Limited Guaranty shall become effective when duly executed by each party hereto.
11. Notices. All notices under this Limited Guaranty shall be (a) in writing, (b) delivered by personal delivery, facsimile transmission (to be followed promptly by written confirmation mailed by certified mail as provided below) or sent by overnight courier service, (c) deemed to have been given on the earliest of: the date of personal delivery, the date of transmission and receipt of facsimile transmissions, or the next business day if delivered by overnight courier, and (d) addressed as follows:
If to Limited Guarantor:
Attention: Mr. Gary Gelman
One Jericho Plaza
Jericho, New York 11753
Facsimile: (516) 822-6241

with copies to (which shall not constitute notice):

Munger, Tolles & Olson LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
Attention: Maria Seferian
Tel: (213) 683-9198
Facsimile: (213) 683-4098





If to HH:
Hooper Holmes, Inc.
170 Mt. Airy Road
Basking Ridge, New Jersey 07920
Attention: Henry E. Dubois, President
Facsimile: (908) 953-6304

with copies to (which shall not constitute notice):

Sills Cummis & Gross P.C.
30 Rockefeller Plaza
New York, New York 10112
Attention: David E. Weiss
Tel: (212) 500-1579
Facsimile: (212) 643-6500

or to any such other Persons or addresses as the Parties may from time to time designate in a writing delivered in accordance with this Section 11.
12. Severability. The provisions of this Limited Guaranty shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Limited Guaranty, or the application thereof to any Person or any circumstance, is held by a court of competent jurisdiction to be invalid or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Limited Guaranty and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction; provided, however, that this Limited Guaranty may in no event be enforced without giving effect to Section 1 (Limited Guaranty), Section 3 (Certain Waivers), Section 6 (Continuing Guaranty; Termination), and Section 7 (Sole Remedy; No Contest; No Recourse) hereof. Upon a determination that any term or provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Limited Guaranty so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable Laws in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

13. No Assignment; Parties in Interest. No party hereto may assign or delegate its rights, interests or obligations hereunder to any other Person without the prior written consent of the other party hereto. Nothing in this Limited Guaranty, express or implied, is intended to or shall confer upon any Person other than HH any rights, benefits or remedies of any nature whatsoever under or by reason of this Limited Guaranty.




14. Governing Law and Venue; Waiver of Jury Trial. This Limited Guaranty shall be deemed to be made in and in all respects shall be interpreted, construed and governed by and in accordance with the Laws of the State of New York without regard to the conflicts of law principles thereof. All actions and proceedings arising out of or relating to this Limited Guaranty shall be heard and determined exclusively in any New York state or federal court sitting in the Borough of Manhattan of The City of New York. Each of the Limited Guarantor and HH Limited Guarantor and HH hereby submits to the exclusive jurisdiction of any state or federal court sitting in the Borough of Manhattan of The City of New York for the purpose of any action arising out of or relating to this Limited Guaranty brought by any party hereto. Each of Limited Guarantor and HH irrevocably and unconditionally waives any right such party may have to a trial by jury in respect of any action, suit or proceeding directly or indirectly arising out of or relating to this Limited Guaranty.
[Remainder of page intentionally left blank]


        





IN WITNESS WHEREOF, the undersigned have executed and delivered this Limited Guaranty as of the date first above written.



/s/ Gary Gelman        
GARY GELMAN




ACKNOWLEDGED AND AGREED:

HOOPER HOLMES, INC.

By:                        
Name:
Title:































Signature Page - Limited Guaranty





IN WITNESS WHEREOF, the undersigned have executed and delivered this Limited Guaranty as of the date first above written.



                    
GARY GELMAN




ACKNOWLEDGED AND AGREED:

HOOPER HOLMES, INC.

By:    /s/ Henry E. Dubois        
Name: Henry E. Dubois
Title: President and CEO

































Signature Page - Limited Guaranty





 EX-10.3 4 exhibit103q32013.htm EXHIBIT 10.3 FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT exhibit103q32013




FIRST AMENDMENT to ASSET PURCHASE AGREEMENT and AGREEMENT

This FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT AND AGREEMENT (this “Amendment”) is entered into as of September 30, 2013, by and between Hooper Holmes, Inc. (“Seller”) and Piston Acquisition, Inc. (“Buyer”).

WHEREAS, Buyer and Seller are parties to that certain Asset Purchase Agreement dated as of August 15, 2013 (the “APA”). Terms used but not otherwise defined herein shall have the respective meanings specified in the APA; and

WHEREAS, Buyer and Seller desire to amend the APA and make such further agreements in accordance with the terms below;

NOW THEREFORE, in consideration of the foregoing and of the agreements contained herein, the parties hereto agree as follows:

1.    The Contracts listed on Schedule A attached hereto are hereby deemed to be “Excluded Contracts” as further set forth on such schedule.

2.     The Leases listed on Schedule B attached hereto shall not be assumed by Buyer and are hereby deemed to be “Excluded Leases.” For clarity, the Leases set forth on such Schedule B shall comprise all of the Leases that are the subject matter of Section 7.2.3(a) of the APA (as amended by this Amendment).

3.     The last sentence of Section 3.16.4 of the APA is hereby deleted in its entirety, effective as of the date of the APA, and replaced with the following sentence:

“As of the date hereof and at all times between the date hereof and the earlier of (i) September 20, 2013, (ii) the Closing Date and (iii) the termination of this Agreement in accordance with its terms, Seller has not incurred and will not incur any WARN Obligations.”

4.    The following language is hereby inserted immediately following Section 5.4.4 of the APA:

“5.4.5    Without limitation of any other obligation or Liability of Seller under this Agreement, in the event that the Closing occurs and Buyer incurs any Losses relating to any Inquiry, regardless of whether such Inquiry is commenced before or at any time after the Closing Date (but within 18 months following the Closing Date), Seller covenants and agrees to pay for one-half of all such Losses; provided, however, that Seller’s liability under this Section 5.4.5 shall not exceed One Hundred Thousand Dollars ($100,000), which such amount shall constitute Seller’s sole and exclusive obligation (and Buyer’s sole and exclusive remedy) under this Section 5.4.5, provided that Seller is not otherwise in breach of the terms of this Agreement; provided, further, however, that all Losses required to be paid by Seller under this Section 5.4.5 which relate to out of pocket costs or expenses shall be documented. For clarity, Buyer shall be entitled to apply the Holdback toward the payment of Seller’s obligations under this Section 5.4.5.”

5.    Buyer confirms that, as of the Closing, it has not incurred any Losses of which it is aware that are currently subject to reimbursement pursuant to Section 5.4.5 of the APA.

6.    Notwithstanding anything to the contrary in the APA, Seller and Buyer shall continue to cooperate on and after the Closing (consistent with the standards, terms and conditions applicable prior to the Closing under the APA) with respect to seeking and obtaining all Consents in connection with the Transactions (other than Consents that Buyer has approved in writing that Seller need not pursue (including on Schedule A attached hereto)).





7.    Schedule 2.1.10 of the Seller’s Disclosure Schedules are hereby amended to delete the security deposits relating to the Leases listed on Schedule B attached hereto.

8.    (a)    Section 7.2.3 of the APA is hereby deleted in its entirety and replaced with the following:

“7.2.3    Transferred Assets. Possession of, and physical control over, all Transferred Assets; provided, however, that (a) with respect to all Transferred Assets that are located at any facilities that are designated by Buyer prior to the Closing as “Excluded Leases,” Seller shall assure that (i) all such Transferred Assets are promptly and safely relocated, at Seller’s expense, to a location designated in writing by Buyer and (ii) Buyer or its designees are granted access promptly upon request to all such Transferred Assets; and (b) with respect to the originals of all Business Contracts and files and records included within the Transferred Assets (other than Business Contracts and files and records that are the subject matter of clause (a) of this Section 7.2.3), it shall be sufficient that, as of the Closing, Buyer have primary control over such Contracts (and Seller shall, at Seller’s expense, maintain and preserve such Contracts and files and records consistent with the terms of the APA and, upon written request from Buyer, deliver possession thereof to Buyer or its designee(s) within 3 Business Days (or earlier if practicable) in a manner mutually-agreed by Seller and Buyer).”

(b)    The last sentence of Section 3.6.2 of the APA is hereby amended by reference to Section 7.2.3(a) of the APA.

9.    For purposes of the APA, the terms “Closing” and “Closing Date” shall be deemed to mean 11:59 pm Eastern Time on the Closing Date.

10.    (a)    Prior to the Closing, Seller has disclosed to Buyer pursuant to the terms of the APA certain matters described or referenced on Schedule C attached hereto (collectively, the “Pre-Closing Matters”). If Buyer or its Affiliates in its or their sole discretion elect to pursue, prosecute, defend, settle, compromise, appeal or take any other action with respect to any of the Pre-Closing Matters, Seller covenants and agrees, without limitation of any of Seller’s obligations or Buyer’s rights or remedies under the APA, to cooperate in connection therewith (including, without limitation, joining any Proceeding as a plaintiff (subject to clause (b) below) and memorializing in writing the parties’ common interest privilege) and to pay one-half of all Losses in connection therewith, provided, however, that Seller’s obligations under this Paragraph 10(a) shall not exceed $100,000; provided, further, however, that all Losses required to be paid by Seller under this Paragraph 10(a) which relate to out of pocket costs or expenses shall be documented. For clarity, Buyer shall be entitled to apply the Holdback toward the payment of Seller’s obligations under this Paragraph 10(a).

(b)    In the event Buyer elects to pursue a claim relating to a Pre-Closing Matter and desires to add Seller as a plaintiff, Seller and Buyer shall cooperate to select counsel that is reasonably acceptable to both parties, and the parties shall cooperate to jointly prosecute such claim. Subject to Seller’s agreement in Paragraph 10(a) above (relating to cost sharing), Buyer shall bear the costs and expenses of prosecuting such claim (if Buyer elects to continue to prosecute such claim). Buyer shall control such claim (but Seller may engage its own separate counsel at its sole cost and expense). Buyer may not settle any action on behalf of Seller without Seller’s consent, which shall not be unreasonably withheld, conditioned or delayed. Seller may not settle any action without Buyer’s prior written consent in its sole discretion. For clarity, Buyer shall not be responsible for any Losses relating to the defense or assertion by Seller of any counterclaim or cross claim (or similar claim), all of which Seller shall be solely responsible for (and none of which shall count toward Seller’s agreement in Paragraph 10(a) above (relating to cost sharing)).

11.    Buyer hereby waives Seller’s obligation under Section 7.2.4 of the APA to deliver to Buyer prior to or at Closing the consents contemplated by Item 1 of Schedule 7.2.4 of the Seller’s Disclosure Schedules.





12.    For clarity, and without limitation of any of Seller’s obligations (or Buyer’s rights and remedies) under the APA, Seller hereby confirms that any and all Liabilities under the Assumed Leases, including, without limitation, such Liabilities as may arise in connection with (i) the consummation of the Transactions on the Closing Date or (ii) the occupancy or use by Buyer or its designees of the subject premises without the consent of the applicable landlord (but not including Occupancy Payments as defined hereafter with respect to periods after the Closing Date) shall be Retained Liabilities. “Occupancy Payments” shall mean all rents, charges, maintenance (including common area maintenance) fees and all utility services associated with the subject premises, in each case, to the extent due under any Assumed Lease through expiration of the term of any such Lease (so long as Buyer or its designee have not been prevented from using and occupying such premises pursuant to such Assumed Lease) unless and until such time as such Assumed Lease is duly assigned (in accordance with the terms thereof) to Buyer or its designee (or otherwise superseded by agreement between Buyer or its designee and the applicable landlord). During the applicable periods, Occupancy Payments shall be paid by Buyer or its designee to Seller in monthly installments, in advance, no later than five (5) days prior to the first day of the succeeding calendar month (or if such 5th day is not a Business Day, the next succeeding Business Day). Buyer or its designee, as applicable, agrees to perform, fulfill and observe all of terms, covenants and conditions of the Assumed Leases to be performed and observed by the tenant thereunder (other than terms, covenants and conditions relating to the use and occupancy, assignment, subletting or license of the Assumed Leases which are Retained Liabilities as described in the first sentence of this Paragraph 12).

13.    Except as specifically amended by this Amendment, the APA remains in full force and effect, and all references hereinafter to the APA shall mean the APA as modified by this Amendment. Nothing herein shall be deemed to waive any right or remedy of Buyer, all of which such rights and remedies Buyer hereby reserves. The terms of Article 10 of the APA are hereby incorporated herein, mutatis mutandis.

[Signature Page Follows]






IN WITNESS WHEREOF, Seller and Buyer have executed this Amendment, by their respective duly authorized officers, as of the day and year first above written.


HOOPER HOLMES, INC.


By:     /s/ Henry E. Dubois            
Name:    Henry E. Dubois
Title:    President and Chief Executive Officer


PISTON ACQUISITION, INC.


By:     /s/ Gary Gelman                    
Name:    Gary Gelman
Title:    Executive Chairman and Secretary
























Signature Page - Amendment to the APA
    




IN WITNESS WHEREOF, Seller and Buyer have executed this Amendment, by their respective duly authorized officers, as of the day and year first above written.


HOOPER HOLMES, INC.


By:     /s/ Henry E. Dubois                    
Name:    Henry E. Dubois
Title:    President and Chief Executive Officer


PISTON ACQUISITION, INC.


By:     /s/ Gary Gelman            
Name:    Gary Gelman
Title:    Executive Chairman and Secretary























Signature Page - Amendment to the APA









SCHEDULE A

Excluded Contracts. Schedule 2.2.5 of the Seller’s Disclosure Schedules is hereby amended by adding the following language after item #2 set forth thereon:

“3.    All “PMD Affiliates” Contracts*, including:

Premier Health Solutions, Inc.
Evansville; Smith Examination Services, Inc.
Highland Health Screenings LLC
Coastal Exams
Statesboro Health Assessments; Health Assessments, Inc.
Springfield; The Parent Company, Inc.
Silver Spring; P & G Goldberg, Inc.
Hagerstown; Medical Services, Inc.
Med Physicals Plus LLC
Spivey Enterprises, Inc
The Parent Company, Inc
Central Texas Paramedical; Express ASAP; ASAP LLC; Exam ASAP

4.    All “PMD Contractor Agreements”*1

5.    All Contracts between Seller or any of its Affiliates and any of the following Persons [bracketed agreements are subject to removal from this list in the event amended per the terms below]:

Genworth; [until such time as this is amended to Buyer’s satisfaction]
John Hancock [until such time as this is amended to Buyer’s satisfaction]
Lincoln Financial [until such time as this is amended to Buyer’s satisfaction]
Prudential; [until such time as this is amended to Buyer’s satisfaction]

RSA Medical LLC*
ExamOne; *
Northwestern Mutual*
GSL*
Ran Chen*


*Seller has no obligation to seek Consents under these Contracts following the Closing Date.










1 As of 9/26/13, there are 319 of these contractor agreements listed in the Project Piston dataroom.





SCHEDULE B


1. Lease relating to 13399 REECK COURT - Southgate, MI 48195 [Detroit MI]

2. Lease relating to 15445 53RD AVENUE SOUTH, SUITE 120 - Tukwila, WA 98188 [Tacoma/Bellevue, WA]






SCHEDULE C

Seller has delivered two cease and desist letters, respectively dated September 25, 2013 and September 26, 2013, to certain third parties. All claims, allegations, demands, and other matters set forth in such letters and all legal theories referenced in such letters or otherwise reasonably related to such claims, allegations , demands or other matters, including, without limitation, to the extent available, breach of contract, breach of duty and/or infringement (and all other claims, allegations, demands and other matters that might not be set forth in such letters but that relate to similar or related facts or circumstances as those from which the claims, allegations, demands and other matters that are set forth in such letters arose) are hereby incorporated by reference into this Schedule C.



EX-10.4 5 exhibit104q32013.htm EXHIBIT 10.4 AGREEMENT exhibit104q32013




AGREEMENT

This agreement (this “Agreement”), dated as of August 15, 2013, is made by and between Hooper Holmes, Inc. (“HH”) and Piston Acquisition, Inc. (“PAI”). Each of HH and PAI is referred to herein as a “Party” and together as the “Parties.”

WHEREAS, concurrently herewith, the Parties desire to enter into that certain Asset Purchase Agreement, by and between HH and PAI (the “APA”); and

WHEREAS, as a material inducement to PAI agreeing to enter into the APA and Gary Gelman agreeing to provide a limited guaranty in connection therewith, HH has agreed to enter into this Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties hereby agree:

1.Claims. In the event that any Person brings any claim, action, suit or proceeding (whether or not on behalf of HH) (i) challenging the APA (or the transactions contemplated therein) or this Agreement, (ii) questioning the validity of the APA (or the transactions contemplated therein) or this Agreement, (iii) questioning HH’s authorization or ability to enter into the APA or this Agreement or (iv) any similar, related or ancillary claim, action, suit or proceeding (including any action in which any claimant asserts the invalidity of, or makes a similar claim with respect to, PAI’s title or interest in any of the assets transferred or required to be transferred to PAI under the APA) (any such claim, action, suit or proceeding being referred to herein as a “Claim”) and such Claim is not fully and finally resolved and dismissed with prejudice (and if such resolution consists of a settlement, PAI and its Affiliates and Representatives are not fully and forever released from any and all liabilities and claims related thereto) within 30 days after such Claim is first made, then, if such Claim is made before the Closing, HH shall have the option, exercisable in its sole discretion by delivery of written notice to PAI no later than the end of such 30 day period to call a shareholders meeting (a “Shareholders Meeting Election”). For clarity, nothing herein shall prohibit either PAI or HH from exercising any termination rights it may have under the APA during such 30 day period or at any other time. If HH fails to timely make a Shareholders Meeting Election in accordance with the foregoing sentence, then PAI shall have the option to either cause HH to make the Shareholders Meeting Election or to terminate the APA (a “Termination Election”).

2.Termination Election. In the event PAI makes a Termination Election, HH shall promptly, but in any event within 2 business days, pay to PAI by wire transfer of immediately available funds all of PAI’s out-of-pocket costs and expenses incurred by or on behalf of PAI in connection with entering into and performing under this Agreement and the APA and the transactions contemplated therein and herein (including, without limitation, all fees and expenses of counsel, accountants, experts and consultants) and expressly including the costs and expenses of enforcing Buyer’s rights hereunder and thereunder (collectively, “Expenses”). HH shall not take any position that any Termination Election delivered in accordance with this Agreement is ineffective, void or voidable. In the event PAI makes a Termination Election and HH complies with its obligations to pay the Expenses, the APA shall forthwith become null and void; provided, however, that nothing herein shall relieve any Party from liability for any willful or intentional breach of the APA prior to such termination.




3.Shareholders Meeting Election. In the event HH or PAI makes a Shareholders Meeting Election

3.1    Within 20 days after HH or PAI makes a Shareholders Meeting Election, HH shall establish, in accordance with applicable law and HH’s certificate of incorporation and bylaws, a record date for of a meeting of HH’s shareholders (including any adjournment or postponement thereof, the “HH Shareholders Meeting”) for the purpose of obtaining the affirmative vote of the holders of such number of outstanding shares of common stock of HH necessary to approve and adopt the APA and the transactions contemplated therein at a meeting of shareholders (the “HH Shareholder Approval”). HH shall duly convene and hold such HH Shareholders Meeting. HH shall, through its board of directors, recommend to its shareholders that the HH Shareholder Approval be given (the “HH Board Recommendation”) and shall include the HH Board Recommendation in the Proxy Statement and use its reasonable best efforts to solicit from its shareholders proxies in favor of the approval of the APA and the transactions contemplated therein. The obligation of HH to establish a record date for, duly call, give notice of, convene and hold the HH Shareholders Meeting shall not be affected by any subsequent event or occurrence.

3.2    Within 20 days after HH or PAI makes a Shareholders Meeting Election, HH shall prepare and file with the SEC in preliminary form a proxy statement relating to the HH Shareholders Meeting (such proxy statement, including any amendment or supplement and any schedules and exhibits thereof, the “Proxy Statement”). HH shall provide PAI with a reasonable opportunity to review and consult with the HH regarding the Proxy Statement (for clarity, including each amendment, supplement, schedule and exhibit thereto) prior to filing the same with the SEC, and the HH shall use its reasonable best efforts to have the Proxy Statement cleared by the SEC.

(a)HH shall cause the Proxy Statement, and the letter to shareholders, the notice of meeting and the form of proxy provided to its shareholders therewith, in connection with the transactions contemplated in the APA (at the time that the Proxy Statement is first mailed to HH’s shareholders and at the time of the HH Shareholders Meeting) to not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading, and to comply, in all material respects, as to form and otherwise with the provisions of the Exchange Act and the rules and regulations of the SEC promulgated thereunder; provided, however, that the obligations of HH contained in this Section 3.2(a) shall not apply to any information supplied by PAI to HH for the express purpose of inclusion in the definitive Proxy Statement.

(b)HH shall promptly notify PAI upon the receipt of any comments (written or oral) from the SEC or any request (written or oral) from the SEC for amendments or supplements to the Proxy Statement (or any additional information), and shall provide HH with copies of all correspondence between HH and any of its Representatives on the one hand, and the SEC on the other hand, with respect to the Proxy Statement, the APA, this Agreement or the transactions contemplated therein or herein. HH shall use its reasonable best efforts to promptly provide responses to the SEC with respect to all comments received with respect to the Proxy Statement by the SEC, and HH shall cause the definitive Proxy Statement to be mailed promptly after the date the SEC staff advises that it has no further comments thereon or that HH may commence mailing the Proxy Statement.

3.3    Notwithstanding that HH or PAI has made a Shareholders Meeting Election, HH need not comply with Section 3.1 or 3.2 hereof if either PAI or HH has terminated the APA in accordance with its terms.





4.Shareholder Approval. (a) In the event that the HH Shareholder Approval is not obtained at the HH Shareholders Meeting duly convened therefor in accordance with this Agreement (including at any adjournment or postponement thereof), then each of HH and PAI shall have the right to terminate the APA upon written notice delivered to the other Party; provided, however, that HH may not terminate the APA unless, in conjunction with such termination, HH pays to PAI an amount equal to (i) $150,000 plus (ii) PAI’s Expenses (collectively, the amounts in clauses (i) and (ii) being the “Payment Amount”). In the event PAI terminates the APA pursuant to the immediately foregoing sentence, HH shall pay to PAI the Payment Amount no later than 2 business days after receipt of such termination notice. Notwithstanding the foregoing, in the event the APA is terminated pursuant to this Section 4 by either Party and within 12 months after the date of such termination, HH enters into or consummates a definitive agreement with respect to any Alternative Proposal, then, in addition to the Payment Amount, concurrently with entering into such definitive agreement, HH shall pay to PAI an additional amount (in addition to the Payment Amount) equal to $300,000 (collectively, such additional amount plus the Payment Amount being the “Total Payment Amount”).

(b)     In the event that (i) HH fails to comply with its obligations under Paragraph 3, including, without limitation, its obligation to hold the HH Shareholders Meeting or make the HH Shareholder Recommendation (but subject to Section 3.3); or (ii) a tender offer or exchange offer for shares of capital stock of HH is commenced prior to the closing of the transactions contemplated in the APA and the board of directors of HH fails to recommend against acceptance of such tender offer or exchange offer by its shareholders (including, for these purposes, by taking no position with respect to the acceptance of such tender offer or exchange offer by its shareholders, which shall constitute a failure to recommend against acceptance of such tender offer or exchange offer) within three (3) business days after commencement (or within one business day prior to the HH shareholders meeting, if earlier), then, in the event of either (i) or (ii), PAI shall have the right to terminate the APA upon written notice delivered to HH, upon which termination, HH shall pay to PAI and amount equal to the Total Payment Amount within 2 business days after receipt of such termination notice. For clarity, PAI may not recover twice under this Section 4(b) and also under Section 8.1.3(ii) of the APA.
5.Indemnity. In the event that PAI or any of its Affiliates or Representatives (each a “PAI Indemnified Person”) becomes party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, any Claim, HH shall indemnify such PAI Indemnified Person against and hold such PAI Indemnified Person harmless from any and all Expenses, judgments, fines, penalties, and amounts paid in settlement of such Claim (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties or amounts paid in settlement). Each PAI Indemnified Person shall have the right to assume control of the defense, investigation and settlement of any Claim with counsel of its choice which such counsel shall be reasonably acceptable to HH, at HH’s sole expense. The Parties shall reasonably cooperate with one another in such defense. Neither any PAI Indemnified Person nor HH shall settle any Claim without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. If so requested in writing by any PAI Indemnified Person, HH shall advance, within 3 business days of receipt of such request, any and all Expenses incurred by such PAI Indemnified Person in connection with the investigation, defense, settlement or appeal of any Claim. In the event and to the extent that it is determined by a court of appropriate jurisdiction pursuant to a final, unappealable judgment that such PAI Indemnified Person is not entitled to be indemnified hereunder, HH shall be entitled to be reimbursed by such PAI Indemnified Person for all such amounts theretofore paid (without interest). The rights of any PAI Indemnified Person hereunder shall be in addition to any other rights available to such PAI Indemnified Person under applicable law or the APA (but without duplication of payments), provided, that in the event of conflict between the terms of this Agreement and the APA, it is the Parties’ mutual intent that such agreements be interpreted in such a manner as to provide to the PAI Indemnified Persons the greatest and broadest scope and coverage of indemnification. All PAI Indemnified Persons are express third party beneficiaries under this Agreement.

6.Payments. All payments under this Agreement shall be made by wire transfer of immediately available funds to an account designated in writing by PAI. PAI has the express right to offset any and all amounts owed to it by HH under this Agreement against any and all amounts that it or its Affiliates may owe to HH.





7.Notices. All notices under this Agreement shall be (a) in writing, (b) delivered by personal delivery, facsimile transmission (to be followed promptly by written confirmation mailed by certified mail as provided below) or sent by overnight courier service, (c) deemed to have been given on the earliest of: the date of personal delivery, the date of transmission and receipt of facsimile transmissions, or the next business day if delivered by overnight courier, and (d) addressed as follows:

If to HH:

Hooper Holmes, Inc.
170 Mt. Airy Road
Basking Ridge, New Jersey 07920
Attention: Henry E. Dubois, President
Facsimile: (908) 953-6304
with copies to (which shall not constitute notice):
Sills Cummis & Gross P.C.
30 Rockefeller Plaza
New York, New York 10112
Attention: David E. Weiss
Tel: (212) 500-1579
Facsimile: (212) 643-6500

If to PAI:

Piston Acquisition, Inc.
One Jericho Plaza
Jericho, New York 11753
Attention: Gary Gelman
Tel: (516) 822 6230

with copies to (which shall not constitute notice):
Munger, Tolles & Olson LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
Attention: Maria Seferian
Tel: (213) 683-9198
Facsimile: (213) 683-4098

or to any such other Persons or addresses as the Parties may from time to time designate in a writing delivered in accordance with this Section 7.




8.Misc. HH may not assign this Agreement without PAI’s prior written consent. PAI may assign this Agreement in whole or in part to any Affiliate. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. This Agreement represents the entire understanding and agreement between HH and PAI with respect to the subject matter hereof. Any provision of this Agreement that is held to be invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, shall be ineffective only to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions hereof; provided, that the Parties will attempt in good faith to reform this Agreement in a manner consistent with the intent of any such ineffective provision for the purpose of carrying out such intent. The Parties acknowledge and agree that money damages would not be a sufficient remedy for any breach of this Agreement by a Party, that the Parties would suffer irreparable harm as a result of any such breach, and that, in addition to all other remedies available under this Agreement or at law or in equity, the Parties shall be entitled to specific performance and injunctive or other equitable relief as a remedy for any such breach or threatened breach. This Agreement may be signed in any number of counterparts with the same effect as if the signature on each such counterpart were upon the same instrument, and a facsimile or portable document format (pdf) transmission shall be deemed to be an original signature for all purposes under this Agreement. This Agreement has been negotiated by HH and PAI and their respective legal counsel, and legal or equitable principles that might require the construction of this Agreement or any provision of this Agreement against the Party drafting this Agreement shall not apply in any construction or interpretation of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. This Agreement shall be governed in accordance with the laws of the State of New York, without regard to the choice of law principles. The Parties hereby submit to the exclusive jurisdiction of any court of the State of New York or any federal court sitting in the City of New York, New York County.

9.Definitions

9.1    “Person” means any individual, corporation, limited liability company, partnership, company, sole proprietorship, joint venture, trust, estate, association, organization, governmental authority or other entity.

9.2    “Affiliate” means with respect to a Person, any Person directly or indirectly controlling, controlled by or under common control with such first-specified Person. For purposes of this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities or interests, by contract or otherwise.

9.3    “Representative” means, with respect to any Person, such Person’s and such Person’s Affiliates’ respective officers, directors, employees, agents, advisors, attorneys, and other representatives

9.4    “Alternative Proposal” means any proposal or offer from any Person or group (as defined under Section 13(d) of the Exchange Act) (other than Buyer) relating to, in a single transaction or series of related transactions, and whether or not pursuant to a bankruptcy or similar proceeding, any (i) acquisition of any assets or properties used or held for use in HH’s “Portamedic” business, (ii) acquisition of all or substantially all of the assets of HH; (iii) acquisition of twenty-five percent (25%) or more of any class of capital stock or other equity securities of HH, (iv) tender offer or exchange offer that, if consummated, would result in any Person or group beneficially owning twenty-five percent (25%) or more of any class of capital stock or other equity securities of HH or (v) merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving HH or any of its subsidiaries.

[Signature Page Follows]







IN WITNESS WHEREOF, this Agreement has been duly executed by HH and PAI as of the date first above written.

HOOPER HOLMES, INC.
By:     /s/ Henry E. Dubois    
Name:     Henry E. Dubois
Title:     President and CEO




IN WITNESS WHEREOF, this Agreement has been duly executed by HH and PAI as of the date first above written.

PISTON ACQUISITION, INC.
By:     /s/ Gary Gelman    
Name:     Gary Gelman
Title:     Executive Chairman and Secretary



 EX-10.5 6 exhibit105q32013.htm EXHIBIT 10.5 HENRY DUBOIS EMPLOYMENT AGREEMENT exhibit105q32013








Employment Agreement

This Employment Agreement ("Agreement") is made as of the 30th day of September, 2013 (the "Effective Date"), by and between Hooper Holmes, Inc., a New York corporation, with its principal office at 170 Mt. Airy Road, Basking Ridge, New Jersey 07920 (the "Company") and Henry E. Dubois ("Executive").
RECITALS
WHEREAS, the Company desires to embody in this Agreement the terms and conditions of Executive's employment with the Company.
NOW, THEREFORE, in consideration of the mutual promises and agreements contained in this Agreement, including the compensation to be paid to Executive, the parties hereby agree as follows:
1.    Employment; Term; Duties and Responsibilities.
1.1. Employment as President and Chief Executive Officer. The Company wishes to employ Executive as its President and Chief Executive Officer, and Executive hereby accepts such employment, subject to the terms and conditions of this Agreement. Executive represents and warrants to the Company that he is not a party to any agreement that would restrict or prohibit him from being employed by the Company.
1.2. Term. The provisions of this Agreement shall be effective as of the Effective Date and shall continue in force until his successor is duly elected and qualified, or the termination of Executive's employment as provided in Section 3 of this Agreement, whichever shall occur first (the "Term").
1.3. Location of Employment. The Company acknowledges that Executive lives in the Washington, D.C. Area. Executive is expected to conduct his primary duties at the corporate headquarters, currently located in Basking Ridge, New Jersey. Company headquarters will likely move to Olathe, Kansas at a date in the near future.
1.4. Duties and Responsibilities. In his capacity as President and Chief Executive Officer of the Company, Executive shall report directly to the Company Board of Directors (“Board”). Executive shall have such duties and responsibilities, and the power and authority, normally associated with the position of President and Chief Executive Officer, as well as any additional duties and responsibilities of an executive character as shall, from time to time, be delegated or assigned to him by the Hooper Holmes, Inc. Board of Directors (the "Board"). As President and Chief Executive Officer, Executive shall keep the Board fully informed of any and all matters of a material nature, from an operational or financial perspective, and seek Board Approval of appropriate matters, in accordance with his fiduciary duties to the Company and its shareholders.




1.5. Devotion of Time. During the Term, Executive shall expend all of his working time, care and attention to his duties, responsibilities and obligations to the Company. Executive may serve on the boards of (i) civic and charitable entities, and (ii) with the prior written consent of the Board, other corporate entities; provided, however, that such activities do not, either individually or in the aggregate, interfere with Executive's duties and responsibilities as President and Chief Executive Officer of the Company.
1.6. Effective Date. The Effective Date of this Agreement shall commence when both the Executive and Company sign this Agreement.
1.7. Elected Officer of the Company. The Company and Executive acknowledge that Executive shall serve as an elected Officer of the Company.
2.    Compensation; Benefits.
As compensation and consideration for the services to be rendered by Executive as President and Chief Executive Officer of the Company in accordance with the terms and conditions of this Agreement, and while Executive is employed with the Company as President and Chief Executive Officer, Executive shall be entitled to the compensation and benefits set forth in this Section 2 (subject, in each case, to the provisions of Section 3 of this Agreement).
2.1. Base Salary. Executive shall receive an annual base salary ("Base Salary") of Three Hundred and Seventy-Five Thousand Dollars ($375,000) per year, payable in accordance with the Company's standard payroll dates and practices, provided such payments shall not be made less frequently than twice in each calendar month. The Base Salary shall be reviewed at least annually by the Compensation Committee (the "Committee") of the Board and may be adjusted by the Board, in its sole discretion, based on the Committee's and Board’s consideration of the Company's performance, financial and otherwise. If the Base Salary is adjusted, the adjusted amount will thereafter be the Base Salary for all purposes of this Agreement. However, the Base Salary shall never be lower than $375,000 per year.
2.2. Annual Bonus. Executive shall be eligible to participate in such annual bonus or incentive compensation plans and programs as may be in effect from time to time in accordance with the Company's compensation practices and the terms and provisions of any such plans or programs. Executive's annual target bonus opportunity will be equal to 50% of his Base Salary (One Hundred and Eighty-Seven Thousand, Five Hundred Dollars ($187,500)), and is subject to Executive and the Company achieving annually agreed upon financial, company and individual goals and objectives. This amount may increase or decrease based on performance. Except as otherwise provided by the terms of this Agreement, any annual bonus earned shall be paid at the same time and in the same manner as corresponding awards to other senior executives of the Company generally.
2.3. Long-Term and Equity Compensation. Executive shall be eligible to participate in any long-term incentive compensation plan (including any equity compensation plan) that may be adopted by the Company from time to time during the Term. Executive shall be entitled to and will receive Two Million (2,000,000) options at the commencement of the Term of this Agreement. The vesting of such options shall be in accordance with an appropriate Company Omnibus Employee Incentive Plan, but at a minimum, must vest as follows: (i) 25% upon receipt of the grant; (ii) 25% on the first anniversary of the grant; (iii) 25% on the second anniversary of the grant; and (iv) 25% on the third anniversary of the grant. Future awards, if any, will be reviewed by the Committee in its sole discretion, commensurate with Executive's position as President and Chief Executive Officer.




2.4. Participation in Other Benefit Plans. While Executive is employed with the Company, Executive shall be eligible to participate in all retirement and other benefit plans and programs of the Company generally available from time to time to employees of the Company and for which Executive qualifies under the terms thereof. Nothing in this Agreement shall limit the Company's ability to change, modify, cancel, amend or discontinue any of these plans.
2.5. Reimbursement of Expenses
(a) For Other than Executive’s Travel to and From Corporate Headquarters. The Company shall pay directly or reimburse Executive for reasonable business-related expenses and disbursements incurred by him for and on behalf of the Company in connection with the performance of his duties as the President and Chief Executive Officer of the Company, subject, however, to the Company's written policies relating to business-related expenses as in effect from time to time. Executive shall submit to the Company, no later than the month after the month during which he incurred any such business-related expenses and disbursements, a report of such expenses and disbursements in the form normally used by the Company and receipts with respect thereto, and the Company's obligations under this Section 2.5 shall be subject to compliance therewith. Reimbursement of any business-related expenses and disbursements shall be made in accordance with the Company's written policies relating to business-related expenses as in effect from time to time. In no event will reimbursement of any business-related expenses and disbursements be made later than the last day of the calendar year following the calendar year in which any such expense or disbursement was incurred.
(b) For Executive’s Travel to and from Home to Corporate Headquarters. Executive and Board will agree on an expense plan that Executive will submit to the Board associated with travel to and from Executive’s home and Corporate Headquarters, wherever Headquarters is located.
2.6. Vacation. Executive shall be entitled to paid vacation in accordance with the
Company's Paid Time Off (PTO) policy in effect from time to time but in no event shall Executive be awarded less than four (4) weeks per annum.
2.7 Executive Change-in-Control Agreement. Executive represents that he has not
entered into an Executive Change in- Control (“CIC”) Agreement with the Company prior to the execution of this Agreement. Executive agrees that, with respect to CIC, he and the Company will be bound only by the provisions contained in this Agreement.
2.8.    Indemnification; Insurance.

(a)Executive acknowledges that, upon commencement of his employment with the Company, he was offered and accepted indemnification in accordance with the Company's bylaws and the terms of the Company's form indemnity agreement for officers and directors, in each case subject to applicable law. The initial policy will be the same as has been in existence since April 2013 when Executive was appointed as the President and CEO of the Company.

(b)Executive shall be covered by directors' and officers' liability insurance, as well as employment practices liability insurance, during the Term and for any applicable statute of limitations period thereafter, to the same extent as other officers of the Company.
2.9. Deductions; Withholdings. All compensation payable to Executive under the terms of this Agreement shall be subject to any applicable income, payroll or other tax withholding requirements and such other deductions or amounts, if any, as may be authorized by Executive.




2.10. Discretionary Bonus. Executive shall be entitled to a one time discretionary bonus of $161,000 based on his performance prior to his entering this Employment Agreement. Such discretionary bonus shall be paid as follows: (i) in a one-lump sum cash payment made within thirty (30) days after the consummation of the Portamedic transaction equal to 40% of the bonus amount; and (ii) one award of Company restricted stock with a value equal to 60% of the bonus amount, to be made on the effective date of this Agreement. There will be a one-year restriction on Executive’s ability to trade this stock. Executive understands and agrees that no other incentive/bonus is intended to be paid to him for 2013, including any annual bonus as specified in Sec. 2.2, except as may otherwise be provided in this Agreement.
3.    Termination.
3.1. Termination by the Company. The Company shall have the right, subject to the terms of this Agreement, to terminate Executive's employment at any time, with or without "Cause." The Company shall give Executive written notice of a termination for Cause (the "Cause Notice") in accordance with Section 7.2 of this Agreement. The Cause Notice shall state the particular action(s) or inaction(s) giving rise to the termination for Cause. No action(s) or inaction(s) will constitute Cause unless:

(a)a resolution finding that Cause exists has been approved by a majority of all of the members of the Board (excluding Executive), at a meeting at which Executive is allowed to appear with his legal counsel; and
(b)where remedial action is feasible, Executive fails to remedy the action(s) or inaction(s) within thirty (30) days after receiving the Cause Notice.
If Executive effects a cure to the satisfaction of the Board within the 30-day period following his receipt of the Cause Notice, the Cause Notice shall be deemed rescinded and of no force or effect.
For purposes of this Agreement, "Cause" shall mean:

•
participation by Executive in fraudulent conduct against the Company, or a material misrepresentation or omission by Executive that, in the Board's reasonable judgment, has resulted or will likely result in injury to the business, operations or financial condition of the Company;
•
conviction of or a plea of guilty or nolo contendere with respect to a felony involving theft or moral turpitude;
•
Executive's violation of any statutory or common law duty of loyalty or good faith to the Company or any of its subsidiaries.
•
Executive's continued violation of a material policy of the Company for a period of thirty (30) days after Executive's receipt of a written notice specifying the nature of such violation from the Company;
•
any refusal by Executive to follow the lawful directives of the Board that are consistent with the scope and nature of Executive's duties and responsibilities as set forth in this Agreement;
•
any continued misconduct by Executive in connection with performance of his duties hereunder for a period of thirty (30) days after having received a written notice specifying the nature of such misconduct from the Company; or
•
any breach by Executive of any one or more of the covenants contained in Sections 4 and 5.
3.2 Termination by Executive. Executive shall have the right, subject to the terms of this Agreement, to terminate his employment at any time with or without "Good Reason."




For purposes of this Agreement, "Good Reason" shall mean the occurrence of any of the following during the Term without Executive's prior written consent:

•
a material diminution in Executive's authority, duties and/or responsibilities as contemplated by this Agreement;
•
a material diminution in Executive's Base Salary, or unless the diminution is a result of a Company-wide diminution in the annual bonus opportunity, target incentive awards and/or benefits of all similarly situated employees as Executive, a material diminution in the amount of Executive's annual bonus opportunity, target incentive award and/or benefits, including health, retirement and fringe;
•
a material failure by the Company to comply with the material provisions of this Agreement (provided that an isolated, insubstantial or inadvertent action or omission that is not in bad faith and is remedied by the Company promptly after receipt of notice thereof given by Executive shall not constitute Good Reason);
•
in the event of the occurrence of a Change in Control as specified in Sec. 3.5, the failure of a successor to the Company to explicitly assume and agree to be bound by the terms of the Change in Control provisions contained in this Agreement;
•
a material breach by the Company of any of the Change in Control provisions of this Agreement; or
•
the Company’s decision, without the Executive’s consent, to discontinue travel expense reimbursement to the Company’s Headquarters from Executive’s out of state residence.
Executive must give the Company written notice, in accordance with Section 7.2 of this Agreement, of any Good Reason termination of employment. Such notice must be given within 60 days following Executive's knowledge of the first occurrence (as determined without regard to any prior occurrence that was subsequently remedied by the Company) of a Good Reason circumstance, and must specify which of the Good Reason circumstances Executive is relying on, the particular action(s) or inaction(s) giving rise to such circumstance, and the date that Executive intends to separate from service, as defined under Section 409A of the Internal Revenue Code of 1986, as amended ("Section 409A"), which shall be no earlier than thirty (30) days following the date of the Company's receipt of the notice. Executive's termination shall not be deemed a Good Reason termination of employment if (i) within 30 days of the Company's receipt of such notice, the Company remedies the circumstance(s) giving rise to the notice, or (ii) Executive's termination of his employment does not occur within 60 days after the end of the 30-day period provided to the Company to remedy the circumstances giving rise to the notice.
3.3    Death. If Executive dies during the Term, Executive's employment shall automatically terminate, such termination to be effective on the date of Executive's death.
3.4    Disability. If Executive shall suffer a Disability, the Company shall have the right to terminate Executive's employment, such termination to be effective upon the giving of notice to Executive in accordance with Section 7.2 of this Agreement. For purposes of this Agreement, a Disability shall mean any physical or mental incapacity as a result of which Executive is unable to perform substantially all of his essential duties for an aggregate of four (4) months, whether or not consecutive, during any calendar year, and which cannot be reasonably accommodated by the Company without undue hardship. Executive cannot be terminated for Disability unless the Company has delivered a written demand for substantial performance to Executive, specifically identifying the manner in which Executive has not substantially performed his duties, and Executive does not cure such failure within sixty (60) days of such demand.





3.5    Termination of Employment following a Change in Control.
3.5.1     Change In Control. A "Change in Control" shall be deemed to have occurred as of the first day any one or more of the following conditions shall have been satisfied:
(a)
Any person (other than (i) the Company or any subsidiary of the Company, (ii) a corporation or other entity owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of the Company, or (iii) an employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary of the Company), becomes the beneficial owner, directly or indirectly, of securities of the Company, representing fifty-one percent (51%) or more of the combined voting power of the Company's then outstanding securities; provided, however, that no crossing of such 51% threshold shall be a "Change in Control" if it is caused (A) solely as a result of an acquisition by the Company of its voting securities; or (B) solely as a result of an acquisition of the Company's voting securities directly from the Company, in either case until such time thereafter as such person acquires additional voting securities other than directly from the Company and, after giving effect to such transaction, such person owns 51% or more of the then outstanding common stock or voting power of the Company;

(b)
Individuals who, as of the date hereof, constitute the Board of Directors of the Company (the "Board", such individuals being referred to as the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Securities Exchange Act of 1934 (the '34 Act") relating to the election of the directors of the Company) shall be, for purposes of this Agreement, considered as though such person were a member of the Incumbent Board; or

(c)
A merger, consolidation, reorganization or share exchange, or sale of all or substantially all of the assets, of the Company, unless, immediately following such transaction, all of the following shall apply: (A) all or substantially all of the beneficial owners of the Company immediately prior to such transaction will beneficially own in substantially the same proportions, directly or indirectly, more than 51% of the combined voting power of the then outstanding voting securities of the corporation or other entity resulting from such transaction (including, without limitation, a corporation or other entity which, as a result of such transaction, owns the Company or all or substantially all of the Company's assets, either directly or through one or more subsidiaries) (the "Successor Entity"), (B) no person will be the beneficial owner, directly or indirectly, of 51% or more of the combined voting power of the then outstanding voting securities of the Successor Entity, and (C) at least a majority of the members of the board of directors of the Successor Entity will be Incumbent Directors.

(d)
All terms used in this Section 3.5 shall be interpreted in a manner consistent with the '34 Act.




3.5.2    Triggering Event. Executive may not invoke Change In Control protections under this Agreement unless (i) a Change in Control occurs under sec. 3.5.1; and (ii) a Triggering Event occurs. For the purposes of this Agreement, a "Triggering Event" means a termination of the Executive's employment with the Company or Successor Entity at any time prior to the end of the twelve (12) month period following the Change in Control (such period of time being referred to as the "Employment Period"), unless (i) such termination is by reason of the Executive's Total Disability or death; or (ii) the Company terminates the Executive's employment with the Company or Successor Entity for Cause; or (iii) the Executive terminates his employment with the Company or Successor Entity for other than Good Reason.
3.5.3    Company Successor. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent as the Company would be required to perform it if no such succession had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Agreement and shall entitle the Executive to compensation from the Company in the same amount and on the same terms as the Executive would be entitled to hereunder if the Executive had given notice of termination for Good Reason as of the day immediately before such succession became effective and had specified that day in the notice of termination. As used in this Section 3.5.3, the "Company" shall mean the Company as defined in the first sentence of this Agreement and any successor to all or substantially all its business or assets or which otherwise becomes bound by all the terms and provisions of this Agreement, whether by the terms hereof, by operation of law or otherwise.
3.6    Effect of Termination.
(a)    In General. Subject to the terms of Section 3.6(c), in the event of the termination of Executive's employment for any reason during the Term, the Company shall pay to Executive (or his beneficiary, heirs or estate, in the event of his death), as provided in Section 3.6 of this Agreement: (i) any Base Salary, to the extent not previously paid, to the date of termination; (ii) any reimbursable business expenses that have not yet been reimbursed (collectively, the "Accrued Obligations"); and (iii) the cash equivalent of any unused vacation time accrued to the date of termination in accordance with the Company's PTO policies then in effect. The Accrued Obligations shall be paid within 30 days after the date of termination.

(b)    Termination Resulting from Executive's Death or Disability. In the event of termination of Executive's employment as a result of Executive's death or Disability, Executive (or, in the case of death, his beneficiary, heir or estate) shall be entitled to the compensation payable in accordance with Section 3.6(a). In addition, any unvested stock rights, stock options and other unvested incentives or awards previously granted to Executive by the Company shall be subject to the terms of the applicable plan(s) under which such rights, options, incentives or awards were granted pertaining to the consequences of a plan participant's death or disability.





(c)    Termination by the Company for Cause and by Executive other than for Good Reason. In the event of termination of Executive's employment by the Company for Cause, or by Executive other than for Good Reason, neither Executive nor any beneficiary, heir or estate of Executive shall be entitled to any compensation other than the payments made or provided in accordance with Section 3.6(a). Executive shall immediately forfeit any right to or incentive compensation not yet paid or payable as of the date of termination, and all unvested stock rights, stock options and other such unvested incentives or awards previously granted to him by the Company, unless otherwise specifically provided in the applicable plan(s) under which such rights, options, incentives or awards were granted. Nothing in this Agreement shall be construed to limit the rights and remedies which may be available to the Company in the event of a termination of Executive's employment by the Company for Cause.

(d)    Termination by the Company without Cause; by Executive for Good Reason or when a Triggering Event occurs following a Change in Control. In the event of a termination of Executive's employment by the Company without Cause during the Term, or by Executive for Good Reason during the Term, or when a Triggering Event occurs following a Change in Control, or if Executive’s successor is duly elected and qualified prior to the termination of Executive’s employment in accordance with Section 3 of this Agreement, Executive shall receive the payments provided for in Section 3.6(a)(i)(ii) and (iii). In addition:

(i)Executive shall be entitled to receive payment equal to the amount of his Base Salary (at the rate in effect immediately prior to his termination). Such Base Salary payment shall be made in twelve equal installments, without interest, on a monthly basis for twelve (12) consecutive months. The first payment shall be made during the next usual pay period following Executive's termination date; provided, however, that if at the time of Executive's termination for Good Reason, if Section 409A is triggered and if Executive or Company would be subject to liability or other penalty for failure to comply with 409A, and if the Employee is a "specified employee" as defined in Section 409A of the Code, then the Company will make the payments consistent with Section 409A. Executive must receive payments on the Company's regularly scheduled pay dates, as set forth in this paragraph, and the Company shall make such payments to the extent permitted by Section 409A and any other applicable law or regulation in order to fulfill the obligations of this paragraph. If 409A is not triggered, payments will not be controlled or limited by 409A.
All rights to exercise any outstanding award of stock options or stock appreciation rights with respect to the Company's common stock, or shares of restricted stock, held by Executive at the date of termination shall be governed by the terms of the applicable plan under which such award was granted. Notwithstanding anything to the contrary in this Section 3.6 (d)(ii), in the case of termination due to the occurrence of a Triggering Event following a Change in Control, Executive shall be entitled to an immediate vesting of all non-vested options and any other equity grants and an immediate removal of any trading restrictions on restricted stock.

(ii)For the one-year period following the date of termination, Executive shall have the right to continue his participation in such retirement and other benefit plans and programs of the Company generally available from time to time to employees of the Company in which Executive was enrolled and/or participating on the date of termination, to the extent, and under the terms and conditions, permitted by the applicable plan or program, and subject to any subsequent modifications or amendments to any such plan or program.

3.7    Conditions of Payment. Any payments or benefits made or provided in connection with the termination of Executive's employment with the Company in accordance with Section 3.6 (other than payments made or provided in accordance with Section 3.6(a) or due to a termination of Executive's employment due to his death) are subject to Executive's:




(a)compliance with the provisions of Sections 3.9, 4 and 5 of this Agreement; and

(b)delivery to the Company of a resignation from all offices, directorships and fiduciary positions with the Company, its affiliates and employee benefit plans prior to the scheduled date for which the applicable payment or benefit is to be made or provided.
Payment of the amounts specified in Sections 3.6(d)(i) and (iii), and to the extent that termination is based on a Triggering Event following a Change in Control, Section 3.6(d)(ii), will be conditioned upon delivery by Executive of an executed, concurrently-effective, General Release substantially in the form attached to this Agreement as Exhibit A, with such changes or additions as needed under then applicable law to give effect to its intent and purpose.

3.8    Mitigation. Executive shall be under no obligation to seek other employment following a termination of his employment with the Company or any subsidiary for any reason. In addition, there shall be no offset against amounts due Executive under this Section 3 or otherwise on account of any compensation attributable to any subsequent employment.
3.9    Cooperation; Assistance. Executive agrees to cooperate fully, subject to reimbursement by the Company of reasonable out-of-pocket costs and expenses (including reasonable attorneys’ fees), with the Company or any subsidiary and its or their counsel with respect to any matter (including any litigation, investigation or governmental proceeding) which relates to matters with which Executive was involved or about which he had knowledge during his employment with the Company or any subsidiary. Such cooperation shall include appearing from time to time at the offices of the Company or any subsidiary or its or their counsel for conferences and interviews and, in general, providing the officers of the Company or any subsidiary and its or their counsel with the full benefit of Executive's knowledge with respect to any such matter. Executive further agrees, upon termination of his employment for any reason and if the /or Board requests, to assist his successor in the transition of his duties and responsibilities to such successor. Executive agrees to render such cooperation in a timely fashion and at such times as may be mutually agreeable to the parties. The Company shall compensate Executive for time spent providing assistance to the Company, based on the number of hours spent by Executive in providing such assistance. The hourly rate of compensation shall be $400.
3.10     Effect of the Occurrence of a Change in Control. Upon the occurrence of a Change in Control, the terms of this Section 3 (other than Sections 3.5, 3.6 and 3.10) shall cease to have any further force or effect, except under the following circumstances: (i) a Change in Control occurs, (ii) no Triggering Event occurs within the 12-month period following the Change in Control, and (iii) either the Company or Successor entity terminates Executive's employment without Cause or Executive terminates his employment for Good Reason. Under such circumstances (and assuming this Agreement is in effect at the time of such termination), Section 3 shall continue to apply to such termination.
4.    Confidentiality.
4.1    Executive acknowledges and agrees that:
(a)    by reason of his employment with the Company and his service as anOfficer of the Company, Executive will have knowledge of all aspects of the Company's operations and will be entrusted with and have access to confidential and secret proprietary business information and trade secrets of the Company, including but not limited to:
(i)information regarding the Company's business priorities and strategic plans;





(ii)information regarding the Company's personnel;

(iii)financial and marketing information (including but not limited to information about costs, prices, profitability and sales information not available outside the Company);

(iv)secret and confidential plans for and information about new or existing services, and initiatives to address the Company's competition;

(v)information regarding customer relationships; and

(vi)proprietary or confidential information of customers or clients for which the Company may owe an obligation not to disclose such information.
(all such information shall be collectively referred to as "confidential information");

(b)    the Company and its subsidiaries, affiliates and divisions will suffer substantial and irreparable damage that will not be compensable through money damages if Executive should divulge or make use of confidential information acquired by Executive in the course of his employment with the Company and service to the Board other than as may be required or appropriate in connection with Executive's work as an employee of the Company; and

(c)    the provisions of this Agreement are reasonable and necessary for the protection of confidential information, the business of the Company and its subsidiaries, affiliates and divisions, and the stability of their workforces.
4.2    Except as may be required or appropriate in connection with Executive's work as an employee of the Company, Executive shall keep confidential all confidential information he learns of during his employment with the Company regarding the Company, its business, operations, systems, employees, customers, clients and prospective clients. In addition, Executive agrees that he will not disclose confidential information obtained from the Company or its officers, directors or management during his employment, including, but not limited to, information regarding, or statements by, the Company or its officers, directors or management, to anyone other than as required by law or in response to a lawful court order or subpoena.
4.3    Nothing in this Section 4 shall prohibit Executive from participating as a witnessat the request of the Company or a third party in any investigation by the SEC or any other governmental agency charged with the investigation of any matters related to Executive's employment with the Company, nor shall Executive be prohibited from testifying in response to a subpoena, court order or notice of deposition. Executive agrees to notify the Company's General Counsel, in writing, at least ten (10) days prior to the response deadline or appearance date (whichever is earlier) for any such subpoena, court order or notice of deposition issued by a court or investigating agency which seeks disclosure of any confidential information. Executive further agrees to take any actions reasonably requested by the Company to allow the Company to protect the release of information regarding Executive's employment from the Company in such court or agency proceeding.

4.4    Executive agrees that:

(a)he will not, at any time, remove from the Company's premises any notebooks, software, data or other confidential information relating to the Company, except to the extent necessary or appropriate to perform his duties and responsibilities under the terms of this Agreement;




(b)upon the expiration or termination of the Term for any reason whatsoever, he shall promptly deliver to the Company any and all notebooks, software, data and documents and material, including all copies thereof, in his possession or under his control relating to any confidential information, or which is otherwise the property of the Company; and

(c)he will not use any confidential information for his own benefit or for the benefit of any new employer or any third person.
4.5    For purposes of this Section 4, the term "Company" shall mean and include the Company and any and all subsidiaries and affiliated entities of the Company in existence from time to time.
5.    Non-Competition and Non-Solicitation.
5.1    Executive acknowledges that the Company is, as of the Effective Date, engaged principally in the business of providing health information risk assessment services to insurance companies and health and wellness providers, performing lab testing services, providing underwriting services in connection with the processing of life insurance applications, and providing health information gathering and assessment services to healthcare and research entities, throughout the United States. By virtue of Executive's position with the Company, Executive will be exposed to and acquire significant confidential information about the Company and its existing and future plans and strategies. As a result, Executive acknowledges that the Company has a legitimate business interest supporting the restrictive covenants set forth in this Section 5.
5.2    During Executive's employment with the Company and until the first anniversary of the date of termination of Executive's employment with the Company, Executive shall not in any manner, directly or indirectly, within the United States (without the prior written consent of a duly authorized officer of the Company):

(a)act as a Competitive Enterprise or accept any engagement in any capacity that involves Executive performing management, consultation, advisory or other services of any kind with a Competitive Enterprise (as defined in Section 5.3 below) in which Executive’s role will include competing with Company in any business in which the Company or any of its subsidiaries is then engaged;

(b)Solicit (as defined in Section 5.3 below) any Customer (as defined in Section 5.3 below) to transact business with a Competitive Enterprise or to reduce or refrain from doing any business with the Company or any of its subsidiaries;

(c)transact business with any Customer that would cause Executive to be a Competitive Enterprise;

(d)interfere with or damage any relationship between the Company or any its subsidiaries with a Customer; or

(e)Solicit anyone who is then an employee of the Company or any of its subsidiaries (or who was an employee of the Company or any of its subsidiaries within the prior 12 months) to resign from the Company or any of its subsidiaries or to apply for or accept employment with any other business or enterprise.




5.3    For purposes of this Agreement:
"Competitive Enterprise" means any business enterprise that either (A) engages in a business that competes anywhere in the United States with any business in which the Company or any of its subsidiaries is then engaged in so that it accounts for more than 10% of the Company’s (or any of its subsidiaries’) revenue for the prior 12 months; or (B) holds a greater than 50% equity, voting or profit participation interest in any enterprise that competes anywhere in the United States with any activity that the Company or any of its subsidiaries is then engaged in; provided, however, that if (i) the Company, including any subsidiary, ceases to do, and exits, a particular type of business activity, then following such exit the Company and its subsidiaries will be deemed not to be "then engaged" in such business; or (ii) the Company, including any of its subsidiaries, was not engaged in a particular type of business activity (and was not contemplating such business activity), while Executive was employed by the Company, then for the purposes of this Agreement, the Company and its subsidiaries will be deemed not to be "then engaged" in such business.
"Customer" means any customer or prospective customer of the Company or any of its subsidiaries whose identity became known to Executive in connection with Executive's relationship with or employment by the Company or any of its subsidiaries and who may be a customer within 6 months after the termination of the Agreement.
"Solicit" means any direct or indirect communication of any kind, regardless of who initiates it, that in any way invites, advises, encourages or requests any person to take or refrain from taking any action.


6.    Injunctive Relief. If Executive commits a breach, or threatens to commit a breach, of any of the provisions of Section 4 or 5 of this Agreement, the Company shall have the right and remedy (which shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity) to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged by Executive that any such breach or threatened breach will or may cause irreparable injury to the Company and that money damages will or may not provide an adequate remedy to the Company.

7.    Miscellaneous.
7.1    Benefit of Agreement, Assignment; Beneficiary. This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. This Agreement Shall also inure to the benefit of, and be enforceable by, Executive and his personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive should die while any amount would still be payable to Executive under this Agreement if he had continued to live, all such amounts shall be paid in accordance with the terms of this Agreement to Executive's beneficiary, devisee, legatee or other designee, or if there is no such designee, to Executive's estate.
7.2    Notices. Any notice required or permitted under this Agreement shall be in writing and shall be sufficiently given if personally delivered or if sent by certified mail, postage prepaid, with return receipt requested or by reputable overnight courier, addressed: (a) in the case of the Company, to the General Counsel of the Company at the Company's then-current corporate headquarters, and (b) in the case of Executive, to Executive's last known address as reflected in the Company's records, or to such other address as either party shall designate by written notice to the other party. Any notice given hereunder shall be deemed to have been given at the time of receipt thereof by the person to whom such notice is given if personally delivered or at the time of mailing if sent by certified mail or by courier.




7.3.     Entire Agreement; Amendment. Except as specifically provided in this Agreement, this Agreement contains the entire agreement of the parties to this Agreement with respect to the terms and conditions of Executive's employment during the Term, and supersedes all prior agreements and understandings, whether written or oral, between the parties with respect to compensation due for services rendered under this Agreement. For the avoidance of doubt, in the event of any inconsistency between this Agreement and any plan, program or arrangement of the Company or its affiliates, the terms of this Agreement shall control. This Agreement may not be changed or modified except by an instrument in writing signed by both of the parties.
7.4    Waiver. The waiver of either party of a breach of any provision of this Agreement shall not operate or be construed as a continuing waiver or as a consent to or waiver of any subsequent breach.
7.5    Headings. The section headings in this Agreement are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or affect any of the provisions of this Agreement.
7.6    Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York, without reference to the principles of conflicts of laws.
7.7    Survivorship. The respective rights and obligations of the parties under this Agreement shall survive any termination of this Agreement to the extent necessary to effectuate the intended preservation of such rights and obligations, including, without limitation, Section 4 and 5 of this Agreement.
7.8    Validity. The invalidity on unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision or provisions of this Agreement, which shall remain in full force and effect. If any provision of this is held to be invalid, void or unenforceable, any court so holding shall substitute a valid, enforceable provision that preserves, to the maximum lawful extent, the terms and intent of this Agreement.
7.9    Construction. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state or local statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word "including" shall mean including without limitation.




7.10     Section 409A.

(a)Notwithstanding the due date of any post-employment payments, if at the time of the termination of Executive's employment Section 409A is triggered and if Executive or Company would be subject to liability or other penalty for failure to comply with 409A, and if Executive is a "specified employee" (as defined in Section 409A, Executive will not be entitled to any payments upon termination of employment that are subject to Section 409A until the later of (i) the date that payments are scheduled to be made under this Agreement, or (ii) the earlier of (A) the first day of the seventh month following the date of termination of his employment with the Company for any reason other than death, or (B) the date of Executive's death. The provisions of this paragraph will only apply if 409A is triggered, and will only apply if and to the extent required to avoid any "additional tax" under Section 409A either to Executive or Company. If 409A is triggered, the parties to this Agreement intend that the determination of Executive's termination of employment shall be made in accordance with Treasury Reg. Section 1.409A-1(h) and that Executive will be paid as set forth in sec. 3.6 (d), to the extent consistent with law.

(b)If Section 409A is triggered and if Executive or Company would be subject to liability or other penalty for failure to comply with 409A, the Parties to this Agreement intend that this Agreement and Company's and Executive's exercise of authority or discretion hereunder shall comply with the provisions of Section 409A and the Treasury regulations relating thereto so as not to subject Executive to the payment of interest and tax penalty which may be imposed under Section 409A. In furtherance of this objective, to the extent that any regulations or other guidance issued under Section 409A would result in Executive being subject to payment of "additional tax" under Section 409A, the parties agree to use their best efforts to amend this Agreement in order to avoid the imposition of any such "additional tax" under Section 409A, which such amendment shall be designed to minimize the adverse economic effect on Executive without increasing the cost to the Company (other than transactions costs), all as reasonably determined in good faith by the Company and Executive to maintain to the maximum extent practicable the original intent of the applicable provisions. This Section 7.10 does not guarantee that payments under this Agreement will not be subject to "additional tax" under Section 409A.

7.11    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which will constitute one and the same instrument.




IN WITNESS WHEREOF, each of the parties has duly executed this Agreement on the date indicated below. The Company represents that its execution of this Agreement has been authorized by the Compensation Committee of the Company's Board of Directors.




Hooper Holmes, Inc.

By: /s/ Ronald V. Aprahamian

Name: Ronald V. Aprahamian
Title: Chairman of the Board of Directors

Date: September 30, 2013




By: /s/ Henry E. Dubois

Name: Henry E. Dubois
Title: President and Chief Executive Officer

Date: September 30, 2013






Exhibit A
General Release
1.    For valuable consideration, the adequacy of which is hereby acknowledged, the undersigned executive ("Executive"), on his own behalf and on behalf of his family members, heirs, executors, administrators, personal representatives, distributees, devisees, legatees, and successors and assigns (collectively, the "Releasing Parties"), does hereby knowingly, voluntarily and unconditionally release, waive, acquit and fully discharge, and agree to hold harmless Hooper Holmes, Inc, a New York corporation (the "Company") and its present and past subsidiaries and affiliates, and its and their officers, directors, shareholders, employee benefit plans, plan fiduciaries and trustees, insurers, employees, agents, representatives, successors and assigns (collectively referred to as the "Releasees"), from and against any cause of action, legal claim, suit, right, liability or demand of any kind or nature, known or unknown, liquidated or unliquidated, absolute or contingent, at law or in equity (each such action, claim, suit, right, liability or demand being hereinafter individually referred to as a "Claim" and collectively as "Claims") that Executive may now or hereafter have against the Releasees, or any one or group of them, including, but not limited to:

(a)any and all Claims in connection with

(i)any and all agreements between the Company and Executive, including but not limited to the Employment Agreement, dated as 4th day of September 2013, by and between the Company and Executive (the "Employment Agreement");

(ii)Executive's employment relationship with the Company,

(iii)the terms and conditions of such employment relationship (including compensation and benefits),

(iv)Executive's service as an officer of the Company (except for indemnification in accordance with the Company's certificate of incorporation, bylaws or any director or officer indemnity agreement between Executive and the Company), or

(v)the termination of such employment relationship and the circumstances surrounding such termination; and

(b)any and all Claims relating to, or arising from, Executive's right to purchase, or actual purchase of, shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any federal or state law; and

(c) any and all Claims for wrongful discharge of employment; constructive discharge; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits.




Without limiting the generality of the foregoing, Executive specifically releases, acquits, discharges, waives and agrees to hold Releasees harmless from and against any and all claims arising under:
(A)
the Sarbanes-Oxley Act of 2002, 18 U.S.C. §1514A;

(B)
Section 1981 of the Civil Rights Act of 1866, as amended, 42 U.S.C.
§§1981;

(C)
Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §§2000e, et seq. (the "Civil Rights Act");

(D)
the Americans with Disabilities Act of 1990, 43 U.S.C. §12101 et seq. (the "Americans with Disabilities Act");

(E)
the Equal Pay Act of 1993;

(F)
the Fair Labor Standards Act, except as prohibited by law;

(G)
the Older Workers Benefit Protection Act of 1990 (the "OWBPA");

(H)
the Age Discrimination in Employment Act of 1967, 29 U.S.C. §626 et seq. (the "ADEA");

(I)
the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. (the "Family and Medical Leave Act"), except as prohibited by law;

(J)
the Worker Adjustment and Retraining Notification Act, as amended;

(K)
Executive Order 11,141 (age discrimination);

(L)
Executive Order 11,246 (race, color, religion, sex and national origin discrimination);

(M)
the National Labor Relation Act;

(N)
the Occupational Safety and Health Act, as amended;

(O)
the Immigration Reform and Control Act, as amended;

(P)
the Vietnam Era Veterans Readjustment Assistance Act;

(Q)
Sections 503-504 of the Rehabilitation Act of 1973 (handicap rehabilitation);

(R)
the Employee Retirement Income Security Act of 1974, as amended ("ERISA") (other than such rights as are mandated or vested by law);

(S)
the New Jersey Law Against Discrimination, N.J.S.A. 10:5-1 et seq.;

(T)
the New Jersey Conscientious Employee Protection Act, N.J.S.A, 34:19-1
et seq.;





(U)
the New Jersey Wage and Hour laws, N.J.S.A. 34:11-56a et seq.;

(V)
the New Jersey Family Leave Act, N.J.S.A. 34:11B-1 et seq.;

(W)
any other federal, state or local fair employment, civil or human rights, wage and hour laws and wage payment laws, and any and all other federal, state, local or other governmental statutes, laws, ordinances, regulations and orders, under common law, and under any Company policy, procedure, bylaw or rule.
This General Release shall not waive or release any Claims that Executive may have which arise after the date of this General Release or that arise under or are explicitly preserved by the Employment Agreement and shall not waive any Claims for benefits required by applicable law (including post-termination health-continuation insurance benefits required by state or federal law) or Claims which cannot be waived or released under the terms of any federal law or the laws of the state(s) governing Executive's employment with the Company. This General Release shall also not waive or release any Claims that Executive may have for a defense, contribution, or indemnification for any claim brought by any third party arising out of the scope of his employment.

2.    Executive agrees not to sue concerning, or in any manner to institute, prosecute or pursue any Claim in respect of any of the matters covered by Section 1 of this General Release in any court of the United States or in any state, or with any administrative agency of the United States or any state, county or municipality, or before any other tribunal, public or private, against the Company or any of the Releasees.

3.    This General Release is not intended to and does not interfere with the right of the Equal employment Opportunity Commission ("EEOC") to enforce anti-discrimination laws or to seek relief that will benefit the public and any victim of unlawful employment practices who has not waived his or her claims. The Company acknowledges and agrees that Executive is not prevented from filing a charge with, or testifying, assisting, or participating in any proceeding brought by the EEOC concerning an alleged discriminatory practice of the Company. Executive, on behalf of himself and any and all other Releasing Parties, hereby waives all rights to any benefits, including, but not limited to, monetary recovery and reinstatement, derived from any actions, suits or proceedings brought on behalf of Executive or any of the other Releasing Parties, including any action, suit or proceeding brought by the EEOC or anyone else. Executive, on behalf of himself and any and all other Releasing Parties, also agrees not to initiate or become a party to or otherwise participate or support any current or former employee(s) in any action, suit or proceeding brought by such employee(s). If Executive or any other Releasing Party files any action, suit or proceeding with respect to any Claim released by Executive under the terms of this Agreement, Executive agrees to indemnify the Company against any damages or judgments arising from any such action, suit or proceeding.

4.    Executive agrees that Executive shall not be eligible and shall not seek or apply for reinstatement or re-employment with the Company and agrees that any application for re-employment may be rejected without explanation or liability.

5.    In further consideration of the promises made by the Company in Section 3 of the Employment Agreement, Executive specifically waives and releases the Company, to the extent set forth in Section 1 of this General Release, from all Claims Executive may have as of the date of this General Release, whether known or unknown, arising under the ADEA. Executive further agrees that:

(a)Executive's waiver of rights under this General Release is knowing and voluntary and in compliance with the OWBPA.





(b)Executive understands the terms of this General Release.

(c)The consideration offered by the Company under Section 3 of the Employment Agreement in exchange for the General Release represents consideration over and above that to which Executive would otherwise be entitled, and the consideration would not have been provided had Executive not agreed to sign the General Release and did not sign the General Release.

(d)The Company is hereby advising Executive in writing to consult with an attorney prior to executing this General Release.

(e)The Company is giving Executive a period of twenty-one (21) days within which to consider this General Release.

(f)Following Executive's execution of this General Release, Executive has seven (7) days in which to revoke this General Release by written notice. An attempted revocation not actually received by the Company prior to the revocation deadline will not be effective.

(g)This General Release and all payments and benefits otherwise payable under Section 3 of the Employment Agreement (other than payments and benefits made or provided in accordance with Section 3.6(a)) shall be void and of no force and effect if Executive chooses to so revoke, and if Executive chooses not to so revoke within the 7-day period, this General Release shall then become effective and enforceable.

6.    This General Release does not waive any rights or claims that may arise under the ADEA after the date Executive signs this General Release. To the extent barred by the OWBPA, the covenant not to sue contained in Section 2 above does not apply to claims under the ADEA that challenge the validity of this General Release.

7.    To revoke this General Release, Executive must send a written statement of revocation to:

Hooper Holmes, Inc.
170 Mt. Airy Road
Basking Ridge, New Jersey 07920
Attn: General Counsel
The revocation must be received by no later than 5:00 p.m. on the seventh day following Executive's execution and delivery of this General Release. If Executive does not revoke, the eighth day following Executive's execution and delivery of this General Release will be the effective date of this General Release.

8.    Executive acknowledges and agrees that this General Release is not intended by Executive or the Company to be construed, and will not be construed, as an admission by the Company of any liability or violation of any law, statute, ordinance, regulation or legal duty of any nature whatsoever.

9.    This General Release shall be governed by the internal laws (and not the choice of laws) of the State of New Jersey, except for the application of pre-emptive federal law.

Please read this General Release carefully. It contains a release of all known and unknown claims.




Date: September 30, 2013
/s/ Henry E. Dubois
Henry E. Dubois



Hooper Holmes, Inc.



By: /s/ Ronald V. Aprahamian
Ronald V. Aprahamian
Chairman of the Board of Directors


 EX-10.6 7 exhibit106q32013.htm EXHIBIT 10.6 TOM COLLINS EMPLOYMENT AGREEMENT exhibit106q32013








Employment Agreement

This Employment Agreement ("Agreement") is made as of the 25th day of September, 2013 (the "Effective Date"), by and between Hooper Holmes, Inc., a New York corporation, with its principal office at 170 Mt. Airy Road, Basking Ridge, New Jersey 07920 (the "Company") and Thomas Collins ("Executive").
RECITALS
WHEREAS, the Company desires to embody in this Agreement the terms and conditions of Executive's employment with the Company.
NOW, THEREFORE, in consideration of the mutual promises and agreements contained in this Agreement, including the compensation to be paid to Executive, the parties hereby agree as follows:
1.    Employment; Term; Duties and Responsibilities.
1.1. Employment as Senior Vice President and Chief Financial Officer. The Company wishes to employ Executive as its Senior Vice President and Chief Financial Officer, and Executive hereby accepts such employment, subject to the terms and conditions of this Agreement. Executive represents and warrants to the Company that he is not a party to any agreement that would restrict or prohibit him from being employed by the Company.
1.2. Term. The provisions of this Agreement shall be effective as of the Effective Date and shall continue in force until his successor is duly elected and qualified, or the termination of Executive's employment as provided in Section 3 of this Agreement, whichever shall occur first (the "Term").
1.3. Location of Employment. Executive shall be based at the location specified by the Company. At this time, the Company anticipates that the Company will relocate at some future date to Olathe, Kansas.
1.4. Duties and Responsibilities. In his capacity as Senior Vice President and Chief Financial Officer of the Company, Executive shall report directly to the President and Chief Executive Officer ("CEO"). Executive shall have such duties and responsibilities, and the power and authority, normally associated with the position of Senior Vice President and Chief Financial Officer, as well as any additional duties and responsibilities of an executive character as shall, from time to time, be delegated or assigned to him by the CEO or the Hooper Holmes, Inc. Board of Directors (the "Board"). As Senior Vice President and Chief Financial Officer, Executive shall keep the CEO and Board fully informed of any and all matters of a material nature, from an operational or financial perspective, and seek CEO and Board approval of appropriate matters, in accordance with his fiduciary duties to the Company and its shareholders.




1.5. Devotion of Time. During the Term, Executive shall expend all of his working time, care and attention to his duties, responsibilities and obligations to the Company. Executive may serve on the boards of (i) civic and charitable entities, and (ii) with the prior written consent of the Board, other corporate entities; provided, however, that such activities do not, either individually or in the aggregate, interfere with Executive's duties and responsibilities as Senior Vice President and Chief Financial Officer of the Company.
1.6. Effective Date. The Effective Date of this Agreement shall commence when both the Executive and Company sign this Agreement.
1.7. Elected Officer of the Company. The Company and Executive acknowledge that Executive shall serve as an elected Officer of the Company.
2.    Compensation; Benefits.
As compensation and consideration for the services to be rendered by Executive as Senior Vice President and Chief Financial Officer of the Company in accordance with the terms and conditions of this Agreement, and while Executive is employed with the Company as Senior Vice President and Chief Financial Officer, Executive shall be entitled to the compensation and benefits set forth in this Section 2 (subject, in each case, to the provisions of Section 3 of this Agreement).
2.1. Base Salary. Executive shall receive an annual base salary ("Base Salary") of Two Hundred and Twenty Thousand Dollars ($220,000) per year, payable in accordance with the Company's standard payroll dates and practices, provided such payments shall not be made less frequently than twice in each calendar month. The Base Salary shall be reviewed at least annually by the CEO and Compensation Committee (the "Committee") of the Board and may be adjusted by the Committee, in its sole discretion, based on the Committee's consideration of the Company's performance, financial and otherwise. If the Base Salary is adjusted, the adjusted amount will thereafter be the Base Salary for all purposes of this Agreement. However, the Base Salary shall never be lower than $220,000 per year.
2.2. Annual Bonus. Executive shall be eligible to participate in such annual bonus or incentive compensation plans and programs as may be in effect from time to time in accordance with the Company's compensation practices and the terms and provisions of any such plans or programs. Executive's annual target bonus opportunity will be equal to 40% of his Base Salary (eighty-eight thousand dollars ($88,000)), and is subject to Executive and the Company achieving annually agreed upon financial, company and individual goals and objectives. This amount may increase or decrease based on performance. Except as otherwise provided by the terms of this Agreement, any annual bonus earned shall be paid at the same time and in the same manner as corresponding awards to other senior executives of the Company.
2.3. Long-Term and Equity Compensation. Executive shall be eligible to participate in any long-term incentive compensation plan (including any equity-compensation plan) that may be adopted by the Company from time to time during the Term. In addition to Executive’s currently held options totaling Three Hundred and Thirty Five Thousand (335,000), Executive shall be entitled to and will receive an additional Three Hundred and Twenty Five Thousand (325,000) options at the commencement of the term of this Agreement. In accordance with the appropriate Company Omnibus Employee Incentive Plan, the vesting shall take place with the following schedule: 107,250 options vest on the first anniversary of the date of this Agreement; 107,250 options vest on the second anniversary of the date of this Agreement; and 110,500 options vest on the third anniversary of the date of this agreement. Future awards, if any, will be reviewed by the CEO and made by the Committee in its sole discretion, commensurate with Executive's position as Senior Vice President and Chief Financial Officer.




2.4. Participation in Other Benefit Plans. While Executive is employed with the Company, Executive shall be eligible to participate in all retirement and other benefit plans and programs of the Company generally available from time to time to employees of the Company and for which Executive qualifies under the terms thereof. Nothing in this Agreement shall limit the Company's ability to change, modify, cancel, amend or discontinue any of these plans.
2.5. Reimbursement of Expenses. The Company shall pay directly or reimburse Executive for reasonable business-related expenses and disbursements incurred by him for and on behalf of the Company in connection with the performance of his duties as the Senior Vice President and Chief Financial Officer of the Company, subject, however, to the Company's written policies relating to business-related expenses as in effect from time to time. Executive shall submit to the Company, no later than the month after the month during which he incurred any such business-related expenses and disbursements, a report of such expenses and disbursements in the form normally used by the Company and receipts with respect thereto, and the Company's obligations under this Section 2.5 shall be subject to compliance therewith. Reimbursement of any business-related expenses and disbursements shall be made in accordance with the Company's written policies relating to business-related expenses as in effect from time to time. In no event will reimbursement of any business-related expenses and disbursements be made later than the last day of the calendar year following the calendar year in which any such expense or disbursement was incurred.
2.6. Vacation. Executive shall be entitled to paid vacation in accordance with the Company's Paid Time Off (PTO) policy in effect from time to time, and Executive shall maintain and continue his current PTO balance accrued prior to this Agreement.
2.7 Executive Change-in-Control Agreement. Executive acknowledges that in connection with Executive's employment with the Company, Executive entered into an Executive Change in- Control Agreement with the Company dated January 1, 2013 (the "CIC Agreement"). By executing this Agreement, Executive agrees that the CIC Agreement is null and void and all rights and obligations therein are hereby waived and revoked, including but not limited to, Executive’s rights to termination benefits and any other benefits as provided in the CIC Agreement.
2.8.    Indemnification; Insurance.
(a)Executive acknowledges that, upon commencement of his employment
 
(b)with the Company, he was offered and accepted indemnification in accordance with the Company's bylaws and the terms of the Company's form indemnity agreement for officers and directors, in each case subject to applicable law.

(c)Executive shall be covered by directors' and officers' liability insurance, as well as employment practices liability insurance, during the Term and for any applicable statute of limitations period thereafter, to the same extent as other officers of the Company.
2.9. Deductions; Withholdings. All compensation payable to Executive under the terms of this Agreement shall be subject to any applicable income, payroll or other tax withholding requirements and such other deductions or amounts, if any, as may be authorized by Executive.




2.10. Transaction Bonus. Executive shall be entitled to a one time transaction bonus of One Hundred and Two Thousand, Five Hundred Dollars ($102,500). This bonus is compensation for Executive’s efforts leading an internal project team as well as new and increased efforts on the transition team. Such bonus shall be made in a one-lump sum payment within thirty (30) days after the consummation of the pending Portamedic transaction. Executive understands and agrees that no other incentive/bonus is intended to be paid to him for 2013, including any annual bonus as specified in Sec. 2.2, except as may otherwise be provided in this Agreement.
3.    Termination.
3.1. Termination by the Company. The Company shall have the right, subject to the terms of this Agreement, to terminate Executive's employment at any time, with or without "Cause." The Company shall give Executive written notice of a termination for Cause (the "Cause Notice") in accordance with Section 7.2 of this Agreement. The Cause Notice shall state the particular action(s) or inaction(s) giving rise to the termination for Cause. No action(s) or inaction(s) will constitute Cause unless:

(a)a resolution finding that Cause exists has been approved by a majority of all of the members of the Board (excluding Executive), at a meeting at which Executive is allowed to appear with his legal counsel; and

(b)where remedial action is feasible, Executive fails to remedy the action(s) or inaction(s) within thirty (30) days after receiving the Cause Notice.
If Executive effects a cure to the satisfaction of the Board within the 30-day period following his receipt of the Cause Notice, the Cause Notice shall be deemed rescinded and of no force or effect.
For purposes of this Agreement, "Cause" shall mean:
•
participation by Executive in fraudulent conduct against the Company, or a material misrepresentation or omission by Executive that, in the Board's reasonable judgment, has resulted or will likely result in injury to the business, operations or financial condition of the Company; conviction of or a plea of guilty or nolo contendere with respect to a felony involving theft or moral turpitude;
•
Executive's violation of any statutory or common law duty of loyalty or good faith to the Company or any of its subsidiaries;
•
Executive's continued violation of a material policy of the Company for a period of thirty (30) days after Executive's receipt of a written notice specifying the nature of such violation from the Company;
•
any refusal by Executive to follow the lawful directives of the CEO and/or Board that are consistent with the scope and nature of Executive's duties and responsibilities as set forth in this Agreement;
•
any continued misconduct by Executive in connection with performance of his duties hereunder for a period of thirty (30) days after having received a written notice specifying the nature of such misconduct from the Company; or
•
any breach by Executive of any one or more of the covenants contained in Sections 4 and 5.
3.2 Termination by Executive. Executive shall have the right, subject to the terms of this Agreement, to terminate his employment at any time with or without "Good Reason."




For purposes of this Agreement, "Good Reason" shall mean the occurrence of any of the following during the Term without Executive's prior written consent:
•
a material diminution in Executive's authority, duties and/or responsibilities as contemplated by this Agreement;
•
a material diminution in Executive's Base Salary, or unless the diminution is a result of a Company-wide diminution in the annual bonus opportunity, target incentive awards and/or benefits of all similarly situated employees as Executive, a material diminution in the amount of Executive's annual bonus opportunity, target incentive award and/or benefits, including health, retirement and fringe;
•
a material failure by the Company to comply with the material provisions of this Agreement (provided that an isolated, insubstantial or inadvertent action or omission that is not in bad faith and is remedied by the Company promptly after receipt of notice thereof given by Executive shall not constitute Good Reason);
•
in the event of the occurrence of a Change in Control as specified in Sec. 3.5, the failure of a successor to the Company to explicitly assume and agree to be bound by the terms of the Change in Control provisions contained in this Agreement; or
•
a material breach by the Company of any of the Change in Control provisions of this Agreement.
Executive must give the Company written notice, in accordance with Section 7.2 of this Agreement, of any Good Reason termination of employment. Such notice must be given within 60 days following Executive's knowledge of the first occurrence (as determined without regard to any prior occurrence that was subsequently remedied by the Company) of a Good Reason circumstance, and must specify which of the Good Reason circumstances Executive is relying on, the particular action(s) or inaction(s) giving rise to such circumstance, and the date that Executive intends to separate from service, as defined under Section 409A of the Internal Revenue Code of 1986, as amended ("Section 409A"), which shall be no earlier than thirty (30) days following the date of the Company's receipt of the notice. Executive's termination shall not be deemed a Good Reason termination of employment if (i) within 30 days of the Company's receipt of such notice, the Company remedies the circumstance(s) giving rise to the notice, or (ii) Executive's termination of his employment does not occur within 60 days after the end of the 30-day period provided to the Company to remedy the circumstances giving rise to the notice.
3.3    Death. If Executive dies during the Term, Executive's employment shall automatically terminate, such termination to be effective on the date of Executive's death.
3.4    Disability. If Executive shall suffer a Disability, the Company shall have the right to terminate Executive's employment, such termination to be effective upon the giving of notice to Executive in accordance with Section 7.2 of this Agreement. For purposes of this Agreement, a Disability shall mean any physical or mental incapacity as a result of which Executive is unable to perform substantially all of his essential duties for an aggregate of four (4) months, whether or not consecutive, during any calendar year, and which cannot be reasonably accommodated by the Company without undue hardship. Executive cannot be terminated for Disability unless the Company has delivered a written demand for substantial performance to Executive, specifically identifying the manner in which Executive has not substantially performed his duties, and Executive does not cure such failure within sixty (60) days of such demand.

3.5    Termination of Employment following a Change in Control.
3.5.1     Change In Control. A "Change in Control" shall be deemed to have occurred as of the first day any one or more of the following conditions shall have been satisfied:




(a)
Any person (other than (i) the Company or any subsidiary of the Company, (ii) a corporation or other entity owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of the Company, or (iii) an employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary of the Company), becomes the beneficial owner, directly or indirectly, of securities of the Company, representing fifty-one percent (51%) or more of the combined voting power of the Company's then outstanding securities; provided, however, that no crossing of such 51% threshold shall be a "Change in Control" if it is caused (A) solely as a result of an acquisition by the Company of its voting securities; or (B) solely as a result of an acquisition of the Company's voting securities directly from the Company, in either case until such time thereafter as such person acquires additional voting securities other than directly from the Company and, after giving effect to such transaction, such person owns 51% or more of the then outstanding common stock or voting power of the Company;

(b)
Individuals who, as of the date hereof, constitute the Board of Directors of the Company (the "Board", such individuals being referred to as the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Securities Exchange Act of 1934 (the '34 Act") relating to the election of the directors of the Company) shall be, for purposes of this Agreement, considered as though such person were a member of the Incumbent Board; or

(c)
A merger, consolidation, reorganization or share exchange, or sale of all or substantially all of the assets, of the Company, unless, immediately following such transaction, all of the following shall apply: (A) all or substantially all of the beneficial owners of the Company immediately prior to such transaction will beneficially own in substantially the same proportions, directly or indirectly, more than 51% of the combined voting power of the then outstanding voting securities of the corporation or other entity resulting from such transaction (including, without limitation, a corporation or other entity which, as a result of such transaction, owns the Company or all or substantially all of the Company's assets, either directly or through one or more subsidiaries) (the "Successor Entity"), (B) no person will be the beneficial owner, directly or indirectly, of 51% or more of the combined voting power of the then outstanding voting securities of the Successor Entity, and (C) at least a majority of the members of the board of directors of the Successor Entity will be Incumbent Directors.

(d)
All terms used in this Section 3.5 shall be interpreted in a manner consistent with the '34 Act.
 
3.5.2    Triggering Event. Executive may not invoke Change In Control protections under this Agreement unless (i) a Change in Control occurs under sec. 3.5.1; and (ii) a Triggering Event occurs. For the purposes of this Agreement, a "Triggering Event" means a termination of the Executive's employment with the Company or Successor Entity at any time prior to the end of the twelve (12) month period following the Change in Control (such period of time being referred to as the "Employment Period"), unless (i) such termination is by reason of the Executive's Total Disability or death; or (ii) the Company terminates the Executive's employment with the Company or Successor Entity for Cause; or (iii) the Executive terminates his employment with the Company or Successor Entity for other than Good Reason.




3.5.3    Company Successor. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent as the Company would be required to perform it if no such succession had taken place. Failure of the Company to obtain such agreement prior to the effectiveness of any such succession shall be a breach of this Agreement and shall entitle the Executive to compensation from the Company in the same amount and on the same terms as the Executive would be entitled to hereunder if the Executive had given notice of termination for Good Reason as of the day immediately before such succession became effective and had specified that day in the notice of termination. As used in this Section 3.5.3, the "Company" shall mean the Company as defined in the first sentence of this Agreement and any successor to all or substantially all its business or assets or which otherwise becomes bound by all the terms and provisions of this Agreement, whether by the terms hereof, by operation of law or otherwise.
3.6    Effect of Termination.
(a)    In General. Subject to the terms of Section 3.6(c), in the event of the termination of Executive's employment for any reason during the Term, the Company shall pay to Executive (or his beneficiary, heirs or estate, in the event of his death), as provided in Section 3.6 of this Agreement: (i) any Base Salary, to the extent not previously paid, to the date of termination; (ii) any reimbursable business expenses that have not yet been reimbursed (collectively, the "Accrued Obligations"); and (iii) the cash equivalent of any unused vacation time accrued to the date of termination in accordance with the Company's PTO policies then in effect. The Accrued Obligations shall be paid within 30 days after the date of termination.

(b)    Termination Resulting from Executive's Death or Disability. In the event of termination of Executive's employment as a result of Executive's death or Disability, Executive (or, in the case of death, his beneficiary, heir or estate) shall be entitled to the compensation payable in accordance with Section 3.6(a). In addition, any unvested stock rights, stock options and other unvested incentives or awards previously granted to Executive by the Company shall be subject to the terms of the applicable plan(s) under which such rights, options, incentives or awards were granted pertaining to the consequences of a plan participant's death or disability.

(c)    Termination by the Company for Cause and by Executive other than for Good Reason. In the event of termination of Executive's employment by the Company for Cause, or by Executive other than for Good Reason, neither Executive nor any beneficiary, heir or estate of Executive shall be entitled to any compensation other than the payments made or provided in accordance with Section 3.6(a). Executive shall immediately forfeit any right to or incentive compensation not yet paid or payable as of the date of termination, and all unvested stock rights, stock options and other such unvested incentives or awards previously granted to him by the Company, unless otherwise specifically provided in the applicable plan(s) under which such rights, options, incentives or awards were granted. Nothing in this Agreement shall be construed to limit the rights and remedies which may be available to the Company in the event of a termination of Executive's employment by the Company for Cause.
(d)    Termination by the Company without Cause; by Executive for Good Reason or when a Triggering Event occurs following a Change in Control. In the event of a termination of Executive's employment by the Company without Cause during the Term, or by Executive for Good Reason during the Term, or when a Triggering Event occurs following a Change in Control, or if Executive’s successor is duly elected and qualified prior to the termination of Executive’s employment in accordance with Section 3 of this Agreement, Executive shall receive the payments provided for in Section 3.6(a)(i)(ii) and (iii). In addition:





(i)    Executive shall be entitled to receive payment equal to the amount of his Base Salary (at the rate in effect immediately prior to his termination). Such Base Salary payment shall be made in twelve equal installments, without interest, on a monthly basis for twelve (12) consecutive months. The first payment shall be made during the next usual pay period following Executive's termination date; provided, however, that if at the time of Executive's termination for Good Reason, if Section 409A is triggered and if Executive or Company would be subject to liability or other penalty for failure to comply with 409A, and if the Employee is a "specified employee" as defined in Section 409A of the Code, then the Company will make the payments consistent with Section 409A. Executive must receive payments on the Company's regularly scheduled pay dates, as set forth in this paragraph, and the Company shall make such payments to the extent permitted by Section 409A and any other applicable law or regulation in order to fulfill the obligations of this paragraph. If 409A is not triggered, payments will not be controlled or limited by 409A.

(ii)    All rights to exercise any outstanding award of stock options or stock appreciation rights with respect to the Company's common stock, or shares of restricted stock, held by Executive at the date of termination shall be governed by the terms of the applicable plan under which such award was granted. Notwithstanding anything to the contrary in this Section 3.6 (d)(ii), in the case of termination due to the occurrence of a Triggering Event following a Change in Control, Executive shall be entitled to an immediate vesting of all non-vested options and any other equity grants and an immediate removal of any trading restrictions on restricted stock.

(iii)    For the one-year period following the date of termination, Executive shall have the right to continue his participation in such retirement and other benefit plans and programs of the Company generally available from time to time to employees of the Company in which Executive was enrolled and/or participating on the date of termination, to the extent, and under the terms and conditions, permitted by the applicable plan or program, and subject to any subsequent modifications or amendments to any such plan or program.

3.7    Conditions of Payment. Any payments or benefits made or provided in connection with the termination of Executive's employment with the Company in accordance with Section 3.6 (other than payments made or provided in accordance with Section 3.6(a) or due to a termination of Executive's employment due to his death) are subject to Executive's:

(a)compliance with the provisions of Sections 3.9, 4 and 5 of this Agreement;
and
(b)delivery to the Company of a resignation from all offices, directorships and fiduciary positions with the Company, its affiliates and employee benefit plans prior to the scheduled date for which the applicable payment or benefit is to be made or provided.
Payment of the amounts specified in Sections 3.6(d)(i) and (iii), and to the extent that termination is based on a Triggering Event following a Change in Control, Section 3.6(d)(ii), will be conditioned upon delivery by Executive of an executed, concurrently-effective, General Release substantially in the form attached to this Agreement as Exhibit A, with such changes or additions as needed under then applicable law to give effect to its intent and purpose.

3.8    Mitigation. Executive shall be under no obligation to seek other employment following a termination of his employment with the Company or any subsidiary for any reason. In addition, there shall be no offset against amounts due Executive under this Section 3 or otherwise on account of any compensation attributable to any subsequent employment.




3.9    Cooperation; Assistance. Executive agrees to cooperate fully, subject to reimbursement by the Company of reasonable out-of-pocket costs and expenses (including reasonable attorneys’ fees), with the Company or any subsidiary and its or their counsel with respect to any matter (including any litigation, investigation or governmental proceeding) which relates to matters with which Executive was involved or about which he had knowledge during his employment with the Company or any subsidiary. Such cooperation shall include appearing from time to time at the offices of the Company or any subsidiary or its or their counsel for conferences and interviews and, in general, providing the officers of the Company or any subsidiary and its or their counsel with the full benefit of Executive's knowledge with respect to any such matter. Executive further agrees, upon termination of his employment for any reason and if the CEO and/or Board requests, to assist his successor in the transition of his duties and responsibilities to such successor. Executive agrees to render such cooperation in a timely fashion and at such times as may be mutually agreeable to the parties. The Company shall compensate Executive for time spent providing assistance to the Company, based on the number of hours spent by Executive in providing such assistance. The hourly rate of compensation shall be $150.
3.10     Effect of the Occurrence of a Change in Control. Upon the occurrence of a Change in Control, the terms of this Section 3 (other than Sections 3.5, 3.6 and 3.10) shall cease to have any further force or effect, except under the following circumstances: (i) a Change in Control occurs, (ii) no Triggering Event occurs within the 12-month period following the Change in Control, and (iii) either the Company or Successor Entity terminates Executive's employment without Cause or Executive terminates his employment for Good Reason. Under such circumstances (and assuming this Agreement is in effect at the time of such termination), Section 3 shall continue to apply to such termination.
4.    Confidentiality.
4.1    Executive acknowledges and agrees that:
(a)    by reason of his employment with the Company and his service as an
Officer of the Company, Executive will have knowledge of all aspects of the Company's operations and will be entrusted with and have access to confidential and secret proprietary business information and trade secrets of the Company, including but not limited to:
(i)information regarding the Company's business priorities and strategic plans;

(ii)information regarding the Company's personnel;

(iii)    financial and marketing information (including but not limited to information about costs, prices, profitability and sales information not available outside the Company);

(iv)    secret and confidential plans for and information about new or existing services, and initiatives to address the Company's competition;

(v)    information regarding customer relationships; and

(vi)    proprietary or confidential information of customers or clients for which the Company may owe an obligation not to disclose such information.
(all such information shall be collectively referred to as "confidential information");





(b)    the Company and its subsidiaries, affiliates and divisions will suffer substantial and irreparable damage that will not be compensable through money damages if Executive should divulge or make use of confidential information acquired by Executive in the course of his employment with the Company and service to the Board other than as may be required or appropriate in connection with Executive's work as an employee of the Company; and

(c)    the provisions of this Agreement are reasonable and necessary for the protection of confidential information, the business of the Company and its subsidiaries, affiliates and divisions, and the stability of their workforces.
4.2    Except as may be required or appropriate in connection with Executive's work as an employee of the Company, Executive shall keep confidential all confidential information he learns of during his employment with the Company regarding the Company, its business, operations, systems, employees, customers, clients and prospective clients. In addition, Executive agrees that he will not disclose confidential information obtained from the Company or its officers, directors or management during his employment, including, but not limited to, information regarding, or statements by, the Company or its officers, directors or management, to anyone other than as required by law or in response to a lawful court order or subpoena.
4.3    Nothing in this Section 4 shall prohibit Executive from participating as a witness
at the request of the Company or a third party in any investigation by the SEC or any other governmental agency charged with the investigation of any matters related to Executive's employment with the Company, nor shall Executive be prohibited from testifying in response to a subpoena, court order or notice of deposition. Executive agrees to notify the Company's General Counsel, in writing, at least ten (10) days prior to the response deadline or appearance date (whichever is earlier) for any such subpoena, court order or notice of deposition issued by a court or investigating agency which seeks disclosure of any confidential information. Executive further agrees to take any actions reasonably requested by the Company to allow the Company to protect the release of information regarding Executive's employment from the Company in such court or agency proceeding.

4.4    Executive agrees that:

(a)he will not, at any time, remove from the Company's premises any notebooks, software, data or other confidential information relating to the Company, except to the extent necessary or appropriate to perform his duties and responsibilities under the terms of this Agreement;

(b)upon the expiration or termination of the Term for any reason whatsoever, he shall promptly deliver to the Company any and all notebooks, software, data and documents and material, including all copies thereof, in his possession or under his control relating to any confidential information, or which is otherwise the property of the Company; and

(c)he will not use any confidential information for his own benefit or for the benefit of any new employer or any third person.
4.5    For purposes of this Section 4, the term "Company" shall mean and include the Company and any and all subsidiaries and affiliated entities of the Company in existence from time to time.




5.    Non-Competition and Non-Solicitation.
5.1    Executive acknowledges that the Company is, as of the Effective Date, engaged
principally in the business of providing health information risk assessment services to insurance companies and health and wellness providers, performing lab testing services, providing underwriting services in connection with the processing of life insurance applications, and providing health information gathering and assessment services to healthcare and research entities, throughout the United States. By virtue of Executive's position with the Company, Executive will be exposed to and acquire significant confidential information about the Company and its existing and future plans and strategies. As a result, Executive acknowledges that the Company has a legitimate business interest supporting the restrictive covenants set forth in this Section 5.
5.2    During Executive's employment with the Company and until the first anniversary
of the date of termination of Executive's employment with the Company, Executive shall not in any manner, directly or indirectly, within the United States (without the prior written consent of a duly authorized officer of the Company):

(a)act as a Competitive Enterprise or accept any engagement in any capacity that involves Executive performing management, consultation, advisory or other services of any kind with a Competitive Enterprise (as defined in Section 5.3 below) in which Executive’s role will include competing with Company in any business in which the Company or any of its subsidiaries is then engaged;

(b)Solicit (as defined in Section 5.3 below) any Customer (as defined in Section 5.3 below) to transact business with a Competitive Enterprise or to reduce or refrain from doing any business with the Company or any of its subsidiaries;

(c)transact business with any Customer that would cause Executive to be a Competitive Enterprise;
(d)interfere with or damage any relationship between the Company or any its subsidiaries with a Customer; or

(e)Solicit anyone who is then an employee of the Company or any of its subsidiaries (or who was an employee of the Company or any of its subsidiaries within the prior 12 months) to resign from the Company or any of its subsidiaries or to apply for or accept employment with any other business or enterprise.
5.3    For purposes of this Agreement:
"Competitive Enterprise" means any business enterprise that either (A) engages in a business that competes anywhere in the United States with any business in which the Company or any of its subsidiaries is then engaged in so that it accounts for more than 10% of the Company’s (or any of its subsidiaries’) revenue for the prior 12 months; or (B) holds a greater than 50% equity, voting or profit participation interest in any enterprise that competes anywhere in the United States with any activity that the Company or any of its subsidiaries is then engaged in; provided, however, that if (i) the Company, including any subsidiary, ceases to do, and exits, a particular type of business activity, then following such exit the Company and its subsidiaries will be deemed not to be "then engaged" in such business; or (ii) the Company, including any of its subsidiaries, was not engaged in a particular type of business activity (and was not contemplating such business activity), while Executive was employed by the Company, then for the purposes of this Agreement, the Company and its subsidiaries will be deemed not to be "then engaged" in such business.




"Customer" means any customer or prospective customer of the Company or any of its subsidiaries whose identity became known to Executive in connection with Executive's relationship with or employment by the Company or any of its subsidiaries and which may be a customer within 6 months after the termination of the Agreement.
"Solicit" means any direct or indirect communication of any kind, regardless of who initiates it, that in any way invites, advises, encourages or requests any person to take or refrain from taking any action.

6.    Injunctive Relief. If Executive commits a breach, or threatens to commit a breach, of any of the provisions of Section 4 or 5 of this Agreement, the Company shall have the right and remedy (which shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity) to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged by Executive that any such breach or threatened breach will or may cause irreparable injury to the Company and that money damages will or may not provide an adequate remedy to the Company.

7.    Miscellaneous.
7.1    Benefit of Agreement, Assignment; Beneficiary. This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. This Agreement Shall also inure to the benefit of, and be enforceable by, Executive and his personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive should die while any amount would still be payable to Executive under this Agreement if he had continued to live, all such amounts shall be paid in accordance with the terms of this Agreement to Executive's beneficiary, devisee, legatee or other designee, or if there is no such designee, to Executive's estate.
7.2    Notices. Any notice required or permitted under this Agreement shall be in writing and shall be sufficiently given if personally delivered or if sent by certified mail, postage prepaid, with return receipt requested or by reputable overnight courier, addressed: (a) in the case of the Company, to the General Counsel of the Company at the Company's then-current corporate headquarters, and (b) in the case of Executive, to Executive's last known address as reflected in the Company's records, or to such other address as either party shall designate by written notice to the other party. Any notice given hereunder shall be deemed to have been given at the time of receipt thereof by the person to whom such notice is given if personally delivered or at the time of mailing if sent by certified mail or by courier.
7.3.     Entire Agreement; Amendment. Except as specifically provided in this Agreement, this Agreement contains the entire agreement of the parties to this Agreement with respect to the terms and conditions of Executive's employment during the Term, and supersedes all prior agreements and understandings, whether written or oral, between the parties with respect to compensation due for services rendered under this Agreement. For the avoidance of doubt, in the event of any inconsistency between this Agreement and any plan, program or arrangement of the Company or its affiliates, the terms of this Agreement shall control. This Agreement may not be changed or modified except by an instrument in writing signed by both of the parties.
7.4    Waiver. The waiver of either party of a breach of any provision of this Agreement shall not operate or be construed as a continuing waiver or as a consent to or waiver of any subsequent breach.
7.5    Headings. The section headings in this Agreement are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or affect any of the provisions of this Agreement.




7.6    Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York, without reference to the principles of conflicts of laws.
7.7    Survivorship. The respective rights and obligations of the parties under this Agreement shall survive any termination of this Agreement to the extent necessary to effectuate the intended preservation of such rights and obligations, including, without limitation, Section 4 and 5 of this Agreement.
7.8    Validity. The invalidity on unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision or provisions of this Agreement, which shall remain in full force and effect. If any provision of this is held to be invalid, void or unenforceable, any court so holding shall substitute a valid, enforceable provision that preserves, to the maximum lawful extent, the terms and intent of this Agreement.
7.9    Construction. The parties have participated jointly in the negotiation and drafting
of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state or local statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word "including" shall mean including without limitation.
7.10     Section 409A.

(a)Notwithstanding the due date of any post-employment payments, if at the time of the termination of Executive's employment Section 409A is triggered and if Executive or Company would be subject to liability or other penalty for failure to comply with 409A, and if Executive is a "specified employee" (as defined in Section 409A), Executive will not be entitled to any payments upon termination of employment that are subject to Section 409A until the later of (i) the date that payments are scheduled to be made under this Agreement, or (ii) the earlier of (A) the first day of the seventh month following the date of termination of his employment with the Company for any reason other than death, or (B) the date of Executive's death. The provisions of this paragraph will only apply if 409A is triggered, and will only apply if and to the extent required to avoid any "additional tax" under Section 409A either to Executive or Company. If 409A is triggered, the parties to this Agreement intend that the determination of Executive's termination of employment shall be made in accordance with Treasury Reg. Section 1.409A-1(h) and that Executive will be paid as set forth in sec. 3.6 (d), to the extent consistent with law.





(b)If Section 409A is triggered and if Executive or Company would be subject to liability or other penalty for failure to comply with 409A, the Parties to this Agreement intend that this Agreement and Company's and Executive's exercise of authority or discretion hereunder shall comply with the provisions of Section 409A and the Treasury regulations relating thereto so as not to subject Executive to the payment of interest and tax penalty which may be imposed under Section 409A. In furtherance of this objective, to the extent that any regulations or other guidance issued under Section 409A would result in Executive being subject to payment of "additional tax" under Section 409A, the parties agree to use their best efforts to amend this Agreement in order to avoid the imposition of any such "additional tax" under Section 409A, which such amendment shall be designed to minimize the adverse economic effect on Executive without increasing the cost to the Company (other than transactions costs), all as reasonably determined in good faith by the Company and Executive to maintain to the maximum extent practicable the original intent of the applicable provisions. This Section 7.10 does not guarantee that payments under this Agreement will not be subject to "additional tax" under Section 409A.

7.11    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which will constitute one and the same instrument.
IN WITNESS WHEREOF, each of the parties has duly executed this Agreement on the date indicated below. The Company represents that its execution of this Agreement has been authorized by the Compensation Committee of the Company's Board of Directors.

Hooper Holmes, Inc.


By: /s/Henry E. Dubois

Name: Henry E. Dubois

Title: President and Chief Executive Officer    
Date: September 25, 2013





By: /s/ Thomas Collins

Name: Thomas Collins

Title: Senior Vice President and Chief Financial Officer
Date: September 25, 2013





Exhibit A
General Release
1.    For valuable consideration, the adequacy of which is hereby acknowledged, the undersigned executive ("Executive"), on his own behalf and on behalf of his family members, heirs, executors, administrators, personal representatives, distributees, devisees, legatees, and successors and assigns (collectively, the "Releasing Parties"), does hereby knowingly, voluntarily and unconditionally release, waive, acquit and fully discharge, and agree to hold harmless Hooper Holmes, Inc, a New York corporation (the "Company") and its present and past subsidiaries and affiliates, and its and their officers, directors, shareholders, employee benefit plans, plan fiduciaries and trustees, insurers, employees, agents, representatives, successors and assigns (collectively referred to as the "Releasees"), from and against any cause of action, legal claim, suit, right, liability or demand of any kind or nature, known or unknown, liquidated or unliquidated, absolute or contingent, at law or in equity (each such action, claim, suit, right, liability or demand being hereinafter individually referred to as a "Claim" and collectively as "Claims") that Executive may now or hereafter have against the Releasees, or any one or group of them, including, but not limited to:
(a)any and all Claims in connection with

(i)any and all agreements between the Company and Executive, including but not limited to the Employment Agreement, dated as 4th day of September 2013, by and between the Company and Executive (the "Employment Agreement");

(ii)Executive's employment relationship with the Company,

(iii)the terms and conditions of such employment relationship (including compensation and benefits),

(iv)Executive's service as an officer of the Company (except for indemnification in accordance with the Company's certificate of incorporation, bylaws or any director or officer indemnity agreement between Executive and the Company), or

(v)the termination of such employment relationship and the circumstances surrounding such termination; and

(b)any and all Claims relating to, or arising from, Executive's right to purchase, or actual purchase of, shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any federal or state law; and

(c) any and all Claims for wrongful discharge of employment; constructive discharge; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits.
Without limiting the generality of the foregoing, Executive specifically releases, acquits, discharges, waives and agrees to hold Releasees harmless from and against any and all claims arising under:




(A)
the Sarbanes-Oxley Act of 2002, 18 U.S.C. §1514A;

(B)
Section 1981 of the Civil Rights Act of 1866, as amended, 42 U.S.C.
§§1981;

(C)
Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §§2000e, et seq. (the "Civil Rights Act");

(D)
the Americans with Disabilities Act of 1990, 43 U.S.C. §12101 et seq. (the "Americans with Disabilities Act");

(E)
the Equal Pay Act of 1993;

(F)
the Fair Labor Standards Act, except as prohibited by law;

(G)
the Older Workers Benefit Protection Act of 1990 (the "OWBPA");

(H)
the Age Discrimination in Employment Act of 1967, 29 U.S.C. §626 et seq. (the "ADEA");

(I)
the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. (the "Family and Medical Leave Act"), except as prohibited by law;

(J)
the Worker Adjustment and Retraining Notification Act, as amended;

(K)
Executive Order 11,141 (age discrimination);

(L)
Executive Order 11,246 (race, color, religion, sex and national origin discrimination);

(M)
the National Labor Relation Act;

(N)
the Occupational Safety and Health Act, as amended;

(O)
the Immigration Reform and Control Act, as amended;

(P)
the Vietnam Era Veterans Readjustment Assistance Act;

(Q)
Sections 503-504 of the Rehabilitation Act of 1973 (handicap rehabilitation);

(R)
the Employee Retirement Income Security Act of 1974, as amended ("ERISA") (other than such rights as are mandated or vested by law);

(S)
the New Jersey Law Against Discrimination, N.J.S.A. 10:5-1 et seq.;

(T)
the New Jersey Conscientious Employee Protection Act, N.J.S.A, 34:19-1
et seq.;

(U)
the New Jersey Wage and Hour laws, N.J.S.A. 34:11-56a et seq.;





(V)
the New Jersey Family Leave Act, N.J.S.A. 34:11B-1 et seq.;

(W)
any other federal, state or local fair employment, civil or human rights, wage and hour laws and wage payment laws, and any and all other federal, state, local or other governmental statutes, laws, ordinances, regulations and orders, under common law, and under any Company policy, procedure, bylaw or rule.
This General Release shall not waive or release any Claims that Executive may have which arise after the date of this General Release or that arise under or are explicitly preserved by the Employment Agreement and shall not waive any Claims for benefits required by applicable law (including post-termination health-continuation insurance benefits required by state or federal law) or Claims which cannot be waived or released under the terms of any federal law or the laws of the state(s) governing Executive's employment with the Company.

2.    Executive agrees not to sue concerning, or in any manner to institute, prosecute or pursue any Claim in respect of any of the matters covered by Section 1 of this General Release in any court of the United States or in any state, or with any administrative agency of the United States or any state, county or municipality, or before any other tribunal, public or private, against the Company or any of the Releasees.

3.    This General Release is not intended to and does not interfere with the right of the Equal employment Opportunity Commission ("EEOC") to enforce anti-discrimination laws or to seek relief that will benefit the public and any victim of unlawful employment practices who has not waived his or her claims. The Company acknowledges and agrees that Executive is not prevented from filing a charge with, or testifying, assisting, or participating in any proceeding brought by the EEOC concerning an alleged discriminatory practice of the Company. Executive, on behalf of himself and any and all other Releasing Parties, hereby waives all rights to any benefits, including, but not limited to, monetary recovery and reinstatement, derived from any actions, suits or proceedings brought on behalf of Executive or any of the other Releasing Parties, including any action, suit or proceeding brought by the EEOC or anyone else. Executive, on behalf of himself and any and all other Releasing Parties, also agrees not to initiate or become a party to or otherwise participate or support any current or former employee(s) in any action, suit or proceeding brought by such employee(s). If Executive or any other Releasing Party files any action, suit or proceeding with respect to any Claim released by Executive under the terms of this Agreement, Executive agrees to indemnify the Company against any damages or judgments arising from any such action, suit or proceeding.

4.    Executive agrees that Executive shall not be eligible and shall not seek or apply for reinstatement or re-employment with the Company and agrees that any application for re-employment may be rejected without explanation or liability.

5.    In further consideration of the promises made by the Company in Section 3 of the Employment Agreement, Executive specifically waives and releases the Company, to the extent set forth in Section 1 of this General Release, from all Claims Executive may have as of the date of this General Release, whether known or unknown, arising under the ADEA. Executive further agrees that:

(a)Executive's waiver of rights under this General Release is knowing and voluntary and in compliance with the OWBPA.

(b)Executive understands the terms of this General Release.





(c)The consideration offered by the Company under Section 3 of the Employment Agreement in exchange for the General Release represents consideration over and above that to which Executive would otherwise be entitled, and the consideration would not have been provided had Executive not agreed to sign the General Release and did not sign the General Release.

(d)The Company is hereby advising Executive in writing to consult with an attorney prior to executing this General Release.

(e)The Company is giving Executive a period of twenty-one (21) days within which to consider this General Release.

(f)Following Executive's execution of this General Release, Executive has seven (7) days in which to revoke this General Release by written notice. An attempted revocation not actually received by the Company prior to the revocation deadline will not be effective.

(g)This General Release and all payments and benefits otherwise payable under Section 3 of the Employment Agreement (other than payments and benefits made or provided in accordance with Section 3.6(a)) shall be void and of no force and effect if Executive chooses to so revoke, and if Executive chooses not to so revoke within the 7-day period, this General Release shall then become effective and enforceable.

6.    This General Release does not waive any rights or claims that may arise under the ADEA after the date Executive signs this General Release. To the extent barred by the OWBPA, the covenant not to sue contained in Section 2 above does not apply to claims under the ADEA that challenge the validity of this General Release.

7.    To revoke this General Release, Executive must send a written statement of revocation to:
Hooper Holmes, Inc.
170 Mt. Airy Road
Basking Ridge, New Jersey 07920
Attn: General Counsel
The revocation must be received by no later than 5:00 p.m. on the seventh day following Executive's execution and delivery of this General Release. If Executive does not revoke, the eighth day following Executive's execution and delivery of this General Release will be the effective date of this General Release.

8.    Executive acknowledges and agrees that this General Release is not intended by Executive or the Company to be construed, and will not be construed, as an admission by the Company of any liability or violation of any law, statute, ordinance, regulation or legal duty of any nature whatsoever.

9.    This General Release shall be governed by the internal laws (and not the choice of laws) of the State of New Jersey, except for the application of pre-emptive federal law.
Please read this General Release carefully. It contains a release of all known and unknown claims.





Date: September 25, 2013
/s/ Thomas Collins
Thomas Collins
Hooper Holmes, Inc.
By:
/s/ Henry E. Dubois
Henry E. Dubois
President & CEO


 EX-31.1 8 exhibit311q32013.htm EXHIBIT 31.1 CEO CERTIFICATION exhibit311q32013


EXHIBIT 31.1    CERTIFICATIONS

I, Henry E. Dubois, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hooper Holmes Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Henry E. Dubois
---------------------------------------------
Henry E. Dubois
Chief Executive Officer and President
November 15, 2013



 EX-31.2 9 exhibit312q32013.htm EXHIBIT 31.2 CFO CERTIFICATION exhibit312q32013


EXHIBIT 31.2     CERTIFICATIONS

I, Tom Collins, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hooper Holmes Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
                    
/s/ Tom Collins
---------------------------------------------
Tom Collins
Senior Vice-President, and Chief Financial and Accounting Officer
November 15, 2013



 EX-32.1 10 exhibit321q32013.htm EXHIBIT 32.1 SECTION 1350 CEO CERTIFICATION exhibit321q32013



EXHIBIT 32.1     CERTIFICATIONS

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Henry E. Dubois, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, the Quarterly Report of Hooper Holmes, Inc., on Form 10-Q for the quarter ended September 30, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Hooper Holmes, Inc.
Dated: November 15, 2013

/s/ Henry E. Dubois
__________________________
Henry E. Dubois
Chief Executive Officer and President
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Section 906 has been provided to Hooper Holmes, Inc. and will be retained by Hooper Holmes, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-32.2 11 exhibit322q32013.htm EXHIBIT 32.2 SECTION 1350 CFO CERTIFICATION exhibit322q32013


EXHIBIT 32.2     CERTIFICATIONS

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Tom Collins, Senior Vice-President and Chief Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, the Quarterly Report of Hooper Holmes, Inc., on Form 10-Q for the quarter ended September 30, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Hooper Holmes, Inc.
Dated: November 15, 2013        

/s/ Tom Collins
__________________________
Tom Collins
Senior Vice President and
Chief Financial and Accounting Officer
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Section 906 has been provided to Hooper Holmes, Inc. and will be retained by Hooper Holmes, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 12 hh-20130930.xml XBRL INSTANCE DOCUMENT 0000741815 hh:July2009NonVestedStockAwardMember 2009-07-01 2009-07-31 0000741815 hh:December2010StockOptionAwardMember 2010-12-01 2010-12-31 0000741815 hh:July2011NonVestedStockAwardMember 2011-07-01 2011-07-31 0000741815 hh:July2011StockOptionAwardMember 2011-07-01 2011-07-31 0000741815 2012-07-01 2012-09-30 0000741815 hh:July2012StockOptionAwardMember 2012-07-01 2012-07-31 0000741815 2012-01-01 2012-09-30 0000741815 us-gaap:StockOptionMember 2012-01-01 2012-09-30 0000741815 hh:A2013LoanandSecurityAgreementMember 2012-01-01 2012-09-30 0000741815 hh:PortamedicServiceLineMember 2012-01-01 2012-09-30 0000741815 hh:A2008PlanMember 2012-01-01 2012-09-30 0000741815 hh:A2011PlanMember 2012-01-01 2012-09-30 0000741815 hh:DirectorStockPlanMember 2012-01-01 2012-09-30 0000741815 us-gaap:StockOptionMember 2012-07-01 2012-09-30 0000741815 hh:A2013LoanandSecurityAgreementMember 2012-07-01 2012-09-30 0000741815 hh:PortamedicServiceLineMember 2012-07-01 2012-09-30 0000741815 us-gaap:StateAndLocalJurisdictionMember 2012-07-01 2012-09-30 0000741815 hh:A2008PlanMember 2012-07-01 2012-09-30 0000741815 hh:A2011PlanMember 2012-07-01 2012-09-30 0000741815 2013-06-01 2013-06-30 0000741815 2013-07-01 2013-09-30 0000741815 hh:PortamedicServiceLineMember 2013-09-29 2013-09-30 0000741815 hh:September2013StockOptionAwardMember 2013-09-01 2013-09-30 0000741815 2013-01-01 2013-09-30 0000741815 hh:Libor90DayRateMember 2013-01-01 2013-09-30 0000741815 us-gaap:PrimeRateMember 2013-01-01 2013-09-30 0000741815 hh:FirstAmendmentMember 2013-01-01 2013-09-30 0000741815 hh:FirstAmendmentMember hh:PriorToFirstAnniversaryMember 2013-01-01 2013-09-30 0000741815 hh:FirstAmendmentMember hh:PriorToSecondAnniversaryMember 2013-01-01 2013-09-30 0000741815 hh:FirstAmendmentMember hh:PriorToThirdAnniversaryMember 2013-01-01 2013-09-30 0000741815 hh:PriorToFirstAnniversaryMember 2013-01-01 2013-09-30 0000741815 hh:PriorToSecondAnniversaryMember 2013-01-01 2013-09-30 0000741815 hh:PriorToThirdAnniversaryMember 2013-01-01 2013-09-30 0000741815 us-gaap:StockOptionMember 2013-01-01 2013-09-30 0000741815 hh:July2009NonVestedStockAwardMember 2013-01-01 2013-09-30 0000741815 hh:July2011NonVestedStockAwardMember 2013-01-01 2013-09-30 0000741815 hh:NonVestedStockAwardMember 2013-01-01 2013-09-30 0000741815 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0000741815 hh:A2013LoanandSecurityAgreementMember 2013-01-01 2013-09-30 0000741815 hh:PortamedicServiceLineMember 2013-01-01 2013-09-30 0000741815 hh:PortamedicServiceLineMember us-gaap:MaximumMember 2013-01-01 2013-09-30 0000741815 hh:PortamedicServiceLineMember us-gaap:MinimumMember 2013-01-01 2013-09-30 0000741815 hh:FinancialSystemSoftwareMember 2013-01-01 2013-09-30 0000741815 hh:A2008PlanMember 2013-01-01 2013-09-30 0000741815 hh:A2011PlanMember 2013-01-01 2013-09-30 0000741815 hh:DirectorStockPlanMember 2013-01-01 2013-09-30 0000741815 us-gaap:StockOptionMember 2013-07-01 2013-09-30 0000741815 hh:A2013LoanandSecurityAgreementMember 2013-07-01 2013-09-30 0000741815 hh:PortamedicServiceLineMember 2013-07-01 2013-09-30 0000741815 hh:A2008PlanMember 2013-07-01 2013-09-30 0000741815 hh:A2011PlanMember 2013-07-01 2013-09-30 0000741815 2011-12-31 0000741815 2012-02-29 0000741815 2012-09-30 0000741815 2012-12-31 0000741815 hh:PortamedicServiceLineMember 2012-12-31 0000741815 2013-02-27 0000741815 2013-09-30 0000741815 hh:AllOtherStockOptionAwardsMember 2013-09-30 0000741815 hh:December2010StockOptionAwardMember 2013-09-30 0000741815 hh:July2009NonVestedStockAwardMember 2013-09-30 0000741815 hh:July2011NonVestedStockAwardMember 2013-09-30 0000741815 hh:July2011StockOptionAwardMember 2013-09-30 0000741815 hh:July2012StockOptionAwardMember 2013-09-30 0000741815 hh:NonVestedStockAwardMember 2013-09-30 0000741815 hh:September2013StockOptionAwardMember 2013-09-30 0000741815 us-gaap:EmployeeStockOptionMember 2013-09-30 0000741815 hh:PortamedicServiceLineMember 2013-09-30 0000741815 us-gaap:InternalRevenueServiceIRSMember 2013-09-30 0000741815 hh:A2008PlanMember 2013-09-30 0000741815 hh:A2011PlanMember 2013-09-30 0000741815 hh:AmendedandRestated2011PlanMember 2013-09-30 0000741815 hh:AmendedandRestated2014PlanMember 2013-09-30 0000741815 hh:DirectorStockPlanMember 2013-09-30 0000741815 us-gaap:OtherRestructuringMember 2013-09-30 0000741815 2013-10-31 0000741815 2013-10-04 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares 6783000 8127000 15983000 17018000 15195000 16474000 150125000 149542000 500000 200000 400000 800000 622000 662000 102000 213000 0 159000 5565000 6280000 6180000 5543000 0 212000 0 0 200000 200000 100000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairment of Long-lived Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine month period ended September&#160;30, 2013, the Company recorded an impairment charge in continuing operations of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, which is included in impairment of long-lived assets in the accompanying consolidated statement of operations for the nine month period ended September&#160;30, 2013. The charge of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the nine month period ended September 30, 2013 relates to the write-off of certain financial system software which will not be utilized in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine month periods ended September&#160;30, 2013 and 2012, the Company recorded impairment of long-lived assets of Portamedic of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which is included in the loss from discontinued operations, including income taxes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 36418000 32730000 30647000 26018000 0 3646000 3646000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2012 Annual Report on Form 10-K, filed with the SEC on April 1, 2013. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any other interim period or the full year. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for additional information.</font></div></div> 556000 570000 100000 74000 0 100000 6655000 8319000 8161000 16917000 -1664000 -8756000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has employment retention or change in control agreements with certain executive officers that provide, in defined circumstances, for the payment of severance payments of </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;"> base compensation, among other things. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. The Asset Purchase Agreement also provides, among other things, that (1) if Piston incurs any losses relating to any governmental inquiry received by Piston or the Company within </font><font style="font-family:inherit;font-size:10pt;">18 months</font><font style="font-family:inherit;font-size:10pt;"> of the closing date, the Company will pay up to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> for one half of such losses, (2) if Piston elects to pursue, prosecute, defend, settle, compromise, appeal or take other actions with respect to certain matters relating to matters disclosed by the Company to Piston pre-closing (&#8220;Pre-Closing Matters&#8221;), the Company will cooperate with Piston (including joining in any legal proceeding related to such matters) and pay up to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> for one half of all losses in connection with such matters, and (3) Piston or its designees will make required payments for rents, charges, maintenance fees and all utility services to the Company associated with Piston&#8217;s or such designee&#8217;s occupancy of each premises that is the subject of a Company lease to be assumed by Piston or its designees, but the assignment of which was not completed by closing, until such time as the lease is duly assigned (or otherwise superseded by an agreement between Piston and the applicable landlord). The Company has agreed to bear all liability relating to the occupancy arrangements until they are transferred to Piston. With respect to Pre-Closing Matters, the Company also agreed that in the event Piston elects to pursue a claim relating to a Pre-Closing Matter and desires to add the Company as a plaintiff, Piston and the Company will cooperate to select counsel and to jointly prosecute such claim, but Piston will control such claim.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 11, 2003, the Company received a determination from the Internal Revenue Service that one individual the Company contracted with as an independent contractor should have been classified as an employee in 2002. This ruling also applied to any other individuals engaged by the Company under similar circumstances. The ruling stated that the Company may not be subject to adverse consequences as the Company may be entitled to relief under applicable tax laws (Section 530 of the Revenue Act of 1978). Management believes that the Company qualifies for relief under Section 530. To date, the Company has not received any further communication from the Internal Revenue Service.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, some state agencies have claimed that the Company improperly classified its health professionals as independent contractors for purposes of state unemployment and/or worker's compensation tax laws and that the Company was therefore liable for taxes in arrears, or for penalties for failure to comply with their interpretation of the laws.&#160;&#160;There are no assurances that the Company will not be subject to similar claims in other states in the future.</font></div></div> 0.04 0.04 240000000 240000000 70140864 69844782 70131469 69835387 2806000 2794000 25529000 25663000 8730000 8762000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loan and Security Agreement</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:8pt;color:#ff0000;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2013 Loan and Security Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February&#160;28, 2013</font><font style="font-family:inherit;font-size:10pt;">, in conjunction with the Company entering into the 2013 Loan and Security Agreement, the Company terminated the 2009 Loan and Security Agreement with TD Bank, N.A. During the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, in connection with the 2013 Loan and Security Agreement, the Company incurred unused line fees of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.04 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.08 million</font><font style="font-family:inherit;font-size:10pt;"> respectively. During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;"> in connection with the 2009 Loan and Security Agreement, the Company incurred unused line fees of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.00 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.02 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any time outstanding which does not exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">85%</font><font style="font-family:inherit;font-size:10pt;"> of &#8220;Eligible Receivables&#8221; (as defined in the 2013 Loan and Security Agreement) less any reserves established by Keltic Financial, provided that in no event can the aggregate amount of the revolving credit loans at any time exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;">. Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, unbilled Portamedic and Health &amp; Wellness receivables, and other receivables deemed ineligible by Keltic Financial. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> in borrowings outstanding under our 2013 Loan and Security Agreement, and the Company's available borrowing capacity was </font><font style="font-family:inherit;font-size:10pt;">$0.04 million</font><font style="font-family:inherit;font-size:10pt;"> based on </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> Eligible Receivables and a </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation method and timeline, available borrowing capacity increased to approximately </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> by October 4, 2013 and the reserve established by Keltic Financial was increased back to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> from a temporary reduction to increase available borrowing at the end of September 2013. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;28, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into the First Amendment to the 2013 Loan and Security Agreement. Under the First Amendment, the annual facility fee increased to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> of the revolving credit limit of </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;">; the monthly collateral management fee increased to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2,500</font><font style="font-family:inherit;font-size:10pt;"> per month from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,500</font><font style="font-family:inherit;font-size:10pt;"> per month; and the monthly collateral management fee increased to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> per month from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> per month if there is an occurrence or event of default. In addition, the early termination fee changed a) if prior to the first anniversary of the effective date, from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the revolving credit limit; b) if after the first anniversary but before the second anniversary of the effective date, from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;"> of the revolving credit; and c) if after the second anniversary but prior to the third anniversary of the effective date, from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2%</font><font style="font-family:inherit;font-size:10pt;"> of the revolving credit limit. In regard to the financial covenants, the first EBITDA measurement date changed from the six months ended June 30, 2013 to the twelve months ending June 30, 2014. The Company paid an amendment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest on revolving credit loans is calculated based on the greatest of (i) the annualized prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.75%</font><font style="font-family:inherit;font-size:10pt;">, (ii) the 90 day LIBOR rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.25%</font><font style="font-family:inherit;font-size:10pt;">, and (iii) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6%</font><font style="font-family:inherit;font-size:10pt;"> per annum. In connection with the 2013 Loan and Security Agreement, the Company incurred a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other issue costs totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">. During the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, in connection with the 2013 Loan and Security Agreement the Company incurred </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.04 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> in facility fees, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans, however the Company would be required to pay an early termination fee as noted above.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As security for the Company's payment and other obligations under the 2013 Loan and Security Agreement, the Company granted Keltic Financial a security interest in all existing and after-acquired property of the Company and its subsidiary guarantors, including its receivables (which are subject to a lockbox account arrangement), inventory, equipment and corporate headquarters.&#160;&#160;The aforementioned security interest is collectively referred to herein as the &#8220;collateral&#8221;.&#160;In addition, in connection with entering into the First Amendment to the 2013 Loan and Security Agreement as March 28, 2013, the Company granted to the lender a mortgage of the Company's headquarters building as additional security.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the 2013 Loan and Security Agreement, Keltic Financial may establish one or more reserves at its reasonable discretion and, at its sole discretion, may establish reserves with respect to (a) any event which in Keltic Financial's reasonable determination, diminishes the value of any collateral or (b) any contingent liability of the Company. A reserve may reduce the aggregate amount of indebtedness that may be incurred under the 2013 Loan and Security Agreement. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Loan and Security Agreement contains covenants that, among other things, restrict the Company's ability, and that of its subsidiaries, to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pay any dividends or distributions on, or redeem or retire any shares of any class of its capital stock or other equity interests;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incur additional indebtedness or otherwise become liable for the indebtedness, except for transactions in the ordinary course of business;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">permit a change of control of the board of directors and certain senior management positions of the Company without prior consent of Keltic Financial;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sell or otherwise dispose of any of the Company's assets, other than in the ordinary course of business;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">create liens or encumbrances on the Company's assets; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enter into transactions with any of its affiliates on other than an arm's-length or no less favorable basis.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keltic Financial consented to the change in CEO and CFO that occurred during 2013 as well as the sale of Portamedic. There were no waiver or amendment fees paid or associated with these consents.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Loan and Security Agreement also contains financial covenants, which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) with the twelve months ending June 30, 2014, as amended, as the first measurement date. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The failure of the Company or any subsidiary guarantor to comply with any of the covenants or the breach of any of its or their representations and warranties, contained in the 2013 Loan and Security Agreement, constitutes an event of default under the agreement. In addition, the 2013 Loan and Security Agreement provides that "Events of Default" include the occurrence or failure of any event or condition that, in Keltic Financial's sole judgment, could have a material adverse effect (i) on the business, operations, assets, management, liabilities or condition of the Company, (ii) in the value, collectability or salability of the collateral, or (iii) on the ability of the Company and its subsidiary guarantors to perform under the 2013 Loan and Security Agreement.</font></div></div> 0.0525 0.0275 2500 1500 0.06 700000 100000 100000000 1828000 2970000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Compensation Plans</font><font style="font-family:inherit;font-size:10pt;"> - On May 29, 2008, the Company's shareholders approved the 2008 Omnibus Employee Incentive Plan (the &#8220;2008 Plan&#8221;) providing for the grant of stock options, stock appreciation rights, non-vested stock and performance shares. The 2008 Plan provides for the issuance of an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company granted </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">325,000</font><font style="font-family:inherit;font-size:10pt;"> options to purchase shares under the 2008 Plan. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">900,000</font><font style="font-family:inherit;font-size:10pt;"> options for the purchase of shares were granted under the 2008 Plan as well as </font><font style="font-family:inherit;font-size:10pt;">205,332</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted stock granted to the Company's Chief Executive Officer as settlement for a discretionary bonus of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,479,900</font><font style="font-family:inherit;font-size:10pt;"> shares remain available for grant under the 2008 Plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 24, 2011, the Company's shareholders approved the 2011 Omnibus Employee Incentive Plan (the "2011 Plan") providing for the grant of stock options and non-vested stock awards. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the 2011 Plan which increased the number of shares of the Company's common stock available for issuance from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares (subject to adjustment as provided in the Amended and Restated Omnibus Plan). The 2011 Plan is to remain in effect until the earlier of (i) the 10th anniversary of the plan's original effective date (May 24, 2011), or (ii) the date all shares of stock available for issuance have been issued. During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> and nine months ended September 30, 2013, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2,000,000</font><font style="font-family:inherit;font-size:10pt;"> options for the purchase of shares were granted under the 2011 Plan. During the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended September 30, 2012, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,225,000</font><font style="font-family:inherit;font-size:10pt;"> options for the purchase of shares were granted under the 2011 Plan. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,092,500</font><font style="font-family:inherit;font-size:10pt;"> shares remain available for grant under the 2011 Plan as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options awarded under the 2008 and 2011 Plans (as amended) are granted at fair value on the date of grant, are exercisable in accordance with a vesting schedule specified in the grant agreement, and have contractual lives of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock granted to certain executives of the Company in December 2010 vested </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> on each of the first and second anniversaries of the grant. Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">325,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,277,500</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">337,600</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock granted to certain executives of the Company in September 2013, July 2012 and July 2011, respectively, vest </font><font style="font-family:inherit;font-size:10pt;">one-third</font><font style="font-family:inherit;font-size:10pt;"> on each of the first, second and third anniversaries of the grant</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:10pt;">Options to purchase </font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock granted to the Chief Executive Officer of the Company in September 2013, vest 25% upon receipt of the grant and 25% on the first, second and third anniversary of the grant. All other options granted by the Company vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each of the second through fifth anniversaries of the grant. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted during the three and nine month periods ended September 30, 2013 and 2012 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="32%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.4%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted during the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.47</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month</font><font style="font-family:inherit;font-size:10pt;"> period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.8671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,429,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,325,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,016,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,371,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at September 30, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,305,100</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.91</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at September 30, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,526,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value disclosed in the table above represents the difference between the Company's closing stock price on the last trading day of the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and the exercise price, multiplied by the number of in-the-money stock options.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the 2008 Plan, during the three and nine months ended September 30, 2013, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60,550</font><font style="font-family:inherit;font-size:10pt;"> stock options valued at </font><font style="font-family:inherit;font-size:10pt;">$0.24</font><font style="font-family:inherit;font-size:10pt;"> were exercised. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> stock options were exercised during the nine months ended September 30, 2012. Options for the purchase of an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,498,850</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock vested during the nine month period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, and the aggregate fair value at grant date of these options was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.5</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">July 2009</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of non-vested stock were granted under the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2008 Plan</font><font style="font-family:inherit;font-size:10pt;">. The shares vest as follows: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> after two years and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each of the next three anniversary dates thereafter. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">337,500</font><font style="font-family:inherit;font-size:10pt;"> shares of such non-vested stock were forfeited and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000</font><font style="font-family:inherit;font-size:10pt;"> were vested. In July 2011, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">305,000</font><font style="font-family:inherit;font-size:10pt;"> shares of non-vested stock were granted under the 2008 Plan. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">112,500</font><font style="font-family:inherit;font-size:10pt;"> shares of such non-vested stock were forfeited and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">155,100</font><font style="font-family:inherit;font-size:10pt;"> were vested. The shares vest as follows: </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on each of the first and second anniversary dates and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">34%</font><font style="font-family:inherit;font-size:10pt;"> on the third anniversary. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.03 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested stock awards. The cost is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.8</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font><font style="font-family:inherit;font-size:10pt;"> - In </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February 2012</font><font style="font-family:inherit;font-size:10pt;">, under the Stock Purchase Plan (2004) of Hooper Holmes, Inc. (the "2004 Plan"), purchase rights for approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">273,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's stock were granted to eligible participating employees with an aggregate grant date fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.05 million</font><font style="font-family:inherit;font-size:10pt;">, based on the Black-Scholes pricing model. This offering period concluded in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 2013</font><font style="font-family:inherit;font-size:10pt;"> and, in accordance with the 2004 Plan's automatic termination provision, no shares were issued. In February 2013, under the 2004 Plan, purchase rights for approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">233,000</font><font style="font-family:inherit;font-size:10pt;"> shares were granted with an aggregate fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.03 million</font><font style="font-family:inherit;font-size:10pt;">, based on the Black-Scholes option pricing model. The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February 2013</font><font style="font-family:inherit;font-size:10pt;"> offering period will conclude in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 2014</font><font style="font-family:inherit;font-size:10pt;">. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the Employee Stock Purchase Plan (2004), to be effective January 1, 2014 (as amended and restated, the "2014 Plan"). The aggregate number of shares of the Company's common stock available for purchase under the 2014 Plan is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2,000,000</font><font style="font-family:inherit;font-size:10pt;">. Unless terminated earlier by the Board of Directors, the 2014 Plan will terminate December 31, 2024.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Stock Awards</font><font style="font-family:inherit;font-size:10pt;"> - On May 30, 2007, the Company's shareholders approved the Hooper Holmes, Inc. 2007 Non-Employee Director Restricted Stock Plan (the &#8220;2007 Plan&#8221;), which provides for the automatic grant, on an annual basis for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10</font><font style="font-family:inherit;font-size:10pt;"> years, of shares of the Company's stock to the Company's non-employee directors. The total number of shares that may be awarded under the 2007 Plan is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">600,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, there remain available for grant approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">360,000</font><font style="font-family:inherit;font-size:10pt;"> shares under the 2007 Plan. Effective June 1, 2007, each non-employee member of the Board of Directors other than the non-executive chair receives </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,000</font><font style="font-family:inherit;font-size:10pt;"> shares annually and the non-executive chair receives </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10,000</font><font style="font-family:inherit;font-size:10pt;"> shares annually of the Company's stock, with such shares vesting immediately upon issuance. The Company believes that the shares awarded under the 2007 Plan are &#8220;restricted securities&#8221;, as defined in SEC Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"). The Company filed a Registration Statement on Form S-8 with respect to the 2007 Plan on April 16, 2008. The directors who receive shares under the 2007 Plan are "affiliates" as defined in Rule 144 under the Securities Act and thus remain subject to the applicable provisions of Rule 144. In addition, the terms of the awards (whether or not restricted) specify that the shares may not be sold or transferred by the recipient until the director ceases to serve on the Board or, if at that time the director has not served on the Board for at least four years, on the fourth anniversary of the date the director first became a Board member. During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, shares awarded under the 2007 Plan totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of share-based compensation expense in selling, general and administrative expenses for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to stock options, non-vested stock, restricted stock awards and the 2004 Plan. In connection with resignations of former members of management, the Company reversed previously recorded share-based compensation expense totaling </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the three and nine month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and nine month periods ended September 30, 2012. The reversal was recorded in restructuring charges on the Company's consolidated statement of operations (See note 8).</font></div></div> -1966000 -1004000 -5470000 -4736000 -4709000 -5446000 -1958000 -997000 100000 100000 100000 100000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the assets and liabilities of Portamedic that were sold have been reclassified and are reported as assets and liabilities held for sale on the December 31, 2012 consolidated balance sheet. The operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Certain costs presented within continuing operations in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among service lines and the continuing operations have been and are being restructured. There is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated in future periods. For further discussion on Discontinued Operations, please see Note 6.</font></div></div> 116000 941000 400000 104000 225000 2080000 19173000 62437000 72077000 21371000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Discontinued Operations </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with its Portamedic service line, including, among other things, fixed assets and intellectual property, to Piston, and Piston assumed certain specified liabilities (the &#8220;Portamedic Disposition&#8221;). The adjusted purchase price (the "Purchase Price") was approximately </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, adjusted from </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;"> at announcement due to changes in working capital, of which </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Holdback Amount&#8221;) was held back by Piston as security for the Company&#8217;s obligations and agreements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Holdback Amount will be released as follows: within </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> business days after the date on which final closing adjustments for inventory and other current assets are determined and (the &#8220;Closeout Date&#8221;) (and after giving effect to any deductions from the Holdback Amount prior to such date), Piston will pay to the Company all amounts, if any, in excess of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and the remaining </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Holdback Amount, less any deductions with respect to indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid to the Company on the first anniversary of the Closeout Date. There cannot be any assurance that the Holdback Amount will be collected by the Company in full however, management currently expects to realize the amount in full and has recorded receivables in other current assets and other assets totaling </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company decided to sell its underperforming Portamedic service line and shift its focus towards the growth of its remaining health care service lines. In connection with the sale of Portamedic, the Company received </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> of cash proceeds and incurred </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> of financial advisory, legal and accounting fees, as of September 30, 2013. The Portamedic sale provides the Company with capital to invest in its Health and Wellness and Heritage Lab service lines. In addition, the Company retains the Portamedic accounts receivable and accounts payable, giving the Company over </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;"> of working capital at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> to utilize in supporting wellness programs, clinical research and government studies. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the operating results of Portamedic and the gain on sale of Portamedic which are reported in discontinued operations in the accompanying consolidated statements of operations:</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.23586744639377%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,446</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of Portamedic and subsidiary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than </font><font style="font-family:inherit;font-size:8pt;">$0.1 million</font><font style="font-family:inherit;font-size:8pt;"> for each period </font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">presented and there were no income taxes on the gain of the sale due to the availability of net operating loss carry forwards with a </font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">full valuation allowance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assets and liabilities of Portamedic are presented separately under the captions &#8220;Assets held for sale&#8221; and &#8220;Liabilities held for sale,&#8221; respectively, in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="78%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets held for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities held for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company sold substantially all of the assets and liabilities of its Claims Evaluation Division ("CED") operating segment. In connection with the sale of the CED, the Company released as the primary obligor for certain lease obligations acquired but remain secondarily liable in the event the buyer defaults. In September 2013, the Company reduced the reserve for this liability by </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and reported the corresponding gain in discontinued operations. At September&#160;30, 2013, the Company maintained a liability of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for this lease obligation. The guarantee is provided for the term of the lease, which expires in July 2015. As of September&#160;30, 2013, the maximum potential amount of future payments under the guarantee is </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> -0.16 -0.02 -0.03 -0.13 -0.16 -0.02 -0.13 -0.03 <div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss) Earnings Per Share</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">6,280,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6,180,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were excluded from the calculation of diluted loss per share for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, and approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,565,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,543,000</font><font style="font-family:inherit;font-size:10pt;"> shares for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, respectively, because their exercise prices exceeded the average market price of the Company's common stock for such periods and, therefore, were antidilutive. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> 0 P9M18D P2Y6M 900000 0 65000 3618000 3543000 0 3618000 2263000 3537000 8530000 10257000 -3291000 -8158000 -1189000 -5456000 -1185000 -5445000 -8144000 -3286000 -0.02 -0.12 -0.05 -0.08 -0.08 -0.05 -0.02 -0.12 -1004000 -1118000 -5405000 1577000 -0.08 0.02 -0.02 -0.01 -0.08 -0.01 0.02 -0.02 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </font><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded tax expense of less than </font><font style="font-family:inherit;font-size:10pt;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;"> in continuing operations for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, respectively, reflecting a state tax liability to one state. For the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded tax expense of less than </font><font style="font-family:inherit;font-size:10pt;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.01 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, reflecting a state tax liability to one state. No amounts were recorded for unrecognized tax benefits or for the payment of interest and penalties during the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;">. No federal or state tax benefits were recorded relating to the current year loss, as the Company continues to believe that a full valuation allowance is required on its net deferred tax assets. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2008, the Company received notification from the Internal Revenue Service that it had completed its audits of the Company's tax returns for the years 2001 through 2006 with no adjustments. An examination of the Company's 2011 federal income tax return is currently underway. State income tax returns for the year 2008 and forward are subject to examination.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company has U.S. federal and state net operating loss carryforwards in excess of </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;"> each. The net operating loss carryforwards, if unutilized, will expire in the years </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2013</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2033</font><font style="font-family:inherit;font-size:10pt;">. </font></div></div> 14000 4000 11000 5000 10000 40000 52000 1718000 1311000 171000 -955000 512000 598000 100000 155000 -1053000 54000 8000 80000 2000 1290000 1773000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in inventories at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> are </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of finished goods and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of components.</font></div></div> 400000 700000 1100000 900000 6000 0 22000 4000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the complaint filed against the Company in U.S. District Court for the District of New Jersey on May 24, 2012 alleging that the Company failed to pay overtime compensation to a purported class of certain independent contractor examiners, preliminary motion practice and discovery is continuing. The Company has denied all of the allegations in the case and believes them to be without merit.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company&#8217;s liquidity, its consolidated results of operations or its consolidated financial position.</font></div></div> 36418000 32730000 16630000 11442000 220000 0 220000 0 2608000 0 20000 80000 40000 0.010 0.015 P3Y 10000000 40000 100000 -314000 1542000 4580000 -3295000 -5147000 -7786000 -2193000 -1714000 -10861000 -9276000 -203000 -419000 -67000 -185000 -5242000 -1118000 -3101000 -7725000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hooper Holmes, Inc. (&#8220;Hooper Holmes&#8221; or the "Company&#8221;) mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. The Company also conducts laboratory testing, assembles collection kits, conducts telephone interviews of life insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2012 Annual Report on Form 10-K, filed with the SEC on April 1, 2013. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any other interim period or the full year. See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for additional information.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the assets and liabilities of Portamedic that were sold have been reclassified and are reported as assets and liabilities held for sale on the December 31, 2012 consolidated balance sheet. The operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Certain costs presented within continuing operations in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among service lines and the continuing operations have been and are being restructured. There is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated in future periods. For further discussion on Discontinued Operations, please see Note 6.</font></div></div> 4439000 5895000 374000 1607000 137000 2094000 920000 1115000 -217000 -131000 -343000 -71000 100000 967000 3346000 1062000 6053000 0 8100000 6100000 49023000 0 0 51000 0 14000 21092000 20829000 5634000 4618000 80000 55000 46415000 0 214000 113000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded restructuring charges in continuing operations totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The restructuring charges for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> month period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> consisted of severance related to the resignation of the former CFO and other employee severance. The restructuring charges for the </font><font style="font-family:inherit;font-size:10pt;">nine month</font><font style="font-family:inherit;font-size:10pt;"> period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> consisted of severance related to the resignation of the former CEO and CFO and other employee severance. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded restructuring charges totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The restructuring charges consisted of employee severance. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> related to restructuring charges are recorded in accrued expenses and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> are recorded as other long-term liabilities in the accompanying consolidated balance sheet. These amounts include </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> related to Portamedic that have been retained by the Company after the sale of Portamedic. These accruals include severance and branch closure expenses.</font></div></div> 671000 362000 0 445000 1700000 100000 1200000 -128404000 -137680000 12299000 34193000 35786000 10993000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the operating results of Portamedic and the gain on sale of Portamedic which are reported in discontinued operations in the accompanying consolidated statements of operations:</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.23586744639377%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(997</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,446</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of Portamedic and subsidiary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than </font><font style="font-family:inherit;font-size:8pt;">$0.1 million</font><font style="font-family:inherit;font-size:8pt;"> for each period </font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">presented and there were no income taxes on the gain of the sale due to the availability of net operating loss carry forwards with a </font></div><div style="line-height:120%;text-align:justify;padding-left:54px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">full valuation allowance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assets and liabilities of Portamedic are presented separately under the captions &#8220;Assets held for sale&#8221; and &#8220;Liabilities held for sale,&#8221; respectively, in the accompanying consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;"> and consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="78%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets held for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities held for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-bottom:9px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month</font><font style="font-family:inherit;font-size:10pt;"> period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.8671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,429,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,325,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,016,950</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,371,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding balance at September 30, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,305,100</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.91</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at September 30, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,526,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted during the three and nine month periods ended September 30, 2013 and 2012 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="32%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.4%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted during the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.47</font></div></td></tr></table></div></div></div> 15054000 4655000 5002000 15372000 7400000 539000 581000 500000 305000 30000 30000 155100 150000 0.000 0.000 0.000 0.000 0.924 0.924 0.896 0.896 0.007 0.015 0.007 0.015 112500 337500 2000000 1500000 600000 5000000 3500000 1479900 1092500 360000 3526850 1.20 1016950 1371650 500000 325000 2000000 1277500 325000 1225000 900000 337600 2325000 900000 325000 2000000 1225000 0.34 0.47 0.47 0.34 4000 6305100.0 6429250 0.91 1280 0.24 2.67 0.63 0.47 P5Y4M24D P5Y4M24D P5Y6M P5Y6M 4000 P6Y3M18D P7Y8M12D 700000 205332 0 60550 100000 23861000 15180000 23932000 15251000 9395 9395 71000 71000 69713178 69952153 69789628 69877878 69789628 69877878 69952153 69713178 30000 50000 200000 P10Y P10Y 6000000 0.01 0.02 0.05 0.02 0.03 0.03 5000 3000 8400000 2000000 2000000 1000000 1000000 P3D 900000 9400000 -3200000 P12M 9000000 0.65 0.75 -208000 -486000 0.85 800000 1500000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company incurred losses from continuing operations of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Restructuring charges are included in results for each of the three and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012.&#160;&#160;The Company has managed its liquidity through a series of cost reduction and accounts receivable collection initiatives, by obtaining a new credit facility in February 2013 and the sale of Portamedic on September 30, 2013.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents and working capital of </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The Company's net cash used in operating activities for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and includes the cash flow impact of accounts receivable, accounts payable, and accrued expenses related to the Portamedic service line that were retained after the sale of Portamedic. For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine month periods</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and 2012, the Company's capital expenditures totaled </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2013, the Company completed the sale of its Portamedic service line to American Para Professional Systems, Inc. ("APPS", "Piston Acquisition Inc.", and/or "Piston"). The adjusted purchase price (the &#8220;Purchase Price&#8221;) was approximately </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, adjusted from </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;"> at announcement due to changes in working capital, of which </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Holdback Amount&#8221;) was held back by Piston as security for the Company&#8217;s obligations and agreements between the Company and Piston (see note 6). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> tranche of the Holdback Amount is expected to be received in early 2014, with the second approximately one year later. There cannot be any assurance that the Holdback Amount will be collected by the Company in full, however management currently expects to realize the amounts in full and has recorded receivables in other current assets and other assets totaling </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2013, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> year Loan and Security Agreement, amended as of March 28, 2013 by the First Amendment (collectively, the &#8220;2013 Loan and Security Agreement&#8221;), with Keltic Financial Partners II, LP (&#8220;Keltic Financial&#8221;), the proceeds of which are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any one time outstanding which does not exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">85%</font><font style="font-family:inherit;font-size:10pt;"> of Eligible Receivables less any reserves established by Keltic Financial, at its sole discretion, provided that in no event can the aggregate amount of the revolving credit loans outstanding at any time exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;">. Eligible Receivables do not include Heritage Labs receivables certain Hooper Holmes Services receivables, unbilled Portamedic and Health &amp; Wellness receivables and other receivables deemed ineligible by Keltic Financial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September&#160;30, 2013 there were </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> in borrowings outstanding under our 2013 Loan and Security Agreement and the Company's available borrowing capacity was </font><font style="font-family:inherit;font-size:10pt;">$0.04 million</font><font style="font-family:inherit;font-size:10pt;"> based on September&#160;30, 2013 Eligible Receivables and a </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation method and timeline, available borrowing capacity increased to approximately </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> by October 4, 2013 and the reserve established by Keltic Financial was increased back to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> from a temporary reduction to increase available borrowing at the end of September 2013. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale of the Portamedic service line, which accounted for approximately</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;"> 60-</font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> of Eligible Receivables prior to September 30, 2013, will result in a future decrease in borrowing capacity, although Portamedic receivables were not sold in the transaction and will continue to be included as Eligible Receivables until collected, in accordance with the 2013 Loan and Security Agreement. The Company estimates Portamedic related receivables to be approximately </font><font style="font-family:inherit;font-size:10pt;">$9 million</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2013. We may request that other receivables qualify but we are not able to reliably estimate the future borrowing capacity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The minimum EBIDTA required for the twelve months ending June 30, 2014 is negative </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain costs presented in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among all service lines. For the nine months ended September 30, 2013, </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;"> of such selling, general and administrative costs were allocated to discontinued operations. While the Company is attempting to reduce these costs for its continuing operations, there is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated or reduced in future periods.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the Company historically has not tracked accounts receivable, accounts payable and other accounts by service line, its service lines had customers and suppliers in common, and its continuing and discontinued operations shared certain selling, general and administrative services, the Company does not have reliable information for the historical impact of Portamedic on the Company&#8217;s cash flows. However, the Company feels that without the Portamedic service line and with selling, general and administrative cost reductions, cash flow from operations will improve.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2013, the Company began relocating its headquarters to Kansas and put its Basking Ridge real estate up for sale. Establishing a new team and transitioning functions to Kansas will take months and transition costs may be higher than expected. In addition, the sale of the Basking Ridge real estate may not occur when expected or for the amount expected. Any sale of the real estate is subject to consent by Keltic Financial.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Heritage Labs service line shared some customers with the Portamedic service line. While not all Heritage Labs life insurance samples originated from Portamedic exams, the sale of the Portamedic service line may have an impact on life insurance related lab volumes. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the increased focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, reduce its selling, general and administrative costs as it seeks to streamline operations and improve efficiency, grow the Health and Wellness service line and maintain Heritage Labs revenues as expected, and timely realize sufficient proceeds from the Holdback Amount and the sale of the Basking Ridge real estate, it may violate covenants or otherwise not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect the Company's liquidity and its ability to generate cash flow in the future.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the Company's anticipated level of future revenues, sale of the Basking Ridge real estate, collection of the Holdback amount and restructuring initiatives, and the Company's existing cash, cash equivalents, working capital and credit facility, the Company believes it has sufficient funds to meet its cash needs through at least September 30, 2014.</font></div></div> 0 534000 0 411000 P18M 100000 0 200000 0 5000 10000 1498850 0.25 0.25 0.25 0.25 0.25 0.33 0.00 0 0.25 0.33 0.33 0.33 0.5 0.34 0.34 0.34 0.34 0.25 0.25 0.25 0.25 0.25 0.33 0.25 0.33 0.5 0.33 0.33 P10Y 273000 233000 false --12-31 Q3 2013 2013-09-30 10-Q 0000741815 70082737 Smaller Reporting Company HOOPER HOLMES INC EX-101.SCH 13 hh-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2437401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1001500 - Statement - Consolidated Balance Sheet (unaudited) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DEI Document link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2431403 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2431402 - Disclosure - Discontinued Operations Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2331301 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Impairment of Long-lived Assets link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Impairment of Long-lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2139100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2439401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2434401 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 2138100 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 2136100 - Disclosure - Loan and Security Agreements link:presentationLink link:calculationLink link:definitionLink 2436401 - Disclosure - Loan and Security Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2135100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2435401 - Disclosure - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - Share-Based Compensation Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Share-Based Compensation Employee Share-Based Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Share-Based Compensation Option Roll-Forward (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Share-Based Compensation Stock Option Valuation Assumptions link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 hh-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 15 hh-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 16 hh-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Income Statement [Abstract] Revenues Revenues Cost of operations Cost of Goods and Services Sold Gross profit Gross Profit Selling, general and administrative expenses Selling, General and Administrative Expense Impairment of long-lived assets Asset Impairment Charges Restructuring charges Restructuring Charges Operating loss from continuing operations Operating Income (Loss) Other expense: Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Interest income Investment Income, Interest Other expense, net Other Nonoperating Income (Expense) Other expense Nonoperating Income (Expense) Loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Loss from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Discontinued operations: Discontinued Operations and Disposal Groups [Abstract] Gain on sale of Portamedic and subsidiary Gain (Loss) on Disposition of Business Loss from discontinued operations, net of income taxes Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Income (loss) from Discontinued Operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Basic and diluted earnings (loss) per share: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Continuing operations Income (Loss) from Operations before Extraordinary Items, Per Basic and Diluted Share [Abstract] Basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract] Basic (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net loss Earnings Per Share [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average number of shares - Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average number of shares - Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Loss Per Share Earnings Per Share [Text Block] Statement of Financial Position [Abstract] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock (in shares) Treasury Stock, Shares Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Groups, Including Discontinued Operations, Name [Domain] Portamedic Service Line [Member] Portamedic Service Line [Member] Portamedic Service Line [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Consideration amount Disposal Group, Including Discontinued Operation, Consideration Disposal Group, Including Discontinued Operation, Consideration Proceeds from the sale of Portamedic Proceeds from Divestiture of Businesses Holdback amount Disposal Group, Including Discontinued Operation, Holdback Amount Disposal Group, Including Discontinued Operation, Holdback Amount Holdback release, business days after closing Disposal Group, Including Discontinued Operation, Holdback Release, Business Days after Closing Disposal Group, Including Discontinued Operation, Holdback Release, Business Days after Closing Holdback release, amounts paid threshold Disposal Group, Including Discontinued Operation, Holdback Release, Amounts Paid Threshold Disposal Group, Including Discontinued Operation, Holdback Release, Amounts Paid Threshold Holdback release, amount less deductions for indemnification claims Disposal Group, Including Discontinued Operation, Holdback Release, Amount Less Deductions for Indemnification Claims Disposal Group, Including Discontinued Operation, Holdback Release, Amount Less Deductions for Indemnification Claims Holdback receivable recorded Disposal Group, Including Discontinued Operation, Holdback Receivable Recorded Disposal Group, Including Discontinued Operation, Holdback Receivable Recorded Divestiture of business related costs Divestiture of Business Related Costs Divestiture of Business Related Costs Working capital Divestiture of Business, Working Capital Divestiture of Business, Working Capital Loss from discontinued operations, net of tax Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Decrease in reserve for lease obligation Increase (Decrease) in Other Accrued Liabilities Lease obligations Capital Lease Obligations Lease obligations future minimum payments due Capital Leases, Future Minimum Payments Due Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Restructuring Charges [Abstract] Restructuring Restructuring and Related Activities Disclosure [Text Block] Expected life (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average fair value of options granted during the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Asset Impairment Charges [Abstract] Impairment of Long-lived Assets Asset Impairment Charges [Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Term of possible loss contingency Possible Loss Contingency Term Possible Loss Contingency Term Estimate of possible loss maximum Loss Contingency, Estimate of Possible Loss Employment agreements, contract term employment agreements, contract term Contract term associated with employement agreements Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options [Member] Employee Stock Option [Member] July 2009 Non-vested Stock Award [Member] July 2009 Non-vested Stock Award [Member] July 2009 Non-vested Stock Award [Member] July 2011 Non-vested Stock Award [Member] July 2011 Non-vested Stock Award [Member] July 2011 Non-vested Stock Award [Member] Non-Vested Stock Award [Member] Non-Vested Stock Award [Member] Non-Vested Stock Award [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Director Stock Plan [Member] Director Stock Plan [Member] Director Stock Plan [Member] Amended and Restated 2014 Plan [Member] Amended and Restated 2014 Plan [Member] Amended and Restated 2014 Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Exercised (options) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (weighted averaged exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options vested in period Share-based Compensation Arrangement by Share-based Payment Award, Options Vested in Period The number of stock options that vested during the reporting period. Aggregate fair value of options vested in period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Unrecognized compensation cost related to stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Weighted average period for recognition of compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Compensation expense allocated to selling, general and administrative expenses Allocated Share-based Compensation Expense Reversal of previously recorded share-based compensation expense Reversal of Previously Recorded Share-Based Compensation Reversal of Previously Recorded Share-Based Compensation Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Non-vested Stock Awards Non-vested Stock Awards [Abstract] Non-vested Stock Awards [Abstract] Aggregate shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Aggregate shares of non-vested stock forfeited Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Aggregate shares that vested in the period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vesting Schedule for Equity Grants Other than Options Vesting Schedule for Equity Grants Other than Options [Abstract] Vesting Schedule for Equity Grants Other than Options [Abstract] Vesting percentage, year one Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year One The percentage of a share-based payment award that vests in year one. Vesting percentage, year two Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Two The percentage of a share-based payment award that vests in year two. Vesting percentage, year three Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Three The percentage of a share-based payment award that vests in year three. Vesting percentage, year four Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Four The percentage of a share-based payment award that vests in year four. Vesting percentage, year five Share-based Compensation Arrangement by Share-based Payment Award, Vesting Percentage, Year Five The percentage of a share-based payment award that vests in year five. ESPP ESPP [Abstract] ESPP [Abstract] Stock Allocated During Period, Shares, Employee Stock Purchase Plan Stock Allocated During Period, Shares, Employee Stock Purchase Plan The number of shares subscribed to by employees under the Employee Stock Purchase Plan during the period. Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan The aggregate grant-date fair value stock subscribed to by employees under the Employee Stock Purchase Plan as calculated by applying the disclosed option pricing methodology. Other Stock Awards Other Stock Awards [Abstract] Other Stock Awards [Abstract] Term over which grants will occur Share-based Compensation, Term Over Which Grants Will Occur Share-based Compensation, Term Over Which Grants Will Occur Number of shares authorized under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Remaining shares available for grant under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares awarded annually to non-employee board members other than the non-executive chair Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Awarded Annually to Non-employee Board of Directors Other Than the Non-executive Chair The number of shares awarded annually to each non-employee member of the Board of Directors other than the non-executive chair. Number of shares awarded annually to non-executive chair of the board of directors Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Awarded Annually to Non-executive Chair of the Board of Directors The number of shares awarded annually to non-executive chair of the Board of Directors. Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] DEI [Abstract] DEI [Abstract] Entities [Table] Entities [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Entity Information [Line Items] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Other Restructuring [Member] Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring charges related to severance Restructuring reserve, current Restructuring Reserve, Current Restructuring reserve, noncurrent Restructuring Reserve, Noncurrent Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] December 2010 Stock Option Award [Member] December 2010 Stock Option Award [Member] December 2010 Stock Option Award [Member] September 2013 Stock Option Award [Member] September 2013 Stock Option Award [Member] September 2013 Stock Option Award [Member] July 2012 Stock Option Award [Member] July 2012 Stock Option Award [Member] July 2012 Stock Option Award [Member] July 2011 Stock Option Award [Member] July 2011 Stock Option Award [Member] July 2011 Stock Option Award [Member] All Other Stock Option Awards [Member] All Other Stock Option Awards [Member] All Other Stock Option Awards [Member] 2008 Plan [Member] 2008 Plan [Member] 2008 Plan [Member] 2011 Plan [Member] 2011 Plan [Member] 2011 Plan [Member] name of equity-based compensation arrangement plan Amended and Restated 2011 Plan [Member] Amended and Restated 2011 Plan [Member] Amended and Restated 2011 Plan [Member] Statement [Line Items] Statement [Line Items] Contractual life of stock options and other awards under share-based compensation plans contractual life of stock options and other awards under share-based compensation plans Contractual life of stock options and other awards under the shared-based compensation plans Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Restricted stock granted to CEO as settlement for discretionary bonus (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted stock granted to CEO as settlement for discretionary bonus Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Option Vesting Schedule Option Vesting Schedule [Abstract] Option Vesting Schedule [Abstract] Liquidity [Abstract] Liquidity [Abstract] Liquidity Liquidity [Text Block] The disclosure for the company's management of liquidity. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Loss Contingency, Information about Litigation Matters [Abstract] Litigation Legal Matters and Contingencies [Text Block] Impairment of Long-Lived Assets [Table] Impairment of Long-Lived Assets [Table] Impairment of Long-Lived Assets [Table] Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale, Name [Domain] Long Lived Assets Held-for-sale, Name [Domain] Financial System Software [Member] Financial System Software [Member] Financial System Software [Member] Impairment of Long-Lived Assets [Line Items] Impairment of Long-Lived Assets [Line Items] [Line Items] for Impairment of Long-Lived Assets [Table] Revenues Disposal Group, Including Discontinued Operation, Revenue Loss from operations before income taxes Maximum tax effect of discontinued operation Discontinued Operation, Tax Effect of Discontinued Operation Assets held for sale: Assets of Disposal Group, Including Discontinued Operation [Abstract] Inventories Disposal Group, Including Discontinued Operation, Inventory Other current assets Disposal Group, Including Discontinued Operation, Other Current Assets Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment, Net Other assets Disposal Group, Including Discontinued Operation, Other Noncurrent Assets Total assets Assets of Disposal Group, Including Discontinued Operation Liabilities held for sale: Liabilities of Disposal Group, Including Discontinued Operation [Abstract] Deferred rent Disposal Group, Including Discontinued Operation, Other Liabilities Capital leases Disposal Group, Including Discontinued Operation, Accrued Liabilities Total liabilities Liabilities of Disposal Group, Including Discontinued Operation Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Internal Revenue Service (IRS) [Member] Internal Revenue Service (IRS) [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options [Member] Equity Option [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Loss from continuing operations Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Borrowings outstanding under Loan and Security Agreement Line of Credit Facility, Amount Outstanding Remaining borrowing capacity under Loan and Security Agreement Line of Credit Facility, Remaining Borrowing Capacity Net cash used in operating activities of continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Capital expenditures Payments to Acquire Property, Plant, and Equipment Term of loan and security agreement Line of Credit Facility, Expiration Period Loan maximum defined, based on eligible receivables Line of Credit Facility, Loan Maximum Defined, Based on Eligible Receivable The contractual maximum of borrowings as defined by a percentage of eligible receivables, with consideration of all undrawn/unexpired letters of credit. Maximum borrowing capacity under Loan and Security Agreement Line of Credit Facility, Maximum Borrowing Capacity Additional borrowing availability under Loan and Security Agreement Credit Facility, Additonal Availability Credit Facility, Additonal Availability Loan maximum defined, based on eligible receivables, reserve Line of Credit Facility, Loan Maximum Defined, Based on Eligible Receivable, Reserve Line of Credit Facility, Loan Maximum Defined, Based on Eligible Receivable, Reserve EBITDA twelve month requirement Earnings before Interest, Taxes, Depreciation, and Amortization Twelve Month Requirement Earnings before Interest, Taxes, Depreciation, and Amortization Twelve Month Requirement Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Eligible receivables generated, percent Estimate of Eligible Receivables Generated, Percent Estiamte of Eligible Receivables Generated, Percent Eligible receivables generated Estimate of Eligible Receivables Generated Estimate of Eligible Receivables Generated Debt Disclosure [Abstract] Loan and Security Agreements Debt Disclosure [Text Block] Stock Option Activity [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding balance (options) at December 31, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Expired (options) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Forfeited (options) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Outstanding balance (options) at March 31, 2013 Outstanding balance (weighted average exercise price) at December 31, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (weighted average exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Expired (weighted average exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Forfeited (weighted average exercise price) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding balance (weighted average exercise price) at March 31, 2013 Weighted Average Remaining Contractual Life, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands), options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Number of options exercisable at March 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted average exercise price of options exercisable at March 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Life, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands), options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value ASSETS Assets [Abstract] Accounts receivable, net of allowance for doubtful accounts of $622 and $662 at September 30, 2013 and December 31, 2012, respectively Accounts Receivable, Net, Current Inventories Inventories, Property Held-for-sale, Current Other current assets Other Assets, Current Assets held for sale Assets Held-for-sale, Current Total current assets Assets, Current Property, plant and equipment at cost Property, Plant and Equipment, Gross Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Short-term borrowings Accounts payable Accounts Payable, Current Accrued expenses Other Accrued Liabilities, Current Liabilities held for sale Liabilities of Assets Held-for-sale Total current liabilities Liabilities, Current Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 10) Commitments and Contingencies Stockholders' Equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, par value $.04 per share; Authorized: 240,000,000 shares; Issued: 70,140,864 shares and 69,844,782 shares at September 30, 2013 and December 31, 2012, respectively; Outstanding: 70,131,469 shares and 69,835,387 shares at September 30, 2013 and December 31, 2012, respectively. Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Stockholders' equity Stockholders' Equity before Treasury Stock Less: Treasury stock, at cost; 9,395 shares at September 30, 2013 and December 31, 2012 Treasury Stock, Value Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Schedule of Discontinued Operations Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Discontinued Operations Discontinued Operations, Policy [Policy Text Block] Finished goods Inventory, Finished Goods, Gross Components Inventory, Raw Materials, Gross Loan and Security Agreements [Table] Line of Credit Facility [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2013 Loan and Security Agreement [Member] 2013 Loan and Security Agreement [Member] 2013 Loan and Security Agreement [Member] First amendment [Axis] First amendment [Axis] First amendment First amendment [Domain] First amendment [Domain] [Domain] for First amendment First amendment [Member] First amendment [Member] First amendment Time period [Axis] Time period [Axis] Time period [Axis] Time period [Domain] Time period [Domain] [Domain] for Time period [Axis] Prior to first anniversary [Member] Prior to first anniversary [Member] Prior to first anniversary [Member] Prior to second anniversary [Member] Prior to second anniversary [Member] Prior to second anniversary [Member] Prior to third anniversary [Member] Prior to third anniversary [Member] Prior to third anniversary [Member] Base interest rate [Axis] Base interest rate [Axis] Base interest rate Base interest rate [Domain] Base interest rate [Domain] [Domain] for Base interest rate Prime rate [Member] Prime Rate [Member] LIBOR 90 day rate [Member] LIBOR 90 day rate [Member] LIBOR 90 day rate [Member] Loan and Security Agreements [Line Items] Line of Credit Facility [Line Items] Unused line fee Line of Credit Facility, Commitment Fee Amount Facility fee, percentage Line of Credit Facility, Commitment Fee Percentage Monthly collateral fee Debt Instrument, Collateral Fee Monthly collertal fee (upon default) Debt instrument, collertal fee (upon default) Debt instrument, collertal fee (upon default) Credit facility - early termination fee Credit facility - early termination fee Credit facility - early termination fee Amendment fee Amendment fee Amendment fee Spread on variable rate Debt Instrument, Basis Spread on Variable Rate Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Commitment fee Debt Related Commitment Fees and Debt Issuance Costs Other issue costs Debt Issuance Cost Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Gain on sale of Portamedic and subsidiary Gain (Loss) on Disposition of Other Assets Depreciation Depreciation Amortization Amortization of Intangible Assets Amortization of debt financing fees Amortization of Financing Costs Provision for bad debt expense Provision for Doubtful Accounts Share-based compensation expense Share-based Compensation Impairment and loss on disposal of fixed assets Impairment of long-lived assets and gain (loss) on disposal of fixed assets Impairment of long-lived assets and gain/loss on disposal of fixed assets Change in assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable, accrued expenses and other long-term liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Net cash used in operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Costs paid to sell Portamedic Payments for Divestiture of Businesses Payments for Divestiture of Businesses Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Cumulative borrowings under credit facility Proceeds from Lines of Credit Cumulative payments under credit facility Repayments of Lines of Credit Reduction in capital lease obligations Repayments of Long-term Capital Lease Obligations Proceeds related to the exercise of stock options Proceeds from Stock Options Exercised Debt financing fees Payments of Financing Costs Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of non-cash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Fixed assets vouchered but not paid Capital Expenditures Incurred but Not yet Paid Fixed assets acquired by capital lease Capital Lease Obligations Incurred Costs to sell Portamedic but not paid Noncash or Part Noncash Divestiture, Costs Incurred but Not Paid Noncash or Part Noncash Divestiture, Costs Incurred but Not Paid Supplemental disclosure of cash paid during period for: Supplemental Cash Flow Information [Abstract] Income taxes Income Taxes Paid EX-101.PRE 17 hh-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 18 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
 9 Months Ended
Sep. 30, 2013
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes

The Company recorded tax expense of less than $0.01 million and $0.01 million in continuing operations for the three and nine month periods ended September 30, 2013, respectively, reflecting a state tax liability to one state. For the three and nine month periods ended September 30, 2012, the Company recorded tax expense of less than $0.01 million and $0.01 million, respectively, reflecting a state tax liability to one state. No amounts were recorded for unrecognized tax benefits or for the payment of interest and penalties during the three and nine month periods ended September 30, 2013 and 2012. No federal or state tax benefits were recorded relating to the current year loss, as the Company continues to believe that a full valuation allowance is required on its net deferred tax assets.
In July 2008, the Company received notification from the Internal Revenue Service that it had completed its audits of the Company's tax returns for the years 2001 through 2006 with no adjustments. An examination of the Company's 2011 federal income tax return is currently underway. State income tax returns for the year 2008 and forward are subject to examination.

As of September 30, 2013, the Company has U.S. federal and state net operating loss carryforwards in excess of $100 million each. The net operating loss carryforwards, if unutilized, will expire in the years 2013 through 2033.
EXCEL 19 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`:,QE5V@$``#$6```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/& MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,90'^@Y&JZJ, MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N M);GWYIY2E^50"1=K`RK[?9HII4'Y3N^GD&&@T>8 MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@ MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E M6,S*L9B58S$KQV)6CL6L'(M9.1:S*TG?'A$%@?0'[%K.M#=PGAGKT],"#.A+J`E:";,FF3>$[ M_`(``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\ M(V(T'4\4"_'L)MI< M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?```` M__\#`%!+`P04``8`"````"$`_GO?E-(!```<%0``&@`(`7AL+U]R96QS+W=O M_%[)K?BL"EJL2UI0]@)88@((EL]X>W MKX40%*F=7J*]1+*C.*/)>KYX9XNOPS[[<#YLFSI7U.NKS-5%4V[K3:[>5L\/ M$Y6%:.O2[IO:Y>KH@EK,[^]F+VYO8WHH5-LV9&F5.N2JBK%]U#H4E3O8T&M: M5Z<[Z\8?;$Q#O]&M+79VXS3W^R/M?ZZAYC=K9LLR5WY9DE'9ZMBF5_^_>+-> M;POWU!3O!U?'7]ZA/QN_"Y5S,2UJ_<;%7%VF@C[=(=-+FI7^0T[R0U;.!,GA MD;`<'D$Y)"V'D!PS$)9C!DC.6%C-&(DA%E9##.5(FT/0'1X*N\-#Y(Z1#D$# M0U"Z='#E2$<@X0A,!!4%!/=1Y?!46LX4R9'F`\2#=.'`NB%Q:Z`W+(U.AN@T MTI%C8.:83FD5*NM=^1I]^ND.:;N>?TQOIM&FDF851!5)JR$HAZ7)R9B"'XJD MK2'H#4O#DB$LN5-87MHUUYRY3)T[.`R/=D8ZA/EWA MUI:F$H92TB_9\+L`6]_T-.??````__\#`%!+`P04``8`"````"$`'M*4QUP# M``"J"@``#P```'AL+W=ON;0YY9[U0J M)OC4]LYPG5F;Y%I:"=V2,M-/D-Y)'>KE3WS_ MO/IG58IG1O?J(ZA:6H<7QA.QK_X*I3VVJP`,[.M'+RS1.WCNNFY[[S=EZ4Z? M;H*\@_3K"L(^]=7B=7J+^V5TJ@HTK*KQ$O+P;$M>,?@AEXE7V<0QN>UI`IR8O]*!I@= M<004&8K,I456DE>)JQ=^CEK5+0 M0[3[!-!K=[_LR]2;0LH0.1I[!W@@T8.`=\( M.P,ZF$&8I;UAUAZZ:$$U81D&*<3T^09]W=,W$.]WX@T0/S^&8+L=I#XF&A:] M',9J>I\7F<#3).SH&%".Z6RTB-\B[`?#[1M4CND\%M7K%NM@NIOW(1Z(8SJW M>R(3["?$1]8WV!UCY8%(&#G(3]C)RV!W3*^9F&0Q?&A5E^K;I:Z8<_K,G/T'``#__P,`4$L#!!0`!@`(````(0`$ M80:;`@<``+H=```8````>&PO=V]R:W-H965T&ULC%G;CMLV M$'TOT'\0]&Y;I.Z+]0;1)6V`%"B*7IZUMKP68EN&I,TF?U]20YF_?#TZ^_/+ZUW=?^6->#(SQ<^JU['(;KPV;3[X[UN>K7[;6^",NA M[<[5('YV+YO^VM75?IQT/FVXYT6;<]5<7/#PT/V,C_9P:'9UT>Y>S_5E`"== M?:H&$7]_;*[]Y.V\^QEWYZK[^GI=[=KS5;AX;D[-\&-TZCKGWEQWP@&]E`1".3HAJJI\>N?7-$>8AG]M=*%AM[$)X5!17'C918VYU$?Y3P<9((MQ>C MWYZB\''S32S23D$R@,2NHR$1AN031*Z4=%M,`WH.PU/*"2'S(4*_Q2]6A<;O M>[=PI16'&\;8<69#.$;D-B(B3@H;0IR4-L)P@ACYB-&T\')4E(VYJ@F.,P-( M8$!(:O*[B.(NHEQ"(!XB$",S$P\YNG7%:NCJ2`D/@"1C=3$O37ULSY&=\Y3, M+TR['S`ZOT3V,$YT=:+XQ6Z8B5^.XOAC#\>7`20:XT]BGYAS;(Y(H12FF8=1 M1-B7V!YRS1Y%'\U&+T=)]&2C90"!Z#FGC\]-LQ_Z=".8YB2DW$O3S#QN;$84 MO&@>QM*/34<3I;,1RE$2L&8_].P,( M1.S3DLY-JWXR='[3%L6D&$O3&@0Z3RAJ)H3;6&A:+J.9Q*\]0?P*`P6S\IE' M`LDQ@#%&FF^!`7',R2-*#`AYH/.#V4BEL\N&@0"*[GMKG+%N7(H%8$1_NV%( M%+ERLP`I[D/*10AF(W5OA@W(H2D#,6DE&0,,%-7*V&0CV1R;]6)"66%K0JJN M).;Y_[M6#([`>DKY78SIG.."8@)6Z&`"B?28#F-1.G;]FK M)@*)5?[(;IS`5-4@LS@ZW`ICM)?8/?08(/H1H5I@0,("JYC0(\+WVZN4.\UFTC$&*HA8Z(I4]0082`<),%<. MP$B"*Y"1$6N)K7KMRD7(8@-7Y;JT8RE MFM9UIC"0&S^D3297=B@KTO<+/#FB*EZBR<:;+2:!%9IN;PXJC`I,)Q<*3&%4 M@;$T(H"<`#R/)+?`@"#VB8<2`\+`>$W!;$2@1H%9;*29I$3W;<4&,,"&A53) MP@#3S<33&9>LKDMV0G9D)G"P&OGBL6TZ>08P*WWR@(# M4D[/9R4&,"^)=%_!-*20VIN>@[ZB34\:3Z8P`OGN&?`^I+@/*13'G(-1F9:4DADQA%BMKTGN=4KU1QX05 M][V4BQ"<$ZFR,Y4%XKM<68"!)1>%1=CFW+3+RM-;51&A`.*AM#R\5UCS"L]! MFA$)$D.F,.^3`!^ZKHB#`CF0+"T2U,,[),3GF;E,C,/XLZ75>!5FJ:[N0XK[ MD'(1@NK*QPH_[?5Q&&NAU;$41B\Y6='<`I##9T$!C`!*"Z"E'[.0JFKO#E\. M$Q:D+C*%66`!3C2`!%E0#S8+XH&]QP)+.CV?^+:TTP^^F<+`^21*TY"+KWKX MU2XGF#A)(ZYK';8\P21QG,0$4Q),+%ZB#0S.CY1SG1^+F323/)%38"9NMR1F MF1G&S#/#F'EF&#/+#*[*X(+I7'PA'Z^Y MR'@AKN[&\.7SW`[B M*FW\\RCN2&MQS^2M!?C0ML/T0]XFW6Y=G_X'``#__P,`4$L#!!0`!@`(```` M(0`]G8!V>0(``-,%```9````>&PO=V]R:W-H965TC>,D%K$=V::T_W['=DE)BK;R M$.)S/G_G.[S^F$LA-W.+RCEX(9;77I$J`C4>C[G.=D M3H!IM2P$9.#+C@POA@9\-ZC@)3TT[H<^?N6BJAUT.\1CNH%(\$12^!&`S.ES M^#^*PM4Y'L\PVG'KML+?P8@=K-/R3W2F/FIW.7N]/`9YK_XLR6ZFZ7263?_' M0J*2D,$]=72U-/J(8"H@IFVIG[%T,8;*,6^\\];@`U46K$^K23I>DB8:1^Q^1>B)P)(+HCPUAR#\*Z2DW008ATQ\]"+47(] M$-#WOM6H%QR&Y$)P;QT&?^M2+'+$Q.!IDHYZOT&Y8-$\X4GIO%,:M<0EBB,H MN:GXAC>-14P?%&2?07Z=->[N.EU`DV$1!O8-['2PD\X!J];2BC]24PEE4<-+ MH(1B@2(3MS(>G&[#6.VT@V4+KS5\/#F,SR@!<*FU.QW\WG>?X]5?````__\# M`%!+`P04``8`"````"$`QQ!K(_`$```A%0``&0```'AL+W=OZ:RT6NW'-2%. M@AIP!+3I^?<[QH9@C'!OTL9^/,SK&9O);+]]%C?K@U9USLJ=C1:N;=$R8Z>\ MO.SL?_XF+VO;JINT/*4W5M*=_9/6]K?]K[]L'ZQZJZ^4-A98*.N=?6V:^\9Q MZNQ*B[1>L#LM8>;,JB)MX&MU<>I[1=-3NZBX.9[KADZ1YJ4M+&RJK]A@YW.> M4WN\O&2ON8.*8W_+F9VO4MHIL M\_U2LBH]WD#W)PK2K+/=?M',%WE6L9J=FP68\F79.P&3X)/J\AY#H#T]+/]^\A/ MS75G^^%BN7)]Y"UMZTCKAN1\K6UE[W7#BO\$A*0I8<231D)P4\Y["V^]1,O0 M;,41'K5*<-JD^VW%'A:D!SRSOJ<\V=`&+$L)TH]>%.QMQNE7CN_LE6V!NS6, M?NP#A+;.!^Q2)IE89\)010X=PK>*V\7=P-/NR&K2$=T2(@;:/7)`3*\(]FF@ MJ'.""0;,B#@8"6PD$B-!Y@A%,K@ZB&8KV7]*YK,[&S:P#^)Z MI"<6R+K-57\9^*[KJGMR&!*C.3R<\T.TUE8G0R)<:O-$S,-G[^+30T4IW`0# MI5W>\E%5H1>-CD8LF.E'M,?K8"2PD4B,!)DC%*EPT0RDCO.8SYKR6#!SDHT$ M-A*)D2!SA"(9KLR!Y"ZZ?%2-;ABIV1D+)&SS%T5H-9'`0\1#_@II68B'2.@% M_DI#DB&R\MR5CA"!3.^ZHI97.*.WRN#4\EE5M8>>AZ+-V%@P0O8+BI;ZR3LH M2!3I_F*%"%9NI*M6D&40A!I"!/(%U=&L:CZKJ@[0Z&T1"T8&&SS1[BH3@$U` M8@*(`+X@%T'!-(ARE]/ML'I^/6\<7@E-/T7<668$FY'$C)!91$EKQ&N.9U[W MBD4I,GP-^:,72=PNW=FS@H69&02;K21FA$A$I%D4*->%JI>7)A-Z1<6BZ!V_ MDY!@9L0@/U6*EZ>5DRH5=4*XK>9X4F[BLT5]'(A#8BV&PE M,2-$(D*OY_*K\YF.JF"(SY1@/JS>5?ZH](V18&8#;$2PV4IB1HA$I&!/J<)4 MO;Q$F0BPJ%R4`*]'[V'X8OU0?6FI@GF!,B%8U"V0 MD'U5Z@U^=,B4GBMN9$H;$8R,2&)&R"RB*N9%RH1B4;L,0^QY6D[/%3A2L1'! MR(@D9H1(1,08N?S:ZC-2%5]/0#C*>8B."S582,\);4]P7\=/4@]Z=%F'1>1+]FH)6 M%WJ@MUMM9>R]A'/KPV^"?K3O>+UZO,&PO=V]R:W-H965TMNCJ:U^;FHLG96WXHK'#G6395U\+4Y:>VM*;)#WZBZ M:*:NVUJ5E5>5*CC-1S3JX[',"Z_.7ZOBVE&1IKAD'8R_/9>W=E2K\H_(55GS M]?7V*:^K&TB\E)>R^]&+JDJ5._'I6C?9RP7.^[MA9?FHW7\1Y*LR;^JV/G8S MD-/H0,5S7FMK#91VFT,)9T#2KC3%<:M^,9S46*G:;M,GZ+^R>&LG?ROMN7X+ MF_+P1WDM(-O@$W'@I:Z_$C0^D!`TUH360>_`7XUR*([9ZZ7[NWZ+BO)T[L#N M!6F2UQ?H"3Z5JB1S`$X]^][_?BL/W7FKSNW98JG/#7.A*B]%VP4E::LJ^6O; MU=7_%#(&*2IB#B+P>Q`Q%C/+7"Q7OZ(R'U3LAXHY,U<+8V'_PEB6XPG!D,AV*N5FRC:&ST8/BAQ",RZB9CX-&&&THZ$M!$@US?$PYS:9KP,:\D M3/(Z]N".@4VFP@E8I'@ MNTE$A!MK*A(3$<8(N"R?&4'"C!%\8,\'/#[@\X&`#X0TP.1KS"CAHT2`$B%* M1"@1HT2"$JF,8-R!F]NS64W"6Q4NCGO&YSJWWKJ4@9[N#.\*2G@HX:-$@!(A M)5;][6=EZ>2'6VU0(D9[25"-5*;!N`*W_F>ND##KBF%PJX!+&9DK*.&AA$\) MN\^HK2_F0D:#48/<\KELA]/6*^.9'V/K=^=6C!+)M!?[62^I3(/Q`YY?GOE! MPJP?HIE"GDA[M*4")&>TE0C52FP;A"BC3^ M673^N+.0P[P[W+.<2QF9.RCAH82/$@%*A"(QU]> M3I^C+>$YVJ"0)/U['/%PQ,>1`$="'(EP),:19$#H5%@_>1Y)I2*L0:1@?680 M+62G!IEK[MV3:U!(:A"*>+B*CR,!CH0X$N%(C"/)@`P&/:NK4JD*ZQ"D=^I0 M_YY@\C1GD./L[<@2'K8'2.H4U9$@'J[BXTB`(R&.1`-"<_S)6"]6PF-YS#+K M]5)`$A:QECJYGMBGQY1E%I9E3QG6+%+)3BXGP2Q:Z4XO*TOGG[WA/3QQE)[: ML_IL/Q!2KV0U]?`:&$4"O*,01R(]]##17Q4),!%0AR)<"3&D01'4BG"^D.*W8D_PH5$BV'&)Z%( M,F05\^`3160^H2+^T,_[(@$^DA!'(AR)<23!D52*L#Z1HE?F$RV*ISZMN-K; MA7U.LMY)5K/]@-`WE?.%);Y7\QB$6\)]YN#<-L2;1<`@]F*ZQ/=3)1P`R3`C M'(EQ),$1LC7\?LJH073KE^Y15D5S*O;%Y=(J>?UZA??24&3M-O?P?<_YRYQL MG''QO>'`'J(8]PT'-@K%>&0XL-$GQA.RI_TD[IJ.^[1?TX$](E'',QW8*A+C MONG`CI$8#TP'-HX@KMU/#':X;]FI^#-K3N6U52[%$7*BSY9P1VSH9CC]TM6W M?FOWI>Y@;[O_\PS_M%#`+JH^`_A8U]WXA71P_S>(W4\```#__P,`4$L#!!0` M!@`(````(0!^0@<2R@H``-)0```9````>&PO=V]R:W-H965T7Z_;TM#U4I_)^^%=Y&?[V\.]_W;U7Y^^7U[*\#EB%T^5^^'J] MOJW'X\ONM3QN+Z/JK3RQ.<_5^;B]LE_/+^/+V[GG[>[TJGVOTXEJ>K*'(N#]LK6__+Z_[MTE0[[KY2[K@]?__Q]FU7 M'=]8BVW;^,Z7;7U*Y_Z90_[G?GZE(]7T>L MW%BL:'>;5^/5F%5ZN'O:LRW@NWUP+I_OA[\;Z\*RAN.'NWH'_7=?OE]N?AY< M7JMW_[Q_2O:GDNUM=ISX$7BLJN^ M@W+_\GIEAWO&7[*K#FQ)[-_!<<\SP#9]^ZO^__O^Z?IZ/[3FH]EB8AGF;#AX M+"]7;\]?.QSL?ERNU?%_`AFRE"ABRB(+MIIROCDRES-C-O\;55CVZE59M57, MQ6AA3%;6XNNK8K!=)3:([[-_O$5&NU_8#[*,:8V,Z>3O;)'1[!BVZYLJ_V#W M&O-FF]@/S3997][!8W'(ZZ@XV^OVX>Y M8Z@O<1O1O,03$T0*>0V?3@B:EWQ:-&Q$4S2B->)FPJ2*D4CV/:,V1%N#S,+8>[WF9FZ,H$P;)>U.24K$W8%79FH2TB1&(JD*ZS% M4EW9M&O(DCQ6?S2#7O+%M,6+03-G2"0R>X=()' M)_AT0B`FW!Y3:T$&G_`+)NHS),QQCS'(LI(>LUB10_L%D_68Y42MDW_!%'WF M8Q!1#O"TYP!/9^V8P6>S,X6;=X^U)&&RA6'_MN\P\A[<0.%`X4+A0>%#$4`1 M0A%!$4.10)%"D4&10U'HA)(C=MYS^]G3G$GPR?=#-MRTV;!F)!VV,&Q)K2%B M`X4CQ+P^5_DVG\QFY&WC-B7XR0R9YS7S/ET!'XH`BA"*"(H8B@2*%(H,BAR* M0B>4X+#3T=O@U.>F-RANB9O3ADTEXEN1DR19&%QXH'"'$ MZ&-,5\ME9_B!-3PH?"@"*$(H(BAB*!(H4B@R*'(H"IU0\L.[8?0"^680XK-I MCLBUB"V,+D=0.$(T@Q`Y$W7AZSTH?"@"*$(H(BAB*!(H4B@R*'(H"IU0,L2Z M6;H,\=DT0^0\QQ9&ER$H'"A<*#PH?"@"*$(H(BCB1M2G=2-RS94T)@XF+B8>)C$F`28A)A$O<0:TG& MX:0'D3=RBDF&28Y)T4.LY4=720T7[QO23[F;:WW>"N\,4>0M94LTE2?*Y%-P M0V:35H%#9G^L:'TB[Y+99*]Z[>Q/W\\^)@$F(281)C$F"28I)ADF.2:%EJA! MXNU#&J2;TR7^;0@-THI<=-L2-4$BUW0;=;;:`W/4F2.2,E>=K;[6:V=J0B36 M7S.`!KA*B$F$28Q)@DF*289)CDFA)6J(>)/R)D3--9LAFI=*RVA%TF%+I#E" M&TP<3%Q,/$Q\3`),0DPB3&),$DQ23#),]4>+32?=Z108+ MVQ!(&R5('%S%Q<3#Q,]DW-HFNICHV MT882OP6`I4X;*$@<7,7%Q,/$QR201/2WK`G[3_U,#1&(\$)B3!)E,3.^'F1% M4EPD4XI8$UY&W9H<%RFT1(T2[V'>1(GVM_GM&)US)7)6;4NDC92N5RKOOH#$ MQ0OR,/$Q"3`),8DPB3%),$DED>\`=IL2#4V&B^1*$8/==D6+%-HB:JQX:U,7 M*]'Z5$B M#!?)29&9T8V5[CBKL>+=3EVL1#=4N1]@U>D_Z5JF,E:0.`8D+B8>)CXF`28A M)A$F,28))BDF&28Y)H66J,'B+=";8+57>Z(UJHQ3T\['GZY_*@,%B6-`XF+B M8>)C$F`28A)A$F.28))*LC)%UX^.47#'YJ3`B-ZR5FA70DF225KD39+JZ:0U M/J6?>!+I3J0P<3!Q,?$P\3$),`DQB3"),4DP225IDC0RR1'*<(VT MAD4^?`KM>JAA8I]B?9]Q)I].1R;RI9(MD39,HHZ&.+B*BXF'B8])@$F(281) MC$F"22J))DQP]^=X,866J''ZI$%N]C3(I^2;-%LB358VF#B8N)AXF/B8!)B$ MF$28Q)@DF*22:.(D#J/F".5X,866J'%B2^H=G?ATVB3OC$X":59V8T+B8.)B MXF'B8Q)@$F(281)CDF"28I)ADF-2:(D:*-(DIYU-_@>!]&-OU1FG8"=\(^MH MLN=@XF+B22*Z,:;%&]WJE8ZOBD57!'@Q(281)C$F"28I)ADF.2:%EJBQ`@US MLZ]A3N]2D4B3F0TF#B8N)IXDS5V=$_)]D4_GDRNB`"\BQ"3"),8DP23%),,D MQZ30$C52I%G>7N6)ONAM-W-*W_.VJ6N>BN83)@XF+B8>)CXF`28A)A$F,28) M)BDF&28Y)H66J('BO>F>;J8I>M;L0J']4Z;IA-Z[(I%V;(*];P=7<3'Q,/$Q M"7J(99$A.>Q!9*2+,(DQ23!),D MT!(E5^RV3&VNZOFD.671RS^)=$,6)@XF+B8>)CXF@23R"_TZ6.JY?HB+1)C$ MF"28I)ADF.28%%JBYHJW5NEX=7,SN25:K[?CU71"[[V32)LKV,)UDY>X1_I.M[YKKME#>+K3/7/-GL73G>Z;:_9('C9]W"Z8/6CN;?M2 MIMOSR_YT&1S*9[9/)B/^.+>S>":=^.5:O=5/H'JLKNP1<_6/K^S9@25[L-=D MQ/!S55V;7_@"VJ<1/OP?``#__P,`4$L#!!0`!@`(````(0"K=$3//`0```D/ M```9````>&PO=V]R:W-H965TBGZ MGH?=*BMJ6V;8MVMRT,NER,D7FM\K4G M`'R(]LZ$=:]%KRO;>5WUM'J;PD2U(6OJPH,B` M.6LR7K)H#YF5$&HV@S2P0CE'?^9PT0DFS:#U_1A$_L%]!ZUSA4DD9F-;`P;I MB+1'\"4"'@,9$,@D$WC#V#RJCQUM],3)'&*02^<(/";1R(`:$S*]`+P5BF`R MN2`*#!82$TXPD8Y(GR$T$I!D0D(LST01'HUMF-*@=!"%^E")Q&"Q5CCT=W[D MZ8A4(N!WR#+2U0CO9N-+R`H- M^&=HW+3]0O!6D\58VU(#B>E9!!N$9RPD9`6+G<;"K$T>-=EL#4TD1K+!@1>A M65E(Q`HR"+X!$TT$FS`:O$.$33H[@XX";44!('\[UH`0+U7Q-6P6;'6R;Y$T M0&WC8F.T1(%VLAR=T%C*5,77L.&F-]:+N5)(>J+.QK#L1(%Z-KYA,ZF*KV'# MS>\)&^F-.AO#Q1,D09*-[TPL7*W4:H-%P/@9&QXVZ@:;?B]RQ':OC1E/57R- M-KK%SJIXP6NQL1()G&,XY9[-SEC)5,77L-&]=E8W"Z:+3=-%O:F.7Y<`&]Z8 M+H#&/)K_(MV`9Y06G-@LCD3DB&VYS0WU4A5 MSNQ80=80>F[(:,&1\J'"O(^`M^/'%`$3;VU<9T0`6:C@9? M+-VTTP70O]2._]R41=BD9`B0*-!R[:C@E*])1=Y(Y`F\(NV5I*0LF973>PVG M+P1>/[3*FU`"-R%QFW"'`-Q/FNQ*?L_::U$SJR07Z.HY&]CWK;S*R)>.-N*X M?*(=W$S$WQM<.0F&UL MI%;9CILP%'VOU']`?A]VR*(DU20P;:56JJHNSPYQ$FL`(]N93/^^UQ@8[*2S MJ'F(X?KHL#UD4/J@NUH?5BBGS_N;J;($1+7.URR MFBS1'R+0A]7[=XLSX_?B2(AT@*$62W24LIE[GBB.I,+"90VI86;/>(4EO/*# M)QI.\*YUJDHO]/W4JS"MD6:8\]=PL/V>%B1CQ:DBM=0DG)18@GYQI(WHV:KB M-705YO>GYJ9@50,46UI2^::=,X.Q=>-^U!?C&G1W9XU,IO[/S)T(/1PG53I1+ MP4I8"?Z=BJH6@,CQ8SN>Z4X>ERA*W63B1T&8(&=+A+RCRAH.Y%AUE?8M+4A&QZB"J^XLUZPQ-O8+KD/4*U&&@?`H`"CP+H=2JK MTMDOL-8&(!F$A^8"FTM$.C$AV27$(LDO$2,20S>TU$AWF_@X&?*L9J'O1W*# M=&JJ66L,--404F(B-B\BLA<1^7,((R`0,@JH+X2R+A&D91`93"R9:XT9!Q(E MOA7*-8S5(MDUC,637\,\\1@!P>=P)2!EM0.RVGNM,;.P_4!\=SI+_?'/:IJ- M!9^%\1CMQV8J,@O^`GMNP?_-;@2?7@U>6>W@[;;4F#YX4_OFN&;^\AN[9H;#Q#4*YOM!?A.9D6>&PRM6R`V' MYU&&H03T MY"-O'82^/N@CJB+\0#:D+(53L%,-.T@$F@;K<&NY#=4^;]G7P1R.F4M[!K>< MUNX-#G#Y:/"!?,7\0&OAE&0/2_GN!+X`B1Y M^O;S>FG]\*,X"&_/;:73:[?\VR$\!K>WY_9??QI?OK9;<>+=CMXEO/G/[7_] MN/WMY???GC["Z'M\]OVDQ11N\7/[G"3W:;<;'\[^U8L[X=V_L913&%V]A/V, MWKKQ/?*]8YKI>NGV>[U1]^H%M[90F$:/:(2G4W#PM?#P?O5OB1")_(N7L/K' MY^`>YVK7PR-R5R_Z_G[_<@BO=R;Q&ER"Y-]4M-VZ'J;6VRV,O-<+:_=/9>`= MGI,/DNJ*B^M^!Q^F%%P7`ZK2'[9;KWZ<&`'/VVX=WN,DO/XC((677HCT,Q'V/Q-1AIU!?SC^^G]4U+PJ MO+59,9..,NB-_D=5E*)!DT+E\19U1>^DO:IYB??R%(4?+695IAK?/6Y\9:HP MY:P_LTXI>I@-]('C?W`^S<7Z+F;1'R]JO__4_<&&[)`Q,YE1JL1<$.-VJU`9 MC:J(EB-\.'C)>A[XS$-4C9S(LYAYX#,++6:1(WD>*P]\YB'%+',BS[(2`>$< M7M5U'OC44/N#:OLV.9.KV+EL0Z9MSN29'*JRRP,-*BY5V9<"7>:+PAS,]I(Y MU%[A!9Y,O:!6FSD33'FDB5OFL@HA-)D8C:O%Z#)"1`R9H"*FC!"1A4Q0$4M& MB,A2)JC(2D:(R%HFU/[7:J=L9(:HV)#8RH2JD@O"D1E2SDXF5)4XQ949HK)O M(BJ^91-NDV]Y,O=M?A7-1&!U1Y@]`<8XP'&K&/(A+EX@+$> M8)8/,*LZAER2ZSIF4NW#S0.,7<.HO:K.MHXA[G$>8'9U#)FXW0>8?1WSZ9^* M5P?-7N7)SVWF_.).J:IDY&>"89\%\UE6>N^<"V*4WJ^'O?2OVH,:U-"AA@$U MS+*&(BI2K<<":EA08PDU5F4-M:X>:ZBQ@80-B2TD'$CL(.%"8M]$5-S*'IV; M9E:>3-U*YH698%B)OW2K((1;E<%X,NF1ZUV#&CK4,*"&"8D%)"Q(+"&Q$D36 M'[U)GQFV>M6LH<8&$C8DMI!P(+&#A`N)?1-1<>NHQJV#8?'\RI.I6\DSU$PP M36Z%A`8)7294E=PK#9DAL[P)B04D+)F0:K*4&5*3%236D-A`PH;$%A(.)':0 M<"&Q;R(JCF4O2N7Y-7_KYF'BU`&9`V:"$;-$7^63!"'F9:(.T,H`FW0E!;T, MU"D89:!.P2P#;.E,+F-1)I1^33NL,E&KL2P3M1HK031X#`=I[+"&BS3V!"A61JH^Y7L'=3X5>PI5 MGY*NF"D":O0I1#2LHF/$P(B9(0T^A96UD,82UV.%D35&-K0F9'!LFB[[%+;6 M01H[7$\7:>PI4)H^JE;EFP=U5A6;"JPUQ<*I.J!;`8J`&JT*$0VKZ!@Q,&)F M2(-5864MI+'$]5AA9(V1#4;L#"D:K))[XA9K.$ACAS5 MIZ]7="M`$5"C6R&B814=(P9&S`PI!J_4)^DVVP)K6$ACB356&%EC9(,1&R-; MC#@8V6'$Q<@^0^K&ISK#\@V$NAE6;"Q49UBZ(<`.F\&'5HAH6$7'B($1$R,+ MC%@866)DA9$U1C88L3&RQ8B#D1U&7(SP\Y+<4K_VK3@-*<[M7?WHS9_[ETO< M.H3O-_8L,&;O(T54G,*<]:?L4`L[WT+B?"N7Q;E$A=E;S[KWY&R]Z"VYQZ^*?6%-ZG3'KBT@< MZQ0_DO">GC%[#1-V2C/]>F;';WUVSJ[78?`I#)/\!R^@.-#[\A\```#__P,` M4$L#!!0`!@`(````(0!WW=,S0`,``($*```9````>&PO=V]R:W-H965T\)&$?"BD:@+=*FW2-.WCV0$3K`)& MMM.T_W[7.#`,%?0E@>MSC\^Y]L7>W;\6N?5"N*"L#)`[O MQ[LULH3$98)S5I(`O1&![O>?/^VNC#^+C!!I`4,I`I1)66UM6\09*;"8L8J4 M,)(R7F`)K_QLBXH3G-1)16Y[CN/;!:8ET@Q;_A$.EJ8T)B&++P4II2;A),<2 M](N,5J)A*^*/T!68/U^JNY@5%5"<:$[E6TV*K"+>/IU+QO$I!]^O[@+'#7?] M,J`O:,R98*F<`9VMA0X];^R-#4S[74+!@2J[Q4D:H`=W&VV0O=_5]?E#R55T MGBV1L>L73I-OM"10;%@FM0`GQIX5]"E1(4BV!]F/]0+\X%9"4GS)Y4]V_4KH M.9.PVDN5$K,<9H)?JZ!J"X!S_%K_7VDBLP#-_=ERYZ`.46%U5YS MM\!\LW#3T9J"TL8*_:#@`5HA"^0*B+[L%^YJ9[]`E>(;YC#$^+X).38052K% M&S:!_[RNF1(U"+4@H+TU`&7I&&ATJJC2V4QPT`$@:85[Y@3'(<+O.0N'D!Y) M-$1T2`S=&ULG-M; MZF0>D%I_]F M\A"3Q8_%;=$-+3S\]6N_Z_W,3L4V/SSVM<&HW\L.F_QE>WA[[/_GW]:W6;]7 MG->'E_4N/V2/_;^SHO_7TY]_/'SFIQ_%>Y:=>RS#H7CLOY_/Q_EP6&S>L_VZ M&.3'[,"FO.:G_?K,_CV]#8OC*5N_E#/M=T-]-)H.]^OMH2\RS$^WY,A?7[>; M;)5O/O;9X2R2G++=^LS6OWC?'HLZVWYS2[K]^O3CX_AMD^^/+,7S=K<]_UTF M[??VF[G[=LA/Z^<=V^Y?FK'>U+G+?UKI]]O-*2_RU_.`I1N*%6UO\_WP?L@R M/3V\;-D6\-W>.V6OC_WOVCS5M?[PZ:'<0?_=9I]%X^]>\9Y_VJ?M2[`]9&QO ML^/$C\!SGO_@U'WA(3;SL#6W51Z!Y-1[R5[7'[OSO_)/)]N^O9_9X9[P63;Y MCBV)_>[MM[P&V*:O?Y6?G]N7\_MC?SP=3.Y&8TV?]'O/67&VMGS>?F_S49SS M_?\$*E?]DD2ODK#/*HDV&1CZY&[VE2SC*@O[K+.PA#>N@E'-S#XO,P_TV42; M3+^P(6R3R[W!/JLL^FB@&:.OY)A6.=AGG6/Z]36YJ[*PSRK+6/_R<6%G<[DY M[+-.\AO'Y;[*PC[K+..O;Y#&:EA4&B]F447Z;^P8[5*Q[(]Z?;Z^:[2Z9OD? M=9K?V#E:7;7\CSK/[^R>NH"UQA&_^4P&4?_98$\OV47%< M\P9;F_/,53M0G0G?,%B_Y\,O3QP_`G:VHVE5D(PWY? MC":+92UX<\/3KFC`%('FMG4[E MS8UK4J]J4@>N\Y"M2VO!9AFR0W4Y7JP8F\>K/BP\S`]+O81%';@N09=7:MDA M9O>R6748LFVF(&QU+P>;+,B"PH;"@<*%PH/"AR*`(H0B@B)NB^F=?&22-B&[ M/6V+1A*IIEC#U*RIL@T8CRZG/)\LU18-+&E@10.F"#2KQ-`->9.L+C.1C=UE M2$4Z78;L/K?+S.1E>5V&G"#^#2:XP80WF*C#C$?R.L3=AT8!-`PX-N#3@T8!?!ZXMF*&3F@JZ#*FI ML,N0FHIJ4[?3,0TD-)`V`M)^9Y>@S?U.SUH^F5VK-]IE8TPZF84P;`&7MIN< M;TLH5E"84%A0V%`X4+A0>%#X4`10A%!$4,10)%"D*B%5&KM1:59:?8;S\&.? M=3.7ZC'&I!-:"*.J,"A64)A06%#84#A0N%!X4/A0!%"$4$1"S,0%_(C]D'ZD M.9U,2YK39NUYT^9T-JK3R"U5%;NV;U85;;_X9+FZQHU,Y5W#0IA[O=R,T6!& M6R\Q75%]*RA,*"PH;"@<*%PH/"A\*`(H0B@B*&(H$BA2E9#JC(]8TCO&=.FK6*J*KM0OA@ M()G?O$R\7B22M;`PL3%Q,'$Q\3#Q,0DP"3&),(DQ23!)E42N.CXJJ>A+^=`[ M:>'T>W(KO:B0J#JCHRNM@++FQ((4Q,19+$QL3!Q,7$P\3'Q,`DQ"3"),8DP2 M3%(ED2N/CV:J*D^,=C9O1L>CUO<2`HG**^]<2'.UY-_UL`(60IN4_:_<(JXJ MHBP]D45!+)S%QL3!Q,7$P\3'),`DQ"3"),8DP215$KGT^%AHH_3JX0_^?1YI M[(QQJ^0$NMRBCLBMQ;+*HJB5%28F)A8F-B8.)BXF7D6JO:(-C'OYQ_Q&+HM] MG#3`),0DPB3&),$D51*Y`%EQ=!8@C\O7>,:8?*FRT`2ZMFAR<[:LIBOK3Z10 M$!-GL3"Q,7$P<3'Q*B)VBLZ:>7FG^#A%@$F(281)C$F"2:HD&NYDX, M%S=[6&-,KN47[`FB:__)QNO(CEU6TQ6EM,+$Q,3"Q,;$P<3%Q*N(J#9^34&K M33407PYT!G@I(281)C$F"2:IDLC5Q@>+NZI-#"++U=:ZDQ!(44U+#9(5)B8F M%B9V1:[7`N1BP6D!T@NZ+4"N)CR\%GXK!SF'@Q8@JQFV`%G-"*]%C$F"2:HD M*N.A/#R'*=D2]V%_RY*-;1*NL,DA7.8F)B86)CXF#B8N)5I.I&.VZ6 M?)PDP"3$),(DQB3!)%42N>3XL'%7R8GA9+GDR',""TTUYESV"4M,5IB8%:D: M)7UP-VE=?%NRF0QT^7I]UIK#Q@MV,'$Q\3#Q,0DP"3&),(DQ23!)E42N03Z@ MW%6#8J!9KD'R;--"$^C:7Y'^=UD!1;NXPL3$Q,+$QL3!Q,7$P\3'),`DQ"3" M),8DP215$JGB=/+%1#U:4L;)S:I!KH07%:IN5CLZE&4E5"6'B8F)A8F-B8.) MBXF'B8])@$F(281)C$F"2:HDH-AG MI[=LF>UV16^3?QS84W!W[`F12_3R'M=W@S^63^*F-F>O$K3CD39GKPNTXPE[ M'ZPKOM#GBZ[\2WW.'K!MYUGI<_:<+8L/+RO$WO8ZKM^R<'UZVQZ*WBY[99LR M8E>"_=Y)O!@F_CGGQ_)]D>?\S-[S*O]\9R_P9>S!W-&`X=<\/]?_\`7P%]+* M%TZ>_@$``/__`P!02P,$%``&``@````A`)$.9Y1Y`@``MP4``!D```!X;"]W M;W)K&ULC%1-;^,@$+VOM/\!<:^_XB1M9+M*M^IN MI5UIM=J/,\'81C%@`6G:?[\#)#1)>V@.CAD>[\T;9ES=/HL1/3%MN)(USI,, M(R:I:KGL:_SG]\/5-4;&$MF244E6XQ=F\&WS^5.U5WIK!L8L`@9I:CQ8.ZW2 MU-"!"6(2-3$).YW2@EA8ZCXUDV:D]8?$F!99MD@%X1('AI7^"(?J.D[9O:([ MP:0-))J-Q$+^9N"3.;()^A$Z0?1V-UU1)2:@V/"1VQ=/BI&@J\=>*DTV(_A^ MSDM"C]Q^\89><*J549U-@"X-B;[U?)/>I,#45"T'!Z[L2+.NQNM\=;?`:5/Y M^OSE;&].WI$9U/ZKYNUW+AD4&Z[)7+9+[,9GDQQVC#C'W@ M[BQ&=&>L$O\"*#]0!9+B0`+_!Y)\GI3%?'G]`98T9.2=W!-+FDJK/8+N`$TS M$==K^0J8#Q8.>4134%KJT&L'K_$2(TC70/2I*$9,'A$I MR$9MT#O1/DJXJ)-P972:=R%PRO>J>,8W.^/S7F993-WM0N%/TBH6\YA8D`J8 M\@3SBCB3`L@[J;MHC2'?Z+PL9Q<2`7,J499EQ)R)0&^\(^*BER*O608?`7/M M+RC/W.]]A<69PF7%W.ZETB(2!:6`.;>SC)A@)PQ0:#O!=,^^L'$TB*J=]%W? M5#$:YW9=^-&+&S!.$^G9#Z)[+@T:60='LV0)3G68O+"P:O)-O5$6!LF_#O"! M9-!(60+@3BE[7+C9CI_&PO=V]R:W-H965T&ULC%C;CJ,X$'U?:?\! M\=X!FWN49-0PZMV1=J35:B_/-'$2U`$BH#LS?[]EE\$7Z)YYF>FXCJM.77P, M[#Y]:Z[.&^N'NFOW+MGXKL/:JCO6[7GO_O/WTT/J.L-8ML?RVK5L[WYG@_OI M\.LONWO7OPP7QD8'/+3#WKV,XVWK>4-U84TY;+H;:\%RZOJF'.%G?_:&6\_* MH]C47#WJ^['7E'7KHH=M_S,^NM.IKMCGKGIM6#NBDYY=RQ'X#Y?Z-DS>FNIG MW#5E__)Z>ZBZY@8NGNMK/7X73EVGJ;9?SFW7E\]7R/L;"L(0->=J=GI[W[2+9%X+O>82<*]&_-[H/VMS-< MNOMO?7W\HVX95!OZQ#OPW'4O'/KER)=@L[?8_20Z\&?O'-FI?+V.?W7WWUE] MOHS0[HAOJ;HK1()_G:;F,P"IE]_$__?Z.%[V;A!OHL0/"(U.8I0,F`.S<^.YU6*A M_&"M$1(+%B3*TF".(^R%84]\HK(P>,0&CZD3?-6,'_BF_QPA,GZ2V.$-,\W4 M;B,ZS*U6A2DZ7[6B$RLZ0F3TV+?&I$!S*(H3).K,&,'Y/:#.WA2A=)89E1QL2"^+PG9.6K8;FJU9HJZPY0M`]C?6N8GC='OAQJ`ICI$Y`;%=R M%\L6`U4\G#N)D12(GUG5*4R`GU(UN2:''V@?ZI9^$@/KJ.4$,=,8A%JGL1PF M("*9\F!RX4*UG`6"^F5P4!V5]4`,<@AC[9Q)"KH]B@-53Y,!UZT5!BAG!@/5 M4\D`,;(C?J8B2`:3)/(+A`1JNTE@70_)4A`#)262`&*00$`36RL*Z40"XE`K MDLEA117UZQ`U#=*9Q3E0PR6Y(`88S1C5FZ3HIE4R=# MZ]3E$H/YDSA>'`H30$*M@B8'4R>G>XHN]3&T)CV7&$PRTY+$&DBSI$B(VFX2 MX`JFI,E^2*4H<+I$:=>>B)1+C'XJM:M)LD$_[V!,1ES1%*.Y)"ATNCZ$UKG+ M*6+T*"IM2>0CB,D#W&@\1&5($,%CA_#T2+G=FA-;L"0&FT!3W[I?"M.>:.IN M4C&E8#3\%?<"`/B0BSZ-U971=,NA3,R%8L MB<$8#W!-Q:E%M+`@-`U]=>K,:JPK)UTJ9V3KEL1,U:`VT<(`T"`+E`>3@ZF= M8CA";3:6&AK9"D81@^?W(;%*5KQK-GFL*RA=*FBDJBDG`S%3+%6GMG7LC_7[>!&PO=V]R:W-H965T M&ULC%7;;MLP#'T?L'\P]%[?[=A!DJ)VT:W`!@S#+L^*+<=" M;'1Y2%+6Z?NH[YY%P0=FP1H'K(X<,%:OIL%NC MW[_NKC+D"(F'&G=L(&OT3`2ZWGS^M#HP_B!:0J0##(-8HU;*<>EYHFI)CX7+ M1C*`IV&\QQ*6?.>)D1-5:P?@6)+.RJ?-2ER^FIYOQL8Q]L.\GX*8EP= MN?7B%7U/*\X$:Z0+=)X1^CKGW,L]8-JL:@H9J+([G#1K=!,LRQQYFY6NSQ]* M#F+RWQ$M.WSAM/Y&!P+%AF-2![!E[$%![VME@LW>J]UW^@!^<*#;Z:EJ`<@J`Q)^$(2@C0&S`.OC)DE7WB/4I'J!%`:R0,X)$MJ(\@W$F<0# M'26=<(])_JFN1VA,)`,GTN:3@ON^5-SUXK-K3?)/;\^)77UI#Z M,PT&DFL-ONO'MKM\UVVI2"^J4-Z9BL`.4QA(JE6$L6\^-J:\C+'T0#=?J(KR MSO25F4+2/(OC179FL=2HU^+]*ZJ\,S61G7EA("6*+A#FM&-YPF^AF M")O1U1.^(R7I.N%4;#_`!0GAY$]6,_N+8`GC`&;QS%["FZ#MWLD!HWK$._(= M\QT=A-.1!BA]=P'-R\U4-PO)1CU_MDS"D-9_6WA\"0P:WP5PPY@\+M2[<7K. M-_\```#__P,`4$L#!!0`!@`(````(0"BV#)BUE,``,YO`0`4````>&PO?*<;]_/-__CT^4H^9!-BWPR_G9C9VM[(\G&@\DP'Y]_N_'CR:N'SS:2 M8I:.A^EH,LZ^W;C.BHW_L?_?_]LW13%+>'=[VWL?U/D^]_,]E^\/$I>3`;SRVP\^^;+V?XW7^KO M[K?GR>\GX]E%D;P<#[-A\]?C[&HKV=O>3':W=_::/[X=S/AQI_O'E^-9/KM. MCL;N'(`G^<_7^3A+CF;99?&_FFM]T?R#?_]]=IX7LVDZGB5OTLNL^=07/[Q] M^^[E^^2'MZ]___(X.7ISV'S"KW/(T:?IB/T,LT_)[[+KYG-?;/-_GC[:>;;S MN/G3X7PZY?7D55X,6.(_LG0J:"4OTEE[0P\?[NP^W-MIKN&W\2H?9=/DD!?/ M)]/V'HXOTY$>>)]=3:8S:"@YG%Q>I>/6DP&;R308_;2;'%^DT*Y*W\YEQ'Z!L+G8X&1>343X$%\/DNW24C@<9 MK\%B17)_/D[GPYQ?'B3W?SQ^D=Q[T'S]:)R<7$SF!:Q=;,)ZHZPHDLGL(IM^ MS(LL*:ZR07Z6MSGJ13:(3+/;7/3@^/CER7'SKX=I<9'PG62@?V1_FN"4#SU]I40#\YND/[*_)138:)MIZP=F;SYQ,9C#F\G7>31<]GU M9G(%KF=V$L'RRLB-TPXF14LZO@:K7R7`=7XY'QFE##-D\2!/9Y)H0DIZ*5;] ML_VAN:^EWS34--]P$.F&A#ME]V^OCPZ^.WI]='*$%#QX\R(Y/GE[^#NDXHN7 M[X^_2%[^X<>CD_]H?NOX@IT_G&73R^1T,IU./L(E;?`'`KE*KT50S46`S70. M!V6?4%M%&\6O\_0T'^4SL'\;'([*UYI?="!"G9Z[O2]Y5#(AGPG!A>%J@*KC MD&AH;>?^F\DL2W:V6[S]Q=_^^K>_-C]K@N5B,AJB[($HE#.[_JKYD!="A1-" M5R@*6'6>)?>VMA\ED%]22"Y]G1S,9P`__W,V_"K9?;2]B>[1_W,_%U\G1T4! M4+]*GFYO[O#SLR>/_$]VC"?/-Y\]>K3Y]-EN_.O/9=:OJR+2?0^-_NC)\[@R M)*[O[3W>W'OV-/[UYWYOJPFQ@R%R%EZ"?Z_2?/@P'R/FKG+XN?5DC0O/\D'> M8MF+SS_?YT\W]Q[_OAG'+.Y6\>LMGHDFNX- MN2*-$%+IK?1VM7YN45LJR=^LTN^S)&F%$7&"?G"5OD4*F MJWI9.7N]O8.6+7.$&W2)114I83'.WV=8"/.V[CA$(VO/4MQNSTWT?S^=8'9= M32=G'<(@&XT0]IL)\I[WL76DK8>7^=@\"ADK"[76$59W/@T$;+IFQ/.\WVFC MO,^@YOE@-I_RP62`C#]OG\9#G@=&VO39='*)S2&%--=;BP_I%)Y7L"V5XKN<>[[HH8'CAQJ._?T@IO2/.`;3'J]U?P[;'\S-7V7%ARPGWQ\ MD8_F[.!KE%S^P>S?%@$>#/\X+[QY.IO(:YN@ M)R%&^6Q"<,)?]6]S_.8%,!/%.FFX?.D7%3>EB8"#)1Y+]3?QQ#`[G25G3H'S MQ;.LS;\X.1]RQ;_,/3M-A^ZE!0+C6`;PP]-4AT%!R&EPOM2"YRN26/+;H,*G M8+RK"8RK/9[EGT1-G9+Y\"+%WA?8W._&V15;JXV3X.^4/G0+?N$1[Q)MRHNN M.4'VE8DYM[W\%#'TC3AN;J-)!BOG],M.*/UC0CUX@,E@BIZ`,U+XMD&KH*%.1_EYMQD4D3#-7)0"O`D5V:=L.E`X2K)5C@[" M0XNW4/[B9C:_`0M=$&UB04L,,T"GX]CY>@:V#'U=$3!%J4X)$8_'9D*=R=8G MNMG\\-+WB3@*/MUO'L^OKD;FR2!KI.T10/",7AA/Q@\'BLAU$6!+KKRJ"*GD MPV1.L!\22D[G,Q::&;('-Q1H^3FYM].S].Q#Z9M$OP.(5HQA/!? M?5__O?_F_M;___2__+R'.*/[9 MP$&\(OS.GQXDEQ,%LOY,X"A-QK9[2&*$J"$[QM>6 M`/52"TOS(=YO%IXKX(-,9,M&1BD")B5&>IW,G`PGI)H7/YG2*@KS0W3\(KV$ M&M&;9`FH6Z.KD^1@JMFAP MY8\9BT^N"6_A,DVPS<;._ZF@Q"V=#M)A=HD1R2HS5(A)E"W"X5E(5Q!M+B9R M;B3,BL[C21U?$D\LJJ?Y*9_Q\?C>+!ME5Q?DS?@23LZ'/,,8`]*C_$Q_"D=( M85$B&P3Y].[E%1:48HV&C0M\/0L]ZR>#6I&8B9^.S-Z:HKD$+H^DPHGWCU,, M-LR=*G0)0%\UOQR!EV2*\Q'SJ+\O'!;-D)?2?E\55^F`=."5>&'Z(=O8/Q!9 M^5U,=AI.]="AH]P: M_T*1#`EO0GRI)#O^MK.U($YL7EYW(D-;*^:7EWR`'(VRC3K&V60^90.+/FTO MS:;$>6&)^%3XW'@\!X6GN/:X_J!RG'WD?P^N!R!_*VG(E6Z0G["KF.AQ)):; M2U[FA;Q68^4BQ#&,`BNP3B[P8]A(-@9]&2%?I+K,38S$Z=!8S,`L7E&(0-K7 M#.57Y'<)/C_\@\%""T[G(EQ!9IJ=*]U@ST(*^O$X&P!+"Z/KB9>?!LZR!>.7 MA)TD("7)CE\>2EAM)8?D.N3?YI4$K`/Z9#96W+M49@4:B%RST(V_.IK+PN+- MSK,O.Z*./+<`.Y!@I1Q9583H"XOSNQ)*MKB.].-8&387(3*HDOV;0G=VD!^W MCK>2[P\.WIGL+6$LX:!$`SH;-B&ZKR6NYM-BKJ0.A%B@6KM!Z434S\%X0::/ M]-,I."(/+^"PC3_.QTX&>S;*B!QB$[(=?KR!A(0)80%6DQW`MJN0%W!*3B;- MNIL<.'IWB6$%+0+Y_&X31(WX:-P%)*`'#L#!*/'9^9X<4:K3"KDO0WG$$H`Q M^R2IZ!M.=9G^A+KRI"C-1DF#IW$4P/S26:,``3LN/3LS(25.L/PWAR*Y!D49 M<73[;TH]NN"A,8YW(AT7.4%5H7-'`"5=5WDCPE_X$-](%7B$?IU<3#[RF>FF MHZ[J>]/L3+J8+^(FI56'WLXT)0/+:L+HY(K((XCQ#%TBN`29XD8H\X*8D\F( M%`O$/ONN:,Q$,YG>OA+6V"VCQ64.<403M'K*VSL$AVZHZ66?J#[U!3J#"&Q M7I^ZY8%BXOQO?PV9\UZ?N>N))%9Z?>B6YY$(ZK7NG0^`:S7&'0ILD)M.(B*+ M,D3+>M8)M(J`022+YP<2N^((C'57A0'78<]$O@@6/34/H^2:"IXM-&J6H#%_ M'PUDK*87>'ASITT%RP,LI6OOMI2R\1`5Y-)8>N:]YT?V]A8>=%I;/H1MI\QN M5H2&MPAAGDHAUEMJ5UKU%IO&XEY4F'$[RG14\62(FP3QZ@7D`!,0NU,V&]9T M)7(3+$J,V''F1&$EXNW-3?M1PL\K\P!6_F`60SNN[L0;;SC=M*5J"2P?OC_" MQ-1&NR6WD%GYOJF`C\C>!-4YK!A5Q.%&K&#%-":!L+`J"H*-N0(1X:(2V,-> MKA2,2"%J*ZW2E;JN/O5E0%9IYT!41EL#U=7WK=T4V3D6FY6':!>E]L(Z[DX0 M!)T@*)N'*735S(8H\TWY-42R=$V'O`\VGRI9*HK`3`-GL[33`V$GI58LOXPZ MHK#F%!Y4+($M+LVEV5;_-.2%F7%L$WRP"WJ]2*Q0`T(5=`-AQP-)VU'/"URD*_ER*U"?M MI"M/I/=%^.-)OJG_>#M+@!\ M)XM(M"Q=7U<[4+M]<>9:,GT5"+[W;&LWN82!L)][K?\Y`-'K0[>D MU'N/MQZO\R#URLPM='20>:9P7*&"R<2J"`N:3A9,EN).@U;Q[C^]@%NY-=&< M^P6\`''QELH83\!;L!\O4H*?9NZBLK`01E'\@]G)_)PJ8VE6U4:"<:D]E&3( M1YGR=!&>:H$QC\5@-/[M3)6QY.,VE:.;G"H$)4HC8IY];";-9'J\RDZG:-MK M:S"(BCR8MA7[$`T8X1G+D3L-:9VZ^G\='X>.A\4:ZF"V$MD5=[U>*JB+\`NB M5BN19T^VGJY3GHED+"$E:K1_*.SDR^&-?)2-,=GF$]T0\KWG6X_")IL\@<]' M"LUC_178_?W]K;V?CE!$G(/CZT+-KJ'09./@W;OCC>9:"FIM"H=CY&U=/M1KQ,2_2[O3%W!.&G86IN2V1\O M[M;VX$JXC8INQF>IA2A461*5B_NTR*U]@,^@X<-VR]QRO!.9CM"]QG M^13/!]8MCZ`.9"JV@B/<.(G"AC$+X9(2KGH4N`(FL@W`'X_L42RY4,R8:![* MIH8CE;HH.4'%##HH!"4I;6&_BATJNT&XVY?N6'!2IVQN)X0:O6O&+@!L%1QL M2HF0S9#7K&9M+=8SGK%C=R0)2-Q`2D;^K`@`F_`Y6;^(P5:>)4J*XWR)R'5R$)@!_H9UA1/P`SA^GR(_ MDMUGKF4_4,4KHW?DF&^]OA]<>G7S.N@A9`3*9,FWQ,Z>OG^7C6@UJQ3G(1IG M].`4R='19O+ZG15X-!]R[XO`D%JNI#B*$P7M'5^9CZ:X5$/V2#12$`[%.<_0 M.@B-@I6KDYYWHO2F4^CCJC%F'>CXPV3TP9Q)**92[:N]--A)*#CW62#6()J6 M7Z$!'*\X44H\!/:F!`(Q4FGX<@)S..&3XG*UW8&O7N1S2_/RV>-_Z;7L7:D2 MM+VD5#E'`!!P#)WHA)M0C";"P(:*WA":Y)H0Y*3;3$0U20+RG5F@BI2@*UC" M2$>UDO,(E>`F`Y%$9&U4!R)/WHF"$AL>!^Q*.&LA=03[P!P5C)CB0V`*4RM$ MQ[V=J%\^+UKVM[KA/Z29!`KSD=[D!Y5AJ/_F=7I:=;$PDWW!3JTLEO";+S6M MR'?UA%(5*_.YXF&)!7]P]9?_2L7JU\F_A\K4RJO&J$X%5/\ZE!J7VB1/YD@( MW=4DC*ZX7[?5=V!RKR,&)V)`JICKA\IY$JT5B*E2[5^EB[E5_E.TZ(*52V2A MG:TB(7`]T@]I3IDO=!Q7ESM"_P!EDK+6[FVK1]PG.1+7(%,->I;APV[L"NBI M5HD!"FC=^.PF-MM*OO-IV(C,*D8D?$4W2D\C&:4\N]B[IF8Y<,8S:P2J-"21GLZ>4C%]>43X^O0;A(5K/H^'ESA,A MXT2?J'S!,?*';;5M%8=PNI-3P5J6.68&`V"O82@5WFNMNSG%G[U^A*'Z6>;[3_9?OCT\;\(CEU\(6N`HX*0$LJA*$SV M$E4!\"DE?7(5*/AS!0'5-IF2@H/`@$II-;",307>5:8UN2:N175*FAJVY<44 MBFDC5T2.]O%05.`-+*\=S&+L/`Z>&W6ET;6P\L8F'XL0;K*TG#T64E-E;6CM M0/*#Z@X%<)0C=%5S;9]'N>GLW#:DM]!!5IJB.E4^!CQ@@;;ZP7>@NP#I0U_. M1[[C99\);CY-5)'!)/*-?"VKP=7CK(VG_GKJI`?$)($5HRP(PT!3<[5.(!-= MXX/#F^1B6>:C1%7H"X#D4&=X?G=T^5``T>)H!4+3&KLW:0&X@@@7#,=YP.NA4RL6*^.JC_BT[PI` M'.D$_S;'4/8\\DBNBS;L?+M+:EVPYEU``N)P5%39]XN3`[!DMC+3RSH[8"JWX%2"^4%/K5C M2LI'B<)/6%95.D#]`+3J7VC](ME-X=R,\2.$'*3H"G5QYOI?$/_`!L7Q-7YH M0%Q_6H!7-YN`A3U7]2$=ORT"P%5JB*Z^%29ZC2*A"@G0'B'E+&+0*R4(*UFQ MBH+DTI/ASYK!'FF^TC!5!4<::X M1BBE5VX8&]3@M]_)[G&D<,5Y]0CMJ%8G\#X?X@(KOFENDCKXK@S^,FIQI$.$ M0DN[*I99EB+?`3%E2$GH#ATGFK1R-J).@K?PN-$RKY.IH0"R@W"&)) M'6F/^@<:+:2NL998P92@@RO.M81(9>WL4ZI4CNBR"J#*$[5-"P'&X&`S9+3' MF`MGXG1,&.L,#$EJ`@/TA(_FI-W:>KP))^MK%?W%J$KL]12/BK==,5?H!\8N M:S<#F_2+&T$F7EEK,*0R27!&0M;(CJ`SVU:13<5%?F6"PR"!OHTHJ1GTN.,A MXA^DH!G3,2SG&];$BE<^.OP%+M0902E9FC"MC_'!=98;D"=CK<80J0AQ<%$3 M!'R0OZEY2EJ2N5_G!*]ED,HD@$Q-5,KD/S/V#]]LB9X3#SR=.7C0,B0AO&#@ M^=!6#06D<^@SKNT(GD;G*,Q)Z#BD9((CX2U!Y52\$*?/EOE#S/"U'D^3S]DG M$H526=K,XJ\FYS$TQ, M,_68C4B@.G:SVQM##D+WF]I#[O7,[JP8 MF%+!,#.&RMR2[^?U-<;:E<2,&],JQ<@&*K)RI;',*SI[Q<)4BO,XD!5SCS,&2(2DBI4%A"M2J^%"D1VE?G+ M'_*)G'#PX%U-9&1ESJVD*[HKX-*YP*X)WL#0*PJ`$2QR=)8>(U7@)!G":KE- MAQ`>N"/O6;:'EEJCK&`U>@;/;MHHT7NHTN:^:>^:TN%JB[QA84&6%N\##4S3 MNE&%7,'!AC&N+!0Q@LC=T"$7IPFHHC/43Q$3Z)>`U0=.1,PB5AZ.V=N0+`(4 M\J[+@7*UNEH=5*^50#`Q(2[6.;W-52F+),C4J(G4$HT!-HLEERSW"IW)DS6^ MN&12LHE2@^[89@`%S8.<55-*QY#01RV@O]::#-44'2]#Z"$^L;!5 MQ<*1]]T"_%O_47_J*=4K73VJP+!G?$\[?)"T=Q(_%;OXM(7N/,3;2GX)SZ2< MQ&.:+M1OU,-:3S9WG[FQL$)8_%HX6->A;ID1?+*YX[[0:_'>$.L&09CNYLF^ MI-^!F]SMP&*!2[)N;@Q!%&:#2MB>!89^,)V-`Z,3SJT=S5K+P)M,Z76P6T)- M`8=>Z]X58.8TA-XP']OH]>%;'BC&2\H<4Z_/W/%\736A=0[HM8M;'O;QYN,G MCS5LN=?B=SSBRFB04SS:6]LIS`,K1P[\D[WNV`>TEF;Z)GN=QE[;C)D2<32< ME1+*SE3=">8/%!\G2.7L8MO(FS(`4`C1H*WN(VZ^=#GQHM9*9L`)://^S&>WB/&[@ M,E]Z[!P/(@(J3"22N]2R7X;S5M:@1+J);UR8W078OPE3'*H2'W+@*XMP9=75 MR0&S/UZCL8`X!#6S>LPT6A"L5E)6%I0H@W\I<&89NI;Q?2R;^Z'S>\3881JK MTXTQ@+?_@M047R7S)D15GTS>^Y&3ATIC^(M7_'S7=V'TY2)FE+V\_]*-G5N/ M2=52^OF=W8-%,$S><<^(G[0IF]W[(UUF.TCMYXLLL*P?)F_'%'=29/Q:YAYGI&3R=O+\KW78!.M%8$"SG&IL@"JFY./C&YO'(MHO980*M%Z(73=$D1J;$I'\* MKD"'L"2M!Z24;.N$14_"9FU'/CA8VB0:O6_/\W5V'..,VDT+Z5TXN+49B0FY M9@.LS'FNXD1FU?5:^*[DNBIW=KV.6=`;O4!V2^KZQ3RRBM@@E@DWPY>K..#> M[OI\,#_SN!9I<5*E%JA$#DJTK);)?LLDNB:O9A7D^'R-LCR08U":L:E+>E-Z MNG"^4F`_`JZ6%O:ZVM0?,5EE]Y2KV-WF9J:]W?`JBUCP.+>1:$ZEAI6(B5?X M&[/@D,(OJA8_T6EEROZMT@E\3"'?;#9S@Z]-N[OI7Z[\7I6FIY,Q]@(?PX"- M%JUEYE:D;W\QB;CZB!3W;3U]O@D)]J+LNRI?3V+4T)%\JM0&BQR=_=9!<%V^ MNHSW;GLT&*.N])D1I'6JLQTL,$9W=OH9HQMX93LFKS<>*/=%S\[-AJBY#NET7D_-JZ_<2_ M51KO@VI\O"Q/%\*BU6O>8"_ZN:4ELK/Y>(VRT1,G@FH59]G[)V*#T#FO@*&:BA;2R[@4/G?^^9> M>HZFT0_BNY_[)>T!J]!TZHL5O2\7>REJQ%I.Y',7IFTEE?C,*A"_7M>F#(<% M%R$JKQ@(4SI_]4[JKAS4M3FI=S%LO#"O4<)O*WWFCJ87F%;D+4YDZ/7-6ZOK[>>[4G.]%K_C@8+/ MT=.6])B5ZO-MZ3X>C249,T!+K$K*Y\ER)*GL-=1DPTR5UHR:D3O;RJ\\L,K# MX`11FV)#U=W%O)3A2$^:!D-MV4/@B3BW3Y!999,,Y4:K8IHH:BF;LV`PQ)"K M&\H[OT,RPIG3<32%.-U/-K;*-0J=Z#:B)E0U@GR\%\IN2P_K(02UIE2*]FK@ MQ++VF,-6B<[N.H3>+V"Y>F.J--Y;'GC(`T5O&Z6M M*`[W>'M-,P$T!J6<).J:N<0.80Y*-$C]]$D!Q/BG'_GX>.+F:IAH<_?IT[4) M54%E%:)@;^_IYI/U*H;/Q`U17TO`[VW2'T@]*/_<-8$:_A=Q!ISO2OY4`IIJ MSNRAN^((4=\B05)3?@X/0'>/E:Y1DQ);2+ES:6%W^*02;%EATK!+*$=_(6CV MFQ%H@FM!&+'^MN1:$Y.&HEV:I^=7H(?L8)9SY[A_SZM/,*,GO*8VR;$4;5:^ M7A$?!\1)76EQ<%!L800JK2M5N6N;:2'Y,^0*V7ZO9=G,G=+`#0KWI(T;99WB M9_E9S?-ODG>%[*(UY@=BZ1(:;R^YD);3:DUX#LO*FM)W*[WA1B5C20NA'=[8 MV?A:`S%D7NFZH%B17;,J$MUOYAH7OAO14_CP>$!(48:4&1L$5ZC9YH'+"=T+ M9[BY[V6XR=>@MZR7>J%V@ M_^,OPQ4FUA]TWZRIUHWS\2$ZA6AUZ[IVU)-9N8_XSI#[V.B#&2;7.?=B-+?[ M][_\[]:K[[F[[N&9KOV)[=Y<;I(U7VU=Q%PUKE5]Y(SVP'(5$G&%8O7U%EO_ M)]@#)?(T-@B#FROEZ(37E8Q5@L16)YNAN2K!_W0?D3!=4H1Q2\NZI.M>J]^5 MMQVT_I&+@/<]5X&#BGQY$R__/K;@89T>9ON1O@Z(5VI:$=DJ=Z?M.YN!^([H MIKUYXXO.2Q7K'ZIOR'M?K]61MX#C#N)$KR->H&V/EJK_R3V/O(`N4^]L@;%6 MM#BU6NP?KI3![8Q&_9Z[E?/S8NWSE MNJT-(A9TEVQSW?L[F]L[3S:?MU=X-9F>9;K;KN.5O:<[FT_:KRP`0EOJ-Y=\ MZT5&U0$'>C>]N%QTE/5`2#./2J?15$)':1MJQG"J2CG)%FYD)?3-53[8E)1" M$6A7F"!7@R(ML.EFE5,-!ZHPK54B@NAN5LZ]$$]QZ`0++$.2)-P?_YL\UF06:L&=DR* MU1*Y\C;@@`I1EL"K5Z,[`7G#+F]IO?Q",L&%0"442H%<,1@A0>?T!5.?)VD. M#4;DRJ;Z;Z_W%HO?9)T,J%*%OL+N*\]R(*?BR*]>W'%7@2E=K3'Q)!W4^G'. M'?7P+OP<*^;Y'^AWU]Y`**DA,GT;A1XA9Y\%=X_'3F5DQ!6Q.:B^:ONFWOIG M&[V.>TMAL+OUN->R=X6B^;6WTN-'XY4E6G4NJ"RFU^)WI%W'P+X\R0*%"#H7CRB^6@F-[JXI:.BO._DX ML<%SFG:PFO3#NL[3"(*.LT^X7?[ZZK+H20:&^72,TM!]+[])E;P.6UI9I367 M&Z`%K=.T6_C@5+A0Q>?Q^FJJ3)XZ5\%F@56276O!+L7EZVJ5]\(5['8C MMJU58CO:/[EWW]^<=$L=ND-KZW\Y[GV\N;.F-'B->T_P>M=I0.SM^9S.#9&# M.UI&2LRV\NHF>V-JO:EV5V5B[#U:VXD!&E9%SA7F9;W`]6]2#''2=?KUVVN] M3"5T78EI\[U54!PAT.UX$TBO#W#JNU07,9*^.AZQ7G13J[:1)"3* M&8:YAF0&-<]^JAN)UEX[OB43^MO-*!'LM?H=X2$39\GE%YZUR`FGR(U`B/8A4:$H2<*4545*V0A2Y:/K/N+,>[>VAFWQJ%M M[EL/RZW5.EG*W/&84 M(8]ZK7[',ZZPYSA.\EEL'-"6;>FGLM'SW]+Q7,W]KCSI4;6'QAPZW]OLYKK) M?M@)]H,CO#*G6Q9TE%$=@%71NK5<>+VI.9HB57GG/Z7T62_4W!+QL?*YU^*] M\H+LEU>UL]UJU-[DM0(CE73E8G"^RP`9&'M295*YN ML'@I?O/DZ9C=Y<-;C&Z#ZW7Y`8GMSDX]AY)5\3$-+NL*6/^&HSU+&CI77]RQ M1R'P6\E5DC:"^)<$LYL_8DCI.>FMIO?56Z0!1)LLXC[ZR=B.*9 MNZ4K\SRY;LEE+BMI``45\DNNO.76/%US8(U08:R+D[0^5(%$]?>)F(R5I/;K M+).S:F7F]FZ9;EY3$I:G$%:WC*`7*4XIN"6%D:OH4(SJXY>'R7LU,^\\>E3Q M-X_C.\G!P!JT=I[C`59:N9W6W:@_N.$GEH03G'$S&A%S]/8Y-YO03J)K$(YG MG-S-R\'C9>QC3H:KCFB4@YI2./B#F,$HH5]>?GSE(115EU]AX ME@I0ZF!R:_3>X&8)NFE4$+#1@,;-D'#T/=<]9C:$I3+L13M&6H[R@1641X?? M^GW#RAT7/,G0BSW!+K:A9% MS`TJ6)C<*48_04$%.[7_H?D-(.57W/I2G1H3P,A$7D(^-F-&E_A0B.GDEY=P M7'>34["KC^J_=%VV/A_?#G>^V;NQB\N]+(N*E]PM$;KGRT6.S?K2(O[JKTIR M)8A7*PVM?<'N!_)9*$F]E76;'RA*@:SM"O==ZJT1(S0/M]D=.X.^@ M$1`_;I#Z*C!*C#S>^=EK_;LRZ:KPRD'BK>YK.4AP%?T@;X(U9:&SJI>Y^D_6 M0I]+M?SCI<,=BO%6P\7K%N+FE6/K%.C6\\853,KIV?1NK.!ZD'>]# MZ+7^KYA'UYJ/LZ`4P,#F4I/VJD3/?P%^6E/"OLY/BSI%VA/Q3=5&Y\V"N=XK M<,Z'^44N$&_>!'G6,7%DN5;F,P`PV]7$^Y43+YG>LE5L?#6OP4CB!@G;J'; M0'U;'503AI/464,6T2A3XD$("W<_AME>C!+):!G70]/<&L)U!>D[[G?%11U2 M"2"7F$G;S'YC3@C1C7>$0R;$'"F)TC46>-,NXE&+!;B[CF+5U,$Y_JON7^>HXD@X>%B,SG+/[%,6)BPGL:"C$9( M&N5)B&Z`YAF&0CR-LQGG*/'.WXTIRD_4PLXD9=3#3/1.)K[`B;1JLH> M'1W8+=M*XS@J=W-T>3FF"EVKO;V_$2'T3A,BF`_=;DJ\]ZPBDN`.=W-F7-:F M*?-,]!X4JR`6,>&.;P,Y4LOP!A^-Q4[M;)8^'(\9;/P\N M675F%ZIHGQ>,9R'KQ`61I`A;X4'5P33/$]ZR-NEXN[*5KA#@;`QU`^D=),:5YKB0MW;J2`^ M*.MR#$GM9Q\T;FQLDP@9:S6.$=2Z9IUI5SE!(6[P87:_BZ@.1FE."-'@`@#\ M)K4W;X-HZNPT%I3@B]Y(A\&I9PJ!"PD2_LM;;GZB& M,&-?D#L0,UEH4MN0<"`RB3R,,+!E*.TY%5)NU.T]U@7H-`'VQFC^JG;':-;Z"9T( M7ETWLFLG/V1(:HTJ>IV>UC2]`U\Z')HZ:P)(%X%;2V(5G1H[RZF,%CT)5D_+ M$/GT6G3)S>-.]E6W;]WD]YY7U!A0;.@I:;8(HW)`C$[K[]836Q1SNYU>P-6] M(V,))2!&Q<0ED!Y@QB![1A(O%+<@006&FED_C+"_DL2S,VQE!:09V^H^?.=9<%QFR;#+U*4AJ,83Y88-`@SR+:2M.S M%WC MM?WEXZ]>ZT9O4[4E>-`>""L%#0?Q-L+6JCN,GO)M"E%`[M]__OQIZ\E'FT]# M\W[ER<>;CQX]:3[+;+O&G[KARI5W<6=H/#-D^(L,^`QE,CT7::2?3(40_H3L MS8472WB-6#DM?%:A4JM<=55@*@&H^=0BHQ0?HT]) M\CA8`.'L3#N\A@/G=9D%+;!*&&`AFC#BY]<51Z/VS*8>\I:1CW;>*`;"6+?B M(@->3M6$^6Y(43_@S3XMEQKW3AI,\(ZRKC5DLFO_K8<6GJ+UY(O,9WH96#9K MD-7^87J%CF+XN&5XF[^>6$M4!3'-!X[&#.%%2BCU7M=CYGZ2!><6')0Q1(!Y MA]7B#[\8[5*HA\YN?5D2T0N4FHKDD_L;AR]?X,J5E%EDY](M-UHD@CGOUG=9 M]73T`%P.BT/_\J0@'9%/<.8-1.Z7X&,-_C37_+SD%#\D)/YMCC#3*#FP``>3 M>2+"')5#SU=.Y]?X2U1;I%)EMO.H>C7/>*^Y21P767Z\*H97!EX;PQ\K(M=0 M:'==ER@2"5'5Z5TR;*+NR=A&SYDL8&L+-"!5;9T&07UKJG60O<+NTLI6P')+ MN+G=BLPJ,'0VV#G5QKIB$%!5;L-Q1\07P/T+=&,X"%(9(Q[HFR4>VN$?AV*\ M",_2E'$[OTRY=V%^F5P1MC+"#$8_>SZ;$Q:3=W,MBO+FM8&]ML/JT5I"[2AZ MM40L-`90*RZ[]W:A%N+>7F>C!$=9D1&L-,>#LBX^WQ#3#G#U^@QD=:=J!M%H MKP_=,I3;%L&]OG+GXX#K7A^ZY7&@N*8HZWEETR&SM/LM9/;HFRG]&][K?\K1EGTOC_O0?8[L"-+FYF?2-_.A,)[ MU;O%[,6ARUZX794&:.=#"V7P;+_V?&.Q;NE<>X/;,UT2I?ZJG-KNMU^XW`L( M1[>L.F?K"L9"?<+G16#W\?Z19U-WGZAN\U2B@55B#*DT3"H?49!+6/$%8QRP M%Q)N*V[6+%C-H[GS04ZH%2V2-]G'Y#VML>.-+_>_.4O)@EYK%NVW&SOZPY<6 M1)GMKUL'UH63,U2G-?$3,!X-56-F4F:$4KT7[\HT.ZPK2[#B#:*',#P+A:HM M\%TI!Y!\X(,A9Q],8+ZFM/WAJ[>&`Q=JCLTY<:4^&VYEE3WKKF2_+]U^;]YW MI*H>)82=HK1UK%`TT#X7U:8"\R%:1PF(&UA[U1P4,&&$P]_^NDO,5F?H]94[JALKB4``_Y'2F;(FL:I\".?&?RN->'?L9)UMN,@D:/MSK6>'45QS/^[[7PKQ5!)?X M6#*+D/P=K+I<0O\*6/4WXY%M1XMR'231C)W$;T;C:;'A\R[4@,4BS9M$NIGH MF`RG&9=!(L05CVE6-U$@3!FY$FB8IZ&2RXQ9BK`P;,G"GIC1L-SB4+&3+E!D M'2SS#Y.1U9D.R`'GNDY\8+DK5 M7NBN]LH,`AF'-^'^05D8"Q*5&D<0`4#R]Y;DP2'Z7<8U8X/D%<7(@#T=,2K/ M(5$9=4`/>BB7<=EYZE$M(%0BRZ.(C6L[+9R/<'DL*QL1N$(LW>,.\#6:#HP^ MZ4!4,IP8-09WL5KE6"U/I#`J5$[4ICGA'%K/0^/9^9CJ?TV%J'BYXE5?7/FO MZ>75U\F_AYI#'/)0B.O:"YQ77ODSA(3#IQJ_.,&S@Q9"73RLU$,T.9^L(T(C MVL`YMM*K5;`GG0-/UHEY\<0IU2)V0RZV<$4FN9(K#6JXB34=8L0U7A!J!J8K M,J,H)BXO:8S@I*5!;0\U^[B<--H%\T[B%,FD6B6:IO"L*YFY02QL)=\Q.0(% M0E69)\4J.2EP)"%L,<0AV!YV4C#D;*8F)KRI(*UPT'5KXWTKJ M5`)E-A5Y$.U$/O'@>D#AX%;R/85I3D2A+2S!U!QC6WO#U)U04.Y#TUN!^6@P M)["DDJI+)HI,@!J0DP:2"P3JEB$*UJ=J7JH6K5L?!$59=Y11JDAZRR`[S41Z MY"(-<3\]D6(T47[.^F'X)A&RV&/K*DQ3RH3('$]5O`5N7*.'MA=>[CP1TE_` M(4LC?R\2F9'VSQ$-J^!]&T6Y[EA-A6N!#I$5DZ2`4S^\RJ>4,1Y0(S6TJF[_ MYYOD@48@PCA=2SBN<8.32C,*/SRBSTAM%>"%DM9S68"9LZLYP?9Z3K#0!D(2 M65EKQ3[YVM`2CO.6O![;WT7FY#S]=46*\/UO9VU7=,23_-U M%-J_!G2N;X1=!(#3,*M@W7OK&YY=GH861:0XY@S%MI@BDX&%0-5UA]_LW"`X MW54.[AKG=V^L.[]X]\O&_WGZ@'KGO@ M.")G?`PR^.YIV*Q45V'@;><;OTVNAYI73CX%#_KW\>;=PNR,63TNNTB%K[:Z M![CJ%S^K4'9+/\T^3E/"VS(8*1(M\P491" MG/M5HDZZK5J`[=4'+,0.Y<2>^WLY$X5'5$\`!CZ]\"BPAT:Z29$2_(N`46W)YE)`!_+3J[]=3C];P&\%FZ:5/-2)@P,ZU$>R`ZJ,@6&C?UF`;_R6-YMK_85S:QJ*@/IMHBSJA9L-12$`-'D"!2(O.`0N1F5JYZ,#-8XY<=4J(B192)7,VOW@>$A[2&T M70MIR76M+=YZL$;'F'G2"[$0Y\L;55FJWQ[8ET.+F@NCL5T6R\0#$8Z(T`I4 M%/.R.UYN4E&PNRSC9B1N(*Q:,Z2P-.::N6`YD)A!2&91@HJA5W\QG5@Y"15L M(.%?H5NP`QW?1RRFJN>2?E/ALWSR-*'QS\"A96SOXK%5\HI[?AUSN>=RK\!3 M,=^XAU"4SR+(SUB66+02;AR-5+?#[D/S5@@E__(N;D3_JY7H`GOJ92/D3PCT M1RF'"`8[BX5U]606E$^Y5%5ZCFK87<(5K2:5)?:$[E-);]B>WT1[.Z&#B:M- M%RS:\.)=R4'";OL4TV67L`GG@*JBJ#J:$EGJQ)(+`X`<*O"XZ6;'`*]K7(@R M$!*'C3HO__-?_^VRMMJUBQ%*'U(^90#!D,I!W1$XX7R$UPX,X@\37L6K[9#R M9?S_3+KIDA;>B($-V)6-J=HB*M-N8@H=Y4HI41 M$V#MVN(\GU1KZ1+_,:Z&4$0EBN-\/(R2E+@9F7=\:#U-^J'`(P@L/"&M@JPO M^#;%TRA@K,W'RI6-G2$"%,;$)K1(AL;J/N?35+3F,C;HBYU-%#_)2IE>3U0\ M,@MPDG%H%=X,:AEFV],#U:YTMRG+J(J35BRIKK%+5=I/X#8P<9W*;-37NB7^ MDZTDA+)J2%PR?U;P';7B`=!1P@<"B,9#PAGB1-C0M_8V")J'$[6M:1[D$@%, M7@A!R"5`^BWBC;E:YP<0@E7->#1]MGGY^.:W.XL]),"-BA:J$XYG`0[[OR$G M57+'VO65//U5"5U=<*B?%:1*N'L`='Q2O5=U,O0XV2`6JC9N@#!1';PH/SM> M6<'/8U6N3WUDL+7OJ3DJI2I14I.S<%VU4KT`ELL-&XU%$1*%M[]7_P#J;V16 M//F:&H;SJ&"V(MVB42OXS'. M]H+H#8W$OEOT5MT<0)\1P ML4+JPD'3*N%,\J<+0\`2V,TFC+1/4-*7E)H59VW$HK-R;ZFR<`9Q<=L0+J=(F*IJ&>9J4G-XE-P& M7FPZVJ^K@54LTWEE^MDS3J@(_CHG/1GA"(>`YCU:AH>::F?.8*/L@IDCK1SN MPF\5&<\+W5(.-:MQQXU5NZN+A^#_#A=D:IMV9;9"*@5H!?32OUR\5$H=>T&K M,Q=SV&4Q-)*3\*.FQ^36E-"2(R'';[-;WG23#0;/6L&=*P0:H$D&+?,*E"PE MT=K!VSQ-[3`2Q'WCH<5#_*&Y67.H[>":^)LNQ?4,@"]2D9Z1L!JI(FX7\Z>K MAHDTPZ:4^3R@;LAC-VR+>?-7HSF264\(J#Y-2H73:[+$N?_J?6\PSPWW#PEH ML8V/L&M+$(5'(.H-QT"QAO[:Y$?O_F'%\@7P(Q&!RN8#56@GO3O&^$?,Q5<; M;2>1E0D;V#VT2'>H]6UJJG"((GY4OH0?V3MLL6:)/OY<5;6%9$<3N6ZL?H2: M=^+.237;`_PC0NA>N?%#TI,=VH$@52E.LWLBC+AO]07ZA13YU4QKDV-GS;WL M9F4Q?NR/AV)>5K'<-PM9/\]/0SGW*SB<:$P&+)DV`$26KY)N0!R$#EW7KI=+ MU0^^XN;)PT$#!UJSV37'TQGZ?T/,L"\TE*!C&XIFAF3$5AB9_!,UB,6_R3YE MCPZA_)3L+8`>J;(7H;&+0^*L)\U*B- M?II?IV@J`)D+L)NUFM$<5L]J]/?LK;U!,^Q:%BLM!C9?@1Q-?@-:`JJN/7G+ MIP2T3+G[XNNX2T`LYLC+(NJ]Z/VIG>A64$]^P42N(FH5\X2^07/&,9,S6\ M8BWN)]`E,"5"RYH^.K[`S'["92^AR5U?HC>&3A`U4JG!`"T)&TF3,1:P&`ME M/E=+]5I@8@GYL0,',P7$>8806=(5U'9OSZJ"$N@;8(N#%1J03PLR[@)00VZS MJ"AR+0$LC8XI96_$#AOL&^V3!/R`6X*Q[:]J[TE7T@'U!@9%QU,)`IO&TBDN MI>H9M@0Y+=:A='SG+YI2:H>#.?,2JB2ESL4`-H;BES?R3"2TW_M9^)^1YGF3 MANKT8UPR[D_L$/S5+ER_"::BQDN"K79DO'/@8,MLCC! MAFP"8?!H.$P-%R)TX[""R#DOUC"<#4I;8<>-;1G^*C)?V%X=I\*! MPH0N?`U7;$Q#K4"T68'10^_]_*(.._?\@BQ]R!?.ASED8M/3&07%4T4HU`KC MO>"):^S":1$0`VHQ<;P:^82C)N\!G$$2#P MXF.E3EX*23D,=&/-5?S#5/*&VZ4\@K4*@A;F*WMBXC@@3&8YP"@6Z1R_VIU> M^PB(H)CJ-'3S_/F]2N[K\5;>J+015F%,N M<"WA=!!CU*-?5MMRF%J@NA&IA[ZF0\ZR^P219RI]D%P(J`I39L MQH=A?=NMC*0*P`PAI@R9Q*3QK8_A,?P\I`<`H`1[=#/MN.F`26]PI:T(#[BA M3#F&W/\$&NOE[O4<8XFS)Q74*J[;U3E3@&QR[)$L$+S8INFF$7Y2.+)AH1JS4]NI$9Q"R?VL2+TW_Y M-_;.[+F$JSPLJ.OE->BNG4U(HU-O"E,0ZMC&34I7GGF?",-],86HXK9C.=YH MBA=.V)`4;+B%),'\#DW?$&B84EB*LM?&5"]-A7I,5VW5>>0P.BON* M-<#EQ8^E++`!`=&.9M>8L(/F*3YMQJ/PYH-=X)HDAVZ;JH'D=9;7]($9XWIL MA6,37K0>1_T>*5=ZN\>ZCI*AR4K0_ZEQ[BW-G,>T^-K%**+/PAPUVOYTAA+. M=3%KY2JO2U2=6\XKC%B5C@_-7\H-ZFTXL`F=0%CS#.8&*/)8FA8'H!G<-)],I`TA-8QZ/L`[Q M#K&"=B)A-AV/9.FI0'MJ9U+Y=,2D&B,K#VT,*S3N\M3]J1_$],I[KG[[`M=& M-0G74%^ANZ!#CF$(.?!$Y%=UT!`FU)IB'*3\%2,57T?)#;]?O7,],TZK;+4` ME_I%*7FPM8K,,_]=\M#\,^6PR90-EB#W]<]N6_?_7FC;(6'Y:W^$2]>C-6SE7_ M/^5=]82^>^/\CRA3UMM2L5+4Y`1'Z>&KB?YY,[&W!:*2U.I3PG*YN/NH?W[G*+\M[\.MJ82\Y.-B1NJ_*%JN9[-4"(,EA MNCSB`Z'A6UC43#*]$#$OHGFV/O7O]GL7)MX;P^M[U*[^U;";G:M/FKD&,GL_ MVUBAP'>KT$<&I*WTU/\;Y-^T]\SFC_0D"]D)JJL+70"N6"*CD$K$LM8X\)2'M]9OT'\!TL<]\N[Q@K9!W]-;/I(,2]O M5%A^@%\K\OM![QWV4_#P;+.CCF_+)+KWN[/UV\[OU+`T`' MO;<>GCZ1`5=.1%&G_=Z!N]K"K5>P)75I/Z8M'99?GN-0(S%K0#V^&`,YPV/6 M^^7MM5Q-_U&.?QM2RSI_#]WR9&Y(5RVG_V%=C;-[%/9^?ZWPJQ:J MZFRELF8F0-95HBYW]2/RVMHAKX2?\)_@&9*-Z>@FOS68V.I0*&?[$-KGZ>&O MR:68\EZ%-SYN1LB]=4S!**J=X&R[L M]X#347B7@`)631<*EWDASGN#_@$G-.M(A2?+HX9TR#Q=$<@H4<1>:Y3#@V_- ME`Q%NI]1F)Q@,O[B"^\MBDS,3BR:1VLD^P\?ZYU\>K@%@<2?T8UFZ)),%UZG M='"'WB]&>:?435LTZ.X8'R49X\Z$@OE6;CBU9G?KKO-G%%\5BU/D%7^Q.D;S MT!HOKA[AQ(!]^3$8J$'EG].2:AKP$`4=-QA6UW?N=X3#K8*O5]JF MG/NWDTK#M>C8NJW$4I3">_-NEML^:2&,'A$XP5<9JG#[*V[\?I^5HRW@(/<6QL6((08&#)Y\M97+@46\)U540 MPS"JDY@*7.UO'?;5U@CL2FN@Z'E33#,ZT-IK:YQ?D(=(ZV][M-`XW2DAE1&= MDSS/_DSM.\:6JH5,QAC*X=4N$ELF.,LG6'>@5'NV=W%'SZ?;WL5TN,0XZ!9\ MG1K*"0;4]([2%ITCSN$:VYR'B)F*2T+IZ1V%H\Z@O^PK@\:<\EE:##$0RR8H M4>)PK;)@]I#VE#"O_-ZLL;4CCK@WJ-3$UWL]F()L,+0PXM9^EJLB!^6J*<6: M>0X*I<[LMBZ=(GF>M8,7]_D2PSJI1L%)4>E-L87M\X?.V%"VXHR']YGQB$#C M.RP-^$A-SQ5(*N91`O/'%"ET\NOU5P0=Y^;5CR0W M.N?8N%%_GAR?Y)1;:/W\T_7HYJ-6[8<4!7+Y[2QDB)`+LMWY_ZQ'-=KYIMG* M+66`*S]5R[/:3IK?ROWU@$4S2)>+;EKSP2!\^_SQFJ5CN<_OO0/"2R-9DCT8:8CF^%P="ET)C@KQB,J"GDKY;B*C$D>G%O8S93)2"^; MOO\I#W+7%$H5YL)M0&00&!#E6^3J:;F-Q,8B!?MN33>6ZX$H>LQ0;2Q2SK7S M/%!9E]ZP0]-WUSPZR*]V`^%)KW(3IR0KA\/P,AJ]\%EP=7A^?G]`6$ZIG?BW M\2"$#QM*M;*QY_)GP99FU`D:P2I)RXT>%K?RVU3T,&%YWO574(YNQ^/&)BN\ M6'BEA*"UE],UQG&H245C?NG#J*!L_-I"P!7.F675BK>BK5PQ-TPY\1(-IE,L M@JG'C!."#L*>QB%/+L[/RRT%KI`N.[1AQKL#]3QS`L2K4/DJ#*W3ZSRQMG+* M"D:VL[W78%'OCH(G*KCZR$$?OF)] M'I&,EFB6JRA7Z/(,_Z@G1[:QC>*.BJRX-`[:Q=UKS@8&JK^6-I7\OY'A65G" M8-5PT#L@O-&Z,9HB1(BPG-PSMT.E_)( MIQ.]:\<'@^-TXT*GN3-P>\\??DUOLW4S)=NSW($D!"8^[Q3+7^3#F^-SQWF, MW^#8WS!NWF7QF62G,@7XLUWT.@]L_5/H3:\F:Y)7`D?AEO5[G?M:/+ST!)$M M1T/N'1\XJZIOKTO16A.1W.*.SZO*O9T+6/7;4`I7P8E.GRV3H:G"\IIEX+LF M3Y_@T2\+PV_\IEE3O.L3+S]FU3_,6=8USIRW:R#:>?0UW^`@71-4^ZG>8[9$ MG3>Q?2#/=U-,"&=9.@+!> MJKF+O_(8EN/A+5GAWO)7)ZJL]FTYH/K^%<+PFN2O7VTD/_LM?3A"0/,HR`5F?+@3:&Q]8`,C`G=XEHVM)4LK9;8TY MRF]V4G6'\I<0=?Y@[^0VGCODI<"S34H?HR?Z[WP=ZMOUMKV`W3U]?_%U M)ZE5ZSF`\_5`DNJA*%K_2"K+M*%76CS=Q,09ELF8Y$:>+9%_8I92DS?\:;%8 MOOI?`0```/__`P!02P,$%``&``@````A`.*GXT+J#```!'X```T```!X;"]S M='EL97,N>&UL[%W[;]O($?Z]0/\'@FF+'E!'+\J2>Y2';T>JHKI;KV=Y3XLU;_>ZU=S53D&AKLS;,\UE^JS>52_N_WUKVZ.P;-M M?GHTS4`!$>YQJ3X&P>'-8'#=@!-;&LJW@.92E*L[VS?L'U_.- MC0U0GT::L4UDAQ]RXAUKZWM';Q^\!G$#;[^WMF8>Y6*P&("DVQOWY.A.<%2V MWLD-ENHXW:1$W[S?+=5K58E,7GL[`/&[?Y^\X-O?1']>_>'5J^&_OOGV'S^8 MNW_^^/O\=S]^HPX2-40F^*!:YNMAI5CX.I(\B"VXO=E[+C%D#I;@EMN;XR_* M%\.&2!@ADJUG>[X2@$/!E'"+:SAF](NU85L;W\*?[0W'LI^CS6/<$,9`_#O' M`H_@QD&DX;)Z-H@FL6F.,!B;)KB%VN2`209NK+;)^*G`)D;7M%Y7%_X87:$5 MU78)TY6/BQR'772EOB)Z_(?-4M5U*!>CX1!II0[K2=EB/01]%U-V/;V891-] MHL^$6L;$8MYOJ'"BBZ2R1J'^=O;N8G2*5U9F75R&+Y4!F'!B6;0@=2OR>Z;C MZQ)QS`1>K?CW M[J/I6P&*9:2D'A8J(>T!^:!L`J1"3&.ZB@R-Y1?E3AE,)BLZ+4LNUTF#W1<'0*6VYO8,0?F+ZKPPA=ZO%6CS2]6(A6NA8AY=@H6^G^!(L5(?_UL(XC7N2)@ID*D\) M+)RL#E_/%HO%?'0]G\\7VF2D:2')FSBB+7=G/IDX?Q5&4Q[!%!`L)O/%]1B` M#+5YJ.JB""8`8#:=SJ>CQ5B#_\/BV#\"T9Q.5=E>)0@D>94@D.35)0@N[=5D6K6^N]/#A:#\R*Q\?!Q.NF#NN/'\ M'1S/2@[2C'#V&&V[O;'-?0!35-]Z>,2_@7>`?S=>$,#1G]N;G64\>*YAP]M! MLD?RMV)/.#X&A\*6:O!H;3^#,F9-)L(;J>A+0UJ)-!SA:S-M.-.FX^MH$B5( MM6/NK).3MR[571@K0"-R6V\XX=!-E<3AD*T+#M`+L?LX]PA='7J:

(B20D M./<086.V1LYK(]F#ST:R`Z>-9`]>&R%UBI(K87+GG>#0[+F#=7T^'$;+D;QZ MJ@42X`414PR"[)/GLW:7`D9K]VEJ*]277&ZLQO@*1ZP%EM;LD;>S9H<"*VOV MX+61C9O$NXSP=#D!RW,!DC.^F9^W@P&*HAT3/&=%,*Y/N"(='2CA+G?%YM:* M)U:#A([MZHPOT<;4BJ\W)F["T-.WIFU_PB[[]WW:V&']ZO;F:4].DX!S5_#D M`CP+`]_"&FS\-FKBT0<@KFRG<>E.BG$XV,\?3\[&]/7PA)901;A5!SW9IU4X M^L@^O[6M!]\%YC8(3[@)U\C+\$Q*\(QB03QXNNC72O0#3]Q\ M=-$/*SR%3@1>I.J'X.+6+S(>\-2B.*C!!32HJ_"(1`#S^`0!.$$&`CP5*N8` MPE,&`I@?)0@@0#,$`*@N!GM$,'RH`=%)95F)EE1CB=LBTC`+X4$&!#EU73,L;E=5\:820 MH@L8,D:@#%0Q(BXJ2D)6B:089-5(X@I9)9)``$:D5$CJ"5DEDF*052,S5TQD ME4@"05:%))Z8]%PB!W39-%I$)>NGBTFK]5/E:5^[D#HJFS2!WY/=H]E3-',$ M7X1S*3*5'@$X(UD[51X]W_H%)IEX9=H6%E--7\6+%@-K2[?\[!N'>_,)IJ+1 MP:2G??E:+R!)UC?.@Y%%6(HITP\KV:K21+EP?CI@Z4Y$K>7AI+YV8?XL,MC% M[=H(J06!BSNR,2#7,0;A(2`H13!S9=,$35(Z!NHJ:)A\M4('YK#X-*AF/YV. M@;5_;E8_<(KQLA!Q`^JCG`JGH[:8T.C`:(V/2,!F9H3)=A+.Z&BD7'1H=F@D MPKU`*QJ>W$!;?N.6VSU`F_BE5RY:E8R1Z$C)>^?%$!0%2ULXD_-5@ZHLUL-U M_D85OSFZ4M_A:GP5NE5\$*`1OF1\_5+Y:Q7^-"'[<'!;LH1T#)J*X3E=S483 MN&[[(CI8'XZAW+2)[/_G7E<&RU,/[C%36;[8XMIO,0O/L8@G/A1Q=8(63U(Y M!WJMB"5S(PJS)G5X<+)LEX[36Z'&T5"U@BM.\U94!2HWWK9#B+Z3J/EXM3QJ>Z*.UB21<"$*N[)YLV7!TG[UT%[UR`RV[151!5:_XT+H4@JTW9DJI8K9RG)G*1 M]=*KB*8<`;ZBQO=6L&;%'C[E[5<%L2>7'D0B-4"M,O M+C!J:R04PZ*Y`5,CZ\8-K<*T\^R`A0B?J@8+/4/DZ31Y%GE:32O@O(G$!3O' MK'38@.AR,2LF@W(DLJ,O;B^+05.S\L.-AK8=WICC#;19(2P?5 M=>VOE8^Y$9+S&,H1YCB47EBX8.=B4SKLDI0Z&[_EZ&9+D("19^>6?H8XQ[1$ MQ"6ML@XQ3VP(8+YC\:VS0CCO70O)&>!<:+\PVDOJRID5N7!_85:0,E-Z7"YG M`QLZ7`LG[Q0BLO]AI7W)R%9X?& M!\SX$?%D*U>T<>/D\:V(A.1<`*,G&DN@C;<'UL-JGEQ4V_C^Z*S M'O-K#&S];060T_U<^.":BZIJW">^DA$PYV2[>W M75XX&\D`U2R++)R6`UY!X&JX:@F.-N=N"7/&9?]P.Q:@B^!MXGO^WL.&96ES M;J(>LMC3TQ5%@$TI:X":^W1 M&W+U8'\`:Z,-QR;[>'B*;XL&`CG*BOM8:=05@0@O:(1+&,D-X=C;P:47/"KX M&!PX)V#X6^5*>;O%`6TZ17!169D?@3DJ"TQN*BOS(SB.R@*3F\K* M_`@(B2P-E#25E?D1O$!E0;@UE97Z46.YGW)R?UWH1S96\:IH'EQ45N9'-E8G MG+%*965^9&,536Z**_,C2*741U(R?['QK7'&=R0E\Q3((Q9I\`6_ M1:F/)BR[&B>[*V.75%TV8+#/\,"`![QN3S8\8]?#)_2&5_WC[)X8A/=XX9+T M:&X_*VNXB6LJB,T';*,\@NZ>#K;A&H'G/RMXI7\JCG7ZE%/<'STOY8B5,(:/ M/(#^!,\SAD^>$$H8JEF M[S_@DR(@BV%B!N7FPQ&>/@!_E9-O+=7_W*UFBW=W^OAJ/ES-K[2).;U:3%?O MKJ;:>O7NG;X8CH?K_P)E^'CT-_``\@Z/'P\?DPYW,QEI;XXV/*3'F##.:.)$8-C^OCVV_\!``#__P,`4$L#!!0`!@`(````(0#[ M8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW M('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PK MT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7'; MJUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:; MN.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D M#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V MJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^ M\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!& M1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H M`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y% M'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$Z MGBD".S1P1%H$B)Z9B1)?7B? M-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV9 M6\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86 MXX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6 MP'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0S MI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0 MH+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ M25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CL MJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#> M$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<&ULC%;;CILP$'VOU']`?M\`";DJ9+4);%NIE:JJ MEV<'3+`6,+*=S>[?=XR!Q;""S4,2SQP?SYD9S.SO7_+,>B9<4%;XR)TYR")% MQ&):7'STY_?CW0990N(BQADKB(]>B4#WA\^?]C?>1*B+2`H1`^2J4L=[8M MHI3D6,Q820KP)(SG6,*27VQ1V7/'6=DYI@72##O^$0Z6)#0B`8NN M.2FD)N$DPQ+B%RDM1<.61Q^ARS%_NI9W$;3[=BD8Q^<, M=+^X'HX:[FHQH,]IQ)E@B9P!G:T#'6K>VEL;F`[[F(("E7:+D\1'#^XN=!UD M'_95@OY2T+I_%W6A#(-M1)5>#,V)."?HN5"3;;@]V/505^[?27TDDHH]U)MB5@&)\&WE5/5`R`=OU2_-QK+U$>+U6RY=A;N?(FL M,Q'RD:J]R(JN0K+\GP:Y-94FF=>S^6;I+E?3++:.J%(28(D/>\YN M%K0'G"E*K)K-W0%S+:&.HQ4%N8T4^D'!?;1&%H0KP/I\\+S-WGZ&+$4UYCC$ MK%8FY-1`5*H4;]`8WGA=NC]3O3]H=X4<-695-9KJA.K3ZS:-&1$=?(`E'&,Q1*E1 MX.WZ;6XO9>V+Z3\U&C,2Z&D2$4PBPC&$(61K".D_/\H[U6X:,R9H$A%,(L(Q MA"$(!H?W2E.9S=H,+K0:,R:EANA+K^I%LP^#:0XUVJBLOG^,UJ)'%_W"SPF_ MD!/),F%%[%K`+;6`)Z&UMB/3PUR]-7OVH[N#E_;0'J@12]GM=@,,/B6^D!^8 M7V@AK(PD<)0S6\/-Q?6,I!>2E=7X<6821I[J;PJS+(%QP)D!.&%,-@MU0#L= M'_X#``#__P,`4$L#!!0`!@`(````(0"L-H9_8`,``&@*```8````>&PO=V]R M:W-H965T&ULE%9=;YLP%'V?M/^`_-Z`(1]-%%(%JFZ5-FG: MY[,#)K$*F-E.T_[[76-"P)"J>TG@7.W(*Q$)L-*O"<'SS*6T'N> M'`M:*I-$T)PHT"\/K)+G;$7RGG0%$4_'ZB;A104I=BQGZK5.BIPB63WN2R[( M+H=]O^`I2J0FD#YC11-(7.(4=W9,?YDU[Z M""$/2&0-T"3R[YEFZVL6MZ7I7I\I'^JV?1-.2C-RS-5W?OI,V?Z@@&FFER<\ M!RS\.@73QH%ZD1U)\[PK\HH" M#(?\2!WJL*7!XH@:3)<$6]:-1S#7A.C3:M@0;`ZQ[AN*+?='#:8KQ+?\&X]@ MK@G1I]J($'/8=87XUAL0Z2D`G>L)L3P?B5BSTKIY#2#I=YD`4>7,$/?W"A>U3-QQQ7,\/KR M`%]T%":2-P%PQKDZW^C!UGXC;OX!``#__P,`4$L#!!0`!@`(````(0`T/_/A M0P,``#D+```9````>&PO=V]R:W-H965TTT[;_?,0:"(8+>M.'X\6:]$BXH*[;(G3G((D7$8EJ[!V0)B8L89ZP@6_1.!'K< M??ZTN3#^(E)"I`4*A=BB5,IR;=LB2DF.Q8R5I("1A/$<2WCD)UN4G."XFI1G MMN8OY_(N M8GD)$D>:4?E>B2(KC];?3@7C^)B![S?W'D>-=O4PD,]IQ)E@B9R!G*T3'7I> MV2L;E':;F((#M>P6)\D6/;GKT'60O=M4"_27DHOH_+9$RBY?.(V_TX+`:D.= M5`6.C+TH]%NL0C#9'LQ^KBKPDULQ2?`YD[_8Y2NAIU1"N>=J2L0R>!/\M7*J M>@"LX[?J_X7&,MTB?S&;+QW?]>;(.A(AGZF:BZSH+"3+_VG(K:6TB%>+P(Q: MQ/5FWL/4DP!+O-IQ=+&@/>*% M5Y,@70'1UYWOKC;V*ZQ25#-[S2R1U3*+A8D<&D0ME=(-FL!UCFM."1M"%01R M;PW`LO0-^$Z;KQHU\_7FIO#^!F(2AR&Q6)I(,$0\DPB'1$?$<.2/.E*CT#^= MU?4]QWS77C/W':9G^C!)!)-$.$88AB"13HF:5E+1+8)E:=MDZ?=\:.2AZK.> MQ\/(6-`=\]Q^);JC5U4C8_@2;F2LHF;&WJK7IGO-P"M:5_VEGR2"22(<(PPC M"\-(]7EWO@XU.M5+FADS-$D$DT0X1AB&8%NY41D5-2LSZ"6-C/F8)(*&4/N> MZUQ[I]K#PNXHG,1M+QOYJ[/_NM\VWX**FOG[7K^S-#-F8)(()HEPC#",K`PC M_CMKMM`NKU& M%;03?5/1YWM.^(D<2)8)*V+G`K8C#_;1-JIO2'MW#6*!N3M7=IQV` M^TR)3^0'YB=:""LC"4@ZLR5L15Q???2#9&5UX!Z9A)M,]3.%*RJ!4]Z9`9PP M)IL'=9:WE][=?P```/__`P!02P,$%``&``@````A`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`S$-)#20TD`F`Y]#1$X#11<8M$):KZ6=T>J# M3S-C/5Z$^?0U:.O,(]W*EPPOJ^\/R[[.VS$R@$0(B0@2,2022*20R""10Z*` M1&DC--_XQ#[FFPC?3_D8TGNR^>P(K2F^1#;M5/C-<[?,<,I<("2(20B"`10R*!1`J)#!*Y M)&1#WBZX\W0(*J!&:2,TW_A&9.A;NV/PG'Z#(#ZF_I&)S)>,O%]WY9B#72`) MB\,AU(B@1@R)I"/$1H<,ZVGWV>?D0)XS@T0.B0(2I8W0G&-\KVZSKOV<>D>6 M]KZ"I'EM6],[9Z``FW=((\(:,482C*08R3"28Z3`2&E%="/%AG,P=M(^R.2& M=+AN<;=DO^@KR.)3@)%0(;(Y?%NO-^:R)-*9)5N8DU.,BTHPDF(DPTB.D0(C MI171[12;U(&=W50H\C%D+&4.W38HR&JCU+$@H5)1-C)GQ9.B9+R+=,;S%J;5 M,;Z;!",I1C*,Y!@I,%):$=U&L6\>LU'NI_7>2->B3$(6CP*,A".(NR4M)AJ! MR,058R3!2(J1#",Y1@J,E%9$MY%[,+31&%S%Y_HLZ=&^XC,);=UV<^',-J2& M`P58_`Z11H0U8HPD&$DQDF$DQTB!D=**Z$:*W?^@/QI&RNS`L%]Z#LFI^?R; M">&V'!C%_D_\HRL>6YI!I;>Q3*2*LC2)&",)1E*,9!C),5)@I+0BNITB(V"S M4V8,=#M):M-G$I)VBOEKQ$U;YD&Y"54B59#53%A0@E52C&08R3%28*2T(KJ9 M(DU@,U.F$70S:>J-24B:*3:19L^T92.4ET@D4L58K1R*,)%(HK>28)44(QE& M0-8VO((M3`49"C$08 MB3&28"3%2(:1'",%1DHKHIGIDCQ/UR/;N+YR98PN>!1D,Q$CH4*Z>7;)5\AD MU13U*B.YM;C_\"^3:PE&4HQD"E%SB%S@Z(Z1`A=46A'=1#[O#0?4 MWD01U_N@Y]#4G"LAJXD0";%*A)$8(PE&4HQD"I$FRI4`&3)RC!2XH-**Z":2 MC`[=0;IF9L=S:&9'058S8?(GQ"H11F*,)!A),9*-(!Y-7>8C$%E2%!@IK8AN M)_=@V"<-.\7GI&\RT@9]5T)6.R$28I4((S%&$HRD&,D4(ONFRH+065(^M`4I M<$&E%='-%!D5NF(=?`\IWNXTS#06.S!S$R@=B]\A1B*,Q!A),))B)%.(Q:D< M(P4NJ+0BNIDB%3(PLY\M98J$SW7]"SC\[5^]Y?DNS*,$&`DQ$F$DQDB"D10C MF4*LLZ6L%PM2X()**Z*;*)(@8R;*Y(AN(LWEN!*R=+,`(R%&(HS$&$DPDF(D MPTB.D4(A_7<-*S*)EA18?P*Z@7^1R7%',CF,9G(49#50ZEB0$*M$&(DQDF`D MQ4B&D5PALA>*%[>,G7"!54HKHILXELD9SHLRDS/LC6MC1)6,?*F19S/-+X,# M?D)$3*\268R]/!=J"%MZ:U,F(HRS%)LW?7R/%6-I-@E&4HQD&,D5(A][/;;3 M++"*.%XC*F_\B:2;\OB,/*IQKJXO55"=3LWD4+]?^%3(WRUXN.O#\MQ.ZN[X M"]#\3`&)\_,\W\?B/MOQ8Q@F'[(=/VMAQG-^+F@L[KL[?TP_<'?\+6]3)W1W M_&5O,QZY._[.MQF/W1U_]=N,)^Z.OP'.X_/^@?GIH;?]2_6O_?7E>&DFI^J9 MUY4S6_-5WE4>-))_W.JW]N3+8WWCYX;:7U_Y@;"*'R)Q9AQ^KNM;]XU>SMM/423%Y6?2W3=Q\E5Q4;%8+%)T/OSYX_@\^;8_ M7PZGE[MI<#.?3O8ON]/]X>7Q;OJ?O_(_UM/)Y;I]N=\^GU[V=]._]Y?IGQ__ M^8\/WT_G+Y>G_?XZH1I>+G?3I^OU-9G-+KNG_7%[N3F][E](\G`Z'[=7^O/\ M.+N\GO?;^Z'0\7D6SN?+V7%[>)F*&I+SK]1Q>G@X[/;9:??UN'^YBDK.^^?M ME?I_>3J\7E1MQ]VO5'?[E3=PQ]0_?&P.Y\NIX?K#54W$QW%9[Z=W7I]+TX'^[;P\N>K$WCQ$?@\^GTA:M6 M]QQ1X1F4SH<1^-=YMQ\_G$_?)Q1RZ`DO MKUL>P(*$5R+GA72<<:;0A-UQ]4]<_VY*(T]SX$+TV\=POO@P^T93;R=U-J@3 MV!JITN!SAE>;N8"Y('=!X8+2!94+:A4+JA<4+N@<4'K@LX%O0$LJY'+@]6B^>AM M7$P!V/*VI6V5C=`)3)=T'#(=54;+`6%`I-81J1I M"T:DM>W-.V8=54:S`F%`I-8 M9B4+FF95$9#CP7KJJ3>"K$U3A?.5[:;IJ*2*94`8D!Q(`:0$4@&I@31`6B`= MD-XDEK$HB_`9BV/;6)+HP)<"R8`P(#F0`D@)I`)2`VF`M$`Z(+U)+,N06YB6 M&5;8:'VC\T!<9'D1VVJ2T-IN3-FUXV*CTNAB0!B0'$@!I`12`:F!-$!:(!V0 MWB26(>GA34.J^H-/H7$`8D!U(`*8%40&H@#9`62`>D M-XEE1;Y3,,VH'&S@MKD4,EP,48:((HM9!N*Y\#N MIN$G(8UOI1R?4\ARNF#N.)W6&KT.$4.4(RH0E8@J1#6B!E&+J$/46\BV*\^2 M#;N.#BBR9TK8E`DV/'GCYC1M%\3N@J"U5,$,$4.4(RH0E8@J1#6B!E&+J$/4 M6\BV'<^.?;:36;-I.XE,VX4!;%%'+6T[0(SOV<4X**T<48&H1%0AJA$UB%I$ M':+>0K;M>`KLLYU,C4W;";32*.6G!F0"`V6(&*(<48&H1%0AJA$UB%I$':+> M0K:A>/KK,Y1(B\D[E1=L^/Z+K!(N1Y0BRA`Q1#FB`E&)J$)4(VH0M8@Z1+V% M;$/Q;-AG*)DEFX:2*#8,!2@+`#%$.:("48FH0E0C:A"UB#I$O85L0_%LUV03-^-,(GJ+8P0Y0C*A"5B"J-S$Y$=B=JK:6F M2(.H1=0AZBUDFY-BNM>6F%"\.^,DE M0Y0C*A"5B"J-WNA`K36T&:%/+6IUB'H+V6;D.;+AE?)4^(:_@;@^'79?-B?R MMV`\I@MD3FUZJT`K6A\-UXQMKTAEP26OBI\D!X[;9%I!/2]#E&LDJW&F0*$5 M5#4EHDHC?V]JK:"J:1"U&OE[TVD%54UO(6LLPC=V)0.W75JBI1D.ENXF3BI% M-#[CP`1K)W/,E-9R&)C@-E@Y(\.4AMX"Y0J]6W6AM$3581"MG-2K5!JZZDJA M=ZNNE9:H>AG&D3.!&Z6AJVX5>K?J3FF)JE=TON=4W2N-H6I[")W]DLKK0]P3 M210944FA]1CW,X6,,*20#O*Y0KI@H9`N6"JD"U8*Z8*U0KI@HY`NV"JD"W8* MZ8*]0D-!VU!O;(!"W``I1"8C2J5E]=YML?)JN2W62LMNT9GVC=)ZM\76J^6VV"DM MNT4G'/5*ZZT6;?_@NRUC71HGDMR%&>M/*!!-)#VF:W`/J40KZ#CP'O>06B(M MB!8QA$*IH&="KII_M^9":L7FPX>AZL\0*MS9$/ M0V<%37DHHX*DI9XW0\00Y8@*1"6B"E&-J$'4(NH0]1:R;<=WACXGDSM&,R8( MY-C.B>`I;=G!=H`8:N6("D0EH@I1C:A!U"+J$/46LFW'=X8^V\FMIFD[@1S; M.9$P#4`&&KEB`I$):(*48VH0=0BZA#U%K)M1S/0:SO.G3DKD4XZTQ!0 MAH@ARA$5B$I$%:(:48.H1=0AZBUD&XH2:Z^A.'<,)5!,+C.NQV'H;AK#44L[ M&2"&6CFB`E&)J$)4(VH0M8@Z1+V%+-O151BO[09NVTXBXQ@V190A8HAR1`6B M$E&%J$;4(&H1=8AZ"]F&>F.+%>$62R**BLI]4D09(F8AN_4W]BT1[EL4TME# MBBA#Q"QDM\ZS.!7%>:XG;NKQU->97Q*M:#G3\RMPYY?26@U[_S@(5XY&IC64 M"9E$\;!QM;MG9H&4EX@;AF^>)468'$I$W5;-I0H9"0XB)M$"M^013Y`\-A-Y MDYF9#IITD&_GZ$Y>G$JMA>YBAHA9R#82SS`\_1&)A]4?@:P8&3E;AC222B+S MOXV=_##38<;:@\97'8]AQ&)D&48@JDI5 MF_(#.)J>QIXA0\0D(D>F@E;C5-#7^(#ME4$BVV.QLUH;#2.P3@6B(^P=AGG%":5 M2O2PPW%NZ$S]3,NU862]GE&S8_7/@B&%4S>&2V2ZDD3Q[>A=&2(F$=T+`E>R M([1:0&@`H'&!;%=R3A5266Y%#CY:%4]5I-9".%RTC!V/9$IA"*FVZ]O!^Z=& MQ*`>"V1YG4!K?4202:VU^&['\+9'H6%G9'?*CN#0J;].K^3YY$-B=8XQLDM$ MQP3*D5*)UH.3BYORB)B%[$[Y0S416G:-+`.-0B4AM M]4X@:Q(*9#25T81T0CR3R!//%V8\-UH?N!TS)>)F'B=8&+K34&F)'"!PS[,S M+1]MHQ#&5'Z;T+0-N+?S1G#0=WJ-D5YJ+8S`A8@IA%GR4^2X07&?XE,UY-H MK0-'II!.NYA"&$\I!K\_N$[L&O2=P95KA9'Y*2V-,D0,48ZH0%0BJA#5B!I$ M+:(.46\A*ZS1%Q?1@#^Y$#F4<8PH%RK+1R&W5P5U+IDA8HAR1`6B$E&%J$;4 M(&H1=8CXUSZ'U6AX(&%7\35.\46UX_[\N$_WS\^7R>[T]87FY2V?>",6WQ_= M1/.$GP]0+',EBYB^6CK,#9`LU)=.74E`7T>EBYJ>VH*0),/R#V4BD@RA$R34 M`YKMGMI"Z@&=;?LD2Y(,<]6MC7?:5X(*>/57"=VI][2P3NA&N8??)G1'VL,# MLC!="O9(%F&RH?""$@JH2>J59"3A40K+4/A,>+!""7U'^)/?\M0QC_Z&ALJK M3P/EK3]./I$S8L,;&C_O\,7K9"/2;F>04I+P]1_KH@0DX6D`2C:+.9G1]R`I M23*OA)&$+Y">VN*8^N9[&DK0D]0KR4C"LUZLC;)QZK5/0CDJ27R.1]DB2;RN M%].3TO*)[=`^E'K@D]!NDVKS238QN9](26$4R,F\$D9E^([(TX-HD?"#&I1L MHF6RH9,*E-!Y2\*/-5!"QRI4FT^RBB0@FKS2>@L@FKS29HP2OB; M2:R-WN@F_&TD2GJ2\)>2*-E$`;7CM7444:]]95*29%X)G0U2;;XRFY!B$[UB M\?0@I.A$[Q1\$HI/=&*.$KJ!0Q)OK^E)-]XG34F2>B492?@+9VR'D82_=T8) MO?9/^.MGE-"K_H2_A48)O=Y/^,MHE-!;_H2_DT8)O=E/^*MIE-#=*:K-9P.Z M0D6U^21T;8IJ\TGHNA1YE4]"MZ82?MT'>T`WI24J2U"NABV@T M"K[:Z`(:C8)/0O?0:!1\$KI[1J/@D]!];5I#?+,^#58)O_:*3THW7ZF,3Y(& M:RKC\UZZXDEE?!*Z"YGPNXW8#EUOI-I\$KJQF/`;B%B&+B%2.X-D-@9%^C<7 MK]O'?;<]/QY>+I/G_0,E4_/A)/XL_B.&^.,JCBHFGT]7^@<7E*/2/H7^<\F> MKKO.;RA9>SB=KNH/:GHV_B^4C_\'``#__P,`4$L#!!0`!@`(````(0#;%6B% M2A$``"Y4```9````>&PO=V]R:W-H965TGM_?!I/I[7[=W= MY?[A\+2_3$XOAV=(/I_.3_LK_GG^PO; M\\_8.'W^?+P_Q*?[;T^'YVMOY'QXW%_1_LO#\>4BUI[N?\;G MIQ>8^.WX>+S^V1F]O7FZWQ9?GD_G_6^/>.X_@OG^7FQW_R#S3\?[\^ER^GR= MP-Q=WU!^YLW=Y@Z6/KS[=,03*+??G`^?W]]^#+;M(KB]^_"N<]!_CH?OE]'? M;RX/I^_9^?BI/CX?X&WTD^J!WTZGKTJU^*00"M]1Z;3K@7^<;SX=/N^_/5[_ M>?J>'XY?'J[H[H4JK===FKJ2O8*FMZ1.A@&<8(ANJ]4O^H]-_?HKL1_1?0WS\$R]6[N]\QZ.ZUSLZC M8VM$HJ$&GC(;NR!Q0>J"S`6Y"PH7E"ZH7%"[H'%!.P)W\.'@2,3"7W*DTE>. M%!?L!!C/AH[71$.*Q"Y(7)"Z('-![H+"!:4+*A?4+FA(Y(0B0EDA')B11$2B(5D9I(0Z0=$\N) M&+;D1*QJKXYAI8_QCCYY8Q!KI;?<.J@,;B62$$F)9$1R(@61DDA%I";2$&G' MQ'(K/#AVJ\R`"G?>DZ?>]62%]>AU?T:#DA2+B21$4B(9D9Q(0:0D4A&IB31$ MVC&QG(6=@\]9"MO.TL1,?!&1F$A")"62$C&)&":.44<8H9U0P*AE5C&I&#:/60K:CU$YXY*@? M1U^_=<9N38)HIW9NRJEV]`5N]`U:4C`V!04EC%)&&:.<4<&H9%0QJADUC%H+ MV4Y56^.14V5I4%FV&WWC7727>T:B90(R9I0P2AEEC')&!:.24<6H9M0P:BUD M.TIM=GV.TIO@<9!I9`>9FY*J(X,^%"6B8D8)HY11QBAG5#`J&56,:D8-H]9" MMN_4WM?GNWY/C.@4%^Q4\@6OK`R*&,6,$D8IHXQ1SJA@5#*J&-6,&D:MA6Q' MJ:VPSU%ZBVR\L@MZ%"X'WT6,8D8)HY11QBAG5#`J&56,:D8-H]9"MJ/45M?G MJ'X+;$641O.1HPC%ZA!$C4:CE3!*&66,JO?$H[O2A[T2]6[@^'.^_[DYP5#"N#T* MN]AG5:-V="H?3@#P\*,C#)=KRR$PJ:##C+#F941`SN2#3FD+08,9I36D4 MQ$S%J!9D+#>"!LM.`UNC`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`Q4S*J&-6,&@O9?E3IA,^/?9IA^;%'\*.T,5*#6+G6M#$69+H_$62T4D:9 M(!.6.:-"D+%5,JH8U8P:"]E><;**83KC5&+6HSDV;68ZVSAA$FDM_"&^BZ6@ M=1ZQ<7*01`I:*\W&V0RFHF7,9\9\OZD/W17%*$B3"C93,JH8U8P:"]G.?25G MF''.H!&<*VV,-()Y0;%HF4DH$2TS5:6"3,&,"^:,"BY8,JH8U8P:"]E>>25! MF'&"H)$]H6VJM,`WR_7I@C7+]YF22$$HOQ5RO:V1^4S:U;\1F$Z6SBC(C8().3)32OUF;J@8 MU8P:"]G.]24BP>+5MTXSSD4TFIM)+-)HY()8M,SQ:Z+1PDR(*1?,N&#.J!!; MYE2R9%L5:]6LU5A:EK>P@?2&8L?M_$&CA;6=V[CY@]8:34^Q%.RW<\O9=!'0 M=DYTS(*3LJ5,M/IW8M.)NVKG1F&(.D'&4IMZS\2H5ESGO$"C)7:!HYG+R10CK34>MH+Z;':V M")=KRF9%QSQM*LC,5)F@M[-9K86'5OM!9+/VN[Y"K)BZ2D&FKDI0'Y_+B3/= MUB(W11J-EOU@>2T^G33DA_')Z0FB4'7.TD1>I)'E=JUEAF&BM?H/,;OU*.6" MF6B9.377:&Y"MA`M$WDEVZHT6AI?UZS5B%9GWH[/5]*3.:,$D8IHXQ1 MSJA@5#*J&-6,&D:MA6S?.0E)-R1_\"6'VA^Z$Z1&8[_B,W![]HFDX-BO0T%9 M0Q/62AEEC')&!:.24<6H9M0P:BUD^U6E#J/%Y:?\VJ<;XSQEKI'M5^?X(#): MXL284<(H990QRAD5C$I&%:.:4<.HM9#M5[6M=_WZUH<.V%=3L/;(^O`HG#I+ M9:0+0LLX=2@H*&&ME%'&*&=4,"H958QJ1@VCUD*V4WU9S`H?D;_^_0B60W)K MCQRW.GN'2!>TW#H4-&XEE'+!C%'.J&!4,JH8U8P:1JV%++6<1$H11.NS2 M0_>B662T)-IB1@FCE%'&*&=4,"H958QJ1@TC]=LBG2>Z5;7W:_];(?UO(CP= MSE\.T>'Q\7)S?_KV#,\$.)_\\&[@_:^4[.;+K5K/X!22K"#I(I,D:TBZ>DFR M@:3;T[J2Q10_A]+MKTDR_%"**PGF6_41@Z=MP0*2+AEPRX20X*:&ITR()^WO M#KAEYJ@'^TQ/F3FL81?ED<`%7@_``=[G#_#\^.;,8RG`\^,C*Y\DA*0[J'-; M',P@Z7);1X*,;*N2"[:&WZ/YZ+<%4Q[]'2KWZJ-JK_WY]B-BDBO>*>_Z.'SK M=2WZR1N0B$=?.")'WJH,CFO.(5&)'$N0$6]5/L<2),9;E=:Q!/GQ5F5W+$%F MO%5)'DN*^13U^+R"`R+4XY/@G`CU^"0X(4(]/@D.BM#M/LD.;=MYVX:#BZW* MHKG5,22Q5Y)`HG)J+H/#BZU*K5FR0]MVWK9%D*AS)BZ#\SRTP"=)(%&G3EP& MAWEH@4^",SW$@5(N"%O@D>)F"%O@D>*>"%O@D>+6"%O@D>#.PW7G; MAKS:V.(5''UBS!BX"M.KUF20J).L1FR0YMVWG;AE=@:(&OU7@3AA;X M)'C[A1;X)"DDZHT.MP`OOA`A?LD<$M\,AG>MZ#F?!*]X?0>*;D7#Q"#WGD^#^$7K.)\$U)/2<3X+; M2.@YGP27DM!S/LD.DIU7@HM;\)NO#.YOP6\^"6YMP6\^"2YOP6\^">YP;=6% M)/9U%")"<&.9);B)O567K5F"R]5;=5F:);@GR0*T=OX5(FMX?LKU..3X)LJU..3X*,HU..3X!LEU..+ M`WQGA'I\$GR^`VL^";[0Q4[7M[/$9Y5;]>TC/P^^=409GR0*-ML8G\=Q&7SV M!VL^";[DVZHO\[@,OL1#/9WD;MC1XT<<7_9?#LW^_.7X?+EY/'Q&%C?M7C*? M^]][[/]Q/;T@N\-/.9ZN^/G&[J\/^%W.`R[_3=5ASN?3Z2K_0-5WPR]]?OB? M`````/__`P!02P,$%``&``@````A`._Y7%:8`@``:P8``!@```!X;"]W;W)K M;I8WS[)#3]Q8H56)TTF"$5=, M5T(U)?[]Z_[J$T;645713BM>XA=N\$==:#?MJ*W!S;)+J&3U#QN^RNF90\4&]$)]Q)(,9)L\=`H;>BF@W,_ISEE M!^ZP.*&7@AEM=>TF0$>BT-,SS\F<`--J60DX@;<=&5Z7>)TN;N>8K);!GS^" M[^SH-[*MWGTQHOHF%`>SH4R^`!NM'WWH0^4AV$Q.=M^'`OPPJ.(UW7;NI]Y] MY:)I'51[YK"(I?`O`R>ES>.]$Y=H23_-)FB=%-L-HPZV[%WXK1FQK MG99_8TRZ9XH.8C*[3J;I_TE(U!/.<4<=72V-WB'H#4AI>^H[+5UD MX!_SX-JC);[&"$190)]6:3%=DB>P@NUC;F,,/%]CA@@"[$,*T'LFA4=]"N^5 MSWD;@3%?=IYO>I;/H^#J6$Z1#P0Q18S)1S&S(>)(,H2Q1\`F$OA[YQ)88 M=$$.*/R9'!X-.09?]LC\G:Q'NHNSG!X]YHQ('GI[7"JH^$@3"NU<0),-C>$# MCJDBDL'5&9GRCJU^ZITVFT>/.2-R*@\\&.T/\N;)H,U_/>;9(^.>2HOB3JO@1/Y.#.@P4]:9M^XMGB_68=:0X0.,@)XV_#LUC5`6 M=;P&RF1R#34U<5K$A=,]*(=)H!W<_O"SA:'.X5XDX#ZJM7:'!20FP]_$ZA\` M``#__P,`4$L#!!0`!@`(````(0`B>A+#V0(``,T'```8````>&PO=V]R:W-H M965T&ULE%5;;YLP%'Z?M/]@^;WATMR*0JJ$JMND39JF79X= M8\`JQLAVFO;?[Q@,"1!5[4L97' M^,_OQYLU1MJ0*B6EK%B,7YG&]]O/GS8GJ9YTP9A!H%#I&!?&U)'G:5HP0?1, MUJR"-YE4@AAX5+FG:\5(VAB)T@M]?^D)PBO<*D3J/1HRRSAE#Y(>!:M,*Z)8 M20S$KPM>ZTY-T/?(":*>CO4-E:(&B0,ON7EM1#$2-/J65U*10PEYOP1S0COM MYF$B+SA54LO,S$#.:P.=YGSGW7F@M-VD'#*P94>*93'>!5&RQMYVT]3G+VOBB>?N<5@V)#FVP##E(^6>JWU$)@[$VL'YL&_%0H91DYEN:7/'UE M/"\,='MA3:@LP1/\(L'M"$#FY*4Y3SPU18S#%48'ILTCMS88T:,V4OQK7P9. MHC4.G3&X;4/^+9TF,,O^,XX%AO"A/-PP6;=SV#7#(O&]) MKV\*FG1H:1#VJMGNYPX!(YSMLN@+^W`"V1[)7"+#KTXY#Q+R24RD+0+ M?GQCEHO9"C)M;_KTUEB3H3^'P'&1PWA8>U+?CG9=M1=8,)6SA)6E1E0>*]!9 MPX7LT7Y+[D+;C1&^A^W9K*(Q'D;)5?YM!-,ZU=G-HUVSA</L?``#__P,`4$L#!!0`!@`(````(0!+X:L'0`0` M`"L0```8````>&PO=V]R:W-H965T&ULC%==CYLX%'U?:?\# MXKT!VY`O):EFMIIMI5UI5;7=9X8X"1K`")/)]-_WVB:`S;4Z+R037BM>=(6EYF76@7UZ*1M[9JOP]=%76 MOER;#[FH&J!X+LJB^ZE)PZ#*MU_.M6BSYQ+>^XTD67[GUCV":/#3A?H1\%O@;^:X,C/V77LOLJ;I]Y<;YT,-VI M&I*+$C+!-:@*U0/PZMF;_KT5Q^X"_]8+DL1+FH;!,Y?=4Z&&AD%^E9VH_N]C M>B;#07L.^.TYV'*1KF)&?D\2&3WZ/3YE77;8M>(60'-`2MEDJM7(ED(!30Q_(`1./ MY%"HSC'4I4>@-\>L28SK7J*<"K4Y#9+HWIY.%?0*(93U8/J>U,BH3,C2@?NX4K;>(+=%C;8)[1,,.K<\E!+$)8W1J M$QWBT*%&67H*B3N%S*W20\AT8\98$TOEW!D$M<8*5TEQ:VC8?OD[9$_1N'9: M+4"5"<9E`K.T#G%2J%$`V2G&+XG33LT/KLI#X-?E?+WCX3T^M1;BU3SZ).<4=IV%'I(?NYP M879*/7L$Q>VD88?6.`R9;L1.)&73?8;.[72'[.GV[#0,MY.&;94]-%?)E`D< MZY"83E7J$(=.C0+(5NE9XQEN'0T[M+Z=B"'6(21=C%NVCG#84.=X5GF&.T?# M#JW/.0QQCB-R;AP]:%9)SR+/<.-HV!'I,PY#C$/):EK)WB<3=^M!D``*.GY2 MIIXUGN'6T;`CTF<=.('-FY*NISN1#G'HL)TH=;<,3B M6L.[J15D0(#:)0ZPF<62;TO[[ M7=LAQ,1(?4'DY/K<<\_UM;.^>ZLK],JDXJ)),9E,,6)-)G+>[%/\Y_?CS1>, ME*9-3BO1L!2_,X7O-I\_K8]"OJB2,8V`H5$I+K5N5U&DLI+55$U$RQIX4PA9 M4PV/KIWTC)-U54/<;F=/LQ&T?1O0U MSZ10HM`3H(N@O9T00:>ZS+%\6*2+*F)7"H7,Q_$)'V$)QU"`M(-"GZ!X'/I(WM&N$_`XH,_"/FL'C1422#2@<`XFR61Y MMM"&7-"950#Y*N=75(;GRFS+B]H[**`R,$ID`8=*/TW$C0HP]/OP!/DBKPP0 M"4^0A2]J/PT,)/+V,IR%(RO];MN("[9N6GR1BRM.AL>%C.>E@P).!B8F7DZ' M3HY'!FZ50+N7%R+=Q>$.[9K)/?O*JDJA3!P:.`C,F=VC_86UM?VZQ.>KK;O( MHOX-W"\MW;-G*O>\4:AB!7!.S39%TEU%[D&+%@R&6T9HN%GLWQ(^&1@!R;[,KKL.5:=NQ[@?/WVK M+LY[T;1E?=V[8NVY3G'-ZT-Y/>W=O_]Z7L6NTW;9]9!=ZFNQ=[\7K?OIZ>>? M'C_JYK4]%T7G*`_7=N^>N^[VL-FT^;FHLG9=WXJKLASKILHZ];$Y;=I;4V2' M_J'JLI&>%VVJK+RZX.&A^1$?]?%8YL67.G^KBFL'3IKBDG6*?WLN;^W@K5S?EXJ6\E-WWWJGK5/G#U].U;K*7B\K[FPBR?/#=?YBXK\J\ MJ=OZV*V5NPT0G>:\V^PVRM/3XZ%4&>BR.TUQW+N?Q4,:>.[FZ;$OT#]E\=%: M_W?:<_WQ2U,>?BNOA:JVZI/NP$M=OVKHUX,^4@]O)D\_]QWXHW$.Q3%[NW1_ MUA^_%N7IW*EVA_J1O+ZH2.JO4Y5Z!E3JV;?^WX_RT)WWKA^MPZWG"QFZSDO1 M=L^E?M9U\K>VJZM_`230%3B1Z,17--$NUS(.11C]OY<-,.HS^9)UV=-C4W\X M:CQ4S/:6Z6$3#\HSIH`\QJ14;7.-_JSA_4.*;JM.WY]VX>/F714I1T@"D*WK MC!!!$>F`T+55-$8N*D/.Q??&T-I*0TL>>@;"0D\1T7:$$#*J&!:9(7]]JKIG M);>+QN?[$B4`"2P(HYDN(0@'Y62&@S[=NRJ3L.8$KOP MXLBTB!!0TVD1Z*?#ZHBVLF*88D(Q`*+"C5QY,980A$NTR$5;65%8I`0@$13% MCP0K6@KVH+=[8T$)!S755CV&H="G-/:.^4X``K%%+)DYMS<;69_2R,(SU"$T8""T%#XEEMI6X??'/+R98PB/((@?,W(IL89F7FAX*I%#V06HF+V&=@88'D`0/HP9 MNQ1]H-F_4WRA1LAJ5B"4"):OV:(@*S1EIBN(A$`025V5M.1A&U>B:UI&65` ME7$L!:B9SH-P2]-D!@%7*I2)E=W-L*JH-N6,;`J^(@C"%0FLKB,'6U;-PS0^5P$P/C@!?O?B:S6;:I0$D;,50E@KCDT8E%"_8!O_&-PVAG<6 M0FH9,]'Y;O9F7@6SYL@"I!"J$(23;T]T@J/B2^N7`.W$O%;J'RVJ$RJ;<>2% MX%\;"%K:BT4()4(EC67EE#/**3E#IV@75J]I5VALCGI"L@G71@N MGQ)`$,H*A!MC6\TZ$1;J9XV],(-<],=\4;AF(@@3W5F_*"$^M=OOR)0"54Q> M"']&.:7)!GJ"(-A)$092*-$2`5`*`\BBMAN MI^@%`?$V-"-.R6C!6R`#>DC)L+P3'T`0*_8%:V%*["+:6<-.N2SKJ@^22;DP MA4@0!%RB:/+Z1>RQN/?;W*>R.AF7&7F5K`5)[T._BQH-9H*7+D)H;:B\CBLT M(ZN3FQL?0#"7H34)N$'$?._WL4]E=20P(Z?2S!I.*X"`P);5*>T]#^_L9N=H M^O-2ZL](J>12BB!,WY^$MY7V7OAE&?5!`\FW+;^&2!"T.`Z#ELY-#*F'NGFU MUW;H1G_,%%6R=4P0!!=8(5MF?:>KWQS`&O!ZP'4M7')617,JTN)R:9V\?KNJ M%PVAKG?&4[@F3M0U<7_5NAD-ZO+VEIV*W[/F5%Y;YU(>JMVJH%[7OC0 MU;?^2O*E[M2U;?_?L[J/+]15J;=6X&-==\,'?=LYWO`__0<``/__`P!02P,$ M%``&``@````A`-?&.5O%`@``8`<``!D```!X;"]W;W)K&ULC%7;;J,P$'U?:?_!\GNY!I)&(543TMU*N])JM9=G!PQ8!8QLIVG_ M?LZE*]$R%9+R.L&LY&-$ZX2FK\PC__O5PL\)( M*E*GI.0UC?`KE?AN^_G3YLS%DRPH50@8:AGA0JEF;=LR*6A%I,4;6L.3C(N* M*%B*W):-H"1M-U6E[3E.:%>$U=@PK,5'.'B6L83&/#E5M%:&1-"2*-`O"];( MCJU*/D)7$?%T:FX27C5`<60E4Z\M*495LG[,:R[(L03?+^Z")!UWNYC15RP1 M7/),64!G&Z%SS[?VK0U,VTW*P($N.Q(TB_"]NSX$V-YNVOK\8?0L!_^1+/CY MBV#I-U93*#8[']H#^"%02C-R*M5/?OY*65XH..TV M7\)+R`3?J&*Z!<`Y>6E_SRQ5183]T`J6CN]Z`49'*M4#TWLQ2DY2\>JO`;DZ M>T_B74A@QX7$]2QO%;A!>)W%-HI:)S%19+L1_(R@.R"G;(CN-7<-S!<+%QV] M*2AMHM'W&A[A)48@5T+T>>N[P<9^ABHE%\QNC@G#,63?0;0_S1MW@?^\[GC+ MH4/H`P'MO0$HR\!`IU-'M(<#F&Q'/(A.0P1PQ(1KK] M-W7K:(2!I9?INY/B[0QF,0XR,@)#!`;0=M`CZAM%/H=T' M8GUW4M:=P;QGZ"HBOHHXO(<8&8)K,#7D.[TA_71Z0JMQG^P,)FSO1^BM'/B, M$?LA(@C"8(:(AXC0?8,#)IM68K($P<(?--.GR-7,/':OP6\R2A,`\<"<,:YZA;ZSO?OQNT_````__\#`%!+`P04 M``8`"````"$`THJC3G0"``#-!0``&0```'AL+W=O3YP$`@PBC*`CVI%:J:KZ6!O'22QB.[(-S/Q] MKV-(88A4-DE\?'W.\7UD\?0J&W3@Q@JM7XU\_-PPPCZZ@J M:*,5S_$;M_AI^?'#XJC-SM:<.P0,RN:X=JZ=$V)9S26UD6ZY@IU2&TD=+$U% M;&LX+;I#LB%I'$^(I$+AP#`W]W#HLA2,/VNVEURY0&)X0QWXM[5H[9E-LGOH M)#6[??O`M&R!8BL:X=XZ4HPDF[]42ANZ;>#>K\F8LC-WM[BAEX(9;77I(J`C MP>CMG1_)(P&FY:(0<`.?=F1XF>-5,E]/,5DNNOS\%OQH+[Z1K?7QLQ'%5Z$X M)!O*Y`NPU7KG0U\*#\%AV@VID_PG0#2O!$ M4O@6@)O3U^Y]%(6KS:8;1EENW$?XP1FQOG99_0E1RX@HLZ8D% MWB>6T23*IO$H2?]+0H*C[B;/U-'EPN@C@NX`2=M2WVO)/(4,,@^N/)KC*49@ MR@)Z6([B!3E`+M@I9!U"X-F')'T$`?)>`>P.*'C4*_AD>#E!Z]I@S(N&OMRT)!N2\L(=_-DW&4]4WA]Z^93LA5T4;ORQ;& M)S2=Y*;BGWC36,3T7H&"[[D>[:=VE7IW[_'Q?-4U#.DW8,A:6O%OU%1"6=3P M$BCCR`^5"?,8%DZWX!PF33N8KNZSAM\FA\:+X8:HU-J=%R!,^A_Q\B\```#_ M_P,`4$L#!!0`!@`(````(0`IW'X3_P8``!0=```9````>&PO=V]R:W-H965T MZTV\?>JC]]O?_UE_=)V7_IS50T1+%S[37P> MAMMJ.NW+<]44_:2]55>L'-NN*0;\VYVF_:VKBH-0:BY3-IO-ITU17V-I8=7] MB(WV>*S+ZD-;/C?5=9!&NNI2#(B_/]>W7EMKRA\QUQ3=E^?;N[)M;C#Q5%_J MX;LP&D=-N?ITNK9=\71!WM^2K"BU;?&/9[ZIRZ[MV^,P@;FI#-3/>3E=3F%I MNS[4R("7/>JJXR9^3%;[?!9/MVM1H'_KZJ6W_H[Z<_OR6UJ/IT'M#OG*F5[@2?\C)J: M[P&D7GP3OU_JPW#>Q&PQ88L\R>I3$64X$,Q%-MUU[Y$V%>(M;\5?)OH5Y2V5S,Z72:C$7DOPKB`. M$PQ*\C/!<'$>#.\4CVZG`2LZQ[.6<#TC]9_QS,4W,7Y:97"2W$F9Q*Y5[D1C M1-QPLI\+AXNC@4C.BL=MBQ)Z*QXCXL:#W6V51V\&C@JWI@$2><`(6H$P)VLC MY'J9![UPE'I1"/C7>$FRA>/%"+E>4(!`+ARE7B2RQ%XU7EB6.EZ,D.N%/QS& MN=(5XRCUHA`[%Y9ECAA\6$U18\H@_P%R#1J`0&H&[4XV0&T&" M7@<2%3#UHZ%Q7O<$(DR0<(H8ZR2PF()L?GWDTN8Q-.XZ_U+5% MU..Y+?9W(%M."&,,)EO%$[8G0QWCY`>R-5)>MF&&X4\"9_0T9.<4\*04`SE! MT$9)P;J>FI`*I45*16S*;O=TXGW%8@'%8 M[IXD1BFO<91Q3'8^KW#2Y2-AUS')/$]&RO-$>44DG&,SO-I*GW"8H9*1<%CN M'C5&*2^$,.$PGW`4E*6&5_<$HB/(9]YG3,9A9R\J*+/,VA`U2PE#%\RTR"<. M)J$%?HU'L=P])"FI)3E\YN-!A@214GK1S@5,44;3R9T3`H M11CG/C5D$K*+1B!J-CST4':?`1JRBZ:D_*V6T:$/;#4AX;1%#ON]JDDI6K7Y M>.2CZ5&6,%7SV2%3D'4((A`U2^=>I#=/)P^P\=JQ(/,Y04.8G?&Q-W=/>*.4 M>RS(PC0A8*>RBA/LY&R()L=G>3P6B.22.R>\3,Z_?9_3$,W./7>-4EYV89;( M?);0D.W)OV6-4JXGO'OV$F;)_,UV"AU:9`W98;"Y>\H;I4P8\L6U?&O;5-VI MVE>72Q^5[?,5^P+,M%T;6+XQWV7Y:H_M"1/>RAPK\^#*`U;$#O!T%E@1-PAO M98F59QX0$16,D8 MHA:')=<:PZ<&7-L".@PZN$R%5A`;KDBAE0PK@OP\/^@/GJLA'>2#DWY@)8&. M_"SA6DN@DX1U4&MY;_-TT%/<>4)^4#=@QV#7N/B"_XVT.X7P#!O#';/6( MD?4=[Q!1**`=NAAL/'H8;"$Z&!P6]$]>ZDV5\*GJ5IRJST5WJJ]]=*F.H(>9 MH*E.?M62_PSM#.```&0```'AL+W=OF#MB3;\H;!X,S, MM=MQ$J-C*[#=RWG[^2F2XO(SZF^ M&]WTNYW]:5<_'$Y/]]W__#7]8]SM7*[;T\/VI3[M[[M_[R_=/S_]\Q]W/^KS MU\OS?G_MP,+I'[>7F_IU?X+DL3X?MU?\]_S4N[R>]]N' MIM'QI1?W^\/><7LX=:6%[/P[-NK'Q\-N7]2[;\?]Z2J-G/?OE!<_],TJW.VV[ M^0^9/QYVY_I2/UYO8*XG'>5GONW=]F#IT]W#`4\@PMXY[Q_ONY^C;),.N[U/ M=TV`_GO8_[A8OWZ_BI4JP>!T+A'K:?-"/SK MW'G8/VZ_O5S_7?^8[P]/SU<,]T`TV=4OZ`G_=HX'D0-X].W/^VZ,'@X/U^?[ M;C*\&8SZ210/NITO^\MU>A!MNYW=M\NU/OY/*D7*E#22*"/XJ8R,;M)X,!HW M1MYIF*J&^*D:QH.;*.T/1>?OM(.T\1H_5;O!S2CJWR:C]]L-53O\_)BC(]40 M/S_D*.93XRA^?LC16]4./S_F:(14:7H4OWS(U4BG@OCE0\Y&2![9I\FBWTR` M2*>.^.5C[NK"?7/0O^^BTS`O+B`?O\4CP=WO>^8CCNE,V&=R-7(M8:8DL)LX8/2 M!U,?S'PP]T'E@X4/ECY8^6#M@XT%>HAA&TB,_H<"*?1%('4()AI8D?6BIC5T MD\('I0^F/ICY8.Z#R@<+'RQ]L/+!V@<;"SA10^)3U))^FVU"C*)L9UM_Z$9E M(G4B.R6]A,Q;E39R1$HB4R(S(G,B%9$%D261%9$UD8U-G"!BVE(0L=Z].8>% M/N8[QL2:Q'Y8E=)[86U5VK`2*8E,B*8)DS\8S\DM:H>IT<",.FM?GP^[KI$:21>UV31R>O`15:(3-BY6/J1O/7&D- MA2F<*/J1ES&%4=#/6S*:&J3,>'D_,PK:S)Q195#8FX51T&:6C%8&A;U9&P5M M9N,@=RS$%MH:"UTMQ3;.C[E$0[L&#&_]D$NE!'.H'9AH/':U"F4]&38#$]U& M(V]D2JUA3C)3C=XU/=-:TG0<)2-ORS37&L9TI=&[IA=:2YH>QFGB3>"EUC"F M5QJ]:WJMM:3I4=P?>:8W6J,Q[0ZAV,&'AE#M[,V>:"+>"&!4$[LJ*31N:WVA MM>2[+7&0+C4R:^54(]-PII%I.-?(-*PT,@T7&IF&2XU,PY5&IN%:(]-PHU'3 MT`V4V).'`J7VZG:@%$+E:=,XCOP#H'BS@7#&6!9:K4"R*RU1W=JW&Y%W,"J# MMFZ]2C,-:OG3:Z:UW!Z]C)IK+<=[O\M%]JK7=[7`6U_![7 M6LOMT2M'&ZWU5H]N?L!6,#\$]Y9WB3"1S)CZ+ZQR<5@6LPW[L7;@`^FAM.2V M(!FD5`J5@ID)T]^R/%-:J?WP<=QW:_%=7RAM93CPXB&FQQ?&9?$ MXC7T)M3:B,W291MQATNS5!(B]V7@7/HU;+Q(Y0R5I31C-&[9G&>7:(1=EYE@$4TP MI352K\CBD:=1B$L,6#M&IMB5"J7-H=;U3^SQ+/]^]:()(^,O3`K!;SWE_1<*6$K+\X_:=\+76'D^A%*;;>9 MM\ZX)=[2IQ.IX9YSF@)6Z36#@[+(L$E'>,Q$'=F_KJ9"=-1J9G@I&I4:!SNVJ;'7. M11EQ%?ZX2>.]J,F5DDJ:V)__A9'KP2VUW<"PB0*JYQ-^ES=SWGSWGLAZ:T\S MA9QA=*R4*G0H+GHYF:R7:BM@'$]QBMC$3`WE;P7#[E2&F'RMV63 M7[PHK8%,N&28>AE9:H6FKKK^VB7\-X(HR[@31(FK[^Q4CUR$MM6&>FZE=T,TT:+#G'-=SI07KNJ>"4:D0Z@.TW,C8]=SJ MG,MYJ@HQDM.*C#\)M98PAYX$R'\?>R^I<-?S%MS.EA8$4<:7WN:6V$O!7 M5&DS%W\91%G4[3F:2H0YH<=4E5+9*MUS?2X M/S_M\_W+RZ6SJ[^=D(9C$8\6RQOADT&&JT5HZO-AAHLU`1Z-,O$N,"090](\ MMF\KNH6D22%?$O(B8"U-LPE"PA+D0"9"RI("$A%9EF#$,Q%@EN!&_.=F MG?`]PTWY9DGQ>0R'`W8F289K@@'[:?8YV/$DQ57\0(-)VL>#A[K.(1'UBCM! MO<3CA223-(:UD&,Y)$50@AH#:Z$VDV283;"ZL@?83V1Y4%)`(A9I;H/-0U8& M)5A2(0FE$A8W2(*IE.!)L=_D?K!MA@$;52:^K[!D`XGXS,*229S`ZV"LXP%B$&J30U($)7BC`6NA M-I,8,QB+D;FKRX.0"O@[[A><2G,;:&3Y=9'I04D(@/9=RFA$1\+V,) M/E=FXK,92_"),A-?SUB"SY*9^(C&$GR=S,2W-);@BV0F/JFQ!'<^8"T4`US] M@+60!-<]8"TDP34/Y$Y(@ML>F;BFP![@A@>R*B290"(N9G";')(\*,$%&HQ" MJ`TNSF`40A+![U$?_04HA+ M:G#I?ZBO^7`M;.QR;\7=X>]R,Z8L/#8]U?=7_ M05!Z[5_V??H_````__\#`%!+`P04``8`"````"$`?0X\)-\-``!B/0``&0`` M`'AL+W=O\/[Q\N1W\^U_)A\7@ZGS9OMQOGXXO^]O! MG_OSX(^[O__MXX_CZ>OY<;^_7,'"R_EV\'BYO(;7U^?=X_YY>QX>7_'J/C>/#PV&WCXZ[;\_[ METMKY+1_VE[0_O/CX?4LUIYW[S'WO#U]_?;Z87=\?H6)SX>GP^7/QNC@ZGD7 MYE]>CJ?MYR<\]\]@NMV)[>8/,O]\V)V.Y^/#90ASUVU#^9F7U\MK6+K[>'_` M$RBW7YWV#[>#3T&XF4P'UWY]OSH_'G^DI\-]=7C9P]OH)]4# MGX_'KTHUOU<(A:^I=-+TP#].5_?[A^VWI\L_CS^R_>'+XP7=/5-%=L#B;SX>QF-`G&L\'5Y_WYDAQ4V<'5[MOY;I3ZI^4_NT`'8ZA?P;]?C=> MC#]>?\>,VVF=%>L$ML9:--2L4V8C%\0N2%R0NB!S0>Z"P@6E"RH7U"[8],`U M?-@Y$J/A+SE2Z2M'B@M6`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`J6KW1R"@79&P5;*O4 M:&[&;,5:M6@U#V1[ZQ>+BS$O+C2:(T?HC49GD;C66OUI*ZA=Q$YFX_F"%K&B M8YXV$62"5RH(`\PT8>$T(=-:9B%KKW]RL6+J*@29NDI![?B<#YUP6XG<%*DU MFK>3Y5?C4RTD>O/_M^.S77CTX\*X17,S\M8:66[76F:"QUIK9D9+P@53T3(Q M-=.H%T!ST3*V"K95:C0WOJY8JQ:M9D;8X]-9GOSVA&S7]O3,H[:=RN M!ZRQIQ%>Q9WG@ALG95Y+0?,^CQC%C!)&*:.,4<^=O,Y,VS[?6U,C%2L969NW,7+R]R\6/1->]`B"I.=O9U-GK;7PH9HR&BZ6UJ[*"%5Q5)5?_9T M6FKHW0RMJ3,:!?$')_2GIB5B-V.[N=%2=M_1WL*4$+LEHXJKJHW6.Q]A8TJ@ M*OL=XRSQFI?[>#YLXD"S*/Z$S0,W$==(;6R82;)P]@#76@N#IIWE$RKFO/(@'-&Y MO[T)WU[Z?=Z?ONS7^Z>G\]7N^.T%'@VPI7GWL>/M'?S5+,1-+UAP^*?Q)%2= MQ!+L9X1J>>^33"'QET$UZ'TN@_X,59>Q!%T4JEY@";P>*B^R!%Z3GQ2XSQ.$ MGQI/.7R%WR`T<]OE8S384\,*#^][]D]3V/<60(M\3<4[`0_N*Y%`HN(W/Q[B M-1[<)T&H1;M\DO5D@GI\34X@47'(5\\$]?@D"!.HQR=93T:HI\E1'5[EDZKL60+U;K* MXQU(U,J&)5A_A!%2;Y9@20%K/@E6":'*^KD,LGS4XY-@USE4VZ1,9>)((F\ MDA@2M9/,9;!E'ZH-999@YQZ^]DJ")?SF&U4Y).H4A*WA.`E^\TEPJ@2_^20X M3X+??!(<*\%O/@G.3T-U*NAKP4VH#@=9@M/44)T1L@2'JJ$Z*F0)SE9#=6+( MDA7:MO*V#<=^Z#E?JR-((J\DAD2=47$]./I#S_DD*[1MY6T;SL!#=4K+UB)( M(J\$Q]^A.K/E,@DDZNB6)3CY#M5QK4\R@\07*7#9`CWGDQ20J!L&;`U7+]!S M/@EN8*#G?!)LX7JW`K$3WGD^!R M(GK.)\$=1?2<3X*KBN@YGR1'X,-]4'9H@;CG%90(>UY!A:CG%=0(>E[!"LU: M>9N%BZ/H-%^#<7\4G>:3Q)"H6Y'\++@\BD[S25;S$#?\N42T"'&CG'FZ"'$= MG/D*L=/[B&N$3J\@0N3T"F($3J\@0=ST"E(D%UY!AO==*[CN!AY^^/JZ_;*O MMZ`Q+4;2]N;)/X9OOF9&9/- MS8MLT#/71J@VQTD48\1;I@K15CG^_>O^ZAHC8VE;T$:U/,>OW.";[>=/FZ/2 M3Z;FW"(@M";'M;7=FA##:BZIB53'6U@IE9;4PJ.NB.DTIX7?)!N2QO&"2"I: M'`AK_1&&*DO!^)UB!\E;&R":-]2"?U.+SIQIDGT$)ZE^.G173,D.$'O1"/OJ MH1A)MGZH6J7IOH%SOR0SRLYL_W"!EX)I951I(\"18/3RS"NR(D#:;@H!)W!E M1YJ7.=XEZ]LDP62[\07Z(_C1#'XC4ZOC5RV*[Z+E4&WHD^O`7JDG%_I0.`DV MDXO=][X#/S0J>$D/C?VICM^XJ&H+[9Z[+4PUD`D^D11N!N#H],5_'T5AZQQG M<93,XD4ZQVC/C;T7;BM&[&"LDG]#C'?>,](3`[[/C$4T7\99\G\("7[\.>ZH MI=N-5D<$PP$I34?=J"7K%`K(G+AS:HZ7&($I`^KS-LVR#7F&4K!3S&V(@<\^ M)NDC"-#[%.!W(H5370I7*Y?S-@A#7CK-RR9Y3H6J#NRDV:P'A!0A9C:(F?<1 M(\L0,F'9J5`G,-H?.""%'"/I`#FC\1`ZG^AQ]74X*S.8@ZV+:]V*2Z=0Q M,R@S/]O#5D''!YZ0'^?5VUBXY3'HI(RZEBVGS;E+[W+4G#IF!N72W&JTWYM; M+B.8_?/4NH`QZJ2,[5U/VTN@PA/^O#RFGJ1+AW#5#!&A?K.D-^C7W['<%I#& M%E?O+(8+*+RXDNN*?^%-8Q!3AQ:&PC6H5_N+;Y>Z]K[79^L=Y((%TJ_`/=71 MBC]278G6H(:7P(RC)0R>#E=:>+"J`Z-P72D+5Y3_6<-?#X>7-XX@N%3*GA]< M@O[/;/L/``#__P,`4$L#!!0`!@`(````(0!%=FFLR0(``"('```9````>&PO M=V]R:W-H965TU6MZ]R0:],M4*=IM@7__>KRYQ4`OZ32TZ%"/)\J=MJS3= M-.#[+9Y2=N3V#V?T4C"MC*KL!.A($'KN>4$6!)A6RU*``U=VI'E5X'6?$KLU=CZ`#AUS!N132PX2/&/H[0V,C\ M@Y&P>,)'+[G>\B^\:0QB:M?"^*;0QA[M%]XZ<6/P$9_FZ\4E/([R-6B!$Z0_ M`HNKHUO^3/56M`8UO()DD9MJI,.."P]6=6`*UI>RL++\;0W_(@X;P;E'E5+V M^.`2]'^WU3\```#__P,`4$L#!!0`!@`(````(0!VDK$>B0(``#$&```9```` M>&PO=V]R:W-H965T[UZ2>W7A27RQSN)QS[KU[]N^W)N@=?2QD(,!B? MTSJ$=L.8%[74W,]L*PWLE-9I'F#I*N9;)WG1'=(-RY+DFFFN#(T,&_<6#EN6 M2L@[*XY:FA!)G&QX`/^^5JU_8=/B+72:NX=C>R6L;H'BH!H5GCM22K38?*F, M=?S00-Y/Z8*+%^YN<4&OE7#6VS+,@(Y%HY$;4`)OD0KO`*0.7_*:08*J@AU3N?7L^4JF:?9 MDI*#].%>X5E*Q-$'J__$H+13CUR=ASL>^&[K[(E`7R':MQQO2;K)('>!X![1 MG*XH`3X/Z.,N6R5;]@AIB'/,;8R!;Q^3]A$,V'L)\#LA@2A*8)ZH>1N!(5\V MS3,N``-;V>J?L2@58Q:#F.6T%(1,6$<4Z@6&^]0ORQ.#WJ`! MO9O00+33Z.MS1N!^#53_4Z+K24Y$QYP1670W9-@RZ/S`4U?B=)'V-<;M,=$9 M&9=]/EU4?+C1_F789UB\U_ABL^]>#-9OP""WO)+?N*N4\:21)5`F M:)JX./-Q$6P+SF&<;8`1[GYK>)HE3$@R@^#2VO"R`&'6/_:[OP```/__`P!0 M2P,$%``&``@````A`#:]\MS0`@``@`<``!D```!X;"]W;W)K&ULC%5=;YLP%'V?M/]@^;U\)2%-%%*EJ[I-VJ1IVL>S`P:L8HQL MIVG__:YM0G%@4E\0'([//?>#R^[NA3?HF4K%1)OA.(@PHFTN"M96&?[]Z_'F M%B.E25N01K0TPZ]4X;O]QP^[LY!/JJ94(U!H589KK;MM&*J\IIRH0'2TA3>E MD)QH>)15J#I)26$/\29,HB@-.6$M=@I;^1X-498LIP\B/W'::B?OD>-$/IVZFUSP#B2.K&'ZU8IBQ//MUZH5DAP;R/LE7I+\HFT?)O*< MY5(H4>H`Y$)G=)KS)MR$H+3?%0PR,&5'DI89/L3;^WB!P_W.%N@/HVJ M%N?/DA7?6$NAVM`GTX&C$$^&^K4P$!P.)ZZTK(<'HLE^)\4906.!K3IBQB3>)I!\;L"#03.\Q@CT%*#/^R1=[L)G M2"/O.?>.`]>!$P^,$-2'$.!W)H1!30B3IXEY[X"Q7C*OM_#TD*G7(AJLF[<` MC&PEZ6H01WA$#>C<3PZ`VQE"?'H'Y MFHWJ^4YG-0WJ:SID:2=DW#+H_,B3+?%Z'<"870;$$'RI'O'ZEZ9#X3U[9G5- MA\Z@OJ9#IO8VWGEK;QEM@G2P9PB^5(_X]M;S]F*H\8P_"_NJ/31U&$.@D82U MF"RB<0DMY4K.G`+(=WG['Y?SWY49RZO<>VC&YLF@$=]NPA,9-XC2^W![=_P^$-K,6.5/0[ MD15K%6IH"9J1\8VDVZ#N08L.R@G+46A8B/:VAC\=A7T3!4`NA="7!X@<#O_. M_3\```#__P,`4$L#!!0`!@`(````(0"$&PO=V]R M:W-H965TT8`U8Q1K;3M/]^QSA0:+C(30@OQ\_YY+"]>Y4U>N':"-5D.`I"C'C# M5"Z:,L-_?C_>K#`REC8YK57#,_S&#;[;??ZT/2G];"K.+0)"8S)<6=MN"#&L MXI*:0+6\@2>%TI):N-4E,:WF-.\.R9K$8;@DDHH&>\)&7\-012$8?U#L*'EC M/43SFEJ(WU2B-3U-LFMPDNKG8WO#E&P!<1"UL&\=%"/)-D]EHS0]U)#W:[2@ MK&=W-Q=X*9A61A4V`!SQ@5[FO"9K`J3=-A>0@2L[TKS(\#[:W$%F`%*GK]WU)');9?@V#!9QDJZB.,'HP(U]%.XP M1NQHK)+_O%5T9GE*?*;`M:J$8#S`I6FI&[9H M$T,)F1/W3LUPBA$$94!]V<5ILB4O4`QVMKGW-O`[V$2#!0'ZX`+BG7'A5.?" M54Z%NH["B=/E`/`NO,UB9/.>U"1D,)D)V:E0)PAT2/FR M+-[H"A_0^!D?3NU\#'4Y*S"=(Z_ID-DD[N4LTZE3IE<6W72/6P4='\6$W$#' M21*DR3`9SF+*.BN3QJ6K^?CFD2X2K\$*'?(O[=DUR7_`NO:X.8.C:NRE"` M01VVUSYV'?JH+S9[O]7(\`2634M+_H/J4C0&U;P`9NCZAK3?2_[&JA9BAXVC M+&R9[F\%WP\.[U\8@'&AE.UOP#,9ODB[_P```/__`P!02P,$%``&``@````A M`,OSP:$R`0``0`(``!$`"`%D;V-07B^CVJQUTWR"M@1H=P*,%N[RHA*6B=?#@6@LN*/!))!E/ MA:W1+@1+,?9B!YK[+#9,##>MTSS$H]MBR\4[WP(N\OP::PA<\L!Q#TSM1$0C M4HH):3]<,P"DP-"`!A,\)AG!W]T`3OL_+PS)65.K<+!QIE'WG"W%,9S:>Z^F M8M=U65<.&M&?X)?5_>,P:JI,ORL!B/7[:;@/J[C*C0)Y/=J?DN;R]6R\1*W)2IH2D9+XF);V:T6+V6N%3:[S/)J`> M!?Y-/`'8X/WSS]D7````__\#`%!+`P04``8`"````"$`5!$G0M`"``#N"``` M$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"VP=+]^!U`2Z`Q3]V9\+O[.S8;<[',9E&"LT&H27IR/P@`4UXE0 MV21\W'PY^QP&UC&5,*D53,)7L.%-_/$#61E=@'$";(`NE)V$6^>*ZRBR?`LY ML^YYKLP=J`22L^+H,&P\7I?N?YTF MFE=\]FGS6B!P3*9%(05G#J.,OPINM-6I"^[V'"2)VD*"=&O@.R/<:SPB4?N3 MK#F3,$/'<&86*IQ)6#(C MF'*(5:DU'_5:%M:9^(*MGF/!+/M+):BH0Y2.@MDTQQH.LZ M+KI3[S1!"_9OD[7#PZK6LE2G]*'`"AUQJEPWY!VPKLF,=7)^-+EE5M0^5P8L M^J\;R>M\*7[N1(+-XY=J:^D*#.:!&3_=(B^PA:H@JAB66F52E)C!J;5O.N)( M5SM#1-2:Z1S'SO;SS87E6CFA=JB-&3*UJC_JA2H10QN<<6\TWP';=<<=#HO* MZ`Q#RGHTEYHIBI<(/8P6G68&FE)Y76,S!E6' M.^S"R]T7ZEU>2.WO]3Z3M=/\A;[KE(>BNKC?93+]Q4SB/Z6O!M^8P6GPGM)G MTE3$:](:GL%J>(=HT&)HF.C<"S,X3OXLM0?&A]-Y6-X\)4NA7NQCL=%SO(\/ M;V5WD]3MD>`+R0Z_:C$?P```/__`P!02P$"+0`4``8`"````"$`&C,95=H!```Q%@``$P`` M````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`( M````(0"U53`C]0```$P"```+`````````````````!,$``!?]^4T@$``!P5```:`````````````````#D' M``!X;"]? MTI3'7`,``*H*```/`````````````````$L*``!X;"]W;W)K8F]O:RYX;6Q0 M2P$"+0`4``8`"````"$`!&$&FP('``"Z'0``&`````````````````#4#0`` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#V=@'9Y M`@``TP4``!D`````````````````#!4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'Y"!Q+*"@``TE```!D````` M````````````3R,``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`/?TP?P5!P``%2P``!D`````````````````9S8` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)$.9Y1Y`@``MP4``!D`````````````````WTD``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`+X]P=%Q#@``4$4``!D`````````````````WM```'AL M+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$OAJP=`!```*Q```!@````````` M````````Y/8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`-?&.5O%`@``8`<``!D`````````````````!04!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$*" M$.-]#```'C@``!D`````````````````XA$!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$5V::S)`@``(@<``!D` M````````````````GR\!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(1S@,6P`@``U@8``!D````````````````` M9C@!`'AL+W=O XML 20 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations (unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Income Statement [Abstract]        
Revenues $ 10,993 $ 12,299 $ 34,193 $ 35,786
Cost of operations 8,730 8,762 25,663 25,529
Gross profit 2,263 3,537 8,530 10,257
Selling, general and administrative expenses 5,002 4,655 15,372 15,054
Impairment of long-lived assets 0 0 212 0
Restructuring charges 362 0 671 445
Operating loss from continuing operations (3,101) (1,118) (7,725) (5,242)
Other expense:        
Interest expense (54) (2) (80) (8)
Interest income 0 6 4 22
Other expense, net (131) (71) (343) (217)
Other expense (185) (67) (419) (203)
Loss from continuing operations before income taxes (3,286) (1,185) (8,144) (5,445)
Income tax expense 5 4 14 11
Loss from continuing operations (3,291) (1,189) (8,158) (5,456)
Discontinued operations:        
Gain on sale of Portamedic and subsidiary 3,543 0 3,618 65
Loss from discontinued operations, net of income taxes (1,966) (1,004) (4,736) (5,470)
Income (loss) from Discontinued Operations 1,577 (1,004) (1,118) (5,405)
Net loss $ (1,714) $ (2,193) $ (9,276) $ (10,861)
Continuing operations        
Basic (in dollars per share) $ (0.05) $ (0.02) $ (0.12) $ (0.08)
Diluted (in dollars per share) $ (0.05) $ (0.02) $ (0.12) $ (0.08)
Discontinued operations        
Basic (in dollars per share) $ 0.02 $ (0.01) $ (0.02) $ (0.08)
Diluted (in dollars per share) $ 0.02 $ (0.01) $ (0.02) $ (0.08)
Net loss        
Basic (in dollars per share) $ (0.02) $ (0.03) $ (0.13) $ (0.16)
Diluted (in dollars per share) $ (0.02) $ (0.03) $ (0.13) $ (0.16)
Weighted average number of shares - Basic (in shares) 69,952,153 69,789,628 69,877,878 69,713,178
Weighted average number of shares - Diluted (in shares) 69,952,153 69,789,628 69,877,878 69,713,178

XML 21 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation
 9 Months Ended
Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
Share-Based Compensation

Employee Share-Based Compensation Plans - On May 29, 2008, the Company's shareholders approved the 2008 Omnibus Employee Incentive Plan (the “2008 Plan”) providing for the grant of stock options, stock appreciation rights, non-vested stock and performance shares. The 2008 Plan provides for the issuance of an aggregate of 5,000,000 shares. For the three and nine months ended September 30, 2013, the Company granted 325,000 options to purchase shares under the 2008 Plan. For the nine months ended September 30, 2012, 900,000 options for the purchase of shares were granted under the 2008 Plan as well as 205,332 shares of restricted stock granted to the Company's Chief Executive Officer as settlement for a discretionary bonus of $0.1 million. As of September 30, 2013, approximately 1,479,900 shares remain available for grant under the 2008 Plan.

    
On May 24, 2011, the Company's shareholders approved the 2011 Omnibus Employee Incentive Plan (the "2011 Plan") providing for the grant of stock options and non-vested stock awards. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the 2011 Plan which increased the number of shares of the Company's common stock available for issuance from 1,500,000 shares to 3,500,000 shares (subject to adjustment as provided in the Amended and Restated Omnibus Plan). The 2011 Plan is to remain in effect until the earlier of (i) the 10th anniversary of the plan's original effective date (May 24, 2011), or (ii) the date all shares of stock available for issuance have been issued. During the three and nine months ended September 30, 2013, an aggregate of 2,000,000 options for the purchase of shares were granted under the 2011 Plan. During the three and nine months ended September 30, 2012, an aggregate of 1,225,000 options for the purchase of shares were granted under the 2011 Plan. As of September 30, 2013, approximately 1,092,500 shares remain available for grant under the 2011 Plan as amended.

Options awarded under the 2008 and 2011 Plans (as amended) are granted at fair value on the date of grant, are exercisable in accordance with a vesting schedule specified in the grant agreement, and have contractual lives of 10 years from the date of grant. Options to purchase an aggregate of 500,000 shares of the Company's stock granted to certain executives of the Company in December 2010 vested 50% on each of the first and second anniversaries of the grant. Options to purchase an aggregate of 325,000, 1,277,500 and 337,600 shares of the Company's stock granted to certain executives of the Company in September 2013, July 2012 and July 2011, respectively, vest one-third on each of the first, second and third anniversaries of the grant. Options to purchase 2,000,000 shares of the Company's stock granted to the Chief Executive Officer of the Company in September 2013, vest 25% upon receipt of the grant and 25% on the first, second and third anniversary of the grant. All other options granted by the Company vest 25% on each of the second through fifth anniversaries of the grant.

The fair value of the stock options granted during the three and nine month periods ended September 30, 2013 and 2012 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Expected life (years)
5.4
 
5.5
 
5.4
 
5.5
Expected volatility
89.6%
 
92.4%
 
89.6
%
 
 
92.4%
Expected dividend yield
—%
 
—%
 
—%
 
—%
Risk-free interest rate
1.5%
 
0.7%
 
1.5%
 
0.7%
Weighted average fair value of options granted during the period
$0.34
 
$0.47
 
$0.34
 
$0.47


The following table summarizes stock option activity for the nine month period ended September 30, 2013:
 
 
Number of Shares
 
Weighted Average Exercise Price Per Share
 
Weighted Average remaining Contractual Life (years)
 
Aggregate Intrinsic Value (in thousands)
Outstanding balance at December 31, 2012
 
6,429,250

 
$
1.28

 
 
 
 
Granted
 
2,325,000

 
0.47

 
 
 
 
Exercised
 
(60,550
)
 
0.24

 
 
 
 
Expired
 
(1,016,950
)
 
2.67

 
 
 
 
Forfeited
 
(1,371,650
)
 
0.63

 
 
 
 
Outstanding balance at September 30, 2013
 
6,305,100

 
0.91

 
7.7
 
$4
Options exercisable at September 30, 2013
 
3,526,850

 
$
1.20

 
6.3
 
$4


The aggregate intrinsic value disclosed in the table above represents the difference between the Company's closing stock price on the last trading day of the quarter ended September 30, 2013 and the exercise price, multiplied by the number of in-the-money stock options.
Under the 2008 Plan, during the three and nine months ended September 30, 2013, an aggregate of 60,550 stock options valued at $0.24 were exercised. No stock options were exercised during the nine months ended September 30, 2012. Options for the purchase of an aggregate of 1,498,850 shares of common stock vested during the nine month period ended September 30, 2013, and the aggregate fair value at grant date of these options was $0.7 million. As of September 30, 2013, there was approximately $0.9 million of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighted average period of 2.5 years.
In July 2009, an aggregate of 500,000 shares of non-vested stock were granted under the 2008 Plan. The shares vest as follows: 25% after two years and 25% on each of the next three anniversary dates thereafter. As of September 30, 2013, an aggregate of 337,500 shares of such non-vested stock were forfeited and 150,000 were vested. In July 2011, an aggregate of 305,000 shares of non-vested stock were granted under the 2008 Plan. As of September 30, 2013, an aggregate of 112,500 shares of such non-vested stock were forfeited and 155,100 were vested. The shares vest as follows: 33% on each of the first and second anniversary dates and 34% on the third anniversary. As of September 30, 2013, there was approximately $0.03 million of total unrecognized compensation cost related to non-vested stock awards. The cost is expected to be recognized over a weighted average period of 0.8 years.
Employee Stock Purchase Plan - In February 2012, under the Stock Purchase Plan (2004) of Hooper Holmes, Inc. (the "2004 Plan"), purchase rights for approximately 273,000 shares of the Company's stock were granted to eligible participating employees with an aggregate grant date fair value of $0.05 million, based on the Black-Scholes pricing model. This offering period concluded in March 2013 and, in accordance with the 2004 Plan's automatic termination provision, no shares were issued. In February 2013, under the 2004 Plan, purchase rights for approximately 233,000 shares were granted with an aggregate fair value of $0.03 million, based on the Black-Scholes option pricing model. The February 2013 offering period will conclude in March 2014. On May 29, 2013, the Company's shareholders approved an amendment and restatement of the Employee Stock Purchase Plan (2004), to be effective January 1, 2014 (as amended and restated, the "2014 Plan"). The aggregate number of shares of the Company's common stock available for purchase under the 2014 Plan is 2,000,000. Unless terminated earlier by the Board of Directors, the 2014 Plan will terminate December 31, 2024.
Other Stock Awards - On May 30, 2007, the Company's shareholders approved the Hooper Holmes, Inc. 2007 Non-Employee Director Restricted Stock Plan (the “2007 Plan”), which provides for the automatic grant, on an annual basis for 10 years, of shares of the Company's stock to the Company's non-employee directors. The total number of shares that may be awarded under the 2007 Plan is 600,000. As of September 30, 2013, there remain available for grant approximately 360,000 shares under the 2007 Plan. Effective June 1, 2007, each non-employee member of the Board of Directors other than the non-executive chair receives 5,000 shares annually and the non-executive chair receives 10,000 shares annually of the Company's stock, with such shares vesting immediately upon issuance. The Company believes that the shares awarded under the 2007 Plan are “restricted securities”, as defined in SEC Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"). The Company filed a Registration Statement on Form S-8 with respect to the 2007 Plan on April 16, 2008. The directors who receive shares under the 2007 Plan are "affiliates" as defined in Rule 144 under the Securities Act and thus remain subject to the applicable provisions of Rule 144. In addition, the terms of the awards (whether or not restricted) specify that the shares may not be sold or transferred by the recipient until the director ceases to serve on the Board or, if at that time the director has not served on the Board for at least four years, on the fourth anniversary of the date the director first became a Board member. During the nine months ended September 30, 2013 and 2012, shares awarded under the 2007 Plan totaled 30,000 and 30,000, respectively.

The Company recorded $0.4 million and $0.8 million of share-based compensation expense in selling, general and administrative expenses for the three and nine month periods ended September 30, 2013, respectively, and $0.2 million and $0.5 million for the three and nine month periods ended September 30, 2012, respectively, related to stock options, non-vested stock, restricted stock awards and the 2004 Plan. In connection with resignations of former members of management, the Company reversed previously recorded share-based compensation expense totaling $0.1 million and $0.2 million during the three and nine month periods ended September 30, 2013 and $0.0 million for the three and nine month periods ended September 30, 2012. The reversal was recorded in restructuring charges on the Company's consolidated statement of operations (See note 8).
XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 23 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Employee Share-Based Compensation Plans (Details) (USD $)
In Millions, except Share data, unless otherwise specified
 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended
Sep. 30, 2013
Sep. 30, 2013
2008 Plan [Member]
Sep. 30, 2012
2008 Plan [Member]
Sep. 30, 2013
2008 Plan [Member]
Sep. 30, 2012
2008 Plan [Member]
Sep. 30, 2013
2011 Plan [Member]
Sep. 30, 2012
2011 Plan [Member]
Sep. 30, 2013
2011 Plan [Member]
Sep. 30, 2012
2011 Plan [Member]
Sep. 30, 2013
Amended and Restated 2011 Plan [Member]
Dec. 31, 2010
December 2010 Stock Option Award [Member]
Sep. 30, 2013
December 2010 Stock Option Award [Member]
Sep. 30, 2013
September 2013 Stock Option Award [Member]
Jul. 31, 2012
July 2012 Stock Option Award [Member]
Sep. 30, 2013
July 2012 Stock Option Award [Member]
Jul. 31, 2011
July 2011 Stock Option Award [Member]
Sep. 30, 2013
July 2011 Stock Option Award [Member]
Sep. 30, 2013
All Other Stock Option Awards [Member]
Number of shares authorized under the plan (in shares)   5,000,000   5,000,000   1,500,000   1,500,000   3,500,000                
Remaining shares available for grant under the plan (in shares)   1,479,900   1,479,900           1,092,500                
Contractual life of stock options and other awards under share-based compensation plans       10 years       10 years                    
Options granted (in shares) 2,325,000 325,000 900,000 325,000 900,000 2,000,000 1,225,000 2,000,000 1,225,000   500,000   325,000 1,277,500   337,600    
Restricted stock granted to CEO as settlement for discretionary bonus (in shares)       205,332                            
Restricted stock granted to CEO as settlement for discretionary bonus       $ 0.1                            
Option Vesting Schedule                                    
Vesting percentage, year one           25.00%   25.00%       50.00% 33.00%   33.00%   33.00% 0.00%
Vesting percentage, year two           25.00%   25.00%       50.00% 33.00%   33.00%   33.00% 25.00%
Vesting percentage, year three           25.00%   25.00%         34.00%   34.00%   34.00% 25.00%
Vesting percentage, year four           25.00%   25.00%                   25.00%
Vesting percentage, year five                                   25.00%
XML 24 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2012 Annual Report on Form 10-K, filed with the SEC on April 1, 2013.

Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented.

The results of operations for the three and nine month periods ended September 30, 2013 and 2012 are not necessarily indicative of the results to be expected for any other interim period or the full year. See “Management's Discussion and Analysis of Financial Condition and Results of Operations” for additional information.
Discontinued Operations
On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the assets and liabilities of Portamedic that were sold have been reclassified and are reported as assets and liabilities held for sale on the December 31, 2012 consolidated balance sheet. The operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Certain costs presented within continuing operations in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among service lines and the continuing operations have been and are being restructured. There is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated in future periods. For further discussion on Discontinued Operations, please see Note 6.
XML 25 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Award Activity (Details) (USD $)
In Millions, except Share data, unless otherwise specified
 3 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Feb. 27, 2013
Feb. 29, 2012
Sep. 30, 2013
Director Stock Plan [Member]
Sep. 30, 2012
Director Stock Plan [Member]
Sep. 30, 2013
Amended and Restated 2014 Plan [Member]
Sep. 30, 2013
Stock Options [Member]
Jul. 31, 2009
July 2009 Non-vested Stock Award [Member]
Sep. 30, 2013
July 2009 Non-vested Stock Award [Member]
Jul. 31, 2011
July 2011 Non-vested Stock Award [Member]
Sep. 30, 2013
July 2011 Non-vested Stock Award [Member]
Sep. 30, 2013
Non-Vested Stock Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award                              
Exercised (options)     (60,550) 0                      
Exercised (weighted averaged exercise price)     $ 0.24                        
Options vested in period     1,498,850                        
Aggregate fair value of options vested in period     $ 0.7                        
Unrecognized compensation cost related to stock options                   0.9          
Weighted average period for recognition of compensation cost                   2 years 6 months         9 months 18 days
Compensation expense allocated to selling, general and administrative expenses 0.4 0.2 0.8 0.5                      
Reversal of previously recorded share-based compensation expense 0.1 0 0.2 0                      
Unrecognized compensation cost                             0
Non-vested Stock Awards                              
Aggregate shares granted             30,000 30,000     500,000   305,000    
Aggregate shares of non-vested stock forfeited                       337,500   112,500  
Aggregate shares that vested in the period                       150,000   155,100  
Vesting Schedule for Equity Grants Other than Options                              
Vesting percentage, year one                       0.00%   33.00%  
Vesting percentage, year two                       25.00%   33.00%  
Vesting percentage, year three                       25.00%   34.00%  
Vesting percentage, year four                       25.00%      
Vesting percentage, year five                       25.00%      
ESPP                              
Stock Allocated During Period, Shares, Employee Stock Purchase Plan         233,000 273,000                  
Aggregate Grant-Date Fair Value, Employee Stock Purchase Plan         $ 0.03 $ 0.05                  
Other Stock Awards                              
Term over which grants will occur             10 years                
Number of shares authorized under the plan (in shares)             600,000   2,000,000            
Remaining shares available for grant under the plan (in shares)             360,000                
Number of shares awarded annually to non-employee board members other than the non-executive chair             5,000                
Number of shares awarded annually to non-executive chair of the board of directors             10,000                
Aggregate shares granted             30,000 30,000     500,000   305,000    
XML 26 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Option Roll-Forward (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Stock Option Activity [Roll Forward]    
Outstanding balance (options) at December 31, 2012 6,429,250  
Options granted (in shares) 2,325,000  
Exercised (options) (60,550) 0
Expired (options) (1,016,950)  
Forfeited (options) (1,371,650)  
Outstanding balance (options) at March 31, 2013 6,305,100  
Outstanding balance (weighted average exercise price) at December 31, 2012 $ 1,280.00  
Granted (weighted average exercise price) $ 0.47  
Exercised (weighted averaged exercise price) $ 0.24  
Expired (weighted average exercise price) $ 2.67  
Forfeited (weighted average exercise price) $ 0.63  
Outstanding balance (weighted average exercise price) at March 31, 2013 $ 0.91  
Weighted Average Remaining Contractual Life, options outstanding 7 years 8 months 12 days  
Aggregate Intrinsic Value (in thousands), options outstanding $ 4  
Number of options exercisable at March 31, 2013 3,526,850  
Weighted average exercise price of options exercisable at March 31, 2013 $ 1.20  
Weighted Average Remaining Contractual Life, options exercisable 6 years 3 months 18 days  
Aggregate Intrinsic Value (in thousands), options exercisable $ 4  
XML 27 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Operating Loss Carryforwards [Line Items]        
Income tax expense $ 5,000 $ 4,000 $ 14,000 $ 11,000
Internal Revenue Service (IRS) [Member]
        
Operating Loss Carryforwards [Line Items]        
Operating loss carryforwards, subject to expiration 100,000,000   100,000,000  
State and Local Jurisdiction [Member]
        
Operating Loss Carryforwards [Line Items]        
Income tax expense   $ 10,000    
XML 28 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Restructuring Cost and Reserve [Line Items]        
Restructuring charges related to severance $ 362,000 $ 0 $ 671,000 $ 445,000
Restructuring reserve, current 1,700,000   1,700,000  
Restructuring reserve, noncurrent 100,000   100,000  
Other Restructuring [Member]
        
Restructuring Cost and Reserve [Line Items]        
Restructuring reserve, noncurrent $ 1,200,000   $ 1,200,000  
XML 29 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation Stock Option Valuation Assumptions (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]        
Expected life (years) 5 years 4 months 24 days 5 years 6 months 5 years 4 months 24 days 5 years 6 months
Expected volatility 89.60% 92.40% 89.60% 92.40%
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
Risk-free interest rate 1.50% 0.70% 1.50% 0.70%
Weighted average fair value of options granted during the period $ 0.34 $ 0.47 $ 0.34 $ 0.47
XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation
 9 Months Ended
Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation

Hooper Holmes, Inc. (“Hooper Holmes” or the "Company”) mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, insurance companies, employers, government organizations and academic institutions. The Company also conducts laboratory testing, assembles collection kits, conducts telephone interviews of life insurance applicants, compiles health histories, collects medical records and provides underwriting services to help life insurance companies evaluate underwriting risks.

As a provider of services to the health and insurance industries, the Company's business is subject to seasonality, with third quarter sales typically dropping below the other quarters due to a decline in activity during the summer months and fourth quarter sales typically the strongest quarter due to annual benefit renewal cycles.

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with instructions for Form 10-Q and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's 2012 Annual Report on Form 10-K, filed with the SEC on April 1, 2013.

Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. The financial information included herein is unaudited; however, such information reflects all adjustments that are, in the opinion of the Company's management, necessary for a fair statement of results for the interim periods presented.

The results of operations for the three and nine month periods ended September 30, 2013 and 2012 are not necessarily indicative of the results to be expected for any other interim period or the full year. See “Management's Discussion and Analysis of Financial Condition and Results of Operations” for additional information.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line. The Portamedic service line is accounted for as a discontinued operation in this Report. Accordingly, the assets and liabilities of Portamedic that were sold have been reclassified and are reported as assets and liabilities held for sale on the December 31, 2012 consolidated balance sheet. The operating results of Portamedic are segregated and reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Certain costs presented within continuing operations in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among service lines and the continuing operations have been and are being restructured. There is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated in future periods. For further discussion on Discontinued Operations, please see Note 6.
XML 31 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Loss Per Share
 9 Months Ended
Sep. 30, 2013
Earnings Per Share [Abstract]  
Loss Per Share
(Loss) Earnings Per Share

Outstanding stock options to purchase approximately 6,280,000 and 6,180,000 shares of the Company's common stock were excluded from the calculation of diluted loss per share for the three and nine month periods ended September 30, 2013, respectively, and approximately 5,565,000 and 5,543,000 shares for the three and nine month periods ended September 30, 2012, respectively, because their exercise prices exceeded the average market price of the Company's common stock for such periods and, therefore, were antidilutive.

XML 32 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations
 9 Months Ended
Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
Discontinued Operations

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. Pursuant to the terms of the Asset Purchase Agreement, the Company sold assets associated with its Portamedic service line, including, among other things, fixed assets and intellectual property, to Piston, and Piston assumed certain specified liabilities (the “Portamedic Disposition”). The adjusted purchase price (the "Purchase Price") was approximately $8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital, of which $2.0 million (the “Holdback Amount”) was held back by Piston as security for the Company’s obligations and agreements.

The Holdback Amount will be released as follows: within three business days after the date on which final closing adjustments for inventory and other current assets are determined and (the “Closeout Date”) (and after giving effect to any deductions from the Holdback Amount prior to such date), Piston will pay to the Company all amounts, if any, in excess of $1.0 million and the remaining $1.0 million of the Holdback Amount, less any deductions with respect to indemnification claims and any amounts in respect of any indemnification claims then in dispute, will be paid to the Company on the first anniversary of the Closeout Date. There cannot be any assurance that the Holdback Amount will be collected by the Company in full however, management currently expects to realize the amount in full and has recorded receivables in other current assets and other assets totaling $2.0 million.

The Company decided to sell its underperforming Portamedic service line and shift its focus towards the growth of its remaining health care service lines. In connection with the sale of Portamedic, the Company received $6.1 million of cash proceeds and incurred $0.9 million of financial advisory, legal and accounting fees, as of September 30, 2013. The Portamedic sale provides the Company with capital to invest in its Health and Wellness and Heritage Lab service lines. In addition, the Company retains the Portamedic accounts receivable and accounts payable, giving the Company over $9.4 million of working capital at September 30, 2013 to utilize in supporting wellness programs, clinical research and government studies.
    
The following summarizes the operating results of Portamedic and the gain on sale of Portamedic which are reported in discontinued operations in the accompanying consolidated statements of operations:

 
Three Months Ended
Nine Months Ended
 
September 30
September 30
(in thousands)
2013
2012
2013
2012
Revenues
$
19,173

$
21,371

$
62,437

$
72,077

Loss from operations before income taxes
$
(1,958
)
$
(997
)
$
(4,709
)
$
(5,446
)
Gain on sale of Portamedic and subsidiary
$
3,543

$
—

$
3,618

65

Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than $0.1 million for each period
presented and there were no income taxes on the gain of the sale due to the availability of net operating loss carry forwards with a
full valuation allowance.

The assets and liabilities of Portamedic are presented separately under the captions “Assets held for sale” and “Liabilities held for sale,” respectively, in the accompanying consolidated balance sheet as of December 31, 2012 and consist of the following:

(in thousands)
December 31, 2012

Assets held for sale:
 
Inventories
941

Other current assets
400

Property, plant and equipment, net
2,080

Other assets
225

Total assets
$
3,646

 
 
Liabilities held for sale:
 
Deferred rent
104

Capital leases
116

Total liabilities
$
220



In June 2008, the Company sold substantially all of the assets and liabilities of its Claims Evaluation Division ("CED") operating segment. In connection with the sale of the CED, the Company released as the primary obligor for certain lease obligations acquired but remain secondarily liable in the event the buyer defaults. In September 2013, the Company reduced the reserve for this liability by $0.1 million and reported the corresponding gain in discontinued operations. At September 30, 2013, the Company maintained a liability of $0.1 million for this lease obligation. The guarantee is provided for the term of the lease, which expires in July 2015. As of September 30, 2013, the maximum potential amount of future payments under the guarantee is $0.1 million.
XML 33 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Impairment of Long-lived Assets
 9 Months Ended
Sep. 30, 2013
Asset Impairment Charges [Abstract]  
Impairment of Long-lived Assets
Impairment of Long-lived Assets

During the nine month period ended September 30, 2013, the Company recorded an impairment charge in continuing operations of $0.2 million, which is included in impairment of long-lived assets in the accompanying consolidated statement of operations for the nine month period ended September 30, 2013. The charge of $0.2 million for the nine month period ended September 30, 2013 relates to the write-off of certain financial system software which will not be utilized in the future.

During the nine month periods ended September 30, 2013 and 2012, the Company recorded impairment of long-lived assets of Portamedic of $0.1 million and $0.2 million, respectively, which is included in the loss from discontinued operations, including income taxes.
XML 34 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations Narrative (Details) (USD $)
 1 Months Ended 3 Months Ended 9 Months Ended 0 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2013
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Portamedic Service Line [Member]
Sep. 30, 2013
Portamedic Service Line [Member]
Sep. 30, 2012
Portamedic Service Line [Member]
Sep. 30, 2013
Portamedic Service Line [Member]
Sep. 30, 2012
Portamedic Service Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Consideration amount           $ 8,400,000 $ 8,400,000   $ 8,400,000  
Proceeds from the sale of Portamedic       6,053,000 0 8,100,000     6,100,000  
Holdback amount           2,000,000 2,000,000   2,000,000  
Holdback release, business days after closing           3 days        
Holdback release, amounts paid threshold           1,000,000 1,000,000   1,000,000  
Holdback release, amount less deductions for indemnification claims           1,000,000 1,000,000   1,000,000  
Holdback receivable recorded           2,000,000 2,000,000   2,000,000  
Divestiture of business related costs                 900,000  
Working capital                 9,400,000  
Loss from discontinued operations, net of tax             (1,958,000) (997,000) (4,709,000) (5,446,000)
Decrease in reserve for lease obligation 100,000                  
Lease obligations   100,000   100,000            
Lease obligations future minimum payments due   100,000   100,000            
Gain on sale of Portamedic and subsidiary   $ 3,543,000 $ 0 $ 3,618,000 $ 65,000          
XML 35 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Loan and Security Agreements (Details) (USD $)
 9 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
Oct. 04, 2013
Dec. 31, 2012
Sep. 30, 2013
Prime rate [Member]
Sep. 30, 2013
LIBOR 90 day rate [Member]
Sep. 30, 2013
Prior to first anniversary [Member]
Sep. 30, 2013
Prior to second anniversary [Member]
Sep. 30, 2013
Prior to third anniversary [Member]
Sep. 30, 2013
First amendment [Member]
Sep. 30, 2013
First amendment [Member]
Prior to first anniversary [Member]
Sep. 30, 2013
First amendment [Member]
Prior to second anniversary [Member]
Sep. 30, 2013
First amendment [Member]
Prior to third anniversary [Member]
Sep. 30, 2013
2013 Loan and Security Agreement [Member]
Sep. 30, 2012
2013 Loan and Security Agreement [Member]
Sep. 30, 2013
2013 Loan and Security Agreement [Member]
Sep. 30, 2012
2013 Loan and Security Agreement [Member]
Loan and Security Agreements [Line Items]                                
Unused line fee                         $ 40,000 $ 0 $ 80,000 $ 20,000
Loan maximum defined, based on eligible receivables 85.00%                              
Maximum borrowing capacity under Loan and Security Agreement 10,000,000                              
Additional borrowing availability under Loan and Security Agreement 6,000,000                              
Borrowings outstanding under Loan and Security Agreement 2,608,000   0                          
Remaining borrowing capacity under Loan and Security Agreement 40,000                              
Loan maximum defined, based on eligible receivables, reserve 800,000 1,500,000                            
Facility fee, percentage 1.00%               1.50%              
Monthly collateral fee 1,500               2,500              
Monthly collertal fee (upon default) 3,000               5,000              
Credit facility - early termination fee           3.00% 2.00% 1.00%   5.00% 3.00% 2.00%        
Amendment fee                 200,000              
Spread on variable rate       2.75% 5.25%                      
Interest rate, stated percentage 6.00%                              
Commitment fee 100,000                              
Other issue costs $ 700,000                              
EXCEL 36 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U M9C`W.#,P-F(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1I M#I%>&-E;%=O#I7 M;W)K5]!9W)E96UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1I#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=F5N=&]R:65S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/DQO86Y?86YD7U-E M8W5R:71Y7T%G#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO M>#I.86UE/@T*("`@(#QX.E=O#I% M>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!296=I2!#96YT3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)S`P,#`W-#$X,34\2!&:6QE3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\ M'0^4V5P(#,P+`T*"0DR,#$S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!#;VUM;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPOF5D.B`R-#`L,#`P+#`P,"!S:&%R97,[ M($ES3L@3W5T3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!S=&]C:RP@ M870@8V]S=#L@.2PS.34@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^)SQS<&%N/CPOF5D("AI M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#`L M,#`P+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U9C`W.#,P-F(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-B,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E.CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@Q.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@Q+#DV-BD\'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#$\'0^)SQS<&%N/CPO2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G1S('5N9&5R(&-R961I="!F86-I;&ET>3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO&5D(&%S&5D(&%S2!C87!I=&%L(&QE87-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#QS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M M8F5R)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE7-I6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C(T<'@[9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^3VX@4V5P=&5M8F5R(#,P+"`R,#$S+"!T:&4@0V]M M<&%N>2!C;VUP;&5T960@=&AE('-A;&4@;V8@8V5R=&%I;B!A2!N;W0@8F4@:6YD:6-A=&EV92!O9B!C;W-T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N M93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXD-2XU(&UI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE2X@ M4F5S=')U8W1U6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SYN:6YE(&UO;G1H('!E3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q M,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/B!A;F0@,C`Q,BXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N M>2!H87,@;6%N86=E9"!I=',@;&EQ=6ED:71Y('1H2!I;B!&96)R=6%R>2`R,#$S(&%N9"!T:&4@'0M:6YD96YT.C0X<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[ M/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#DN-"!M:6QL:6]N/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^+B8C,38P.R8C,38P.U1H92!#;VUP86YY)W,@;F5T(&-A6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L M(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1&9O M;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P M,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P M,3,\+V9O;G0^/&9O;G0@3II;FAE'!E;F1I='5R97,@=&]T86QE9"`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`R,#$S M+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@=&AE('-A;&4@;V8@:71S(%!O3II;FAE3II;FAE2!0:7-T M;VX@87,@2!A;F0@ M4&ES=&]N("AS964@;F]T92`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`@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BX@($5L:6=I8FQE(%)E8V5I M=F%B;&5S(&1O(&YO="!I;F-L=61E($AE'0M86QI9VXZ:G5S=&EF M>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,@=&AE3II;FAE3II;FAE2!!9W)E96UE;G0@86YD('1H92!#;VUP86YY)W,@879A:6QA8FQE M(&)O2!W87,@/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N,#0@;6EL M;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[/B!B87-E9"!O;B!397!T96UB97(F(S$V,#LS,"P@ M,C`Q,R!%;&EG:6)L92!296-E:79A8FQE3II;FAE3II M;FAE2=S(&)O2!C86X@9FQU8W1U M871E(&EN(&%C8V]R9&%N8V4@=VET:"!I=',@;6]N=&AL>2!B:6QL:6YG(&-Y M8VQE2!I;F-R96%S960@=&\@87!P2`\+V9O;G0^/&9O;G0@ M3II;FAE3II M;FAE2!+96QT:6,@1FEN86YC:6%L M('=A3II;FAE3II;FAE2!R961U8W1I;VX@=&\@ M:6YC'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR M-'!X.V9O;G0M#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE3PO M9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US M:7IE.C$P<'0[8V]L;W(Z(V9F,#`P,#L^(#PO9F]N=#X\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B`V,"T\+V9O M;G0^/&9O;G0@3II;FAE3II M;FAE&EM871E;'D@/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)#D@;6EL;&EO;CPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A2!E2X\+V9O M;G0^/"]D:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA M;&EG;CIJ=7-T:69Y.V9O;G0M#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!! M9W)E96UE;G0@8V]N=&%I;G,@=F%R:6]U&5S+"!D97!R96-I871I M;VX@86YD(&%M;W)T:7IA=&EO;BD@8F5G:6YN:6YG('=I=&@@=&AE('1W96QV M92!M;VYT:',@96YD:6YG($IU;F4@,S`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`@/&AE860^#0H@("`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`\ M+V9O;G0^/&9O;G0@3II;FAE3II;FAE3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DL(&%N9"!A M<'!R;WAI;6%T96QY(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E M8V]R871I;VXZ;F]N93L^-2PU-C4L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^("!A;F0@/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXU M+#4T,RPP,#`\+V9O;G0^/&9O;G0@3II;FAE M3II;FAE2P@8F5C875S92!T:&5I&5R8VES92!PF4Z,3!P=#L^/&)R(&-L96%R/3-$ M;F]N92\^/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z,3!P=#LG/CQD:78@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$;&EN92UH96EG:'0Z,3(P M)3MT97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,C1P>#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE2!R96-O6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^)#`N,B!M:6QL:6]N/"]F;VYT/CQF;VYT('-T M>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!W M:&EC:"!I6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)#`N,B!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&9O7-T96T@6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)#`N,B!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!R97-P96-T:79E;'DL('=H:6-H M(&ES(&EN8VQU9&5D(&EN('1H92!L;W-S(&9R;VT@9&ES8V]N=&EN=65D(&]P M97)A=&EO;G,L(&EN8VQU9&EN9R!I;F-O;64@=&%X97,N/"]F;VYT/CPO9&EV M/CQD:78@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3I4:6UE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E M:6=H=#IB;VQD.SY3:&%R92U"87-E9"!#;VUP96YS871I;VX\+V9O;G0^/"]D M:78^/&1I=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIJ M=7-T:69Y.V9O;G0M#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE3II;FAE3II;FAE3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q M,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/BP@=&AE($-O;7!A;GD@9W)A;G1E9"`\+V9O;G0^/&9O M;G0@3II;FAE3II;FAE3II;FAE3II;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`U+#,S,CPO9F]N=#X\9F]N M="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[ M/B!S:&%R97,@;V8@3II M;FAE&EM871E;'D@/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXQ+#0W M.2PY,#`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIUF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CQD:78@'0M86QI M9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2=S('-H87)E:&]L9&5R3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXS+#4P,"PP,#`\+V9O;G0^/&9O;G0@3II M;FAE2`R-"P@,C`Q,2DL(&]R("AI:2D@=&AE(&1A=&4@86QL('-H M87)E6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]P=&EO;G,@9F]R M('1H92!P=7)C:&%S92!O9B!S:&%R97,@=V5R92!G3II;FAE3II;FAE6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]P=&EO;G,@ M9F]R('1H92!P=7)C:&%S92!O9B!S:&%R97,@=V5R92!G3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^+"!A<'!R;WAI;6%T96QY(#PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^,2PP.3(L-3`P/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^('-H87)E'0M86QI9VXZ:G5S=&EF M>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II M;FAE'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^3W!T:6]N6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO M;CIN;VYE.SXQ,#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN M:&5R:70[9F]N="US:7IE.C$P<'0[/B!Y96%R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXU,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E2=S M('-T;V-K(&=R86YT960@=&\@8V5R=&%I;B!E>&5C=71I=F5S(&]F('1H92!# M;VUP86YY(&EN($1E8V5M8F5R(#(P,3`@=F5S=&5D(#PO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L M;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^-3`E/"]F;VYT/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&]N(&5A8V@@;V8@=&AE(&9I3II M;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"`\ M+V9O;G0^/&9O;G0@3II;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXS,S6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^('-H87)E2=S('-T;V-K(&=R86YT960@=&\@ M8V5R=&%I;B!E>&5C=71I=F5S(&]F('1H92!#;VUP86YY(&EN(%-E<'1E;6)E M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^3W!T:6]N3II;FAE3II M;FAE2!T:&4@0V]M<&%N>2!V M97-T(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[ M9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ M;F]N93L^,C4E/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]N(&5A8V@@;V8@=&AE('-E8V]N9"!T M:')O=6=H(&9I9G1H(&%N;FEV97)S87)I97,@;V8@=&AE(&=R86YT+B`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`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`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`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`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`N M-#<\+V9O;G0^/"]D:78^/"]T9#X\=&0@#MP861D M:6YG+7)I9VAT.C)P>#L@#L@'0M86QI M9VXZ8V5N=&5R.V9O;G0M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II M;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D M9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^17AP:7)E9#PO9F]N M=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1'9E#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`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`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`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$)W9E M"!S;VQI9"`C M,#`P,#`P.V)A8VMGF4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A M8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F M;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P86X],T0R('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.W!A9&1I;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^,"XY,3PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HQ<'@@"!S;VQI9"`C M,#`P,#`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`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^)#0\+V9O;G0^/"]D:78^/"]T9#X\ M+W1R/CQT#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P M.C%P>"!S;VQI9"`C,#`P,#`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`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`Q,SPO9F]N=#X\9F]N="!S M='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@ M86YD('1H92!A9V=R96=A=&4@9F%I6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M+B!!3II;FAE M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M+"!T:&5R92!W87,@87!P2`\+V9O;G0^/&9O;G0@3II;FAE'!E M8W1E9"!T;R!B92!R96-O9VYI>F5D(&]V97(@82!W96EG:'1E9"!A=F5R86=E M('!E3II M;FAE'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O M;G0M2`R,#`Y/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M+"!A;B!A9V=R96=A=&4@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXU,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE M.SXR,#`X(%!L86X\+V9O;G0^/&9O;G0@3II M;FAE3II;FAE M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&]N(&5A8V@@;V8@=&AE(&YE>'0@=&AR964@ M86YN:79E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB M97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@86X@86=G6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXQ-3`L,#`P/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^('=E3II;FAE3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!A M;B!A9V=R96=A=&4@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SXQ,3(L-3`P/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E3II;FAE3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T M:&5R92!W87,@87!P2`\+V9O;G0^/&9O;G0@3II;FAE3II;FAEF5D(&-O;7!E;G-A=&EO;B!C;W-T M(')E;&%T960@=&\@;F]N+79E6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('EE87)S+CPO M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MP861D M:6YG+6)O='1O;3HQ-G!X.W1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N M=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SY&96)R=6%R>2`R,#$R/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!U;F1E2`R,#$S+"!U;F1E&EM871E M;'D@/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXR,S,L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('-H87)E3II;FAE3II;FAE6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY&96)R=6%R>2`R,#$S/"]F;VYT M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^(&]F9F5R:6YG('!E3II;FAE'0M:6YD96YT.C(T<'@[9F]N M="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FET86QI8SL^3W1H97(@4W1O M8VL@07=A6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^("T@3VX@36%Y(#,P+"`R,#`W+"!T:&4@ M0V]M<&%N>2=S('-H87)E:&]L9&5R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB M97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=&AE2`\+V9O;G0^/&9O;G0@ M3II;FAE3II;FAE3II;FAE2!N;W0@8F4@2!T:&4@2!O9B!T:&4@9&%T92!T:&4@9&ER96-T;W(@9FER6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!A;F0@,C`Q,BP@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`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`Q,SPO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M M9&5C;W)A=&EO;CIN;VYE.SXD,"XR(&UI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&9O3II;FAE2P@2!R96-O3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B!A;F0@ M/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)#`N,"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&9O2=S(&-O;G-O;&ED871E M9"!S=&%T96UE;G0@;V8@;W!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M,3!P=#LG/CQD:78@'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE'0M:6YD M96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3VX@4V5P=&5M8F5R(#,P M+"`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`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`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`\+V9O;G0^/"]D:78^/"]T9#X\=&0@8V]L#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,3X\ M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY397!T96UB97(@,S`\+V9O;G0^/"]D M:78^/"]T9#X\+W1R/CQT#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV M('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF M;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@ M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S M<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^,C`Q,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS M<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R M+6)O='1O;3HQ<'@@#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC M96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`Q,SPO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!C;VQS<&%N/3-$,R!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB M;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,C`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`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`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`P,#`P,#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`[)R!R M;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$;W9E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^3&EA8FEL:71I97,@:&5L9"!F;W(@#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$=&5X="UA;&EG;CIL M969T.V9O;G0M#L@ M'0M86QI9VXZF4Z,3!P=#L^,3`T/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T M>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`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`P,#`P,#MB86-K9W)O=6YD+6-O M;&]R.B-C8V5E9F8[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M'0M M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^26X@2G5N92`R,#`X M+"!T:&4@0V]M<&%N>2!S;VQD('-U8G-T86YT:6%L;'D@86QL(&]F('1H92!A M65R(&1E9F%U;'1S+B!) M;B!397!T96UB97(@,C`Q,RP@=&AE($-O;7!A;GD@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#`N,2!M M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"!R97!O2!M86EN=&%I;F5D M(&$@;&EA8FEL:71Y(&]F(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/B0P+C$@;6EL;&EO;CPO9F]N M=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE M.C$P<'0[/B!F;W(@=&AI2`R,#$U+B!!&EM=6T@<&]T96YT:6%L(&%M;W5N="!O9B!F M=71U3II;FAE3II;FAE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`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`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XY(&UI M;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE2P@;V8@8V]M<&]N96YT M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U M9C`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`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M M8F5R)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XT(&UI;&QI;VX\+V9O;G0^/&9O;G0@ M3II;FAE3I4:6UE3II;FAE2X@(%1H92!R97-T3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/&9O;G0@ M3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&-O;G-I'0M:6YD M96YT.C(T<'@[9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N M92\^/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M3II;FAE3II;FAE6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O M;G0@3II;FAE'0M:6YD96YT.C(T<'@[9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD M:78@'0M86QI9VXZ:G5S=&EF M>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(')E;&%T960@=&\@3II;FAE3II;FAE'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,V(R M-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U9C`W.#,P-F(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.3-B,C'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z.'!T.V9O;G0M=V5I9VAT.F)O;&0[/B`\+V9O;G0^/&9O;G0@3II;FAE'0M86QI9VXZ:G5S=&EF>3MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MT97AT+61E8V]R871I;VXZ=6YD97)L:6YE.SXR,#$S($QO86X@ M86YD(%-E8W5R:71Y($%G6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@ M'0M86QI9VXZ:G5S=&EF>3MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M3II;FAE2!!9W)E96UE;G0L('1H92!#;VUP86YY('1E M3II;FAE3II;FAE2!!9W)E96UE;G0L('1H92!#;VUP86YY M(&EN8W5R6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XP."!M:6QL:6]N/"]F;VYT/CQF;VYT M('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(')E2X@1'5R:6YG('1H92`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE3II M;FAE6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN(&-O M;FYE8W1I;VX@=VET:"!T:&4@,C`P.2!,;V%N(&%N9"!396-U2!!9W)E M96UE;G0L('1H92!#;VUP86YY(&EN8W5R6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SXD,"XP,"!M:6QL:6]N/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&%N9"`\+V9O;G0^/&9O M;G0@3II;FAE3II;FAE2X@(#PO9F]N=#X\+V1I M=CX\9&EV('-T>6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^ M/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO M'0M9&5C;W)A=&EO;CIN;VYE.SXX-24\+V9O;G0^/&9O M;G0@3II;FAE2!!9W)E96UE M;G0I(&QE2!T:6UE(&5X8V5E9"`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M+B`@16QI9VEB;&4@4F5C96EV86)L97,@9&\@;F]T(&EN8VQU9&4@2&5R:71A M9V4@3&%B2!+96QT:6,@1FEN86YC M:6%L+B`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`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`R,#$S/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"!T:&4@0V]M<&%N>2!E;G1E2!!9W)E96UE;G0N(%5N9&5R('1H92!&:7)S="!!;65N9&UE;G0L M('1H92!A;FYU86P@9F%C:6QI='D@9F5E(&EN8W)E87-E9"!T;R`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`\+V9O;G0^/&9O;G0@ M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^(&]F('1H92!R979O;'9I;F<@8W)E9&ET("!L:6UI=#L@8BD@:68@869T M97(@=&AE(&9I2!O9B!T:&4@969F96-T:79E(&1A=&4L(&9R;VT@/"]F M;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXR M)3PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[/B!T;R`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&]F('1H92!R979O M;'9I;F<@8W)E9&ET.R!A;F0@8RD@:68@869T97(@=&AE('-E8V]N9"!A;FYI M=F5R2!B=70@<')I;W(@=&\@=&AE('1H:7)D(&%N;FEV97)S87)Y(&]F M('1H92!E9F9E8W1I=F4@9&%T92P@9G)O;2`\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('1O M(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N M="US:7IE.C$P<'0[8V]L;W(Z(S`P,#`P,#MT97AT+61E8V]R871I;VXZ;F]N M93L^,B4\+V9O;G0^/&9O;G0@3II;FAE2!P M86ED(&%N(&%M96YD;65N="!F964@;V8@/"]F;VYT/CQF;VYT('-T>6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN;VYE.SXD,"XR(&UI;&QI;VX\+V9O;G0^ M/&9O;G0@3II;FAE6QE/3-$;&EN92UH96EG:'0Z M,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C(T<'@[9F]N="US:7IE.C$P<'0[ M/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CQD M:78@'0M86QI9VXZ:G5S=&EF M>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0MF5D('!R M:6UE(')A=&4@<&QU3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^+"`H:6DI('1H92`Y M,"!D87D@3$E"3U(@3II;FAE M6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^('!E6QE/3-$9F]N="UF86UI;'DZ M:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C M;W)A=&EO;CIN;VYE.SXD,"XW(&UI;&QI;VX\+V9O;G0^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@:6X@ M8V]N;F5C=&EO;B!W:71H('1H92`R,#$S($QO86X@86YD(%-E8W5R:71Y($%G M2!I;F-U3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&EN M(&9A8VEL:71Y(&9E97,L(')E2X\+V9O;G0^/"]D:78^/&1I M=B!S='EL93TS1&QI;F4M:&5I9VAT.C$R,"4[=&5X="UA;&EG;CIJ=7-T:69Y M.V9O;G0M#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE2`R."P@,C`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`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@ M'0M86QI9VXZ:G5S=&EF>3MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P M)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^/&)R M(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQT86)L92!C96QL<&%D9&EN M9STS1#`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`[)B,Q-C`[ M)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X M.V9O;G0M2!O M9B!I=',@;W(@=&AE:7(@2!!9W)E96UE;G0@<')O=FED97,@=&AA="`B179E;G1S(&]F M($1E9F%U;'0B(&EN8VQU9&4@=&AE(&]C8W5R2!O2!O9B!T:&4@0V]M<&%N>2!A;F0@:71S('-U M8G-I9&EA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U9C`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`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&9O2!W:6QL(&-O;W!E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)#$P,"PP,#`\+V9O;G0^/&9O;G0@3II;FAE2!S97)V:6-E2!A2!O9B!E86-H('!R96UI2!C;&]S M:6YG+"!U;G1I;"!S=6-H('1I;64@87,@=&AE(&QE87-E(&ES(&1U;'D@87-S M:6=N960@*&]R(&]T:&5R=VES92!S=7!E2!A;'-O(&%G M2!A2!W:6QL(&-O;W!E2!P#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C(T<'@[9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^3VX@2G5L>2`Q,2P@,C`P,RP@=&AE($-O;7!A;GD@2!N;W0@8F4@2!M87D@8F4@96YT:71L960@=&\@2!H87,@;F]T(')E8V5I M=F5D(&%N>2!F=7)T:&5R(&-O;6UU;FEC871I;VX@9G)O;2!T:&4@26YT97)N M86P@4F5V96YU92!397)V:6-E+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$ M;&EN92UH96EG:'0Z,3(P)3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE2!I;7!R;W!E6UE;G0@86YD+V]R('=O2!W M87,@=&AE7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`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`@("`\=&%B;&4@8VQA&5S M/&)R/CPO"!$:7-C;&]S=7)E(%M!8G-T'0^)SQD:78@&5S(#PO9F]N=#X\9F]N="!S='EL93TS1&9O;G0M9F%M:6QY M.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(V9F,#`P,#MF;VYT+7=E M:6=H=#IB;VQD.SX@/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE'0M M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M"!E>'!E;G-E(&]F(&QE M3II;FAE M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"`\+V9O;G0^/&9O;G0@3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A M=&EO;CIN;VYE.SYN:6YE/"]F;VYT/CQF;VYT('-T>6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^(&UO;G1H('!E6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#MC;VQO'0M9&5C;W)A=&EO;CIN M;VYE.SY397!T96UB97(F(S$V,#LS,"P@,C`Q,CPO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=&AE M($-O;7!A;GD@3II;FAE2!T;R!O;F4@"!B96YE M9FET6UE;G0@;V8@:6YT97)E3II;FAE3II;FAE3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^(&%N9"`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`Q,SPO9F]N=#X\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[/BP@=&AE M($-O;7!A;GD@:&%S(%4N4RX@9F5D97)A;"!A;F0@3II;FAE3II;FAE3II M;FAE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X M.V9O;G0M2!I;F-L=61E9"!I M;B!F:6YA;F-I86P@2!A8V-E<'1E M9"!I;B!T:&4@56YI=&5D(%-T871E6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CQD:78@'0M86QI9VXZ:G5S M=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M'!E;G-E6QE M/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I M=#MF;VYT+7-I>F4Z,3!P=#L^(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS M1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P M,#`P,#MT97AT+61E8V]R871I;VXZ;F]N93L^4V5P=&5M8F5R)B,Q-C`[,S`L M(#(P,3,\+V9O;G0^/&9O;G0@3II;FAE2!O=&AE7-I3I4:6UE6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT M+6%L:6=N.FIU#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE2!S96QL:6YG+"!G96YE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U9C`W.#,P-F(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-B,C'0O:'1M;#L@8VAA3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQD:78@3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M3II;FAE3II;FAE'0M86QI9VXZ8V5N=&5R.V9O;G0M6QE/3-$<&%D9&EN9RUL969T.C!P>#MT97AT+6EN9&5N=#HP<'@[ M;&EN92UH96EG:'0Z;F]R;6%L.W!A9&1I;F6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MM87)G:6XM M;&5F=#IA=71O.VUA6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$ M=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E M:6=H=#IB;VQD.SY.=6UB97(@;V8@4VAA6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D M:6YG+7)I9VAT.C)P>#L@#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N M/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US:7IE M.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY796EG:'1E9"!!=F5R86=E M(')E;6%I;FEN9R!#;VYT#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D M:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[)R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([ M9F]N="US:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH M97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.SY!9V=R96=A M=&4@26YT6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T M=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3W5T M#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$ M,2!C;VQS<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A M9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ M,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I M;F6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[ M<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@'0M86QI M9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D M9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E M#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P M86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[ M<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P M=#L^17AE6QE/3-$=F5R M=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O M;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@ M'0M86QI9VXZF4Z,3!P=#L^,BXV-SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!S M='EL93TS1'9E'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X M.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O M=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P,#`P.R<@'0M86QI9VXZ M:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN M9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E#MP M861D:6YG+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@F4Z M,3!P=#L^/&9O;G0@3II;FAE#MP861D M:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)O6QE/3-$=&5X M="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)O6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('-T>6QE M/3-$)W9E"!S M;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[ M8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MB86-K9W)O M=6YD+6-O;&]R.B-C8V5E9F8[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R M9&5R+6)O='1O;3HQ<'@@#MB M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^,2XR,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HQ<'@@ M6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P M86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@ MF4Z,3!P=#L^/&9O M;G0@3II;FAE#MP M861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O M;G0@3II;FAE#MP861D:6YG+7)I M9VAT.C)P>#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@'0M86QI9VXZF4Z,3!P=#L^)#0\+V9O;G0^/"]D:78^/"]T9#X\ M+W1R/CPO=&%B;&4^/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/CQD:78@'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O M;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L M:6=N.FIU#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE'0M M:6YD96YT.C!P>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`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`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&-O;'-P M86X],T0R('-T>6QE/3-$)W9E"!S;VQI9"`C,#`P,#`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`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`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`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`[/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.V)A8VMG#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+71O M<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E6QE/3-$=&5X="UA;&EG;CIC96YT97([9F]N="US M:7IE.C$P<'0[/CQF;VYT('-T>6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^)#`N,S0\+V9O;G0^/"]D:78^/"]T9#X\=&0@#MP861D:6YG+7)I9VAT.C)P>#L@F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P M>#L@'0M86QI9VXZ8V5N=&5R M.V9O;G0M7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG M/CQD:78@'0M86QI9VXZ:G5S M=&EF>3MT97AT+6EN9&5N=#HR-'!X.V9O;G0M6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD M.SX@/"]F;VYT/CPO9&EV/CQD:78@'0M86QI9VXZ:G5S=&EF>3MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE'0M:6YD96YT.C!P M>#ML:6YE+6AE:6=H=#IN;W)M86P[<&%D9&EN9RUT;W`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`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P M86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT M.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E#MP M861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$)W9E"!S;VQI9"`C,#`P M,#`P.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#LG(')O=W-P86X],T0Q/CQD M:78@F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE M/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG#MP861D:6YG M+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O M;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^4F5V96YU97,\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG M'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE6QE/3-$=F5R=&EC86PM M86QI9VXZ8F]T=&]M.V)A8VMG6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG M+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT M/CPO9&EV/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E#L@'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^-C(L-#,W/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.V)A8VMG M'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^ M/&9O;G0@3II;FAE#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O M;G0@3II;FAE6QE/3-$=F5R=&EC86PM86QI M9VXZ8F]T=&]M.V)A8VMG6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z M,3!P=#L^/&9O;G0@3II;FAE6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$ M9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^3&]S#MP861D:6YG+6)O='1O;3HR<'@[ M(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!S='EL93TS1'9E6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP M861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD M:78@#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P M=#L^/&9O;G0@3II;FAE6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+6)O='1O M;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR<'@[<&%D9&EN M9RUB;W1T;VTZ,G!X.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#L@'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*#4L-#0V/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('-T>6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M.W!A9&1I M;F#MP861D:6YG+6)O='1O;3HR M<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^*3PO9F]N=#X\+V1I M=CX\+W1D/CPO='(^/'1R/CQT9"!S='EL93TS1'9E6QE M/3-$=&5X="UA;&EG;CIJ=7-T:69Y.V9O;G0M6QE/3-$=F5R=&EC86PM86QI9VXZ8F]T=&]M M.W!A9&1I;F#MB86-K9W)O=6YD+6-O;&]R.B-C8V5E9F8[(')O=W-P86X],T0Q M(&-O;'-P86X],T0Q/CQD:78@F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL M93TS1'9E#L@'0M86QI9VXZ M6QE/3-$9F]N="UF86UI M;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,RPU-#,\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X] M,T0Q/CQD:78@6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR<'@[8F%C:V=R;W5N9"UC;VQO6QE/3-$=&5X="UA M;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O M='1O;3HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE/3-$=F5R=&EC86PM86QI9VXZ M8F]T=&]M.V)A8VMG'0M86QI9VXZ;&5F=#MF;VYT M+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#L@'0M86QI9VXZ6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF M;VYT+7-I>F4Z,3!P=#L^-C4\+V9O;G0^/"]D:78^/"]T9#X\=&0@6QE/3-$=&5X M="UA;&EG;CIL969T.V9O;G0M6QE/3-$;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N M.FIU3II;FAE"!E>'!E M;G-E3II;FAE6QE/3-$9F]N M="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z.'!T.SYP&5S(&]N('1H92!G86EN(&]F('1H M92!S86QE(&1U92!T;R!T:&4@879A:6QA8FEL:71Y(&]F(&YE="!O<&5R871I M;F<@;&]S2!F;W)W87)D'0M86QI9VXZ:G5S=&EF M>3MP861D:6YG+6QE9G0Z-31P>#MF;VYT+7-I>F4Z.'!T.SX\9F]N="!S='EL M93TS1&9O;G0M9F%M:6QY.FEN:&5R:70[9F]N="US:7IE.CAP=#L^9G5L;"!V M86QU871I;VX@86QL;W=A;F-E+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$ M;&EN92UH96EG:'0Z,3(P)3MT97AT+6%L:6=N.FIU6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT M+7-I>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CQD M:78@'0M86QI9VXZ;&5F=#MT M97AT+6EN9&5N=#HR-'!X.V9O;G0M2P@:6X@=&AE(&%C M8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E="!A3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M(&%N9"!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F'0M86QI9VXZ;&5F=#MF M;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE M#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR M:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q/CQD:78@6QE M/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T M>6QE.FET86QI8SL^*&EN('1H;W5S86YD#MP861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T M;VTZ,G!X.R!R;W=S<&%N/3-$,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR M:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE6QE/3-$ M=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$ M,3X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+6)O='1O;3HR M<'@[<&%D9&EN9RUR:6=H=#HR<'@[(')O=W-P86X],T0Q(&-O;'-P86X],T0Q M/CQD:78@6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z M,3!P=#L^07-S971S(&AE;&0@9F]R('-A;&4Z/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&-O;'-P86X],T0S('-T>6QE/3-$)W9E#MP861D:6YG+6)O M='1O;3HR<'@[<&%D9&EN9RUR:6=H=#HR<'@[8F]R9&5R+71O<#HQ<'@@6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^)B,Q-C`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`P M,#`P,#MP861D:6YG+6QE9G0Z,G!X.W!A9&1I;F#MP861D:6YG M+6)O='1O;3HR<'@[8F]R9&5R+71O<#HQ<'@@F4Z,3!P=#L^)#PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[8F]R9&5R+6)O M='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[<&%D9&EN9RUT;W`Z,G!X.W!A9&1I M;F#MB;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P.R<@ M'0M86QI M9VXZ6QE/3-$9F]N="UF M86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^,RPV-#8\+V9O;G0^/"]D M:78^/"]T9#X\=&0@6QE/3-$=&5X="UA;&EG;CIL969T.V9O;G0M#MP861D:6YG+71O<#HR M<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.W!A9&1I;F6QE/3-$;W9E#MP861D:6YG+7)I9VAT.C)P>#MB;W)D97(M=&]P.C-P>"!D;W5B;&4@ M(S`P,#`P,#LG(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`[ M/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$=F5R=&EC M86PM86QI9VXZ8F]T=&]M.W!A9&1I;F#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ M;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+6)O='1O;3HR<'@[<&%D9&EN9RUR:6=H M=#HR<'@[(')O=W-P86X],T0Q/CQD:78@F4Z,3!P=#L^)B,Q-C`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`C,#`P M,#`P.R<@'0M86QI9VXZ;&5F=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP861D:6YG+7)I9VAT.C)P>#L@'0M86QI9VXZ;&5F=#MF;VYT+7-I M>F4Z,3!P=#L^/&9O;G0@3II;FAE#MP M861D:6YG+71O<#HR<'@[<&%D9&EN9RUB;W1T;VTZ,G!X.V)A8VMG6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I>F4Z,3!P=#L^ M)#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CIB;W1T;VT[8F]R9&5R+6)O='1O;3HS<'@@9&]U8FQE(",P,#`P,#`[8F%C M:V=R;W5N9"UC;VQO#MP861D:6YG M+6)O='1O;3HR<'@[)R!R;W=S<&%N/3-$,2!C;VQS<&%N/3-$,3X\9&EV('-T M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MF;VYT+7-I>F4Z,3!P=#L^/&9O;G0@ M3II;FAE6QE/3-$9F]N="UF86UI;'DZ:6YH97)I=#MF;VYT+7-I M>F4Z,3!P=#L^/&)R(&-L96%R/3-$;F]N92\^/"]F;VYT/CPO9&EV/CPO=&0^ M/"]T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2`H1&5T86EL2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;F1I='5R97,\+W1D M/@T*("`@("`@("`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`U,E\S9C@U9C`W.#,P-F(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-B,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L=61E9"!F3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U M,E\S9C@U9C`W.#,P-F(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.3-B,C'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`R M,#$R(%-T;V-K($]P=&EO;B!!=V%R9"!;365M8F5R73QB'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S$P('EE87)S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'!E8W1E9"!L:69E("AY M96%R7,\7,\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S M9C@U9C`W.#,P-F(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-B M,C'0O:'1M;#L@8VAA&-E M<'0@4VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES960@*'=E:6=H=&5D(&%V97)A9V5D(&5X97)C:7-E('!R:6-E*3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M&5R8VES92!P&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2`H1&5T M86EL2`R,#`Y($YO;BUV M97-T960@4W1O8VL@07=A'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES960@*&]P=&EO;G,I/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!R96-O'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(&-O;7!E;G-A=&EO;B!C;W-T/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!''0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(%-T;V-K(%!U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D('5N9&5R('1H92!P;&%N("AI;B!S:&%R97,I M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO2!T;R!N;VXM96UP M;&]Y964@8F]A'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U M9C`W.#,P-F(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-B,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7,@869T97(@8VQO M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO2P@<&QA;G0@86YD(&5Q=6EP;65N="P@;F5T/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C7S0Y,F)?8C`U,E\S9C@U9C`W M.#,P-F(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-B,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!$:7-C;&]S=7)E(%M!8G-T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS+#`P,#QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,V(R-SAE8U\U-S9C M7S0Y,F)?8C`U,E\S9C@U9C`W.#,P-F(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.3-B,C'0O M:'1M;#L@8VAA&5S("A$971A:6QS*2`H55-$ M("0I/&)R/CPO69O M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO"!E>'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO69O'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1087)T I7SDS8C(W.&5C7S4W-F-?-#DR8E]B,#4R7S-F.#5F,# XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 77 208 1 false 29 0 false 4 false false R1.htm 0001000 - Document - DEI Document Sheet http://www.hooperholmes.com/role/DeiDocument DEI Document true false R2.htm 1001000 - Statement - Consolidated Balance Sheets (unaudited) Sheet http://www.hooperholmes.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (unaudited) false false R3.htm 1001500 - Statement - Consolidated Balance Sheet (unaudited) (Parentheticals) Sheet http://www.hooperholmes.com/role/ConsolidatedBalanceSheetUnauditedParentheticals Consolidated Balance Sheet (unaudited) (Parentheticals) false false R4.htm 1003000 - Statement - Consolidated Statements of Operations (unaudited) Sheet http://www.hooperholmes.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (unaudited) false false R5.htm 1004000 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://www.hooperholmes.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (unaudited) false false R6.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.hooperholmes.com/role/BasisOfPresentation Basis of Presentation false false R7.htm 2107100 - Disclosure - Liquidity Sheet http://www.hooperholmes.com/role/Liquidity Liquidity false false R8.htm 2110100 - Disclosure - Loss Per Share Sheet http://www.hooperholmes.com/role/LossPerShare Loss Per Share false false R9.htm 2113100 - Disclosure - Impairment of Long-lived Assets Sheet http://www.hooperholmes.com/role/ImpairmentOfLongLivedAssets Impairment of Long-lived Assets false false R10.htm 2122100 - Disclosure - Share-Based Compensation Sheet http://www.hooperholmes.com/role/ShareBasedCompensation Share-Based Compensation false false R11.htm 2131100 - Disclosure - Discontinued Operations Sheet http://www.hooperholmes.com/role/DiscontinuedOperations Discontinued Operations false false R12.htm 2134100 - Disclosure - Inventories Sheet http://www.hooperholmes.com/role/Inventories Inventories false false R13.htm 2135100 - Disclosure - Restructuring Charges Sheet http://www.hooperholmes.com/role/RestructuringCharges Restructuring Charges false false R14.htm 2136100 - Disclosure - Loan and Security Agreements Sheet http://www.hooperholmes.com/role/LoanAndSecurityAgreements Loan and Security Agreements false false R15.htm 2137100 - Disclosure - Commitments and Contingencies Sheet http://www.hooperholmes.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R16.htm 2138100 - Disclosure - Litigation Sheet http://www.hooperholmes.com/role/Litigation Litigation false false R17.htm 2139100 - Disclosure - Income Taxes Sheet http://www.hooperholmes.com/role/IncomeTaxes Income Taxes false false R18.htm 2201201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.hooperholmes.com/role/BasisOfPresentationPolicies Basis of Presentation (Policies) false false R19.htm 2322301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) false false R20.htm 2331301 - Disclosure - Discontinued Operations (Tables) Sheet http://www.hooperholmes.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) false false R21.htm 2407401 - Disclosure - Liquidity (Details) Sheet http://www.hooperholmes.com/role/LiquidityDetails Liquidity (Details) false false R22.htm 2410401 - Disclosure - Loss Per Share (Details) Sheet http://www.hooperholmes.com/role/LossPerShareDetails Loss Per Share (Details) false false R23.htm 2413401 - Disclosure - Impairment of Long-lived Assets (Details) Sheet http://www.hooperholmes.com/role/ImpairmentOfLongLivedAssetsDetails Impairment of Long-lived Assets (Details) false false R24.htm 2422402 - Disclosure - Share-Based Compensation Employee Share-Based Compensation Plans (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationEmployeeShareBasedCompensationPlansDetails Share-Based Compensation Employee Share-Based Compensation Plans (Details) false false R25.htm 2422403 - Disclosure - Share-Based Compensation Stock Option Valuation Assumptions Sheet http://www.hooperholmes.com/role/ShareBasedCompensationStockOptionValuationAssumptions Share-Based Compensation Stock Option Valuation Assumptions false false R26.htm 2422404 - Disclosure - Share-Based Compensation Option Roll-Forward (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationOptionRollForwardDetails Share-Based Compensation Option Roll-Forward (Details) false false R27.htm 2422405 - Disclosure - Share-Based Compensation Award Activity (Details) Sheet http://www.hooperholmes.com/role/ShareBasedCompensationAwardActivityDetails Share-Based Compensation Award Activity (Details) false false R28.htm 2431402 - Disclosure - Discontinued Operations Narrative (Details) Sheet http://www.hooperholmes.com/role/DiscontinuedOperationsNarrativeDetails Discontinued Operations Narrative (Details) false false R29.htm 2431403 - Disclosure - Discontinued Operations (Details) Sheet http://www.hooperholmes.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) false false R30.htm 2434401 - Disclosure - Inventories (Details) Sheet http://www.hooperholmes.com/role/InventoriesDetails Inventories (Details) false false R31.htm 2435401 - Disclosure - Restructuring Charges (Details) Sheet http://www.hooperholmes.com/role/RestructuringChargesDetails Restructuring Charges (Details) false false R32.htm 2436401 - Disclosure - Loan and Security Agreements (Details) Sheet http://www.hooperholmes.com/role/LoanAndSecurityAgreementsDetails Loan and Security Agreements (Details) false false R33.htm 2437401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.hooperholmes.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R34.htm 2439401 - Disclosure - Income Taxes (Details) Sheet http://www.hooperholmes.com/role/IncomeTaxesDetails Income Taxes (Details) false false All Reports Book All Reports Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearFive had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearFour had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearOne had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearThree had a mix of decimals attribute values: 0 2. Element hh_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageYearTwo had a mix of decimals attribute values: 0 2. Element us-gaap_AssetImpairmentCharges had a mix of decimals attribute values: -5 -3. Element us-gaap_IncomeTaxExpenseBenefit had a mix of decimals attribute values: -4 -3. Element us-gaap_ProceedsFromDivestitureOfBusinesses had a mix of decimals attribute values: -5 -3. Element us-gaap_SellingGeneralAndAdministrativeExpense had a mix of decimals attribute values: -5 -3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice had a mix of decimals attribute values: -1 2. 'Monetary' elements on report '2407401 - Disclosure - Liquidity (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2431402 - Disclosure - Discontinued Operations Narrative (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2431403 - Disclosure - Discontinued Operations (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2435401 - Disclosure - Restructuring Charges (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2436401 - Disclosure - Loan and Security Agreements (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '2439401 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values. Process Flow-Through: 1001000 - Statement - Consolidated Balance Sheets (unaudited) Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 1001500 - Statement - Consolidated Balance Sheet (unaudited) (Parentheticals) Process Flow-Through: 1003000 - Statement - Consolidated Statements of Operations (unaudited) Process Flow-Through: 1004000 - Statement - Consolidated Statements of Cash Flows (unaudited) hh-20130930.xml hh-20130930.xsd hh-20130930_cal.xml hh-20130930_def.xml hh-20130930_lab.xml hh-20130930_pre.xml true true XML 38 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheet (unaudited) (Parentheticals) (USD $)
In Thousands, except Share data, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 622 $ 662
Common stock, par value (in dollars per share) $ 0.04 $ 0.04
Common stock, shares authorized (in shares) 240,000,000 240,000,000
Common stock, shares issued (in shares) 70,140,864 69,844,782
Common stock, shares outstanding (in shares) 70,131,469 69,835,387
Treasury stock (in shares) 9,395 9,395
XML 39 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Loan and Security Agreements
 9 Months Ended
Sep. 30, 2013
Debt Disclosure [Abstract]  
Loan and Security Agreements
Loan and Security Agreement
    
2013 Loan and Security Agreement
  
As of February 28, 2013, in conjunction with the Company entering into the 2013 Loan and Security Agreement, the Company terminated the 2009 Loan and Security Agreement with TD Bank, N.A. During the three and nine months ended September 30, 2013, in connection with the 2013 Loan and Security Agreement, the Company incurred unused line fees of $0.04 million and $0.08 million respectively. During the three and nine months ended September 30, 2012 in connection with the 2009 Loan and Security Agreement, the Company incurred unused line fees of $0.00 million and $0.02 million, respectively.

Proceeds from the 2013 Loan and Security Agreement are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any time outstanding which does not exceed 85% of “Eligible Receivables” (as defined in the 2013 Loan and Security Agreement) less any reserves established by Keltic Financial, provided that in no event can the aggregate amount of the revolving credit loans at any time exceed $10 million. Eligible Receivables do not include Heritage Labs receivables, certain Hooper Holmes Services receivables, unbilled Portamedic and Health & Wellness receivables, and other receivables deemed ineligible by Keltic Financial.

As of September 30, 2013 there were $2.6 million in borrowings outstanding under our 2013 Loan and Security Agreement, and the Company's available borrowing capacity was $0.04 million based on September 30, 2013 Eligible Receivables and a $0.8 million reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation method and timeline, available borrowing capacity increased to approximately $6.0 million by October 4, 2013 and the reserve established by Keltic Financial was increased back to $1.5 million from a temporary reduction to increase available borrowing at the end of September 2013.
    
As of March 28, 2013, the Company entered into the First Amendment to the 2013 Loan and Security Agreement. Under the First Amendment, the annual facility fee increased to 1.5% from 1.0% of the revolving credit limit of $10 million; the monthly collateral management fee increased to $2,500 per month from $1,500 per month; and the monthly collateral management fee increased to $5,000 per month from $3,000 per month if there is an occurrence or event of default. In addition, the early termination fee changed a) if prior to the first anniversary of the effective date, from 3% to 5% of the revolving credit limit; b) if after the first anniversary but before the second anniversary of the effective date, from 2% to 3% of the revolving credit; and c) if after the second anniversary but prior to the third anniversary of the effective date, from 1% to 2% of the revolving credit limit. In regard to the financial covenants, the first EBITDA measurement date changed from the six months ended June 30, 2013 to the twelve months ending June 30, 2014. The Company paid an amendment fee of $0.2 million.
    
    
Interest on revolving credit loans is calculated based on the greatest of (i) the annualized prime rate plus 2.75%, (ii) the 90 day LIBOR rate plus 5.25%, and (iii) 6% per annum. In connection with the 2013 Loan and Security Agreement, the Company incurred a commitment fee of $0.1 million and other issue costs totaling $0.7 million. During the three and nine months ended September 30, 2013, in connection with the 2013 Loan and Security Agreement the Company incurred $0.04 million and $0.1 million in facility fees, respectively.

The revolving credit loans are payable in full, together with all accrued interest and fees, on February 28, 2016. The 2013 Loan and Security Agreement provides for the prepayment of the entire outstanding balance of the revolving credit loans, however the Company would be required to pay an early termination fee as noted above.

As security for the Company's payment and other obligations under the 2013 Loan and Security Agreement, the Company granted Keltic Financial a security interest in all existing and after-acquired property of the Company and its subsidiary guarantors, including its receivables (which are subject to a lockbox account arrangement), inventory, equipment and corporate headquarters.  The aforementioned security interest is collectively referred to herein as the “collateral”. In addition, in connection with entering into the First Amendment to the 2013 Loan and Security Agreement as March 28, 2013, the Company granted to the lender a mortgage of the Company's headquarters building as additional security.

Pursuant to the terms of the 2013 Loan and Security Agreement, Keltic Financial may establish one or more reserves at its reasonable discretion and, at its sole discretion, may establish reserves with respect to (a) any event which in Keltic Financial's reasonable determination, diminishes the value of any collateral or (b) any contingent liability of the Company. A reserve may reduce the aggregate amount of indebtedness that may be incurred under the 2013 Loan and Security Agreement.
        
The 2013 Loan and Security Agreement contains covenants that, among other things, restrict the Company's ability, and that of its subsidiaries, to:

•
pay any dividends or distributions on, or redeem or retire any shares of any class of its capital stock or other equity interests;

•
incur additional indebtedness or otherwise become liable for the indebtedness, except for transactions in the ordinary course of business;

•
permit a change of control of the board of directors and certain senior management positions of the Company without prior consent of Keltic Financial;

•
sell or otherwise dispose of any of the Company's assets, other than in the ordinary course of business;

•
create liens or encumbrances on the Company's assets; and

•
enter into transactions with any of its affiliates on other than an arm's-length or no less favorable basis.

Keltic Financial consented to the change in CEO and CFO that occurred during 2013 as well as the sale of Portamedic. There were no waiver or amendment fees paid or associated with these consents.

The 2013 Loan and Security Agreement also contains financial covenants, which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, income taxes, depreciation and amortization) with the twelve months ending June 30, 2014, as amended, as the first measurement date. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013.
    
The failure of the Company or any subsidiary guarantor to comply with any of the covenants or the breach of any of its or their representations and warranties, contained in the 2013 Loan and Security Agreement, constitutes an event of default under the agreement. In addition, the 2013 Loan and Security Agreement provides that "Events of Default" include the occurrence or failure of any event or condition that, in Keltic Financial's sole judgment, could have a material adverse effect (i) on the business, operations, assets, management, liabilities or condition of the Company, (ii) in the value, collectability or salability of the collateral, or (iii) on the ability of the Company and its subsidiary guarantors to perform under the 2013 Loan and Security Agreement.
XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities:    
Net loss $ (9,276) $ (10,861)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on sale of Portamedic and subsidiary (3,618) 0
Depreciation 1,828 2,970
Amortization 0 159
Amortization of debt financing fees 213 102
Provision for bad debt expense 80 55
Share-based compensation expense 581 539
Impairment and loss on disposal of fixed assets 486 208
Change in assets and liabilities:    
Accounts receivable 955 (171)
Inventories (598) (512)
Other assets (155) 1,053
Accounts payable, accrued expenses and other long-term liabilities 1,718 1,311
Net cash used in operating activities (7,786) (5,147)
Cash flows from investing activities:    
Capital expenditures (1,062) (3,346)
Costs paid to sell Portamedic (411) 0
Proceeds from the sale of Portamedic 6,053 0
Proceeds from sale of equipment 0 51
Net cash provided by (used in) investing activities 4,580 (3,295)
Cash flows from financing activities:    
Cumulative borrowings under credit facility 49,023 0
Cumulative payments under credit facility (46,415) 0
Reduction in capital lease obligations (113) (214)
Proceeds related to the exercise of stock options 14 0
Debt financing fees (967) (100)
Net cash provided by (used in) financing activities 1,542 (314)
Net decrease in cash and cash equivalents (1,664) (8,756)
Cash and cash equivalents at beginning of period 8,319 16,917
Cash and cash equivalents at end of period 6,655 8,161
Supplemental disclosure of non-cash investing activities:    
Fixed assets vouchered but not paid 556 570
Fixed assets acquired by capital lease 74 0
Costs to sell Portamedic but not paid 534 0
Supplemental disclosure of cash paid during period for:    
Income taxes $ 52 $ 40
XML 41 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (unaudited) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
ASSETS    
Cash and cash equivalents $ 6,655 $ 8,319
Accounts receivable, net of allowance for doubtful accounts of $622 and $662 at September 30, 2013 and December 31, 2012, respectively 15,983 17,018
Inventories 1,773 1,290
Other current assets 1,607 374
Assets held for sale 0 3,646
Total current assets 26,018 30,647
Property, plant and equipment at cost 21,092 20,829
Less: Accumulated depreciation and amortization 16,474 15,195
Property, plant and equipment, net 4,618 5,634
Other assets 2,094 137
Total assets 32,730 36,418
LIABILITIES AND STOCKHOLDERS' EQUITY    
Short-term borrowings 2,608 0
Accounts payable 8,127 6,783
Accrued expenses 5,895 4,439
Liabilities held for sale 0 220
Total current liabilities 16,630 11,442
Other long-term liabilities 920 1,115
Commitments and contingencies (Note 10)      
Stockholders' Equity:    
Common stock, par value $.04 per share; Authorized: 240,000,000 shares; Issued: 70,140,864 shares and 69,844,782 shares at September 30, 2013 and December 31, 2012, respectively; Outstanding: 70,131,469 shares and 69,835,387 shares at September 30, 2013 and December 31, 2012, respectively. 2,806 2,794
Additional paid-in capital 150,125 149,542
Accumulated deficit (137,680) (128,404)
Stockholders' equity 15,251 23,932
Less: Treasury stock, at cost; 9,395 shares at September 30, 2013 and December 31, 2012 (71) (71)
Total stockholders' equity 15,180 23,861
Total liabilities and stockholders' equity $ 32,730 $ 36,418
XML 42 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Gain on sale of Portamedic and subsidiary $ 3,543,000 $ 0 $ 3,618,000 $ 65,000  
Portamedic Service Line [Member]
          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Revenues 19,173,000 21,371,000 62,437,000 72,077,000  
Loss from operations before income taxes (1,958,000) (997,000) (4,709,000) (5,446,000)  
Maximum tax effect of discontinued operation 100,000 100,000 100,000 100,000  
Assets held for sale:          
Inventories         941,000
Other current assets         400,000
Property, plant and equipment, net         2,080,000
Other assets         225,000
Total assets         3,646,000
Liabilities held for sale:          
Deferred rent         104,000
Capital leases         116,000
Total liabilities         $ 220,000
XML 43 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Impairment of Long-lived Assets (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Impairment of Long-Lived Assets [Line Items]        
Impairment of long-lived assets $ 0 $ 0 $ 212 $ 0
Portamedic Service Line [Member]
        
Impairment of Long-Lived Assets [Line Items]        
Impairment of long-lived assets     100 200
Financial System Software [Member]
        
Impairment of Long-Lived Assets [Line Items]        
Impairment of long-lived assets     $ 200  
XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges
 9 Months Ended
Sep. 30, 2013
Restructuring Charges [Abstract]  
Restructuring
Restructuring Charges

During the three and nine month periods ended September 30, 2013, the Company recorded restructuring charges in continuing operations totaling $0.4 million and $0.7 million, respectively. The restructuring charges for the three month period ended September 30, 2013 consisted of severance related to the resignation of the former CFO and other employee severance. The restructuring charges for the nine month period ended September 30, 2013 consisted of severance related to the resignation of the former CEO and CFO and other employee severance.

During the three and nine month periods ended September 30, 2012, the Company recorded restructuring charges totaling $0.0 million and $0.4 million, respectively. The restructuring charges consisted of employee severance.

At September 30, 2013, $1.7 million related to restructuring charges are recorded in accrued expenses and $0.1 million are recorded as other long-term liabilities in the accompanying consolidated balance sheet. These amounts include $1.2 million related to Portamedic that have been retained by the Company after the sale of Portamedic. These accruals include severance and branch closure expenses.
XML 45 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Details) (USD $)
In Millions, unless otherwise specified
Sep. 30, 2013
Dec. 31, 2012
Inventory Disclosure [Abstract]    
Finished goods $ 0.7 $ 0.4
Components $ 1.1 $ 0.9
XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Litigation
 9 Months Ended
Sep. 30, 2013
Loss Contingency, Information about Litigation Matters [Abstract]  
Litigation
Litigation

With respect to the complaint filed against the Company in U.S. District Court for the District of New Jersey on May 24, 2012 alleging that the Company failed to pay overtime compensation to a purported class of certain independent contractor examiners, preliminary motion practice and discovery is continuing. The Company has denied all of the allegations in the case and believes them to be without merit.

The Company is a party to a number of other legal actions arising in the ordinary course of its business. In the opinion of management, the Company has substantial legal defenses and/or insurance coverage with respect to all of its pending legal actions. Accordingly, none of these actions is expected to have a material adverse effect on the Company’s liquidity, its consolidated results of operations or its consolidated financial position.
XML 47 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories
 9 Months Ended
Sep. 30, 2013
Inventory Disclosure [Abstract]  
Inventories
Inventories

Included in inventories at September 30, 2013 and December 31, 2012 are $0.7 million and $0.4 million, respectively, of finished goods and $1.1 million and $0.9 million, respectively, of components.
XML 48 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Liquidity
 9 Months Ended
Sep. 30, 2013
Liquidity [Abstract]  
Liquidity
Liquidity

For the nine month periods ended September 30, 2013 and 2012, the Company incurred losses from continuing operations of $8.2 million and $5.5 million, respectively. Restructuring charges are included in results for each of the three and nine month periods ended September 30, 2013 and 2012.  The Company has managed its liquidity through a series of cost reduction and accounts receivable collection initiatives, by obtaining a new credit facility in February 2013 and the sale of Portamedic on September 30, 2013.
        
At September 30, 2013, the Company had $6.7 million in cash and cash equivalents and working capital of $9.4 million.  The Company's net cash used in operating activities for the nine month periods ended September 30, 2013 and 2012 was $7.8 million and $5.1 million, respectively, and includes the cash flow impact of accounts receivable, accounts payable, and accrued expenses related to the Portamedic service line that were retained after the sale of Portamedic. For the nine month periods ended September 30, 2013 and 2012, the Company's capital expenditures totaled $1.1 million and $3.3 million, respectively.



On September 30, 2013, the Company completed the sale of its Portamedic service line to American Para Professional Systems, Inc. ("APPS", "Piston Acquisition Inc.", and/or "Piston"). The adjusted purchase price (the “Purchase Price”) was approximately $8.1 million in cash, adjusted from $8.4 million at announcement due to changes in working capital, of which $2.0 million (the “Holdback Amount”) was held back by Piston as security for the Company’s obligations and agreements between the Company and Piston (see note 6).

The first $1.0 million tranche of the Holdback Amount is expected to be received in early 2014, with the second approximately one year later. There cannot be any assurance that the Holdback Amount will be collected by the Company in full, however management currently expects to realize the amounts in full and has recorded receivables in other current assets and other assets totaling $2.0 million.

In the first quarter of 2013, the Company entered into a three year Loan and Security Agreement, amended as of March 28, 2013 by the First Amendment (collectively, the “2013 Loan and Security Agreement”), with Keltic Financial Partners II, LP (“Keltic Financial”), the proceeds of which are to be used for working capital purposes and capital expenditures. The 2013 Loan and Security Agreement provides a revolving credit facility to the Company in an aggregate principal amount at any one time outstanding which does not exceed 85% of Eligible Receivables less any reserves established by Keltic Financial, at its sole discretion, provided that in no event can the aggregate amount of the revolving credit loans outstanding at any time exceed $10 million. Eligible Receivables do not include Heritage Labs receivables certain Hooper Holmes Services receivables, unbilled Portamedic and Health & Wellness receivables and other receivables deemed ineligible by Keltic Financial.

As of September 30, 2013 there were $2.6 million in borrowings outstanding under our 2013 Loan and Security Agreement and the Company's available borrowing capacity was $0.04 million based on September 30, 2013 Eligible Receivables and a $0.8 million reserve established by Keltic Financial. Because unbilled receivables are not considered Eligible Receivables, the Company's borrowing capacity can fluctuate in accordance with its monthly billing cycles. Given the timing of the Company's billing cycle and the borrowing base calculation method and timeline, available borrowing capacity increased to approximately $6.0 million by October 4, 2013 and the reserve established by Keltic Financial was increased back to $1.5 million from a temporary reduction to increase available borrowing at the end of September 2013.
    
The sale of the Portamedic service line, which accounted for approximately 60-75% of Eligible Receivables prior to September 30, 2013, will result in a future decrease in borrowing capacity, although Portamedic receivables were not sold in the transaction and will continue to be included as Eligible Receivables until collected, in accordance with the 2013 Loan and Security Agreement. The Company estimates Portamedic related receivables to be approximately $9 million as of September 30, 2013. We may request that other receivables qualify but we are not able to reliably estimate the future borrowing capacity.

The 2013 Loan and Security Agreement contains various covenants, including financial covenants which require the Company to achieve a minimum EBITDA amount (earnings before interest expense, taxes, depreciation and amortization) beginning with the twelve months ending June 30, 2014 as the first measurement date. The minimum EBIDTA required for the twelve months ending June 30, 2014 is negative $3.2 million. In addition, the Company has limitations on the maximum amount of unfunded capital expenditures for each fiscal year, beginning with the year ending December 31, 2013.

Certain costs presented in the financial statements, notably selling, general and administrative costs, may not be indicative of costs going forward because those costs have historically been shared among all service lines. For the nine months ended September 30, 2013, $7.4 million of such selling, general and administrative costs were allocated to discontinued operations. While the Company is attempting to reduce these costs for its continuing operations, there is no guarantee that costs allocated to Portamedic and included in discontinued operations will be eliminated or reduced in future periods.

Since the Company historically has not tracked accounts receivable, accounts payable and other accounts by service line, its service lines had customers and suppliers in common, and its continuing and discontinued operations shared certain selling, general and administrative services, the Company does not have reliable information for the historical impact of Portamedic on the Company’s cash flows. However, the Company feels that without the Portamedic service line and with selling, general and administrative cost reductions, cash flow from operations will improve.

In the fourth quarter of 2013, the Company began relocating its headquarters to Kansas and put its Basking Ridge real estate up for sale. Establishing a new team and transitioning functions to Kansas will take months and transition costs may be higher than expected. In addition, the sale of the Basking Ridge real estate may not occur when expected or for the amount expected. Any sale of the real estate is subject to consent by Keltic Financial.

The Company's Heritage Labs service line shared some customers with the Portamedic service line. While not all Heritage Labs life insurance samples originated from Portamedic exams, the sale of the Portamedic service line may have an impact on life insurance related lab volumes.

The Company's Health and Wellness business sells through wellness, disease management and insurance companies who ultimately have the relationship with the end customer. The Company's current services are aggregated with its partners' offerings to provide a total solution. As such, the Company's success is largely dependent on that of its partners.

Through the increased focus on the Health and Wellness sector, the Company believes it will be able to capitalize on the opportunities that exist in the Health and Wellness sector given the macro-economic focus on health care costs and improving the efficiency of health care delivery in the United States to grow revenue. 

If the Company is not able to realize the benefits from the consolidation in Kansas and control the costs of transition, reduce its selling, general and administrative costs as it seeks to streamline operations and improve efficiency, grow the Health and Wellness service line and maintain Heritage Labs revenues as expected, and timely realize sufficient proceeds from the Holdback Amount and the sale of the Basking Ridge real estate, it may violate covenants or otherwise not be able to borrow under the 2013 Loan and Security Agreement. These and other factors could adversely affect the Company's liquidity and its ability to generate cash flow in the future.

Based on the Company's anticipated level of future revenues, sale of the Basking Ridge real estate, collection of the Holdback amount and restructuring initiatives, and the Company's existing cash, cash equivalents, working capital and credit facility, the Company believes it has sufficient funds to meet its cash needs through at least September 30, 2014.
XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details) (USD $)
 9 Months Ended
Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]  
Term of possible loss contingency 18 months
Estimate of possible loss maximum $ 100,000
Employment agreements, contract term 12 months
ZIP 51 0000741815-13-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000741815-13-000046-xbrl.zip M4$L#!!0````(``DP&UL M550)``-!\XE20?.)4G5X"P`!!"4.```$.0$``.Q=67/CR)%^WXC]#UAY/;L; MT93JPJ4^'$`5X-6XIULM]7CMIPF(*(KP@``-@#K\ZS<+!T42/"0U)9$2YJ%' M!.K(X\NLS*P"\.%/-Z-8NY)9'J7)QP-\B`XTF?33,$HN/Q[\>MYSSOG)R<&? M/OW[OWWXCU[O;^[99TVD_Q0?U,V'PVGKZ^OKPV&:CF4V3..1S`_[Z:CL@6R*FO91GC*"S;E.Y31I=@F- M$3VJ6S0=@//?U[16MR^"7#;-)WGO,@C&TQZ#(+\H6]>UO-$F3*YD#%/,B[?\>7`=9^%LMR-\<]>L[#.?< M1/EOP^%O/T_B6]7M2YK\M>QTKCJ5S7Z1HPN9541/YP.D1\5M?6UZ-0K5]4$D M,ZUD3,Y)I0$C/_G+P2<$_YD,6UC_<+38>7'87%XJTYI>KF^$0,;-.([Z45'1 MJ(41M*N,MN;T>([3@T_#X?%&5C\<+1W]CJJC960U5^2*JL$N,WXX#6L/HB.,(/=D!5EQW%T6OW1NOY[!"$R3?Z`MK^01&2AXL0 MNM@]BIY(A.<_8H3DC1CA"CY?Q`@?AZ`G-,*_?Q=[:8=XI^P0I'AG;L!3&,63 M(KJ2Y[(_R:(BDKEWTX\GH0S]+!UQ,-5)45KJUX$79(FJ0)S*['P89-*]73Y` M:;S-'#.(WG.C?3IA'7QJ)FE)ZZ5,?W=!*^1%<9+D1596R9J%PE%ECL]ID`1) M6`OWUKG,I%2-]AMX;8;+)>,>''?@603/20+!ASP'(RW%Y`:QJJ.=#Z4LG"1T MPC`J@Y)81'D_3O-))G/W%GZ,TSR(_YREDW$.0X#%@VFK-C!;E$QD^!6H*PT_ M;P!YFF9%,))AU#^7V574EY^C1.XW$)]'>"6XUTBO`_4BJ$]!#U]`6C.^$%GJ MXG[#;9:MQN/-\M4!X1Y`P/AU`F&6KPX(FX`@HDSVBS0KP\M7"(@5_'7`4,#H MTKTNW=NO6F&7Z^U/KK>CR.D2O2[1>XV(_A[<.)-BF)8>8'[AA4E!.Y_3?A#_ M#!XB!YGN_S*\G.O9%70MVQV&YC#450HZ%'1E@K>+`OJ-_#Q)Y/YMH](>,AXH MQK++4XEQ#T^$T((O8,87WW$ MZ]S M=)%F-A+!K;JZG[8&1K6,O=+:EO'W4N:U/\"8IDD92/D5`F.:+\WSUP%C!AA^ ME.6%`WR&LQL/\U?W%A9MYDIOL8R[#A2/`H6Z_AUD?EK..,TUX$?V/:TZ)$FD MG@L.LML.1_>><5ZF50JR3J@=?++WQ52[0"\?0!_'T99A]\M MXW>Y4#OXSL#W]0<$W?+\%/!X/0MNM_P]"4!>S8+6+2^/A4=WQ/PF7[HT_'5SN!91=AH\W8'&[D!C!^JG`/64FK,@N9Q?Q'\);J+19-2!_^G! M_Q".IHJZ"T/F--49VMX96I1TAK8?AC:KJ<[0%@WM1"K8J^Z-%M'\",(@?M1$)_?0JH].D\'!219>QYKW5L"]5&#-2+HX+4( MK^[QVPX(W1.X'1"Z%W7MPHNZ=@X8W2[^HRK;;VH7?[<>X>Z*X_M3'-]1Y.Q$ M;6-?4;@?-8LWAN@NR^M0T*5X;Q,%)TH:W]A>O+JA^HIH47T]:^X[?LV=;4B# M?,/>^>EIKF+M?-_D0GJ(S+Q/9KMRV8]W2,U+8]9FMBN-O;,9\I0VP[KXN(N/ M=Q.<=)\=.BT=NODT"F5=]_W?HEWW.V`XKMGN=ZPVKMGLMZHVE^[B]^-CZ;OCL*[#W2_%86_ M`8?>.?+NK=1OU<*[!V"?>2/K^17>592[BO*.@W/E5\[*MUF#>,_DE02QU8(Y M.3M_#:A:_96S#6R_7CAT9VE>OT*[8S&O2J%`?RC#(`G/((>"93)\K1K>P.@; M5SE[*RIG;U'EW7-*KTS!"M#9I%],,DA,>*I>UJQ`#H'F?%V@W,Z>:[S?FM_` M]UT(OHKQUP8)]A5P#PQ0G!?[=YX%HR<[]=0(AA7#O90+8MN0RR2)*J&4U8H% M08QDH"H>G^H!X<]FI.;.[.AJJ*5#+SU:-C]VU>11HT_R<,7049XR@LWC7\_% M8T=NGBI\'%OLF9UN'S$F>F$3-)1E*R?<).( M%V=L#]K&[+;UI9;;?3R=)D9\&M\%%+/DDRP#E6@V^,SFX.R*LA;(?C8(X M_WC0HP>ET/V@7_0,YEK$)3YS=6)9%!LZ<1QB&81;.B4F-%73ED.5ZC=,BX+- M?3A:3\.CZ%3G`%?1B:CO&89K$!UQ[&#LF:95TBF(1TW77J33PL1\-)UGLB^C M*]7LBRP>0ZUP&,6Z8PKBV,BU;&SJO*(6"0>9:)%:K-LKQ+J,E!\@>AT4&-(M MPZ$Z]@Q/"-,R=>K6(O:Q+\P6T2;"UN.)GHPFL4H$A!Q#Q!B5)5SX.Y;E_E$2 M.J,T*Z)_E==/LQ2<;'&KXDD59WC_G$3CT4,9M#C3.4>N[@IN>1YER*^U@C'W MC1:&L(YM?9'!K9#]3,)8!U''LUV+FL*S*1788L#9NO`[P]Q$,=I7^FU M>LX_R&6HW@0`&4"I2>]&_2GGN!#5@SGJX[NSC.@SC)@NS3EE-46ICCXEY4;8N3E6Q8'O=MU^=((&(P02AUJY6(<\X,[B^R05Z. MC47#F&5#9Z[)'.(9/N,(&8+9O-8&-TPN6FRP%V5C':Y\@0WLV;[E>I1C;/@V M]RI.7(L[=CLTV!(GUVK_TD\SD4XNBL$D;J]^CPD=L`L+,'%U#T'8`#$9F+-9 MF[MO8==M!62$M+BY-V7;9&JM#T/4LY&M8XPAT+&%:8K:"X,=,5]O,65LCZF9 M)>CKH'[M6E6PR._CP>;#.H,+W62ZZ[M$<-/#A#8!A&=PH^6*T0(;:VCY`:J7 MV,FFBS8<?`Z`:!!A,V'-"+>IA.BZL1#-;4-HSZ&'EW^MU4H]>+J)#$0!S\+QA/GOA*U4A6.:6+@F\AW;A:B:>K#FU/4;T_4MMDP5 M>%]5079:%89'J.$:!K5M%UCMD\@+D461CK#C%H&QW58ZGB>U2H.S?*TE(!'$;DA8J">:QD.8I711S_(Q]QGS7/"!V!;$0\@3 MK?SN^9C?;=!`VNC;V$.ZKINV07V?,UN!!N0#D.%>.Z'+$6.>MC M[PI>ODN121"!W)&9'N6PSE&J.X(YQ$0>/_CT4UR\#Z,K+2]N8_GQ8``C]@;! M*(IORP_3YMH7>:V=I:,@>5_>RZ-_R6.,QL7[@Y\NB_<+W6.06V\HH\MA<0P. M^H_O%7F]((XND^-8#HJ58ZCKRVB(DJ&$A72Q7_GSNIKG(HW#:J`[26GI0%.V MTXN5\6B5]:AYCE3/9M(CH/P%F9CVN\BT?BR#[.-!DB;RX&A*WS:(+7]'B=I: M/R9L?+-5ZD5Y)D0KAE*#8$9J(V@SU*I-=:T\-J9-'S/Z*1B-W_\!&^@]1>\T MA=9W94<5%07)K9;)?IJI'D&B17>:[)>@UZ)$JPU839A.35AINB6KQ[#RG^B0 M:-`JAE&W,N`[[7H8]8=:E`/Q51"HN(CF0!K?@32HBA;01$DEZ/0UC MRUXZ&"@N^Q*\/HA[T*R;6EXNG%I>KYRU`J^!!RU)"^U":A#=QT!5V*AI,"E@ MW3G!V;[Q+0^^+.9A\,[#!EX3J#[+"U6PR1KAX%QMLTS+P=BU# ML;F;1OL.A)V/95]EQ?'M"I^H=`,1'/@PR)*U<"96FW%P[^HN"@]1&1IJ17`C M\\<;WXM;6O/WIJAP&O$M"0_S!^WF0,B*N8&(L+##A:Y.#^AU=FA9NF@=':`& M6SPHLJR:O9R0=8DT1PXRD"DLD^@>=P1QS+K8;@N+.:W]&'6@:4D`O920QVQS M^8;E8&QBGPN/8E,GOF@J0!:V>.LP%44&,Y?0LWPC:RU9:[<4N<\=!T%.IA/7 M=)GGF$9=;[`1\:Q6=F:T#O9L(FLFJ7P,A8Y.=6IS9/H.$X9E@P!!,AXS7,BD M3;*QNK1D_D=2N4Z]`"[AF9#.(M_%PJ(NMKV:2FIPIY7E`NZ-)6*\'ZU?!W-9 MZ/HD=!D;.YP"SPG5AJS2H@YX#AO;)D#`8LQ"+D;PCV&T5+]"J`\2U[R\W2"/ MH'^]GPQ]3B%,[M]6_SX@3]9M@W'L^[;)=(OXKNLQVAPU4H6@Y\R3GR6N4O'^ M)`E`SD6Y!!?0+O4B8`8S4XW%=1ZS3Z^34I M%5%:>LFW,P*-](,YQGX]/#_4_NPXI[/LS>@`U!>J\RX0-65:.HH*->1XDN63 M`!`"*5`^@=AKJ:BK#/`QB,B'Z20.56Z4R2"L\_1_3))2W94PRGRV'GCS@(HR MI95<]0QAIODM\O>GLC+^`\UFRG"`4S_G$20@H-##2ZK<@<@813\+J=YNP0.1J6] M*,A`QC89C2N_40R#0@L&`T@[*N]20D.E=>4F6VE@=8:GNL91<`%IO7(P*ETI MWS90W9'5`;+J1ZKP..LK*J.Y`_&L?YEB5F%8^9[\SKK>:\/T&J;)WE46.=LO MDX,8R(89XU@+0J6F2FP53YE\UUA!.HX2U6/>)8-1W(GLG9;(OLSS(+LM_6Z@ M#2"QF*\@`1^3N+@K'S66W^38H*XB=P52K$GU01G!*D`ZG,+43TBH"[M8-#6!--@[:S.SNY MRV)F`J**O&EF-.M*VL68^V47\QE)?3Z_/'D,-*AE`A(:E2N&[J3XDA9_ MEX4ZR?_0\Q$"(]VS/3RZP6X]]K);BIWS&[[VH9N M6L3U35,PR_%;.O57XT^#VS(`$Q/Y(*#HW+(1;Q=-P^;]?#AK'H7^]/W1;YVN!Y3=TF+L:F1T!3CN\9)C,JOBAB MNMLZ%`>^HA5R/)HO5=BK\EXU0%D$OI00#\\]^SI1RG4XLNVN$^O^ZZ@]_\]P=QO:9&P[ MTF1B:(ZM.6-,9>/)MH:K.>YKN+L/FAG6`"`9$2T0_N7RPH[FTZC#!)D04,]A M\CJE08X=7=!WE0K8)!RQ^`/N@T!]L M%9`D0]8)?P)_#.*Y"!B7YQ%\)IQ,EF$&?_NK50!'CN>*81:&2CX/VQ(GYJE< M^.P2MY=^GB,G;F)1^1T/E3"L:<*[0G&,+ER5Y](,=7Z"[SW^_6_L<1)/[\RSIG[%])&+/<,8;]P0UL%C8_"P+ZG:6*SJLX*=_%.U(8S@HY M,'3$B9N)U3AH1&.;FQ-IS(&! MQ[#<8?ACZ:-#.";!N@C*V!P\@S)G\X>2UU4IN>4A`I-,L`U-&:YE"RH/739_ MS'!QM/AR=>T?9[,"'C1[0`@$/EP&N(6(S;6$,&.\N9C^"U$8P52].R(#B;FY M*8ZXSNA:,!&%:<'BBG`M?%5J%#Q;V,_(M5Z+!'@21W%10#]RQ':1@QX-3V#) MC[0`6.*\B![X8^'.2SQ8),-[V`?Z<>UH@3KSN\Q`X"ON,RJ`(J. MPAGV5Q`B^"Y*TOD[)E6:FAD]9LZV[Z<,>WA$]*%%UQ1UK,`,YC9J;@P5V+[@ M@@>*+>3P4[8(R./7D&?_7&,B'53>IFR2<>7ZZ!19[!-CM/DVA@<'.XO\<-F6 M;!TO(SCAL:8,'?WY?`TEX;95A!@=+A;B.G2WL!_D'[0D`<,&\">[(2$&E,/Q M5NR8X0&ME>$4?P%_(-.&ZVM>F&5^SNK<03<`^AT.NA)D2@B1-LM2F.;C`ZH` MTE#//V2FE*N,5Y9S"@0^J$#@&70,8Y$Q8V@-U#3,4FEKC7#$_JQB>8AOJ*'- M`PQKE"F.>`5R/I9GT\CVB9!/+$+*5L<;`S[5!8D$]J$@I0-+28L(49Z1$C($ M1I/-"%ZY.LRHO_%O-@5V`.*\1/^$M8?FFV\>?\2Q">OH"@9 M,-';'3(TR@D"X1+@XTJ.V+P3@X_8`31B*P>R#H,%7U.#Q>7^-V!S]YEP^87+ M.UV52N6O/!N'\7[9-BU@A74P$EX"3[TKI45S"?\&R""<2X'7>'OC10"'I$.U MO.7BH$8C^')1I`1YD!'+(J:HZRX(-3"`PVS@0\R=`UD.FC$6%A`>@^#AOCXB M.N+!7<@=H@H-S#]Z:-(DJ@RWH$]C_D2:+`**EK$$RF=49VV&_9_G;=WTU/*^ M?)_\]&-*"9US"DF4C1Z>"L"M=:8P%4VW)%V51Y8^F1B6-2[;D1H>?-EV)->= M>*5K;'W\C&6]?!]K(;CV/ES;4L>Z8SB:[4S&U'M+X_VWQM+8G!Q^'_1KQF<- M_6'$(7UW6N%1+8O9_]U/PIW M3\84=D`:P[9,5_'DB<6;?\B&!PAUZ'5_`-I^+JQ5W74FCN&9SD21U8FJ2V[9 MJVUB&Z[[(T5N2)8I6=26UMTM7P!D"L MRIIA/[+FQG)>L/#'\1D4=-=2;,4Q1DB3KJ'S'HNR*JECM1O8JJY:Y@L7OD?V MA.JZXXD\,G7D%Y)A5(UWY)%CFAO9$XHE&=O(KBNJ_=3:'LN)<">F8QF2X9JV MICJN"4Q"YLVG',_8S"90X+IGK2W+/RY^3I(YRE"NOV9?DNC9&4"6K(U`!(X] MTU;'\(^EC;RR2];('6^DBBFZKJQE;VQ=R]YK?JJ9D:J,;->5#%U3QJ:KV:ZD MEIW9%7FSV:2B&X9ZA#5OS\=S)`_6"4O0#-E0;,\K%^Q)(#,V@&RM%V,>8+V/ MY<+(BC9QW(GJ*HKK.F-;-T9\O>[(ELR-;FOK^U[BB+?JI.O% M@I*N=WW'J9JP7396YU^G%V-=SWJQ2$/<6I58>AD"*F*@X""/\_0>L@#4?$+",'U5&3/])&FY0ECXT3P(6,`Z^ M(62.1D66_GUOR9:-/+XQX!+.P!#J42^M8MU+/ZMRMGG0[JE3>2?`,U@&:\IF MUF;8"@(>'6:W+'7A_P11'L[J$F*Q/,DZBRA.>!+1S.<--ZL3X^=4%4&O'7P$ M2\M:IWCDH_I.[I=;`S5T'1.@(B$B[V0A_((/\&\"X5=_FO%\!KI0K))!?Z$D M*/A/A/ZKTJO6OK:(I[!V`%5&.K!@:&!Q,#[>C[O@.!T;*`5"N,=_'8UBE6NC7P4+B&V:I&ERCXG^ M+3'"$I.2(MW!.%W+9/P!V-J='T:4&%(]'B4HR+J<)9#TD_[%<>A3:76WG\HP9EM&#@"NANQ^`R:+^]S/H]DSP@PBGEN+K;91: MMU2D4B^$E67YT8SW4!.607Z;S-F5H!8@4Q8?)ZB05\&RA,P5*"G?J*,5++@? M+#"N>S;LX,3Y1'A!:[18YMUB=D$0XB+UQJ?^[,\>RRJN]9Y;CJ-=X@O`#%;` MUJD0:LXZ&0JL,1VKK>XZ99[(%J#"LFA4D+&>C=E`;Q<#ZUKX!^D0'8]@+_19P\7*`EY0SGF#E1T+ MMD#N/5FM1.?'6[;4G['=;:."3,O[ZU??L\%).G@EF@%J6'B7^E&SV>.KX=1W MBJCW59B'QC!KH7=4_/I./L`6?JP$_:D>G-Y?1>5K'9QZB"V$"V[SAE0FA!5\ MV+H MSM!?Y%SL;QX@EB=.6>4(E=$&V&SZY(Y8.;\C[@LKMQPQ8]NSM?/M.#X\X!81 MY[=A>GHG+)_?"?>%E(\J>]?(MC&`D=9\?4J))>%W]H!^K\7<5"/V"K1Y3Z([H+&A;C"YI5:N_)\A6U# MT0:IS!,4*L<->_<;-CZG%CQOS:9_#!(>/ZF>F)57M3'*U4=3AET<<="GFB&3%-`OG(1+@#9`A MO#Q)V].&\U82HG#)4G61]IO=K`2L#)XFW\KA?\T.>>_P>>AJ3]('44#J6560 M`]F!R05@N-P&_OS?L`1LA+>M;0[L+F'N&@`RCH/?!$E&H9E2+N!(L:H3WRV; M1L:;;#42=>M@3B,]M[&&5E"@0YW8K*#;,_J,:Z.8>99N)/$VH"M,BC.A0L6=:/26HA.(@1`^6ZM^80TE6`DB*:L+GTPQB@QE@ M8[@JU8BZ["48\$J#.BL<,[V)=/T,#AE%-':D38-REI187I$EK=_$M8=7#UQO M@GOIOZ,L0[.+H`BOA;\Q6XJ1Y!UU\L#NI'$KP@J;NYR^ M$\JV@=21*F_TZ6QC_;7@5/E8N!?*6@JVYKGCF4^!J"C=FC+D>=N]1GW2KKS\ M6A`.E]RD6:_E-WQK_L6=%$S$-#^D"5D\@$#8T=UL'&5/&L[R->[+$;1,-O89 MPC7%+HW=S)/W;XKUYD3KLR"*5BAFXIN?+J0+^IQA\B?_W+&2]=X?PK8EY6GU MU[Q\T'TXSV\9E5P(:7(/[XI_NI`OD).4?U>KS>>-!^Q^\=\:+^Y8`M@,P/S\ MB!](GJR>7,EC9[NV>P[,*YRWP8BB!_('7<=X_#3;L-JZTZ>!_HIHS.RT!X&: MO8+61/VT0>@!T4X+/F\[IM:/*"Z``PC4[93L1[R/M=.J1!-VNBQ)N:RQR[`; ME%`VK28UMZ&89CO#N(%B?R-".@'P#5Q@X`)O@`N01M>>C]K0_5K]YJ?!#'OA M-AO%TGSH^GJ12A]7.?L1>[Z7XR+*&=4IG!,:UF`08Z=GX!?3(@OQWH$9#,Q@ M8`:OK!*@(9ICC)4-X<*910D;.\#MR6F""468'@IJ`&M232XK7O";!3%FC#72 M?U=)%G)EHNUM0]LYJ7+,J.4[,S[7K>6!,0R,86`,KXO&&>!>6QD`0P%[:I3J M_X:3E"1/3Z)_S%XLP"FDR2A(W133^/UW^D`'P MXQNX!^@_3EA_I85_EZ2LI-W/PNR)(2K]DWL++?J/^^S#`$XI?K,1#^4651T9 MKP^./;.KUY"./P,QX6&_.LC99'P?`&U3[>&Y`.<2V;M/$NJ:5O7,`3^Y] M+`U"I&D5<62LM@._7IOI",\MQWW%^1,H=6[2X9208Z?@'@V$JR)\G<5"+*+- MD[W:#8\3P9_=XL`T3+T(XW!9+,N*(AY7O@3HQ=2>B-<-5@DJU(HOHX'=Y&&D M^5,XFW:5!H@N/#R/#P)V_!_ZXEV=M?ITI9%(V1U+RN(52X1F54_KY4Y=]:[- MV6U47.67X1%6_^Q_H^W6\?,B7A24,=S5;)"NE8$W$C[\.K-C@U)V3U$EN7,QOJ-IL?">$7O/1=5>,.?#9>O2]`;$ZR0; MYCMD:^#)"-T9-Y33\Z]B?E/NMYJ>Z>/T8SAKS"CD$RA922N52G$B+UT4HL#F MNB+L<0/B-)\Q#)/KTKB25'LKJ7TU$E`%)QE M]4%\E=W9/X]G-E+.;I`"5UH^)ZWGEL$IF]-5/@`>I@6^PD4]\PM@ MNC__&/^/GU+;)GB[Q:3+PV6K.E"),H*ETNJ*W=[O+1HZS M??[\/SYAF=_3VY=ESS,-J=*\4>?V%;/G[7L5FD^"X)$= M4UIIE55:'G?[V\W]2HW]:JKGCA3;E!QG9"F&K7K*F!WWV%*5\>;H*[TY.>B1 M5;]T>]L6//'&D@?+U29CU53-B:XI(SY+2!LKDK*^8+F/!3>QBHU9_!2D,Y1! M-\\<8:F-94UU7<,Q+3D6JIKCDV^%0L15=-9QWN)I4$K2V\N8#-]7T.J'JW M'CD*IX(3J5Z\=E>R'=TP;&.DCCT3YU^YY;Q*19DX&Q.RY(ZU[[RX]7VQ?/.O M_C>'Y.5')D'CFU^3+/-`;WD`X0/ZRSS[PM+GOR;C;ZN02=DNW*HXV@.7@9#XWF3<@_O#YRR9#N#*:\]IDSQD;RL2V/$_79-N3+%/7#,FU M#'XXE2ZXM:9ZE*:4LLT:>--K`6=E2 MK+6-U"]_QK*>F.(W&KOR1'&!"XSP%!:>E3MBQR&YX(GR(_SOI9^I7P M,19^\Q\$Q48_B&2M=P:FM-1;P%VL[J$>NG?U%"Y+^+B,0[#EA!*@8,.BLH#= MBW"5PN5:'13=A+\TRJ#><3,6_3)E&AR5(;$9[93SNN(6(ON(ZZA898J(!3\! M8E[=@>:"15OL*K"TN"5&%9DLP[8:3L$7LEGF&7+9RRSC1D7'$7LC4+.]_KK5 M55N?\#T>:Q_#Z*7D378\Z"H9/-;N5*7'5I2+C8@'F)88Y!;#X\H@WP,60 M0*.:E)HK)G'1WXB4WCN+@-P];E/TP_/_?J8;%T/ M&4`48PIHIP@8[+2AR^!N&RIM*S;+0WZ.;27+N]E6%W0I?K[8W8XB77K37B+W M&1:8MVS"M0X16]?=:C:*+T#.#_RAV2^G6FQ5S5]U,H=?XX)"\K4,W$B#QF9U M8/+Q];8(MK+:CMLO%UO!]VVG';4_\D$V<-ELW#)'6BM[CU23`GFDUF%I)(0P MGQG"S"O,1TQY5T^3Y*@3$H`XUX;_\^AR`:0150W50X9(97=.6:(,@8UFRRMX MX`\86`YO0BS7:S=?%BZ;Y/NN#!"S1](%V!RG1M9'\9*"X],@B%ESPCGLZ_QG M(:-YTK8LZDD\IG7B_(2K9TC;_O0WTPKQXU#5U[OT&51.82#X&6' M/NC__1RM9/!&.DBD:X/O@7I+,S*-I/KDPY]`?5D9-K9[#:8%W`5 M]J@*%V&MQS!\\=O#/TGD4\FOCW,4(R$*[XX[?%[NB50P=[8Q1KP%0V!O'SN\ MJ*\6.CF`/KMAB&RXLLJ2[:!T7VU4:,./5=8Q(*\D<./K>'#I:U!&+)39M'7B M-Z+[QMB3L(;",3&E]RC!\;S,H+R89G\2[IBJI:J:HG&:=->>#BH*?R]`:4$M ME0!4?I+;#9]%(M!^D!&`=$4#?PY'@6)-?O.-X4+KA/C29=#'C<26KK&K+Y'^ M31[13XCC$%'U'9"4?MX2W7@:6PD-%?U[H5C1M))9$*[RUG$RA0BNX"K.TPCQ ML,Z7'>Q(P'H,<^B7ZY\^M!;8"U'L;,#W-J&M33$<,F!_)\4-5@XM6NZA#KEU M-JKSV>O^O!HHK7NUTHFU_-1'75V2*)(C:QFO%+-$L` MRS#-V\^R8LEVU&MWSK/%KQE57&]];>,IK?)E";;8W#-^;KXFQ@RPJ"IYSI,5 M/KA1"-];ZX&UE2_]]":,V2+](D_*+RAEC7W#^@^8^O<_3L'F#-(KJD=:9<'[ M\H\F@/!)6_H9U*7S:JNFOCJ.I_L1T%I^NE"5[Y_9"H'?*$M[WJCO>9]Z+@O= M%Z+VOAL<#F+_!AS3),^3Y8]3X/$WH!_$\RNNKLQF0;!8K'74`#[29"S-S^Q! MK:\8Y2N[=!MI<+MU#M`K/]\MK-X^A6JY^L7I`/%QP#TA6WHQ@+Z2#O);0I&1 M\:;.\0P(GPQ4SQ8UC6.BYHDAXN^H`K\<#_?BFP,.ULM5GL)!IO-Q2,BK;UA7 M'\Z%TC)^DURR,PRY)R<0;3.E>4"V%R.;^@K(=GJH-?"Q@8^='A][ M0^;N(;)CQM\PQ@'011WZCQR]()KK4W:,XFL,)%E-R_OPWG M\V![/X$3Y(IO&]GT`=E.2;M[$[Z3@8\-?.QD^=CY^=X.JJO=)9&?4S?&0R#= M6\`MR[XV-K-ESL8>/5^.]1:0QU:NM0%Y^D.>WN&S)T\F&'P&633X.E^F/\_Y6&KA(0RBG8=+#89;BVHM15;ZX_LGA(7G MR_`&K!NP;O!_#CAV?C@V<+9G8MW@$<7[/H?9GU<+S#.N!GZE?K[9U&4P)N@^ M^;JCA'`P1`=#=`<(2=?F@#NOH%V=GQ(U<)F!RQR#R[PA;U?O_OA_KI=7MXO( M'RD=9U7B@P[_3(!_)UVK0^[,*;'#MXYNFCF@VPGI:6_("S;PLH&7G2HO:RA] M?Z-.)5W7[W6`48^M7$SM^W7(VZMOY]V>YD3V]+751H@UJ\F*Y=)/X;JRW1CO M0N1C]SH<+;UXA4%%K.O22]](C^-*^/?+>[9G.Y;ZS6>C>;8^.\\(S"9B=G(XZP*S7% MB`;X;@[J'1#O\)Z)OR+B50YPASO`QVRL02!\2L,9_!NPDE!RP,CCB(I7P,+= MXR^O@I%LU`I:L5Y23\7X=;\^#`-N#KBY/VXZU<2)#X")89R%,^%_*%AX22-= MDB+SX_GN"/F&0K.'2%O[6.19#@!%VI_Z$0W7\?-Z(HHJ;YD*/?C@C\P8#A;4 M>W[NSRSQ=G#PG*Z:>3(*E")N&]^Y)S1.A0@. MK2P-5''8XI%GA'SZIXH^$Z`'@OC+$,0`GP$^`WQ.2;/?T4XZ>Y6_3$#H3>D? M#,Q3`-S)F`F7AB3J1XCI;&+*X:#4.Q'VEE(Q$-^IE36]LC6B'+YB[E2(Z-!F MRD!;`^`&P`V`.V?`#4$.ZK<;ID.0XY2]#Z=CO`SP.<%BO]?)08R2=)%$/:8^#38GP7NC,1)95$U9 M-'H,D[P4CG]M\V2@WR-TEGA+819CL_?4L2GW5(CPT);20)L#X`;`#8`[9\"] M8M"&<#G]9@15]T=A:]/'P4-P,AZ40R#;(1H/J)(NROU5LAQBVV>G MIPWT]+I-^'9'PN.;2[9\-'-I(,6!%,]7LSI`7WOSNK?@[(!7YXI7_3/U[W9. M--XO%'5,9^(96TU\@E;`JGJH&_Q!K:;!Q#^'2-=YL!!5U!5#M$X@"C9HC0-I M'P[M]J+@LT;5_EK/O91KGCV3E*^5@3\._/$M\\N_K74.GUYJ`Z%<-^\.J83^;[CT/LUF49,%7+`'#'W[(!'P2QH795,45 M34Y)V$61G^5"GOH4-Y[[#SCC![__=^&GP*'?V*Q"P8_GM+V@'"-#P!"%91'E MX2H*8:_3![HBKD8>A?$5?'&UA%4^",W!E-GU.>/?/^"Y;)RF(DF6\"GR8[$Y M03Z_38.``%:/P!=D^3:8OK M-/D6+N'4HH=C'I'=ZQ$1QB6Y'PE%G,(;;V+X'?-6EJL@SNCU\`$TJC2(?*3< M/%G3&`14^^B2$*-.JV#&+YNB6E<]$9O?&5%]'3.J2U-GR^H5"$EYPQ64C(R]2,FY8-W:@ MS5*S/1J1E!IT3X(`F03?+6Y3\%'YB:+D/GM_O#WIW_=D^28M`^VLVL!Q!<7*[+\B@[/OA"M!.*(O81),TP)Y;>@CUM!V/[=!0@5L$@/0A!GE7/N96A"M86WPC!!P=,^$^S&_;2E[#%]YP MDA^1DR!CUGMES*(P]3%.Q*6K&_FS/Z^^S&Z3"""`T5J$R3*9!Q'RW1"ANP@H M/,+Y**@8LZB8L\CYL>#PFP\(W&^<6L3U^S-XV9R*N>GTN0G#*`I,LP9H(+".)Z_4HJE]5YU&*8G&)3<(ZGN^TA8=]Z79MEG`/T*SXPJNPA7[B_F!9?(R% MWWR`E5VF7:Q)%L1L.%F@9:ZKWY&1+/C+()[#/\P0`^S/`<7I,Y=.CVD]7*"+ M7*<-`+RS',P=X>]^3$,V?+O*!KF,R'K;03H.I\FVU2 MLQ49]^_\,**4*.1)%9]J4M1I!_I`61_E-_)/P(YWM^&P%Y(VL^#.C^F5@I(N(G(^9$%Q$"L$0J#D%U[ M-+]93V*;K$WQ,1;!>`-PJ?;7:+B7:K0P+PF%B3GF!-C@/OFMGPM+P`#@=V3F MKWN1S:,S%Z-7UO(V751IL/11;6Y)!V8EO8[>JAK]!\`[\!!$Q;B6RD4<,)&, MC(M!S,>XYQP05/$I;4@S.`(8$]AD#7$G8A!D7FP`"6$+/LO8T_X M7`"%RYK6=$=5]PK.C)1;V595NKE43)G_J7UAI9"66UJ$$>JP()]O0E@8LZN_ MU$HSV,])NA2^7%D,>K!\]/N6LJ?>)ESI@'45";)!%&GQ%U5B"*1X4J+9(Q1. M\+KP%[`P/)#L8@T>3\."H7F1E4PR*Z;_:BP9^"/H5<0T*_\!R8CRR=?DM427 M;4ZN!0I^@%Y9R6'F#AN,D%^J3?2<@D$!/W$`4E+1X+4C;#+0J MO!6`'F=@QZ5U3CY`*5R%"/\BS@&D>0..PBP``R"CC+L@O:L*'#A[2T4A7`CT M4OQ7N`S:=X/U0`N@>^?MF\GKD0M1@+42BZ1(*TV$785?D?.@#FMQB)!GKO4> M%@R;!C/`1D`O]@+&D*^%49WG>RQV@_G$_3";5B+W6]$KB&C0;R[NPM)(ESSB M[M4>9<510[#]K5LL.2^07O1PO;F%MUK!]AKE:J5PQ*!F>DPR_TZZUOH-_QX3 MW6'U5N_!:V)'5\RSVXI:8P`ZSLC-F07PSOA&%&Z".$C!S,5=^_-E&'.=YBXH M+Z^]!W7=UYG*(.[U?6NBJ,WIQ&-CL'+6]-=OC'*@E8/12E\)"FU:V5:.(V[D M](A"TQ!M9/E47H(J/,KLH5D2Q_BB)*X,09#)?EY:3X`J2U`4F8I/WRS]V+\A M,[+E588[T7J`UZ[@KS`ILJ@A:9]D]Z1[HO70"P"!9.33(_@#\:(GBIY/CD9Z M-&WZ.A'IT/QUZW%TE@Q_)6,1I2U6=`1:$1%X,^'N0?UQ\];_AIA$C/P>+GRY&B&K_5[T0 M`#W#I1]E/UU:SO::.S9MJR98]-49-FR'/," M;.20/:K(YA?_?27;A@$XWX;`RQ=]%$`HCP#"G8P\5;$LS=)E4Q]-])'N$2!4 M9^RYYG@3$"!"SA@0_^_K:"LL'$5V7&EDC)61[8X5RQQ+#L'"&$\FIJ9LP$+7 M3.E<8:$^#@O;&(\F-ARU)[F:,I9'GL)@H>N2(FO6!BPT4WTE`OD0@U(1X%,G M:;+LO,0-@"L'[,+MP/B#O^8/=F'E,7?92)(OMT&0._'N)W.^A=D?M[=_?$K2W,Q+D-Z%L^!7D!6_D4S8>C2R M9(R\D:GJ8UN3=<5S-=50-5FU964\D29NQ]%(]M-'\WPP'N=LE',ZFXD^5CT= MZ$0Q/4V6Q[:MJJJFV"/34"S%W"0;7=-V()M3/1N@FS,Y&-U0/-4>C4U9,31U M--*-B<.(1I5E2=\D&MG6K?,]&.5L#D8>.;:A3FP@&L>=>)8GNS:G&%LS7&/C M8&S;?*5S@:M8HL(6F75^8D5O'81F.JXR=N%_ANK:IBI;^L@:CSW/F8R=#=8E M2SOH/D^![!!0/VW<;X)<`;R?R&/@1MY8M3T9$%YE((=]J*9T3B`_'T1W)=4; M:^I$0Q[CC,>JXI90MT>>.SH;J)^V]&V"W)F,7,<96Y+JF-;$`>A[(PYR79$G M]FN!//N41.'LH?)+;+62&ES2]48N*!.V//9,2W$=U=0LV9QH\)5DZ!?_O1;\ M;/J-OH;+(!-^#^Z%S\G2W]X0]Y1BIQ_CSHZ)3>;2U@XLU'X4[/@-RUX%`]$BP`O>J4\\-6ABZZ*/2G8<3RC6#MC?=3S@U5 MVU!RSZU_AYU*`W3%S2)X0K@(><&`3SF<^"[\(MOV^-L@8FMG@&*NN[7,=EEI MN_#*H9@9TC.'$=\HP!-HN8CR]87C/0X,F"E<>,7"CN$C+/!2O!=FTM9A#%L/O2CQJLQ M^(%=91]VBA/36\5FHA902SAC/U+?0ES538+OAUU@S(32G`J,3=PF&7\".WQ` MJ3Q)L7]T],`P@>(;\-)E@GUJ&_A:!UZZ-U@C4XD_TX`?*/?R$O"^WK+R-RR( MNRE\*OH*&&*R=<%2DED9)&JB0(Q.X[JB<-N94YD%%L=$85FJ`59RP MC@GF@&&Z&.`I/JK(,,\.4;C)7(6:NXK""A//$`\#X7?T-!O[.)J?9-L;G+Z6 M:H\+-6`)*7S^M4&>30GP@50;[82%;,NG;2O*R-$TQS$-V7!UVS0]S9)<63)M MT](WW)>RO.%YV!]N>Q_!A_@.0)FD#V<,>6VDJ[)C`9A5Q_5,;V+;.H.\9

2.:8&OROI"OP+4WP*GNR"O2%)[CE++Y7"&OCFU7E2?F1`)[25$EUW9-#OF) M)1O:.N2U3<5R?[B][`C>!M,QS9$Z41U%UV5W;(\,U5,0]4>N+2DCU]UD.IO1 MHWVA]C+P_Y[$LS="!++A*)+GC53)="::YTSL$9I5MF3+FFH:D_4S4!3]16>P M#KJ]#^)3BDI(_H`9*0C(\;^+<(4`_CW(S_@\=-655-G07<7S+,LU/-W2.%,: MRZZS01.*9.W-E1X#X=[G\CD`(5,$9^9P:!Z!I\DJZ#T*1EC]D*T4L.,'M/5B3;E21%-]U)B>.69$\VM$Y3D>9XXM;P+RRC(4SU'2/K)F=>^G231G#]KBI1CJ;MZ&[YB< M7^B'(VU,B9"G+39D(,51?MSQ`M,XRZ!PP9NL;+CNJ\.?GGQ M[@!--5E.KM5W`C>ZF/WL5JPWN$B396^K[;N^"^N=XZ0`X4=IN_."\O\*6,M17A#54Z6=+2M])T>L(^0L0%PY4%)PE1G.:F$A814$2 MNF#Z4*-^65W_4"59\(MR[?O!U&F18>0FPX&"63G_H2R'QT(9(C.,2475;$+& M55A,##$SK'S:B'^,_7./2<7X4WADP%I;\>C<.HUX.$,Q*7)A!*]N4<@EH34M M[2:\HT:;%`A'+H&B:Q[,BQD/RB&?RSO.!A@[TE#">F?@[MZ)):71N:W\A[5N M1!3=\^GVC+4DB!^HTV/P;880ZZ$G#V,_X1_54:];Y0KJ&L'98H M4">UM:-=[]V!E+V,01F8\721R`^7G`7BX;&#XU4D=!/-H'O8=B,L).91PU61 M!V)%SBL_G*^C1ME.@O=+W^@FT4+F*J8Y0SE'`5E:(>@V*<6YJQ8;VSC*+"&- MJ6ZO4:Z#XI9PS6URCS4T8J-BK21!4%-8HVMJN)$&P"3_PSI=,!!5ST#(W38+ M<%BG$VPS0F#L)NR*XOD7/1>W]2V:SZ*%WML1D26>HI-ASJLZ0?LGBX+:=PNH#M_/6&9( M(TT!!U5VE(,V+;)Z+>N%G]3\IZ]J/*-OS1^-2=#\T:Z:!<&\M+B(:/LK(>Q_ M4E^=].+/[\(,=`D4`C=E?@M+@J)\E0!;-?HD?3>-[8Y\*K]LDC1GXYZJHZ0S MYQ8%DRP#1P%\*L_7<>JC99+-=:@\ MW\Q78=O*&HRVN=T,=1+\4BS5GI8$PA$%_1RHW;=%A^99VV3K;3+OP4MM`1.* M/"0928VW5IA#ACNY+]$`L.DF]9>`AC,X>,R,0@TCH/[!>'PW>#0QB>`L+^8A M8SAGP[9KP#[QU[ELZ"OU_4(SC`:K%\NEG\(5C!R?3"ODJO0->I^PI?&&@.`F M4BL=\I'DL[T3#M^_%+_IXX:7^"_I(IAA.F:ZB\N^G'L2!8O\O50./>&HBI^; MKXE!D_&C:E9*GJSPP=_J!^?$XV?`2?@U/UU(%_0Y6_FS\O/S@PV`T3=AS!:) M+87++V@6`/OF/ISGM^\M]5I1=H4FAK_*@O?E'TUX MX8,;NTBKO[##!:X]_NE"5B\$T,3XA^KBO^7S^L^T\Q&TM)\N-/G[UA,:C^YZ M6GWCWO>IQW[AL-!36:ARE!=NPWA.X:`GY*@_<"ICLY5^;+$3ACAWW)S-@F"Q>%-BA>[C M>;6;H[:VHV+O.LQ6:.\))_)%]0FD[_J"SI-XM:NFMSLP".MZA89LB[+Y'-ZU M'TA.Y?#QOF=[F0>*&2BF(:]D437E@6(&BADH9C=H&(JHJ>9`,0/%#!2S&S1, M193,@6(.:A:^.>L/^X&RC/A&_LF4^H!B3F""@_7\;Z]K'9X*QO7&;LZ)JUS* MHJU;?>^\IH4S.O_G>-@'(GA31&#;O0G6@00&$CA'$M!$4[('(AB(X*],!+JH M:<9`!,\A@B'\]B@-$!%;<4T"^>AG_Y_]JZLN8TC2;]OQ/X'A%YV)H*B MN^ZJ.1Q15\_(85FRI=V->7*T@":)'1"@<`L[;YKQM M#CYG.&HM-/CBU[Z%#;,`C[?E\+5I_^Z0JG>$>UQV%I#=/:7O8A7HHY_?O_)V M17;8:@FUW(_XQ=?>+-T57:1RY]2CL.Q4E:;AS?E\\TD:XAXJFU/;G*7[I[7: MZ=`6)W;[F=X4!W7'6J!M:1[ZXO=BBZNRZ,ZG6;=:,'W,97L8.Y.*V('5D=_# MT?2>#$^:1Q7:*CP( M\J2\*\95Z\W8/:@:-E3%32SWEXD.7/O[CIH%5%\M?2GW$ M^I_+0=4(KKF1P\H4J]2RY@"%],"\^?2LI18H:8Q6*S\?F1,HZ4^F2E"F/.)<4H8YB3]GI%T`-;10AYXGX!(!/G?@''-K2K M/\/'6ZZ$W.:1?4F.5_RSWNM]?:!B6X[9"Q"+;S0CL'46/F83-1_G>Q8IML.V M=-;$@[%6Y[AM][VL3@IGX?OK?)!??Z=TTZ]2@\?O*=I:Q=!+6>)G4=$O,YF@ M==Z^>Z3W\C'VT=<3FZ;9+EUK\81',71@O&&$@Y'RYX$>*=YV,+ MOH M\NWQ8;U,M_98.RY#ER3Y$3G?-;#Y7>+>#'LILM.BFMM<"7,R8$U)P,_. MM1W+"XZ:L?]FV/EA-BP[.,ODZG13.(VK7@;38CCM%X-!-3D]98YOSO(/8U9M M-7O;/U1>N/[G_B3\SY]>6>]>_7FIS&127H?;V,MMPWLC.._69[!&ZZT7$O'# MZW?C_FT`AN>G#5N[!E0Q%,_&3U3JI:*KJ_S?K!M_HTFZ81PP`'0/2* M,7`NDC8HYS4!H>MZ-=#[T^R^''=ZY5419DM&Y`]#5,*0@'60O5FWG`]O#^-E MRPAL>M.?+-AW'X:`U^1FKV.@G5*IM=*!Q13,6)PQ&H>R"6!46,%88K1Y.&:8 MDZJGG889KZOL"LL0%BRLZA)[VJJS:)\]#VNY)F&7<6[Q]:P8PQXJ09`F\Z'% MO?2ELC,MQ[=S\8[?G]?BE7_<@6S&T:(_S$`8@5'LLJ-79R1OXN5M\4?_=G;; MN1M-R[A]YV/APU3FV706ZF^*^VH>Z4/-S0K2E\GLYLJM^?__[;O9Y/5U4=S] MQ?5!3$&%_`,.W[O)FV%W,`LRZY9$]=U"4L.K@]$$N/,1E*X9C+K__OX__Z/3 M^=O\UWPQ#D/()^_+\8>;8ER:8M+O!JT5E/0OY=7?7[F0IOTS^==']RJ.1[\M M!I/H*/9[?W^5%]WI:V^=-YPID5M$.96("8=9EANGB&4"K(#9L%_]V&S2FS_I MU?>O@97\@;!'H>R#EOQ,-D&E"F6&$8LUE1D2BDN=+:!B8AN@9O@(4/%FJ-8; MX0QBP%)CXS\<):@4*]0(E1R'JPTRH!4F3G)F/$'&.B0UH*S0(@.O-,G`86A= M?S`+6GQ'F25,\0Q)::US5`-09@->AT&:C:5[RFP"LQ_B!KDE'*!9SY&DVF%A M=(Y,!3?'QEBSI]P>"K>)P2`!A"*!K."&94H)K!-B;844>PK$08@;=AO77-C, M<6L]!LB`V\@$EU)BLSUWVY/@+E3S1A8_^(3NP(SMQ2QX<)/@:*XQ/XK^_ MFTV#@Q[=L,DT*,51*IN?CCIWLW'W)G@DQ1VX'>`05#7VK=CA_`++[")[)!U_ M;P_ST%]*@;44<8MLA]-K5-GV?PF+.X>.VH0^"3M@LHA05$[L?TU"+Y7;T"4R MKDKLT%'^$;R/X/N%[OU5DX-!=S:H0B3P`[UT$L?.&^"55+_]X"K&F=*G9!7L M\_KFWHM+P(KIO-?*I%,^/N?Y2%0T>,NM$'>QUD,BK%"[6^ZIE+(+QEE[HGU2 M66.A!6;KV_*\=XZU=]II2[*^=SZ5W6(V">M5]L>@,"D`589,5U[%7U[W):?62+&HZ96[/N`S-!("ZJ)DIA?LI%I:=#P#NJ8L!T MN7^OHV)SD?C]%+X'-K@(N_%\@63C09.*BTP93E7&;6Y M%(1827,D3.;]J^_?J[=(NA/P]E&BOQR&SU]=8`Q,?Q<-^#K7.=6$&$8T5=H+ M#S:LA;]SE5.44:&!Z_A?_.U7SO0E#DUV4"9/8/0&C:*SC'F"C:58("%=YE5> M:90<%`WWZQI%Q0/U!*NPS(E5YH?^],%3?S?\4`S*=U=F-H&C:3+9%N![39;H MQLI[G"DOG3,.88R1$9AE0B-",1*L09-N>O[^*-<"IRM`+>&4Z]PY2ZEP).<` ML0)*"I M%2(B!]0>`9.Q,7('F5U"L3_<+<+@P%#)/=>4F;"E3(Z52W"1RV5-#(5L'A3+,GLBJJG-PD+Q\/+JU MU3TZN!4/%^D[21FGE!MLI9%2"\>P@^,61_7(04&RVA'[FF"%5I!N!]0&`4W< MUE@;EX&)1O,\-XID0LYW2B!!UVB0B,E3T]"TL;AW"!D%^%6NN/:8^BPM@E=. MU,3E-4)2/0,!38L@-5AI&2@MV(5P%)#<.)EHT#(WM$8#@]UY9!I,#"Q4G_L8 M^C*_[0]'X.7?OPG]1\'HT\/>ZJ_XWV;P]MMR>C/JO8EV896FL\MJ:IT+Y"DE M`GNEB"+"1TY0GBD0TOJ6@M5D.W*B-%$N;Y(LX15&..873!B0']"GS%5<1 MF'.N9E^`?-$S5[>J3ITYZG4PWIT5GC.+>9)5ZX6NG9Z@.BD]<[7Y1,72@B%) MM/9:2BZ]G[,4:]`%CYRH,*>98E"@EC MO%%$Y2DI3)E:^]`(Y.2Y1R($+2T8S8RHF)S'C3748=\FC>]!I=J<(DLTXA6)#I&:+728 M,CWR*C;(JLLI8S@'.T\:[23X^90D*G'N?1.5.RO4IU+Y>.KZ3^7TW16(1<0+N M98C)(>LX0LP8YRJ.,`Q*L!8@!(\H:_*(O@".--G=N7(&4:-EQCFUN;!PT"4! MR77&:M%)Q(1X:=PXQ'Q!`DXX)8F2!GP-3V2(@(&ZE,ZH#+LF^W/ST;X#W&-1 MW7#4LQP+IQG/G&1\,&)5(UBHS>A/)3!\6UNZ'5OH`//6DSP'\0;35C&6H7`1FB6RM7.NL6$,QREX7SBQN5R#:&;%[M@_;UR:AN=+R!;"L44QHV.0'7 MM/+8@'!A:-9XK&$>&4TQMG#P.@&F:KHE-58[XEJI>WJ> M*8F/%Z:D6:8Q#ME6:NS554R-??R!K4[`?/9$T2:\:QU71M"'IMY5ILRMUZ]D1FBB<*FO["/#[L3M'"EPLC_X]9]A_6=4IX_)J M$/Z"52S@MXII'!B\U&AC.NH`N.JMRTXG/Z_O"Z^@F)[UX[/KQP-WV4^CU*!E M4I6@+)8Q:-?9KJT^Z)*UIH"B^5V4/3()!$,D'<5\(ZJI0C\M!U?LKS:&?3T"[ M!Z,U%K]>S/MYS=7:W(^*=9S@"&/UNQ8Y%K7',RP!=T/DE M-#*;E9U4DE"QL3_MW!2A/NOV;E"&&N3`K6+6BUIFO:8N,&Y<3F?C)?,OK-TD MH$)!NXQFUS?A#U[U<1N">NL%]L2,C\N.'L+9!+0.%Z7/JP\`T40+B>I7SMW# M0\/")I&9CXS_O;B_['R(BT[^"_3F;@LD#MLL%*`-0U55C MNWE7Q4IOG/#,:^FDGBNYTR$G[2#?L^>8\VU M5DPZC@G&SFN6I9H[IK&K7Z,^EG900[$?U*8,"6-UIC*'C:]B4FN*U6ET>[0P]Z/HVXQ^`&\ MK$FOW]U06TJ7J]4],5FF&*.:,21SKBVCDG"%A;?,U/))4'8`N>7D?=%_2M^_ MU>I*1&$)8!$H-IS!@CBA?2:H0.%?H@:1;H!8/7TW:%NT!#/2>VERE&-*YVHWO^OK@/"1>PVK':[MW\]%L>$K0C M(198BHVU0DC.E+7*>Y*$GF2$UQ*MD*AG%>V/]IB$;ZO7)`A)C8PC"&LF,+,V M=6M0FKB\5F.,2%TO'9_P7Z);537YVXT^(B0.553.9<09XI'FO%I8I#)#:Q(* M"_M$\AXPM4#%%O%$*M=$&RH=',+&H'A%%3O M[E+&J'0/WYC^P2'8"/K0$8XV1`1QL-Q MQRDEC&BO:R5Y**L=($]#]B2"%FI@OX)M[)25"(1;*@]F5,[A/*PDB60FE_7S M>NM&>`Q5*Y1L*P[6W"&=,:^5M";CW.ETY*#0Z+=FN;Y&&2,MT%+%I9.]LEMJ M)>?1NN+:I>4-"9K\VNB18%.@ M>;US#/Z9;M;#H,,,H\82`$<`I=(FG1_86TQJNQZK=38^`5(;5#26!&KFP9:D M8"M[38#E<`ZF'>^0('4/4(CU#;\W%?=[)3&9S-.,@XIRP;TFH=UTB@*XT)7> M?X5)3`L.G^/.1[L]22U8X\22!]NLF'XUP>B3WB'"\;]."VHQMR'>S9PP*4!\ MT2D-]*@9#6%R3'_8G]S`[KD>I>:9IR,/'6.HT0D71QU[<<+5+3PPW*_N'.#? M?$YO.-'S)`G_B(*PS9Q:]@@I`JN/"ZYS(C$XY3EX2?,6G4SP6M"'UCS"QR#L M!7/=7EJ&B1P3%%$GE01S/C29TB*E4"/&;:TKA3@$YB_%[V\+,&K[@&,GE-0A MG@MFB.3"A$`^]RI%T'(CUJM24ES_49C+$/9!V;3D(0N=9\19XC.3B=#>8]ZT MRPO*:DN^WD/QB2"K[((JKCOW$79R2V"A9:Y";TUE\CQT\9*A^H'G@)X;7\.Y MWC+C<0A[`FTRYCVW""FMF,X(MXP;DR6@+#=D?7S02J.[EE%NA/QQ*0)W*77MLL;6S.2,!?!A?/2F&,))9)C!-8ZX7;>IWW%*P_ MEM?%`&08WIOH8:\J!;\NAUTP0G?PC;!7PEI%P/_$),P.PBHIT1QIR_E7YQO] MV)^FF7I?3J;6<9RE8Z']WY"GE8R*15Y>R`8+TQC!\AN$<8QATN-DNI+M`HY4 M3'8!VV$Z[L-W[6@VGBY2KA8O@X421.X'$/SR/J3CO2WN.YA6SD)(VBNOJ^S4 M8O7WKXKXZ##.!+XPBE-X;BMH\_:XX M&L,>&HU3IA<`NNC\[MZ/XHW?A4R$_+AB*<;0E//L^YIZ-YG40 MEYW.Q[7,'WA(/[!J:59JH"T52Z2DEVZKBX+L/I4<\E6QK"FYX; M,EB'DS)Z8-^!(,.FG(UCRFL4TC`4X?>U[9SD,>`(.R'F:RW3<-D)EW(!^'7P M)\+R)?D-DIKH[$]B24%W6FW(F^(SO->Y3299I^A]#KN[4UY=A:>.ALND5!$" MB9'X:QAZ^]NLW^M/X4G]ZO9B,AK\/WM7V]Q(;IS_"NLJKG*J5A>\#H"[-1J,; M>+I[,AXN,SEX@5UULZPW648XRMU/0C@*@\9??IHO)J<)F_W(YUG;\=+0?)./-8I]5(%6ST7B0FDM..%K'H%Z_FA=BY^S\% MYX7@CWFAUA8^,2TB(XZY4%`66O#2D-0K&S'X2T[``WAV04IP[84D MIL",YO8$P9E&`.M(`&4(3H+`0=K#GP=D*9W6)# M&,P)P2X%^/&NOJ'KG.&?!=:9"$&1DB(JHJ).6FFL_")YC$54O'/: M0V;;TM[@:'*!.(A*N(;`E!,O-'&4:(K]-\]2B#-$MBOX6?GQSE>`?0FP8JXP"W(#'28Z/4UG6WS_*N0SE+432$#RL\#NM M9EH<[9_GX"W!?E&.5IF+>5^5>46IC^NL)X14E$)J3GGA&))[1!^\*)AG#&C$@]9U2\A20^ ME=4(_HGCO*W3/&.MD,8D2RS:/N540Y\+)J6MEN5Y(\E%;.@YX]E`N_:8 M<";3I%HL+7QCW)W?[7?[$[I=KM!&QZ,OB$K$!?#*DFZ6.85=3.Z7@'PE"43, M^LD[]J>0'^+PPA>4U=LS*+)&CXYM\_\?\^CG;W1T_#_,OP ME\GCZM'-JVK^&38V/\0FWL^(C(JN+Q15+#3C/HDB8;EX9EOJ9BR4[X<:]07B M">4[!.WTH'XL'X<3;/QW_K"Z!D(*<.:?8(_3&ZGN>;2J<'\Z8?4940%F`OC((:RCG,; M-(2SPB=KL0!SH?I91KM3]!Q(VZ/XH5SZX>+A4S7_>3(NQ^[+WQ?E^$^S5)]C MS.XMWN?6X=OZB/'R=A@0F1%J--&<*!H\M81A@@1HI90P8;T!WO"=1*J7P7W5 MH9^XR@&K9[Q3N)T;J6RA(-AOABZ<*?JT8[D32;_!T.L+HZL//3)*I'$^.L$I M&)P`UA*'+DT@4IL>;5S('8_F97!?=>BGF/Y2@7,_9EX7W7L M)U1>%V#)H[4>5!S4VH-9EJ]YM@W90#/RR<-!%OM%?"O,(7% M/+#,&KX[C@VOWT.K*,G"-$8XR@Q$!DQ%HR6H6A@J:AE7[Q4 M]3>2RV"=4/ID"#CW,6`F8K3@*RH\Q8H6`VE8%9-"H)ZF5NO M,4\E!]>[KW%D1^$.(;D4\*ED-(\G%QZ,O#&:6@7Q30M8.%?TS9R@YG4!'UO0 MB40I@L0>LCSX`B*O1!NT$,ST6VC>%.K5I7M8M%0;KP+X2!ZBQ2`3RTD9`)8$ M"*7W+*:=EF'/1/MQ^S.7K'N8:KX"K0#PVX9X1+RV>A2AEJ`M8 MV;H][PFZ?R$&\0&AKP+QV%P;"4Z[)A!L,E.@_0Z2-7,=%>N?VL+FSN29**O[ MX6SR?\.ZU7)[P0PO[&S\J2H7>,2!+S_>I?;&>7T+L[@HMT6KI,!V,>HM&#+K M\=2Q%CV$:3+0WQQ_"PN9YRO]KCS?LUQ>BILBT6N:YB+*`VQ.ADLKVFNK3B?#1;U_63^H<_E=)J[7#>$+4Q+ M[1!K,F4,UCE*I$N86;]9UJW:D0YVCS2:65U/L6,H*P+\)7;W\=)/)&.\+[.7U1%;=C. M7":G=><+%W*C!#C!FTD#-"LD9:).;)?=:QEJ2/3J5,3#E83+.?.U,K%L^3"I MQH/_70TK4$M8EJAPRR]/J%73+X-Q-7]ZPNF_+:?SSS75+;/FFB]@*=*RYM7! MIH]21.;(EWP\1"5;['VK';* M0M9TPUO8-)"M^S2LZBS.8:8M9L7.JCG)=Z*C36WR-*\>!Y3<_%?6'WQ@M9K6 MW$E0@?O5M&48UK_6W)I.FD_$7T8/0]"F0;[XROO:UE;ZU^B[N^2W`[_F',./ M/S8E2;/BSI>S.1C(\8:>,YCA1U!O)YV\U+VR.#;D85U.!1?-$RR=T>0)QW=TW/)3_S[+$Y%]V#QNBU3CT7!K8)G4_1_6?MIR`C9S@)L4!G=C M=!KFCY,E/O)I52U6L!%EJ[$:/>P7=5T\\!*-6#S,5U-D3XT+N("= MZ:FV&W45XIKRG*U+V:0AM`6]88'558;S5Z<;GALF<>92O/5?FFKM]8MZP^S8 MBGK1;)2X:U_6.HLZ/,GU<=>KZ_O!P_PS_$SUH5Z1W>]5=9'R16:'=PKT-F.J MR@]K2ON&JKZ]*+K$]5F)E4N1^(YV=XBI&]5F,O"[+;>[S0YI5WY;S?NIC@[+ M\?LZ>=7=>#_'_NMV\M@N['ZE4K7OU>&_>G7X7,,!]MBU>9AD?V><"Y3_W&:9 MK%6RSH%:IYED2P+.7VT/M^U%>UR1"\!C'>%OP7LK!QTGYB]KZP2F"D_J5K4' MAX*T$-%\:4ZE-GN'![=FLG;:?MRLD\UU7_?`),-;,Z^[QO4]<>O-!O!Q-E@O MO4&[XK;SJ#9U[7.$B&D#G?S`85M$[?&IS>2"EQL6?!M7#W"HS4G/@;_FS+': M'V^U%X/T<8>ZOC&Y]>X*WZC=R9TAFT%5ZVW>O;.AT!7/2R7#8R MVM0&[VPX'>"Y\GYY7V%Z9(.PBVZ_T-9)E"CF/+L-)7Z#93N&W-GAT-?9XV^L M`[?1?+'L_"7[B@>;7S50]L46F$2'S7F_P!"GTWSFUX1D]52,'[$RQ+*JK6#^ MU0_@3GW)MO*VW#&1-:K[.?Y^V[C@MAP-5PO+Y@GUY#>'?O612-:$Q4/V M@L$EW9SJ97U=K*/B_0/<*%.K/[=E,Z$YS`;7=%S/=I5U?S8?W*^&%<2`9=-9 MHL:%73E&PR9QL*L"^6AJ$W(=FO-<.1XWACI-MXEF[U8(H)W.IEG5'9X0-7%N$N&UKX]V+J?VU[N\),$L,FX8"XYP M9@-1CK$VP2Q2X8M>MVXA^/;E^7$L+\)]]&9:."*L-E1%J;'!L%"IK>`J=/_2 M7^H=6M?YN+-=O$3&@F,UO40#%C&VMN#*MC5_I9+]="&NQ!ZHW9\_&][1)$A` MP8BBD=@(`RF(-HTHJ="4]DL2%T1=BN^'^6QT@02#,%I;IISCJO"BX*YESCCA MF>C--N4'$6X07`+R*"=*6:N%HDPX8WADSOAFF@G7IE\JAA%S<)Z/HNRHZX50 M">$J>2\#C\I[SKWB+1.!,^Y[7%BSD^YS&,;%<(].ORM4Y$(&L$@^%=&+Z!L- M=4A*Z6?!TCV+_;EXK\:D,L07*D6G992%U$$'@2W1%?&)ZJ*_[F\8W:.VSZ70 MG`?]:$*L=<))91/8>BFC,EJ1!C=Q7O3$?4,Y?4/<1T5.0:F-P+0E8Z6B-EG> M0,=N$7WH7/"W@GZ4%0;;6!$*4=!(F:=.&F%JW!%V:-++\[Y1ETO\4]T5<+'V M/6;W/OMCYZJWT41R:@/3R+HRAH`Y(8J[%+2W13\W?2=9XA"."]&>T`P"GD)1 M@(0YTP),2>+4-&AIE/TV(F:'=W<>VK_-[2B?'[=U<3]!)(0IV5C$X.EQUP`^ M1]I*!UN8%&%[9L%J[GR;N>6%TCW-YEP4>P=P&MK5AG2*#PMK3W+GE!+.!A4= M<:3MA9"8Z^_JI&5(U'Y7EN&G(GGG\&#-\O'/-9??YE?D-4;#C(\\>2#T."H]O)> MWQH^S,'Z4(>9Y<,-)\N'7W$MA&[!P\)8PA23!0_$*B$)%Y1)KK'12?2Z9RUU MSUR^D82[J=6_;I%ZHD%1)3'(5F485!DC?'3,%DY;WA-I<561(L!%F[MX]F[D ML5:*#."LT"2TM<*2MJF5M/VT#F$(.VPOMJ!(4<1L/D+$[#BSW/!GT!UO>&< MF`NPR6!#.+@QB2BO&)AIU@S'1"M[A6@E/:@ZEP\)*S-]K.^[XR]E-9HLRK-; MB2D=A0_)0ISD"6A2Y(60/I_5<.IX;R"'!K$/RTNAGTHG%2(E,.C)!ZII3-IQ M5T.GU+O4JPRZD_YT/OS]$P1&]G22\_:)'U:MP5(?!JM9)1%,T^?%@]-E3"\+ M@6'OM%WL1\"\"/BQ4P"N(H>P@D?)K0D$$[V:6BW@?"77.Z=B1#-S?>`_E.<= M7CB#E7FMM%QHF315HDG\#XP:T=^EP$/HJ:?)W@@G^95F*]NEW>K:=L+[.SV6`6!G91P],`+SYB7 MJ2V!ZU5P/2=<]]R!@U!>`/J$#40G6RH(XVS@!?'2T]B>#A?.R?Y)MKP0](_E MTSJ&?9'S$@J1E"F"A06&*;9!BM`LQ*AR>O3#I\ER./TSWB5]O)U.VH*OYVZ26,`G MJ:`D(UP)C68;=WN;L/,>[RU&MK/5G`'M>F,Z%?H7Q%"CF:+$6QTB,77&E-[1XDIW+/QC^44+PXWR=P7Y6YQPX+$^PG!A#):P'^;^PG84B'F M^\WE;FV)<>`?AM4]C.&=H/=:=):PR7]X9^+].IEXV^2B.H^J+EW<62FC9J4< M)(\LYV#"\+TW;$-SW1Y!YZGF">.W/8KZC_B0[^HLB2WKU+QU=*C7;>:TW7&G M(3CMG_"61WN5W\TFX#J3U5W65UJ0;\-[17+79(&]':SN3&OUY',/^-DQGHR3T_J/\R. M_^ZR'%TPU[=^B[=9,=\VNB4N'MVS)>>5^J1T?8/^2J?,7&@-8IW0BIW<[=?(J6,`P7+O?:!?[<-$V$IK/ M[F^69?6XE8!Q,L-A3[8%]NEI,DX;0OV5)$&_9:\VS;M9+-W<%3T>2\6W?J10H*VS)+ MGH)F08;FUITF(_OG(+UX"$=[J07/F`%!6YU`\:(+;5=LE1*C M/=+2#>6JT+LS<.X0FN(3Y]C)Z*VAU!,NK,)T$A?;^V`KG*']Q0W#,CLPZY]] M)IA3-``MP<84/B0/=@>0L=3DM"7E1-_8<+%;,_E,/*=NGQDMO+<%B8%961@B M!&_;CE@P*CT\99P_CIZ M*,$KQ?8S:5Y??ZZ`XV^G\QJD,/5]KFBQ=_C[_U M#[X#_;4`96_R@XF^KC^_]5:] MX/&=DS`[1@ZK^-[!_OC=PV0,ANVZ9GQ]?'O\U&A+V&NXQ3?7E]5>,]61QO/W MB:MLP'_+%X%_F>?2K7'_==N[I/!!/R`IX")!O:_#]W5X2KNZI;'>170U$5VT M]!J?M)$$??IED..C07O9]O9+\Y7)Q#6!#ZG:DU']I-_G0'&^6D`$NOC72Q22 MGU#(KR#DMU3AMCIC_[KX77;/E5V?F/,NNW>]^Q7IW66[RW#TTWTU7\W&-PV' M8S0JR[N[W]2VTJ2DU,?29ZCBU7V8@]*^4$[Y+.J:0OJ7:TGGI%X]U]-[OC"R MUEU5&M1\H.H@QW_]9A:++1[%YM%5["*9+S)D ML.$;XOQ@_+^2=_Y/?CV(*^S#'J3;._7M<[[`KC&E,WYZ15_@'[DHJF5_Y- M%LYH_P^)L"Q;'-]N+!F)=P63VQV1P-\B*QQ0)2I&@/='`?4K2]5P2F"0P^U*H&D,+46.L MZ3P#DM@DL7GQ.<-@8Z'!SN]]`P+S]/)H5PY?D_;O`:EZ+=SCTD20PSVE_RBK M0&L_?WSE[0IWZ&H)M3AN\4^/O5VZ*^I7Y<[5#/"\-Z\TC?_XU!^H/^]<%"N; MJRZ52_=/:[73<1SR,)_$8NQL]))&3$]OVU!'JJ?O*QN;YMGM4T?89[>\0]OV M;31W5<0>H"[Q'HU7KO\6@\OG)>[WWWI&W=C9@W<^&P][7;#B;MU*-8[C_++L+-KF`5U=(>[YO MJ3U;[\F0E5-]2W(N]W1;BY/$L>5/1)[D7[+`N7SXV`M'1=7?[#:;CPGJ+2Q] M!/XYGQC<^YP/[TKYC7Q^^F=8]<[\]O&E,;BKS_27'UKN6-D_L/=^,"!OLHUJ"4S7=_-93N.J?L=F%XEA^G8LP7&VO""YN).&8"8(@H(CA MYGI%D!>VBN#BQ/T"`B=2OX"V#>WY7^/'&ZZ$W.61G9/C5?YUHS)W<23TMIX$ M1SIF':#%E68$-@YAG4WT_'%^9)%B,[!59TUY,&[4.>Z2OFYU4DCD^^?;T==@ M!8V+P4'IIA>IPTM.M_./>^Q/&\90PD7PSH[<=X9SJVPG.H#T1C-UWXUF,0K^DO=#^?OQ%Y/[L M"^&)$6LE0:BY=/F=L)T%BZ[=D%B/NBUNU%C#M\C5J(5E^-K04"2KY7T^KX0 MFNQ+3$CH!0@G[=Q?M='7]74E#+;D&R3K_QK/MGFT8RE-M-LACZZ?":<+=UQ$ M+11"S=TE'@U85[C3H)K;KQ)FC7F^O%C7.L!1?G MTI<[_)^1^/.7',6Q1`_AV<\O_<5Y^GU59I373SAJ:1%/HUV6B@I`F4JZV6S@ MF%4U4C=PM:GX0MP(QJ'@M,%YC>BE\QK)90[M>\7GSN9%3S[G\;`?/).81;=B MJPF?;L=S#H_=GWH^XZPL01G?]TJK^%7["E\J\:Y\0%0]\?Y=_H]@+:L`2O8I M[[F_\N(V=B?X4`QNPY^!E24E$R-/G[CJS"RR!^RP2AZL28\4`1G=98- M>_\:W.>]?SSF67%086/B9N+F\=Q4GSX5^:=LFO?>!B8.1I/!;>_7;#@+3#RJ MTO:"[BW::-3Q?C:=3`.@4?87+2&R::^UBMT.(7MFBJ&U](97G;74)TCV$4W5 M4)WDR34)6+I*?1&MSD';P!N4FD8F17-))WD"+@&7@'O%J@!P[LEK;XHL=B], M`9[NFIF=,:!0'R/:!\TUK^B*$+1M+"6IN."V$^"&-#:C+PG$U0A$PB?AD_#I MDF6_IY]T]B;_(@&A,:,_.9A=`*XS;L(_&.C3$]SI;#*E/92Z.\LU"5^J'E_Q M1E`J'T^R=4D'6P(N`9>`2Y<<+_%XO@R*=,G1Y>A#=[P7V`>0]65S#DSR4Y+0 M7/@="+IAZ0XD"<2KGR()GX1/PN<%AO^UW('X<7&?#QI,?$K^9TLE;Q=Z1P+[ MF,,^:_":Y*4X7K=[DN3W!)TE+NF:A6WVGCJUY'9%"-OVE))L)N`2<`FXYH3-")ZZ/_:V-GU,$8+.1%#.8SX4ZV-`^[#!,:S7,`(JR=/I7*5V M9>_T[I)L;*3X3G7Y MOWR@XK'S#'?/1_R0/<:IB^K/K+A;_K[8>K[\$369S![F_^_068E"0DNHL9X@ MCP3A<4XBQ@)0)!!E`KM^&%E;S!B?5P,'-H$;Y^=BAOO=G%CX55O>0Q>\= MC\KOO(N3!,(+E#_7FTT6OZ6'08R_#TP8#P.\U9#&+\4@SLL+OWR7#WM_#L+/ M3U=F//ZY&)R158,SLF^L:&2&X$FVYR@C:<\%7.T0Q$:''^(7#C_$1\\B!$<^ M2(]\[NA1?:=^T6,1E2>>17BA&W%!8UR:=WI?E*=`3]D99P>(IW2XRK]NC!_Z M6-H@[Z+I,>FY39OC`MVS[E*3=;1ITTG&5483^.4\/)-9L]WE8)JE6D/.\\[! M360[-[(U-GXND>UUA_5VCUI)CR4]UCT]=D'N;ALI;^ZO+_EMC,,.CQM1_#IM M83O$T/(Y>M-^H]ATVYC(5I&-)K)UR;J[B-A)TF-)CW56CYU?[*U56^WK>)A- M!\/!]+$-TET"MX2\87\_7W_T?#76)9!'HAN2R'.B),$7&TFOF;P7U4S30)QE M[[@D+AT6EPO#)YU%*=;Y,OLY_.0@4/FN]SC(AX>TK4V.VS>I%0BBYO1^AUAX MO@HOL2ZQ+L4_$\?.CV-)LQW(NA01C<_]/)C\S_?W,<]X$'.+.*UA7YV=$)2V3M,PIM,P%1;L:C\?_>[V\>K6(_)G2 M\7F5>++A#P3\;^`&I]R9+JG#2Z<;::P1;:);BH(E799TV3GHLI::(!W?M&BM M(5(^'`9LW^2C8'8-U>A.W3T,1H/)M`C?\C6/-Y"C2;[1Z`A5C8[N\MO!0S:< M_-=WW^/EMD<".F`E]HHB`2QF&KC8^@A99)62@?BST6#^;;/)W7<_0`HH`0`L MK7FO]VIJ+5L7`HUA!!(+'#74$>,MQ]5"&)."KR^$,$I?:QWXF74X!2@0SEJJ MM/),60]LN0ZC)?*0K:\C+`*]XCJ>XY;"B%&%`Y,CV_%#_LLTF^91>O5\T-$OG_-\6G[EW2`*;#:T@\GM<#R9%?E$ M/X:_?!E/LN&;H$^_3,)7#&=1'<;/A%\;C&;YW?O@!&7S)FA_#2:_?_[\^X=Q M,\KO![2]Y\75PF_]K,,K?E3T$5I"ERV3G5G$+,:7$:$:0=H10CBP&3"B` MS3JRG)0E>R\$MK:OVZ$*!QG")0):(ZD"";@`9*%P'+?$;O`;R]4WKWV+H]YT M!WVQLE@H(3A%SG#K#8-J_J80!4U)-MY4P(;>5!7!>?XT)]YC_4GB_G<2H%0L)2H97S MUBM7'3'&>:.]7,)Q$MN>0-PPQL`I-.$6`80%)P0 MA9`R\PV0U&BAKF\#YDIDWPUH4AU9I:.1@PQ%6`NC`.=@OA=&!-D0-7L!*86G MV8Q56,YJ,XXZP7DX#C@-9IOT2E/-G.9BOAG<.@1<[6:<2C):V0R?#8KHH.=+ MSODBQ]=6*;X_QZZUNZW?99/22@&@HH8;9[3!0#((,59*0.(Y(,NL+KV$[WX` M-\W`N.^".H#?-O"T-,0Z*YQG%C+J"4.B`B]XCM@G\#8=FA7R,>!)0!C;@*`3 MUDI'Y_AA1TTBWT9<9B5.YH*L,D$\1-X!02`BH"(?EX2#JP#OUZ?BX"-TG_;& MJV!;6<;"L6&$=M!$!)F1W$I"ZQ"4B+2,X.J2.H'A-@"-DAPJI@W77#D!`FBH M`I`ZY4@"<+<.C-:DL\X8HZV!6'BNY!Q#I3&"L`Y#(=GU8;A5BK$'W``=CE\H M*,=,0U:1D&A/:TEX00#&K&!?Y/G;*B?X"#THF:?8(&VU$X9Q:1AV$4')"/`" M;#E)>$L(UBWHM?%[AGXF6'X6.6ND$QYY'U5')@+`CP^0H\YX7>8D!?&?.>,Z"M042$D];`H`$)@<[".7Z4*X##:;SN.F4T"'--,#"$P6`$(4.U=X*8'Z&P,\B#E7:QD3-II_' MQ>#_\M4HV]LYUEL#SNJAG'^4!7\LP!P''(4'R#Z19VI\C&X09RD/OA%QF%>A M?VNU(:`&9@2:NB/;MO9.01L5QSY(2L4P43A@)E3@K*?.5Y>-07DK7W>)`AN[ M;3P')`^^%7%42V<\H3*XZQY1[3FKKJ6D!:1.!;!K`C10$XA]@.18*"LU,DI@ M38%B`I'JAE50QNNH2:]+R.OTYUY2+P`4P8EBEEN+E0'0^@I:2Z@S=?8!/E.I M_YH-AC%+,)R!Y9U@4US]'BV?1UI+ZR'DW'E/@\/E%LD`F@E,ZV0^QD%E&WBN M+[B+L!Y`W!6YQ=JSFAVDJF M)#8Z.+W&!;3! MQ])$21Z,)V.\K7+RI&/8UJI/Q`1M`JAM2V@-H44!FYK7KU7_DG\H!K?Y+MQ6 MA!=H!AR"@5H,8DR$K#*.C83!/7*K^8$?\J)\P2#!-Z@=W)Y;6--H?AE4::P[ M\A&><2T9X<@#YX*/"4BP*P%<)((:*0FKU7V0R69)M[&.9H%:\E2/!HI)IIFG MTD(G*8:>.UUE7PA'L:H])#"'K$F@:M;1+%"K^4UOBO%D,\X!?B+SZM(=69`V MORW/A?C(4L7%?LFJ6EM/#=-.!:8!2!V75=Z1Y<[5'1F-&9+;H3@]UH&43Z/L MMB/]])'XQ&ZHPQ','B8`4QI32XS5A,%@#C%3=^:@AO)-.P;TRZ,> M6@`"!$!.$*(T"QJ"X>`.&6"%XY:A5N-'74(3_32GX;&9T^A0?4&"H^F"I4Z` M51@+BS6I](5S3'M?IYP1;RA"VB7D&PF1.&,IDMA214BPU[&5*%A6C&$M/?*, M7HM20$TH!4@91-HSJ`V16@472*NY4I!$4%&;M8FN$,W]J`D(DT0#%*@9#BP- MC<&HHJ:U7M2%1.0E:M@7UZ8JC>UASBX. M^%UN0G!`A?166.5A./--L*>J6))`PK.ZC'ETJ&^U-,*:\QX9* M#;2A,<8L#`IG$^)UQ+M(B=]19K,WGE20X*YR3[5@EE"&%)<5GB0Z_==RN._& M<]OYONP_.6R8XT1`I@'Q`!#NH\EOI38!"Y\5GG+%<1G3 MBW#J<,S@.CC/W5A:"Q>6_VBS:?Z4;+3'$;0<#]64((\@AX:&/YT7G-N8'J4D MIUX!ORT>&EO"M`7BSC5V"^#-S%&T$C$51!E!M`__=<90;TT%L'5^)4MD#6#2 M1!+?A0"\#5T+G=/`TFCC673JM=*1SQP@1O2"@8 M,(S).(LL$B+P.I#?_4`:/:*VKJ$UJ(ZYSR2&0T\D#WX@4@BYX/U4Z7228,_J M,FT8!K%Z^*8=K-JXT=R-$?J)/'.K1&PX,ICQ5DHAB"$(ZD7C)TUL+48$Q=R# M=.88RJ1&3#??!N]'8U)F$KN)WNSO=8--=8^#U<3HEC M@5#6<(44(U(;(8$(CHP3B,1L[ZUP0B3:H6&#<$[VN[C/MQU'VU'=;8HS$_P9 MQ*"R,1*&F+<85C1U.AP8VVEZ4+U@HTML'-Z-J_TF`18:6BN"TK0>4N""ZU@% M);F('O@V@-$-.\18;'B1#4-?A# M>%;APKDA<[*P=Y<.RG*8$'DAK*7!C17*.$C5O`T)93KXMO(,$=G,Q%SUC>%! M#GXL)Z4JUH<8"579][7**)&QM@'MX>"WLHC6P%K3^C_G#]E@%&QQ$T`K`B*S M;+BG9J90R[070 M;B2Q"R8!4\%;H%H([V+B;412$Q!./T(#DOPW\0ZB!I$\8B'-(KG:2>Q)>VPG MWI;NO((32(,3H&',J&<`8U@EACL.H);K$LSKKN5:6,<:6C$/XVW0C/F=+6>T MS#]>?O,DUK$$JVNE5OC'?/K^_H`ZY`,NBI=OXB@WP0*U")%@8BECA46>&$LA M$(9K6I<#AD`X0=`2@"]=V@%(+;=T7QBLVWJ%/I/X1B!27D$$*>-(:@N#XL+: M:HQB*5O=HL&>ZZU]P<87N"L[11"GH1/>8TLQ4+^@HU7H#;0I%#=X'O:#.[\=%_K'(L\FL>"S__2!0 MA0,(>T8@8#*<*U)*@.,[4^ZP^7_VGK3';2/9OT)XLUD'D">\#QO[`)Z)=YWU MP)Y@L1\IJ37BAB(5'C-6?OU653=%4J)&DH<:C//F@X$QQ:.JNNZJKI9[@.HH>6+X=!LWH$5<>;*MS-**_N. M85B>ZGH&\(8GBA*1KNO>8*/:(T`\OV;I.:H*\(1FH%EZ0-N((UQYTW;`2_?V M0AJKO^S[7S\;NH?$*]!"6%G+50(%U*_AFY8NH+-#1PWWW;7SH-OQ99M]H4&2 MUJB7B=H=U_<$UT'NE3H=63==B'4T`%DU_%"S4&R0.65M1R;(J8>1\T/5 MC,S(5VU+50T[4%35:9`SK5Z-IK-RMF.JSVCE'N!,$_=O*+9FRJ86*I'IZF8D M\//#*!K:5(SG]%CVI3ES[RDO+I/9.4MGR(IL.0Z@Y!A@&F1-QHT!-E44S%P*[.A>5%H!(8)MEK@YBAF,"QS)R[;D^!V"#%+`V]: M=AW5!N\ITA09!P-QQ,#W]@<;'DY5)I='[&$KX)F1AH$,7PGDN!BJ)V%H^J`B M@2T#V]9EQP.CIXN!%;826OLNLC$2ABN6S3&+%+&#!V-!1!LE15EM[VWBW/[5 M(\&N*4>.KE!R5E5Q;KLGBU/:(-AWP_WX4&XQ[`"YA;R3$/R0+/#I.L&,\%;8^:@_\4-_G-,BGF;I8EH.C+N-CLRVRW M4P#/[@M=Q0/7VS%ESU=<68R?""+7<;K9A\[4TP%,!Z"_+)Z?&3QT.J(008/. MU0S/=L#*V*H#0;5@4=V.5',04?4)$3U=_SY(%O[`J51Q/$]V/5O!(V`"UU:Q M,M0/;H\IY0@$AJ1,J$':[KHW;_`/3%\U)GNMY!ZCRE+PRTNK+ MMJ+I1N1YKN,9AAU%BI@,Y8,6[Y_=U^*I?7NK?Z:JB`Q3]RS?U'5%-\W(L()0 M+'\D&X$]>);%V60)V+1JA][Z>9JRHHI3N.77=9X%;!'7:36ZN];;%">KNN6I MH1WA>!9'U^6F:!.I=J0/G47+3=Q)H(^"Z,'LBFY;(43COA_:,C!NZ#4^6`!_ M67M)/>TK0>^>^/KP@:_@UI3)7/SGP;%WS_OL63`(P!(!Y9S=*+!,.8QPL!Z$ M8J8=[I\]:^NMZ_.UY/H:>O^H9N:'LF!ZH:!ZD2! M9AA`<,=19*R@A,,QT]D$[]/K,13_Q&8LN<..&/@K+^9'QL`^;^HKLJHXIH=U MM]"P'4.-#%VWY2@"ESZ2];&IOT^[QZU$RB`PXDOZ@95EP.;UC&BRR(OW$#VM MLF21S+C$I7&R&JR.?2-+9;B1IFJV':JA:9JRX[MRJ&D&K)^A6*9^H)+^B*4Z MF[BCK65Y'2?SFR70%\NAW_":X;`2/!7,5#0C<'19!Q=3TT&S.9JE.^9>;7O, M->L3<82U\>H2,`9&B#=EO*A8X0-!#U1.VM%Y3K4$3ZM:/K<5:U6@8EJNXEM. MJ+NAYWB^8\JP1J&CA+9A.IB[T8)'KL@ATG56!0\KIY:5?-'<#0_CM&4_+ZNC MN:IG0M5#1EZV?44+--6P%"W2(RL,/1VB"5^+/%4/]C*_3E<,CE#F81K^.R]^ MP];*>)V`G_MM4Q%X5.<'!)NR%SJ1HQ@V4%%39,MW/&O/6#OZ$3+VB;,E)(1M MV(Y:3JG]I#F!YR;^PL`(K`L`CD_$`HJL`(WD#_KOS3U+[]@O@/+R$_N]3@HB MX5EYQT"S_5!6+$T)?26"B`QD$&?`!&:DF9:_U[[T1NMDT,>$NB4%51QB?,;,;O9R,[:OAX9E^A"F8W.EYMI@ M0TW+5CPW\/;<':=C.D^CSYGDO&;%;)>AGRM5M]!\PJ9J>J"Y\DN2):MZ=20Q M!E;0.#Z@]>/2Z#HH!YU;_`X-NLQ2_!^M8Z3`@GV\+#]F#:$^+J+D2W/'"17]7E>:8;F^%YI>E>U&NA\%Z(70'=@ST3\=V-(LW[(C58DBPU(]B+M%Y=MQ7&_/9P)7@S8`FZ84YWQ8[;/-N=,D0CLR`8W)0+OV8W`,7&CL#FN M)@Q\<_`D;IMS[B.A[&&;G_:>?.`]GU@)XGR\"[3KNT2N9[J:X\I>9+NV%BJR M$N`)LJ$;^*[J[85Z=FNNQH'V\LCK'V=5#BI+KY8'R2#;JJ&[KAM:NFQ`L.M% MAH(,KT803;GJ?L1K7)`.X,_!JS8W@(:7[C9T']C];+B^JIN&98/=D[')H:D( M04CH*:_^[_NT>C=/[J2RVJ3L[Z\6\,8WBWB5I)NW6'\II7^Q>^E3OHJS=_1; MF?S!WBKRNGKWZOO;ZMW.XRE@]&9)K4EO%57^ZSL$[TT,N&5O_UN#'E]L#KX& MKP^!D61+5B35[G/TWWO^J2F$I_Q%6R))^,H?\:;F_3\"G*>`/!)\V^>FA32# MJ+GX^ZLLS]BK'[?P?`UP`_2D2TDV!XWZ5M777T9%(,H+J5JR?6J>^;)9GN;% MV[]PIY:#/,>4*?D?;Y$P_'L0\C!IA>&+M*;27_G8+]-K)3KRZ8`FBNRAR'M&! MNX>)K7SK\$GYXLF(\9U]I4KPHA0NCX?]DT%O7!FC0C^1P#_';>W@]Z2;*XEV M?=6SBG:#2;-E7-S"TL4%P^4$IQV6,\GPF3H%1VT!\LCBV1(7$)>^6D)D_:0$ M>9'0LR3TJOU`^]=-1VB7<2F!=8UO<:%AA=.M!8.US>O;I11+X`@DC(1VEI<5 M,(,H7=!7XMF,\N-PN>/>IBGCMT!\7&&JZ(Z5$VFZD?)IQ;=GPWLSL.TS\D^D MA7!0D-DB-BWJN-@0.>@;R&K@BS,$H0T2)7C]EI!20[^K2QDWW1[9N`TMS:/^ M^E:LNEO]:02M;P&7\1-:!O/*&M>N@>C-XG))$D=_8`;W#L0.I1LOWO,$-_S( MT_\C6'&.BG.ECXK*,:WWMQ)T3\61K$MNXH1W@HH)C2-H+<;MW8O_^=R$;FO= MI'NP7D\F<-:5_4T[DLH%';W4@)"-ZM070PX"Y/VXCK> MB"OD+LOU-&%J?SE,&1W%@?"_XC MO@00*%9QVDM>B4L/H*I=:1<-0;\^5W:Y]-Z?(WWV%`A\:_!>E.`?AR+2?HR` MIZ"EC`Q9QR!AZ'W0HN62NX)/SN),NHZ+6+HN\@4K2ZJZ2I\W)7P/@NOW&1BS MUZ_@;QW,D$<"U M%ML^I37-BGU-MI&4O*VJ\KMF5ZA$HU:W/RCO?B!W+%ZOB_P+54S3@33X5\4' M]MC*5H0ZDQ9I2E:.!>VXT8P$#DV<9>`CS7@3T+PFIH!5R#!9!\CL1&839*G[ M93);CH22>B6/B](N4S4=?A+OMMSCJB5+YQ+=,-U(@K7AEXQ)65XQR00I>=&:%]*: MJ'T6N-5H)&Y5QN;6JHBSV9(U6>\=9I62DIS1F8A.IDR$-SRQP'#;%AH"?2+= M)^#TD]ZG/60[RA)63MK`[1(&.@57RP4&4B#\%;Z6V+,L:P1'1#I#\-P#[GB[ M2,,"&-/-3J5&6M0IJ(EE?L_NP%3Q###O,,0:3E8!.!PG]*T!'V"'/QB]).;] MT,U+2%XPBUPT^S?:V(YNRG$+=O-:!)^)=!+_05P@!QY5V/-46*-FE5^$O_/< M>ZY]N?S_7L<%QNH@:/N>$Z,F5)0IX,CXR4(]JG&-HT=(N+$'@_C_!0?4[GEEQA<+4FUN1_92#'MRI2VVS*EUTVYA2=B=BPK/?G`-[NF5BBH M?[*T`B.]FUL&)W2=8]J'9Z/W0W[AM1Y##[]^EV!.*@;%=)>G=_25G:J3 MR"EU]".^L!F3@HXPX+8&"+CRXQX95]@5A.)2WIE\Q5&M(LS9Q;,B!ZEDM@CM`(Q5PKM$L@""\L\-Y*ICE.(.DN@U@B6IXG7H/O ME)&-CS2\%/.<.$QD7:6?\05@QJ4/\;3L6>$9;DL&^OZ<8Y4#_05,'XDFV]ZM M$ZG.I@`Z4*L3CJ)H_0PN`.@&$F_\)_V;I2EN>^A]J;7KW:MSE$54W*Q!8X!/ M7DSLQ>JMI'H?2-BB3(%*IJSY6/Z7.7K$/LV+(K_'32D]0:]QK@]<*8[;@J:7 MH$TFQWR0#G)D\W:T-F`7X,$QJDN<'/*5/').@.:Y]SH@!I9U4&M0"#P:7B.7 MQ!JKGH#V@)=E)_`*>.F#`P1-<$M=C_9?63+H2T@ MN-``1#JK4SX-8L6J93[G=X)Q0^TR>9B/P4#@W%D>G5XB/V>.'7##BHON:$F? M]/N`3F00$MX6<0J/`?NQ$@SC-N7Q[&,L@2"OP9TH-IT>*P"Z06-PE44.@*'A M[2AYW@LU;FWELK6*/UN7TTTGO?]`P7K2Q$2\"B["H9Z4CN2W+A;DMW*.&X=O M3?G-*"^R+AVUK'%T$\K24'F&\F6\Q944O+2H,<3$31E<[KK.QU:M@M(%AYA: M)#M+VS5"Y$^A%2IQ[D(B[$`!D4K<]D_2QYM-<2(JWK;>@@X;1`<8)4G;_-YD MR"Y5)T3'5U*W%Y2)G6YE'R'>=M%%C$-Y"4OBC%PYZ7N^;9.H!.&+M(I1T?Y> M`]X\!-V/7'ZO06,LP+#7V%2R=2M(!U->-$W@[Y9T/)?%V6>?95Y"G$LJVZ/N M/TH9A,&E=!>#.JAQWR%X9WBHY$2('"[68NM";'\6*KK@6]I[J2+TJ&;+A(%' M$@/OTFY@*?3>WP1ND[-XS<1>>HEOIL<$)NVF;WJ;P`O%??434#CMSGKNIW?V MUO\`C]\F&?5.;P6\H@WWW/\LT0G`7_]19ZQA=1UEH$VPKNC\`5%&!'X56;0. MX,&-VR`ZWY;53OA,@CV5M]3I/9(NT$;>N`&XO@>RB@W+NYV[V/J^2JIF@PI7 MUBN^5ZZ3?:JS14T9VL$VI.W^B$52@L]."=_)T+I1)EC0,0!]P[63TFBG%SUQ M(3WABTS8C*;`K#&8()\K::H0C>R7S7YW$$O0^*3D2T:AVD2ZI5W?O/05SU%X MRJK@K$\OGI!I$44[0(7F.MVQ9@=%*=WFI&GR`B<3PTT\D@5OHA1O`(:$^Y=8 MAL;&CQ1C2RQ4TTQPT@OH^H/GT'4ERTXS8]MD6(K&P"'/9QQ!M<9N>``ZE35( MT2$` MG?-B+'D=HJ7TQ=6XE`KYG/#B>\=X=,44+0E*/LZ9^8T-[H_:;WGNUL.;GZ:; MG3B1:BA=<:?])C/`.5]A<0[?4=;K=9K@_TC)K59HZ(C%^JR+EPYQFM`Q3='@ M%"$48/7S:6T-C)29\)51(2ZPYY2JGS=8``=JV=TKJ[$HP8%>`6_DBGI?N)\CK M`I;PP88"\,MBW-M*BAFE`H5DR>*Y>(H"W7]BN,Z%:UWS0J87EU2K_I3,;QGU MQE`V$J*_>DTY+P3:6]?2_<"LU+P*R&(2,6@A\$82=D+@M,_2+PSU])_1]"5:D M8TVVHSK[$JW*? M2P]I:>11LBO`\8W)R'8_VR2OTG@JW>5IO4(?^47U/A''4<,`:JUMJ\!4C$HD MTUINMYC?B]\GZ)-0QK73D,@=Y&9%9_1^W)MYO\RE.JV:_"/Q`MB+7AR) M2SG3X8*T!<)%#MS1N)E#K%N"XPT`/&/0+2BTC=93B#H6J`#(4M*66M!J>9K,8S%:H^N<8BA7 MY*FX#QD`#>C679Q(35*#AY&G)E9B8NZ2L=^(#^!7\&#)`'VT\E&;$>P-+[FI.U_V&R)5M;BVU7;<[JEW6Z3_.Y.X2W+T*#JE`9!."MSOP7(U*;]F-7D%2'0HG5R/*[OI@$6,"@!C]SK% M)<(C9Q#G&.S/K-JQ*NWPEB;D;\XK0Q$6HRJ[&[.S3KWJ)22]E,A[3:_63N]9 M!F%/LN8.*O`X#=006;R&YR>G\F=GY,[N+I6X9?BB-^VI-YMGOS>.C!,O7^)6 MN=V1().]GFU20_W.ZL/V$O-D'8'%J@IIF!5C/,JF[V4DQ-M11)6$`^"K_5RV M_C#W-G^+P8B[DPRW0P[_E6?XV;S`CG?QG\ZL;YJ0_EZ,.9O6<$>%QP*<.ZY5 MQ[/Q=,,(/-4WE/I)I(6& M9RF*8?NZQ5&+3-\V]E`S-+V95_E(_*YCFO6-QVD,3F=G9T_5C?S(T"S;"31+ MUA75L1TE!%P<7<.C=7Q[>)F.P_$8D(^07W,4694].9(5TW&"*#!-78"L&ZZN M[H*L*TI#_G/@SLL26U)P4JY/&>1;M/>G37!7W<#S-,M5+-/7(U5U0DW6?8!4 M-BU/X/?&<+RR=&A["E^>(:="96]?]7WM4VM9$CX;]"\3V+WEM* M[:5*4G??YFYOR5O=UGYD-PZACL-;#CG"O[_6S!AC&#"8EWB!*BACCT?=C[I; MW1I)S^'IG`UGG.QS%0_T\CFTH"D%3#%X\57ET>3L*GE27FN.EZ@6].+\U=M+ M=I]*F>N(`4I@:KSD;#&ABY6-%J6"]N",\9=8N39!GQ'#7R(:(TJB1756V0Q> MQP!SE7*-^A+7@=F@?KI.+U]2MI!$L0"H/5:N5O0"#U$<"?C>NVK\XSR;M;WF MW?GOIXM+AIC1\>LN4X!W;TT:2>+7]E3LPU0"^IQ;NDSEL]U/>##KBMLO'4?O MA\][1^V:;Y(3MXRD?MX[F%W+57213WA^OYZZ^ARO\`+:U[_P$@&(+@@R0)4: M6>>(J@YLI15P^1CQ.1'Z&6GA1L'T*)VWU.+NIXO2/6Q7.:.3B?)+)CH)68C% M#72[)A72(UVEU6/TU0I4[MXS`Y7UOR?ME(K71STAZ0VBXS)^QA0`DRPJ'7-% MFQ0,!`$*LM)U##^78O1W1'!4^KN#TNXGR<#`N;"W/_E-2D,^&#]C_LP*NZ]^ M./WSS`S_\?7P5`:")!W92]C98W?9"O9G9ZAE`>P!L#"SB0/-=<00:93]V?B[ M07FESAL#9SX\[&+4.0KVGGE]E7>G'))2!:(,W,H5)XG)P.>04>NDGP2<;8/: M;6)DEL_U36*CQ>IR8P:@#"K&6`.P&*=I'/.N,:X]&GJBXO="[_Y\&VV4Z)@@ M6`J4:V"E\L"E8HGU*-_&TX=S;=^6DADX:+%E]-YP$6!Q&'F\`?,DX-P]NF6D M7/`YRH47(5V%:%3H-!-R+4$259-+:"6!"M$UEJ]11*U]`$1%[4T!=&UO]ZXB MH'76D.)2,;8*O_?V9*1V'"5GOV-2M.E@KNWK5)!(TA],&).SDEB:.9A*QB(> M`?-)(;GV$$ZL;-68?0!RAH-8GFI#>&5L0\[CY9,;9(6]2VM]Z_#H76$*-MB* MWL44I>H9(Y8SK<^R77JMG@:04_0E"J=ZI\/$F67 MSP+4M8=W,LF+FU>TOFJ5&!O!9N_UVOLR/KP_`T#7KH"\58J21DF:"LF+#/[L M.84-#A\MD?^^@*Y=""6?JU?6.ZRQ2*YDC8%N+M.PRQD?;RYSPPQR[?D-ZY2- MH;#DG*EZ9P']G!D:*J91#__K`7HR?20X30156ATD/FZC9X_9#D\J"F48'8$> M!LZ3Z::`N7:P%!"]0G3%%>28*;?ZO`?38DK^.8*Y;KY9EV!9=(NOA MB23GK&F4W_Y!BLOOA^7:@T[)OE1-E2)I9=IKTS]`T[Z`./ESM,,[Y>E&T$RQ M9@**,;.AZ%R7IZ>(FO7H\]PG9HSW.M,14\F*V6+UV445V:?A^3AQ*7G4N9^X M?:X[SV&U=I`#@7%@N4:+N?108O801A/,IVZ::Y>/T9408T6C``%DVN(^OIKK]ZK7%M'GQ21*;B#7Y MFCB0]F1MK8ZJQL"^K7%6OUT#Q'7B+C3MNFE^K`QV>SKZ%5;]@K7Y0L)>SH&U MJ[8,;UUQ M'T!A>U.%0047P$A%ZEQ.29GI$\\.'>_NJU]:IX MT#8`5]:%)1D$FC^`Y2;_]JM/HN7DQYU+]UXT6?N]T-P=8-:*%-A*"^_:O:F@A"D[_^/K?LTMZZ+C;\+I2 M%LK%Y=">`Q@45\PUYCJ7I6:PVZ_>VEZ,*QNY2HY^,M1.R6:4*U*AG16M>VP\"K.D;"4N)?AA4HO MK%J69*FARW*T(61U\YFUBH4=5&N\8FD2!J-0Q5!(;:'NB[?+#;<[+]JCH^.# MX],J[\_V#E\??9Q\^^?D='7#2-F'`LYH1L7)U:CMH#>A>(<,1O(#3D?M^^9' M&[HD1W>F4N>RO1?OGCN*_G*8<<,QUE9_.;ZF>O-5I^2466+T M,J*]%\7DEEOO)FV7>T-CV/5W7L*E5B^*]&ZRW^T^/CINH^T-9%+)0]WWK]2STORW)SO3"'!T?_>?EI.CUN MI&\_RS];W[JW9M.VW_/S\?&?+W=V3DY.?OCV^^SPA^EL?\ MG3>!HDJV,++DI:0<^^N7E.V.#UF2+9**,R\Y;!99_/B)+%:1I2^_OLRBWA.0 M-$SBKV?J)^6L!S%._#">?#W[\=`?/5S]"P(H`[_W'&;3WG_`NPXC*I;V^\O2O<5?],._/)1"[R4-/Z=X"C-TFV"4 M%2U.LVS^>3!X?G[^].*1Z%-")@--4?3!3ZF])=A__56Q/ONHKVI]7?WTDOIG M/=JO.&U0_[+DYQ?VP4;Y9[THK3J.,RB^_5DT#R'<9JA M&,,9Q:#7^T*2".XAZ+'?/^YO-BJ8)LD-G.HK]BR3.*".4 MCI;/GO9S%#%6/TP!LA\QROV0?GB'"-5F"EF(4;WV1U4FN"OIS^:/TWY77H#" M#_3)@6+@__6X1IM*F6$*M9H'FLD*E3-[XBPOYZ@A;[[ZA"J^"/RHKH%K8DD M)R5O9G,4$D;[<7";Q)-;"H<_2E,Z+U;KV$!0O(J-!K^Y/"^%J1D^@T?T4C?. M)07YJ]`,H[WEN2GT1`<@(;7&7$E!_BHTQ&1?>4X*W8;_S4.ZZKU6Z[%3C'?S MC=#85YJ;,EDX:;!3VBW'2X$$Q=0F?P"<$]K+T83`PDRIT:=.3+1ZS0:OH30W M9=/T#LC#E.X'ZA3;+2E`B88@[17@I-(]I!G)<48'(9Y3:'.&TP453+"%5L](R(/\+4LFPZN1Y>C]`.7-%:DU>` M\F_OZ-ZY&4-XU2ZTL^,Y^WF?1-%U0ACB+;I65Y?0CCQD"?YKH<$?*,H7%$K3 M?#9OL.-L5:70;C79,#61+%42HPCG45'ZEA9:%F7:M'/S+AJ#EPQBGSDU!#57 M[HGEVVQC[ZJT9DL?*MZMMW!URE%EG\_L9^M%V[3U*,&;#\^BQ2*H$J#4*T(@ M>=J?(#0?L,=J`%&6KCXI'K2^HB[#,[\L/W9O0^2%$;7&@8U/,5%0S7T@Z17= M*+QM5B+D0?3UC"KA-A5U35#!5WVE[YB&V5=5T/JV#59?U715]U6D:-9PL],1 M"TLE9(6XC%Y?Y(2L>0NK^[DLS'IF!9ZIM>G9&IM&!/<20I'[>J:>]9XAG$RS MXL]%#8C@'9)MQM*6)09T2I\5-?8IH68K^8`D,Y%#EPC`B_9(.`M&&"#`F$[^A&I,T4.<$=+1G<6%-T'"P\S;]!Y-,]P0.*H-F*42)(@=0\Q=01?V[HI\@- M[FC)X48,X^""`#7=KA%F^K^.9FS>&^<9.W?"#O!44J2!O&NI0\_T`P%,&9XF M4\2`)FVA6Q+C9HM,J9!K&[JCZ*;]`188_B8H5]QDL..@C5<)6,C'NN8' M`DQ0Z4L*?S9PP:L;%IQ#D!!X)(#2G+P6WQ]$C!)YUG=MJ%GX5+SEAU\ M0)-!&.9=6[IWF6.WRB;=+NK2+B!#503L4+JB0>MQ2[A#)L6-X5-SB.*%HCL4 M^C?Q!9J'&8K6M*]R:=0*NXIIFHJ#!!BAF*IXX0$&509P."NL5GM[#K:9IC M!4,!+O2U6:5_.F8(%XBD+#<;AT/+EI2B@*M@4'70WV'T9Z%@`W?_>CE7\375 M1(YYJO;2,<.RO/'IS`C@L,*1_1U`,3^R/9@G)PO\MSH+O MZV/UAH1+$ZYBJGAH@P#+5))33ACU.H18LC';_&#*=GEJM5F^J3JM7'[=;VQ: M+6.\@%D;]"^#K8L'G&\C')*,1-*MA'*GTAV0,/%O8LQA'41PPK!>EZK)JFZ@DP*^3LCCMD#7=D)>VKGT*6 M#_,Z(9=)[F5!'JV""=6[ZKUBU/;WC,`$`<>EY9BF'7*(,ZY2#M)69HTH.SE; M*N`BS[(#4SU9'WV'K.&&:`U?ME((3*=N1:(P:NU]0V',4L2,X\LPG2_2*]*!S3J M`'0Y`>;-;<5-O!LEKXPOUXN[IH;5H88$F$OFAZ6;8("[H59)#KY&G%J37/*_MOR"M.$'>[`B[S M1="U?;,[:W<#CUH:&]1+L5(<30D$.*:OB?K.HQ1C%EVQ"0]P(^U M*<9\+:IF(1'W[92/SC'.P,J@T-O^A!UI&@=K@<$*!E5(N8838,5R1(1;U`^_ M9O(%5@:!*%B+=-ZWU8>)-LJY%L8:U@T19X<^O+.\+9*26%$&#]M8I")BP0TK MIF@YMN^#@-M1IGI#4^P) MR0Y60B$LV`[GB(194G@0`_CI-45UL9@?Q;;FM;B.K@>^;WZT`+04M@F%63;= M+L,"L2PGM"/G>1K&0$W(FJ!TG;3K:(:B8>MDLR2\$WKQ@_?@D.-J3@T2LJ9% M4DV11G*N[VF!J>BH/P3%8=KK?4_1C;Y&ATI!*MBJHK4.07^PI4X4LAT:^#]] M'KP-_(85TW&PD8]%1!7E3%)=&_CB<):3*&B^?*`6L?A'(+-EEJ-;AMC8BY;O MH=JGFVFH M0R9Q!%6VK7[+UOE5MN"&%OJ&##4&_V@,PY/5*5[H][>LY5>O0#!8?IV@:[.!U4FZ](]I@V&+<`U("=+Q#N9 M@GB!V]&MS-H7K$NZEME=2%+86:2EDHPD!^ZGZX5=4]$41\4GFR6NQ3CN'A+B M#Y:DXVHUBB\RPJZ]>?OW,$[8ZWEOX@P(I,S'O5G+(EOH[Y!-F>N!.:X:4''P;!]182C1PYI>5/M8"9W.1128T[5XRDW+B&B-8Y^08QG=8BE@W+GX5QF&9LDGN" MJQ=V!;CJ:F.S"ER$,"B^+?8HCDB&\)[WA>$F9TF@>N8XRPD++$P1F=0L#[O% M7:0&`7A8P%*AGR8C.*$DY9X-.X#_=L^[G@'E`JZ";<\Q17!`DL.=-P>XX23E MR$L2)YO]KU\N]LJXEF]KMB7B-)VOBMR=C88 M@H_/74)XF>!\_>+OUO&X5>/MFBD=-ODM7K)71T?[&I;Q)K2"(057OI$DGU-V M1[E/.5JJ;YU7][#:7,57G4!#K4*%PB;3IKU8Y0.L,@B/J8X^F[9G:^;)KN+" M&;$[)9\^;:]VM14K>IU=:P[IC840$B9;[A[EX3D@O8[8^:1 M+UGDU`)[LDW0;0%VILP76;U+MG+&_9WQ=N7NQ((FU>VJZ9.NF;IJ"S@Q-?R[ M,Y47X#(HNI92E9=1?FR5K@D&.(K2RN_X/A[D9IF'6]3*)CP_L'6QH66!CZ\< MDK1\AML!_LY6F!'&A/[/G9J[]3*L-,\6D7!6CLW^WLG)!7+1/K5R'R4BB^.E MU3XH@MG.FI6`MAKA\HD-2.E4SOO01'IN3!;91>Z3*+I. M"$.K,TW6DIW\@:)\,7XI-9KGP@.5Y0K5VVI?!NPKCPK2?_X/4$L#!!0````( M``DP`L``00E#@``!#D!``#L75ESV\AZ?4]5_H/B^RRK]V5JG%N] MSG6B&;NLF=R;)Q1$0A(R)*$!2-OZ]VE0!"W)7$`0@$C)52Z9HGKY^IS3R]?K MSW__.AZ=?$[R(LTF[][`M^#-23(99,-T__]O-_ MG)[^2W\Z/['98#9.)M,3DR?Q-!F>?$FG-R?_3"Y].@K1BM/31>B3^T_ARS\O MXR(Y^5JD/Q6#FV0#>#K/\68ZO?WI[.S+ER]OOU[FH[=9?GV&`,!GRUAK M0Y2_G5;!3LNO3B$ZQ?#MUV+XYB24:U+42'\1\J?RK\/I,L+#P/3L_H_+H&7< M1TE_P?.P4$IY-O_K,FB1K@H8$H5G__KU_&*.QFDZ*:;Q9)"\"7"=G/R<9Z/D M4W)U4O[_QZ?WCQ*XR;+;)+_)1N.D>#O(QF=EH#,=%VGQX>ICGA2!F#FTP8+2 MD)]N\N0JI'`3`((82`Q*>/ZV(<+T[C9Y]Z9(Q[>C`,Y9BR9]S$;I($V*G4U[ M&K$E$TTV'J?34LJ%F@Q--ID&^0;U;S6Q1L3N3;3)-$Y'S2U]$K\U@R=%8&M8 M-@PZ'I6JOKA)DND?DW@V3,.7'^,\6'.33--!O-WZ1HEU7)1BF7TSZ[^/WX'! M%Z'F)'/>/UR9N+CQH^Q+$\/KI=-Q`3Z$L/.&8-\2;$BHI2+8)*WZQ\TFK@C8 ME@EI,9A7]%DR_%;@+=9LC-.I8;7:L5I1.S7SMS@O/WU.]K!W71J=&OY[?#G: MUJ'5B=F2D>_'MW&:E[+_<'6>3:[/`QQ#512A7=QL8XV(W9M8B_SZ\=LR.(S8 MQ\GO\==M/*\(V+X)]3!:&[XU@SX'`K)\ZV!N1<#V3:B)R;KP+1ETGOXU2T.O M=[?9CN^"M9U]+336A6[-F&EZ7<-3^CY<6P9D\22,R2^2P2P/I537>7(_3-EB MS[9H79M7C[R:L5LSMB@^)OG%3?`'MAGV?<@.C*@)TMH(+9GT*2FF^6PP#21, MKDW(YWI;:[@I1H=&U<*K1L263)Q3HN,B"2[S^#:9%#4:BLUQ.C5,?8GSH1J$ MD67=QG7W=#HM@`NI9G=)LOJO'X/O7$\A;:7>:6$_W)8_/V6CD<_R$O$]BK8M MK4X+6_`_\6AV+Z&BF(UO:WB<>R79:;'J.$QU8JXT,LX'E9V+CP]- M7 MC9[.=M0U;VTZ'1F;C>/T:4/>P-9'R;1JZCSETW$RODSRIG:N2J--(V]"6OE@ M=IF<+B%I:.J&E%8:'$223M*RKIV',(N0I4W[+9++%DWV=Q9YKM,VO=BQ-9Y]U:M6#NUOLQEGD?( M990-5K5;\S:K2`9OK[//9\,D/2O[_O+#?!!P"N!BE?EOX:O(!;5/[]Y/KK)\ M'"\,3MZ'HB^E-HHOD]&[-R&S:'.$R#N!,57880\E%X`X[A02#%EKK*?@<7%& MY2IZEE>8M5F>4'/G@YE-1:C"1)1;IC07VGKOH.;<$;&P6CL"Y3:KOW&M\L%) ME@^3_-T;6,5:=#H[C9&N\FS<+N!9.X4/MH8OYIW@3X-1%L:/[]X$GS;Y]F5H M/(-,W6A>=4+_EUS?Z[A5CL^3ZWAT#XOZFJX3ZI-0$0`JX"4%L=H0HSR0EE=@ M24YY3SQO&#.LX'UWHK*V$)B3W7[=O+./1I\K6Y?[()'FR`8KD1+&$:(4!LQ7 M]AK%>+1RT-T9M3\EU6DSS>#+] M+1YO[`^?!(VDU4(`#3WQ'AFBC5"XLM]Q1?MB;Y4WV'T'N1\:7;%I0E^:QZ/W M813X];^3NXUT/@D;(>^Y\8QZZRR02FFF:54"!!ANQ"TE_#X<,@$1)2,PLHUD1`!B@"7E?VA^^6>?WKPD=`>&0 M!,AH*RWQH<,7H=^O&A-CF@UH^1&1NA\@7=-Z+[GZQ#X('W&C!`*:&0T!I`@Z MS$A5$J6`;T2M.#IJFT/2/KDJF#6:2$"FP7'8; M2#<<^<@C('$?&#KS-+/Q>+&?8;Y9H/@PFY:GO,J3=9O=S@T1(P:=(M`']XHC M"JQV&"S1,8@UJZ<0'`''K8/S@/B?SQXO-[6P!%7C/$6[:U[U#TCLM`IV%1>7 M8)2HK%&D@<94HV@I59@ M[0`@B(AME?-8>5BW4MBS!<%M\EQABHUCX2>CP#E0X1_^->O_6EJ'/&@]9L?` M5\=+IX=:G+.^5V-SHM9%#Y#535F,&((<4<>T\915V5IIFB]RM M[QPZ)ID^#S//INI@JKNZ2@;3#UE%RFC"4"2>HJP"?V$-Z@<'#EG MN)3&D4:*;7UOU-$KMF4>^M#G_?5$Z37`0(A5XZ)Z4WSF,$ MF5JB0BWJZ^1;38WVPG]SWZ8IK`D#4^F\UOV6308=-9A/ MDXX\=THXP*WD+(RZK0\.8866P\X=E@MTX+IL`^(#]6[:]6HBYQQ0`@0W#UBL MM!"8ZR4FR#8[/-B9-_,U3Z4=I[&E^EH?NU`V\[TODE'!!,KC-1&VD"0 M0LK29;T4EC1;-&[]4,XQ>=0]4W*(??<#"%KLMA^D&CF.E'10,`P,$%PIPL5R M?`-=7_O.:LJV/TGLV6TWA_C`9*@&@SS\WKH0OT\WPH1Y"ZUBN#R&B0&1@9![ MG+B`NED+VIG#?0Q2W!OD0^[4.^C,RQU.%'-B0R4U%$D7?E;#*\X@;;:$TYE? M_6P2[`G?9SA$M/D1D1^'>SH:(@I.G7#>4TLX-D@)"Q<[;B`'DML?AWNZW6&O M")!A:(Z#7P<8D1(89"O\)6\X;W/$AWMJZ_&9#O?LQM>/PSW/5[_F&Z<1Q"8T=)3[W1EJY94 M']8D:>>,U#O7%^.EP_;;1':A$@5D/%$(0<,RFEUY96I10* MO^(#.[OZ4/VQT$>']S'/!DDR7.RJ_YP4TW0:X/QV.&3C1'J-V)&%4GD-,+,0 M`4^%X,!5989@^X4H+_<<3U/OO7W4NVS5_I&-AI?QX$\USF:354O;^R07$6`- M1$1SRJ%A`BIAEIV!E.1`+NX]!G7U2$,?.[(KZ:)KD)N*Z^ M?:V3?"*D@*&$?'I5[7[.*CW$Z_#TD M7]R$/[>MVE5Y1%0+1"'$\_57)X"@U?4)8<@=_AW6+K47J]@6N.E=K>=E#4N& ML\$Q>G*Q;S>\HX\\T00Y2`P%E#N@96@0A"1ANWQ MB]C_]@SJ[H2S?E0_2-+/Y<)`^%2*H,VF^6G2$8;2.8ZM5%1C**SE?%GK-?+- MUF5:OW/[)6MV3TH:2'+IUF5+MRY4G?)-19,5*T]'U(D6`8$PU(1I#92D@(4Q MS[(J`:2;W:K1^AW?1R.E=N%N1R;_S/(_0WE-?)M.X]$.0GD<,1),&\F(]Z3< M;N44ID14MCL`FST\UOI-XL:GI0];!MKP$O"-$--ZV]RK67KL'O0WR+UOZ\M/O#Y2B]O@=E@]36Q(@PH<9`R!SP!%$M MC*QN2(!">]-06*]Z::4=J/N64>%GY<#BU\#F>#;^&-_-7URW&R]]K!4_X@82 M9!`B3C+M58"@.A,'1:A(#7<$OLKUE2Z!/[:['37BTEI&`&/`2"&8D-5(5U@. MFTW"P5>Y*M(RUL]PEF6^O[;+9W'>CV_C-"^9^W!UGDVNSX,O-GQ\R42_N38\ MM/.]__\MC^QI'DM%K9X`J!,S,IY0(12`Q&.L2>CRI"+&8@V88-!NO;YEOQ*L M.W12(U;$B&-80VT1]EQ"+ZQ""\NYA[S930LM'11I'?VL*UP.]D#&D[+](QD- M?9:7#9^^FW]5OJ"ZY4Q%[32BT`%K8A'AD`=7UE@%N*]`X_V=.JIU+*)5$3P] M3MD18KVZU=W'6B1T:6Y^81\@`BB@P)0S9;E5I8#`_WG$$'S-;6SMX` MOA;Y'-R._R-1S9YK+#Z=A-%^&H\N[HK0+U]D5],O<;YQC_[&*!&VH95UP6CO MB!9($<),9:\18.LAXIZO,FF5@JP3C'J:,WX59T`UP((QIYC`/M2"0)]:(B]= MP_OL=Y]3?/;!SD'"_;J.P!ECRDLLH>"8"$N$`90L>PVG#W@\=6CB:>DL7#-" M?HCV(48'-XI[I5K=N MIC%;!:?3Y8SE%I=N5R^^Y?*28<`HCK4:.J5=IP3N77.ON]R;[L4:TO,"$-*F"]7U'/VG$2*BH*?(,$F0PYYX M9K2OX%`<-'L*J>/+F5JC>*5SOB=$_-]WOWNT&JGTH^TX#;<+3AQ3F$RQJ,CP/5(S^ M:Y:G1?!J2_RW2F%+S,A0:EWYTCDAW(1:A(SGU?A+*G60%ZRT*(5VX>FU,W!? M;T,3FNAD$BC8].K'FA@1!]0![8+:O8&<0X$)J,H&N6]V#WAGK4"7SD0["/4R M59U<)7F>#,LJHEKELGJ%J([/S]*]9.@S=1A]Y_+A= MO\^M[RST^4H+)RW05BK#I2B?>4`LM-24\MVW&Q\)#X=RNSY0SE%@=!B)(:E0 MN5%++_`GP)-F![Z/^';]VGI\IMOU=^/K8"=(/\63ZVV;M9=A(H0<1!X)RHB# ML#PIK_"BT-2'[O40IT$/3A!9.^CV,5R>V[;51WX0*N)86FL!4IPRKK@&='Z" M:EX&;;T]W'G2!CRL8G(O'(Z3TX.;\^R7ROXI7!Q9W4KBHW"1Y$X:2*%"!CM" M6'#'5%4.IB(&LO?+WPF/\M1Z/#\-%7@6+$31*,*P5WC9"B;@US!%FB2$:(BL]6"#/K-'-UCTZVIY^+,._@Z3N M=>T:IM@&@HA!0'GHN0)Z?DA_CHT15![NF/70Q-/2]N%FA/P0[4.,#FY0_DJU MNI-&.][JK@G@EI8>$'9&`V2466+C$3JP=]P[9Z3>5O?=0.NC$>K^V1@,@(4& M6,J=]V!^]PVI)E^M M(.NH=\M2@NT+32_W2:)=M=4?"UUJK=LGBK@BW#B'F;2&`X6-H=5D`7>N84OV M(J[0ZU9M>]'0A]P.Y8DB+)RSA"@KH;.6,<+4LM''"C6[W^A%7,;7CT#;Y:=' MY3[;$T42`,^X`9!HH\JK#26G2T2\:+8%_D4\4=2K8EO@IG>U'L$310$O+%'Y M+)EUH8)3@VDU,!)&DF;S*B_BB:)G4':`.XMDIQ'<93%HIJ MQD,H[9L]&O>7L3310TDUB7T'4EI'PU%PD-% ML$>(2RRLI]:6YX(D(T:6[R,WVT#T(AXSZDP\.V+>RR&\9!32O+XW<32'*V[/_S].&"!)>S[P7'O69(4Z8]+K-3J82`ZDCV;]M$3E]Z7 M%^X)D]FF5MCLV^Z?F[A'/I3#-43P_?IPD)J+B*&$E/&X71N*M:I@X!0EGF/# M1MOUP-1?\D$[`C-.6O'K25X6]W/BE<`DU`)Z1*4'!CB"5'DC_$P=8MC/-QJM M"ZO.,R-:[,Y\*9E5J],.M]$Y="2O6A:"*0E!+:/<9ON MD.J$1P<.G=OFWC\5+(]29ERD"EI`B21.BEIW@@;,\F!*1?88;SKA,!D@ MFH`Y'9GR*0Y5?,V?]]7-9O68%=M%\70VG^7<*T%;AA!SN`Q[`G'/B.8"JN8+ M]6BM1IN/I'2D\T&@2&5=-.'RS;(=[TZ\$X#3@&@N`87`ZFA00EY9D\X!FQ9J MU7LF0+_,ZP>+5.Y]O5\5+9EW_)5@(_U"4\\IDEAR#!4TU7P!1VD>JM[CZOOE M72]0M&:=7FRS?<7=;+O[7%9;/:D6'GLR0!#I\X"[4MLE1$/O83T[K-(\&.WC MRZ=3#GM`I3//SJD@QY\-7A$+XSENJ!:<6TZIK\34*8]F>`W0&>O3/.N$R1RY M-R#)0)QU09VJFMD=XB!GQ%BQ9@)H7?>^#% M+]FK77!HO0`_K+[EA01V\7262R>>#`+'21#G(/0.&8AM-(FJV3&;6*5P"+VR M)R[U@\,8*^_8P6[R'S]6N]+!YK/L9!)HRR\$:FV40^F=J7K9$.EN6:V%YL_DUIO74PN_TT4`059!J M0T39PXX:!U_6AE5D)GO$,/(Q.GQ3;2T':G1>%/E?J\V=6?R,_WFI7G[A_G+J M,R%NJ(Q:IJ`KFUL`QH&H%XY4(JUJ_V#)Y>-M,CT!UGJG>3N+?>AT&3FM'A>K MR.K]C\=WDPM>#!$>##"(TEWV36.$1)N_FKOP..V*#[U M;AYVV]UBLSR>Z]_J_1"5-6L,ATQ*I!7#D)O:6++8I47W#)81/=X^T!6IJ23D M?;]>0X_:&X%<;UP0B`SF$-HL9/(:Z0,!:E7=H.EF<\GLST!EF2GII? MIA/E1W2BS]DV*Q[/J*O=OQV,)((AB@W""&B+B)`OMP3"I2D<@R7Z#J*UCH[B M+.SB0R[HXJYMELF)KP1L`2%42(<-%D*6-?)J]+%.;#[,KLO#CO,S)RYJW@+'5"(6LA\U9!;(UTM<_7),K$8&FZP\A$?_BT/G]^ M'3HK=ON1__TSW]BW5QOORDA<\FI@!`EI4%3/E?-4$@ZYJF48R\060X,EQO9^ M?`R!4D<;U2V*]=/7K/BQVNR358\OWDM>"XP2*Q2@5G.!-93*DDJU]HC0Q':4 M5^+R'`"A]@DD5:#H22:^?B(@B93QS#/@J,)*0^4K7X@'DB1VDKX>%V0',,8_ M7J-.N=I^^5EDB^7-YH]%L=KKD_%H@!>?M:<_$>(.XR"BAD"/RF*`YE6:Q1>F:-R2,A&VVQ:B,=;>J@QQEE,-(8D[I;``*HK>B*E MB;WH')-OMW&O>O+_:+(W@[;NJU,)Q9!7T-$4"D@3+C MJ&3QU.!8$"T1)9AP)YAL#E@?!L$OM_?9\F$=UTE'0INJV/0[4,!0,0P((8!A MS80'UK(#F@AX.5;NQMG2-^.+SOO*6U-BOIAK:9V.6.BGXQ]HJ-$SX*B!$JB5 M0TA:!@`3#FE?,T8(D.B]:;T86H7I3R6;^5S9,H;Z=WRR%Y6;:7HUQ`TJ6DG, M$*L!`]+PJ`4=J.64"#:_G(-9RW_ MW/PL06K,N_CEV>`Q92`J3Y26#AO)!%>DHL

2$"H"%YI)+Z)6M%7)`H+@&@1K1#ID"]$'=+)^STG5\NXN4;.Y, MG.-=-F39WF/#3>EV>3N?O"PHL#S$1UWB4KGD]>"$H]0Y2Y$SP&(/A)+$N,A] M`!UH+LXPM+OD#1%[`@Y>X>UN>[DOI/$K@4.&&110*1`QD,I1X2L<*-.S<'3T MR]"33HR^P9JMA^(,G@U>AH8W`[9QZX26*><%5?%O(VHF<($3+XO'\A3T*`#Y MD+B-H2A]C2.]0Z31O#KY3F!(1MBH)4"!J/=Q&V&KZ#,4\_D:[[UQ+A\6J]]/ M)F9G:\]/%,87@9O=?5:\F6JCO7SJE>`Y,[U>-J]S2EO^K$](IBL;E[[IOV]/+(I\73OC1W.?E+ MO%G=/QZ(QC)J))"[:+\R`(R%ZEETJ#.8--Y/#.WK:B1Q>XK&RSUA'<<(@DB* MI8V:O9%&:4TP/BP_*I@5:2=7SWZR,47EI!=M7*!GZV-[IBC.L2ENY_5SP7)" MO5;4QO$3I>+_!S0?4_XIL/^C.SL%XQ9(Z MOH2Z'S_7^5.6M0G=.?E.I(]"C*A2S$IKO922L(H^+4<[>"^T0Z=E<3X,J*US MFO_UL'Y"`,AH)/\1;>=LN9_!GL)S95D;7PN48,6B^6XE$MX+3A4X^%^I10JD MQ7,-YJ6:A3`,@&NB/$"8)`]G7@O.&0,(E)1`BA%S!$A9S=LRG);2.IB3:E[R MT!^NK>6AI1R>8R@3%;4- MQOKKQX+0"CMJ%)=0*S32F:2K#P.TWI[?5.T`XIB`T6BSOUP=#I'2< M48^0=MAC(RJ1CHN&SM@\3F/(":YV0N.:^3L[6W(*MG8\K^VJR&XC;/OSHASZ MW&E]XN&`@!;$"([BE#0SG&IFJSDJP<;RTU]X5J<"G/>,0UH]J6RYV-]_[DN: MQ"=($].:WBI+'4@BE?"2&R(DM4;5UP_6P+0B((-97MVYUS,@HZ5*E04JLJ7= M7U4_-S#;ZPK;5SZ`K?L[ZB6K;7D%?-KOU_IC@5FN.7(`:4J)!LA`0RI$2+0H MY[7`I[R2&QK;>?NAWQ&W_>?FF?X_L]7=?5QHZC$K%G=9]?]/Q>KV[$WRJ!,) M'BGO#1710B*6.08UA!4G/-)I*??3N:`&E/(Y\Z7UL9H,Y(&89X.[HN3X(=SO M&`%Y2XVF!F/N`<6JU#7J/2C;=/?F@G\=A&!?K$J_EBL M'\X6L!QJR(`M)`A**HU3$G$1=3I=H8L$3&M^,)VW;^"M=WH.C'K9F!6/\1@X M#OK'?/.X)VE/Y/9KOENL7_^_#!C]F._^D^T^9[?YW6;U?P??Z`&/2RXNAQP_ M,*F!$`+%/848)`B3KMY7L&1I?<<&J\`XH>3/D1U7O0P.6T!>''XJGSNW^8\[ MD0`80(![2DA9;E-"P&C-">-96I_JP>I2_HX+HP^^C%)?9+WG?K8\3KK[N_SS MG)UYV0>"DAY8+)%D#BEJ&4:Z=N]1F)AH/5BSG0DE_#ZO=TTL'ANT^U_[K_6)S,*[^$3^QVYYQE(X]A>`E<5`8+K&Q3@IO*:R" M91U#?"81R+W)4%LW_C0PSUK((R.>:?P%@V@G?<]6NX?B;)6&80<.E`#!=-2F M(^1*06:1JD(&O0[IKX%:2R\QKM^/Y#STM;K/]FBN-F<:+78 M^S#!:T.QQPI2Y+3R$.FJ]!CUP)*91#V.P/<>[MQ[`GEBX?OZ5SZ&\,5A`@9* M4>&=H4*;"!'`I$H%\(30F01M7K'PM0=Y:N&+XXRR]^T'"M1@@8"&RBEHN.6` M45=A8X21U#+5Y\0VD?JY0"06/FJ'T$E:4E_+J2"CY2HV M[@9IW,E'AZA]=MS=79'=Q4GM]S4;_ZBC6UM*0*X;2%O'O ME`'4'WH]J8I?L^+'S6-6_'F_NKU_UFC^7*W7-[>W[4R1<]\)"$K#H_DO/)0> M$%QV(JDH8]BEQ6@/L;EWYTV3,M;W,T%RVN2S)#>`-G*ZD=(1W/\_)NWN5/V5)M-@^+]?KI M:_XQWU1JH,[+O+/O5;6,%U=#^V^=Z2YC]ICSTZ;(:889#S6E-'`1FV9 M138H[.L-!!N0%BLVA+]Q>"7@.E@PJR7QAI";[^^)'G\!-$PH4(&DYQYX)D`9 M:*^BU#QCS8#R:#[NS6L1]WX!?R7<8_4:J:W[H_\MS?Q)&]A^*4OYE`SY<$F# MCU\>#DHX3\K:$HIXA[G!5!P2H(6G4C2&3@Y$U54U[)#0`DT1> M30..BUE_M@%'.PQG8=Y>03<#B9E%3@!15L"0$'"$184J1(3,M\)HHG2,T=8@ M#=3_BFP_Z(XOJJT:<%R5I':T-VUVNS=KXN_@51&2QJ+IS>^%,CI6&X<(55YB M;"V2H)JYM2[M-O*Z6FM M*6-Y-7>$P+75-QQ)*/I'MK54'+HZH#8">&ZVFLDR$*OH*:*`4P0@Q/O!$\(AUHI).-NYATRT(N7XY:G17%?5Y>-=#'H M!]3V@4[K]8O/\]7HV[-5P,^_%`P52#NM%71,6@D5!Y4+)/Z*TD)?IBM#-Y(@ M](OJ&"9.2M,5H#GC"`B@N!1:`JBKJW/AA,%IU8RNINE*JG^F`X1C"D+;IAQ$ MEH5H!%>1!J.=D+*JY2`\Q-S,UR62QI#SW3G2T+AF_L[.?S`%6[N>X`@`T=BW MX^U#`=KX#>VE-I`Q[J%!'E=SXLJ.YMA):M-Q,:!Y3_2G\`3""WCR^J'`$0$L MRAEDUB&*%8@'?34G272:%356ZY0TGG2@OSU/?ASIU-+,I(:W@J>0Q9D"ZQ7F MW%`*&'B9M4C3=0>S?7O@6K^`S,(3/^NX71"U?4H0(XI:A3@!RE5.;&^,2DP3 M&\R8ZO%"?&(HKTDTYQ"V"YS17@LOA!;*86N@K=0E7U8!FM?Y-4-![8AHZQ/1 MY)M]<-O#8OUA];VT;E\5KU>;Y=X;\>R"^'?<\XLSL5K'#\\>!P@80:4IX@QB M[3S5$*/Z6-%`JGF=LSU(UZ3XS7KO.UH7\A]%OAVD5N+IT0(TP`NI;=17@972 M$*9$;44@/9/B7W/:\7H#X_"-S)T$XK:/A%Z&$F[^-,!B6C(:>N`HF7H M.(;$U'PB2*=9N,/U3AE1I2%;_=PK`1.$!$*8>(L%IE8# M(%_--RTK:;B>)+WH6'TB,G'%HA'+51K)C!>028DD9S1NJ%6?6>$ML_,I5]D3 M>X>L2MD.RXEE;,2JE(P#*``1+%K!V`E1JH>U0BC-?,J/SUS&VF,YM8R-6WQ2 M64ZLL893I(`"CB!^T`8EC4LS[2YLD'3SF=< MU*N1Z>8>\'H[O-;:Z(.DDH`:@1P`4$L#!!0````(``DP`L``00E M#@``!#D!``#D76MOXSB6_;[`_@=NS9=N(.GH+;'1/0-2C]H"TI5"I7I[@,;" M4&RF(K0C920YE=I?O]33=N+8(D5*S"XPF*1=BGCNN>2YEU=7]"__>+I?@T>2 M%TF6_OI._TE[!TBZS%9)^O77=[]?GZ-K_\.'=__X^[__VR__<7[^3_SY$@39 MDF7_^4Y5\O#$TS+_J_>O6*ZK_.N\O. MJX_.=>/JQ!PS27?[TXOIO9GVU#B&\J/^UO[1(#EU(;ZM? M_/.WR^O:SO,D+%;K/-\[PX51;"B2'(A?SREJ)!-Y,M3%V/R'`]>BNN.WO4&R^O4=_6VQ*$JEA)J@"%;HHRCY?E0M<"S_6@ MZ^L&]BQLAUBS+&A;462:@>Y9B_IV"Y*>_W[=C5Y_).;V[U@(>,EM3HILDR^; M^$1Q59&Y@?KW!A'H(8$_.U#__AMB_G>#F.9O94AB;#3GK*HG(\F[F[T5%\N,ANR'\GS/([=Y=B_8C$SL)&MHH48%DPME\$U95D;Y2EPZLCPZ'*^OA9&<#-,- M*72P"<5I)J2H0C?L$1E@)D>1=<^..QLY*QA7MI\5Y=7M^RQ;%2A=79/\,5F2 MXCI;KQ;8#9W0LFTG0IJEVUBW3-B-Z!F^S;+61PPC>?57R$!V"[('DM<;358= M&,/@,&68B#PVK>AXJV&!.%V!#ABHD$TL(:]3=$14!/"JB,R(L"03/ND8I>A] MGA7%ISR[3;"O5,O]]A M>A\D:%%.+%+#J#NB7X*Y5T3:1%N529VPC(*(BH*4'^X?XB2ORCO^79Q_K?:` MAF_HV,!&Y.)`#R&"J)=?S7$L%@'D'$*RX&T!57N+=99^/5]3NJGH57!9-8Z7 MQF&:-@&#;!I6`P([%+:0)A:LP[P<$:B11"HB2&.MR(3.+N8"+U6VS;+5AU2;>1"\_'D88< MP\-VJ",K"O7M4!%$$4M=A^?^DNL[/22:NA0%J)P)J)OI)YOJ0^X:,Q>5PT1& M-HML&K,EL'UH_4,%Z,>)5>8`)T=$9@R#BFC,*!,R<1.*46$^9FFV/UJ[+^N? MA]M."#6:*=&MF(L,RS0TV^@&#C3;8TEAQH\F.9^Y*N](WM6#?F:4&`%<#A.< M:6EDDY]=;+T"M?!^G*]MYB1E1]1)'-V*:)5`@S)9,Y-1QSZD=+73S*RK*GG0 M,[!EZ,B%/G0U!V$OZH8QH8$6+YHP!W2EL0TQ:(V=ZC(=T)G6H.I$BU&SF'D; MIE!2N.+LW&OYF:?T_(R((RK#2YDBFL(-_T5;WA@:&/3BD0Y2E84:F>J&72!= M0T'@!SZ]N>'[EJF%7C>>'^D12[K#/8CL$G&W)I(:%K-D\%(W5#LF8(U51#I( M;4IS!CI4D^O)87*."LM(/I51F+%VO)`:(<0,K^94FXM7,Z2%9]B:#CU/TST4 M:"'RM7"[P_-]IL;@D4--N09R^3`NLYT)#*6>&K^CNZTIB[W'*7J M6.5'#,>*2)0H:Y[7@T22-+XTM+!,3P\"C8[K6KZ'H(7M7A_I3\Q2@N8?178A M>E>D1%6"3E,WL@(DE#6!E1]5RCT\99[!G"JB0@(,&5K68:2&87O6%;XC:I[? M/_^YZA__8'*;Y:2Y[DO\1(K?DC3+D_)[E\6A=+5_E_!?&_K/OY'R+EMM4[]B M8;G0L3!T'#L((\UQ/=U!K0DVA$;`HF8JX9:LCY?''\^!F]K0=HL)RLI4YHVF M.F0RO;FJ!F29V^&=!XO-'-B:"JY>S('&`M"8`'9L..OB1,W$&0B?RCRF^IBD M:7(E%/26H.OG.L&$:>R$RA MM1D`)BFIWFM`GN?BZGT&1[/LB&8"R.A>F[:Q;3`])N8=0WK9M`MEW`];.+EC M"3YR:>,*%!12]_@%_-"BFGI'\`HY)[66GTZE='&$&0(Y]FEY1J;%09B5EM*@L\^1F4\8W M:QH),O`ISFFT52X7'95"#O:#4@HGQB+FA(V1K,&Z%R1%N[[):CL:S?[H/SQD M1;Q^GV>;AZ+OJ_$]RW>P9@=ZY-G("P(G"CH8MH]"EOQ+]-B2\[)=N#M*R-J^ M)YSQ8;HX)]EL(KG'\XXF5N]Y=F!!@W:^1C]&.H\(I2S'***:TLS+IIG?K$=C MQ$E:Z?A5>AVOR=4MWA1)2HKJ=3#/#D,+!H9NNHZ)K0AU#49VI,&`13BY!Y&L MD!4ND*6`LDVJMT(_97D9WY-5LJP7;[&Y*9)5$N??64_4X"9UF#9.PB>;"-94 MMGDB9;29Q$DUIRMB.X!3G\+Q"D]'U&TTM8K(V'@[GA_6(8:8<8G>%D2GDE>W M!R_\2,JK6[H97SB&;MAFX!I:Z`<(0F3K75^U[6.=J7MH(DB216^[45X=3A#K MSJ-JU8YX1C65]T;DDO,Z3D2*>08.JB[--JGS7ON3CXUOJ3TJ9*#,3F!-3.5Y M61&AG]KJ(6FL;-(YJZ2'4^X.PVX)ZTOVF3S09#!)OX;T#\KO"\..((P,-X(1 M-+%I8=MU.H`AA".*J3)12:ZY=N7!];8\^,IF>%3Y5:K?>*JTJKAL=#'W%6_M M1HDS%6N[(QPPN`0\A9,5B2$S&'ZTH#P=]<.[?DFY\]:YJ5E6J#D.-D,C#*(` M>OV1R;:+V`Z;8+NS9$6OUGVEYJR-O6SL#--<><2PZ6;%R;YV*J&(>_0($_[Q/=P0%@Q4BC/.T^OJI3R2_OJ,3`L=%LJSKN>M-276LZINOA(TN MKPV=;7UAU]0C!QI!2-&XFA[Y!@JZ<[=L`X60I4(A"X/DDD0-LRZYKAJ@@+2& M=+DE#0*@J"QB?7HES2O#-$P%A["I78<84,B@QGP&MOYI<9^!YC60'>CS/=KB MY/B(9,KVFB+B*MW,;-K%,*HX\+S7=*_GNFZYIK"?(:ZMZ&&ZAN-[$?2\T*I^ MTEQ3ZY_0:9Z'V%L]I\,F6>!WFH8$M61-X"Z>RH!:GAI='SCPSL*A5Q&J4/$B M1C3!8^YO!!/FF,%U@^FF@")A9#;SC]80IG:#P,[=#E@-9Q$BA/5(TYS`UXW0 ML.T(]0W$IA=H_&%E_-B3[`M^2%*PRM;K."^V^X`C??+3L,X3':8E?+3Z'VSU MW57[&K-R3;Y[C([J^.7SC9*R+-`\YE[@,32*E=5=G5]$IF,'E@]#VPLA1*%O M:W8')/!8C[02/;KTYN`F29M.7-FX%RBOTFB7*;![2;2*$KO+ZEB1Y?+06Y)9 M/@-YA'8$E4*[*G8:F5_I_>B?YYW*PR&R/<^+G-##3J1[CNZ;;FN%HVDZYM?I MV:'/\P:(A&:,*=TMKF-#44_+:NO8?R/EU1[!9^T?;Z"X(]N[(WM&9IAF2@9' M==CAZ#Z9S8E2FAWWMV2^!X-`1Q"[R`PT$QM6T#T1=]S(8GK71QZ*MUIL$NH) M\>V*\IR@:AR;?T_%X!%!_8I\7GY#862DH2/Z$<=0*TO<][:!+D1>9#A6&`:1 M[D#3=5&W#70"#$V)\LZ$X^V6O`3[0XK(2W.%>C*O3O&,R2OBI)[+UV]3[/E, M'2?W(^CE;B?=[AX\+=1TS_)].T"!8>M&_\T?CA_:3-]5SSV(9*GF;$/GYXRO MFU,*76/;-=5IQ.3HM&1F5!'1&F_'B5Y)3F+&=:\OD!6XEF,9'@Y##7NVCW'7 M`N,@?9S6#!OA[6SZ.1GD4Q[QY(V5G;9+7(7>;];.[L$\*BHVC$8,ZD?OCQ[ICNXK^;BYOR'YU6T]='&U M*8LR3E<43Z-_D8D,A""T;81\VS3#J#^0PC$UR'1NM]B1)P2C,NFF-5BI'6W3+:+91&Y$.N!@0-;CWP8&(9APGX/&]E,;\J)'EL! M>=W-%(4*++]#1DGL)+Z0*K+S9)J,=+(+[6C'J"VUX\T;)K:":.3>1'\A3R6F M?/RUT'7+")"I8\,+?3\R;!S:AFWZ$*$(H]`>LXT>/HID":T/L.RW@2,WS@S< M\6V=Y=`V_B%!A0O4P.9^3-`SQ+"%9F=5$:D28,B);30O-8/EY[J,2U)]F=;5 M;92D<;I,XO6G]K#G_C&%9V%/-VW7T,T06V;HA79D6)&MV5K@!M;0U21D+'D+ MJX=7)0X]0-`AG.]1W!#>CBPWH;0KLO+$VI1)G*>,ZQ&MU]DW.B2)LCS(-C?E M[6:-ELMLDY;%9[(DR6-U3IF_R:M#RA9TEV=@W_1#T\0.CC06G#;T8,%MEH-5"Q?$+5[&/$(PZB@@BW6,]"BG5@? MF9@\(I1R/**(8DHR+IMB4C-JJ)_=WV?I=4G3ID]Q?I77>K[ZKWB](5U>5:=3 MFFTBPW<"J&L08COLAL:FR=0,(6(\R7K90`1%A?$,/,0Y>*S@B7E^*83O8:(Y M-=5L4MFR?-VP3`'290T:B*#&.&2G*T4B!_!V1!A%LJZ('`HU*9,W2?FEKZE@ MH4UYE^7)_Y#5`D:AY1MN@'7;-2/;-GPWZ(:,3,C4EC%FG$FEKJW#QSV\$87X M4>0RZYM47L?H6EM3WR*;3\N><.(=8PZ-2FIH(O5I**&2YHY2( M9:`YY"C;XA.I24S\<@J3+&I%J-,.MKDE:EB[@1!V514K+EM.*18_08-EZTM. MXF*3?]\9=>&9AF,YKFW:AA>Y;F0;EMFG:1IF.EJ+Y_Z21:J#U,C4"$GBXFZ8 M$LFFC4V`>L;V)&ABU3E`R1&Q&4.@(AHSRH1,W'SB.I.B?_2)XW55QK^^(Z1$ MZ0JM5O7CSWB]\YT.^/O^UYO36ZPWE>H=?N?Z2U7Z7R!+@WJDF50&-<>"4/.- MP`X\JI&Z"]TP9#^_8G[,DI6O/66AM[/J$Z\M!;6I]=$*6V/WOL?EYOOVT(7& MX#/0F_SJ60U_UF8?:7-0>P8-TVI5X,K3?_7FC<1#.J0[\DC44FTJ*1()E:/E MX$$A"N%3+6*CIZ18&+891HYFAMCP0\NP;=VT.O15[46M@#T(LN1XO:^5B5@"KO;S3B55;-&O"87/W_)MZQL3)YN.-PVN!H MQP2D6II!=A\GZ4+S7<_0+=WU<10AW_`]['1P`BWT6<*7+`R3QJ,AF?Q9*VX- M?M:P)TS12*$=#.S:9?"0`V_NUM\RO*2 MWG^5+*])_I@LR662DM](]<[EPH.A9D`G=+30\3&,["C$W6@8VH,>7(P<0K(" M;Z&!%ANHP($_&WA#!78LC\?U11$?96V7)3)4[U:E&!Q3U`$[#Y/);< MU?%!@Z961X?CEA\0?T%4S:SMHJS(A,X?Y6I)E0WU-[4N/-<.O3"*[,!R3=]` M7J!'G0D:=#F^H$(-W/_GG@+5LE#;KE[ABF$ZJ5*]DC.35'\D-&@2O=$J6>_1 M64ME[/-*D=V0DM1,7C3C==^07=<>D.,X?`HE6;7_L="L`.O(,73=-1T(880# MNX/B(7-0U4SF^-(;8G?`@/B^>G]U^"Y#'NLG-W!*$#ZF^'4ZIIR!/>0JN&7P MSE`)]_!M&Z6YZ?2NDI>UPUM.Z3Z8?S\JW\1LNBG-N)/]E&=+0E;M=[\\DJ), M2AJ5KV[QIJ"1MBA(L0ATB"*L52<0&UID>YZKA=W0NF8QG04=`=1?I#KE:%MI8-S@"6%YV,9L:H(9:Y-[W.[@J^C=(IQXZS.`LR-;%I&, M*[+5$&I2)F^"2DGM_S-;KV[BY5^HSF,7EA;XNF%AUW9UW_%TY/G]PQT(+0FY M/2,`R7+8H9&9U[-2+C*QE\BV[,R^=PU2QS4RDGN)+IHJNQ_L*J'Y_3YQHQ-\ M3C^\J0R?UT:N%'\4H9+"WF>R)G%!NF@W>"9$&ZE^=+%%B] M+3-'.$2SZ/Q@E"O?8$`ZJ?("2ZKU(6L-LNZM>S^1'EF+O#?Z$29+(.98<+,G=D( MF3CRDYYAGI&3#`F>%6\_21)-B+CD28JKI"55W7?%T-\J=Z\6I@[#T#4#B&QL MZEX0N&Z?[&$C&G0.S61@IDN).FC5KS4VR2&,W2]R4AFI+IDP4^G]]UE5_\G- M,*3Z<88$@L&?DC*#YXP*#/SR31PZ)RWZJ8]:V*-&&HOJO( MSXJR6&B>8>K8:$S(_BB26,S)?;BJ:$PPNLZ)]0>G`)9C<9CEI+OP2/RV,".H&]`U7 MUSW+QSAPMKU6>F`9BT>2WV0,IV9.@HIE<>X:,'AM5FB;]_Q6NW6`;.=4QI24 MU;(MXR?V,S.G<=WQ**2RSYB+<@=+->T).#]49OS8O;5Y^-*;VICN+[X<\ZFL M8S9%..&`EL_E9D7>!IW<[)?'6B%B!(4D`O(_G_ MSG49/;P\6\V`XCI(8ZUBYEIWNW%]_ M27W921R;E/B5O#0:B6.>.D6=JB(IUF/9;`PW6VV@NEHM;V5N)M'`NIC&VR%< M3L5[C."W'N7OG/8&*.B0@@.HYJ\8$Z/PA`:K=X,C*JO!L->7_'H61I`0WX\+CT8!S%*"<-(/EU$BI8MCQ]"L@G^\4#O1%=W)U(F) MFPG6Y*2L0P1:XBY%B-/3!O8X,R<4:BJ7CNC19#->]GU50LLHK:GICJ\O_&NY M7M[O[K_.G_A"4YWOREE"_"@@01`5*,XH9CC\/B5,F>1)=6M2,Z)I'0(W#5)P MWT(%#QU6<+TK)VC4!,KE% M0;538-0)[5-%F=0R9WO7ZN4-J>X?RG7=//J'>VE-L]PKANZZ!X2OZNUFOMC. M<)'Z!4L`"T1@CBD)TYP$,`Y#[$'"L$HLD6E$H7=EK`7.ERH/H3_?0^X:1G]J M\.^?[[][$RQTG9E`^)E5,`.>=$083%E[9,W+&,GJI20[1/6]_+7-&*?_G;%B M,@@A^Y=@&*,DAW&4=;`2OPBD>AGHQJ(Y$6O%HL'V3%1&;(1H]8AB=3?@#+/R MSFT`C1'."OQQSE4H_$1OOC>)GVKN6(U70K.PR/^YN"NO=RL&:C_X(;P_MVSP MRX>F>L2+[?)QN7UJ.C?OD04HC_W0(Y"$"8T\$@5%%$9!E$>4,GR1C,X;@*-; MZCL+N,`T:$$+%_1P)37?A(/$9-\QW\@I_S.W'&C[H0$7SQS&@D!O!1/^YK4% M>_(_G?L3$<"@8QT)`B8MKJP]10I"01>'\,_YYOH0V8_Y:M?`Q76]NV]_]@(E MB1.?>C"+LSR/$?(B2+P>98@(G1H6-$(S&"(&M.``KH(0H=-QX\.%(SY3$SHZ M8T!CS:O8<=2Q;@:2\5Z1#"H&W.]P@#%AO4"P,>8$X<#SK:RWF]UBN]OP8\`, MZ&VY7]R"*85AXL=!&&8XAE[F(XR#-`[R%$&$S[T/IF0,?=KR#!;H<-E;1C[% MTHEG70FYCCRY:FRI-,R^*4\57E]W"PU=3KDLZ_V*Q/X)3W`":5%P("C#,"QP M$/58"A2&,DF;%@":4[-GF"73,#V$CY`W&UQ/D3W>6+5??MTC/FBP:G/A=0RS MHE*IVE$N2JAR&T])JQY"Q2OH88_NL*+'FPV;^VV+U*=7VWA-'D;GRPW/O\J# MW*OX]5`NF"7?R\V]SWN;YWD81(B@($0PAYE'PA`G19`D:0Q]J6K:'DS-\MV# M`:OE30E^>RKGF_IWV6K:HA,%*^OWX3_)*ON-15EP8!?OLWVB`N?F-75W>5AS M7X!A5G`;3=?;VGQUJO:V/T$<"44N,/&R)G<`THBP]FJA^C7B5\L+IQ#_J%B< MYJ\@/'UC\7J6%7D0IF%,,@_1@-(L(2F#GD9%$<=%+%5XN(#75*!['&"-"7.V MG2H1[]Z1/]T+?'MC`;?61@S4Z[]SP="1V>-25'2%DF/AT15L#L3)G)6QUR6K M:SEP+XX1]"A-"0T*'"8XQPWPM$@SZ$GNJ5I':RI&7G>@P-.R%&ZXX@Y--J.D M-G^Z%R-[4S],A#STG>GX.&K>?.3H.(X0$[%Q@JOL1,9OR_J_=%.6G]A%GB)R'&/J09#J(\\3$'3KPLY'?"6HN,H]#JWN5BF#[=,%!@V:$"FY.B MYZI3+41&[?YT)C)R2P$W%?2VOOO0>,QYID+CI(GS$4/C-$)TAD8%KM(?&KMC M6_]@']S6G]=?R\VRNOZK7-[>\>W/QW(SORV;7^8,_6`EB_`DIGD6>Y'O4Y@' M14(1,P-[24$\Z`FU5W,5N^:PV0,$\Q8AN.'*^=@H9W4#JNZ,YRT'SLO.]G3# M]JX$#XV!IN*KKIFA.=HZ,"F,Q][AN'!K-;^_J[7[`@RSK3.]_0C@QA^$[/<2 MC<%[81AF?A1E6>PC06F=.(H^)6R`@3TR^R>93U-U0E<4<>R(#*BRIM(R M$94\9/M3?="+(AIF-*88P1P%$"'2#YO2$,NDME/'TIR*'CQJ+//\HUK??EHM M'WFRP''+OD`VF=@I\J6'4U7Z9>_@\1FVI"5,GF>G-6R$.4(B-I8FF6MU]CW/ MZM--SXX>7O93@HH,)V'A^TGF)3E,?9@$>8:1'R6>U`6JVL%HUL'CU]/+ZI]^ MEX@)I%/>D%/0YWTAZ_.-(=E'W'C!8RKI)X38F#\=46IS]KZ^7,

+WTE;W M]\MM>UO;FE6X',MMN5X\>RUE2)M1%`:#QU$ ML.+MGA9[D.*-[281>5H`#7(HIW0]*M!TR3K`=>:-)*7<"3<#-,7AN":`8[D\ MW_KOA-U'M%T14?9;_2FQHE(Z>R2SK!=#%?5V>3_?EI225;(BFL626/,,RTGZ2_6Y M`(=T/Q,IPTFK$',GDE6US#N2I"HVJM(Y6<63TN+^856U6Z*WF[+9+FUP\!RX M$5Q$XZ!(62G'"+82F59TUD] MFZ8:)51.V$K'N!1.6XUR.BYW)8%JKC$C[N:TZ4RKU\TR^\VC;VO3(>@Z'?WV?@>SD5? MM)XRA#Y%VO<8=F)1\`1))[(J%=0ZDDLI,>5UMTI%]$QYGO;[`6GJX:SP/>*% M,80A]@*2#F/2"$DV[QT_D.YS),.S=:H_K`;^1@N2'NJ4*)*]/2".(PP/\]>=]L^%A-:-]TKI\JF/6NET8>P(T[( MOGEG.Q(C+!@NV?U#%_7B9ZR;$=C?X%_+>I8G$7_9$18)#C*29R1DI6PWB)^$ M4B\+RGVSYBC0/N(<#2LD&1Y9`9>D24R$]3$D)Z02Y.@Y^7S(PZESSJ/X89Y`@7J7E%^4ZKV\-;77]D<^S*_+_/J?KY35W!*6G MDDB;'G1$P^UR(/LFK7Z'"$>4=@^E+`_Z#_VKO+\J-VQ`Z(=N]<2L1E^J]8^RWI9M)[1&"/LQHQ#',"AR%*24 MI@G$7MB-F0?8\P2/SDP?2+,6<8"`(P0,XJ?'!F/W='7IC)P\J2'W[`D:L[S* MB92;E`H?I#%+[;B3-`HH/G]\YBP1Q\_/J.//_@$:A;94&B:8K.#[_MMC%@4A M7N0C&/DP#.(B\EB8Z<;,XS"3$OPI`YD1?-]7K4Z3R!44?%.\CA)\QRB5%'Q3 MU$X2_"D4BPK^"2).";X*_EP1?"6VO!1\=02)"/[;8V5I'F9%0@,8$$PQ/YSI M]6-E!1+-[,HB6E M>3I+]B59@0V5PFDCN=3;+R@W&Y1IAL,"$IP@'^,P\;PD'O+Z+(12J[M27ZQ9 MN0T59P9+4NTARR<6)4=198C"['CL%<*9LM()>BW MEN(@0E%$(`V"K`AI2-)>;XHL@E('`"2_VIP:C-NYEV5*3A$TD#1:$^QLE0MO MLTKTL+H4N7DHY$N-T=R=K=!,T":G&Y89$R[-3#`WKC`;Q^#Y MJNP-BX_79%/IL5^13;:@4C97Q%46L^ER75[/U]??6`'(7SMG7HP.AH2$H`CA ME**$1"F".<']Z=$B)[[0O;(JQM%]L++%UUPYV"/D*\O16$&93NQ9+3;*J9PH M.TBGL%`;I76<8D^F][QXGV/AN(HKX\Z^G*LSI5(_M4RU$_MCN2X_;\O[>A9E M(<_O_:1(_#CV/)+[`S(21D+[(P;A:`X7DYL\F>KZ)>%`L?4"QWPG%Y8FNPW\ MS4_R_R)-0V#;G5D'<2DQ:K:6XTE6SQ0\(+CY62P9O%F<)UD2%%Z001AE7D!\$O5((HB]V;J\Y9'NNT1\4(]" M2%-0JRFO``OKRX`'_-;U??Q=5N@U.$!0V"V1;KW)8F_/09]%T\HN3?TI)=?G M1U>46Z.%+Y5:-YD&7K=]@?"MMHC][[]NEHMR1@-,*8$I#$B4QT7L9[[?6T&# M3.I>9,>@:RX-#F+`SQ>M@:]!V?T2/'"HTL'!+2*UO]5KW?WJ@]+IZV5.1Z4C MW7_[3X'&=M<*$J6.G5*\V)EAKH1+1]E1]J:R`2>*;*5,;5K5'';SN#VH[WS??]L_H=5,W ML1^58%,^5!O>#Z%[:O]GR@:56D*/;V=9VGY9170BCI M?+GY,5_M2G\6YGX4^`@B4F`4)&F$HJS'&Z0^E*Z_;8#4?6;C]G;3+-6"&X8) M/')07(NJ:4F"==IDZFK7W6IO6?=E#G$!N(F@L=%&H:S!4^=*8IN3PZ7BURH/ MQ\I<^XZ1OY2KW#RRNOEX6/Y2K5NQ;9#6WZOM?'7X>U+5VR_5]C_E]ENYJ&[7 MR__K7C7KC)K%*//2-`U8:(Y(D$8Q*H;P'**8CKK@RRIBS;'OW^O-@`LL#J5R MP9"S3'O5G`G;5L\S\[&WB=EUOE@\=`.LON"XO^6L-?#-Z\POP&!E&Q59-'P6 M39F!X*G<@KV)%\^N3C/=G-"(YTX$2[=FCB.1TS%2WKH6S@UTCL34+BFH-MV/ M^.?\F1=[@9=0&$4!1@7RO1@.5A`:$R>"ZSCHFJ/L7R\V<+M"$MQ4&[#9X^1% MYZL8[$JH'3DG+,=<_=/!5O#EUAZ-P%_W<^O`Z(\2BH\ZU$9,GC:S/GIPGLB. MJ2BMPHGBW4]6C;_+Z^/XBU_\O^4,(^KE(0I07`08YG$89,/+>=`/?:FV*&J& MU!P>G^E:V6("\QYZ4WR6*_95MQ?@MERS"+IJWEB:7]\OUTO>QW&[?"S[/Y2M M355Y12S067"(7(`:`+[=Y:H#:;IOBQ!S)R*!8NH=47#55KUL`:.#-)%3,-]* MEBK7\U5U\W53/BZK7;UZXB+-^'P#RRSR8S\NBH2BH"@0#N)HN->U@"D.!4^Z M:!A9LW[VB'G]\#!@;BH+#AK4!T_RXHC6BA^+T.&5LR=;+#M$3C\/?;&'"WJ\ MG:IFKU35K@^$CY]8]L6X(R;J?7+^6(D\4<>/CF@DW/[Q$)W&52;FK"L+=K,T M2R@)"6 MPSN5@CKN8[&RQ!F\3A\_[WH^'U@+&G/Y*U'K_>'TUF1[%XX8\N6Y`^HN32=' MBAOW>%%U>95>Q^F/K2P1:(&^,H16FYMRN=TQ:9G!R$OC+,"0P8=;#R2\O*HZ^3].JA> M@`,[WTOP%'*:CI"I=K:\]T"IF`U5X5&'DQPH.%^\APUA@I."HHS"B&:9E\1# M/S$:9('4(3EG0)L.E(?7*[`2@E^M,/X-9Q<(M%Z":G2XJR6H^!TK;D5125]: M*4%'3J?W'EFU\6*L!)WD.)'=-S[`0Z](>R#8(T*O<.D;77/\ZU"#'G;SBDRG.W3`-^-V%?7YZ/R>XSC2CN]&:G:`_7U*W096 MIN:R@1LR.PM85%[P!^*V_$\YWURNRQG-"`QIB'T8%!FF?I"EJ,?HY1&:/9:; MJTKG-9FCH.)H; M!BX==[3^RS.-.'S\_9G[1Y-O?LR?O?#ST#EYWO0=&I9\FDWC_C&V M#^3V?&<_QENT7<%-FHH<8#XS^/ZSFH4>QC"E!8%I1AA<+XR"'F,4P<)29B`" MS5YFL/U9V0H80CXSG!FH=I8[F<%WQQUM*3-0[7!+F0%[C!W*#!BI)C(#&=]] MM,Q`RG9=F8&\`RQD!FS.ES-(PC3P,A\7V"=)GG@Q+'J4)$6^K=Q`")S%[(#C MLQ8VQ#QG.D-0[C*'8)RM]O*%+@A+N4*'(^1;$'*@Q\N7Y"S7EO& M,,()YG,&RIZ^61JC-,N\'&QG##_L)6!!%S MF^%\0;F_W$D7J/.^MI0L*/>YI5R!/\P.I0J<5A.9@I3[/EJB(&>\KCQAA`LL MI`G+QW*613E,8A)Z8![!?OJ''O)<"@RI;'@07RI[]1\O+[X\^M7<4668^-LW-1&A%S$ MXQR,.J@N1X=P:-%&R[B@($S/>74_M.RX+H^RW;ZBCH-=37.Y1+'3W%[5WPJ? M-TVYV[><&H6MARL,^>>^LGEPQS3W*YL%LPB%*8V"R"]0#(E/,A_205'3*!>4 M/'T`-.MC=SG;T%^AA3YTE6W17X#]%:?-YWL+`#=!(N'5YZ;S-8P3'I(L53Z( M<\2+#B><-+ZV6._NK\H-KRN:JJ(&]>ZJ7FR65VW#&%95EIT%-=BMKYL7ETB(>%S*(@4#">:AE;ETWK<(7.A\U\X0CI?6G3(^5,X'!S4WC'ZZYO^]X0YZY/"[&]*FQ\]Y#1;SU6+7 MM@QGWS!_>%@]]2'U>EDO5A5?^FM[B(.'S7+!?WE?;N^JZVI5W3Y-"KAC/'0\ MUFKUM?TPJ]>\RLPC(QY3CUVZ3,(@)#B.`Y*',/%2WP_ZIF4TP7$@&$!' M?[_F(-F^GC_N;OKQG)V-;D;HDHM@KYD:M88WGC3A*&2$O'&19B2)YW7]+9N/ M:_=DANSK\W03*G439NHQB._EYO[RL=S\=;=4$G%84%%EP35CZQ9FSDV4#%PX"='UR9F-?C)\(&*`YRZM3V- M]I''%(PQKN88P@5HW,`1@P9R?[$-!PTN[;MAX@D"8^X8%S"TN&7LL8!37,EL M^ROAW'X(TFG&WY;K[T._&KF\?[=?3L?-] M.%1-?)6YI'V8#*U=8&_8>[E/]BW''(D>]B?!>[\A=CH!RJY;5^,*XY'J<;YD M7]O++W>S5>KI^_5EVK=[T%E%?O=Y4V^W)0+-D_V%]GRS_PJ M%[OM\K$D=_/E9H98W8E)YN6%CV)F%@[I$--#X@FUN7QW1FE>"GU=![9F@7EG M%]^.YOV\^OUH<,5M`_!P M"G4SWK:_.008W3813O"9T'5:FV6:=J[Q_&!#>M],Z5$S_7#<3%MGFC\8O>E/ M3/\TM-4/S]IJ\:=NJ^&_AIM]F_6XV?44(\OE[9?GH.P0V?Q9T]I.M,?+[+S. M%W@AJM(DBS_WUC;7%P2S]\W#)X,SJ/AK3YR?:?]X]S+.14I@+C,))"8`X@10 M6/1["S"@$NI^W#CG$&8S*7Z.ZX'UGP?6KX:(YC&Q<&XY5YWR3MEH9CS!?3YC M?7MZ\2=I.CJJB@RRK;WMF<\>C,:Q$DS:%N7NA-#/_99XRB,SIG>0$T MSOLP>5JXKL+%>ZNOMHR\T%X+AO+$;FVFZ\WE)=517*>7.#:!7W_)8:6Z4981Q*47,LDPD9"A`)'&N,V$P?VK@V<$@ M1@UNC1S=_FOASGFC^ZN@3W1M M>V.NW+L=A%>N;<*@C]^4]\M-6\H3_;ZN%T"MWP7)2<)9D114@IQG?1%%GJ69 M;B\W?6[@?M[*B3H]:DA2BDRZNK%)ESM[2'_,NKN1-1YZ_(O(W^CSMO[,H-=; M2Z_.L78KIITI\9X M:->V1G-D#^&*Q<"N8XBO<;T/^=RP;NK*#/JWG>Z7@[I=X`8]^_WVKMH]M`NV MF_6V?+\O'^J%@@A"*44"R3C/"$A$)H;2N$R!63^W*F*:7G\D+?I'(RYJU9E3 MP,Y&728$=]"*$.;F>2/&*4/.\L/)P=G0Q"V*5VSQ8(H!:7XK[]=-%F*[_[!\ M*!6(C&H=$&G]\&GH8>?4##CA)/_5 MG,/%!BTZ\'Z3RR?U)PM(KZF'1YZ_''`;W1U*T]FT,?M=%>.C<&B5W>7[`R3"\"3O*`L MI@DC`+`\R<"8Y,`BIJ;=V^SI4_7S3I7-ZL'2-?V^'\XP2PAH>^61!\],N``& M.\-F1`C+`$Z@PL4*(V8<%B52_:1>`")@#F#!>,X321DF(!\G'87>W5+Z%:9!3F,O=-G1TC;+.EAX)A'?KPPX@)!;&V;$4.L0SA!$3<[+#C28:LK M+"LH@8#A@L4@3F$L$$Z&PIK#Q>U(8E+"Q"SIAUTNTV$)52:NVM,WR?M%\F04P9#Q&69XD.4'YN'"" M3#^+:?;4P`P9Q42-&@-J&'ISF13A;#&C@ZXC'GCP+.0W&&!GRPSZO:7PRK5% MF.^9J!X>JFU[DU9W7L/'QWV]7VY7Z^W]`L>")K$$&&4P!9P)!,8=707$VI,( M#T5-M)NBE=C=]C;/M_OVIG.Z7?U6MA?U%E6][S]K MRV*,<$SB9B($2$Y%2OK+E=1<"3.M?6`AR@W,M$%J<_#4,[&1JIJHEQNU>@T_ M3PU2">=A=VW_S6%!<'LT^;HLX*;XMK" MZW+WK6P_#$0\R[.88RHD2:GZ]X+D0[$90;$).UW+"LS+YQVU>5UH]B6O-TOU M2#BEFV;TLS`R".,N.'2&:[Z\G0G+O(53A6F"ALQJ6M0+9/8?.V*8*T:F/`$4 M8`DRKA@Y%%BD2.LS8_=2`G.J[5"O)A:&GR%[\%(/4]/8:`8H6P>#4.I-@\[P MR=W4F9#)0R"5[_9F2*/V^/MGY?W2WD^QD%E2`)D1@M3SD"4.@M=\Y`R-G0F3#(/8[*I8F3[WVNSES[D,0WV?".;\QZ2\%;0VSY-^7Y>Z^K!(6990LWN?K8HPZ7>6=S8?=[_;3E:TZ]/+^RJJ2_7F/II,2L(:*7+9."WP<7BDHOA"?3<(ET061H[ M1Q[9AG(.2T[V.-'I@W*@+Q60E&<2Q@DIW-]W\/%.KK=JEKY>;GY7/VDOUZK'@_=I<^!-1A!, M!(H3%!,A`4QC`F0,)[8Q11(-.W7Y-7V`3#1NBZNL((,H_[RGS72JB1Q:4!_!D& M&:?X?8XW[A6A=__:;?NB4[5:T'X.\/%K*["Y`K9_!4I2"5@A8))2F2.D9M=Y MGR8@@G.A=<*!GY("#PJ#PJB1V'W\$G4BNQO(3;=)>++W//6G=]8,X3,UU>#Z MO$G-M;Q5S]UDG0OW+CEQ8DSRZ^`E0*GJCU"Q'#,'+^)_:G/-^#];7[5'@*G] MM1L"?/A\>0S0\.+T(.#3Q.N/`EZCJ8*T-/UQX+\?-T^J0/A&@8`)Q)(8(R!B MH@I-A"C&@2>&6AL*W$L)3/]&7=-QH!]`N5IZD?D3NFF&^YD9J0WY"0VUX[NC ML9?1?MZ!TU3WY-KU@>XKD,IW@S+&>/Q&@3))LIA1"G.U?)`"%K$D0X&"95I? M!;N7,A'&8Z_TL;94%^-3N&F'\9D8:8KQ*0QUP[BEL=H8?\.!LQAW=6TV&'<. MY!7&_5BC@W&ZV;0?([TLL.Y++%("F6",Q@+G/(]I!MA0(F,0:G+GN9YQ<\.`UT7\9=G^C> M(JF\MRH#IJN@R:^JX?0EQ%Q5,9,Y*V*,,QD74/8?E1*94:Z;53=];&!F-VJB M1HX-4TP=NLSC@.:8\7=27_39&M`?.Y::^*3!S>?QO<%)2Q-FP$5;Y95S"S#B M7AP?E9#!!&#"\AAS`5-$@4+L4$*>,-U4LNEC@W-/K>;L^[>90SK<"V:.*?\'\L>7>2Y^B[?*A/>VH_.-QO7_ZZ?.R+E?1;?7PM=S6_>['W4X]H]TI M%GU5?^N(RF-+WD2EE6^S0*6=\LJYT1B@LCD[O%PMVT_PFSV`JQ=%RC3&JAC` M)4595J0IP.!0)-%>][N6$WKAW^D;SJ1H%49.)'$V]C)RI_34<.T_/SOU23VE MK9;+?U=[->!\P84W:.W+NQG@VULHE?^F97H$^K"[^V8\8(42(1,<-W?528&R M`J5DR#;(-"=&YU]:/#[TKKI!D3*XJQDZT\2BVK8?(3XN-S?KN_+CW5$2LZ;;59O8[+*9?U.$V[67 M.[!F^5`;[EUV*_[$)*:J;F$XMTYJEF>[==E-7[\5Y[5QKU@RKM_^O M*E5[=CW7RK6;B%OW7/63KJ)7%C5]>?;NT>73$_UK5./UUP17B;JZ:M\Q76F< M+)(>LH;LZ?`KORZ?FA^UBOLH?E:_N*_?;[L;*W_>576]B`L@2CW?]CH_Z7=1%%JE*[V)K?J*BFWK]YK]^SBT` MK]@:YK*"O*8%+Y>@5Z\.@TR8&C'?U_5CN>+M$5]=F=UEA.W97^M;!='VUUJ) M'\K]QSM9[>[*]?Y1_ M81#:5U$A/D;+.JK+_7[3$>VNVD6K=7V[*YMJ7^Z>HL_5]K%V&;'"5Z=N1F]. M-6F:`&QJKA,?=>K'L:0+X%UT5-'=K_?#D`JC/0#G$,CDB4-'X\_F&:>JU+D, M*M,%_"J+.:W5K@/&WY>;QU)+%R0498P+0%,J(49Q4HS)V`0RK1?HDXGY$88+ M/T.$QPIT&B&N4W?^!HA6_X\W/FC;;CX\^*_1>8\.`>+5&QQ"&:WS0JQ;N?Q= M%:[D#)?SCD=UH@1"`B%*)$<$I9P!D!^51S1?<;D5,DG:*>K518,\_?<3CA9> M?(TTG7MF-'W#.*T3ASU[J/W69CHO[=[#N'AZ^6W*V>A/OQ_Q8]CUWWAXBJ/R MW)+T07VS_N-QO5KOG\8R&,(YQ90Q"AB+LSR):4XA44L'(2&4ES+25L\,1Y-1 MBQ4_+-S19D98E^PX8>;693*\BO$T#>RMN#X!'+17'MJ"14\_G%M;0%&P'.$D MS:G$``N>IT,AE">Z'_Y8/#GPY&M49-'5#>S1)V$89ZQ1J'7>M@^'S&D8QBD[ M''[Z4K89EOZ8\B;ATFQ,:?:B++=/_U9'#\OMLG\=J5;QFR&&OWAAYKDSQ=T< MFQ$U+<2?P*:M!=IISJ)Z>%CONPLGMJMFHXF:GI7;VW5Y\D!P$J=QFF2B8%J92:IPU#159,T;4.6WE1U?2C[Z?U6C:L/W9:(S]7C_F:]7]^W M__G++S=#62\H=6`3 MPP@*"3#)92I8DN*B2+K",SIBM.E;2L.P=(K];/A89^@WJ)O@"6Z:3BWC]\7:YWS3RLNKNIMO6Q)+RY1I4C!IH3@#*MRYA]E!.8:0=]3?JD M4?A3*S'J-*K>V*@T2%&Y&WLQI3>IIV9PFZ&=VOF_26VURP8ZVWLY]W?)A=.9 M0&_>73\OZ"^4RG_3,E[G/BOKO\K-2E:[WY>;DCVU/_JDGD>_K^L%9I(E'"9J M62WSN.`49'(0D&5"&$UFO94:>D*KA$;/.E"C]2>U^OBI5FJ;[WO:GT>-8+64 M59)-3ZCP6`.ZJ85KF&^:2_#I>Z#T@::-9_,%OJMB+E-B_X&]R@B$L/2S7VT61%X!D$$H0PQ0621QS/I1-.-*Z.<-K@=?EY;NHD1K]HQ/KCY0F MCKM",I#97OFH[?/$9#QX9P5%"^MGST.;F+11:&V83H+@<._T4[TO'WZO[O;_ M7.[*_A0TQ-6T5*A"I4@8@31)<#&45Q"@]8FEA/+_[]&';]E;^G."K/+3NC?')D]Y<=LGRAC'8MEM`KYL'OCES`*AO4Z\_*O@-1RLG;&N3=G:#K^NOE5I* M_KRK'K^^W]YN'E?K[7VS`:M]__A8KCY^+7=M(_VM_%:J'RR(X)Q12"%**4DP MYJB0*2>("0`2*HV.^`I0?."1I)=ANGTTA,]Z&8XK6VPVE@QBHU9ML[.LUQL= M"XY&Q280$K*&9I$5"1EA-UMS-T?JZ3*6H>BB;;6Y2N73R M5UBI!O:R^\5/R^\+R3#E#&$09W$*L^8$2-S+BWE>:$W3I]84//UV7WR<_O\*3N^=1,6G]S8_H+48;5G2[7)W*WBVT)U9Z7C)PUIDA98,!8G!9(H92)/LV&P2`B4)GP. MJ2,PI?M$UI=RLVHS7LU[[[\:XCAH->A!>2XU8(;FWOP.OT8K\^M][^7@]!E2 M3U%_,^'U)*%6TW>/<*G1]]MO3?9V][0`21K+7(@\EX60",:8CEI2#K5.,0DJ M(/2+MEZ(^0?V8>SVGB,-XW3H+.FH>KYYTE&BGTRI>3W-A+YA8[3/EMH:&H*W M[>4YQ>-NUUQ.T(X<"PD3RN(4YS3&&&89S!'L14&?__B?KZQ=MRWTXVKO5E7?N3U9-H4>`0YVVH;QK*U4<*O7# MN4J]]H!PKA;\#`U>ZOG'&R3\A&T_7'BT/=@BX(-R_?F`E@E*!,AXGN%"#64R MYOF@2R"SSY>#BYED*3#)$L"\'L*L`H)6P30+@4,(/\9:X*7E'I<#UK7YX\'> M,5['18&CT2'?ARZ$$(`2`-,4<$09(2ACHQ3(T6)?[9>;8.]!+Y9O!/%1JC9& M/C5_8@?Q(&X'>]WIU>BI7G/._]VFWW>:VI4T$P('#=']'::AG?J'5JR7G]>; M]7Y=6KY335#"29&S(N=8-)NC>3KRG_#$[$C+T&)"[S8^Z'?;AA*^5O3@/*L* M,2/U<5W\4+M27#T_@_')JG,F3)\NWI<'<$QK=+"DR5$<"Y%!FHN88`2:@T,H M33(RYG%B@4/F2TQT!&8\+^]*M?Y91)248[F(A)TMH;'1A, M;'[8'(I7WR?-G?P@"9,`B1+M.IL)H\/'Z2DQ8FBL-IG[`K;W[7U2R]WNZ:[: M_7.Y6_6'["/U:"P)E2F0)!&,B!2G22HI$Q@AJG5HJ:^R0N\!&>1%W;UMQP(- M+^'PYJX>8:4%L\Y`T9?-,V&?MW"J,*W1D&3CV2'TI2: MP#TS.%D9%X1)IZTY@R)'+V="(-[*83;^R>K:UY4,D2'6M;%CT4Y<3SZQ>D1$JQ91D@ M`1!V=5=UTG&(<\\%SP$N0,"'F+,DB!.:<-CI6PH#I1LN>C^Q[U<8PY"2'BU.<@CU`\$%`_$7U MZ@1M!,M*E#UN595J(*V&-.LL7V>E2P_3SBB8IG">"9E.FJ3U[+*:53E9+SX) M7E?_N2V7F\5R7I>_]LVR,.0I39F/4,3$0"Y@6;1O-DH(B57T;&A;AO6L@==\ MW=@`!,<(^ZK98'KEU,PFLVIJ-I!4(UKV"EMGM$P7SXYHF;9P"C/=45ME_5-W M54'"PS1@8FR(LR!)`R\(:=(V':%$ZL)PG>V-6F'_I'SYB5:JAY;:S;"LL]PN M1;#EFONG,_>BF.#<$:W3&I)T_;TO7?*;]?9[@^L9\.X3GQ>Q7&ZO_R^?5U=% M^N-^N5_CA"F-LI@S3`B*4Q^1,/!:5##*U,[9-@O%FE*NZA=Y?@QW`C8[P*`J M0-Y!5MW39SA5+[W,X^ M.XET1+YM1?MT;Y]-DN4G[?/;?+%=Y5]NR+I:+I:K;;5\R"_SN1AJU_MY`053\^9<0&3#G?Z/+O+]UM)0LRRV,<,<>IA+V&1 M%])]NU&(8J5C"`8W-HY/3$`-L>]^L^$,#Q%]0^1J46YI7BTJ^($O91GN0;73 M6MHG'BE![$V4PL:.8O[GE_NC5=<,AM@+$QR&2932!,<106U##&>>VE8.U:<; MW[PA`($=HDW_W1K*G,GNSS!)EYH2U2M=V+>EWA;CD/NBNVZFM:C9Q3& M'HQIE$2)GQ'>@?.0K[1=V0XBFUZS.:A2_I,JS9^HTL4E^+!<@TT=Q^87N]XB MFTDKQF(@B:.XR@3L(GE;AK+#;,Y-%+/[/JQ$-6B]/M*+EAMLK7U894 MS5XY@>#OL]4VGW+1K!^%D8]QAA`,"*=PWSA,4ZI4B]33HN$7L4;7?`8UKW^1 M'W`J#JXTT2LW>++/K-K@J".U^<41Q`F85:!%"1J8EJ5.BKHS:J>7>D<$3W-0 MAJGS>YCK_7Z&A3Y?4\AB?]EM*B+(OOS7RD..`"V_6B/BZ]F*V; M5W@_EGP$Y%N9YW?J)]UKRH"<,MJG7DT9FQJBF`GN$((68CL-!$-UG'?!:(13+:J-D34Z<'4J8FEC7N6H*`"UTSQWHXN+DJR/R?VV69"WRB MT>KQ0KPS%5DOZM+(??TC4^RG&:$9BWP<)"C&8J&NZN9\A_WN9C\5-M2^8H/G3S+Z;-M@GMI<0NR/G)A#Q.T M.">@03II9C`=6,N:*\_B&7TUD`I'M-1$9(7Q?JRA)'$XM.$B+Y?%8LHQR6"$ M`A32($VR",>T;1OY&58:"VMIT/"(]RHO[^H![:JM,6S:&L-,8XU!G>;^E06C M#&NJ)QPP@AU(!XH(3WE3+!WTIMT1"=0;DT298"!AK\K>[>W)9NMBXN^S'\N[ M[1W/;\0/+.A,C&"_K-/5\MOR>I5_S>?Y\J$Y%X`AC+V40QQG'(:4)AXF+2)" M?"8CAA9@&-],(Z3Q;H<5+'9@)^"ZA@O$"YSO`8.R0RP[JK21HO-"ZEAV-,EK MD[$]?L#;C-$V8VT0X!"%0PE;%/-M;;N[HZ3>2.)^`BT_^+C-FTI:?1']5DS, MVI=,Y/3ZL'H\V[1O75WAF0$Q:IS737UKDG_J]9N`[\OJMG[T1LS1RVZ#[&RU MJI=4RMGW];]OU\V)?N*AJ[RJ5:$IZS5D_E7>C6\;A_42Z#7^.CPK)US78JI' M]F*;D1;6WR,-TY4]I.<+"S".PI0@DC*?9AAS+^Y6<1%DG`R=MO1NV+`WMR(_ MTMII_WSTG]]8284F(V[3X^2JZ4M$*DY\!N?#X0G0\-@D)D*:")29$#W9#+,0 MORG6LQ5YF"U7N^MB'ZY6PB?M-@5ZO(V,B<5"7-L:2-5E"K]TPZFD>E`IMC^>QGB7;S M*EWG[]?EU?E.4>7/%8KZIKF8_\@W/[X7; M+)OW1TQIR%U15LM_-;^]^IZO'O+?BW5U^S5OMB@TNQ$H1@D-`E3?8!WX+.1> MVGXPBT(4PG:_U)64L5N%UF-'U96ZRZ?TXQ4GH&HP@KL:I##Q#J6\`=A-VZMV M[EZJ^AW\UYX*LHL#M(%,0!/*!!P'L]NE=1P/V`4$FHC`5_?S*FWOSN:WG\G; MS_/K1J^3XM-V/TH2QS?]<<(NQGUW%!?0OHJW(V].$`^"U`^R(`XQ2GT?\3`A M[:;K,(-1IK(Z)O]4PY/K!DB_BQP4F)%;IS)#BIK/R?%A9'6I"__,TI$Z18ZL M"_4`7@SM'7W>]/W)N!%,..=>0*(01R2B7NAG;1.49U(%N#[/M?.V]SN(7XD? MA3?>`#6]WOEQCM$_HN"U]UZ1*)?>?%7HI][]7N%+O_V_+]=UN6'?2!*E"?-# MGP0,I@CA)$3M;IR0$*9TT)O:DTUO==F!Z7O(O2)+<4H1==KBA"/_!/%6$`!5*+`9MJ>3>K M\N+F^1+$YK=\7>\/SQ<7NTWE4XI)"GD8,\H"GK`096&[L2!.?!1(KM_K;=2P MCJ0GUN'!MQ;DI-UPKU#PU4OYZY7ZT=A6+,7O<3:'=3]?6]V`WPZD7XQ,NGP9 M?33R>];)!=[9G:8D2)3`5>AYH<9MA&$'BMAFXBH,=TW=UC.-,Y\@F`5!E,"8 MBRDQ9V'($XQ8$GCBMUH]Y]761C4;W7+W.K>:S$4KK:9W)^FIDSL_2!5#HR M71\:1:&U?PUZ5Z[R'Q45L?TYI1G"C%#NI6%,L>]3CV?[YG`29DH?OO9MP_"( MZOK3(WZA= MWU_5;&*N;[C*UYMFO$C*LE[9K%]"^GCXD?TI9^3[K%SL;Z4^.FS]:[%:9459 M_^'4"^.4Q+X8/OB^!VD8XC*-WV/E$LY^7P#:513WP;MK[OOO8Y#`DZ'/_`_@0(S0G&\S39W%JW,P,)=<+))F`7V=NUL!U^.^ZEV`O>GW&I$F#. MLWJEPII='8Y6W7QL3U<-0NX3&#(.&8$HHAS3L(4*8Y\J?,8Y)DPIB1O^2>?^ M:,3.J"Q[4J\$VG$E8TD;W9>.(JNOOAGE8&H#V3'H34/ZPCMQIT$4:/:GX>FP MYE!BOG>3[VX@Z:!RG\:,!`AF,4)>')*,^=W<#X=C.%0?F'8<:H]L1(_JE4([ M'F4L;:-[U%%D;]:C3F3'H$<-Z0OOQ*,&4:#9HX:G8\2B'XM\3L7,SL^$HPH[ MS4BV-]/,@PEF^Z)?NI:\/,P^0O627QN,OH+?[R*#MVVU#[XQ\1JW]".;WG3E?;O*+CKE\,0C[>JL;W/6PPV^$&^1XXN*^1N[;:,:Q_6%\#L=8I M'%D9:>,%^X!!&S%H0GZ[OGDND7;<5$M7>G\>JX<6<\ZK,6WZ_'CS"O[?Q$]6 MW5SG;`@H(+3^[@KY!*4^]#(.NQ`0\Y7NWG0)M^%]<@W2NA#VFO_JMEJ;J==D MMXYF7;_E;F0]=Q?QH9CVYHQ77TJ'F.\('>NM&/`8U*B:\&CILV?$)U;'SL:! ML1#?!9VK'YC@'WK`E=_LG7+-D[9W`DB^/F?\1S?GDEHQW MY]"*R35ITZ;ZV7OQ:F/\Z#9LLXFTY]HGU@M?*0/`,,2>3[*(9VGJ$>A';1P\ MA4K'WSH'WK!K'^TI<AQ#&+E>="CN$W/!UZ-EKMD((CJ.#3\B:?@/T&1U`< MXNPS1W*,895IDF/0W\..G],=KHY_#->VF^#7'-S1[N:2F[M*T2EG=Q7K:-.F MCP+QAP@088^+!<@^JVV&X$[,TOVNQZG%1;WWIK,,N.6.^3_O)V)\4_I\K.-+AG M]W#)*L7/E^&_5./U MIS[T8!#$E/F9'V4I37CJ=1^B0*CNQH[A=W'Y\\BC+2]_&NDA=I8_Q^X9P MJ?;GO&+;LA12-25^DGK<]WF4,$;CQ(.0M&VR)`N4Y&%(0Z;%8H\-E!VX"5CG M5;VT,UNMBN_-ETLW10D6Q?:ZNMFNP*S]*^)'_H*#H+G]]R\8!_6ZSZ7H)?LC M-+W=VD_SQ\\.UIR(!C?W>7UO9KYZ5!6K09F3E"Y;25,4LI;\KT?Y$L@F8(_- MMK"=H>F5H]_RU>+K"@O M9ZN\;1Q%XI^01$E$(P9I',1^TC8.$5(Z>4E/BX8E\@BDHDYI(E1.L.QSJ:9< M1_@FH$4(:HB_"GOY=3.KE6P<$9.B[HR:Z:7>$5G3'%1ALKEFJHFH]'F]8PAI$8+X#`V8--$4MZ\.9G'`9 MIDM-I79,[=",)4?/"3FC/0/8:%+`@X M#_U.LCR&U>M*/1HQ/6G<55-N!;!F:EA[=Z]Z4Q_^5"I/AJGK58-R8L3S$CVO M5J8&,.J(W`R/XV2U:C`QBM+3-L(9R:+Z;B[Q+_CV6UEL-M.$I7&6Q@G._"B"D*,LX6VK?A0H;=`8 MV)3AL4F+;@+N:WQ-]3EO$=85ZGFQ.?.R&"%73E@L\JJF-`=*+SI*.W#U'0T" MGF7Y.<_5&3W21+(C`J4KFL)(3U1?C]O>;5?UE)SCZ213P\2ZX>)TM9R:Z`,R^*G?+/Y#W`4 M#5@<`@MS39@T9'-&9@$"\O4/:F1'&A8%I?\,=X MD!!(6>1GH1_$[0@+^@@1]16"5Q]I96E@P)+`ZYRHK`5HI://(L`HM?]7B_[2 MM#CRIJNB/EGF5PQ:^EW^M)Q=+U?+:IEOQ)CDLBKF?]X6*\'(IAZ?5(_=9GD_ M$,U#YE&/)`'U49"FJ&U?C%N4-C)I:]1T<>LCH1\_?;SZF%X"\IF#RZLO[+_^ M]N433[]>_AM(__N/CU?_JZ@3^OB64Y)1J%;3FB.(W>RG>ASOFQI9RLX(E7;6 M'9$R_7$5AKNKLARN\R\WK,P7RRJ;S6LHC^2NWC%_=+SJ%$9(3-*(VOXKW!Q(DY/A&>/$!]",U<"Q(0C>J8=W3WG M9BXJ[W6OWDIFOX"%32J08R2P;*5Q^ MDB6D_NN2[)&.X'VDJ(DA5ZB=F3M; MX_;=%`$O12CR4LP_PV4F!XNN+S4?I&%FDHZ6;5U]ZV9AU<&B(Z5$G69?194: M[05NYNUWN2C0M=),3]6%$,A$))=*,A/B"!,IJ1\?RSUOW^,+57RKY;+Z5E1K M9GP5((Q@&A(_IC&($A#!86N`R`MCJ5I,QXYE)IVYUJ[;KL^=\+QP4_ M2?))2U@Q0$VEJ1RA7LOYPJ^)"36BT`BB3.BZ$$89":4V?]O);LT^LH">9`2% M<8`)2MPH79+. M(?O]KKP_[-OCV/:UW=>YLO3I*W3D&Y%X(IDQ$\GH#;E/B2*52==7:[[\I_%9M?'.B#&P#:_W2_;GYU;IOFP'^'P(W+?AV% M_O%7;>X0XIO(]V]0!(>?JFZA^^OYD>F=/?8/_1"_MN<%-UZ$M.W]0R%?E+M[ MQ)-$:S>.?&;([IDOW3W3>G-SO`%FR`O/1;F2#"KIMQ"TJOM_(>W3$$*\7VJS M*?DGL?GV+B\WMU62/Y7[?'MF?@6)[\5A%'HQ(M2#7D!PWS2)@Y@`J=XI?7.V MFQH&#QEGR\W/9>6L.R=E.ZH,*"L&G8E%E?3OQCE'U-2-5U"A7)?[5>S2*($! MADGJ^2"*0A3T"Y@89J[4YBP&S-EOV#K;<*5U21)J)B05@]K$:LI!K7?.Z;US M/KS<(:5U<&02TPK3KDLVPC2#>B^$:28CJJW=G-IS+EM%/1NJD]8:>DK.K+I"+\0TAD.ZNK']3NSW>\)P=I_V.NX7^ZN`; M#P<*4V:20%217HQ^MC170MU+G-W,Q6TLZ\^&D. M/J5>&*48AA!$B"9]WQH._03HI5E7+V\YI^J:4AL;F=5UY533**.B65OZG#UI MDLJ0A#5="%YT(KB:^TB*86Q+E56,HB"FQ$-Q2)`+`<1XP!IQPUBQ`U[-V"3H M.6M7;1,:`RC25UD,3),*+(>IRQNG+&RWE!$^&9-V(;0R%X_DKBB20HDG2NOO MQ>:P+3X]I&7S5#?Y]K==?7AJ;JOU]L#[`=B/NZ[/0['Y]%3LVCUY^:_KQ^++ MGI5+[8GM^98?]OOE>U'P?2]/JPC\_[VM6?49;YJ873.*3S9G&^!(HHFE0MTW6+6 M^G+HVWB=+N`;9PCYO;NB_2(^\8Y1NZTH7>[PI_6@,^B=_[ZVF;%7`6G ME6'R/L#I1WHL\5[P?;>0=^6B)7I=.BS95[DW>IPW)?_^M]MFA;E^5V_+]7/W MWR?K?N01D%(_0X&;Q0GPV)]^!%`6TS@),9%Y"1LR:?F]V7K)R7G'_A$;+973 M2DR)*_9RFT%7N??1(.G)Q1NG<\_YZ_CG?&\,,?E&(&]8_X5PV714M=6;5I)^ MESG]VC@E21;&,`@1<%.`WO:YR M['LWR5X,_X04',&?V1%8"/T,!U7;O&DEV7=;_6!I3;U[SLJJ;%A"^UM=;YI5 MAHF/(A>X"42^ET44X8#`*(1I$`89EIIN431AF6Z],\XW[HTDU%15$Z/8!(+) M86MPZ,899&M]FN^NS+?-BA', M3V&01"@DV",!H0'MC:$@5,.,E`7+E$GJQZ>ZXM]VJQ)&3B])P%B32IDOS"-G M<&EFO)RK(T(7)367!A>U(-YCBX8D6IOSMQ//JQA#-W5=''INF@4H]JB+`@11 M2D@:^3C4W9!?S(IEQ'RL\^YHUB_%^K!K6U*^[8JBVS&DFX$?*2),*RJZ>CZ% MF+++YE6[1M)YY?1N79=PLF,-6D=&%\YU55T(C`P$(G!D@8HTXG-*Q?W^MFKV MNP-_$,G?9;/",8H(H=CE-5R<)H$7D]X2"J#4[+G"Y6W/%C&/G)-+SE_<*5GP MJ*@F.#-D5S#):2!)K>S,]+Q19&Q:1UV^A3!%)X+7$S:Z8BA2Y(_\L4CKQ[RL M5B%VX\C-8(`SD`#J0P+2WAX,/;G):%4CTQ+EQN&N.7]USNF1149)%;Y8$E&+ M,L+Z34";DS["S%&0=)'D48ECE#_*PERET/?O*\*'DU<8K,#HZXNAO/B]_?IH M13"!F1LAF`1)$J:0&1_8YX=$J,HR9,HRD=HOKT;J+>>OSD]1.)D2>!Q1,V@K M!ZJERKJIU^T3UB[(+$G>%XY-*?/K5\/W%O<`>Z"%O9@4%Y!O6,.9P6\ZFMK* MC2;^$LC*7;,GS,1FR'=)&H84XHC`R`>$_1U%?F\$,\."S%>XLO5E0>:1D_1H/8="PB2VK)0:>%\IIH/7M_%=IJF&#O/#4\?YVL2MH(K& M8QI.*0ZS,'4!`BF%``/BT\%,AH0F^E2O/34>Y:IQ9<4D$6E!+$U(3J23(B@M MZ*6&REZG]O0V:]Q\=^I!5YBEL5/6_??HJ22#/#^/&:R+28`I`2`,_#"!_#3W MP0P-0Z$]^U2O/34_I2M;-<4D^6E!+$U^3J23(C\MZ+6P5'.L=-?28FG(E'7_ M/60JR2""S*_E8W%7[,IZTZT\A12[;A!G*&+%/0((AZ>5)P@"05A*7M4R)KDW M?-M[YHYT?2FKSU4T6I1&#HI3JB(,0HOJJ"%01J7K%'P9WF7^*4HP/_E4':]U M1U^%=L<<-$4LTTRHYZ9N"@(?^Q1'PQJ7FPAM5J]RW2F))UTLRJLD03T+`FEP M;P)M%-AG02,#!;0M%([5S\J:+`F'LJY?`J)2^")(O&-7WWVMNW2SJLH?C#;Y M[OF8<,9I"&%(/0"R$+@X3/T0]O;<&(D6SWI&+,.R=8YOMO?0E3LG_Q0*14TY MKX)T.B7EJ+HD$86).YV8:OC5$O4Z@D?#O\QC,XK-#V=#<=2&;R5I;'\I6*R; MMP8!C8$?(PP"%Z0Q2("+^MXM2D&*Y;BM:F4J<#>M?V:@HZRH*+JG$%.1W8O0 M49;>4^BIB6\E787Y_8X`HP#7%6TQ!-<.Y`W"S4@CP?"OW\O=!7LI2_2C.,A0 M`+&'D><2-^GM`02%FO*UC4Q%\#UWSPQX5.44Y?<$2BKB>P$BRL)[`C$UV:TB MJC"Z+X<_2FY-Q18#;MTXWG#;B#`BV([SIKBM&.V*9O\YWQ?M7+4+*(XR@"CO M8?#]V,TR=S#C$=$65J5K6X8T]\DICTXY.^:5]'J1FF17B6Q=+3D0SR:4,'6M M"Z8&V[?"Z;#U4I"7D:HEQ_PDU7._-G-7J'/S.*6=$3]U0Q(F01PAE*(@R/HI M;4HRX3Q7\>HSL%-ZS4E5.&E^6M!,GZ"3R:5,40NR&5BNLPO5L44[37V6!U;9 M`-Y'JY(4PA_XLTSXL>!FCKEO$$8T)%D4)W&:X"R%(USL,TOSYS$SDL:OYE+IN1F'B>FF<];L6T3!%HBF8TK4M<^+C;?SILX.! ML\F?E7"AK-G5[,NZ7'*XF$\IX<3+NF)J:9>*J/()51WITAQ2[;I.KI;)'?3 M:?TTL66DA+QBF=ITRDJ"^+VM(X7TG&S_R$&JD;3.C,0+2?(,!2.PEZ2J1%KX M2NK'QW+/']VL*,@C/SIE%:0IRS)Q1BD-(C\)410.BR<9X8?(ZH%,Q:9EI/U9 M'9IBXVSYL_90C,R9V!56'6&V-34"LQOGY*;#_'0Z1Q>`M0OR20).9P`6C#JM ML`2@IR^;.?S=%>QN9F7`MV+EI<#W@PA3+_&B"(,81P.!O=A'1A$H8=L M@S'PAG_UKOE)S#D6V9\1=.`1@2FJ1MF*6'%=8+[S]$I2.38J&/',@M_KZO]]^VS MLQZ<4L@,M704(]]4$LJ1[LW&P2?'..%FW3GXA48C&#.A[$*P9224T2V$=>01 M6<)X:ZW8[5MC?S[555H\Y(?M?A7Z,,()3(G/4L4`^\A%9,"AAX789,S8A(!J MW>-\`ML#7T7]5ALO8-Z?>_,@W&$MMX?:2.$RDWQN/7QYB MR$^TSD)``^*1V"59/U&<`>R[HJ>&R%S3,L`'7^2H(B?+52);4T0.OI.((7Y" MARU1U,`I*([`<1MG<5TFH5+D\T-/S>U:;\"U)EKCO"F;+T^[(M]\JOXWWY7\ M>$G>U^2N6)),71@DOIO!+()I3&F?-6=Q"H589]RH91AV3CDL`_AQ=.O*%PV6 M)5:9D)U(7'O^:=>-T[3N MJ:_4F]1;A8Z32:W)QT'VSZWLG:OS+=.+BR@,22,CL4A,FHEL%)0&Q9-"Y>>" MK[EM7C0'-*3:M-XUS2%G>15P&21T=?-3`U[>14E>WS+Y/^^_% MSBF92X6S'G_\3,DED01:4THEUSNGU!S)G`2(U(1;$&P4`[B4@6E((0R--J'C MM/KTD.3-]VQ;_[,A]RSUR]?[%?1\"!(<(YP!EP(((^`%28"BA&0>#D3W#]"R M8>_9&-QJFY:98T[KF?-7[]O4GZ2-Z33RV!B1=R%/D)E8:@OWG^1S]4>QY[;N M=O6/%4_>N.OG@ZR^2KW@;@R"&O)GUEP,A<[;C M7^^N<__L?.`>.V7UDS,X[9R\G@^2\LJ.H-/B,"T$J#8CK">[Y^7A>UNMZ\?B M8]TT*XJ9B0RC#-`@]"A"29#V1F@82LT.R5W9,C+Y<[ME?DS_!)XT&'^X%+1: MSG.CXOS;1T)9`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`DFZ^O:Q_%%LNI*15)O3S'>WQ)%O>:[V M=_\O5BCQ`^BY.`P"D)',S5SH#W-?/L']&MI7H$CY"&&=FFM M[>7@V_0=7>8%S0-WVLFOS,!,/%#CT%O&X"AA\6Q`F/9;YOG/6^[Z<0#:4?K6 M+N=M^^6\Q0^6\+X\RQDTM8U\1`?O?]2?L^N;`&F)>.'%-]FXS+_-T$1QUA/? M\)()_6VUWA7L79X6W9_GK3"=:WT;C!^%K(J(00C]E!!,/1\-[W<T9,6F_>ZWWB7>)'I[2!J"*M*@MM:6H2@X/&GP4TG@A_ M;W63(I^&[(N%GDY,5WFG+9@&ZFZK'RQEK7%*!R^ M:DN"4)=Q,K:LP^W,&6VH28FH2C/CZIG$F)":$^'KS!UZ>Q(NR2>7#6JH_YB(:<7U?4Z5%\T`T7H7?[,4T)2;5[Z M\_$T3[7R"0899.5Q!J+$38/8R_J/V%R4$JD5>KN>V.Z'[,NII\[7&R=?KW>' M8M.OY'=S?'7[F+>S^OQ(D_,Y/V,5KI%QTRU]IQXRLS7QT?MVR%Z3^:/(D$U< M,`NHK51)FQS%Q<+<2K#"M;=YB2ULN974%?O!@?WL^,NZ:E8HPL!-:$PH#0&) M:$S3P2L8\&_TZGV^%6._95>DX#]X+8R3/T2VK5CLMD^7%!VAQ41#M1!<3!6M M\M90!D36!08OSIMW=CD@)/#C$+N49"3T<`+Y!X)'3XCD0346S-M>YWVU1U_9 MNVI^CSZM01#+]F;67R[%N[)'W^#T(C:8D5=6'M`FAFG94#82H1B(S8DITK'* MI>6K>']85?4#_&A*:NB8<7E*L&$$.C'+L8A2;(X1`%OS$^`CWW` M/^R5:DLU8'":WM/VXRE6[3 MGI-[O*OPY."TB@KW?$ZLK%ICIZ["U[LVK\MPN373H'SS]U^:#*:V<8?)?\&Y M+HI-D[$@N[UXV$]8IK]_OF.WUYY4&_K_A_*)>[="29@E)$VH&Y`(NQX%D3ND M_;'8N>8V[%K.LGM7NQR[W_&KZ-V3_\#3G.!BB?5<6DN^(E[(_*7?6.WHZ8W3 M^GK3SIG2Z]K;^B945,B1!-K&<"PD<[82VML/2"W)9V&BXO+TB>N[001!2BD- M48)A!G'OE9=YD8&935.N3#6S^71>11_Z*OK2?(:UZ0RUH3(]M6%]E*Q/<]PX MIQB<4Q"+G?(P,S]M>B@7`O2IHE6>%C$@LB[VAZU6+DS6T#`#"(3>O[L[M]VV M<2`,OPH?(`OH3.E2%$5@@:()VL4">V4XMI(:ZUB&+/7P]DO2.CB.H_`HJ7O3 M.+DHA_^(G\F9T3`.(2$H0QBE72L[-PK/30P,GX_%I+2=H07PJ M_8V">V@!M>#X](BR\H`VX:9E0]G(#,5`;$Y,I4#%)Q84N7_*JF*[JU>)$\4! MAL@+/4BW^#CSLNX:#]?UH-3=[.JCV$9I\]+LZ=?;]P(\EE55_J#BGT!SH(\: MV'`+P=-ZPRHZ9%N.:P@K'WZPIZE.L(%;Q6\=Y';-&%5XI8]@#$%-TX6PS,!$ M1N(#.M((D^E+<6S#M_=/KP?$*4XA0;[O$#_PH!^$?8=0ET#/E2KVKSPBE]#5="*4,3*0T_;CI4*H\/-.U M_9*MCSL6LV,EH_>/^]US>WY.`D3R+,CB/,^7%O0A!B76YI#C\-R;X4 MVV;#F^7M#F!S-A7L>5EW.1BK@S%=+RB`;0KE3:"N?X.AM11P4\&]B/#V\3>N MHB@0#?EBB8@T-;4Q:!J53RU?7I>;?^^/?+S\9U%M=O1PO$(D1=#'.($XBR/* M4.IEREEQIM*ERXU6Q9YQE95+UMP(4K8%L,9^8X:`\JO#2@-P*.7+K M2FMEQKF:YJ-(-:^>T)=3$%X6150K^!S]OLFWA-G#%"Z M>BZ%2]KSN,:1&6$L9%QOYH$3WTTSWX\)]#TO#%TWB;W.JB0BKH%"&U.FS%MH M:K7)^UX#(PMAG)J6' M+?O!:CF_K_?L2^>AJ';E]OI5]Q5RK#J:/ZA&,R7!+E9\<6P/9ON-X=#FQ[14^QYR$6L9JO ME)1>QJJ>6/3Z59Z4T,+5D\SPB@T"E!(O2V&"72=-7>(Y71==#T4A:5=L?A!L M$VEF5/GUVAEH9K46K`':_WJ=BGK@MUJGPI-26J=RDDFM4[(O?WRF2M"/PXL) MA^V-LQ/>G3;[\M1415\EFWF9$Y$P"!,W0\B-,-T`='9%7NC(9`FM&V,YB?BU M.1[W!7_E?<_N&VK-8XOY4![^X&O=1&L;^TX3/^TLQE\*)R!F^QUHK;]X!XR! M^>:+!<,4YGO'0%?T#^`]B3\7Q/5IYGL#^1,*+?%MP&M0RV7PK*A;>;FI*]YHWUY'FN"FY17D]@]*R7#Z7R5W:"#HCN=;43/"KJ,'# MJ-Z6T"NFWRAB#;M@,2@U/:\WR+0BG"P:K\OS.AM6893'&?03SXLQCB'TB=^5 MK\"<'JT5B*@\UI0@7&_HF:4ZI_E>%1>KL5!=7RD$3B*M&OG>%`CW^)N'=N]) M]3'DM$5>%MOTIW,;:89D$FF0V.XWR^IA7=7M+Q=]NG@)3#?\(ZQ%],-IYL07IJ7D]C)$R<6:DYK;W3+M#NW3GS;-5%EXV?1!>/X6X;ZDI4D M[;F\K``SN3^G7QA]=R[$>[M!'-\<3N43X<:,"_"-6K-&>S[ZN(VCFF@WOK;L M.V#^=H^V)UA.]2Q+;MLO0[)=U.7/PU-9O?`'?;BZ-@IRY+F>%SC$3[(@'!+7 M,$LBJ=X+IL:<+UI]KK!DW8*W3<5BH.=<%&O)*ANK-N8`L?W]'-K+?:V]DKT/ M0X,+(^>++0NJ-[+U-ZW_0HX`QJ=5VGULY2\W*U^*O]8_BQ.',4JB$+NQ[Z&UL550) M``-!\XE20?.)4G5X"P`!!"4.```$.0$``.Q=;7/;.)+^?E7W'WS9SQ[C_65J MYK;PNILJW]B59.[V/K%HB;9Y(XL>4DKL_?4'RJ(L6[)$T22E*%LS%3L*&NI^ M\!#H;C3`7_[Z<#G_]"?SD]L-IC>)>/)B)(,3[ZED]N3_TFN?#H*8L7IZ;SU MR=-OX<,_KN(B.7DHTI^+P6UR%Y]G@W@R^\;;R>3^Y[.S;]^^_?1PE8]^RO*; M,P0`/EM(O=FB_-MIU>RT_.@4HE,,?WHHAA].@EWCHD;_\Y8_/Y0?O&C_#<]: M0RGEV>Q?%TV+=%W#T"T\^\=_G7^>F7B:CHM)/!XD'P(&)R>_Y-DH^91@N*7X:9'=G9:,S'1=I<7%]F2=%0'N&5]"@5.3GVSRY M#CWJ6$.P>Q5M,HG347--7\FWIO"X"*,U+)]V'8]* M5G^^39+)[^-X.DS#AY=Q'K2Y32;I(-ZN?:/..C:E6'Q],^U7Y3M0^'-XUL(GBO!1LZ:LD$FZ35HK=9Q34-VU(A+0:S M!WV:#)\-WJ+-1IE.%:LUC]42[53-W^*\_.UK\@Y]W^JC4\6_Q%>C;0M:'4G[B^OS;'QS'N`8JJ((\^)F'6L(=J]BK<&O+]^6PL$-OTN^Q`_; MQGE-P_95J(?1F^U;4^AK&(`LW^K,K6G8O@HU,7FK?4L*G:=_3M.PZCUNUF.E M6=M?7PN-MUJWILPDO:D1*:VV:TN!+!X'G_QS,ICFP4IUDR=/;LH6?;:)=:U> MO<&K*=V:LD5QF>2?;T,\L$VQU98=*%$3I#<%6E+I4U),\NE@$@9A?&/"]]QL MFPTW272H5"V\:@BVI.)L2'1<)"%DOKM/QD6-B6*S3*>*J6]Q/E2#X%G6G5QW M[Z=3`USH-7M,DO7_>AEBYWH,::OW3HV]N"___)2-1C[+2\3?8=JVOCHUY/,D M&_SQI,%_QZ/I$X6*8GIW7R/B?%>7G9I5)V"J([FSDLM99_FDX3BY*7,8Y_%5 M,GJET1JY49Z_$"LSW;+,=$,VTWI=;RUJ^5LR:5?1UQVVJ&M8=]-LZ,8M0[N^ MV];U_CR)\Y:Q?JOC%G7_DN1%TJ[6JUVVJ6\VB4)L.GG;#P?:-LL,ZHF4'7<7$ULVI:G-[$ M\?U9.46?):-)47TRF[1/`9QO]?UE_G%TD=_$X_2?,P6><\7E6C,>+BMW<>W3 M<3P>I/'H.8VLKH(;&@\6:=M1"=JO'X*F4:O]1\H"J;C`B#@,"8;">8`H%,!# MY)7D+Z$;E1NE65Z-U&%B5R8:1UDQS9,O8:AUT/"/KF!<\U41I9ACC`TC5%&N MG,53CTY]U M9JEZ'41$8`6L(YY3Z+4!./RLK#(ACG=-Z0A^A<-NQ^-SM>UVH5-/:UKF\J7%EY" MC?5KIWXBRQ5SPFC%)/<(8T&H54@P9#ETGMK]K%.U;*@S3^S6420@A53RP%'L M(33,2ZTJ-#@E1^0S=\22K$?X]SE#K$T]'_5$(0E#1&MJ,;*0`$@4I<1"K)15 M0A.V\T3Q*LM\>QM=9D617HV2U[);>G6)^A:VK4Y`3YNGI:G/11RE4J5E;\]"VZ0BZ1ER M(M@O!*5!6^J)JK1&2C;E"O[1N-(^UCVX$.^HZN_)GU@$@DO!87CJTAG=MKL1 M=<0C0;0(@\$1Q$X3[(2C'A%/`0666T+W$V:HT2C[5HZ)SW*;3:\FU]/1/)=2 M?$H&2?JUW.0VTSQ?JEQ?`\%._41`"J0--@YCS;0'VD%88:'X=D_J^_%,VJ5& MUA_H??@IY5PY+P()D\!%/@-K6%:")*^+]MYPWK=(1Q`2!"A6R#`K(9!24U?9 MK''C':`#]%$Z)5K[4/=,KYF*A9I.;K,\_>?S,:#-M'HM%9961PSB5D/*L:<4 M&6XK&SV6\GC/-^:/<6<;]U"OJ(@FPH+>)*0W88M(:- M+QM&'%NE/>7""J^%Q\!94UGC!&R:-?M>P^3:@_LZ3'X/JKVX"7%Q6R8+PP_W MYS1$[:-9^G!BXCQ_#.O1+-#:Y"_4D8]"B(\=5E-`OR63&BF\#6)1>.H5I$ MLP_.+!U&O\Q+IV+R^/=D-/19_CFND_^M)1\1'OZCBDNNN<%:(`%E93"&TM!6/4)7>`%O#N>3$E+ M1'DWAKTL3#/]=II7WA*)(,2"DA!K:0^H0,57:4-S#VEN!8.?1WT(QH!E\?-*A6O/+(_B0X MXJ43?E\&B7_+-]%Q-&R<4_([W7&"[%CD_DNB$4N+.@04J^185B8\AS+XNFT##1U MI>71+HLMHMESJ/5;-A[L$FT]MX^"6<@A80PV1GN/--9H;A?&QC5=$R$XVFFH M#1S[M$1)D0:BZ3"VG#H*42BF@TQ)*3Q@=7=\\/?RT31"+A>ZO_3^"H= MI9,T*6N09SN5M]DH#$=1SF63QQH[476[B"`*QF,#-%`2:1@07 M`TP,=[I'U1'>_;!MG%Q:>RH( ML,8*O<"-NZ8;H0KW"`.UJ=X9!Q,7%D+2U#Q`]QEZYQ)[<'V%D"_:AI1J94. M02<4D'CH,7&+Y(5`BC8]['*`V:(VAO3MHU%-T.PE%30@R3H2.)=KPOIOO@#;O M1G0_T\].FRG5)1DQ3%^@`RZE[F5AVQ/,0RD3>41X2 M:2ZH=@ISS12'""`I%\^#@JQI`':`58=]YJ';P+K7ZP=V>9]\_]<0+#3:[?J! M%;$(88*`D9I+#Z`#"(G@(1C*15@/L*1;3\=V8VEYX#2H>IEG7].`JW[\O4A" M.#:_GGY\,W_U8\FK[?;OWEDD:>`Z0$)*";Q"DBD'GU#1@'';]+:L@TS"M$&. MK&?$^UAC@A%/[_[>$!,J?+05[E M4V.(^\GI_=^T>-KE^))]2@;9>)#.3LT_:_TE:V]"Z^+K(HU06'$=(!`YS"T+ M08&J4*52'%7>L(,I[P#&I`^F_RU.QZ4M%^.R"N7B>NDHP0;";I"*<`!6"V2T MT,8B$[[6ZLI&[UCW5_WW&-#OER195X/2!_&6S\MM8-IRLPAJJ26V0@8#K#%" M*VLJ*["B31/7!SBE'12QWC$&O2S62R?C(MM?MQZ@4@*)A#C MI5D2E*]7A@I7EBG!FV97#K#&]Z#8ULIH;.'9Z@N=/M[=QVG^%*B?9^.;\_1K M,IP?@!X/G\,7FQ;W61&/RAGXH6JQAEOO[3+BAE"$H624`J\\]!"1A2]+5-.L MAZI4ZD;'QH]P"KD@^!KUP.T'X*N7@J[$S=7Q2,4/!,,K*(B_,(55`POS?D^R':TKVQ.S%L22[2V!J$@-$6"8LHM(BSQ3Z3H4V+ MQ.HG_HZ<6LVQWM/J6J:V7\&RV]*ZIH/(.>E(6``$D8!!0$*$7^$)`];='Z`_ MYMK8_$CU5MM1T@I\.;$[#9_-_S,9;2F'>T7'$A030.*V<8T`)IYU=((5H MX_VZW7=0>JC;W6O550OH[Y&GI?=1M%4%N*&S2"E*-)/0*1\\96E0N6,Y1T19 MU/1:[@.<0_OD8WN(][)G$C_.\PEJ\.>G>R!0%\CWM-<[2))AX0-H M2UI?;.;9#M*15<%.(:$PE@H:AWXOLGV5$S8 M:)6LWTO$#?-&6>,@50$*[("`"V=5TZ;OESQ`UVQ/Y&MW``XK6F@GJJW9<<0A M@50@8%T(K+B1R"-9(84];KK]=H#WVNTYBF@!_3WR=%$]UD94NZ&SR+'@V0*& M!>7>:Z.M5E5%+F0$-MT<.<`:FC[YV![B?2_8YZ5?45VJ77-Y?B$32<`$L5PC MBGA8":Q!QBX<$L2/Z,JJ+@=_PV+\'KC[N8'H?AXC75S7I=.;,L&_M8I[C3'P MX1F=W5U2E6Q#SQNGW;Z[,+8+5K6%>N^LRL8W82#NYA=RG9?;,!=7H_1FJ_>V M0R^1)-H[0XQPSH9@WCJ#Q0(#0IO>U]AT1_=XF=?J./0>X9;W6%S;86LFM$2P\A^5[3.?V:@6:OL+J^XEFNUY`VX"]S]V& M'_0VX3QQSXZZO1=T;PW9#NB^& ME0B4KV@)OSYOBXR':WP!FQ:#459,\Z3&WL)[NXX,,H!Y2JB$1@>'VH85H$*+ MH<85`@W>R_M];C7T/`#]T'66\7$/]\EX."MM*#X^O5MHJ*>3W[+)_R:3\NK] MC;2LUT4$,!>`!2^7"^*LI\#3*A;CS,$CNL2Q/Z*L,+23L>B1B:]SCY7ZVPGX MEF1$F1.&8QF>8&UU`![@40`#P9?M[30>0&?K/[AJFL9@\18<1I!!$B(*!J"'T.WKF1 MC>]$AP=8[-F))]<-SCV=;LSNDB_Q0U)L\M8RT9-1"@;&RU""GK">TL@5! M?D2OO6]]=%?/'[X#V266]'MK_G.Z>;_7YC_!M]"LWMTJZR0B"((S(20W$&E! M-'4:$"(I\1[C,"!;JXZ[JI/XFHRG&^OYJR81%%IH3:2#@30.>*L`G%M`D"%- MB_\.\*%\]QBNU"\T@K"74"9X+!?7?\NRX>PU&TG^-1TDQ>=LM#&*>5,H"CXR M6XHTD52WNC?7X#2 M4++$QPSFP2&EJE2@('VAW38Q\%`3^Q99*Z:WI;S,LTY&N_%QKUS\-:U7@=!1:RD%)ZIN!HPQ%@( M7,W<$Y/[0'&$<4Y=\Z<7@(>@UB8%QU/^/O-]LKPYJ*KL;A`@,@AJI)'GVD(G ME53;10,8RWWP-<(\LUU3IQ-`AXGWC3.]NUK?+5,XU5&B[/H\$*R0=MX1R")-ML)K5J,^WX.D0KV0/%D(C80$6\@T]S M\E+EWI:/,/"L:XJT1W.0@,?%?/'K0!]/QSK/Z8ZU33<+$L0=,QZF7"&"$:"H MFJ\%](*2J7;-GJZQ'<;[&7&.&^-Q#?C%ET%(@31!4'%I)`=1(1.^F@N62/7N M:!D\^KH[\;YR?[:!=AB:I-NCM$H>9EZ-^"!?=C<)"@)EK;$FW5X:0S!PHIJ= M\3#W>!JA\Z5/QG0"[B#Z3,H;N!>)0ZK-P89!(`J@%`)`H2QPR@#W="X;D^OH M'>&%77\TZA3BDZH^.2I/5/X%M!;$:7)BA)+QK-\NEOAG[J5OS.UZ-J*+Z\6R>'8=^7LY7RS+]7VUP:KY]-=>'NI\_UZLOZ,",O4H`RHERKVB'F&I]ZZ5^?%*:="@B,?% MK(MY5EA0DYU5?HQ1IUTSK5^H!XD7>%$P MNDI)>2AX8$^3`)&@SA%I$<2<84V\JGPXU`-Y0<&!O^]6Q0S)[#!AZ M)I%U$1H.H#=(V2J(B2+ELI_XOH&(PF$@'_[L?>F!='_'<4>YEO/)\OY#!"_- M^,5D-P#4?A?2V2\%CI@17@KA2/HS[NY@>]H`(?H/$AB,O;VS[>!Y/+2DQN%4 MK.:TF4DK#^,O/06GE(8>`&;CGN,0I5YM':Q8V/X+]PZ\YYZ`18V]E&TD-!JV M/L>L+5^?]Q4\9M02(QT54856SE!`*SRLN*28FK-B;`L9C<6F?V9)[G%:;,V^ MKM2.O@<2I*)"",^M#:B'"'5LW2?1KT&+I7PB!'G MK(=,8LY5=<(RJV5N)M(1[NN72?<6PCR%5S##[?>$J``.0$&,H5991"':AO@S MXVCN0^$11B\/K8)T!/G)W,Q-G@BB/:ZAZ9^QD/VIOAT=_NM6/YQO1GUZH^[]6H]F4_C5([M-XWZ"1XKI)24 ME"IE*,;.;V,6&`;9=^[P#60PZ!/H$Q+NN3[W?!K-*;>OI^"YU-`B;6E4$:1% M"&V3#C'C:?8%TQO(A]`OU+TGY;-%:1=7=\]+;M=-NOT*!^67_R/EZLN_E78 MQ-*4Q>IKBK'9,>17WP3*;4J:([3UWD'-N2.B&K4CEY`L/%=,BVX@J[_1UA7R MQ^)F,GN(FE)_E[LBDW9\%0!0W@DI2%1'B%$I`I8_CMI(3G-SF(U(T"TDM>@* MM^ZE_3`4N[B=E/-#*_KQDZ`YLG&42`GC"%$*`U;QVQC%+D3.V5)ZN:KS8.M+ MS,^RY\:CK]A<51X4^JX&(2*!,57880\E%X`X[JJYI!H$YV_-=;/4.X.P+SK\ M6=QL4MW-UY\FMP?/\Q>?!FFU$"!5C?4>&:*-4+@:?\J^?!F[0!<"?,6'5DCV MQ003D5A.9A^B!OOWOXI=T?)[OPW(>VX\H]XZ"Z12FFE:S0`!=@'W'[UQH1V4 MW9/!I.(,\[4O5U>3V7^*R=+-IS9:?GOXL._SH`DTWAF'.)%.:D^AV)YV&JC< MPLLCNF?H@1(=H=G7%N'+6;$T<3PWB^7A#>*7+X-*-1P@1]():+@@WN(MIS65 M%U"$N[?MH0V0W=.@\GM\C?WOD?_S3P(24C,+*-9$0`8H`EY7X^5:Y9K^(W+, M]B#X%@CV)_'/5?W)`V?!SF]#BFHT2D-%M`#IL3\'6^V&.9CK*!V1G[1'#K2! MLC\R/)U//O[-/O-QS]DZUB9GL&@C-L\2>(R':@=DW M)1[H6I\4S[X/W"B!@&9&0P`I@@XS4LU$*9`;23ZB]*^]TR(?SNZ)H>*PIINA MS2:[[MU>?1-@'!Y@2%N(N21$"BRW1QW2V5IB\Y1AYT2`-A#VYDE8W-XNYE_6 MBZN_ZMS`UFL8&'2*0!]-8(XHL-IAL$7'(#9<*>ZSXD?GP/9_O;HS6+/I3>N9 M9X,"FCB#H'0I"3.U0!%!*$3L_%GCV1UZY]+KC#)#BN1$ M&XLMUI-R]M;V%YX2.%H+D)0&6AG5!*FI%5@[$`U+<-0&Z_-AQS;02$]FD_E5 M\>5[4:PW=9FF99K69/8L:EO?-Z+IOJB5@4<0D/!<88J-8_'?C`+G0(5__"=7 MU[V`W:HV,W>^^!B;Y(9[#M7GS/?$``T[@``A9B(5^N64$T4E91I5R"NL+K?` MZNFY//A:RQ#X0.D5Z\\AW>WO#:IJV6/`2:MS*?(D[9):>@?I=IM4V=78WN1B M:$:V-EIRM@"/D/MU7/'GQ7(=?VQ:7CV6RDUNA-^+%&F].\[X0(,X5A9M!:L@ M4%I:7I79J+'@"_#"7CXX%HQ!.,(@`K*"4::R0Y](!J!&TE M`X)([JNB$<4TO:L;;:4^N,YQ>!Y_%C^+^!=UU8U:G061MC6%%,)4Q0.266S\ M%A'E+\A4'27/#JD;?0AP"$IWFNX>"N0T,V4U9@!R"%%7#M/686=E28W@FI$H;3G M1/'32/5D*R)5@;J^+J[6>U+Y-.7_L?Z",IH`)*FG")MX/GF#DBGEG.%2&G?T MZG/\P<)GS_:.93@$M]5J5:Q7F_'6U9]J7+NUZ#500@US6D-B<*J?YB3EU?HG M`N7&LXPH-OJ<>#Z<)$=F,Z9RD//U[O<<;;H+@%#HI7-2>N,\1I"I+2K4H@MX M]C\H=_+MP%R1C(RHFWQMCP^D'A#OAK&O^PT>$:4A95)!QA#G2.+J+@`QF5W[ M8H0VY'^E,_%0[IXA>"08Q;$'4R M(205B!D,U!8[EET48X2&Y,AYW:&41L;PS8K]M)A?];11O^PZ>.Z4<(!;R5FT M,JR/QG.%EL,N-^YSA.;BR#G=A7A&:@EV:P$&YQQ0`D23&%BLM!"8ZRTFR.9F M2VAN^?5>ONT4E.U?(D.P]&,Y^5;.-MEGNG9:M.TZ$$RL,%(;::.`%%*6;M>T ML"0W]FA$+WK/R7,QL#C'J&\\@Z!#5>-9K\%QI*2#@F%@@.!*$2ZV.AET%Q1[ M.AR=6JH:^>(9&875U=4R_G_G)'[=;\"$>0NM8CCECL"`R"B0!YRX@#IWYQZA M8^,<:-Q:0&-61'I00%*,+L6<6)[23R/IXK\KE9`S2'.O!D=8]_AD]!U(-B=Z M[/=ILDS_];-XFZ_^-(AVE-6*,(R%`4@3_"@CR(D41T-:SS6T>"RO_A0!,JKV M.-J4@!$I@4&VPE_R;%_5"+7(WIAYHE=_S21W&0'YXWCUARAVG@'L-#*.($HA M)A7R%-@+LKQ&Q^73O/IK)O"W]>H/&"X0))`;[;TRR`C-*FPL<.^Q^+V1K:-7 M?\T$>-I7?T)&6T$RQX!C1DM/O=/56+6DN<6*1TBVWJ59[]5?,\`O0\GX.+)7 M?X)3)YSWU!*.#5+"0E_)`$B>6[AXA!ZR=W4C5^J-M^4&?A03QU5.]_O06O06 M`+$:*H8@Y)A)*;VVM)JE4/A=>^B7.XNA)3C$"?%YN;@JBNGCLY>?Q6I=KB.< M3R^_#MYFU&@=+)3*:Y!*6B+@J1`N;N5 M[8"L?UB5J\^3,W_4;@6J!*(1X<_GN!!"TROX4C?OXS_MC MO-&SO0.Y#L[TCVEU%M.[JPUPUXME*@-V.R^ORZL'[7\V*7>Z1@;[[>"9)X(H M!X&Q@'(/K`05@HADGP-O/-CS!"NC%WD/LV*NBO)G\B7%_TKTZ?)(>-EUP%`Z MQ[&5BFH,A;6<;W<,C7SN?>.(JM-<,M];BC.#SEL3>+$U@>.RBYA.S6*U\^E3 MG68!"(2A)DQKH"0%+.IIVV4(D,Y-:S2B:CAG0\-N1=4-Q?Z]6/X5YVLF/\KU M9-:`9+\V#()I(QGQGJ3X0*M#/8OEM\8:Y?EK!#G1IODQJMRT>_OSP\%ZE MT3./VGT$H)'V$&-HXA^>>DQ5A;\@1&?'E+[?ZF71NB_!#4'SDO;^]N/T_N$[XK>S"_<:WV@1M(D$&(.,FT5Q&"ZJDM%'$19L<4O]_]P& MK7$&22^T)%`Y"J2%F"27M;'<'L^2W`\>7ZZ^%].[1*%&#,Y8(W6J;)Y@-$$D M?P66`CK.D2,2<$5Q"K6G3%N)CB60`CIJ`':>>D@P!AK M&"U$S>#13)1#SK;.!G2D9:"`$(^U9UY)&GE%I335?(7'N1D*1[A9="7X7=FO M.@/XE.OXE$_T^UK.ED!!K*6>8J8E=<1008S%&C`>;>_FR_GU=='3CR]>(KKO M&7R-5H$1QR)+M$780Y^:L.[^%65N$B[[`'23KRZ_#_&4TY?T-D]-K)UE/"DF0!/G?!$H8B/M)Y2:9W`4M)JK%K: MW.RH(R1;[]*LF_"D">"-R7'@8-C>$#9VASS=+1I/J!`*0.(QUD1Q*M7CZ`6# M]@*JJ?1QN/:#[A"GXF['4&-G8(!,**@I(`PBS[G&<+L%"^CL!9QIG)U)?](GN<#Z\B(*Z6W]?+,OU?2V? MV\L&@2CH*3),$N2P)YX9[:N9*0YRZS"/D#>=R7C?=M\&V--0YJCC:E^3X`@" MSD/,K)%(R&BNXBU8#J,+T.*[$N]1MF0A.@Q?(KKSR>S/XF'1@?_ORR MU\-4LV6(JHZ.Y@JS*8K.ZFCK>%7-U>/\YXCGP)ZFXG[%GRZA'8)&&Z>NFD\_ M1C'._O=N6:ZFY28+QU$:'6D9#*76:6<@(=S$%8B,YX]SY5*IB\N-V"&-NH5V M"!KM/[X/>3,;M`[24H=,!)1Y)!T"B&I9S9D3F1OD-4(Z]:4*=8_RH'J1^_M' M,5\5NI@7UV4MP_/7%H$#ZH!VR9(WD',H,`'5W"#W%Q3LWZFD]ZE(K=`=Y*;X M42AI8WZHN[L7EB]WW_ZON%I_7<1)E4=KQ+7K.&"GN1?6,*6(<)!$DWB+%,[G MX5GM9.UY.*@0!O#T_4S7$=;SQ^]O%ISPPC$B&&:*1CYIB6`U4ZWT1:6N[T#>K\Z3SJ#] M?_:N;,MM',G^$O;E$6NWY[C*/K:[YA%'3M%IG9'%:DGIJNRO'T`2E8NUD.`B MFNZGLLL$A;AQ$0@$$1%#KM+;QN.[7JPIGT=QQXS'T$&ON-3T@#-C%E^-3_C%;UF++\^<#)()81(W@3$FLJ'+457)QRB;DG?5*EA:8 M]F[&WR[^_;"8+[:/3:WWC]>XCJ^Z8(!//18T9E(QI;4"6D.>DJSE'A+G$?)7 MG88F<[ODX9Q\+ACDC):8$1IW=`:8L]7B=E[9*5PQ:*>4LCOPAF-[ILO2(>D] MT2J>NPSS&@BCG+1:42L0X\``!F]4!N-E83^SOV0:SY%/MTRO!ILN#0Z`0*$1 MD2(>.'$TI4XQN9<:1LLZA5Z%[91],L#4(:+#U`;;?%6K>?J/BT!\GRU3:2BU MW<4AXN3_F"VOU`:K,3[8*#%,[6`8\X1@I*S&![FQ<]F%ET?DFW3*I#Y`'5>) M9(L)EDQRJ)@WP&+((:WFKIW))<2XKGFW)T0O:`Z2@ARG^>Z+B6I8;/WL+I7G M?-QW3'CWL-UL9ZOYZ;9+C<8'YJ2.DAL&-#+*"\V0.\K-3&ZA[<;EW?HL/]RI M8>D#UEO1Z4.1/E7'^>IRO2[_VB^'^&]/IZ.:O#K_HN`1C@L+&D!29K?V4!!8 M(6&AR$U>&E$'H][IU1FZ0_#L]V*;-MWWZ_+[(IXM].._-L7\S>KXA4;=;1?? M=Y6&&WK;[5X#HCT$+ZN2K9]* M=1=!6A=1M#C?[>/[Y6R54EF3F_AG>N0"!^N_)#`83_S:F^A;(DD$H\(>=P`J ML\,H]?OUR#W?5L5]:@DR?L;UANVM=M>G+\[OB_6B/-4=JLGP8)GRF!-$J$9. M>LZ$KJ0FT+-<1HVH]4[O.VE+3!L?`$_-X6TY6_TV^SN5D;;%E_C`7,^B;7VW MI<;*W52X,AC`%G,1/>8JJU!$Q5,BL%<[]9CZBW3E<'QV&1 MOI6=.DC3]@QP[C4!IV+7BBAGH/:,62".9R&"378^>O,6-R,GW`#@-C9@K\ZY MJ=I'*O:AOL\6RWW+D%,TJ3H> MSJR]K*QG#,L3QO!#U-7Z^X4MK?V[`Y1IT]:<$6^(LPQR;H^[N8/9J993"Y+? M"O'&G'.S=8I[;#X?FFM%7(O-]I`4'55RM]CI:K::JV_E>KOXS^ZOG_XJEM^+ MW^*Y].N'8G>4.'.LZ_@7@F9$:H1(2C-#T%`+7/5MBM!X#L[E7_V8_,M#WZ?1 MT_"&\$^CGM^U[/2!9A"`/J(^,3U\Z1Z;7H98 M$Q]FJ_MK)9J/SP2$'$0>"M;W<86,$G4"RPEC)UE$=[F8* M;!Q`[+0.MR:`6YI\9NR,!L@H<\3&(Y3=GGE\9.M=F_7J<#<#?!I.QML:-7.& M[%3,M+1*"R5YC=,``6&B`I=QY#W9]N$DELU4N-Z%BA.9]E$QZ?1VP:?XNLW7\OEJ3R"SG\C2``\XP9`HHUB!##)Z1$1 M+W++B(\H;6_R;.]`KX,S_6U:G<7\85?Q>/.E7+]9S8MOJ\67Q=W>KUK.%N>: MHPWSVR'BA24"AA+KHG&@!M/*F1,F/[%K1(F$O\C*Z$7?PZR8IVNX=XD^76X) MKU\=F!?:`*ZM4EQ'']!"4<5T14K"R^1[_43&__+]=NIL?F-[LUU\BP"67WZ\ M-+[Y1[%*$RSF[XOUW?DKV4U>$313#ELJC#;(RKA*/:VR'H2$V1TK1I05^9/0 MLT^U]43#-OP+PD-%L$>(2RRLI]:FU@R2$1-WB_C73.*-*(UR4L1KJ*\A/FE\ M+);QG??[*2YW4'Y+=5:W"97OQ:'(_H6O&O5>$!C3G&)`A&040P&I-!6FPA$_ MA03,GX&JO6IM@%*2V\7]B\\;@]:]WA7VWVGCOEC=/;Y917_]VYZ1G\N'[=/L M?IMM$\UJ%,7.?640TB$C%4(:)43'L)&"%*0.0P`TA0CKA5RD:C>/731$_;[XFJ'=>2<\^.":G9 MB850,@SC485K[%*9VKV,@L@);;-ME5RC>$H.I(-@U1.&O!6:9A?'X81T"$BCBCK/SV7>% M1[2V6VKEG&ZS\&NIW4N&_-23`4I%I5,`,$I2YV^@P7%VCK'L^E(CUFY3O9S3 M;Q:"C?7[:?&MV%>6/6^=7SX3)(MN":3:&>Z4\O< M"L46>KUDD5\_%2R/W#0N2@4MH$02)X^'6`2S6[2,:[WF:N*4+K-P:YX4'']J M_:G<&XC5:O$]PC-;/UY,"[XT)&C+$&(.I[N5(-(X.GNHFB_4?!IV.5]+92\P MYJH].N_E:MY,[V?&!.`T()I+0"&P.AXE(*_.$*[P;'7,U_ M^KI8-U3\Z2'!1OF%IIY3)+'D&"IHJOD"CG*#*2/:M+O5>R*SIXYLD`093/`^Z2JTF(AM[#X^RPRCTSCS#AIU//K`,L6VOZDI=V^MG@ M%;$P>BR&:L&YY93ZBMQ.^>PE/:X]O)UNSNLX"\-AJ@9$(Y9F>+4TW*LG`V7" ML=2YS6AKI+>(`5_)H@7(O5<\;CXTU>,/.?MM,&R\ZM\N/I=K">SL\:*&SSP9 M!(Z3(,Y!Z!TR$-MX9JEFQVQV:=EQ.6\=:;@;#(=8\:?VLK`88!^*XZ*02Y.>/D0QOW#H" MN[&%Z[4-6(0'`PSBRH"4,$:(T+2:N_`X]YOU3Q)G:66INH?W5M:H^\[V\7AC M36H1*R72*CJMW!S#&A:[W&M.C5WV/CO;#V^!VN)\*WX-T>K>ZKBZ&`'0.:Q! M/&%3B"LDC$6YG_)'6!ED.+YU!G>65S_R?H0(2UETON7U@7#+2(*;K9>/GXKUM\5JIY+31J/.L,`HL4(!:C47 M6$.I+*F.(1X1FNL+C:F9^$!AA/;H-L]WJJYIGR7`\R<"DD@9SSP#CBJL-%2^ MBG9Y($EN<=(Q]?GN3=G8C^]V+S,>ID-G^W^F.V7NQ\[[B=P=J^Q?E7 MA&C9'$34$.A1*LNNG:M,G8^^?#:-?ID0=4](#\^SYS9H,TFVLV/7R-(+W]Z MH))`\:B18OO'2=0H"G1N2'`LGDV$$5AJ9A0V)#58H]C(]`F\1EF#822L4[7K M[)@`L#"`8TU@W-B$PW(MNKN>P'U$$7Y2W+=76Y-BF4 MTB..)916$`Y6^^_(#EZ[4^>KVAP*&BF%`"`$,:R8\L)8=T$3` MRPFDFW9'J->U=V^IB2%Z3:MUR/4MAO8=_/A3I&]?=-DJS MNC=QGO?%;>(_IR92(P9T:5B@PE/,(4,8:\4H2#=)%!(,62&I5%<]E`$D5:OY MX9./NHO$VE&J6=.%G-<%KCCUZ2*[8E(KBIU*7Y/VR#B))Q33Z88@Y>"8WV3E MWS(`W(L!L,I11C7&!A%#N?3>$>.B\070$73U&D3?@>`S/-I]O:L?Y;WZEA`I MCAD44"G@@9`1%.$K'"C3O\QRKTN'LV'PI%]"4F92B'.#PDE5^*L5T8& M;*,+`RU3S@NJXI^-D)6L7.#L&VWCHU4O#+BTJ;1&>PAF?8J_]`J1JU',LV," M0S+"1BT!"C`/N(VP5?*9N$U/ATV=:;KL!]LAN/-N^[58OYCJU1#DN2'!]@'KCC:Q.E+'.\."$H]0Y2Y$SP.)HP-5Q MZ3F075MYU!'$FVQIN9`/3[2709&:1Y!`E<`&,V$]YEIBQ#`PE52:D\%:8PQ1 M#Z);-5_D4!:Z@W/F(+QY6"?XZE+GY:B`"1>,(,6B4;?1%D.$024C\&9"'S.& MXT\KB&]%H]_+U5T6DYX&!A!=`^X1),)(H*10ZZ^-L+W.P++J"CE`%N91< M$>NDW-]>3A>:^82NQPU%K-=9'(,JZ$8F2/TU6U=?2QYOVB1ZI&:)SU?V^];=^_(&E.ZW7_ZS1\C>"())B M:;V@1AJE-<$851@R*W+]Y^F9JMID._M99%A5#7+[9S>Y^'/7KJ(_?RY83JC7 MBKKH]VECM<%$57)`CB=T&^<&NG]]':<%\H-D#JM;8[)S<\?$YDTVO+>+ME3`$M=VW/Y?E8U$TN3]^ M=DR4CT*,J%+,2FN]E)*P2CXM)V4T;TJ/UQFJ'2FD&!>>,`01*2B#%B#D"I*SF;1G.+:`SPGCIN+C4G4X:,>46245]%UL*":IW8RUPZ-L/;26+C3E2Z&<)XJ::\<+)\_%H16V%&CN(1* M80X`9TH2TPQX;42V$N-3H MA(YR>0H\PX(L]!IO/7:Q+NXBWCOSE7[ZTL9SYN&`@!;$"([BE#0SG&IFJSDJ MP284[\Q53MDQAGF%9XOY;/=%>E=',#Y!KBG\VJA4YTL2J827W!`AJ36J"E%^M%.=\)LGD6G]JXOXOUW2)*=HG0C5\6 MF.6:(P>0II1H@`PTI$*$T.MYHJUW3KDG\*JX3P;IT^W/;1VRZ%3)BS[5,PJ+ M?';UOQ)N\V:UE_]_B\7]UY1"^KU8S^Z+ZM_?KQ=W%[^6#SJ1X)'RWE`1#]/$ M,L>@AK#2A$NTL1!F'U1_`OO`<+#!(!D%V!O-$.+82"Z.1LI+L M3?;7+UMR=V1;EM14-YNMZ"F.I&Z2]5615<4Z4KTM)>HS^;E\:+BR'0^?CB_P MTTD+]#?3Y>\WLX>#72CZ&C)@"PF"DDKCE$0\ZJU$U]1%`J9VF1RC,[OG+7]X M]++&#DR6C_'XV4_T=XOYXV9)FT6N/B[6-[/=[ZN(MG>+]9^3]8?)[>++?/J_ M)]?_$SU.B4/H<_S`I`9""!3W(V*0($RZ9D_"DOE$J2FP%<*`4E,BE*,6H:?M M8[%\^JCZW:%#)^]$`F```>XI(57?"PD!HPT2QC.3*%0%-HBX1*'J`M,LD;^S M#>=,[O8OW7VK_CQDDY_V@J"D!Q9+))E#BEJ&D6ZN&BA,+IY28#?E`;FY%RQ: MV\`?)M'P7MW,%I]_6TX>IXN'U>Q[)041L30""#S#GN)7).*L1( M$W_EJ%"I>9\%=DL>QI;M'9)1*Q1#Z`Y!:.X-4II)0Y&&M"KR5]-7$I5Z&UI@ M0^=+5!-:PM=%E-^A?+XC3P0`G3?&,":PXL5P<$MA76>@&.(7T#B1F?\U]4M?K\0%2T@$8CM&E_1(-J4GR?3](LF5@LPB54P]@:O7"@JY&BQ.&/H`I6@2.2O_1R]+<4PB4$9DLON+)N1Q`-S;IQG"S[[F:@0`T6 M"&BHG(*&6PX8=35MC)#95-`K^W8&TL`,[!9>M_KZ];!9O_N+(&6D@W)0(@AWV.]?&%U$'X;Q.^'I6A.JWA^7M?5QJE8S[Q@:5^KI`)!8^ZL30248- M-!I2W_"X(!=0_B`9V45V\K;/F__R9;G)C=SLIS;^T<2XM^2@E#<%[6S5*$!5 M6>4&,.0=:XYW%VVNB[C;.9=Y,E"V-=]L#MZ3`SW>^G4P&&&C&$/&8LJ!@!#5 MX8&>*W:T&O-;FT=!###LD=01Y3M2K#].EG^_CPKC'_?3V_NM!O?'=#9[?WO; MSNP[])Z`H#2<8B`\E!X07+56JE?&L$O-$"GK0#H?UV.*;X[$2CVL[Q?+(Q&6G8\5)5L[*HW!$$"@,:)2-EY&BO"E.(([X]I2D!@39S_> M3&=5A91H0F_$.0.#OQPR>.&-$LP:S5D\R;SWH`D9P=9F*VCSL_+YF8#D\Z^] MF'?UT>1.S>Q@%?4>+T;"'O/[]< M='[A.3*A0`62GGO@F0!5JH^*7+.E-0/*HVP.\*NH=`[6<\$H/[NXJ",_6R1[ MSKYFC:-K[[>5QVMU[7;VN@$5M)`QHZWF*FIVR%K'GR)0A3/B>%FQGBR:474[ MD]`"31SCFFEJB4=&DH:&/#E(JR!_4FYFZZW;63NHLM0\2.IVAI4$O&KN`;RV MG,AHG\EZ'4[[U,B4`EEN`.P/=CMK1_DBW#\CZ'8F,;/("2"JRE@2`HZPJ*D* M$;F@WK:)W)2CVUD[$%K;IG9RNRGS'3\'.V6>CG9[.?YM46H854&N\-*8J%M$ M[X[6C7OO#*"Y3'&V2]OQ'`=KX#NVE M-I`Q[J%!'M=SXLI>D#,G%8Q%1[1+P1/"$_#<_5'@B``6>10RZQ#%"L0SJYZ3 M)#K5B"EPD^\$SS-HUQ[/O_>TU#L.\)&G@J>0Q9D"ZQ7FW%`*&/@Q:Y&J+A9H MMG:`>+?$S')C4$VSTDI^/:5+X:L?!R6BX5QU*U+$NT@53$6MNWHJ16K!M0+9 M8WBM[VSR%W$%571L/8@6&"6($46M0IP`Y>I+&&^,2DY[+2GFN`MVZCVTOAT0 M8V+L$D+K@3/::^&%T$(Y;`VTM<7AJRITEY!"4C";GXE':]70+.:;J)N'F]FO MT\_5";;36D?-[S;>J:U+ZM]1@5D>")S;KT5V.$#`""I-$6<0:^>IAA@U.I(& M4EV01G$^9PY*^Z)WW;WQJ[\L%ZM>JA._/5J`!G@AM8U&'[!2&L*4:,QXI"^@ M[&5).VUG0.0QO@YT8:Y,R.7T]EDIT7>3]?O/)Q;:/O?=P0(,-4,6*8F$580! MW?@KM&:IQ3I*O"CJD'$SDWU`-MT4E>B'2T]^=4!"8:ZM`XI6J2$8$M/@1)!. M=4\5E"^2CTG[HGK[@B&;3?Q%-:\C54,./1(P04@@A(FW6&!J-0!R9[ZIF9(E M=GGK1*?LDIH#U]G+6%S:2&:\@$Q*)#FC<2,WM5_/6V8OI;AT1\S19PWI=D@, MS*$9:T@S#J``1#!G-'9"5`IQHP)+DZT]RL_-H>V1&)I#\Y:*5I83:ZSA%"F@ M@".(/VG`DD;!3@T:**[P1^%4@=BG!F665OBY="9M#\5` MI1.VA/RPF,VBN5^MYUHHX77NNI.($`E(U<$ILI:21G`B:;2NG?=Q!SHF5&7> ME+Q_6*_6-_.[R+T[^/=X6;)_P`"H<$I`X"F$`&N*+&FHJ[&^H'SV7&S8\=U* M)[B-X>YP9Z';"_P\PK`=*P@!%:/2,*R,UM%4M-K6]&2>I-KJK>7@Z_8"8WVS M7)=9\[@CMNQ/2I(`'8.`#'^Y'I4GHIT`0#@),.+**-WL@?'+RXE'OS#Q.!_, MP2_H=^-LW+>H\$]7AZ-56[\L<`9)U011(N0)T\XZ@6J*8")2BUF<[@F36_:> M;UH*W'W\Z;B\;\C&L,N[;U^GR\TSJSY[6K\]6D#40H6IL=@H3+BV3-.&I@+V MWWSM9Q>#P3$=@YSL!$ADD),]HP4+M3`*$>P%(4!0Y0UL\&4T54Y.]_9=Y61@ M3,<@)\.:U89#JZ/!!7WX M^KG.%;+!0!Z%H-4+'%S66DTD;/IX1?X@OM*UI5:,NQH)8Y)K-^5K&4[F6DTE,`:H1`9SS)Q#M/K'-KJ\2?9V0W`5N_[%KD^H1R%X>YPW M0PE>RZE$#1]3R@!4GMO(*D!AR<HKZ?W):]P)B;2Q.\?J$N0O`NQE^B!2$" M`ZTT4IP:+I1H-CVJ07)D6^MHA:OOL1B4LTG8I^,K_]1ZY1\F5:F\^/E.$9*J M%S@Z)FUY9Q-X5:B9$L&(Y!Y#I`!L,!'"I.;_%A@F-&1,:=&@CNPH^U=<['2^ MFMYNDO+S'%[/QPR&,$T!95$UAU$_5Q924],7Z.1JS`468AI_(/99T(U!-)[. MV*IJ6N^7QJ_&"@1X9KV66$KD*?7".E;3,Y[S%]1X8Z2B<"YD(Q.!@0R=$V<0 M%)7$6,2XI9Q1XTQ$HJ8]DS9;UN%57+(".09;YNV5OZ5HPAYMF839!(@!1DAH M`SWDWFEI'6AN"7%RGY4"*UZ-U);I']21"=ISY323/+T8-&`FO02.:09+N^:0;_;_9T!+I0V M&'B`,`$",X2QXEQ!CX48,H,^A8/]S72Y8=4=O-VWKY/;;1!\/RK$T4&#D,Y: MC(@T$F%)+=7`5%1VB'/!:*K56N"M7BYV[&K+ZQJ[HLW70XO]?1$!FLZFZ^\? M(E!]F*ZGCQZTLPA'[(T&TB/O-3+4%10G,&A*,3F0_3U5]^ M.:FLBDEDMG5.D=DW=D!8<\BQ4I!ZK1"Q'*J*W@9HC*'(5CGP*C*9("Q:9$[) M4]A\:>/"&P+U>,O0S:M'*]>G5W^\LHBPB@QDGF#$,48*4SBYDB\QUX=[<71T\9XI&_GLW99 MM^NH&*V_;\#]&.'4<4Y_'=KKSGYY0-(RB(&A!G-/@"'(D9IJ#.,+:I&=B[U> M;E^Y,[HLS@\?:!@&(=5'"S3UC(I`:$&-"#*9'/Q\GPL M77)[-KR.G<7__$?UXVK!\3__!U!+`P04````"``),')#Q4DI%%D-```2C``` M#P`<`&AH+3(P,3,P.3,P+GAS9%54"0`#0?.)4D'SB5)U>`L``00E#@``!#D! M``#M75MSXC@6?M^J_0]>GF8>"!#2,Y-49Z:2D/2RE6ZHD)Z>?9H2ML"J%A(M MR4G87[]'\A4POD$:I^$E9>1S/IV;CHYDV7G_Q\N,6D]82,+99:-STFY8F-G< M(6QZV?@\:EZ-;OK]QA^___,?[__5;/YU_7!O];CMS3!3UHW`2&''>B;*M;[@ M\1VAP":;S8#:\J]>I',A;1?/D(64$F3L*7S'Q:R')\BCZK+AL6\>HF1"L`.] M4ZS!EP@2MQ424ZP^H1F6R(+Y]IF4$3."KB24KUKN7?3)*2#!T(DPHQ.]+A94WGYZZA[IR? MG[?,W8A4.FF$`-MI_?7Q?F1%"6$R/DVXD8YRTD;.UN\)RM MFOAE3A%#BHO%'?PN)AH58@GE-@;1,IYK&3N_;".C@69XJI-X<9F27+L5I(1A M0H[M!4A/S$7D2')^\AEW*4XU4;:0(WT:*3B*0@;=\[N2?4ILGTSY4\OF'E-B M43BWI?&%/RHEM6543P@HA0SL:2EQDHS1KV8,4U$@!Y/2I@EY],7V)L$OMEM: MA(C)7&TO!&%/6*K28B38@NOM16&(V&8J[I21).;R+YLQ0$4Y)+%+2Q'RZ(L= M2*#FHKP((9.YRA(",<:503)M8>M\3MB$!TW0J.?PBW`B?\`3R]2K%\$LFEW5 MMN9"KP84@>(J4=@;`%?@"7#[P:L7"'_;B)Y`%1P2K,$O%QAFM@(6VZ-&B?M8 MQ!!!9^_+A@1K4QRJ_IUUK8^K#(=9OT4(!_@Z&(2,HNC=R&N$=4;2",78_69(<\AT#A$L.Q2+E8$1"[I MQW+064Z%$=AY9T;A"*QM=K:-3^,>K*`+R_1A_>2%O?P,N7.IHZ./`T?(R!.[ M<&L"+<^3[1*>E$E7'K+G(G-!K7&#I'M'^?/V'LQ!S?'D68XG8W1=T&A\RW1P M].FZ]0?@*2/=;IV:!IOCU6XIK\8='+)7>YB$SW/+>"W)EN65=I0UHZ?&<'G; MCWX>G+VAMC,5G`<(4026,GTZ0LY:(&TQG41*#(>C2[05*BP`LH%R:O_.6;M; MT$&'6_6G6_@3$OKJ">_,9VN(^J\"/OHQF6C/Z(Q+;H=:ZDA-5-&3=EP61/6S!OK4];,9PN MXS1@DVI$RX<\.BFR;H5\6``M.Q=VNBF;6#DN.]Q,V&=@>?R(7LHEOB1;3N%W MGC:"#+ME^`_8XE6&QSIW3FEPGC8<$O8_Y-A_`@6X*/E`),F6$_MGJ;$?L1^P MP2N%_AIW3NB?I89^A'*XD7]/OGG$(6I1QOXQ4\YS\[3'?A'SP9JZ0L2O\6;' M>SOM\5V$<IHR:@Q2TT!92:RC3S3TU3,2SI6MR%.UA6()U.QA M=0JKR'=%?6>9#JRPA^-`6S;_[6Q.^0+C]+M#BBH]X]^ZK_P`6'N2O#$`PFXW M4YBNCY&Q[(_!7/]]X)3><:''T,[B8"-ROM?/"GO=[\32O32#;HX>7O;#2''[ MJV^G/Q'U_'0LI3.^RST=^FK]#K46]6HKNCTS5T^?,CF3C9 MYT=.3U/.CVQTX0$<('G?6GTE-VA9?G77O+@;?./'0F-8,"!;739@W8`;QK>N M^_?5:;O]FYZY/N+9&(N&>?GXLK'>3"C5=@W9I0=X1'FZLP^">_/+AOG\S051 M>-:P_)<=_8_T7#A\A@CKPPVM0\/R"2%&"'<>#:'CB:!@;Y61O--)E7REN9:2 M=_7N'TK945S7)I]T?QJ&&DU!)OV5D@\",=6#BSM$A,Z?."K7=&8=>L)V8(5;CK8 M@1#4NP[Z>/^&H9=/]S9T.RNHVUE-=$OJ8C[HAO&2W'';[D?-V'\1"R3$8Z)V MY18]K_>9PC`KJP>P]M4+D:%*&^X54\U1%PZ!GO4W^/IK2H(LA$UW'6.K`O>, MMS>I$]W=>SSIUU^U.AZB]V2"!Y-$SM*OW9H\YB>OSS`X1,:*/%1VMY#5HSE4 M?VL3">P0=8=L0O7,[,`/SA"]>H(%(AJ;QDCU0J2O.$!M(T#9V2Y5T5LDZ.(1 MBQEAQD2)A%.$L%)D0UB#S#;(M*W3>GBL^DSOG^O6&UC;8Z$0!=D^SSD+OH09 MZE.4^*UDUAZVS80%TU=[M099GO(*4=9N0N]AC_AADN5&)GYA+6K.+.4_,+%5WWP!,;T"7^$0'8?\#(3!2MWO+RZS".JW?+^C@BIHDWMY+9PZIWZ;@HOB[N\);SA7LV=L1I9 MJ??VOFF1\=+]%7,^0`_Z%/J`A17H8')'7N(O,?C*;0M2OXIF@X=C1?FJHO=0 MK&DI4HR225NW_;<,LD4U"Z;L+;:9>_6YU+55:_30GIMIJJ=7O=DS,5Y MNX<6^G'NLC8;[NU]5M0)>C!9?G:GCQU]1"]DYNG_#@<$CGD0.V#KY7"LWK8P MKUA$%UB6:OEY,?EYBOP/6&+QM&2-G:#5;O]O8^0'+^"OKG[3;NQ["1S)](A? MU#6%[+(F;?+.%D-4A3"[SC2Y\]V;FN=2A)6K@91#L^^8`O%L)%TNADBHX$=B MC]/LW/:9^3=5SM@#"J6W^A/*5>-^,\N)X!2_UHA-]3^M=#R*5WV<1U2W!41\ MG#,]9C/N[SM>A\CLK>I'=ZE;\3A:W!6B?#-Q..1"@5H.L43U&_;?`CLXI'[&T>,$?V?DB$D5MR20U2[ M62T0>(1MSIP\M393U56O1Y>(7+4V$NU]&#U@(Q+E^E\S/1'N2;H(CXEL>J?< M5ZT2YYM)D",\5^'AOV[V`KT8Z=X]O>&]<2$0I$5->+V(28+9SJCPR=,J#";F MKC1-6`>SARA=//)/\1O)UQSN#2;AB3UI)OY'%S%-\X)M3W^)^L9%)+9=S83: MHAXQ@FRY_'Y-"1?A+=J_^``O[\TZ[.AZ79KDVY"?4TKO6HJ M"=8TP2-C-,7_Q4C&UL550%``-!\XE2=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`"3!R0Y(MU*6L#@``$\D``!,`&````````0```*2!):L``&AH+3(P M,3,P.3,P7V-A;"YX;6Q55`4``T'SB5)U>`L``00E#@``!#D!``!02P$"'@,4 M````"``),')#R&O8:`$J```I#0(`$P`8```````!````I($>N@``:&@M,C`Q M,S`Y,S!?9&5F+GAM;%54!0`#0?.)4G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(``DP&UL550%``-!\XE2=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`"3!R0XFHC,UQ3```P.$#`!,`&````````0```*2!*64!`&AH+3(P,3,P M.3,P7W!R92YX;6Q55`4``T'SB5)U>`L``00E#@``!#D!``!02P$"'@,4```` M"``),')#Q4DI%%D-```2C```#P`8```````!````I('GL0$`:&@M,C`Q,S`Y M,S`N>'-D550%``-!\XE2=7@+``$$)0X```0Y`0``4$L%!@`````&``8`#@(` '`(F_`0`````` ` end XML 52 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Stock Option Activity
The following table summarizes stock option activity for the nine month period ended September 30, 2013:
 
 
Number of Shares
 
Weighted Average Exercise Price Per Share
 
Weighted Average remaining Contractual Life (years)
 
Aggregate Intrinsic Value (in thousands)
Outstanding balance at December 31, 2012
 
6,429,250

 
$
1.28

 
 
 
 
Granted
 
2,325,000

 
0.47

 
 
 
 
Exercised
 
(60,550
)
 
0.24

 
 
 
 
Expired
 
(1,016,950
)
 
2.67

 
 
 
 
Forfeited
 
(1,371,650
)
 
0.63

 
 
 
 
Outstanding balance at September 30, 2013
 
6,305,100

 
0.91

 
7.7
 
$4
Options exercisable at September 30, 2013
 
3,526,850

 
$
1.20

 
6.3
 
$4
Schedule of Valuation Assumptions
The fair value of the stock options granted during the three and nine month periods ended September 30, 2013 and 2012 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Expected life (years)
5.4
 
5.5
 
5.4
 
5.5
Expected volatility
89.6%
 
92.4%
 
89.6
%
 
 
92.4%
Expected dividend yield
—%
 
—%
 
—%
 
—%
Risk-free interest rate
1.5%
 
0.7%
 
1.5%
 
0.7%
Weighted average fair value of options granted during the period
$0.34
 
$0.47
 
$0.34
 
$0.47
XML 53 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies

The Company has employment retention or change in control agreements with certain executive officers that provide, in defined circumstances, for the payment of severance payments of 12 months base compensation, among other things.

On September 30, 2013, the Company completed the sale of certain assets comprising its Portamedic service line to Piston. The Asset Purchase Agreement also provides, among other things, that (1) if Piston incurs any losses relating to any governmental inquiry received by Piston or the Company within 18 months of the closing date, the Company will pay up to $100,000 for one half of such losses, (2) if Piston elects to pursue, prosecute, defend, settle, compromise, appeal or take other actions with respect to certain matters relating to matters disclosed by the Company to Piston pre-closing (“Pre-Closing Matters”), the Company will cooperate with Piston (including joining in any legal proceeding related to such matters) and pay up to $100,000 for one half of all losses in connection with such matters, and (3) Piston or its designees will make required payments for rents, charges, maintenance fees and all utility services to the Company associated with Piston’s or such designee’s occupancy of each premises that is the subject of a Company lease to be assumed by Piston or its designees, but the assignment of which was not completed by closing, until such time as the lease is duly assigned (or otherwise superseded by an agreement between Piston and the applicable landlord). The Company has agreed to bear all liability relating to the occupancy arrangements until they are transferred to Piston. With respect to Pre-Closing Matters, the Company also agreed that in the event Piston elects to pursue a claim relating to a Pre-Closing Matter and desires to add the Company as a plaintiff, Piston and the Company will cooperate to select counsel and to jointly prosecute such claim, but Piston will control such claim.

On July 11, 2003, the Company received a determination from the Internal Revenue Service that one individual the Company contracted with as an independent contractor should have been classified as an employee in 2002. This ruling also applied to any other individuals engaged by the Company under similar circumstances. The ruling stated that the Company may not be subject to adverse consequences as the Company may be entitled to relief under applicable tax laws (Section 530 of the Revenue Act of 1978). Management believes that the Company qualifies for relief under Section 530. To date, the Company has not received any further communication from the Internal Revenue Service.

In the past, some state agencies have claimed that the Company improperly classified its health professionals as independent contractors for purposes of state unemployment and/or worker's compensation tax laws and that the Company was therefore liable for taxes in arrears, or for penalties for failure to comply with their interpretation of the laws.  There are no assurances that the Company will not be subject to similar claims in other states in the future.
XML 54 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Loss Per Share (Details) (Stock Options [Member])
 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Stock Options [Member]
        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of EPS (in shares) 6,280,000 5,565,000 6,180,000 5,543,000
XML 55 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Discontinued Operations (Tables)
 9 Months Ended
Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operations
The following summarizes the operating results of Portamedic and the gain on sale of Portamedic which are reported in discontinued operations in the accompanying consolidated statements of operations:

 
Three Months Ended
Nine Months Ended
 
September 30
September 30
(in thousands)
2013
2012
2013
2012
Revenues
$
19,173

$
21,371

$
62,437

$
72,077

Loss from operations before income taxes
$
(1,958
)
$
(997
)
$
(4,709
)
$
(5,446
)
Gain on sale of Portamedic and subsidiary
$
3,543

$
—

$
3,618

65

Income taxes, which comprise margin tax expenses, relating to the operations of Portamedic were less than $0.1 million for each period
presented and there were no income taxes on the gain of the sale due to the availability of net operating loss carry forwards with a
full valuation allowance.

The assets and liabilities of Portamedic are presented separately under the captions “Assets held for sale” and “Liabilities held for sale,” respectively, in the accompanying consolidated balance sheet as of December 31, 2012 and consist of the following:

(in thousands)
December 31, 2012

Assets held for sale:
 
Inventories
941

Other current assets
400

Property, plant and equipment, net
2,080

Other assets
225

Total assets
$
3,646

 
 
Liabilities held for sale:
 
Deferred rent
104

Capital leases
116

Total liabilities
$
220
XML 56 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEI Document
 9 Months Ended
Sep. 30, 2013
Oct. 31, 2013
Entity Information [Line Items]    
Entity Registrant Name HOOPER HOLMES INC  
Entity Central Index Key 0000741815  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Document Type 10-Q  
Document Period End Date Sep. 30, 2013  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   70,082,737
XML 57 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Liquidity (Details) (USD $)
 3 Months Ended 9 Months Ended 0 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Oct. 04, 2013
Dec. 31, 2012
Dec. 31, 2011
Sep. 30, 2013
Portamedic Service Line [Member]
Sep. 30, 2013
Portamedic Service Line [Member]
Sep. 30, 2013
Minimum [Member]
Portamedic Service Line [Member]
Sep. 30, 2013
Maximum [Member]
Portamedic Service Line [Member]
Liquidity [Abstract]                      
Loss from continuing operations $ (3,291,000) $ (1,189,000) $ (8,158,000) $ (5,456,000)              
Cash and cash equivalents 6,655,000 8,161,000 6,655,000 8,161,000   8,319,000 16,917,000        
Working capital                 9,400,000    
Borrowings outstanding under Loan and Security Agreement 2,608,000   2,608,000     0          
Remaining borrowing capacity under Loan and Security Agreement 40,000   40,000                
Net cash used in operating activities of continuing operations     (7,786,000) (5,147,000)              
Capital expenditures     (1,062,000) (3,346,000)              
Term of loan and security agreement     3 years                
Loan maximum defined, based on eligible receivables 85.00%   85.00%                
Maximum borrowing capacity under Loan and Security Agreement 10,000,000   10,000,000                
Additional borrowing availability under Loan and Security Agreement 6,000,000   6,000,000                
Loan maximum defined, based on eligible receivables, reserve 800,000   800,000   1,500,000            
EBITDA twelve month requirement 3,200,000   3,200,000                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Proceeds from the sale of Portamedic     6,053,000 0       8,100,000 6,100,000    
Consideration amount               8,400,000 8,400,000    
Holdback amount               2,000,000 2,000,000    
Holdback release, business days after closing               3 days      
Holdback release, amounts paid threshold               1,000,000 1,000,000    
Holdback release, amount less deductions for indemnification claims               1,000,000 1,000,000    
Holdback receivable recorded               2,000,000 2,000,000    
Eligible receivables generated, percent                   65.00% 75.00%
Eligible receivables generated                 9,000,000    
Selling, general and administrative expenses $ 5,002,000 $ 4,655,000 $ 15,372,000 $ 15,054,000         $ 7,400,000